diff --git "a/classification/cdr/test.json" "b/classification/cdr/test.json"
new file mode 100644--- /dev/null
+++ "b/classification/cdr/test.json"
@@ -0,0 +1,4675 @@
+{
+	"0": {"data": {"text": "Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal mastocytosis.", "entity1": "Indomethacin", "entity2": "interstitial cystitis", "span1": [0, 12], "span2": [61, 82]}, "bert_text": "<e1> Indomethacin </e1> resulted in histopathologic findings typical of <e2> interstitial cystitis </e2>, such as leaky bladder epithelium and mucosal mastocytosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1": {"data": {"text": "Indomethacin resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal mastocytosis.", "entity1": "Indomethacin", "entity2": "mastocytosis", "span1": [0, 12], "span2": [129, 141]}, "bert_text": "<e1> Indomethacin </e1> resulted in histopathologic findings typical of interstitial cystitis, such as leaky bladder epithelium and mucosal <e2> mastocytosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2": {"data": {"text": "Urinary protein excretion was unaltered by rhIGF-I treatment in rats with chronic PAN nephropathy.", "entity1": "PAN", "entity2": "nephropathy", "span1": [82, 85], "span2": [86, 97]}, "bert_text": "Urinary protein excretion was unaltered by rhIGF-I treatment in rats with chronic <e1> PAN </e1> <e2> nephropathy </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3": {"data": {"text": "Thereafter, seizures were induced by pilocarpine injections in trained and non-trained control groups.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [37, 48], "span2": [12, 20]}, "bert_text": "Thereafter, seizures were induced by <e1> pilocarpine </e1> <e2> seizures </e2> were induced by pilocarpine injections in trained and non-trained control groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4": {"data": {"text": "The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.", "entity1": "MT", "entity2": "hippocampal cognitive dysfunction", "span1": [49, 51], "span2": [91, 124]}, "bert_text": "The present study aimed to explore the effect of <e1> MT </e1> induction on carmustine (BCNU)-induced <e2> hippocampal cognitive dysfunction </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"5": {"data": {"text": "The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.", "entity1": "carmustine", "entity2": "hippocampal cognitive dysfunction", "span1": [65, 75], "span2": [91, 124]}, "bert_text": "The present study aimed to explore the effect of MT induction on <e1> carmustine </e1> (BCNU)-induced <e2> hippocampal cognitive dysfunction </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"6": {"data": {"text": "The present study aimed to explore the effect of MT induction on carmustine (BCNU)-induced hippocampal cognitive dysfunction in rats.", "entity1": "BCNU)-induced", "entity2": "hippocampal cognitive dysfunction", "span1": [77, 90], "span2": [91, 124]}, "bert_text": "The present study aimed to explore the effect of MT induction on carmustine (<e1> BCNU)-induced </e1> <e2> hippocampal cognitive dysfunction </e2> in rats.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"7": {"data": {"text": "The severity of pain due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated.", "entity1": "etomidate", "entity2": "pain", "span1": [28, 37], "span2": [16, 20]}, "bert_text": "The severity of pain due to <e1> etomidate </e1> <e2> pain </e2> due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"8": {"data": {"text": "Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).", "entity1": "CCNU", "entity2": "Neutropenia", "span1": [122, 126], "span2": [0, 11]}, "bert_text": "Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of <e1> CCNU </e1> <e2> Neutropenia </e2> was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"9": {"data": {"text": "Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).", "entity1": "CCNU", "entity2": "neutropenia", "span1": [122, 126], "span2": [81, 92]}, "bert_text": "Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of <e1> CCNU </e1> <e2> neutropenia </e2> after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"10": {"data": {"text": "Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).", "entity1": "CTX", "entity2": "Neutropenia", "span1": [127, 130], "span2": [0, 11]}, "bert_text": "Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/<e1> CTX </e1> <e2> Neutropenia </e2> was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"11": {"data": {"text": "Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).", "entity1": "CTX", "entity2": "neutropenia", "span1": [127, 130], "span2": [81, 92]}, "bert_text": "Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/<e1> CTX </e1> <e2> neutropenia </e2> after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19-43%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"12": {"data": {"text": "This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.", "entity1": "temsirolimus", "entity2": "tumor", "span1": [20, 32], "span2": [36, 41]}, "bert_text": "This dual effect of <e1> temsirolimus </e1> on <e2> tumor </e2> tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"13": {"data": {"text": "This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy.", "entity1": "temsirolimus", "entity2": "MCL", "span1": [20, 32], "span2": [116, 119]}, "bert_text": "This dual effect of <e1> temsirolimus </e1> on tumor tissue could contribute to its recently reported efficiency in refractory <e2> MCL </e2> resistant to conventional chemotherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"14": {"data": {"text": "Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.\n", "entity1": "Paclitaxel", "entity2": "breast cancer", "span1": [0, 10], "span2": [59, 72]}, "bert_text": "<e1> Paclitaxel </e1>, 5-fluorouracil, and folinic acid in metastatic <e2> breast cancer </e2>: BRE-26, a phase II trial.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"15": {"data": {"text": "Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.\n", "entity1": "5-fluorouracil", "entity2": "breast cancer", "span1": [12, 26], "span2": [59, 72]}, "bert_text": "Paclitaxel, <e1> 5-fluorouracil </e1>, and folinic acid in metastatic <e2> breast cancer </e2>: BRE-26, a phase II trial.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"16": {"data": {"text": "Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.\n", "entity1": "folinic acid", "entity2": "breast cancer", "span1": [32, 44], "span2": [59, 72]}, "bert_text": "Paclitaxel, 5-fluorouracil, and <e1> folinic acid </e1> in metastatic <e2> breast cancer </e2>: BRE-26, a phase II trial.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"17": {"data": {"text": "The influence of d-ribose on adriamycin-induced myocardiopathy in rats was studied.", "entity1": "adriamycin", "entity2": "myocardiopathy", "span1": [29, 39], "span2": [48, 62]}, "bert_text": "The influence of d-ribose on <e1> adriamycin </e1>-induced <e2> myocardiopathy </e2> in rats was studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"18": {"data": {"text": "Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.", "entity1": "Thiopentone", "entity2": "pain", "span1": [49, 60], "span2": [166, 170]}, "bert_text": "Neither the type of induction agent (Althesin or <e1> Thiopentone </e1>) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"19": {"data": {"text": "Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.", "entity1": "suxamethonium", "entity2": "pain", "span1": [90, 103], "span2": [166, 170]}, "bert_text": "Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of <e1> suxamethonium </e1> used (chloride or bromide), affected the incidence of scoline <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"20": {"data": {"text": "Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.", "entity1": "chloride", "entity2": "pain", "span1": [110, 118], "span2": [166, 170]}, "bert_text": "Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (<e1> chloride </e1> or bromide), affected the incidence of scoline <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"21": {"data": {"text": "Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or bromide), affected the incidence of scoline pain.", "entity1": "bromide", "entity2": "pain", "span1": [122, 129], "span2": [166, 170]}, "bert_text": "Neither the type of induction agent (Althesin or Thiopentone) nor the salt preparation of suxamethonium used (chloride or <e1> bromide </e1>), affected the incidence of scoline <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"22": {"data": {"text": "Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.", "entity1": "CsA", "entity2": "kidney lesions", "span1": [6, 9], "span2": [52, 66]}, "bert_text": "Short <e1> CsA </e1> treatment presented slight or even absent <e2> kidney lesions </e2> and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"23": {"data": {"text": "Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.", "entity1": "TP53", "entity2": "kidney lesions", "span1": [98, 102], "span2": [52, 66]}, "bert_text": "Short CsA treatment presented slight or even absent kidney lesions and TGF-b, NF- kb, mTOR, PCNA, <e1> TP53 </e1> <e2> kidney lesions </e2> and TGF-b, NF- kb, mTOR, PCNA, TP53, KIM-1, and CTGF as relevant gene and protein changes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"24": {"data": {"text": "In the seven men who completed six months on thalidomide, subclinical evidence of peripheral neuropathy was found in four before treatment, but in all seven at repeat testing.", "entity1": "thalidomide", "entity2": "peripheral neuropathy", "span1": [45, 56], "span2": [82, 103]}, "bert_text": "In the seven men who completed six months on <e1> thalidomide </e1>, subclinical evidence of <e2> peripheral neuropathy </e2> was found in four before treatment, but in all seven at repeat testing.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"25": {"data": {"text": "A patient with renal disease developed Coombs-positive hemolytic anemia while receiving cephalothin therapy.", "entity1": "cephalothin", "entity2": "renal disease", "span1": [88, 99], "span2": [15, 28]}, "bert_text": "A patient with renal disease developed Coombs-positive hemolytic anemia while receiving <e1> cephalothin </e1> <e2> renal disease </e2> developed Coombs-positive hemolytic anemia while receiving cephalothin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"26": {"data": {"text": "A patient with renal disease developed Coombs-positive hemolytic anemia while receiving cephalothin therapy.", "entity1": "cephalothin", "entity2": "hemolytic anemia", "span1": [88, 99], "span2": [55, 71]}, "bert_text": "A patient with renal disease developed Coombs-positive hemolytic anemia while receiving <e1> cephalothin </e1> <e2> hemolytic anemia </e2> while receiving cephalothin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"27": {"data": {"text": "Two hundred thirty-five patients aged 76 and older admitted to a major healthcare network between July 1, 2001, and June 30, 2002, with atrial fibrillation on warfarin were enrolled.", "entity1": "warfarin", "entity2": "atrial fibrillation", "span1": [159, 167], "span2": [136, 155]}, "bert_text": "Two hundred thirty-five patients aged 76 and older admitted to a major healthcare network between July 1, 2001, and June 30, 2002, with atrial fibrillation on <e1> warfarin </e1> <e2> atrial fibrillation </e2> on warfarin were enrolled.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"28": {"data": {"text": "7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).", "entity1": "alanine", "entity2": "hepatitis", "span1": [103, 110], "span2": [69, 78]}, "bert_text": "7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with <e1> alanine </e1> <e2> hepatitis </e2> (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"29": {"data": {"text": "7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).", "entity1": "alanine", "entity2": "jaundice", "span1": [103, 110], "span2": [89, 97]}, "bert_text": "7 g/dL) was observed in 5.4% of patients (CD4, 165 cells/microL) and hepatitis (clinical jaundice with <e1> alanine </e1> <e2> jaundice </e2> with alanine aminotransferase > 5 times upper limits of normal) in 3.5% of patients (CD4, 260 cells/microL).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"30": {"data": {"text": "Hypokalemia, sometimes severe, was observed in some L-dopa-treated parkinsonian patients.", "entity1": "L-dopa", "entity2": "Hypokalemia", "span1": [52, 58], "span2": [0, 11]}, "bert_text": "Hypokalemia, sometimes severe, was observed in some <e1> L-dopa </e1> <e2> Hypokalemia </e2>, sometimes severe, was observed in some L-dopa-treated parkinsonian patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"31": {"data": {"text": "Hypokalemia, sometimes severe, was observed in some L-dopa-treated parkinsonian patients.", "entity1": "L-dopa", "entity2": "parkinsonian", "span1": [52, 58], "span2": [67, 79]}, "bert_text": "Hypokalemia, sometimes severe, was observed in some <e1> L-dopa </e1>-treated <e2> parkinsonian </e2> patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"32": {"data": {"text": "The role of vasopressin as a pressor agent to the hypertensive process was examined.", "entity1": "vasopressin", "entity2": "hypertensive", "span1": [12, 23], "span2": [50, 62]}, "bert_text": "The role of <e1> vasopressin </e1> as a pressor agent to the <e2> hypertensive </e2> process was examined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"33": {"data": {"text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "entity1": "thalidomide", "entity2": "cutaneous lupus erythematosus", "span1": [177, 188], "span2": [128, 157]}, "bert_text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with <e1> thalidomide </e1> <e2> cutaneous lupus erythematosus </e2> (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"34": {"data": {"text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "entity1": "thalidomide", "entity2": "CLE", "span1": [177, 188], "span2": [159, 162]}, "bert_text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with <e1> thalidomide </e1> <e2> CLE </e2>) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"35": {"data": {"text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "entity1": "thalidomide", "entity2": "neurotoxic", "span1": [177, 188], "span2": [228, 238]}, "bert_text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with <e1> thalidomide </e1> and use these findings to identify the <e2> neurotoxic </e2> potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"36": {"data": {"text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "entity1": "thalidomide", "entity2": "cutaneous lupus erythematosus", "span1": [252, 263], "span2": [128, 157]}, "bert_text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of <e1> thalidomide </e1> <e2> cutaneous lupus erythematosus </e2> (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"37": {"data": {"text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "entity1": "thalidomide", "entity2": "CLE", "span1": [252, 263], "span2": [159, 162]}, "bert_text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of <e1> thalidomide </e1> <e2> CLE </e2>) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"38": {"data": {"text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "entity1": "thalidomide", "entity2": "neurotoxic", "span1": [252, 263], "span2": [228, 238]}, "bert_text": "The study's aims were to measure variations in sural nerve sensory action potential (SAP) amplitude in patients with refractory cutaneous lupus erythematosus (CLE) treated with thalidomide and use these findings to identify the neurotoxic potential of <e1> thalidomide </e1> <e2> neurotoxic </e2> potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"39": {"data": {"text": "The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia.\n", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [35, 50], "span2": [51, 60]}, "bert_text": "The risk and associated factors of <e1> methamphetamine </e1> <e2> psychosis </e2> in methamphetamine-dependent patients in Malaysia.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"40": {"data": {"text": "The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia.\n", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [64, 79], "span2": [51, 60]}, "bert_text": "The risk and associated factors of methamphetamine psychosis in <e1> methamphetamine </e1> <e2> psychosis </e2> in methamphetamine-dependent patients in Malaysia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"41": {"data": {"text": "Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.\n", "entity1": "sodium chloride", "entity2": "nephropathy", "span1": [34, 49], "span2": [99, 110]}, "bert_text": "Comparison of effects of isotonic <e1> sodium chloride </e1> with diltiazem in prevention of contrast-induced <e2> nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"42": {"data": {"text": "Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast-induced nephropathy.\n", "entity1": "diltiazem", "entity2": "nephropathy", "span1": [55, 64], "span2": [99, 110]}, "bert_text": "Comparison of effects of isotonic sodium chloride with <e1> diltiazem </e1> in prevention of contrast-induced <e2> nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"43": {"data": {"text": "Thrombotic events, however, could be avoided by using low-dose heparin.", "entity1": "heparin", "entity2": "Thrombotic", "span1": [63, 70], "span2": [0, 10]}, "bert_text": "Thrombotic events, however, could be avoided by using low-dose <e1> heparin </e1> <e2> Thrombotic </e2> events, however, could be avoided by using low-dose heparin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"44": {"data": {"text": "BACKGROUND: The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma.", "entity1": "carboplatin", "entity2": "carcinoma", "span1": [47, 58], "span2": [152, 161]}, "bert_text": "BACKGROUND: The activity of the combination of <e1> carboplatin </e1> and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical <e2> carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"45": {"data": {"text": "BACKGROUND: The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma.", "entity1": "doxorubicin", "entity2": "carcinoma", "span1": [73, 84], "span2": [152, 161]}, "bert_text": "BACKGROUND: The activity of the combination of carboplatin and liposomal <e1> doxorubicin </e1> was tested in a Phase II study of patients with recurrent cervical <e2> carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"46": {"data": {"text": "A case of fatal aplastic anemia due to carbamazepine treatment in an epileptic woman is reported.", "entity1": "carbamazepine", "entity2": "aplastic anemia", "span1": [39, 52], "span2": [16, 31]}, "bert_text": "A case of fatal aplastic anemia due to <e1> carbamazepine </e1> <e2> aplastic anemia </e2> due to carbamazepine treatment in an epileptic woman is reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"47": {"data": {"text": "A case of fatal aplastic anemia due to carbamazepine treatment in an epileptic woman is reported.", "entity1": "carbamazepine", "entity2": "epileptic", "span1": [39, 52], "span2": [69, 78]}, "bert_text": "A case of fatal aplastic anemia due to <e1> carbamazepine </e1> treatment in an <e2> epileptic </e2> woman is reported.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"48": {"data": {"text": "These data are consistent with the hypothesis that exercise-induced tachycardia results largely from beta 1-receptor activation that is blocked by both cardioselective and nonselective drugs, whereas isoproterenol activates both beta 1- and beta 2-receptors so that after cardioselective blockade there remains a beta 2-component that can be blocked with a nonselective drug.", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [200, 213], "span2": [68, 79]}, "bert_text": "These data are consistent with the hypothesis that exercise-induced tachycardia results largely from beta 1-receptor activation that is blocked by both cardioselective and nonselective drugs, whereas <e1> isoproterenol </e1> <e2> tachycardia </e2> results largely from beta 1-receptor activation that is blocked by both cardioselective and nonselective drugs, whereas isoproterenol activates both beta 1- and beta 2-receptors so that after cardioselective blockade there remains a beta 2-component that can be blocked with a nonselective drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"49": {"data": {"text": "OBJECTIVE: The objective of this study was to determine the risk of lifetime and current methamphetamine-induced psychosis in patients with methamphetamine dependence.", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [89, 104], "span2": [113, 122]}, "bert_text": "OBJECTIVE: The objective of this study was to determine the risk of lifetime and current <e1> methamphetamine </e1>-induced <e2> psychosis </e2> in patients with methamphetamine dependence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"50": {"data": {"text": "OBJECTIVE: The objective of this study was to determine the risk of lifetime and current methamphetamine-induced psychosis in patients with methamphetamine dependence.", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [140, 155], "span2": [113, 122]}, "bert_text": "OBJECTIVE: The objective of this study was to determine the risk of lifetime and current methamphetamine-induced psychosis in patients with <e1> methamphetamine </e1> <e2> psychosis </e2> in patients with methamphetamine dependence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"51": {"data": {"text": "Metronidazole-induced encephalopathy: an uncommon scenario.\n", "entity1": "Metronidazole", "entity2": "encephalopathy", "span1": [0, 13], "span2": [22, 36]}, "bert_text": "<e1> Metronidazole </e1>-induced <e2> encephalopathy </e2>: an uncommon scenario.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"52": {"data": {"text": "There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "entity1": "cyclosporine", "entity2": "infectious deaths", "span1": [64, 76], "span2": [14, 31]}, "bert_text": "There were no infectious deaths in renal transplant patients on <e1> cyclosporine </e1> <e2> infectious deaths </e2> in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"53": {"data": {"text": "There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "entity1": "cyclosporine", "entity2": "deaths", "span1": [64, 76], "span2": [152, 158]}, "bert_text": "There were no infectious deaths in renal transplant patients on <e1> cyclosporine </e1> or Aza, but infection played a major role in 3 out of 6 cardiac transplant <e2> deaths </e2> and in 8 out of 9 liver transplant deaths.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"54": {"data": {"text": "There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "entity1": "cyclosporine", "entity2": "deaths", "span1": [64, 76], "span2": [194, 200]}, "bert_text": "There were no infectious deaths in renal transplant patients on <e1> cyclosporine </e1> or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant <e2> deaths </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"55": {"data": {"text": "There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "entity1": "cyclosporine", "entity2": "infection", "span1": [64, 76], "span2": [89, 98]}, "bert_text": "There were no infectious deaths in renal transplant patients on <e1> cyclosporine </e1> or Aza, but <e2> infection </e2> played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"56": {"data": {"text": "There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "entity1": "Aza", "entity2": "infectious deaths", "span1": [80, 83], "span2": [14, 31]}, "bert_text": "There were no infectious deaths in renal transplant patients on cyclosporine or <e1> Aza </e1> <e2> infectious deaths </e2> in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"57": {"data": {"text": "There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "entity1": "Aza", "entity2": "deaths", "span1": [80, 83], "span2": [152, 158]}, "bert_text": "There were no infectious deaths in renal transplant patients on cyclosporine or <e1> Aza </e1>, but infection played a major role in 3 out of 6 cardiac transplant <e2> deaths </e2> and in 8 out of 9 liver transplant deaths.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"58": {"data": {"text": "There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "entity1": "Aza", "entity2": "deaths", "span1": [80, 83], "span2": [194, 200]}, "bert_text": "There were no infectious deaths in renal transplant patients on cyclosporine or <e1> Aza </e1>, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant <e2> deaths </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"59": {"data": {"text": "There were no infectious deaths in renal transplant patients on cyclosporine or Aza, but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "entity1": "Aza", "entity2": "infection", "span1": [80, 83], "span2": [89, 98]}, "bert_text": "There were no infectious deaths in renal transplant patients on cyclosporine or <e1> Aza </e1>, but <e2> infection </e2> played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"60": {"data": {"text": "The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine.", "entity1": "quetiapine", "entity2": "agitation", "span1": [49, 59], "span2": [103, 112]}, "bert_text": "The withdrawal and the gradual reintroduction of <e1> quetiapine </e1> 2 weeks later, which led to another severe <e2> agitation </e2>, enabled us to attribute the agitation specifically to quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"61": {"data": {"text": "The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine.", "entity1": "quetiapine", "entity2": "agitation", "span1": [49, 59], "span2": [142, 151]}, "bert_text": "The withdrawal and the gradual reintroduction of <e1> quetiapine </e1> 2 weeks later, which led to another severe agitation, enabled us to attribute the <e2> agitation </e2> specifically to quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"62": {"data": {"text": "The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine.", "entity1": "quetiapine", "entity2": "agitation", "span1": [168, 178], "span2": [103, 112]}, "bert_text": "The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to <e1> quetiapine </e1> <e2> agitation </e2>, enabled us to attribute the agitation specifically to quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"63": {"data": {"text": "The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to quetiapine.", "entity1": "quetiapine", "entity2": "agitation", "span1": [168, 178], "span2": [142, 151]}, "bert_text": "The withdrawal and the gradual reintroduction of quetiapine 2 weeks later, which led to another severe agitation, enabled us to attribute the agitation specifically to <e1> quetiapine </e1> <e2> agitation </e2> specifically to quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"64": {"data": {"text": "RESULTS: A total of 76 cases of hyponatremia and/or SIADH associated with vincristine use were identified.", "entity1": "vincristine", "entity2": "hyponatremia", "span1": [74, 85], "span2": [32, 44]}, "bert_text": "RESULTS: A total of 76 cases of hyponatremia and/or SIADH associated with <e1> vincristine </e1> <e2> hyponatremia </e2> and/or SIADH associated with vincristine use were identified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"65": {"data": {"text": "Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.\n", "entity1": "lamivudine", "entity2": "chronic hepatitis B virus infection", "span1": [30, 40], "span2": [73, 108]}, "bert_text": "Rate of YMDD motif mutants in <e1> lamivudine </e1>-untreated Iranian patients with <e2> chronic hepatitis B virus infection </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"66": {"data": {"text": "Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice.", "entity1": "Doxorubicin", "entity2": "cardiotoxicity", "span1": [0, 11], "span2": [20, 34]}, "bert_text": "<e1> Doxorubicin </e1>-induced <e2> cardiotoxicity </e2> monitored by ECG in freely moving mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"67": {"data": {"text": "Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area.", "entity1": "CYA", "entity2": "toxicity", "span1": [134, 137], "span2": [29, 37]}, "bert_text": "Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of <e1> CYA </e1> <e2> toxicity </e2> generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"68": {"data": {"text": "Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [134, 137], "span2": [224, 238]}, "bert_text": "Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of <e1> CYA </e1> in patients transplanted at our institution to determine whether the incidence of CYA <e2> cardiotoxicity </e2> correlated with the dose per body surface area.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"69": {"data": {"text": "Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area.", "entity1": "CYA", "entity2": "toxicity", "span1": [220, 223], "span2": [29, 37]}, "bert_text": "Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of <e1> CYA </e1> <e2> toxicity </e2> generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"70": {"data": {"text": "Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [220, 223], "span2": [224, 238]}, "bert_text": "Since chemotherapeutic agent toxicity generally correlates with dose per body surface area, we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of <e1> CYA </e1> <e2> cardiotoxicity </e2> correlated with the dose per body surface area.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"71": {"data": {"text": "PURPOSE: This retrospective study used a pharmaceutical company's global safety database to determine the reporting rate of hyponatremia and/or syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) among vincristine-treated patients and to explore the possibility of at-risk population subgroups.", "entity1": "vincristine", "entity2": "hyponatremia", "span1": [219, 230], "span2": [124, 136]}, "bert_text": "PURPOSE: This retrospective study used a pharmaceutical company's global safety database to determine the reporting rate of hyponatremia and/or syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) among <e1> vincristine </e1> <e2> hyponatremia </e2> and/or syndrome of inappropriate secretion of anti-diuretic hormone (SIADH) among vincristine-treated patients and to explore the possibility of at-risk population subgroups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"72": {"data": {"text": "MEASUREMENTS: Information regarding major bleeding episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.", "entity1": "warfarin", "entity2": "bleeding", "span1": [74, 82], "span2": [42, 50]}, "bert_text": "MEASUREMENTS: Information regarding major bleeding episodes, strokes, and <e1> warfarin </e1> <e2> bleeding </e2> episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"73": {"data": {"text": "MEASUREMENTS: Information regarding major bleeding episodes, strokes, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.", "entity1": "warfarin", "entity2": "strokes", "span1": [74, 82], "span2": [61, 68]}, "bert_text": "MEASUREMENTS: Information regarding major bleeding episodes, strokes, and <e1> warfarin </e1> <e2> strokes </e2>, and warfarin use was obtained from patients, relatives, primary physicians, and medical records.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"74": {"data": {"text": "Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.", "entity1": "Vasopressin", "entity2": "hypertension", "span1": [0, 11], "span2": [64, 76]}, "bert_text": "<e1> Vasopressin </e1> plays a major role in the pathogenesis of DOCA-salt <e2> hypertension </e2>, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"75": {"data": {"text": "Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.", "entity1": "Vasopressin", "entity2": "diabetes insipidus", "span1": [0, 11], "span2": [169, 187]}, "bert_text": "<e1> Vasopressin </e1> plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated <e2> diabetes insipidus </e2> after DOCA-salt treatment.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"76": {"data": {"text": "Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.", "entity1": "lithium", "entity2": "hypertension", "span1": [153, 160], "span2": [64, 76]}, "bert_text": "Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with <e1> lithium </e1> <e2> hypertension </e2>, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"77": {"data": {"text": "Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with lithium-treated diabetes insipidus after DOCA-salt treatment.", "entity1": "lithium", "entity2": "diabetes insipidus", "span1": [153, 160], "span2": [169, 187]}, "bert_text": "Vasopressin plays a major role in the pathogenesis of DOCA-salt hypertension, since the elevation of blood pressure was not substantial in the rats with <e1> lithium </e1>-treated <e2> diabetes insipidus </e2> after DOCA-salt treatment.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"78": {"data": {"text": "STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of cocaine-induced myocardial infarction (MI).", "entity1": "lidocaine", "entity2": "myocardial infarction", "span1": [43, 52], "span2": [87, 108]}, "bert_text": "STUDY OBJECTIVE: To evaluate the safety of <e1> lidocaine </e1> in the setting of cocaine-induced <e2> myocardial infarction </e2> (MI).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"79": {"data": {"text": "STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of cocaine-induced myocardial infarction (MI).", "entity1": "lidocaine", "entity2": "MI", "span1": [43, 52], "span2": [110, 112]}, "bert_text": "STUDY OBJECTIVE: To evaluate the safety of <e1> lidocaine </e1> in the setting of cocaine-induced myocardial infarction (<e2> MI </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"80": {"data": {"text": "STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of cocaine-induced myocardial infarction (MI).", "entity1": "cocaine", "entity2": "myocardial infarction", "span1": [71, 78], "span2": [87, 108]}, "bert_text": "STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of <e1> cocaine </e1>-induced <e2> myocardial infarction </e2> (MI).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"81": {"data": {"text": "STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of cocaine-induced myocardial infarction (MI).", "entity1": "cocaine", "entity2": "MI", "span1": [71, 78], "span2": [110, 112]}, "bert_text": "STUDY OBJECTIVE: To evaluate the safety of lidocaine in the setting of <e1> cocaine </e1>-induced myocardial infarction (<e2> MI </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"82": {"data": {"text": "These results indicate that delayed toxicity of CY in female DBA/2 mice causes a bladder pathology that is not observed in C57BL/6 mice.", "entity1": "CY", "entity2": "toxicity", "span1": [48, 50], "span2": [36, 44]}, "bert_text": "These results indicate that delayed toxicity of <e1> CY </e1> <e2> toxicity </e2> of CY in female DBA/2 mice causes a bladder pathology that is not observed in C57BL/6 mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"83": {"data": {"text": "Toxicity of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity.", "entity1": "CAA", "entity2": "Toxicity", "span1": [12, 15], "span2": [0, 8]}, "bert_text": "Toxicity of <e1> CAA </e1> <e2> Toxicity </e2> of CAA was determined by protein content, cell number, LDH release, trypan blue exclusion assay and caspase-3 activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"84": {"data": {"text": "The levodopa-treated MPTP-lesioned marmoset was used as a model of neuropsychiatric symptoms in PD patients.", "entity1": "levodopa", "entity2": "neuropsychiatric symptoms", "span1": [4, 12], "span2": [67, 92]}, "bert_text": "The <e1> levodopa </e1>-treated MPTP-lesioned marmoset was used as a model of <e2> neuropsychiatric symptoms </e2> in PD patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"85": {"data": {"text": "The levodopa-treated MPTP-lesioned marmoset was used as a model of neuropsychiatric symptoms in PD patients.", "entity1": "levodopa", "entity2": "PD", "span1": [4, 12], "span2": [96, 98]}, "bert_text": "The <e1> levodopa </e1>-treated MPTP-lesioned marmoset was used as a model of neuropsychiatric symptoms in <e2> PD </e2> patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"86": {"data": {"text": "The levodopa-treated MPTP-lesioned marmoset was used as a model of neuropsychiatric symptoms in PD patients.", "entity1": "MPTP", "entity2": "neuropsychiatric symptoms", "span1": [21, 25], "span2": [67, 92]}, "bert_text": "The levodopa-treated <e1> MPTP </e1>-lesioned marmoset was used as a model of <e2> neuropsychiatric symptoms </e2> in PD patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"87": {"data": {"text": "The levodopa-treated MPTP-lesioned marmoset was used as a model of neuropsychiatric symptoms in PD patients.", "entity1": "MPTP", "entity2": "PD", "span1": [21, 25], "span2": [96, 98]}, "bert_text": "The levodopa-treated <e1> MPTP </e1>-lesioned marmoset was used as a model of neuropsychiatric symptoms in <e2> PD </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"88": {"data": {"text": "We wish to draw attention to the possibility of adverse reactions to ACE inhibitors after long-term use and in patients with pre-existing angio-oedema.", "entity1": "ACE inhibitors", "entity2": "angio-oedema", "span1": [69, 83], "span2": [138, 150]}, "bert_text": "We wish to draw attention to the possibility of adverse reactions to <e1> ACE inhibitors </e1> after long-term use and in patients with pre-existing <e2> angio-oedema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"89": {"data": {"text": "We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats.", "entity1": "clentiazem", "entity2": "cardiomyopathy", "span1": [31, 41], "span2": [108, 122]}, "bert_text": "We investigated the effects of <e1> clentiazem </e1>, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced <e2> cardiomyopathy </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"90": {"data": {"text": "We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats.", "entity1": "1,5-benzothiazepine", "entity2": "cardiomyopathy", "span1": [45, 64], "span2": [108, 122]}, "bert_text": "We investigated the effects of clentiazem, a <e1> 1,5-benzothiazepine </e1> calcium antagonist, on epinephrine-induced <e2> cardiomyopathy </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"91": {"data": {"text": "We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats.", "entity1": "calcium", "entity2": "cardiomyopathy", "span1": [65, 72], "span2": [108, 122]}, "bert_text": "We investigated the effects of clentiazem, a 1,5-benzothiazepine <e1> calcium </e1> antagonist, on epinephrine-induced <e2> cardiomyopathy </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"92": {"data": {"text": "We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on epinephrine-induced cardiomyopathy in rats.", "entity1": "epinephrine", "entity2": "cardiomyopathy", "span1": [88, 99], "span2": [108, 122]}, "bert_text": "We investigated the effects of clentiazem, a 1,5-benzothiazepine calcium antagonist, on <e1> epinephrine </e1>-induced <e2> cardiomyopathy </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"93": {"data": {"text": "Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.", "entity1": "melphalan", "entity2": "Acute renal insufficiency", "span1": [48, 57], "span2": [0, 25]}, "bert_text": "Acute renal insufficiency (ARI) after high-dose <e1> melphalan </e1> <e2> Acute renal insufficiency </e2> (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"94": {"data": {"text": "Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.", "entity1": "melphalan", "entity2": "ARI", "span1": [48, 57], "span2": [27, 30]}, "bert_text": "Acute renal insufficiency (ARI) after high-dose <e1> melphalan </e1> <e2> ARI </e2>) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"95": {"data": {"text": "Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.", "entity1": "creatinine", "entity2": "Acute renal insufficiency", "span1": [134, 144], "span2": [0, 25]}, "bert_text": "Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum <e1> creatinine </e1> <e2> Acute renal insufficiency </e2> (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"96": {"data": {"text": "Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.", "entity1": "creatinine", "entity2": "ARI", "span1": [134, 144], "span2": [27, 30]}, "bert_text": "Acute renal insufficiency (ARI) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum <e1> creatinine </e1> <e2> ARI </e2>) after high-dose melphalan was defined by a minimum increase of 0.5 mg/dL (44 micromol/L) in the serum creatinine level that is greater than 50% of baseline immediately after conditioning.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"97": {"data": {"text": "The purpose of this study was to assess the use of galantamine, an acetylcholinesterase inhibitor and nicotinic receptor modulator, in the treatment of interfering behaviors in children with autism.", "entity1": "galantamine", "entity2": "autism", "span1": [51, 62], "span2": [191, 197]}, "bert_text": "The purpose of this study was to assess the use of <e1> galantamine </e1>, an acetylcholinesterase inhibitor and nicotinic receptor modulator, in the treatment of interfering behaviors in children with <e2> autism </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"98": {"data": {"text": "OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments.", "entity1": "tacrolimus", "entity2": "inflammatory facial dermatoses", "span1": [87, 97], "span2": [38, 68]}, "bert_text": "OBSERVATIONS: Six adult patients with inflammatory facial dermatoses were treated with <e1> tacrolimus </e1> <e2> inflammatory facial dermatoses </e2> were treated with tacrolimus ointment because of the ineffectiveness of standard treatments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"99": {"data": {"text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "entity1": "L-dopa", "entity2": "hypokalemia", "span1": [17, 23], "span2": [91, 102]}, "bert_text": "The influence of <e1> L-dopa </e1> on the renal excretion of potassium was studied in 3 patients with <e2> hypokalemia </e2> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"100": {"data": {"text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "entity1": "potassium", "entity2": "hypokalemia", "span1": [50, 59], "span2": [91, 102]}, "bert_text": "The influence of L-dopa on the renal excretion of <e1> potassium </e1> was studied in 3 patients with <e2> hypokalemia </e2> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"101": {"data": {"text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "entity1": "potassium", "entity2": "hypokalemia", "span1": [225, 234], "span2": [91, 102]}, "bert_text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of <e1> potassium </e1> <e2> hypokalemia </e2> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"102": {"data": {"text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "entity1": "potassium", "entity2": "hypokalemia", "span1": [278, 287], "span2": [91, 102]}, "bert_text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of <e1> potassium </e1> <e2> hypokalemia </e2> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"103": {"data": {"text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "entity1": "sodium", "entity2": "hypokalemia", "span1": [239, 245], "span2": [91, 102]}, "bert_text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and <e1> sodium </e1> <e2> hypokalemia </e2> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"104": {"data": {"text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "entity1": "sodium", "entity2": "hypokalemia", "span1": [289, 295], "span2": [91, 102]}, "bert_text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, <e1> sodium </e1> <e2> hypokalemia </e2> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"105": {"data": {"text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "entity1": "aldosterone", "entity2": "hypokalemia", "span1": [300, 311], "span2": [91, 102]}, "bert_text": "The influence of L-dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and <e1> aldosterone </e1> <e2> hypokalemia </e2> and in 5 normokalemic patients by determination of renal plasma flow, glomerular filtration rate, plasma concentration of potassium and sodium as well as urinary excretion of potassium, sodium and aldosterone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"106": {"data": {"text": "Population-based study of risk of venous thromboembolism associated with various oral contraceptives.\n", "entity1": "oral contraceptives", "entity2": "venous thromboembolism", "span1": [81, 100], "span2": [34, 56]}, "bert_text": "Population-based study of risk of venous thromboembolism associated with various <e1> oral contraceptives </e1> <e2> venous thromboembolism </e2> associated with various oral contraceptives.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"107": {"data": {"text": "The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.", "entity1": "caproate", "entity2": "hyperglycemia", "span1": [93, 101], "span2": [114, 127]}, "bert_text": "The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of <e1> caproate </e1> resulted in <e2> hyperglycemia </e2>, an elevated glucose tolerance curve and, occasionally, glucosuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"108": {"data": {"text": "The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.", "entity1": "caproate", "entity2": "glucosuria", "span1": [93, 101], "span2": [184, 194]}, "bert_text": "The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of <e1> caproate </e1> resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, <e2> glucosuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"109": {"data": {"text": "The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.", "entity1": "glucose", "entity2": "hyperglycemia", "span1": [141, 148], "span2": [114, 127]}, "bert_text": "The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated <e1> glucose </e1> <e2> hyperglycemia </e2>, an elevated glucose tolerance curve and, occasionally, glucosuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"110": {"data": {"text": "The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated glucose tolerance curve and, occasionally, glucosuria.", "entity1": "glucose", "entity2": "glucosuria", "span1": [141, 148], "span2": [184, 194]}, "bert_text": "The chronic feeding of small amounts (0.3-3% of diet weight) of certain amino derivatives of caproate resulted in hyperglycemia, an elevated <e1> glucose </e1> tolerance curve and, occasionally, <e2> glucosuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"111": {"data": {"text": "RESULTS: Postprocedural creatinine level decreased nonsignificantly in the PTRA group (1.46+/-0.8 vs. 1.34+/-0.5 mg/dl, P=NS) and increased significantly in the PCI group (1.44+/-0.6 vs. 1.57+/-0.7 mg/dl, P<0.02).", "entity1": "creatinine", "entity2": "NS", "span1": [24, 34], "span2": [122, 124]}, "bert_text": "RESULTS: Postprocedural <e1> creatinine </e1> level decreased nonsignificantly in the PTRA group (1.46+/-0.8 vs. 1.34+/-0.5 mg/dl, P=<e2> NS </e2>) and increased significantly in the PCI group (1.44+/-0.6 vs. 1.57+/-0.7 mg/dl, P<0.02).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"112": {"data": {"text": "RESULTS: Postprocedural creatinine level decreased nonsignificantly in the PTRA group (1.46+/-0.8 vs. 1.34+/-0.5 mg/dl, P=NS) and increased significantly in the PCI group (1.44+/-0.6 vs. 1.57+/-0.7 mg/dl, P<0.02).", "entity1": "PTRA", "entity2": "NS", "span1": [75, 79], "span2": [122, 124]}, "bert_text": "RESULTS: Postprocedural creatinine level decreased nonsignificantly in the <e1> PTRA </e1> group (1.46+/-0.8 vs. 1.34+/-0.5 mg/dl, P=<e2> NS </e2>) and increased significantly in the PCI group (1.44+/-0.6 vs. 1.57+/-0.7 mg/dl, P<0.02).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"113": {"data": {"text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.", "entity1": "phenylephrine", "entity2": "hypertension", "span1": [200, 213], "span2": [228, 240]}, "bert_text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during <e1> phenylephrine </e1> (Phe)-induced <e2> hypertension </e2> and sodium nitroprusside (SN)-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"114": {"data": {"text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.", "entity1": "phenylephrine", "entity2": "hypotension", "span1": [200, 213], "span2": [279, 290]}, "bert_text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during <e1> phenylephrine </e1> (Phe)-induced hypertension and sodium nitroprusside (SN)-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"115": {"data": {"text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.", "entity1": "Phe)-induced", "entity2": "hypertension", "span1": [215, 227], "span2": [228, 240]}, "bert_text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (<e1> Phe)-induced </e1> <e2> hypertension </e2> and sodium nitroprusside (SN)-induced hypotension.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"116": {"data": {"text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.", "entity1": "Phe)-induced", "entity2": "hypotension", "span1": [215, 227], "span2": [279, 290]}, "bert_text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (<e1> Phe)-induced </e1> hypertension and sodium nitroprusside (SN)-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"117": {"data": {"text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.", "entity1": "sodium nitroprusside", "entity2": "hypertension", "span1": [245, 265], "span2": [228, 240]}, "bert_text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and <e1> sodium nitroprusside </e1> <e2> hypertension </e2> and sodium nitroprusside (SN)-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"118": {"data": {"text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.", "entity1": "sodium nitroprusside", "entity2": "hypotension", "span1": [245, 265], "span2": [279, 290]}, "bert_text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and <e1> sodium nitroprusside </e1> (SN)-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"119": {"data": {"text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.", "entity1": "SN)-induced", "entity2": "hypertension", "span1": [267, 278], "span2": [228, 240]}, "bert_text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (<e1> SN)-induced </e1> <e2> hypertension </e2> and sodium nitroprusside (SN)-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"120": {"data": {"text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (SN)-induced hypotension.", "entity1": "SN)-induced", "entity2": "hypotension", "span1": [267, 278], "span2": [279, 290]}, "bert_text": "Sensitivity of cardiac component of baroreflex (CCB), expressed as a slope of the regression line was determined from relationships between systolic arterial pressure (SAP) and HR period (HRp) during phenylephrine (Phe)-induced hypertension and sodium nitroprusside (<e1> SN)-induced </e1> <e2> hypotension </e2>.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"121": {"data": {"text": "Acute renal failure due to rifampicin.\n", "entity1": "rifampicin", "entity2": "Acute renal failure", "span1": [27, 37], "span2": [0, 19]}, "bert_text": "Acute renal failure due to <e1> rifampicin </e1> <e2> Acute renal failure </e2> due to rifampicin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"122": {"data": {"text": "RESULTS: Dermal exposure of rats to S-53482 at 300 mg/kg produced patterns of developmental toxicity similar to those resulting from oral exposure.", "entity1": "S-53482", "entity2": "developmental toxicity", "span1": [36, 43], "span2": [78, 100]}, "bert_text": "RESULTS: Dermal exposure of rats to <e1> S-53482 </e1> at 300 mg/kg produced patterns of <e2> developmental toxicity </e2> similar to those resulting from oral exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"123": {"data": {"text": "Mefenamic acid-induced neutropenia and renal failure in elderly females with hypothyroidism.\n", "entity1": "Mefenamic acid", "entity2": "neutropenia", "span1": [0, 14], "span2": [23, 34]}, "bert_text": "<e1> Mefenamic acid </e1>-induced <e2> neutropenia </e2> and renal failure in elderly females with hypothyroidism.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"124": {"data": {"text": "Mefenamic acid-induced neutropenia and renal failure in elderly females with hypothyroidism.\n", "entity1": "Mefenamic acid", "entity2": "renal failure", "span1": [0, 14], "span2": [39, 52]}, "bert_text": "<e1> Mefenamic acid </e1>-induced neutropenia and <e2> renal failure </e2> in elderly females with hypothyroidism.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"125": {"data": {"text": "Mefenamic acid-induced neutropenia and renal failure in elderly females with hypothyroidism.\n", "entity1": "Mefenamic acid", "entity2": "hypothyroidism", "span1": [0, 14], "span2": [77, 91]}, "bert_text": "<e1> Mefenamic acid </e1>-induced neutropenia and renal failure in elderly females with <e2> hypothyroidism </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"126": {"data": {"text": "Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [20, 27], "span2": [36, 52]}, "bert_text": "Clinical aspects of <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> and thrombosis and other side effects of heparin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"127": {"data": {"text": "Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy.\n", "entity1": "heparin", "entity2": "thrombosis", "span1": [20, 27], "span2": [57, 67]}, "bert_text": "Clinical aspects of <e1> heparin </e1>-induced thrombocytopenia and <e2> thrombosis </e2> and other side effects of heparin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"128": {"data": {"text": "Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [94, 101], "span2": [36, 52]}, "bert_text": "Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of <e1> heparin </e1> <e2> thrombocytopenia </e2> and thrombosis and other side effects of heparin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"129": {"data": {"text": "Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy.\n", "entity1": "heparin", "entity2": "thrombosis", "span1": [94, 101], "span2": [57, 67]}, "bert_text": "Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of <e1> heparin </e1> <e2> thrombosis </e2> and other side effects of heparin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"130": {"data": {"text": "We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis.", "entity1": "carbimazole", "entity2": "Graves' disease", "span1": [69, 80], "span2": [25, 40]}, "bert_text": "We report a patient with Graves' disease who developed ANCA positive <e1> carbimazole </e1> <e2> Graves' disease </e2> who developed ANCA positive carbimazole induced vasculitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"131": {"data": {"text": "We report a patient with Graves' disease who developed ANCA positive carbimazole induced vasculitis.", "entity1": "carbimazole", "entity2": "vasculitis", "span1": [69, 80], "span2": [89, 99]}, "bert_text": "We report a patient with Graves' disease who developed ANCA positive <e1> carbimazole </e1> induced <e2> vasculitis </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"132": {"data": {"text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.", "entity1": "bupivacaine", "entity2": "cardiotoxic", "span1": [15, 26], "span2": [429, 440]}, "bert_text": "The cumulative <e1> bupivacaine </e1> dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced <e2> cardiotoxic </e2> effects as well as reduced plasma bupivacaine levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"133": {"data": {"text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.", "entity1": "bupivacaine", "entity2": "cardiotoxic", "span1": [89, 100], "span2": [429, 440]}, "bert_text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma <e1> bupivacaine </e1> levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced <e2> cardiotoxic </e2> effects as well as reduced plasma bupivacaine levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1], "label": 1},
+	"134": {"data": {"text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.", "entity1": "Bupivacaine", "entity2": "cardiotoxic", "span1": [161, 172], "span2": [429, 440]}, "bert_text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. <e1> Bupivacaine </e1> levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced <e2> cardiotoxic </e2> effects as well as reduced plasma bupivacaine levels.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1], "label": 1},
+	"135": {"data": {"text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.", "entity1": "bupivacaine", "entity2": "cardiotoxic", "span1": [409, 420], "span2": [429, 440]}, "bert_text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of <e1> bupivacaine </e1>-induced <e2> cardiotoxic </e2> effects as well as reduced plasma bupivacaine levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"136": {"data": {"text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.", "entity1": "bupivacaine", "entity2": "cardiotoxic", "span1": [475, 486], "span2": [429, 440]}, "bert_text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma <e1> bupivacaine </e1> <e2> cardiotoxic </e2> effects as well as reduced plasma bupivacaine levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
+	"137": {"data": {"text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.", "entity1": "propofol", "entity2": "cardiotoxic", "span1": [316, 324], "span2": [429, 440]}, "bert_text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with <e1> propofol </e1> in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced <e2> cardiotoxic </e2> effects as well as reduced plasma bupivacaine levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"138": {"data": {"text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels.", "entity1": "propofol", "entity2": "cardiotoxic", "span1": [354, 362], "span2": [429, 440]}, "bert_text": "The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C. CONCLUSION: We conclude that pre-treatment with propofol in intralipid, compared with <e1> propofol </e1> in medialipid or saline, delayed the onset of bupivacaine-induced <e2> cardiotoxic </e2> effects as well as reduced plasma bupivacaine levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"139": {"data": {"text": "Reports about cases of hepatotoxicity due to clopidogrel are increasing in the last few years, after the increased use of this drug.", "entity1": "clopidogrel", "entity2": "hepatotoxicity", "span1": [45, 56], "span2": [23, 37]}, "bert_text": "Reports about cases of hepatotoxicity due to <e1> clopidogrel </e1> <e2> hepatotoxicity </e2> due to clopidogrel are increasing in the last few years, after the increased use of this drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"140": {"data": {"text": "Barium-supplemented Long-Evans hooded rats were characterized by a persistent hypertension that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment.", "entity1": "Barium", "entity2": "hypertension", "span1": [0, 6], "span2": [78, 90]}, "bert_text": "<e1> Barium </e1>-supplemented Long-Evans hooded rats were characterized by a persistent <e2> hypertension </e2> that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"141": {"data": {"text": "Barium-supplemented Long-Evans hooded rats were characterized by a persistent hypertension that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment.", "entity1": "barium", "entity2": "hypertension", "span1": [125, 131], "span2": [78, 90]}, "bert_text": "Barium-supplemented Long-Evans hooded rats were characterized by a persistent hypertension that was evident after 1 month of <e1> barium </e1> <e2> hypertension </e2> that was evident after 1 month of barium (100 micrograms/ml mineral fortified water) treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"142": {"data": {"text": "Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.\n", "entity1": "dobutamine", "entity2": "left ventricular dysfunction", "span1": [98, 108], "span2": [10, 38]}, "bert_text": "Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both <e1> dobutamine </e1> <e2> left ventricular dysfunction </e2> occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"143": {"data": {"text": "Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.\n", "entity1": "dobutamine", "entity2": "coronary artery disease", "span1": [98, 108], "span2": [63, 86]}, "bert_text": "Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both <e1> dobutamine </e1> <e2> coronary artery disease </e2> after both dobutamine and exercise induced myocardial ischaemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"144": {"data": {"text": "Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia.\n", "entity1": "dobutamine", "entity2": "myocardial ischaemia", "span1": [98, 108], "span2": [130, 150]}, "bert_text": "Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both <e1> dobutamine </e1> and exercise induced <e2> myocardial ischaemia </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"145": {"data": {"text": "Despite concerns of fatal bone marrow toxicity due to carbamazepine, this is only the fourth documented and published report.", "entity1": "carbamazepine", "entity2": "bone marrow toxicity", "span1": [54, 67], "span2": [26, 46]}, "bert_text": "Despite concerns of fatal bone marrow toxicity due to <e1> carbamazepine </e1> <e2> bone marrow toxicity </e2> due to carbamazepine, this is only the fourth documented and published report.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"146": {"data": {"text": "After the end of fenoterol-hydrobromide infusion, tremor amplitudes decreased significantly faster than those following ritodrin-HCl infusion.", "entity1": "fenoterol-hydrobromide", "entity2": "tremor", "span1": [17, 39], "span2": [50, 56]}, "bert_text": "After the end of <e1> fenoterol-hydrobromide </e1> infusion, <e2> tremor </e2> amplitudes decreased significantly faster than those following ritodrin-HCl infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"147": {"data": {"text": "After the end of fenoterol-hydrobromide infusion, tremor amplitudes decreased significantly faster than those following ritodrin-HCl infusion.", "entity1": "ritodrin-HCl", "entity2": "tremor", "span1": [120, 132], "span2": [50, 56]}, "bert_text": "After the end of fenoterol-hydrobromide infusion, tremor amplitudes decreased significantly faster than those following <e1> ritodrin-HCl </e1> <e2> tremor </e2> amplitudes decreased significantly faster than those following ritodrin-HCl infusion.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"148": {"data": {"text": "OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders.", "entity1": "olanzapine", "entity2": "schizophrenia spectrum disorders", "span1": [63, 73], "span2": [124, 156]}, "bert_text": "OBJECTIVE: The authors compared 4-month treatment outcomes for <e1> olanzapine </e1> versus risperidone in patients with first-episode <e2> schizophrenia spectrum disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"149": {"data": {"text": "OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders.", "entity1": "risperidone", "entity2": "schizophrenia spectrum disorders", "span1": [81, 92], "span2": [124, 156]}, "bert_text": "OBJECTIVE: The authors compared 4-month treatment outcomes for olanzapine versus <e1> risperidone </e1> in patients with first-episode <e2> schizophrenia spectrum disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"150": {"data": {"text": "OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).", "entity1": "AMI", "entity2": "myocardial infarction", "span1": [53, 56], "span2": [30, 51]}, "bert_text": "OBJECTIVES: The risk of acute myocardial infarction (<e1> AMI </e1> <e2> myocardial infarction </e2> (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"151": {"data": {"text": "OBJECTIVES: The risk of acute myocardial infarction (AMI) with COX-2 inhibitors may offset their gastrointestinal (GI) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).", "entity1": "AMI", "entity2": "GI", "span1": [53, 56], "span2": [115, 117]}, "bert_text": "OBJECTIVES: The risk of acute myocardial infarction (<e1> AMI </e1>) with COX-2 inhibitors may offset their gastrointestinal (<e2> GI </e2>) benefit compared with non-selective (NS) non-steroidal anti-inflammatory drugs (NSAIDs).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"152": {"data": {"text": "We evaluated the association of alcohol consumption and depression, and their effects on HIV disease progression among women with HIV.", "entity1": "alcohol", "entity2": "depression", "span1": [32, 39], "span2": [56, 66]}, "bert_text": "We evaluated the association of <e1> alcohol </e1> consumption and <e2> depression </e2>, and their effects on HIV disease progression among women with HIV.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"153": {"data": {"text": "We evaluated the association of alcohol consumption and depression, and their effects on HIV disease progression among women with HIV.", "entity1": "alcohol", "entity2": "HIV disease", "span1": [32, 39], "span2": [89, 100]}, "bert_text": "We evaluated the association of <e1> alcohol </e1> consumption and depression, and their effects on <e2> HIV disease </e2> progression among women with HIV.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"154": {"data": {"text": "We evaluated the association of alcohol consumption and depression, and their effects on HIV disease progression among women with HIV.", "entity1": "alcohol", "entity2": "HIV", "span1": [32, 39], "span2": [130, 133]}, "bert_text": "We evaluated the association of <e1> alcohol </e1> consumption and depression, and their effects on HIV disease progression among women with <e2> HIV </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"155": {"data": {"text": "We report mefenamic acid-induced non-oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females.", "entity1": "mefenamic acid", "entity2": "non-oliguric renal failure", "span1": [10, 24], "span2": [33, 59]}, "bert_text": "We report <e1> mefenamic acid </e1>-induced <e2> non-oliguric renal failure </e2> and severe neutropenia occurring simultaneously in two elderly females.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"156": {"data": {"text": "We report mefenamic acid-induced non-oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females.", "entity1": "mefenamic acid", "entity2": "neutropenia", "span1": [10, 24], "span2": [71, 82]}, "bert_text": "We report <e1> mefenamic acid </e1>-induced non-oliguric renal failure and severe <e2> neutropenia </e2> occurring simultaneously in two elderly females.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"157": {"data": {"text": "The binding sites from seizure sensitive and resistant mice were equally affected by treatment with dithiothreitol, trypsin or heat.", "entity1": "dithiothreitol", "entity2": "seizure", "span1": [100, 114], "span2": [23, 30]}, "bert_text": "The binding sites from seizure sensitive and resistant mice were equally affected by treatment with <e1> dithiothreitol </e1> <e2> seizure </e2> sensitive and resistant mice were equally affected by treatment with dithiothreitol, trypsin or heat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"158": {"data": {"text": "The binding sites from seizure sensitive and resistant mice were equally affected by treatment with dithiothreitol, trypsin or heat.", "entity1": "trypsin", "entity2": "seizure", "span1": [116, 123], "span2": [23, 30]}, "bert_text": "The binding sites from seizure sensitive and resistant mice were equally affected by treatment with dithiothreitol, <e1> trypsin </e1> <e2> seizure </e2> sensitive and resistant mice were equally affected by treatment with dithiothreitol, trypsin or heat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"159": {"data": {"text": "A case of oral penicillin anaphylaxis is described, and the terminology, occurrence, clinical manifestations, pathogenesis, prevention, and treatment of anaphylaxis are reviewed.", "entity1": "penicillin", "entity2": "anaphylaxis", "span1": [15, 25], "span2": [26, 37]}, "bert_text": "A case of oral <e1> penicillin </e1> <e2> anaphylaxis </e2> is described, and the terminology, occurrence, clinical manifestations, pathogenesis, prevention, and treatment of anaphylaxis are reviewed.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"160": {"data": {"text": "A case of oral penicillin anaphylaxis is described, and the terminology, occurrence, clinical manifestations, pathogenesis, prevention, and treatment of anaphylaxis are reviewed.", "entity1": "penicillin", "entity2": "anaphylaxis", "span1": [15, 25], "span2": [153, 164]}, "bert_text": "A case of oral <e1> penicillin </e1> anaphylaxis is described, and the terminology, occurrence, clinical manifestations, pathogenesis, prevention, and treatment of <e2> anaphylaxis </e2> are reviewed.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"161": {"data": {"text": "Animals became somnolent after diazepam and then active after flumazenil administration.", "entity1": "diazepam", "entity2": "somnolent", "span1": [31, 39], "span2": [15, 24]}, "bert_text": "Animals became somnolent after <e1> diazepam </e1> <e2> somnolent </e2> after diazepam and then active after flumazenil administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"162": {"data": {"text": "Animals became somnolent after diazepam and then active after flumazenil administration.", "entity1": "flumazenil", "entity2": "somnolent", "span1": [62, 72], "span2": [15, 24]}, "bert_text": "Animals became somnolent after diazepam and then active after <e1> flumazenil </e1> <e2> somnolent </e2> after diazepam and then active after flumazenil administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"163": {"data": {"text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [17, 28], "span2": [29, 42]}, "bert_text": "The reduction of <e1> amphetamine </e1> <e2> hyperactivity </e2> induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"164": {"data": {"text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "entity1": "amphetamine", "entity2": "neurotoxic", "span1": [17, 28], "span2": [165, 175]}, "bert_text": "The reduction of <e1> amphetamine </e1> hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the <e2> neurotoxic </e2> action of DSP4.", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"165": {"data": {"text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "entity1": "DSP4", "entity2": "hyperactivity", "span1": [54, 58], "span2": [29, 42]}, "bert_text": "The reduction of amphetamine hyperactivity induced by <e1> DSP4 </e1> <e2> hyperactivity </e2> induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"166": {"data": {"text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "entity1": "DSP4", "entity2": "neurotoxic", "span1": [54, 58], "span2": [165, 175]}, "bert_text": "The reduction of amphetamine hyperactivity induced by <e1> DSP4 </e1> was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the <e2> neurotoxic </e2> action of DSP4.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"167": {"data": {"text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "entity1": "DSP4", "entity2": "hyperactivity", "span1": [186, 190], "span2": [29, 42]}, "bert_text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of <e1> DSP4 </e1> <e2> hyperactivity </e2> induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"168": {"data": {"text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "entity1": "DSP4", "entity2": "neurotoxic", "span1": [186, 190], "span2": [165, 175]}, "bert_text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of <e1> DSP4 </e1> <e2> neurotoxic </e2> action of DSP4.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"169": {"data": {"text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "entity1": "noradrenaline", "entity2": "hyperactivity", "span1": [96, 109], "span2": [29, 42]}, "bert_text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the <e1> noradrenaline </e1> <e2> hyperactivity </e2> induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"170": {"data": {"text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "entity1": "noradrenaline", "entity2": "neurotoxic", "span1": [96, 109], "span2": [165, 175]}, "bert_text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the <e1> noradrenaline </e1>-uptake blocking agent, desipramine, which prevents the <e2> neurotoxic </e2> action of DSP4.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"171": {"data": {"text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "entity1": "desipramine", "entity2": "hyperactivity", "span1": [133, 144], "span2": [29, 42]}, "bert_text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, <e1> desipramine </e1> <e2> hyperactivity </e2> induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"172": {"data": {"text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, desipramine, which prevents the neurotoxic action of DSP4.", "entity1": "desipramine", "entity2": "neurotoxic", "span1": [133, 144], "span2": [165, 175]}, "bert_text": "The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline-uptake blocking agent, <e1> desipramine </e1>, which prevents the <e2> neurotoxic </e2> action of DSP4.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"173": {"data": {"text": "Alfentanil 50 micrograms kg-1 effectively inhibits the incidence and intensity of suxamethonium-induced muscle fasciculations; moreover, intragastric pressure remains at its control value.", "entity1": "Alfentanil", "entity2": "muscle fasciculations", "span1": [0, 10], "span2": [104, 125]}, "bert_text": "<e1> Alfentanil </e1> 50 micrograms kg-1 effectively inhibits the incidence and intensity of suxamethonium-induced <e2> muscle fasciculations </e2>; moreover, intragastric pressure remains at its control value.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"174": {"data": {"text": "Alfentanil 50 micrograms kg-1 effectively inhibits the incidence and intensity of suxamethonium-induced muscle fasciculations; moreover, intragastric pressure remains at its control value.", "entity1": "suxamethonium", "entity2": "muscle fasciculations", "span1": [82, 95], "span2": [104, 125]}, "bert_text": "Alfentanil 50 micrograms kg-1 effectively inhibits the incidence and intensity of <e1> suxamethonium </e1>-induced <e2> muscle fasciculations </e2>; moreover, intragastric pressure remains at its control value.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"175": {"data": {"text": "Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).", "entity1": "glycopyrrolate", "entity2": "dry mouth", "span1": [80, 94], "span2": [34, 43]}, "bert_text": "Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% <e1> glycopyrrolate </e1> <e2> dry mouth </e2> and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"176": {"data": {"text": "Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).", "entity1": "glycopyrrolate", "entity2": "headache", "span1": [80, 94], "span2": [105, 113]}, "bert_text": "Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% <e1> glycopyrrolate </e1>), a light <e2> headache </e2> in 1 patient (1.5% glycopyrrolate).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"177": {"data": {"text": "Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).", "entity1": "glycopyrrolate", "entity2": "dry mouth", "span1": [133, 147], "span2": [34, 43]}, "bert_text": "Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% <e1> glycopyrrolate </e1> <e2> dry mouth </e2> and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"178": {"data": {"text": "Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% glycopyrrolate).", "entity1": "glycopyrrolate", "entity2": "headache", "span1": [133, 147], "span2": [105, 113]}, "bert_text": "Adverse effects included a mildly dry mouth and a sore throat in 2 patients (2% glycopyrrolate), a light headache in 1 patient (1.5% <e1> glycopyrrolate </e1> <e2> headache </e2> in 1 patient (1.5% glycopyrrolate).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"179": {"data": {"text": "CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine, at least in Chinese patients with schizophrenia.", "entity1": "chlorpromazine", "entity2": "schizophrenia", "span1": [182, 196], "span2": [232, 245]}, "bert_text": "CONCLUSION: Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by <e1> chlorpromazine </e1>, at least in Chinese patients with <e2> schizophrenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"180": {"data": {"text": "Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.", "entity1": "Codeine", "entity2": "catalepsy", "span1": [0, 7], "span2": [8, 17]}, "bert_text": "<e1> Codeine </e1> <e2> catalepsy </e2> was increased by clonidine and decreased by naphazoline and xylometazoline.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"181": {"data": {"text": "Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.", "entity1": "clonidine", "entity2": "catalepsy", "span1": [35, 44], "span2": [8, 17]}, "bert_text": "Codeine catalepsy was increased by <e1> clonidine </e1> <e2> catalepsy </e2> was increased by clonidine and decreased by naphazoline and xylometazoline.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"182": {"data": {"text": "Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.", "entity1": "naphazoline", "entity2": "catalepsy", "span1": [62, 73], "span2": [8, 17]}, "bert_text": "Codeine catalepsy was increased by clonidine and decreased by <e1> naphazoline </e1> <e2> catalepsy </e2> was increased by clonidine and decreased by naphazoline and xylometazoline.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"183": {"data": {"text": "Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline.", "entity1": "xylometazoline", "entity2": "catalepsy", "span1": [78, 92], "span2": [8, 17]}, "bert_text": "Codeine catalepsy was increased by clonidine and decreased by naphazoline and <e1> xylometazoline </e1> <e2> catalepsy </e2> was increased by clonidine and decreased by naphazoline and xylometazoline.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"184": {"data": {"text": "Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: a placebo-controlled, double-blind crossover study.\n", "entity1": "methoxamine", "entity2": "stress incontinence", "span1": [10, 21], "span2": [73, 92]}, "bert_text": "Effect of <e1> methoxamine </e1> on maximum urethral pressure in women with genuine <e2> stress incontinence </e2>: a placebo-controlled, double-blind crossover study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"185": {"data": {"text": "The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02). CONCLUSION: In this study early postoperative delirium was found to be a very common complication after major surgery, even in a population without known risk factors.", "entity1": "thiopentone", "entity2": "delirium", "span1": [11, 22], "span2": [87, 95]}, "bert_text": "The use of <e1> thiopentone </e1> was significantly associated with an eight-fold-higher risk for <e2> delirium </e2> compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02). CONCLUSION: In this study early postoperative delirium was found to be a very common complication after major surgery, even in a population without known risk factors.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"186": {"data": {"text": "The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02). CONCLUSION: In this study early postoperative delirium was found to be a very common complication after major surgery, even in a population without known risk factors.", "entity1": "thiopentone", "entity2": "postoperative delirium", "span1": [11, 22], "span2": [214, 236]}, "bert_text": "The use of <e1> thiopentone </e1> was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02). CONCLUSION: In this study early <e2> postoperative delirium </e2> was found to be a very common complication after major surgery, even in a population without known risk factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"187": {"data": {"text": "The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02). CONCLUSION: In this study early postoperative delirium was found to be a very common complication after major surgery, even in a population without known risk factors.", "entity1": "propofol", "entity2": "delirium", "span1": [108, 116], "span2": [87, 95]}, "bert_text": "The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to <e1> propofol </e1> <e2> delirium </e2> compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02). CONCLUSION: In this study early postoperative delirium was found to be a very common complication after major surgery, even in a population without known risk factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"188": {"data": {"text": "The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to propofol (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02). CONCLUSION: In this study early postoperative delirium was found to be a very common complication after major surgery, even in a population without known risk factors.", "entity1": "propofol", "entity2": "postoperative delirium", "span1": [108, 116], "span2": [214, 236]}, "bert_text": "The use of thiopentone was significantly associated with an eight-fold-higher risk for delirium compared to <e1> propofol </e1> (57.1% vs. 7.1%, RR = 8.0, X2 = 4.256; df = 1; 0.05 < p < 0.02). CONCLUSION: In this study early <e2> postoperative delirium </e2> was found to be a very common complication after major surgery, even in a population without known risk factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"189": {"data": {"text": "This is inconsistent with the well-established finding that nifedipine induces tachycardia in normally innervated hearts.", "entity1": "nifedipine", "entity2": "tachycardia", "span1": [60, 70], "span2": [79, 90]}, "bert_text": "This is inconsistent with the well-established finding that <e1> nifedipine </e1> induces <e2> tachycardia </e2> in normally innervated hearts.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"190": {"data": {"text": "Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa.\n", "entity1": "Minocycline", "entity2": "vasculitis", "span1": [0, 11], "span2": [20, 30]}, "bert_text": "<e1> Minocycline </e1>-induced <e2> vasculitis </e2> fulfilling the criteria of polyarteritis nodosa.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"191": {"data": {"text": "Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa.\n", "entity1": "Minocycline", "entity2": "polyarteritis nodosa", "span1": [0, 11], "span2": [58, 78]}, "bert_text": "<e1> Minocycline </e1>-induced vasculitis fulfilling the criteria of <e2> polyarteritis nodosa </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"192": {"data": {"text": "Nephrosis was induced by injection of PAN (15mg/100g body weight) in male Sprague-Dawley (SD) rats.", "entity1": "PAN", "entity2": "Nephrosis", "span1": [38, 41], "span2": [0, 9]}, "bert_text": "Nephrosis was induced by injection of <e1> PAN </e1> <e2> Nephrosis </e2> was induced by injection of PAN (15mg/100g body weight) in male Sprague-Dawley (SD) rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"193": {"data": {"text": "Testosterone ameliorates streptozotocin-induced memory impairment in male rats.\n", "entity1": "Testosterone", "entity2": "memory impairment", "span1": [0, 12], "span2": [48, 65]}, "bert_text": "<e1> Testosterone </e1> ameliorates streptozotocin-induced <e2> memory impairment </e2> in male rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"194": {"data": {"text": "Testosterone ameliorates streptozotocin-induced memory impairment in male rats.\n", "entity1": "streptozotocin", "entity2": "memory impairment", "span1": [25, 39], "span2": [48, 65]}, "bert_text": "Testosterone ameliorates <e1> streptozotocin </e1>-induced <e2> memory impairment </e2> in male rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"195": {"data": {"text": "The authors report on six cases of famotidine-associated delirium in hospitalized patients who cleared completely upon removal of famotidine.", "entity1": "famotidine", "entity2": "delirium", "span1": [35, 45], "span2": [57, 65]}, "bert_text": "The authors report on six cases of <e1> famotidine </e1>-associated <e2> delirium </e2> in hospitalized patients who cleared completely upon removal of famotidine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"196": {"data": {"text": "The authors report on six cases of famotidine-associated delirium in hospitalized patients who cleared completely upon removal of famotidine.", "entity1": "famotidine", "entity2": "delirium", "span1": [130, 140], "span2": [57, 65]}, "bert_text": "The authors report on six cases of famotidine-associated delirium in hospitalized patients who cleared completely upon removal of <e1> famotidine </e1> <e2> delirium </e2> in hospitalized patients who cleared completely upon removal of famotidine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"197": {"data": {"text": "The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity.", "entity1": "PTRA", "entity2": "toxicity", "span1": [21, 25], "span2": [80, 88]}, "bert_text": "The effectiveness of <e1> PTRA </e1> on renal function seems to be barely influenced by CM <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"198": {"data": {"text": "The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity.", "entity1": "CM", "entity2": "toxicity", "span1": [77, 79], "span2": [80, 88]}, "bert_text": "The effectiveness of PTRA on renal function seems to be barely influenced by <e1> CM </e1> <e2> toxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"199": {"data": {"text": "These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.", "entity1": "glibenclamide", "entity2": "hypotension", "span1": [104, 117], "span2": [48, 59]}, "bert_text": "These findings suggest that helodermin-produced hypotension is partly attributable to the activation of <e1> glibenclamide </e1> <e2> hypotension </e2> is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"200": {"data": {"text": "These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.", "entity1": "K+", "entity2": "hypotension", "span1": [128, 130], "span2": [48, 59]}, "bert_text": "These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive <e1> K+ </e1> <e2> hypotension </e2> is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"201": {"data": {"text": "These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.", "entity1": "K(ATP", "entity2": "hypotension", "span1": [141, 146], "span2": [48, 59]}, "bert_text": "These findings suggest that helodermin-produced hypotension is partly attributable to the activation of glibenclamide-sensitive K+ channels (<e1> K(ATP </e1> <e2> hypotension </e2> is partly attributable to the activation of glibenclamide-sensitive K+ channels (K(ATP) channels), which presumably exist on arterial smooth muscle cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"202": {"data": {"text": "We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [44, 52], "span2": [61, 71]}, "bert_text": "We studied the prevalence and predictors of <e1> levodopa </e1>-induced <e2> dyskinesia </e2> among multiethnic Malaysian patients with PD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"203": {"data": {"text": "We studied the prevalence and predictors of levodopa-induced dyskinesia among multiethnic Malaysian patients with PD.", "entity1": "levodopa", "entity2": "PD", "span1": [44, 52], "span2": [114, 116]}, "bert_text": "We studied the prevalence and predictors of <e1> levodopa </e1>-induced dyskinesia among multiethnic Malaysian patients with <e2> PD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"204": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "angiotensin II", "entity2": "renal disease", "span1": [84, 98], "span2": [168, 181]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of <e1> angiotensin II </e1> type-1 receptor blocker, losartan, and its potential in slowing down <e2> renal disease </e2> progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"205": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "angiotensin II", "entity2": "nephropathy", "span1": [84, 98], "span2": [257, 268]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of <e1> angiotensin II </e1> type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"206": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "angiotensin II", "entity2": "hypertensive", "span1": [84, 98], "span2": [211, 223]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of <e1> angiotensin II </e1> type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously <e2> hypertensive </e2> rats (SHR) with adriamycin (ADR) nephropathy.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"207": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "losartan", "entity2": "renal disease", "span1": [124, 132], "span2": [168, 181]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, <e1> losartan </e1>, and its potential in slowing down <e2> renal disease </e2> progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"208": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "losartan", "entity2": "nephropathy", "span1": [124, 132], "span2": [257, 268]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, <e1> losartan </e1>, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"209": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "losartan", "entity2": "hypertensive", "span1": [124, 132], "span2": [211, 223]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, <e1> losartan </e1>, and its potential in slowing down renal disease progression in spontaneously <e2> hypertensive </e2> rats (SHR) with adriamycin (ADR) nephropathy.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"210": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "adriamycin", "entity2": "renal disease", "span1": [240, 250], "span2": [168, 181]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with <e1> adriamycin </e1> <e2> renal disease </e2> progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"211": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "adriamycin", "entity2": "nephropathy", "span1": [240, 250], "span2": [257, 268]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with <e1> adriamycin </e1> (ADR) <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"212": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "adriamycin", "entity2": "hypertensive", "span1": [240, 250], "span2": [211, 223]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with <e1> adriamycin </e1> <e2> hypertensive </e2> rats (SHR) with adriamycin (ADR) nephropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"213": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "ADR", "entity2": "renal disease", "span1": [252, 255], "span2": [168, 181]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (<e1> ADR </e1> <e2> renal disease </e2> progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"214": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "ADR", "entity2": "nephropathy", "span1": [252, 255], "span2": [257, 268]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (<e1> ADR </e1>) <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"215": {"data": {"text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy.", "entity1": "ADR", "entity2": "hypertensive", "span1": [252, 255], "span2": [211, 223]}, "bert_text": "BACKGROUND: The aim of the study was to investigate the antihypertensive effects of angiotensin II type-1 receptor blocker, losartan, and its potential in slowing down renal disease progression in spontaneously hypertensive rats (SHR) with adriamycin (<e1> ADR </e1> <e2> hypertensive </e2> rats (SHR) with adriamycin (ADR) nephropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"216": {"data": {"text": "However, it is currently unknown if the acute toxic dosage of METH also causes a long-lasting depressive phenotype and persistent monoaminergic deficits.", "entity1": "METH", "entity2": "depressive", "span1": [62, 66], "span2": [94, 104]}, "bert_text": "However, it is currently unknown if the acute toxic dosage of <e1> METH </e1> also causes a long-lasting <e2> depressive </e2> phenotype and persistent monoaminergic deficits.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"217": {"data": {"text": "CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.", "entity1": "methadone", "entity2": "rhabdomyolysis", "span1": [24, 33], "span2": [81, 95]}, "bert_text": "CONCLUSION: Those using <e1> methadone </e1> and heroin simultaneously may increase risk of <e2> rhabdomyolysis </e2> and ischemic stroke.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"218": {"data": {"text": "CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.", "entity1": "methadone", "entity2": "ischemic stroke", "span1": [24, 33], "span2": [100, 115]}, "bert_text": "CONCLUSION: Those using <e1> methadone </e1> and heroin simultaneously may increase risk of rhabdomyolysis and <e2> ischemic stroke </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"219": {"data": {"text": "CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.", "entity1": "heroin", "entity2": "rhabdomyolysis", "span1": [38, 44], "span2": [81, 95]}, "bert_text": "CONCLUSION: Those using methadone and <e1> heroin </e1> simultaneously may increase risk of <e2> rhabdomyolysis </e2> and ischemic stroke.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"220": {"data": {"text": "CONCLUSION: Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke.", "entity1": "heroin", "entity2": "ischemic stroke", "span1": [38, 44], "span2": [100, 115]}, "bert_text": "CONCLUSION: Those using methadone and <e1> heroin </e1> simultaneously may increase risk of rhabdomyolysis and <e2> ischemic stroke </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"221": {"data": {"text": "The baby showed warfarin-induced embryopathy with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata).", "entity1": "warfarin", "entity2": "embryopathy", "span1": [16, 24], "span2": [33, 44]}, "bert_text": "The baby showed <e1> warfarin </e1>-induced <e2> embryopathy </e2> with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"222": {"data": {"text": "The baby showed warfarin-induced embryopathy with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata).", "entity1": "warfarin", "entity2": "nasal hypoplasia", "span1": [16, 24], "span2": [50, 66]}, "bert_text": "The baby showed <e1> warfarin </e1>-induced embryopathy with <e2> nasal hypoplasia </e2> and stippled epiphyses (chondrodysplasia punctata).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"223": {"data": {"text": "The baby showed warfarin-induced embryopathy with nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata).", "entity1": "warfarin", "entity2": "chondrodysplasia punctata", "span1": [16, 24], "span2": [91, 116]}, "bert_text": "The baby showed <e1> warfarin </e1>-induced embryopathy with nasal hypoplasia and stippled epiphyses (<e2> chondrodysplasia punctata </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"224": {"data": {"text": "DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.", "entity1": "indinavir", "entity2": "nephrotoxicity", "span1": [39, 48], "span2": [57, 71]}, "bert_text": "DESIGN: A prospective study to monitor <e1> indinavir </e1>-related <e2> nephrotoxicity </e2> in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"225": {"data": {"text": "DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.", "entity1": "indinavir", "entity2": "human immunodeficiency", "span1": [39, 48], "span2": [90, 112]}, "bert_text": "DESIGN: A prospective study to monitor <e1> indinavir </e1>-related nephrotoxicity in a cohort of 30 <e2> human immunodeficiency </e2> virus type 1-infected children treated with indinavir.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"226": {"data": {"text": "DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.", "entity1": "indinavir", "entity2": "nephrotoxicity", "span1": [157, 166], "span2": [57, 71]}, "bert_text": "DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with <e1> indinavir </e1> <e2> nephrotoxicity </e2> in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"227": {"data": {"text": "DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.", "entity1": "indinavir", "entity2": "human immunodeficiency", "span1": [157, 166], "span2": [90, 112]}, "bert_text": "DESIGN: A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with <e1> indinavir </e1> <e2> human immunodeficiency </e2> virus type 1-infected children treated with indinavir.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"228": {"data": {"text": "Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats.\n", "entity1": "betaine", "entity2": "myocardial injury", "span1": [91, 98], "span2": [138, 155]}, "bert_text": "Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by <e1> betaine </e1> attenuates isoproterenol-induced acute <e2> myocardial injury </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"229": {"data": {"text": "Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats.\n", "entity1": "isoproterenol", "entity2": "myocardial injury", "span1": [110, 123], "span2": [138, 155]}, "bert_text": "Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates <e1> isoproterenol </e1>-induced acute <e2> myocardial injury </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"230": {"data": {"text": "One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.", "entity1": "halothane", "entity2": "myocardial infarction", "span1": [65, 74], "span2": [27, 48]}, "bert_text": "One day after experimental myocardial infarction, six additional <e1> halothane </e1> <e2> myocardial infarction </e2>, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"231": {"data": {"text": "One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.", "entity1": "halothane", "entity2": "VT", "span1": [65, 74], "span2": [144, 146]}, "bert_text": "One day after experimental myocardial infarction, six additional <e1> halothane </e1>-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until <e2> VT </e2> appeared.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"232": {"data": {"text": "One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.", "entity1": "epinephrine", "entity2": "myocardial infarction", "span1": [126, 137], "span2": [27, 48]}, "bert_text": "One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 <e1> epinephrine </e1> <e2> myocardial infarction </e2>, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"233": {"data": {"text": "One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 epinephrine until VT appeared.", "entity1": "epinephrine", "entity2": "VT", "span1": [126, 137], "span2": [144, 146]}, "bert_text": "One day after experimental myocardial infarction, six additional halothane-anesthetized dogs received 4 micrograms.kg-1.min-1 <e1> epinephrine </e1> until <e2> VT </e2> appeared.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"234": {"data": {"text": "Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.\n", "entity1": "chlorpromazine", "entity2": "extrapyramidal syndrome", "span1": [38, 52], "span2": [61, 84]}, "bert_text": "Association of DRD2 polymorphisms and <e1> chlorpromazine </e1>-induced <e2> extrapyramidal syndrome </e2> in Chinese schizophrenic patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"235": {"data": {"text": "Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients.\n", "entity1": "chlorpromazine", "entity2": "schizophrenic", "span1": [38, 52], "span2": [96, 109]}, "bert_text": "Association of DRD2 polymorphisms and <e1> chlorpromazine </e1>-induced extrapyramidal syndrome in Chinese <e2> schizophrenic </e2> patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"236": {"data": {"text": "For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.", "entity1": "levodopa", "entity2": "RLS", "span1": [65, 73], "span2": [29, 32]}, "bert_text": "For example, the symptoms of RLS can be dramatically improved by <e1> levodopa </e1> <e2> RLS </e2> can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"237": {"data": {"text": "For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.", "entity1": "levodopa", "entity2": "RLS", "span1": [65, 73], "span2": [170, 173]}, "bert_text": "For example, the symptoms of RLS can be dramatically improved by <e1> levodopa </e1> and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate <e2> RLS </e2> symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"238": {"data": {"text": "For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.", "entity1": "dopamine", "entity2": "RLS", "span1": [78, 86], "span2": [29, 32]}, "bert_text": "For example, the symptoms of RLS can be dramatically improved by levodopa and <e1> dopamine </e1> <e2> RLS </e2> can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"239": {"data": {"text": "For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.", "entity1": "dopamine", "entity2": "RLS", "span1": [78, 86], "span2": [170, 173]}, "bert_text": "For example, the symptoms of RLS can be dramatically improved by levodopa and <e1> dopamine </e1> agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate <e2> RLS </e2> symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"240": {"data": {"text": "For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.", "entity1": "dopamine", "entity2": "RLS", "span1": [113, 121], "span2": [29, 32]}, "bert_text": "For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central <e1> dopamine </e1> <e2> RLS </e2> can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"241": {"data": {"text": "For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms.", "entity1": "dopamine", "entity2": "RLS", "span1": [113, 121], "span2": [170, 173]}, "bert_text": "For example, the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists, whereas central <e1> dopamine </e1> D2 receptor antagonists can induce or aggravate <e2> RLS </e2> symptoms.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"242": {"data": {"text": "Patients who did not receive mannitol were more likely to develop nephrotoxicity: odds ratio [OR] = 2.646 (95% CI = 1.008, 6.944; P = 0.048).", "entity1": "mannitol", "entity2": "nephrotoxicity", "span1": [29, 37], "span2": [66, 80]}, "bert_text": "Patients who did not receive <e1> mannitol </e1> were more likely to develop <e2> nephrotoxicity </e2>: odds ratio [OR] = 2.646 (95% CI = 1.008, 6.944; P = 0.048).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"243": {"data": {"text": "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.\n", "entity1": "adriamycin", "entity2": "nephropathy", "span1": [23, 33], "span2": [34, 45]}, "bert_text": "Reduced progression of <e1> adriamycin </e1> <e2> nephropathy </e2> in spontaneously hypertensive rats treated by losartan.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"244": {"data": {"text": "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.\n", "entity1": "adriamycin", "entity2": "hypertensive", "span1": [23, 33], "span2": [63, 75]}, "bert_text": "Reduced progression of <e1> adriamycin </e1> nephropathy in spontaneously <e2> hypertensive </e2> rats treated by losartan.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"245": {"data": {"text": "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.\n", "entity1": "losartan", "entity2": "nephropathy", "span1": [92, 100], "span2": [34, 45]}, "bert_text": "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by <e1> losartan </e1> <e2> nephropathy </e2> in spontaneously hypertensive rats treated by losartan.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"246": {"data": {"text": "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan.\n", "entity1": "losartan", "entity2": "hypertensive", "span1": [92, 100], "span2": [63, 75]}, "bert_text": "Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by <e1> losartan </e1> <e2> hypertensive </e2> rats treated by losartan.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"247": {"data": {"text": "We presented a patient admitted to our out-patient clinic with diffuse skeletal pain after three consecutive administration of alendronate.", "entity1": "alendronate", "entity2": "skeletal pain", "span1": [127, 138], "span2": [71, 84]}, "bert_text": "We presented a patient admitted to our out-patient clinic with diffuse skeletal pain after three consecutive administration of <e1> alendronate </e1> <e2> skeletal pain </e2> after three consecutive administration of alendronate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"248": {"data": {"text": "Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients.", "entity1": "cyclosporine", "entity2": "infections", "span1": [50, 62], "span2": [34, 44]}, "bert_text": "Heart and liver patients had more infections than <e1> cyclosporine </e1> <e2> infections </e2> than cyclosporine renal patients but fewer infections than the Aza renal patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"249": {"data": {"text": "Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients.", "entity1": "cyclosporine", "entity2": "infections", "span1": [50, 62], "span2": [88, 98]}, "bert_text": "Heart and liver patients had more infections than <e1> cyclosporine </e1> renal patients but fewer <e2> infections </e2> than the Aza renal patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"250": {"data": {"text": "Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients.", "entity1": "Aza", "entity2": "infections", "span1": [108, 111], "span2": [34, 44]}, "bert_text": "Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the <e1> Aza </e1> <e2> infections </e2> than cyclosporine renal patients but fewer infections than the Aza renal patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"251": {"data": {"text": "Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients.", "entity1": "Aza", "entity2": "infections", "span1": [108, 111], "span2": [88, 98]}, "bert_text": "Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the <e1> Aza </e1> <e2> infections </e2> than the Aza renal patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"252": {"data": {"text": "In isolated hearts, Iso induced a significantly greater increase in left ventricular (LV) pressure and maximal contraction (+dP/dt(max)) in the TGR than in the Sprague-Dawley (SD) rats.", "entity1": "Iso", "entity2": "LV", "span1": [20, 23], "span2": [86, 88]}, "bert_text": "In isolated hearts, <e1> Iso </e1> induced a significantly greater increase in left ventricular (<e2> LV </e2>) pressure and maximal contraction (+dP/dt(max)) in the TGR than in the Sprague-Dawley (SD) rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"253": {"data": {"text": "Other ECG parameters before the application of d,l-sotalol did not identify patients at increased risk for torsades de pointes.", "entity1": "l-sotalol", "entity2": "torsades de pointes", "span1": [49, 58], "span2": [107, 126]}, "bert_text": "Other ECG parameters before the application of d,<e1> l-sotalol </e1> did not identify patients at increased risk for <e2> torsades de pointes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"254": {"data": {"text": "Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "entity1": "ethacrynic acid", "entity2": "convulsive", "span1": [37, 52], "span2": [58, 68]}, "bert_text": "Intracerebroventricular injection of <e1> ethacrynic acid </e1> (50% <e2> convulsive </e2> dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"255": {"data": {"text": "Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "entity1": "5-hydroxytryptamine", "entity2": "convulsive", "span1": [134, 153], "span2": [58, 68]}, "bert_text": "Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of <e1> 5-hydroxytryptamine </e1> <e2> convulsive </e2> dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"256": {"data": {"text": "Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "entity1": "5-HT", "entity2": "convulsive", "span1": [155, 159], "span2": [58, 68]}, "bert_text": "Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (<e1> 5-HT </e1> <e2> convulsive </e2> dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"257": {"data": {"text": "Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "entity1": "gamma-aminobutyric acid", "entity2": "convulsive", "span1": [193, 216], "span2": [58, 68]}, "bert_text": "Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of <e1> gamma-aminobutyric acid </e1> <e2> convulsive </e2> dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"258": {"data": {"text": "Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "entity1": "acetylcholine", "entity2": "convulsive", "span1": [221, 234], "span2": [58, 68]}, "bert_text": "Intracerebroventricular injection of ethacrynic acid (50% convulsive dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and <e1> acetylcholine </e1> <e2> convulsive </e2> dose; 50 micrograms/mouse) accelerated the synthesis/turnover of 5-hydroxytryptamine (5-HT) but suppressed the synthesis of gamma-aminobutyric acid and acetylcholine in mouse brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"259": {"data": {"text": "Tubular proteinuria and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats.", "entity1": "maleate", "entity2": "proteinuria", "span1": [79, 86], "span2": [8, 19]}, "bert_text": "Tubular proteinuria and oxidative stress were induced by a single injection of <e1> maleate </e1> <e2> proteinuria </e2> and oxidative stress were induced by a single injection of maleate (400 mg/kg) in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"260": {"data": {"text": "Lateral antebrachial cutaneous neuropathy after steroid injection at lateral epicondyle.\n", "entity1": "steroid", "entity2": "cutaneous neuropathy", "span1": [48, 55], "span2": [21, 41]}, "bert_text": "Lateral antebrachial cutaneous neuropathy after <e1> steroid </e1> <e2> cutaneous neuropathy </e2> after steroid injection at lateral epicondyle.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"261": {"data": {"text": "BACKGROUND AND OBJECTIVES: This report aimed to present a case of lateral antebrachial cutaneous neuropathy (LACNP) that occurred after a steroid injection in the lateral epicondyle to treat lateral epicondylitis in a 40-year-old woman", "entity1": "steroid", "entity2": "cutaneous neuropathy", "span1": [138, 145], "span2": [87, 107]}, "bert_text": "BACKGROUND AND OBJECTIVES: This report aimed to present a case of lateral antebrachial cutaneous neuropathy (LACNP) that occurred after a <e1> steroid </e1> <e2> cutaneous neuropathy </e2> (LACNP) that occurred after a steroid injection in the lateral epicondyle to treat lateral epicondylitis in a 40-year-old woman", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"262": {"data": {"text": "BACKGROUND AND OBJECTIVES: This report aimed to present a case of lateral antebrachial cutaneous neuropathy (LACNP) that occurred after a steroid injection in the lateral epicondyle to treat lateral epicondylitis in a 40-year-old woman", "entity1": "steroid", "entity2": "lateral epicondylitis", "span1": [138, 145], "span2": [191, 212]}, "bert_text": "BACKGROUND AND OBJECTIVES: This report aimed to present a case of lateral antebrachial cutaneous neuropathy (LACNP) that occurred after a <e1> steroid </e1> injection in the lateral epicondyle to treat <e2> lateral epicondylitis </e2> in a 40-year-old woman", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"263": {"data": {"text": "Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.", "entity1": "5-fluorouracil", "entity2": "Cardiotoxicity", "span1": [55, 69], "span2": [0, 14]}, "bert_text": "Cardiotoxicity is a rare complication occurring during <e1> 5-fluorouracil </e1> <e2> Cardiotoxicity </e2> is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"264": {"data": {"text": "Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.", "entity1": "5-fluorouracil", "entity2": "malignancies", "span1": [55, 69], "span2": [91, 103]}, "bert_text": "Cardiotoxicity is a rare complication occurring during <e1> 5-fluorouracil </e1> (5-FU) treatment for <e2> malignancies </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"265": {"data": {"text": "Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.", "entity1": "5-FU", "entity2": "Cardiotoxicity", "span1": [71, 75], "span2": [0, 14]}, "bert_text": "Cardiotoxicity is a rare complication occurring during 5-fluorouracil (<e1> 5-FU </e1> <e2> Cardiotoxicity </e2> is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"266": {"data": {"text": "Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies.", "entity1": "5-FU", "entity2": "malignancies", "span1": [71, 75], "span2": [91, 103]}, "bert_text": "Cardiotoxicity is a rare complication occurring during 5-fluorouracil (<e1> 5-FU </e1>) treatment for <e2> malignancies </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"267": {"data": {"text": "Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane.\n", "entity1": "methoxyflurane", "entity2": "Hepatitis", "span1": [59, 73], "span2": [0, 9]}, "bert_text": "Hepatitis and renal tubular acidosis after anesthesia with <e1> methoxyflurane </e1> <e2> Hepatitis </e2> and renal tubular acidosis after anesthesia with methoxyflurane.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"268": {"data": {"text": "Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane.\n", "entity1": "methoxyflurane", "entity2": "renal tubular acidosis", "span1": [59, 73], "span2": [14, 36]}, "bert_text": "Hepatitis and renal tubular acidosis after anesthesia with <e1> methoxyflurane </e1> <e2> renal tubular acidosis </e2> after anesthesia with methoxyflurane.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"269": {"data": {"text": "A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).", "entity1": "minocycline", "entity2": "palmoplantar pustulosis", "span1": [38, 49], "span2": [54, 77]}, "bert_text": "A 47-year-old man who had been taking <e1> minocycline </e1> for <e2> palmoplantar pustulosis </e2> developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"270": {"data": {"text": "A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).", "entity1": "minocycline", "entity2": "fever", "span1": [38, 49], "span2": [88, 93]}, "bert_text": "A 47-year-old man who had been taking <e1> minocycline </e1> for palmoplantar pustulosis developed <e2> fever </e2>, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"271": {"data": {"text": "A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).", "entity1": "minocycline", "entity2": "myalgias", "span1": [38, 49], "span2": [95, 103]}, "bert_text": "A 47-year-old man who had been taking <e1> minocycline </e1> for palmoplantar pustulosis developed fever, <e2> myalgias </e2>, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"272": {"data": {"text": "A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).", "entity1": "minocycline", "entity2": "polyneuropathy", "span1": [38, 49], "span2": [105, 119]}, "bert_text": "A 47-year-old man who had been taking <e1> minocycline </e1> for palmoplantar pustulosis developed fever, myalgias, <e2> polyneuropathy </e2>, and testicular pain, with elevated C-reactive protein (CRP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"273": {"data": {"text": "A 47-year-old man who had been taking minocycline for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular pain, with elevated C-reactive protein (CRP).", "entity1": "minocycline", "entity2": "pain", "span1": [38, 49], "span2": [136, 140]}, "bert_text": "A 47-year-old man who had been taking <e1> minocycline </e1> for palmoplantar pustulosis developed fever, myalgias, polyneuropathy, and testicular <e2> pain </e2>, with elevated C-reactive protein (CRP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"274": {"data": {"text": "The topical application of a glycopyrrolate pad appeared to be safe, efficacious, well tolerated, and a convenient method of treatment for moderate to severe symptoms of gustatory hyperhidrosis in post transthoracic endoscopic sympathectomy or sympathicotomy patients, with few side effects.", "entity1": "glycopyrrolate", "entity2": "gustatory hyperhidrosis", "span1": [29, 43], "span2": [170, 193]}, "bert_text": "The topical application of a <e1> glycopyrrolate </e1> pad appeared to be safe, efficacious, well tolerated, and a convenient method of treatment for moderate to severe symptoms of <e2> gustatory hyperhidrosis </e2> in post transthoracic endoscopic sympathectomy or sympathicotomy patients, with few side effects.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"275": {"data": {"text": "It was hypothesized that progestins could equilibrate the effects of the estrogenic stimulation on the mammary and endometrial target tissues of women on hormonal replacement therapy.", "entity1": "progestins", "entity2": "endometrial", "span1": [25, 35], "span2": [115, 126]}, "bert_text": "It was hypothesized that <e1> progestins </e1> could equilibrate the effects of the estrogenic stimulation on the mammary and <e2> endometrial </e2> target tissues of women on hormonal replacement therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"276": {"data": {"text": "Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania.", "entity1": "FDA", "entity2": "mania", "span1": [22, 25], "span2": [127, 132]}, "bert_text": "Cases reported by the <e1> FDA </e1> showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of <e2> mania </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"277": {"data": {"text": "Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania.", "entity1": "clarithromycin", "entity2": "mania", "span1": [33, 47], "span2": [127, 132]}, "bert_text": "Cases reported by the FDA showed <e1> clarithromycin </e1> and ciprofloxacin to be the most frequently associated with the development of <e2> mania </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"278": {"data": {"text": "Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania.", "entity1": "ciprofloxacin", "entity2": "mania", "span1": [52, 65], "span2": [127, 132]}, "bert_text": "Cases reported by the FDA showed clarithromycin and <e1> ciprofloxacin </e1> to be the most frequently associated with the development of <e2> mania </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"279": {"data": {"text": "Acetaminophen (APAP) produces proximal tubular necrosis in Fischer 344 (F344) rats.", "entity1": "Acetaminophen", "entity2": "tubular necrosis", "span1": [0, 13], "span2": [39, 55]}, "bert_text": "<e1> Acetaminophen </e1> (APAP) produces proximal <e2> tubular necrosis </e2> in Fischer 344 (F344) rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"280": {"data": {"text": "Acetaminophen (APAP) produces proximal tubular necrosis in Fischer 344 (F344) rats.", "entity1": "APAP", "entity2": "tubular necrosis", "span1": [15, 19], "span2": [39, 55]}, "bert_text": "Acetaminophen (<e1> APAP </e1>) produces proximal <e2> tubular necrosis </e2> in Fischer 344 (F344) rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"281": {"data": {"text": "Citrate dialysate is a safe alternative for intradialytic support of liver transplantation in fulminant liver failure.", "entity1": "Citrate", "entity2": "fulminant liver failure", "span1": [0, 7], "span2": [94, 117]}, "bert_text": "<e1> Citrate </e1> dialysate is a safe alternative for intradialytic support of liver transplantation in <e2> fulminant liver failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"282": {"data": {"text": "These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.", "entity1": "lithium", "entity2": "status epilepticus", "span1": [126, 133], "span2": [83, 101]}, "bert_text": "These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the <e1> lithium </e1> <e2> status epilepticus </e2> and brain damage in the lithium-pilocarpine model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"283": {"data": {"text": "These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.", "entity1": "lithium", "entity2": "brain damage", "span1": [126, 133], "span2": [106, 118]}, "bert_text": "These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the <e1> lithium </e1> <e2> brain damage </e2> in the lithium-pilocarpine model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"284": {"data": {"text": "These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [134, 145], "span2": [83, 101]}, "bert_text": "These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-<e1> pilocarpine </e1> <e2> status epilepticus </e2> and brain damage in the lithium-pilocarpine model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"285": {"data": {"text": "These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-pilocarpine model.", "entity1": "pilocarpine", "entity2": "brain damage", "span1": [134, 145], "span2": [106, 118]}, "bert_text": "These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium-<e1> pilocarpine </e1> <e2> brain damage </e2> in the lithium-pilocarpine model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"286": {"data": {"text": "A total of 115 patients with a DSM-IV diagnosis of bipolar disorder, manic or mixed, were randomized to olanzapine, 5 to 20 mg/d (n = 55), or placebo (n = 60).", "entity1": "olanzapine", "entity2": "bipolar disorder", "span1": [104, 114], "span2": [51, 67]}, "bert_text": "A total of 115 patients with a DSM-IV diagnosis of bipolar disorder, manic or mixed, were randomized to <e1> olanzapine </e1> <e2> bipolar disorder </e2>, manic or mixed, were randomized to olanzapine, 5 to 20 mg/d (n = 55), or placebo (n = 60).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"287": {"data": {"text": "A total of 115 patients with a DSM-IV diagnosis of bipolar disorder, manic or mixed, were randomized to olanzapine, 5 to 20 mg/d (n = 55), or placebo (n = 60).", "entity1": "olanzapine", "entity2": "manic", "span1": [104, 114], "span2": [69, 74]}, "bert_text": "A total of 115 patients with a DSM-IV diagnosis of bipolar disorder, manic or mixed, were randomized to <e1> olanzapine </e1> <e2> manic </e2> or mixed, were randomized to olanzapine, 5 to 20 mg/d (n = 55), or placebo (n = 60).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"288": {"data": {"text": "Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.", "entity1": "cyclosporin A", "entity2": "nephropathy", "span1": [29, 42], "span2": [152, 163]}, "bert_text": "Protocols of conversion from <e1> cyclosporin A </e1> (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced <e2> nephropathy </e2>, but the molecular mechanisms underlying these protocols remain nuclear.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"289": {"data": {"text": "Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.", "entity1": "CsA", "entity2": "nephropathy", "span1": [44, 47], "span2": [152, 163]}, "bert_text": "Protocols of conversion from cyclosporin A (<e1> CsA </e1>) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced <e2> nephropathy </e2>, but the molecular mechanisms underlying these protocols remain nuclear.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"290": {"data": {"text": "Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.", "entity1": "CsA", "entity2": "nephropathy", "span1": [140, 143], "span2": [152, 163]}, "bert_text": "Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent <e1> CsA </e1>-induced <e2> nephropathy </e2>, but the molecular mechanisms underlying these protocols remain nuclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"291": {"data": {"text": "Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.", "entity1": "sirolimus", "entity2": "nephropathy", "span1": [52, 61], "span2": [152, 163]}, "bert_text": "Protocols of conversion from cyclosporin A (CsA) to <e1> sirolimus </e1> (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced <e2> nephropathy </e2>, but the molecular mechanisms underlying these protocols remain nuclear.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"292": {"data": {"text": "Protocols of conversion from cyclosporin A (CsA) to sirolimus (SRL) have been widely used in immunotherapy after transplantation to prevent CsA-induced nephropathy, but the molecular mechanisms underlying these protocols remain nuclear.", "entity1": "SRL", "entity2": "nephropathy", "span1": [63, 66], "span2": [152, 163]}, "bert_text": "Protocols of conversion from cyclosporin A (CsA) to sirolimus (<e1> SRL </e1>) have been widely used in immunotherapy after transplantation to prevent CsA-induced <e2> nephropathy </e2>, but the molecular mechanisms underlying these protocols remain nuclear.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"293": {"data": {"text": "Results from our behavioral phenotyping indicated that anxiety-like behavior was increased in mice exposed to BPA.", "entity1": "BPA", "entity2": "anxiety", "span1": [110, 113], "span2": [55, 62]}, "bert_text": "Results from our behavioral phenotyping indicated that anxiety-like behavior was increased in mice exposed to <e1> BPA </e1> <e2> anxiety </e2>-like behavior was increased in mice exposed to BPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"294": {"data": {"text": "After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.", "entity1": "quinine", "entity2": "premature ventricular contraction", "span1": [18, 25], "span2": [111, 144]}, "bert_text": "After 30 hours of <e1> quinine </e1> infusion the patient felt palpitation and electrocardiography (ECG) recording showed <e2> premature ventricular contraction </e2> (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"295": {"data": {"text": "After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.", "entity1": "quinine", "entity2": "PVC", "span1": [18, 25], "span2": [146, 149]}, "bert_text": "After 30 hours of <e1> quinine </e1> infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (<e2> PVC </e2>) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"296": {"data": {"text": "After 30 hours of quinine infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--sinoatrial block, positive U wave.", "entity1": "quinine", "entity2": "sinoatrial block", "span1": [18, 25], "span2": [191, 207]}, "bert_text": "After 30 hours of <e1> quinine </e1> infusion the patient felt palpitation and electrocardiography (ECG) recording showed premature ventricular contraction (PVC) > 5 x/minute, trigemini, constant type--<e2> sinoatrial block </e2>, positive U wave.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"297": {"data": {"text": "The glomerulopathy was induced by seven serial injections of PAN over 12 wk.", "entity1": "PAN", "entity2": "glomerulopathy", "span1": [61, 64], "span2": [4, 18]}, "bert_text": "The glomerulopathy was induced by seven serial injections of <e1> PAN </e1> <e2> glomerulopathy </e2> was induced by seven serial injections of PAN over 12 wk.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"298": {"data": {"text": "Prevalence of heart disease in asymptomatic chronic cocaine users.\n", "entity1": "cocaine", "entity2": "heart disease", "span1": [52, 59], "span2": [14, 27]}, "bert_text": "Prevalence of heart disease in asymptomatic chronic <e1> cocaine </e1> <e2> heart disease </e2> in asymptomatic chronic cocaine users.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"299": {"data": {"text": "Bort-dex was an effective salvage treatment for MM patients, particularly for those in first relapse.", "entity1": "dex", "entity2": "MM", "span1": [5, 8], "span2": [48, 50]}, "bert_text": "Bort-<e1> dex </e1> was an effective salvage treatment for <e2> MM </e2> patients, particularly for those in first relapse.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"300": {"data": {"text": "After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced.", "entity1": "glucose", "entity2": "nephrogenic diabetes insipidus", "span1": [78, 85], "span2": [138, 168]}, "bert_text": "After recovery from hyperglycaemia, he remained polyuric despite normal blood <e1> glucose </e1> concentrations; water deprivation testing indicated <e2> nephrogenic diabetes insipidus </e2>, likely to be lithium-induced.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"301": {"data": {"text": "After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be lithium-induced.", "entity1": "lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [183, 190], "span2": [138, 168]}, "bert_text": "After recovery from hyperglycaemia, he remained polyuric despite normal blood glucose concentrations; water deprivation testing indicated nephrogenic diabetes insipidus, likely to be <e1> lithium </e1> <e2> nephrogenic diabetes insipidus </e2>, likely to be lithium-induced.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"302": {"data": {"text": "RESULTS: Ribavirin-induced anemia occurred in 18 (20.5%) patients during treatment.", "entity1": "Ribavirin", "entity2": "anemia", "span1": [9, 18], "span2": [27, 33]}, "bert_text": "RESULTS: <e1> Ribavirin </e1>-induced <e2> anemia </e2> occurred in 18 (20.5%) patients during treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"303": {"data": {"text": "We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.", "entity1": "AMI", "entity2": "GI bleeding", "span1": [53, 56], "span2": [61, 72]}, "bert_text": "We aimed to compare the risks of hospitalization for <e1> AMI </e1> and <e2> GI bleeding </e2> among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"304": {"data": {"text": "We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.", "entity1": "acetaminophen", "entity2": "GI bleeding", "span1": [134, 147], "span2": [61, 72]}, "bert_text": "We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX-2 inhibitors, NS-NSAIDs and <e1> acetaminophen </e1> <e2> GI bleeding </e2> among elderly patients using COX-2 inhibitors, NS-NSAIDs and acetaminophen.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"305": {"data": {"text": "Treatment with L-DOPA+benserazide (12 weeks) resulted in less severe dyskinesias in CB1 KO than in WT mice.", "entity1": "L-DOPA+benserazide", "entity2": "dyskinesias", "span1": [15, 33], "span2": [69, 80]}, "bert_text": "Treatment with <e1> L-DOPA+benserazide </e1> (12 weeks) resulted in less severe <e2> dyskinesias </e2> in CB1 KO than in WT mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"306": {"data": {"text": "Treatment with L-DOPA+benserazide (12 weeks) resulted in less severe dyskinesias in CB1 KO than in WT mice.", "entity1": "KO", "entity2": "dyskinesias", "span1": [88, 90], "span2": [69, 80]}, "bert_text": "Treatment with L-DOPA+benserazide (12 weeks) resulted in less severe dyskinesias in CB1 <e1> KO </e1> <e2> dyskinesias </e2> in CB1 KO than in WT mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"307": {"data": {"text": "We describe a case of clopidogrel-related acute hepatitis.", "entity1": "clopidogrel", "entity2": "hepatitis", "span1": [22, 33], "span2": [48, 57]}, "bert_text": "We describe a case of <e1> clopidogrel </e1>-related acute <e2> hepatitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"308": {"data": {"text": "Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.", "entity1": "tranexamic acid", "entity2": "postoperative seizures", "span1": [229, 244], "span2": [26, 48]}, "bert_text": "Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and <e1> tranexamic acid </e1> <e2> postoperative seizures </e2> included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"309": {"data": {"text": "Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.", "entity1": "tranexamic acid", "entity2": "calcification", "span1": [229, 244], "span2": [97, 110]}, "bert_text": "Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and <e1> tranexamic acid </e1> <e2> calcification </e2> of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"310": {"data": {"text": "Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.", "entity1": "tranexamic acid", "entity2": "congestive heart failure", "span1": [229, 244], "span2": [131, 155]}, "bert_text": "Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and <e1> tranexamic acid </e1> <e2> congestive heart failure </e2>, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"311": {"data": {"text": "Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and tranexamic acid.", "entity1": "tranexamic acid", "entity2": "deep hypothermic circulatory arrest", "span1": [229, 244], "span2": [157, 192]}, "bert_text": "Independent predictors of postoperative seizures included age, female sex, redo cardiac surgery, calcification of ascending aorta, congestive heart failure, deep hypothermic circulatory arrest, duration of aortic cross-clamp and <e1> tranexamic acid </e1> <e2> deep hypothermic circulatory arrest </e2>, duration of aortic cross-clamp and tranexamic acid.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"312": {"data": {"text": "A patient taking diphenylhydantoin for 3 weeks developed a generalized skin rash, lymphadenopathy and pure red cell aplasia.", "entity1": "diphenylhydantoin", "entity2": "skin rash", "span1": [17, 34], "span2": [71, 80]}, "bert_text": "A patient taking <e1> diphenylhydantoin </e1> for 3 weeks developed a generalized <e2> skin rash </e2>, lymphadenopathy and pure red cell aplasia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"313": {"data": {"text": "A patient taking diphenylhydantoin for 3 weeks developed a generalized skin rash, lymphadenopathy and pure red cell aplasia.", "entity1": "diphenylhydantoin", "entity2": "lymphadenopathy", "span1": [17, 34], "span2": [82, 97]}, "bert_text": "A patient taking <e1> diphenylhydantoin </e1> for 3 weeks developed a generalized skin rash, <e2> lymphadenopathy </e2> and pure red cell aplasia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"314": {"data": {"text": "A patient taking diphenylhydantoin for 3 weeks developed a generalized skin rash, lymphadenopathy and pure red cell aplasia.", "entity1": "diphenylhydantoin", "entity2": "pure red cell aplasia", "span1": [17, 34], "span2": [102, 123]}, "bert_text": "A patient taking <e1> diphenylhydantoin </e1> for 3 weeks developed a generalized skin rash, lymphadenopathy and <e2> pure red cell aplasia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"315": {"data": {"text": "Although all of the currently available H2-receptor antagonists have shown the propensity to cause delirium, only two previously reported cases have been associated with famotidine.", "entity1": "famotidine", "entity2": "delirium", "span1": [170, 180], "span2": [99, 107]}, "bert_text": "Although all of the currently available H2-receptor antagonists have shown the propensity to cause delirium, only two previously reported cases have been associated with <e1> famotidine </e1> <e2> delirium </e2>, only two previously reported cases have been associated with famotidine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"316": {"data": {"text": "Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.", "entity1": "serotonin", "entity2": "paranoid", "span1": [45, 54], "span2": [14, 22]}, "bert_text": "Five cases of paranoid exacerbation with the <e1> serotonin </e1> <e2> paranoid </e2> exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"317": {"data": {"text": "Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.", "entity1": "fluoxetine", "entity2": "paranoid", "span1": [75, 85], "span2": [14, 22]}, "bert_text": "Five cases of paranoid exacerbation with the serotonin reuptake inhibitors <e1> fluoxetine </e1> <e2> paranoid </e2> exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"318": {"data": {"text": "Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.", "entity1": "amitriptyline", "entity2": "paranoid", "span1": [90, 103], "span2": [14, 22]}, "bert_text": "Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and <e1> amitriptyline </e1> <e2> paranoid </e2> exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"319": {"data": {"text": "In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration.", "entity1": "LF", "entity2": "hypertension", "span1": [71, 73], "span2": [98, 110]}, "bert_text": "In this study, we investigated the effect of chronic administration of <e1> LF </e1> on oxidative stress and <e2> hypertension </e2> upon Dex administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"320": {"data": {"text": "In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration.", "entity1": "Dex", "entity2": "hypertension", "span1": [116, 119], "span2": [98, 110]}, "bert_text": "In this study, we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon <e1> Dex </e1> <e2> hypertension </e2> upon Dex administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"321": {"data": {"text": "Hypertension in neuroblastoma induced by imipramine.\n", "entity1": "imipramine", "entity2": "Hypertension", "span1": [41, 51], "span2": [0, 12]}, "bert_text": "Hypertension in neuroblastoma induced by <e1> imipramine </e1> <e2> Hypertension </e2> in neuroblastoma induced by imipramine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"322": {"data": {"text": "Hypertension in neuroblastoma induced by imipramine.\n", "entity1": "imipramine", "entity2": "neuroblastoma", "span1": [41, 51], "span2": [16, 29]}, "bert_text": "Hypertension in neuroblastoma induced by <e1> imipramine </e1> <e2> neuroblastoma </e2> induced by imipramine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"323": {"data": {"text": "Antitumor effect, cardiotoxicity, and nephrotoxicity of doxorubicin in the IgM solid immunocytoma-bearing LOU/M/WSL rat.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [56, 67], "span2": [18, 32]}, "bert_text": "Antitumor effect, cardiotoxicity, and nephrotoxicity of <e1> doxorubicin </e1> <e2> cardiotoxicity </e2>, and nephrotoxicity of doxorubicin in the IgM solid immunocytoma-bearing LOU/M/WSL rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"324": {"data": {"text": "Antitumor effect, cardiotoxicity, and nephrotoxicity of doxorubicin in the IgM solid immunocytoma-bearing LOU/M/WSL rat.\n", "entity1": "doxorubicin", "entity2": "nephrotoxicity", "span1": [56, 67], "span2": [38, 52]}, "bert_text": "Antitumor effect, cardiotoxicity, and nephrotoxicity of <e1> doxorubicin </e1> <e2> nephrotoxicity </e2> of doxorubicin in the IgM solid immunocytoma-bearing LOU/M/WSL rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"325": {"data": {"text": "Dermal administration of S-23121 at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121.", "entity1": "S-23121", "entity2": "embryonic death", "span1": [25, 32], "span2": [84, 99]}, "bert_text": "Dermal administration of <e1> S-23121 </e1> at 800 mg/kg resulted in an increased incidence of <e2> embryonic death </e2> and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"326": {"data": {"text": "Dermal administration of S-23121 at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121.", "entity1": "S-23121", "entity2": "ventricular septal defect", "span1": [25, 32], "span2": [104, 129]}, "bert_text": "Dermal administration of <e1> S-23121 </e1> at 800 mg/kg resulted in an increased incidence of embryonic death and <e2> ventricular septal defect </e2>, but retarded fetal growth was not observed as it was following oral exposure to S-23121.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"327": {"data": {"text": "Dermal administration of S-23121 at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121.", "entity1": "S-23121", "entity2": "embryonic death", "span1": [211, 218], "span2": [84, 99]}, "bert_text": "Dermal administration of S-23121 at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to <e1> S-23121 </e1> <e2> embryonic death </e2> and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"328": {"data": {"text": "Dermal administration of S-23121 at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to S-23121.", "entity1": "S-23121", "entity2": "ventricular septal defect", "span1": [211, 218], "span2": [104, 129]}, "bert_text": "Dermal administration of S-23121 at 800 mg/kg resulted in an increased incidence of embryonic death and ventricular septal defect, but retarded fetal growth was not observed as it was following oral exposure to <e1> S-23121 </e1> <e2> ventricular septal defect </e2>, but retarded fetal growth was not observed as it was following oral exposure to S-23121.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"329": {"data": {"text": "We studied whether a negative coronary CTA in patients with cocaine-associated chest pain could identify a subset safe for discharge.", "entity1": "cocaine", "entity2": "chest pain", "span1": [60, 67], "span2": [79, 89]}, "bert_text": "We studied whether a negative coronary CTA in patients with <e1> cocaine </e1>-associated <e2> chest pain </e2> could identify a subset safe for discharge.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"330": {"data": {"text": "OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day.", "entity1": "morphine", "entity2": "OIH", "span1": [62, 70], "span2": [0, 3]}, "bert_text": "OIH was achieved in mice after subcutaneous administration of <e1> morphine </e1> <e2> OIH </e2> was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"331": {"data": {"text": "CONCLUSIONS: QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding.", "entity1": "methadone", "entity2": "QT interval prolongation", "span1": [41, 50], "span2": [13, 37]}, "bert_text": "CONCLUSIONS: QT interval prolongation in <e1> methadone </e1> <e2> QT interval prolongation </e2> in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"332": {"data": {"text": "Aza patients had significantly more staphylococcal infections than all other transplant groups (P less than 0.005), and systemic fungal infections occurred only in the liver transplant group.", "entity1": "Aza", "entity2": "staphylococcal infections", "span1": [0, 3], "span2": [36, 61]}, "bert_text": "<e1> Aza </e1> patients had significantly more <e2> staphylococcal infections </e2> than all other transplant groups (P less than 0.005), and systemic fungal infections occurred only in the liver transplant group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"333": {"data": {"text": "Aza patients had significantly more staphylococcal infections than all other transplant groups (P less than 0.005), and systemic fungal infections occurred only in the liver transplant group.", "entity1": "Aza", "entity2": "systemic fungal infections", "span1": [0, 3], "span2": [120, 146]}, "bert_text": "<e1> Aza </e1> patients had significantly more staphylococcal infections than all other transplant groups (P less than 0.005), and <e2> systemic fungal infections </e2> occurred only in the liver transplant group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"334": {"data": {"text": "Patients with hypercalcemia resulting from medical diseases and bipolar patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.", "entity1": "lithium", "entity2": "hypercalcemia", "span1": [86, 93], "span2": [14, 27]}, "bert_text": "Patients with hypercalcemia resulting from medical diseases and bipolar patients with <e1> lithium </e1> <e2> hypercalcemia </e2> resulting from medical diseases and bipolar patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"335": {"data": {"text": "Patients with hypercalcemia resulting from medical diseases and bipolar patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.", "entity1": "lithium", "entity2": "hypercalcemia", "span1": [86, 93], "span2": [105, 118]}, "bert_text": "Patients with hypercalcemia resulting from medical diseases and bipolar patients with <e1> lithium </e1>-associated <e2> hypercalcemia </e2> had significantly higher frequencies of conduction defects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"336": {"data": {"text": "Patients with hypercalcemia resulting from medical diseases and bipolar patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.", "entity1": "lithium", "entity2": "diseases", "span1": [86, 93], "span2": [51, 59]}, "bert_text": "Patients with hypercalcemia resulting from medical diseases and bipolar patients with <e1> lithium </e1> <e2> diseases </e2> and bipolar patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"337": {"data": {"text": "Patients with hypercalcemia resulting from medical diseases and bipolar patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.", "entity1": "lithium", "entity2": "bipolar", "span1": [86, 93], "span2": [64, 71]}, "bert_text": "Patients with hypercalcemia resulting from medical diseases and bipolar patients with <e1> lithium </e1> <e2> bipolar </e2> patients with lithium-associated hypercalcemia had significantly higher frequencies of conduction defects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"338": {"data": {"text": "Their combined cardiac toxicity may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of ethanol.", "entity1": "cocaethylene", "entity2": "cardiac toxicity", "span1": [113, 125], "span2": [15, 31]}, "bert_text": "Their combined cardiac toxicity may be due to independent effects of each drug; however, they may also be due to <e1> cocaethylene </e1> <e2> cardiac toxicity </e2> may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of ethanol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"339": {"data": {"text": "Their combined cardiac toxicity may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of ethanol.", "entity1": "CE", "entity2": "cardiac toxicity", "span1": [127, 129], "span2": [15, 31]}, "bert_text": "Their combined cardiac toxicity may be due to independent effects of each drug; however, they may also be due to cocaethylene (<e1> CE </e1> <e2> cardiac toxicity </e2> may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of ethanol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"340": {"data": {"text": "Their combined cardiac toxicity may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of ethanol.", "entity1": "cocaine", "entity2": "cardiac toxicity", "span1": [134, 141], "span2": [15, 31]}, "bert_text": "Their combined cardiac toxicity may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a <e1> cocaine </e1> <e2> cardiac toxicity </e2> may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of ethanol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"341": {"data": {"text": "Their combined cardiac toxicity may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of ethanol.", "entity1": "ethanol", "entity2": "cardiac toxicity", "span1": [184, 191], "span2": [15, 31]}, "bert_text": "Their combined cardiac toxicity may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of <e1> ethanol </e1> <e2> cardiac toxicity </e2> may be due to independent effects of each drug; however, they may also be due to cocaethylene (CE), a cocaine metabolite formed only in the presence of ethanol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"342": {"data": {"text": "ROC curve analysis revealed that unresponsiveness to verapamil defined as PRL <7%, discriminated anatomical or functional stalk effect (sensitivity: 74%, specificity: 73%, AUC: 0.855+/-0.04, P <0.001, CI: 0.768-0.942) associated with pseudoprolactinoma or risperidone-induced hyperprolactinemia, respectively.", "entity1": "verapamil", "entity2": "hyperprolactinemia", "span1": [53, 62], "span2": [276, 294]}, "bert_text": "ROC curve analysis revealed that unresponsiveness to <e1> verapamil </e1> defined as PRL <7%, discriminated anatomical or functional stalk effect (sensitivity: 74%, specificity: 73%, AUC: 0.855+/-0.04, P <0.001, CI: 0.768-0.942) associated with pseudoprolactinoma or risperidone-induced <e2> hyperprolactinemia </e2>, respectively.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"343": {"data": {"text": "ROC curve analysis revealed that unresponsiveness to verapamil defined as PRL <7%, discriminated anatomical or functional stalk effect (sensitivity: 74%, specificity: 73%, AUC: 0.855+/-0.04, P <0.001, CI: 0.768-0.942) associated with pseudoprolactinoma or risperidone-induced hyperprolactinemia, respectively.", "entity1": "risperidone", "entity2": "hyperprolactinemia", "span1": [256, 267], "span2": [276, 294]}, "bert_text": "ROC curve analysis revealed that unresponsiveness to verapamil defined as PRL <7%, discriminated anatomical or functional stalk effect (sensitivity: 74%, specificity: 73%, AUC: 0.855+/-0.04, P <0.001, CI: 0.768-0.942) associated with pseudoprolactinoma or <e1> risperidone </e1>-induced <e2> hyperprolactinemia </e2>, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"344": {"data": {"text": "Hepatocellular carcinoma in Fanconi's anemia treated with androgen and corticosteroid.\n", "entity1": "corticosteroid", "entity2": "Hepatocellular carcinoma", "span1": [71, 85], "span2": [0, 24]}, "bert_text": "Hepatocellular carcinoma in Fanconi's anemia treated with androgen and <e1> corticosteroid </e1> <e2> Hepatocellular carcinoma </e2> in Fanconi's anemia treated with androgen and corticosteroid.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"345": {"data": {"text": "Hepatocellular carcinoma in Fanconi's anemia treated with androgen and corticosteroid.\n", "entity1": "corticosteroid", "entity2": "Fanconi's anemia", "span1": [71, 85], "span2": [28, 44]}, "bert_text": "Hepatocellular carcinoma in Fanconi's anemia treated with androgen and <e1> corticosteroid </e1> <e2> Fanconi's anemia </e2> treated with androgen and corticosteroid.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"346": {"data": {"text": "No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations.", "entity1": "NCQ436", "entity2": "necrosis", "span1": [47, 53], "span2": [3, 11]}, "bert_text": "No necrosis was observed in cells treated with <e1> NCQ436 </e1> <e2> necrosis </e2> was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"347": {"data": {"text": "No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations.", "entity1": "NCQ436", "entity2": "necrosis", "span1": [47, 53], "span2": [154, 162]}, "bert_text": "No necrosis was observed in cells treated with <e1> NCQ436 </e1> but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and <e2> necrosis </e2> at higher concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"348": {"data": {"text": "No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations.", "entity1": "NCQ344", "entity2": "necrosis", "span1": [58, 64], "span2": [3, 11]}, "bert_text": "No necrosis was observed in cells treated with NCQ436 but <e1> NCQ344 </e1> <e2> necrosis </e2> was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"349": {"data": {"text": "No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and necrosis at higher concentrations.", "entity1": "NCQ344", "entity2": "necrosis", "span1": [58, 64], "span2": [154, 162]}, "bert_text": "No necrosis was observed in cells treated with NCQ436 but <e1> NCQ344 </e1> had a biphasic effect in both cell types, inducing apoptosis at lower concentrations and <e2> necrosis </e2> at higher concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"350": {"data": {"text": "\"Real-world\" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.\n", "entity1": "lenalidomide", "entity2": "myeloma", "span1": [48, 60], "span2": [125, 132]}, "bert_text": "\"Real-world\" data on the efficacy and safety of <e1> lenalidomide </e1> and dexamethasone in patients with relapsed/refractory multiple <e2> myeloma </e2> who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"351": {"data": {"text": "\"Real-world\" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.\n", "entity1": "lenalidomide", "entity2": "Myeloma", "span1": [48, 60], "span2": [216, 223]}, "bert_text": "\"Real-world\" data on the efficacy and safety of <e1> lenalidomide </e1> and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek <e2> Myeloma </e2> Study Group.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"352": {"data": {"text": "\"Real-world\" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.\n", "entity1": "dexamethasone", "entity2": "myeloma", "span1": [65, 78], "span2": [125, 132]}, "bert_text": "\"Real-world\" data on the efficacy and safety of lenalidomide and <e1> dexamethasone </e1> in patients with relapsed/refractory multiple <e2> myeloma </e2> who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"353": {"data": {"text": "\"Real-world\" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.\n", "entity1": "dexamethasone", "entity2": "Myeloma", "span1": [65, 78], "span2": [216, 223]}, "bert_text": "\"Real-world\" data on the efficacy and safety of lenalidomide and <e1> dexamethasone </e1> in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek <e2> Myeloma </e2> Study Group.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"354": {"data": {"text": "An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [86, 97], "span2": [106, 120]}, "bert_text": "An integrated characterization of serological, pathological, and functional events in <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"355": {"data": {"text": "Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting.", "entity1": "Gemcitabine", "entity2": "HL", "span1": [0, 11], "span2": [43, 45]}, "bert_text": "<e1> Gemcitabine </e1> and cisplatin have activity in <e2> HL </e2>, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"356": {"data": {"text": "Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting.", "entity1": "Gemcitabine", "entity2": "toxicity", "span1": [0, 11], "span2": [63, 71]}, "bert_text": "<e1> Gemcitabine </e1> and cisplatin have activity in HL, non-overlapping <e2> toxicity </e2> with first-line chemotherapeutics, and may be delivered in an outpatient setting.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"357": {"data": {"text": "Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting.", "entity1": "cisplatin", "entity2": "HL", "span1": [16, 25], "span2": [43, 45]}, "bert_text": "Gemcitabine and <e1> cisplatin </e1> have activity in <e2> HL </e2>, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"358": {"data": {"text": "Gemcitabine and cisplatin have activity in HL, non-overlapping toxicity with first-line chemotherapeutics, and may be delivered in an outpatient setting.", "entity1": "cisplatin", "entity2": "toxicity", "span1": [16, 25], "span2": [63, 71]}, "bert_text": "Gemcitabine and <e1> cisplatin </e1> have activity in HL, non-overlapping <e2> toxicity </e2> with first-line chemotherapeutics, and may be delivered in an outpatient setting.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"359": {"data": {"text": "The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.", "entity1": "CCK-8", "entity2": "memory impairment", "span1": [37, 42], "span2": [185, 202]}, "bert_text": "The present results demonstrate that <e1> CCK-8 </e1> attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced <e2> memory impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"360": {"data": {"text": "The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.", "entity1": "CCK-8", "entity2": "memory impairment", "span1": [159, 164], "span2": [185, 202]}, "bert_text": "The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of <e1> CCK-8 </e1> on morphine-induced <e2> memory impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"361": {"data": {"text": "The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.", "entity1": "morphine", "entity2": "memory impairment", "span1": [68, 76], "span2": [185, 202]}, "bert_text": "The present results demonstrate that CCK-8 attenuates the effect of <e1> morphine </e1> on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced <e2> memory impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"362": {"data": {"text": "The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on morphine-induced memory impairment.", "entity1": "morphine", "entity2": "memory impairment", "span1": [168, 176], "span2": [185, 202]}, "bert_text": "The present results demonstrate that CCK-8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK-8 on <e1> morphine </e1>-induced <e2> memory impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"363": {"data": {"text": "Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.\n", "entity1": "bepridil", "entity2": "atrial fibrillation", "span1": [46, 54], "span2": [74, 93]}, "bert_text": "Clinical evaluation of adverse effects during <e1> bepridil </e1> administration for <e2> atrial fibrillation </e2> and flutter.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"364": {"data": {"text": "Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter.\n", "entity1": "bepridil", "entity2": "flutter", "span1": [46, 54], "span2": [98, 105]}, "bert_text": "Clinical evaluation of adverse effects during <e1> bepridil </e1> administration for atrial fibrillation and <e2> flutter </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"365": {"data": {"text": "These findings result in a model that allows the testing of protectors against doxorubicin-induced cardiotoxicity as demonstrated by the protection provided by ICRF-187.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [79, 90], "span2": [99, 113]}, "bert_text": "These findings result in a model that allows the testing of protectors against <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2> as demonstrated by the protection provided by ICRF-187.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"366": {"data": {"text": "These findings result in a model that allows the testing of protectors against doxorubicin-induced cardiotoxicity as demonstrated by the protection provided by ICRF-187.", "entity1": "ICRF-187", "entity2": "cardiotoxicity", "span1": [160, 168], "span2": [99, 113]}, "bert_text": "These findings result in a model that allows the testing of protectors against doxorubicin-induced cardiotoxicity as demonstrated by the protection provided by <e1> ICRF-187 </e1> <e2> cardiotoxicity </e2> as demonstrated by the protection provided by ICRF-187.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"367": {"data": {"text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.", "entity1": "amphotericin B.", "entity2": "nephrotoxicity", "span1": [81, 96], "span2": [15, 29]}, "bert_text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating <e1> amphotericin B. </e1> <e2> nephrotoxicity </e2> by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"368": {"data": {"text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.", "entity1": "amphotericin B.", "entity2": "NS-718", "span1": [81, 96], "span2": [97, 103]}, "bert_text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating <e1> amphotericin B. </e1>\n<e2> NS-718 </e2>, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"369": {"data": {"text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.", "entity1": "amphotericin B.", "entity2": "toxicity", "span1": [81, 96], "span2": [204, 212]}, "bert_text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating <e1> amphotericin B. </e1>\nNS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"370": {"data": {"text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.", "entity1": "amphotericin B", "entity2": "nephrotoxicity", "span1": [138, 152], "span2": [15, 29]}, "bert_text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating <e1> amphotericin B </e1> <e2> nephrotoxicity </e2> by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"371": {"data": {"text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.", "entity1": "amphotericin B", "entity2": "NS-718", "span1": [138, 152], "span2": [97, 103]}, "bert_text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating <e1> amphotericin B </e1> <e2> NS-718 </e2>, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"372": {"data": {"text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating amphotericin B, is effective against pathogenic fungi and has low toxicity.", "entity1": "amphotericin B", "entity2": "toxicity", "span1": [138, 152], "span2": [204, 212]}, "bert_text": "Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B.\nNS-718, a lipid nanosphere incorporating <e1> amphotericin B </e1>, is effective against pathogenic fungi and has low <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"373": {"data": {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity1": "lithium", "entity2": "bipolar", "span1": [59, 66], "span2": [21, 28]}, "bert_text": "Recent findings in a bipolar patient receiving maintenance <e1> lithium </e1> <e2> bipolar </e2> patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"374": {"data": {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity1": "lithium", "entity2": "bipolar", "span1": [59, 66], "span2": [187, 194]}, "bert_text": "Recent findings in a bipolar patient receiving maintenance <e1> lithium </e1> therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of <e2> bipolar </e2> patients with lithium-associated hypercalcemia.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"375": {"data": {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity1": "lithium", "entity2": "hypercalcemia", "span1": [59, 66], "span2": [89, 102]}, "bert_text": "Recent findings in a bipolar patient receiving maintenance <e1> lithium </e1> therapy who developed <e2> hypercalcemia </e2> and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"376": {"data": {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity1": "lithium", "entity2": "hypercalcemia", "span1": [59, 66], "span2": [228, 241]}, "bert_text": "Recent findings in a bipolar patient receiving maintenance <e1> lithium </e1> therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated <e2> hypercalcemia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"377": {"data": {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity1": "lithium", "entity2": "bradyarrhythmia", "span1": [59, 66], "span2": [114, 129]}, "bert_text": "Recent findings in a bipolar patient receiving maintenance <e1> lithium </e1> therapy who developed hypercalcemia and severe <e2> bradyarrhythmia </e2> prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"378": {"data": {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity1": "lithium", "entity2": "bipolar", "span1": [209, 216], "span2": [21, 28]}, "bert_text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with <e1> lithium </e1> <e2> bipolar </e2> patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"379": {"data": {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity1": "lithium", "entity2": "bipolar", "span1": [209, 216], "span2": [187, 194]}, "bert_text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with <e1> lithium </e1> <e2> bipolar </e2> patients with lithium-associated hypercalcemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"380": {"data": {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity1": "lithium", "entity2": "hypercalcemia", "span1": [209, 216], "span2": [89, 102]}, "bert_text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with <e1> lithium </e1> <e2> hypercalcemia </e2> and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"381": {"data": {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity1": "lithium", "entity2": "hypercalcemia", "span1": [209, 216], "span2": [228, 241]}, "bert_text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with <e1> lithium </e1>-associated <e2> hypercalcemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"382": {"data": {"text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "entity1": "lithium", "entity2": "bradyarrhythmia", "span1": [209, 216], "span2": [114, 129]}, "bert_text": "Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with <e1> lithium </e1> <e2> bradyarrhythmia </e2> prompted the authors to conduct a retrospective study of bipolar patients with lithium-associated hypercalcemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"383": {"data": {"text": "We report here a retrospective study of 123 children (median age, 6.5 years) receiving high-dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors, brain tumors excluded.", "entity1": "busulfan", "entity2": "tumors", "span1": [97, 105], "span2": [186, 192]}, "bert_text": "We report here a retrospective study of 123 children (median age, 6.5 years) receiving high-dose <e1> busulfan </e1> in combined chemotherapy before bone marrow transplantation for malignant solid <e2> tumors </e2>, brain tumors excluded.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"384": {"data": {"text": "We report here a retrospective study of 123 children (median age, 6.5 years) receiving high-dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors, brain tumors excluded.", "entity1": "busulfan", "entity2": "brain tumors", "span1": [97, 105], "span2": [194, 206]}, "bert_text": "We report here a retrospective study of 123 children (median age, 6.5 years) receiving high-dose <e1> busulfan </e1> in combined chemotherapy before bone marrow transplantation for malignant solid tumors, <e2> brain tumors </e2> excluded.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"385": {"data": {"text": "The effect of exercise on the severity of isoproterenol-induced myocardial infarction was studied in male rats.", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [42, 55], "span2": [64, 85]}, "bert_text": "The effect of exercise on the severity of <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2> was studied in male rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"386": {"data": {"text": "Increase in intragastric pressure during suxamethonium-induced muscle fasciculations in children: inhibition by alfentanil.\n", "entity1": "suxamethonium", "entity2": "muscle fasciculations", "span1": [41, 54], "span2": [63, 84]}, "bert_text": "Increase in intragastric pressure during <e1> suxamethonium </e1>-induced <e2> muscle fasciculations </e2> in children: inhibition by alfentanil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"387": {"data": {"text": "Increase in intragastric pressure during suxamethonium-induced muscle fasciculations in children: inhibition by alfentanil.\n", "entity1": "alfentanil", "entity2": "muscle fasciculations", "span1": [112, 122], "span2": [63, 84]}, "bert_text": "Increase in intragastric pressure during suxamethonium-induced muscle fasciculations in children: inhibition by <e1> alfentanil </e1> <e2> muscle fasciculations </e2> in children: inhibition by alfentanil.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"388": {"data": {"text": "Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine.\n", "entity1": "carbamazepine", "entity2": "nystagmus and oscillopsia", "span1": [64, 77], "span2": [22, 47]}, "bert_text": "Two cases of downbeat nystagmus and oscillopsia associated with <e1> carbamazepine </e1> <e2> nystagmus and oscillopsia </e2> associated with carbamazepine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"389": {"data": {"text": "trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "entity1": "trazodone", "entity2": "catalepsy", "span1": [0, 9], "span2": [74, 83]}, "bert_text": "<e1> trazodone </e1> enhanced dexamphetamine stereotypy, and antagonized haloperidol <e2> catalepsy </e2>, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"390": {"data": {"text": "trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "entity1": "dexamphetamine", "entity2": "catalepsy", "span1": [19, 33], "span2": [74, 83]}, "bert_text": "trazodone enhanced <e1> dexamphetamine </e1> stereotypy, and antagonized haloperidol <e2> catalepsy </e2>, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"391": {"data": {"text": "trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [62, 73], "span2": [74, 83]}, "bert_text": "trazodone enhanced dexamphetamine stereotypy, and antagonized <e1> haloperidol </e1> <e2> catalepsy </e2>, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"392": {"data": {"text": "trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "entity1": "ergometrine", "entity2": "catalepsy", "span1": [85, 96], "span2": [74, 83]}, "bert_text": "trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, <e1> ergometrine </e1> <e2> catalepsy </e2>, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"393": {"data": {"text": "trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "entity1": "fluoxetine", "entity2": "catalepsy", "span1": [122, 132], "span2": [74, 83]}, "bert_text": "trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and <e1> fluoxetine </e1> <e2> catalepsy </e2>, ergometrine-induced WDS behavior and fluoxetine-induced penile erections.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"394": {"data": {"text": "Methyldopa-induced hemolytic anemia in a 15 year old presenting as near-syncope.\n", "entity1": "Methyldopa", "entity2": "hemolytic anemia", "span1": [0, 10], "span2": [19, 35]}, "bert_text": "<e1> Methyldopa </e1>-induced <e2> hemolytic anemia </e2> in a 15 year old presenting as near-syncope.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"395": {"data": {"text": "Methyldopa-induced hemolytic anemia in a 15 year old presenting as near-syncope.\n", "entity1": "Methyldopa", "entity2": "syncope", "span1": [0, 10], "span2": [72, 79]}, "bert_text": "<e1> Methyldopa </e1>-induced hemolytic anemia in a 15 year old presenting as near-<e2> syncope </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"396": {"data": {"text": "We report a case of myocardial ischemia induced by cocaine.", "entity1": "cocaine", "entity2": "myocardial ischemia", "span1": [51, 58], "span2": [20, 39]}, "bert_text": "We report a case of myocardial ischemia induced by <e1> cocaine </e1> <e2> myocardial ischemia </e2> induced by cocaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"397": {"data": {"text": "Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.\n", "entity1": "morphine", "entity2": "neuropathic pain", "span1": [27, 35], "span2": [115, 131]}, "bert_text": "Studies of synergy between <e1> morphine </e1> and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and <e2> neuropathic pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"398": {"data": {"text": "Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.\n", "entity1": "sodium", "entity2": "neuropathic pain", "span1": [48, 54], "span2": [115, 131]}, "bert_text": "Studies of synergy between morphine and a novel <e1> sodium </e1> channel blocker, CNSB002, in rat models of inflammatory and <e2> neuropathic pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"399": {"data": {"text": "The aim of our study was to re-examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies.", "entity1": "OC", "entity2": "VTE", "span1": [79, 81], "span2": [71, 74]}, "bert_text": "The aim of our study was to re-examine the association between risk of VTE and <e1> OC </e1> <e2> VTE </e2> and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"400": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "doxorubicin", "entity2": "ovarian cancer", "span1": [56, 67], "span2": [135, 149]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal <e1> doxorubicin </e1> (Doxil) to be an active antineoplastic agent in platinum-resistant <e2> ovarian cancer </e2>, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"401": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "doxorubicin", "entity2": "toxicity", "span1": [56, 67], "span2": [170, 178]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal <e1> doxorubicin </e1> (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting <e2> toxicity </e2> of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"402": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "doxorubicin", "entity2": "hand-foot syndrome", "span1": [56, 67], "span2": [267, 285]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal <e1> doxorubicin </e1> (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"<e2> hand-foot syndrome </e2>\") and stomatitis.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"403": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "doxorubicin", "entity2": "stomatitis", "span1": [56, 67], "span2": [292, 302]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal <e1> doxorubicin </e1> (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and <e2> stomatitis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"404": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "Doxil", "entity2": "ovarian cancer", "span1": [69, 74], "span2": [135, 149]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (<e1> Doxil </e1>) to be an active antineoplastic agent in platinum-resistant <e2> ovarian cancer </e2>, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"405": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "Doxil", "entity2": "toxicity", "span1": [69, 74], "span2": [170, 178]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (<e1> Doxil </e1>) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting <e2> toxicity </e2> of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"406": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "Doxil", "entity2": "hand-foot syndrome", "span1": [69, 74], "span2": [267, 285]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (<e1> Doxil </e1>) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"<e2> hand-foot syndrome </e2>\") and stomatitis.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"407": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "Doxil", "entity2": "stomatitis", "span1": [69, 74], "span2": [292, 302]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (<e1> Doxil </e1>) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and <e2> stomatitis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"408": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "platinum", "entity2": "ovarian cancer", "span1": [116, 124], "span2": [135, 149]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in <e1> platinum </e1>-resistant <e2> ovarian cancer </e2>, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"409": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "platinum", "entity2": "toxicity", "span1": [116, 124], "span2": [170, 178]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in <e1> platinum </e1>-resistant ovarian cancer, with dose limiting <e2> toxicity </e2> of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"410": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "platinum", "entity2": "hand-foot syndrome", "span1": [116, 124], "span2": [267, 285]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in <e1> platinum </e1>-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"<e2> hand-foot syndrome </e2>\") and stomatitis.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"411": {"data": {"text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in platinum-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and stomatitis.", "entity1": "platinum", "entity2": "stomatitis", "span1": [116, 124], "span2": [292, 302]}, "bert_text": "BACKGROUND: Several studies have demonstrated liposomal doxorubicin (Doxil) to be an active antineoplastic agent in <e1> platinum </e1>-resistant ovarian cancer, with dose limiting toxicity of the standard dosing regimen (50 mg/m(2) q 4 weeks) being severe erythrodysesthesia (\"hand-foot syndrome\") and <e2> stomatitis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"412": {"data": {"text": "OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.", "entity1": "CNSB002", "entity2": "neuropathic pain", "span1": [64, 71], "span2": [206, 222]}, "bert_text": "OBJECTIVE: This study determined the antihyperalgesic effect of <e1> CNSB002 </e1>, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and <e2> neuropathic pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"413": {"data": {"text": "OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.", "entity1": "sodium", "entity2": "neuropathic pain", "span1": [75, 81], "span2": [206, 222]}, "bert_text": "OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a <e1> sodium </e1> channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and <e2> neuropathic pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"414": {"data": {"text": "OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain.", "entity1": "morphine", "entity2": "neuropathic pain", "span1": [163, 171], "span2": [206, 222]}, "bert_text": "OBJECTIVE: This study determined the antihyperalgesic effect of CNSB002, a sodium channel blocker with antioxidant properties given alone and in combinations with <e1> morphine </e1> in rat models of inflammatory and <e2> neuropathic pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"415": {"data": {"text": "This case further supports the concern about thromboembolic complications associated with ATRA therapy in APL patients.", "entity1": "ATRA", "entity2": "thromboembolic", "span1": [90, 94], "span2": [45, 59]}, "bert_text": "This case further supports the concern about thromboembolic complications associated with <e1> ATRA </e1> <e2> thromboembolic </e2> complications associated with ATRA therapy in APL patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"416": {"data": {"text": "This case further supports the concern about thromboembolic complications associated with ATRA therapy in APL patients.", "entity1": "ATRA", "entity2": "APL", "span1": [90, 94], "span2": [106, 109]}, "bert_text": "This case further supports the concern about thromboembolic complications associated with <e1> ATRA </e1> therapy in <e2> APL </e2> patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"417": {"data": {"text": "Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?\n", "entity1": "Vincristine", "entity2": "Hyponatremia", "span1": [90, 101], "span2": [0, 12]}, "bert_text": "Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of <e1> Vincristine </e1> <e2> Hyponatremia </e2> and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"418": {"data": {"text": "Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure.\n", "entity1": "caffeine", "entity2": "glomerulosclerosis", "span1": [136, 144], "span2": [78, 96]}, "bert_text": "Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal <e1> caffeine </e1> <e2> glomerulosclerosis </e2> in adult offspring induced by prenatal caffeine exposure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"419": {"data": {"text": "Our data showed ADR induced 4HNE-protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared.", "entity1": "ADR", "entity2": "mitochondrial injury", "span1": [16, 19], "span2": [96, 116]}, "bert_text": "Our data showed <e1> ADR </e1> induced 4HNE-protein adducts in mitochondria at the same time point as when <e2> mitochondrial injury </e2> initially appeared.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"420": {"data": {"text": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "entity1": "valproic acid", "entity2": "hyperammonemia", "span1": [145, 158], "span2": [290, 304]}, "bert_text": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of <e1> valproic acid </e1>; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced <e2> hyperammonemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"421": {"data": {"text": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced hyperammonemia.", "entity1": "valproic acid", "entity2": "hyperammonemia", "span1": [268, 281], "span2": [290, 304]}, "bert_text": "Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of valproic acid; a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through <e1> valproic acid </e1>-induced <e2> hyperammonemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"422": {"data": {"text": "A busulfan dose calculated on the basis of body surface area, resulting in higher doses in young children, was followed by increased neurotoxicity, close to neurotoxicity incidence observed in adults.", "entity1": "busulfan", "entity2": "neurotoxicity", "span1": [2, 10], "span2": [133, 146]}, "bert_text": "A <e1> busulfan </e1> dose calculated on the basis of body surface area, resulting in higher doses in young children, was followed by increased <e2> neurotoxicity </e2>, close to neurotoxicity incidence observed in adults.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"423": {"data": {"text": "A busulfan dose calculated on the basis of body surface area, resulting in higher doses in young children, was followed by increased neurotoxicity, close to neurotoxicity incidence observed in adults.", "entity1": "busulfan", "entity2": "neurotoxicity", "span1": [2, 10], "span2": [157, 170]}, "bert_text": "A <e1> busulfan </e1> dose calculated on the basis of body surface area, resulting in higher doses in young children, was followed by increased neurotoxicity, close to <e2> neurotoxicity </e2> incidence observed in adults.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"424": {"data": {"text": "After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75).", "entity1": "OCs", "entity2": "VTE", "span1": [107, 110], "span2": [44, 47]}, "bert_text": "After adjustment for age, the rate ratio of VTE in users of third-generation relative to second-generation <e1> OCs </e1> <e2> VTE </e2> in users of third-generation relative to second-generation OCs was 1.68 (95% CI 1.04-2.75).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"425": {"data": {"text": "Ethambutol is known to cause optic neuropathy and, more rarely, axonal polyneuropathy.", "entity1": "Ethambutol", "entity2": "optic neuropathy", "span1": [0, 10], "span2": [29, 45]}, "bert_text": "<e1> Ethambutol </e1> is known to cause <e2> optic neuropathy </e2> and, more rarely, axonal polyneuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"426": {"data": {"text": "Ethambutol is known to cause optic neuropathy and, more rarely, axonal polyneuropathy.", "entity1": "Ethambutol", "entity2": "axonal polyneuropathy", "span1": [0, 10], "span2": [64, 85]}, "bert_text": "<e1> Ethambutol </e1> is known to cause optic neuropathy and, more rarely, <e2> axonal polyneuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"427": {"data": {"text": "Assessment by conventional static perimetry may neither be sufficiently sensitive nor specific to reliably identify retinal toxicity associated with VGB.", "entity1": "VGB", "entity2": "retinal toxicity", "span1": [149, 152], "span2": [116, 132]}, "bert_text": "Assessment by conventional static perimetry may neither be sufficiently sensitive nor specific to reliably identify retinal toxicity associated with <e1> VGB </e1> <e2> retinal toxicity </e2> associated with VGB.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"428": {"data": {"text": "The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.", "entity1": "aldosterone", "entity2": "hyperkalemia", "span1": [83, 94], "span2": [13, 25]}, "bert_text": "The cause of hyperkalemia was considered to be several doses of spiranolactone, an <e1> aldosterone </e1> <e2> hyperkalemia </e2> was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"429": {"data": {"text": "The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.", "entity1": "ramipril", "entity2": "hyperkalemia", "span1": [146, 154], "span2": [13, 25]}, "bert_text": "The cause of hyperkalemia was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of <e1> ramipril </e1> <e2> hyperkalemia </e2> was considered to be several doses of spiranolactone, an aldosterone antagonist, in addition to the long-term intake of ramipril, an ACE inhibitor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"430": {"data": {"text": "The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse.", "entity1": "CE", "entity2": "cardiotoxicity", "span1": [55, 57], "span2": [74, 88]}, "bert_text": "The purpose of this study was to delineate the role of <e1> CE </e1> in the combined <e2> cardiotoxicity </e2> of cocaine and ethanol in a model simulating their abuse.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"431": {"data": {"text": "The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse.", "entity1": "cocaine", "entity2": "cardiotoxicity", "span1": [92, 99], "span2": [74, 88]}, "bert_text": "The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of <e1> cocaine </e1> <e2> cardiotoxicity </e2> of cocaine and ethanol in a model simulating their abuse.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"432": {"data": {"text": "The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse.", "entity1": "ethanol", "entity2": "cardiotoxicity", "span1": [104, 111], "span2": [74, 88]}, "bert_text": "The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and <e1> ethanol </e1> <e2> cardiotoxicity </e2> of cocaine and ethanol in a model simulating their abuse.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"433": {"data": {"text": "The nursing staff, by reviewing the patient's health history with his family, discovered a history of polydipsia and long-standing lithium use.", "entity1": "lithium", "entity2": "polydipsia", "span1": [131, 138], "span2": [102, 112]}, "bert_text": "The nursing staff, by reviewing the patient's health history with his family, discovered a history of polydipsia and long-standing <e1> lithium </e1> <e2> polydipsia </e2> and long-standing lithium use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"434": {"data": {"text": "Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine.", "entity1": "Indomethacin", "entity2": "seizures", "span1": [0, 12], "span2": [74, 82]}, "bert_text": "<e1> Indomethacin </e1>, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate <e2> seizures </e2> produced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"435": {"data": {"text": "Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine.", "entity1": "ibuprofen", "entity2": "seizures", "span1": [30, 39], "span2": [74, 82]}, "bert_text": "Indomethacin, 1-10 mg/kg, and <e1> ibuprofen </e1>, 10-100 mg/kg, failed to modulate <e2> seizures </e2> produced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"436": {"data": {"text": "Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by pilocarpine.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [95, 106], "span2": [74, 82]}, "bert_text": "Indomethacin, 1-10 mg/kg, and ibuprofen, 10-100 mg/kg, failed to modulate seizures produced by <e1> pilocarpine </e1> <e2> seizures </e2> produced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"437": {"data": {"text": "The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.", "entity1": "nitroglycerin", "entity2": "ischemia", "span1": [71, 84], "span2": [4, 12]}, "bert_text": "The ischemia probably induced by coronary artery spasm was reversed by <e1> nitroglycerin </e1> <e2> ischemia </e2> probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"438": {"data": {"text": "The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.", "entity1": "nitroglycerin", "entity2": "coronary artery spasm", "span1": [71, 84], "span2": [33, 54]}, "bert_text": "The ischemia probably induced by coronary artery spasm was reversed by <e1> nitroglycerin </e1> <e2> coronary artery spasm </e2> was reversed by nitroglycerin and calcium blocking agents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"439": {"data": {"text": "The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.", "entity1": "calcium", "entity2": "ischemia", "span1": [89, 96], "span2": [4, 12]}, "bert_text": "The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and <e1> calcium </e1> <e2> ischemia </e2> probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"440": {"data": {"text": "The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents.", "entity1": "calcium", "entity2": "coronary artery spasm", "span1": [89, 96], "span2": [33, 54]}, "bert_text": "The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and <e1> calcium </e1> <e2> coronary artery spasm </e2> was reversed by nitroglycerin and calcium blocking agents.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"441": {"data": {"text": "CONCLUSION: Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated.", "entity1": "Olanzapine", "entity2": "bipolar mania", "span1": [12, 22], "span2": [92, 105]}, "bert_text": "CONCLUSION: <e1> Olanzapine </e1> demonstrated greater efficacy than placebo in the treatment of acute <e2> bipolar mania </e2> and was generally well tolerated.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"442": {"data": {"text": "< .01), and death, 100% (P < or = .01), compared with group 4. Group 6 received cocaine and diazepam followed by 10 mg/kg flumazenil.", "entity1": "cocaine", "entity2": "death", "span1": [80, 87], "span2": [12, 17]}, "bert_text": "< .01), and death, 100% (P < or = .01), compared with group 4. Group 6 received <e1> cocaine </e1> <e2> death </e2>, 100% (P < or = .01), compared with group 4. Group 6 received cocaine and diazepam followed by 10 mg/kg flumazenil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"443": {"data": {"text": "< .01), and death, 100% (P < or = .01), compared with group 4. Group 6 received cocaine and diazepam followed by 10 mg/kg flumazenil.", "entity1": "diazepam", "entity2": "death", "span1": [92, 100], "span2": [12, 17]}, "bert_text": "< .01), and death, 100% (P < or = .01), compared with group 4. Group 6 received cocaine and <e1> diazepam </e1> <e2> death </e2>, 100% (P < or = .01), compared with group 4. Group 6 received cocaine and diazepam followed by 10 mg/kg flumazenil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"444": {"data": {"text": "< .01), and death, 100% (P < or = .01), compared with group 4. Group 6 received cocaine and diazepam followed by 10 mg/kg flumazenil.", "entity1": "flumazenil", "entity2": "death", "span1": [122, 132], "span2": [12, 17]}, "bert_text": "< .01), and death, 100% (P < or = .01), compared with group 4. Group 6 received cocaine and diazepam followed by 10 mg/kg <e1> flumazenil </e1> <e2> death </e2>, 100% (P < or = .01), compared with group 4. Group 6 received cocaine and diazepam followed by 10 mg/kg flumazenil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"445": {"data": {"text": "The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias.\n1.", "entity1": "propranolol", "entity2": "cardiac arrhythmias", "span1": [52, 63], "span2": [85, 104]}, "bert_text": "The biological properties of the optical isomers of <e1> propranolol </e1> and their effects on <e2> cardiac arrhythmias </e2>.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"446": {"data": {"text": "No arrhythmias were induced by these doses of denopamine.", "entity1": "denopamine", "entity2": "arrhythmias", "span1": [46, 56], "span2": [3, 14]}, "bert_text": "No arrhythmias were induced by these doses of <e1> denopamine </e1> <e2> arrhythmias </e2> were induced by these doses of denopamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"447": {"data": {"text": "Significantly more P9605 patients developed leukoencephalopathy compared with P9201 patients (68%, 95% confidence interval 49%-83% vs. 22%, 95% confidence interval 5%-44%; P=0.001) identified as late as 7.7 years after the end of treatment.", "entity1": "P9605", "entity2": "leukoencephalopathy", "span1": [19, 24], "span2": [44, 63]}, "bert_text": "Significantly more <e1> P9605 </e1> patients developed <e2> leukoencephalopathy </e2> compared with P9201 patients (68%, 95% confidence interval 49%-83% vs. 22%, 95% confidence interval 5%-44%; P=0.001) identified as late as 7.7 years after the end of treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"448": {"data": {"text": "Cocaine induced myocardial ischemia.\n", "entity1": "Cocaine", "entity2": "myocardial ischemia", "span1": [0, 7], "span2": [16, 35]}, "bert_text": "<e1> Cocaine </e1> induced <e2> myocardial ischemia </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"449": {"data": {"text": "Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.", "entity1": "Phenylalanine", "entity2": "hypotensive", "span1": [0, 13], "span2": [131, 142]}, "bert_text": "<e1> Phenylalanine </e1>, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the <e2> hypotensive </e2> and antiparkinsonian effects of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"450": {"data": {"text": "Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.", "entity1": "amino acid", "entity2": "hypotensive", "span1": [31, 41], "span2": [131, 142]}, "bert_text": "Phenylalanine, a large neutral <e1> amino acid </e1> (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the <e2> hypotensive </e2> and antiparkinsonian effects of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"451": {"data": {"text": "Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.", "entity1": "LNAA", "entity2": "hypotensive", "span1": [43, 47], "span2": [131, 142]}, "bert_text": "Phenylalanine, a large neutral amino acid (<e1> LNAA </e1>) competing with levodopa for transport across the blood-brain barrier, reduced the <e2> hypotensive </e2> and antiparkinsonian effects of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"452": {"data": {"text": "Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.", "entity1": "levodopa", "entity2": "hypotensive", "span1": [64, 72], "span2": [131, 142]}, "bert_text": "Phenylalanine, a large neutral amino acid (LNAA) competing with <e1> levodopa </e1> for transport across the blood-brain barrier, reduced the <e2> hypotensive </e2> and antiparkinsonian effects of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"453": {"data": {"text": "Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of levodopa.", "entity1": "levodopa", "entity2": "hypotensive", "span1": [175, 183], "span2": [131, 142]}, "bert_text": "Phenylalanine, a large neutral amino acid (LNAA) competing with levodopa for transport across the blood-brain barrier, reduced the hypotensive and antiparkinsonian effects of <e1> levodopa </e1> <e2> hypotensive </e2> and antiparkinsonian effects of levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"454": {"data": {"text": "Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.\n", "entity1": "olanzapine", "entity2": "schizophrenia", "span1": [25, 35], "span2": [90, 103]}, "bert_text": "Randomized comparison of <e1> olanzapine </e1> versus risperidone for the treatment of first-episode <e2> schizophrenia </e2>: 4-month outcomes.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"455": {"data": {"text": "Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.\n", "entity1": "risperidone", "entity2": "schizophrenia", "span1": [43, 54], "span2": [90, 103]}, "bert_text": "Randomized comparison of olanzapine versus <e1> risperidone </e1> for the treatment of first-episode <e2> schizophrenia </e2>: 4-month outcomes.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"456": {"data": {"text": "Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.\n", "entity1": "isoproterenol", "entity2": "cardiac hypertrophy", "span1": [9, 22], "span2": [31, 50]}, "bert_text": "Enhanced <e1> isoproterenol </e1>-induced <e2> cardiac hypertrophy </e2> in transgenic rats with low brain angiotensinogen.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"457": {"data": {"text": "Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.\n", "entity1": "Flumazenil", "entity2": "seizures", "span1": [0, 10], "span2": [19, 27]}, "bert_text": "<e1> Flumazenil </e1> induces <e2> seizures </e2> and death in mixed cocaine-diazepam intoxications.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"458": {"data": {"text": "Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.\n", "entity1": "Flumazenil", "entity2": "death", "span1": [0, 10], "span2": [32, 37]}, "bert_text": "<e1> Flumazenil </e1> induces seizures and <e2> death </e2> in mixed cocaine-diazepam intoxications.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"459": {"data": {"text": "Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.\n", "entity1": "cocaine-diazepam", "entity2": "seizures", "span1": [47, 63], "span2": [19, 27]}, "bert_text": "Flumazenil induces seizures and death in mixed <e1> cocaine-diazepam </e1> <e2> seizures </e2> and death in mixed cocaine-diazepam intoxications.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"460": {"data": {"text": "Flumazenil induces seizures and death in mixed cocaine-diazepam intoxications.\n", "entity1": "cocaine-diazepam", "entity2": "death", "span1": [47, 63], "span2": [32, 37]}, "bert_text": "Flumazenil induces seizures and death in mixed <e1> cocaine-diazepam </e1> <e2> death </e2> in mixed cocaine-diazepam intoxications.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"461": {"data": {"text": "Six patients (3.6%) in the methadone group presented torsades de pointes.", "entity1": "methadone", "entity2": "torsades de pointes", "span1": [27, 36], "span2": [53, 72]}, "bert_text": "Six patients (3.6%) in the <e1> methadone </e1> group presented <e2> torsades de pointes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"462": {"data": {"text": "The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).", "entity1": "FDA", "entity2": "HIT", "span1": [7, 10], "span2": [42, 45]}, "bert_text": "The US <e1> FDA </e1>-recommended argatroban dose in <e2> HIT </e2> is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"463": {"data": {"text": "The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).", "entity1": "FDA", "entity2": "hepatic impairment", "span1": [7, 10], "span2": [91, 109]}, "bert_text": "The US <e1> FDA </e1>-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with <e2> hepatic impairment </e2> and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"464": {"data": {"text": "The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).", "entity1": "argatroban", "entity2": "HIT", "span1": [23, 33], "span2": [42, 45]}, "bert_text": "The US FDA-recommended <e1> argatroban </e1> dose in <e2> HIT </e2> is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"465": {"data": {"text": "The US FDA-recommended argatroban dose in HIT is 2 microg/kg/min (reduced in patients with hepatic impairment and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).", "entity1": "argatroban", "entity2": "hepatic impairment", "span1": [23, 33], "span2": [91, 109]}, "bert_text": "The US FDA-recommended <e1> argatroban </e1> dose in HIT is 2 microg/kg/min (reduced in patients with <e2> hepatic impairment </e2> and in paediatric patients), adjusted to achieve activated partial thromboplastin times (aPTTs) 1.5-3 times baseline (not >100 seconds).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"466": {"data": {"text": "Dermal developmental toxicity of N-phenylimide herbicides in rats.\n", "entity1": "N-phenylimide herbicides", "entity2": "toxicity", "span1": [33, 57], "span2": [21, 29]}, "bert_text": "Dermal developmental toxicity of <e1> N-phenylimide herbicides </e1> <e2> toxicity </e2> of N-phenylimide herbicides in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"467": {"data": {"text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice.", "entity1": "cholecystokinin octapeptide sulphate ester", "entity2": "seizures", "span1": [34, 76], "span2": [168, 176]}, "bert_text": "Intraperitoneal administration of <e1> cholecystokinin octapeptide sulphate ester </e1> (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of <e2> seizures </e2> induced by picrotoxin in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"468": {"data": {"text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice.", "entity1": "CCK-8-SE", "entity2": "seizures", "span1": [78, 86], "span2": [168, 176]}, "bert_text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (<e1> CCK-8-SE </e1>) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of <e2> seizures </e2> induced by picrotoxin in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"469": {"data": {"text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice.", "entity1": "cholecystokinin octapeptide", "entity2": "seizures", "span1": [105, 132], "span2": [168, 176]}, "bert_text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated <e1> cholecystokinin octapeptide </e1> (CCK-8-NS) enhanced the latency of <e2> seizures </e2> induced by picrotoxin in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"470": {"data": {"text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice.", "entity1": "CCK-8-NS", "entity2": "seizures", "span1": [134, 142], "span2": [168, 176]}, "bert_text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (<e1> CCK-8-NS </e1>) enhanced the latency of <e2> seizures </e2> induced by picrotoxin in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"471": {"data": {"text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by picrotoxin in mice.", "entity1": "picrotoxin", "entity2": "seizures", "span1": [188, 198], "span2": [168, 176]}, "bert_text": "Intraperitoneal administration of cholecystokinin octapeptide sulphate ester (CCK-8-SE) and nonsulphated cholecystokinin octapeptide (CCK-8-NS) enhanced the latency of seizures induced by <e1> picrotoxin </e1> <e2> seizures </e2> induced by picrotoxin in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"472": {"data": {"text": "This study examined the frequency of atrioventricular (AV) dissociation and accelerated junctional rhythms in 59 patients receiving oral verapamil.", "entity1": "verapamil", "entity2": "atrioventricular (AV) dissociation", "span1": [137, 146], "span2": [37, 71]}, "bert_text": "This study examined the frequency of atrioventricular (AV) dissociation and accelerated junctional rhythms in 59 patients receiving oral <e1> verapamil </e1> <e2> atrioventricular (AV) dissociation </e2> and accelerated junctional rhythms in 59 patients receiving oral verapamil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"473": {"data": {"text": "EDRF (endothelium-derived relaxing factor)/nitric oxide does not seem to play an important role in the peptide-produced hypotension.", "entity1": "factor)/nitric oxide", "entity2": "hypotension", "span1": [35, 55], "span2": [120, 131]}, "bert_text": "EDRF (endothelium-derived relaxing <e1> factor)/nitric oxide </e1> does not seem to play an important role in the peptide-produced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"474": {"data": {"text": "Nifedipine induced bradycardia in a patient with autonomic neuropathy.\n", "entity1": "Nifedipine", "entity2": "bradycardia", "span1": [0, 10], "span2": [19, 30]}, "bert_text": "<e1> Nifedipine </e1> induced <e2> bradycardia </e2> in a patient with autonomic neuropathy.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"475": {"data": {"text": "Nifedipine induced bradycardia in a patient with autonomic neuropathy.\n", "entity1": "Nifedipine", "entity2": "autonomic neuropathy", "span1": [0, 10], "span2": [49, 69]}, "bert_text": "<e1> Nifedipine </e1> induced bradycardia in a patient with <e2> autonomic neuropathy </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"476": {"data": {"text": "Histopathological examination of the kidney showed tubular necrosis in D-AmB-treated rats but no change in NS-718-treated rats.", "entity1": "D-AmB", "entity2": "necrosis", "span1": [71, 76], "span2": [59, 67]}, "bert_text": "Histopathological examination of the kidney showed tubular necrosis in <e1> D-AmB </e1> <e2> necrosis </e2> in D-AmB-treated rats but no change in NS-718-treated rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"477": {"data": {"text": "Histopathological examination of the kidney showed tubular necrosis in D-AmB-treated rats but no change in NS-718-treated rats.", "entity1": "D-AmB", "entity2": "NS-718-treated", "span1": [71, 76], "span2": [107, 121]}, "bert_text": "Histopathological examination of the kidney showed tubular necrosis in <e1> D-AmB </e1>-treated rats but no change in <e2> NS-718-treated </e2> rats.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"478": {"data": {"text": "In conclusion, we believe that physicians should carefully consider the risk of drug-induced hepatic injury when clopidogrel is prescribed.", "entity1": "clopidogrel", "entity2": "hepatic injury", "span1": [113, 124], "span2": [93, 107]}, "bert_text": "In conclusion, we believe that physicians should carefully consider the risk of drug-induced hepatic injury when <e1> clopidogrel </e1> <e2> hepatic injury </e2> when clopidogrel is prescribed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"479": {"data": {"text": "CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers.", "entity1": "CAA", "entity2": "necrosis", "span1": [0, 3], "span2": [107, 115]}, "bert_text": "<e1> CAA </e1> reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in <e2> necrosis </e2> markers.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"480": {"data": {"text": "CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular thiols and an increase in necrosis markers.", "entity1": "thiols", "entity2": "necrosis", "span1": [81, 87], "span2": [107, 115]}, "bert_text": "CAA reduced hRPTEC cell number and protein, induced a loss in free intracellular <e1> thiols </e1> and an increase in <e2> necrosis </e2> markers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"481": {"data": {"text": "Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis.\n", "entity1": "daptomycin", "entity2": "Staphylococcus aureus meningitis", "span1": [45, 55], "span2": [69, 101]}, "bert_text": "Cerebrospinal fluid penetration of high-dose <e1> daptomycin </e1> in suspected <e2> Staphylococcus aureus meningitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"482": {"data": {"text": "When the total busulfan dose was taken into account, there was a significant difference in terms of neurotoxicity incidence among patients under 16 mg/kg (1 of 57, 1.7%) and patients under 600 mg/m2 (6 of 39, 15.4%) (P less than 0.02).", "entity1": "busulfan", "entity2": "neurotoxicity", "span1": [15, 23], "span2": [100, 113]}, "bert_text": "When the total <e1> busulfan </e1> dose was taken into account, there was a significant difference in terms of <e2> neurotoxicity </e2> incidence among patients under 16 mg/kg (1 of 57, 1.7%) and patients under 600 mg/m2 (6 of 39, 15.4%) (P less than 0.02).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"483": {"data": {"text": "The epidemiology of aminoglycoside-induced nephrotoxicity is not fully understood.", "entity1": "aminoglycoside", "entity2": "nephrotoxicity", "span1": [20, 34], "span2": [43, 57]}, "bert_text": "The epidemiology of <e1> aminoglycoside </e1>-induced <e2> nephrotoxicity </e2> is not fully understood.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"484": {"data": {"text": "METHODS: Seventy-five patients with non-Hodgkin lymphoma treated with epirubicin were studied.", "entity1": "epirubicin", "entity2": "non-Hodgkin lymphoma", "span1": [70, 80], "span2": [36, 56]}, "bert_text": "METHODS: Seventy-five patients with non-Hodgkin lymphoma treated with <e1> epirubicin </e1> <e2> non-Hodgkin lymphoma </e2> treated with epirubicin were studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"485": {"data": {"text": "A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide, administered twice daily for one month to hypertensive patients.", "entity1": "timolol maleate", "entity2": "hypertensive", "span1": [135, 150], "span2": [227, 239]}, "bert_text": "A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of <e1> timolol maleate </e1> and 25 mg of hydrochlorothiazide, administered twice daily for one month to <e2> hypertensive </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"486": {"data": {"text": "A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide, administered twice daily for one month to hypertensive patients.", "entity1": "hydrochlorothiazide", "entity2": "hypertensive", "span1": [164, 183], "span2": [227, 239]}, "bert_text": "A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed-ratio combination containing 10 mg of timolol maleate and 25 mg of <e1> hydrochlorothiazide </e1>, administered twice daily for one month to <e2> hypertensive </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 0},
+	"487": {"data": {"text": "Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline.7.", "entity1": "adrenaline.7", "entity2": "arrhythmias", "span1": [85, 97], "span2": [12, 23]}, "bert_text": "Blockade of arrhythmias with both isomers was surmountable by increasing the dose of <e1> adrenaline.7 </e1> <e2> arrhythmias </e2> with both isomers was surmountable by increasing the dose of adrenaline.7.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"488": {"data": {"text": "BACKGROUND: Acetaminophen-induced hepatotoxicity is the most common cause of acute liver failure (ALF) in the UK.", "entity1": "Acetaminophen", "entity2": "hepatotoxicity", "span1": [12, 25], "span2": [34, 48]}, "bert_text": "BACKGROUND: <e1> Acetaminophen </e1>-induced <e2> hepatotoxicity </e2> is the most common cause of acute liver failure (ALF) in the UK.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"489": {"data": {"text": "BACKGROUND: Acetaminophen-induced hepatotoxicity is the most common cause of acute liver failure (ALF) in the UK.", "entity1": "Acetaminophen", "entity2": "acute liver failure", "span1": [12, 25], "span2": [77, 96]}, "bert_text": "BACKGROUND: <e1> Acetaminophen </e1>-induced hepatotoxicity is the most common cause of <e2> acute liver failure </e2> (ALF) in the UK.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"490": {"data": {"text": "BACKGROUND: Acetaminophen-induced hepatotoxicity is the most common cause of acute liver failure (ALF) in the UK.", "entity1": "Acetaminophen", "entity2": "ALF", "span1": [12, 25], "span2": [98, 101]}, "bert_text": "BACKGROUND: <e1> Acetaminophen </e1>-induced hepatotoxicity is the most common cause of acute liver failure (<e2> ALF </e2>) in the UK.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"491": {"data": {"text": "Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.", "entity1": "Busulfan", "entity2": "nervous system disease", "span1": [0, 8], "span2": [147, 169]}, "bert_text": "<e1> Busulfan </e1> levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central <e2> nervous system disease </e2> under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"492": {"data": {"text": "Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.", "entity1": "busulfan", "entity2": "nervous system disease", "span1": [186, 194], "span2": [147, 169]}, "bert_text": "Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 <e1> busulfan </e1> <e2> nervous system disease </e2> under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"493": {"data": {"text": "Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.", "entity1": "busulfan", "entity2": "nervous system disease", "span1": [211, 219], "span2": [147, 169]}, "bert_text": "Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:<e1> busulfan </e1> <e2> nervous system disease </e2> under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"494": {"data": {"text": "Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.", "entity1": "clonazepam", "entity2": "nervous system disease", "span1": [200, 210], "span2": [147, 169]}, "bert_text": "Busulfan levels were measured by a gas chromatographic-mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg/m2 busulfan with <e1> clonazepam </e1> <e2> nervous system disease </e2> under 600 mg/m2 busulfan with clonazepam:busulfan cerebrospinal fluid:plasma ratio was 1.39.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"495": {"data": {"text": "Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.", "entity1": "isoproterenol", "entity2": "cardiotoxic", "span1": [79, 92], "span2": [57, 68]}, "bert_text": "Acute insulin treatment normalizes the resistance to the cardiotoxic effect of <e1> isoproterenol </e1> <e2> cardiotoxic </e2> effect of isoproterenol in streptozotocin diabetic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"496": {"data": {"text": "Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.", "entity1": "isoproterenol", "entity2": "diabetic", "span1": [79, 92], "span2": [111, 119]}, "bert_text": "Acute insulin treatment normalizes the resistance to the cardiotoxic effect of <e1> isoproterenol </e1> in streptozotocin <e2> diabetic </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"497": {"data": {"text": "Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.", "entity1": "streptozotocin", "entity2": "cardiotoxic", "span1": [96, 110], "span2": [57, 68]}, "bert_text": "Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in <e1> streptozotocin </e1> <e2> cardiotoxic </e2> effect of isoproterenol in streptozotocin diabetic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"498": {"data": {"text": "Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.", "entity1": "streptozotocin", "entity2": "diabetic", "span1": [96, 110], "span2": [111, 119]}, "bert_text": "Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in <e1> streptozotocin </e1> <e2> diabetic </e2> rats.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"499": {"data": {"text": "These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [58, 69], "span2": [28, 46]}, "bert_text": "These results indicate that status epilepticus induced by <e1> pilocarpine </e1> <e2> status epilepticus </e2> induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"500": {"data": {"text": "These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause brain damage through an excitatory NMDA receptor-mediated mechanism.", "entity1": "pilocarpine", "entity2": "brain damage", "span1": [58, 69], "span2": [193, 205]}, "bert_text": "These results indicate that status epilepticus induced by <e1> pilocarpine </e1> is initiated by cholinergic overstimulation and propagated by glutamatergic transmission, the elevation of which may cause <e2> brain damage </e2> through an excitatory NMDA receptor-mediated mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"501": {"data": {"text": "Furthermore, apigenin did not prevent the amnesia induced by scopolamine (1mg/kg, i.p.", "entity1": "apigenin", "entity2": "amnesia", "span1": [13, 21], "span2": [42, 49]}, "bert_text": "Furthermore, <e1> apigenin </e1> did not prevent the <e2> amnesia </e2> induced by scopolamine (1mg/kg, i.p.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"502": {"data": {"text": "Furthermore, apigenin did not prevent the amnesia induced by scopolamine (1mg/kg, i.p.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [61, 72], "span2": [42, 49]}, "bert_text": "Furthermore, apigenin did not prevent the amnesia induced by <e1> scopolamine </e1> <e2> amnesia </e2> induced by scopolamine (1mg/kg, i.p.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1], "label": 1},
+	"503": {"data": {"text": "PURPOSE: To determine the natural history of visual field defects in a group of patients known to have Vigabatrin-associated changes who elected to continue the medication because of good seizure control.", "entity1": "Vigabatrin", "entity2": "visual field defects", "span1": [103, 113], "span2": [45, 65]}, "bert_text": "PURPOSE: To determine the natural history of visual field defects in a group of patients known to have <e1> Vigabatrin </e1> <e2> visual field defects </e2> in a group of patients known to have Vigabatrin-associated changes who elected to continue the medication because of good seizure control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"504": {"data": {"text": "PURPOSE: To determine the natural history of visual field defects in a group of patients known to have Vigabatrin-associated changes who elected to continue the medication because of good seizure control.", "entity1": "Vigabatrin", "entity2": "seizure", "span1": [103, 113], "span2": [188, 195]}, "bert_text": "PURPOSE: To determine the natural history of visual field defects in a group of patients known to have <e1> Vigabatrin </e1>-associated changes who elected to continue the medication because of good <e2> seizure </e2> control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"505": {"data": {"text": "Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.).", "entity1": "METH", "entity2": "depressive", "span1": [115, 119], "span2": [26, 36]}, "bert_text": "Thus, we now assessed the depressive-like behaviour in mice at early and long-term periods following a single high <e1> METH </e1> <e2> depressive </e2>-like behaviour in mice at early and long-term periods following a single high METH dose (30 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"506": {"data": {"text": "STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine-benzodiazepine intoxication.", "entity1": "benzodiazepine", "entity2": "seizures", "span1": [40, 54], "span2": [88, 96]}, "bert_text": "STUDY HYPOTHESIS: Administration of the <e1> benzodiazepine </e1> antagonist flumazenil may unmask <e2> seizures </e2> in mixed cocaine-benzodiazepine intoxication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"507": {"data": {"text": "STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine-benzodiazepine intoxication.", "entity1": "cocaine-benzodiazepine", "entity2": "seizures", "span1": [106, 128], "span2": [88, 96]}, "bert_text": "STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed <e1> cocaine-benzodiazepine </e1> <e2> seizures </e2> in mixed cocaine-benzodiazepine intoxication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"508": {"data": {"text": "STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine-benzodiazepine intoxication.", "entity1": "flumazenil", "entity2": "seizures", "span1": [66, 76], "span2": [88, 96]}, "bert_text": "STUDY HYPOTHESIS: Administration of the benzodiazepine antagonist <e1> flumazenil </e1> may unmask <e2> seizures </e2> in mixed cocaine-benzodiazepine intoxication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"509": {"data": {"text": "Clonazepam monotherapy for epilepsy in childhood.\n", "entity1": "Clonazepam", "entity2": "epilepsy", "span1": [0, 10], "span2": [27, 35]}, "bert_text": "<e1> Clonazepam </e1> monotherapy for <e2> epilepsy </e2> in childhood.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"510": {"data": {"text": "In the inpatient setting, the frequency of QT interval prolongation with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.", "entity1": "methadone", "entity2": "QT interval prolongation", "span1": [73, 82], "span2": [43, 67]}, "bert_text": "In the inpatient setting, the frequency of QT interval prolongation with <e1> methadone </e1> <e2> QT interval prolongation </e2> with methadone treatment, its dose dependence, and the importance of cofactors such as drug-drug interactions remain unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"511": {"data": {"text": "Patients with the diagnosis of methamphetamine based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for methamphetamine-induced psychosis and other Axis I psychiatric disorders.", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [31, 46], "span2": [175, 184]}, "bert_text": "Patients with the diagnosis of <e1> methamphetamine </e1> based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for methamphetamine-induced <e2> psychosis </e2> and other Axis I psychiatric disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"512": {"data": {"text": "Patients with the diagnosis of methamphetamine based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for methamphetamine-induced psychosis and other Axis I psychiatric disorders.", "entity1": "methamphetamine", "entity2": "psychiatric disorders", "span1": [31, 46], "span2": [202, 223]}, "bert_text": "Patients with the diagnosis of <e1> methamphetamine </e1> based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for methamphetamine-induced psychosis and other Axis I <e2> psychiatric disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"513": {"data": {"text": "Patients with the diagnosis of methamphetamine based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for methamphetamine-induced psychosis and other Axis I psychiatric disorders.", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [151, 166], "span2": [175, 184]}, "bert_text": "Patients with the diagnosis of methamphetamine based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for <e1> methamphetamine </e1>-induced <e2> psychosis </e2> and other Axis I psychiatric disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"514": {"data": {"text": "Patients with the diagnosis of methamphetamine based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for methamphetamine-induced psychosis and other Axis I psychiatric disorders.", "entity1": "methamphetamine", "entity2": "psychiatric disorders", "span1": [151, 166], "span2": [202, 223]}, "bert_text": "Patients with the diagnosis of methamphetamine based on DSM-IV were interviewed using the Mini International Neuropsychiatric Interview (M.I.N.I.) for <e1> methamphetamine </e1>-induced psychosis and other Axis I <e2> psychiatric disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"515": {"data": {"text": "Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with clonazepam.", "entity1": "clonazepam", "entity2": "epilepsy", "span1": [118, 128], "span2": [69, 77]}, "bert_text": "Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with <e1> clonazepam </e1> <e2> epilepsy </e2> than infantile spasms were treated with clonazepam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"516": {"data": {"text": "Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with clonazepam.", "entity1": "clonazepam", "entity2": "spasms", "span1": [118, 128], "span2": [93, 99]}, "bert_text": "Sixty patients (age-range one month to 14 years) with other types of epilepsy than infantile spasms were treated with <e1> clonazepam </e1> <e2> spasms </e2> were treated with clonazepam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"517": {"data": {"text": "After granisetron doses of 5, 10, 20, and 40 micrograms/kg, a major response (< or = two vomiting or retching episodes, and no antiemetic rescue) was recorded in 23%, 57%, 58%, and 60% of patients, respectively, and a complete response (no vomiting or retching, and no antiemetic rescue) in 18%, 41%, 40%, and 47% of patients, respectively.", "entity1": "granisetron", "entity2": "vomiting", "span1": [6, 17], "span2": [89, 97]}, "bert_text": "After <e1> granisetron </e1> doses of 5, 10, 20, and 40 micrograms/kg, a major response (< or = two <e2> vomiting </e2> or retching episodes, and no antiemetic rescue) was recorded in 23%, 57%, 58%, and 60% of patients, respectively, and a complete response (no vomiting or retching, and no antiemetic rescue) in 18%, 41%, 40%, and 47% of patients, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"518": {"data": {"text": "After granisetron doses of 5, 10, 20, and 40 micrograms/kg, a major response (< or = two vomiting or retching episodes, and no antiemetic rescue) was recorded in 23%, 57%, 58%, and 60% of patients, respectively, and a complete response (no vomiting or retching, and no antiemetic rescue) in 18%, 41%, 40%, and 47% of patients, respectively.", "entity1": "granisetron", "entity2": "vomiting", "span1": [6, 17], "span2": [240, 248]}, "bert_text": "After <e1> granisetron </e1> doses of 5, 10, 20, and 40 micrograms/kg, a major response (< or = two vomiting or retching episodes, and no antiemetic rescue) was recorded in 23%, 57%, 58%, and 60% of patients, respectively, and a complete response (no <e2> vomiting </e2> or retching, and no antiemetic rescue) in 18%, 41%, 40%, and 47% of patients, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"519": {"data": {"text": "We conclude that levodopa has a central hypotensive action that parallels the motor effects in fluctuating patients.", "entity1": "levodopa", "entity2": "hypotensive", "span1": [17, 25], "span2": [40, 51]}, "bert_text": "We conclude that <e1> levodopa </e1> has a central <e2> hypotensive </e2> action that parallels the motor effects in fluctuating patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"520": {"data": {"text": "High PELD and Child-Pugh scores before LT and high post-operative serum Tbil may be contributory risk factors for TAC-related seizures.", "entity1": "TAC", "entity2": "seizures", "span1": [114, 117], "span2": [126, 134]}, "bert_text": "High PELD and Child-Pugh scores before LT and high post-operative serum Tbil may be contributory risk factors for <e1> TAC </e1>-related <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"521": {"data": {"text": "There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).", "entity1": "clozapine<olanzapine<risperidone", "entity2": "glucose effectiveness", "span1": [98, 130], "span2": [51, 72]}, "bert_text": "There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (<e1> clozapine<olanzapine<risperidone </e1> <e2> glucose effectiveness </e2> (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"522": {"data": {"text": "There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).", "entity1": "risperidone", "entity2": "glucose effectiveness", "span1": [183, 194], "span2": [51, 72]}, "bert_text": "There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and <e1> risperidone </e1> <e2> glucose effectiveness </e2> (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"523": {"data": {"text": "There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).", "entity1": "risperidone", "entity2": "glucose effectiveness", "span1": [239, 250], "span2": [51, 72]}, "bert_text": "There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and <e1> risperidone </e1> <e2> glucose effectiveness </e2> (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"524": {"data": {"text": "There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).", "entity1": "clozapine", "entity2": "glucose effectiveness", "span1": [169, 178], "span2": [51, 72]}, "bert_text": "There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between <e1> clozapine </e1> <e2> glucose effectiveness </e2> (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"525": {"data": {"text": "There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).", "entity1": "olanzapine", "entity2": "glucose effectiveness", "span1": [224, 234], "span2": [51, 72]}, "bert_text": "There was a significant difference among groups in glucose effectiveness (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and <e1> olanzapine </e1> <e2> glucose effectiveness </e2> (F(30) = 4.18; P = .02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t(30) = -2.59; P = .02) and olanzapine and risperidone (t(30) = -2.34, P = .03).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"526": {"data": {"text": "Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice.\n", "entity1": "dehydroepiandrosterone", "entity2": "schizophrenia", "span1": [11, 33], "span2": [57, 70]}, "bert_text": "Effects of <e1> dehydroepiandrosterone </e1> in amphetamine-induced <e2> schizophrenia </e2> models in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"527": {"data": {"text": "Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice.\n", "entity1": "amphetamine", "entity2": "schizophrenia", "span1": [37, 48], "span2": [57, 70]}, "bert_text": "Effects of dehydroepiandrosterone in <e1> amphetamine </e1>-induced <e2> schizophrenia </e2> models in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"528": {"data": {"text": "Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.", "entity1": "LF", "entity2": "hypertension", "span1": [26, 28], "span2": [136, 148]}, "bert_text": "Chronic administration of <e1> LF </e1> strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced <e2> hypertension </e2>, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"529": {"data": {"text": "Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.", "entity1": "LF", "entity2": "LF", "span1": [26, 28], "span2": [255, 257]}, "bert_text": "Chronic administration of <e1> LF </e1> strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of <e2> LF </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"530": {"data": {"text": "Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.", "entity1": "Dex", "entity2": "hypertension", "span1": [124, 127], "span2": [136, 148]}, "bert_text": "Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in <e1> Dex </e1>-induced <e2> hypertension </e2>, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"531": {"data": {"text": "Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF.", "entity1": "Dex", "entity2": "LF", "span1": [124, 127], "span2": [255, 257]}, "bert_text": "Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in <e1> Dex </e1>-induced hypertension, suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of <e2> LF </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"532": {"data": {"text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "entity1": "PTU", "entity2": "fever", "span1": [178, 181], "span2": [90, 95]}, "bert_text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping <e1> PTU </e1> <e2> fever </e2>, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"533": {"data": {"text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "entity1": "PTU", "entity2": "ulcers", "span1": [178, 181], "span2": [102, 108]}, "bert_text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping <e1> PTU </e1> <e2> ulcers </e2> and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"534": {"data": {"text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "entity1": "PTU", "entity2": "polyarthralgia", "span1": [178, 181], "span2": [113, 127]}, "bert_text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping <e1> PTU </e1> <e2> polyarthralgia </e2>, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"535": {"data": {"text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "entity1": "PTU", "entity2": "fever", "span1": [269, 272], "span2": [90, 95]}, "bert_text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing <e1> PTU </e1> <e2> fever </e2>, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"536": {"data": {"text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "entity1": "PTU", "entity2": "ulcers", "span1": [269, 272], "span2": [102, 108]}, "bert_text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing <e1> PTU </e1> <e2> ulcers </e2> and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"537": {"data": {"text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "entity1": "PTU", "entity2": "polyarthralgia", "span1": [269, 272], "span2": [113, 127]}, "bert_text": "In the third patient, the MPO-ANCA titre increased to 204 U/ml and she developed a higher fever, oral ulcers and polyarthralgia, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing <e1> PTU </e1> <e2> polyarthralgia </e2>, but the symptoms resolved 2 weeks after stopping PTU therapy, and the MPO-ANCA titre decreased to 20.7 U/ml by 4 months after discontinuing PTU.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"538": {"data": {"text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "entity1": "lithium", "entity2": "seizures", "span1": [67, 74], "span2": [47, 55]}, "bert_text": "Third, although it is relatively easy to block seizures induced by <e1> lithium </e1> <e2> seizures </e2> induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"539": {"data": {"text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "entity1": "lithium", "entity2": "seizures", "span1": [67, 74], "span2": [242, 250]}, "bert_text": "Third, although it is relatively easy to block seizures induced by <e1> lithium </e1> and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"540": {"data": {"text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "entity1": "lithium", "entity2": "status epilepticus", "span1": [67, 74], "span2": [192, 210]}, "bert_text": "Third, although it is relatively easy to block seizures induced by <e1> lithium </e1> and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing <e2> status epilepticus </e2> and block the lethality of the seizures.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"541": {"data": {"text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [79, 90], "span2": [47, 55]}, "bert_text": "Third, although it is relatively easy to block seizures induced by lithium and <e1> pilocarpine </e1> <e2> seizures </e2> induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"542": {"data": {"text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [79, 90], "span2": [242, 250]}, "bert_text": "Third, although it is relatively easy to block seizures induced by lithium and <e1> pilocarpine </e1> by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"543": {"data": {"text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [79, 90], "span2": [192, 210]}, "bert_text": "Third, although it is relatively easy to block seizures induced by lithium and <e1> pilocarpine </e1> by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing <e2> status epilepticus </e2> and block the lethality of the seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"544": {"data": {"text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [137, 148], "span2": [47, 55]}, "bert_text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to <e1> pilocarpine </e1> <e2> seizures </e2> induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"545": {"data": {"text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [137, 148], "span2": [242, 250]}, "bert_text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to <e1> pilocarpine </e1>, it is more difficult to terminate ongoing status epilepticus and block the lethality of the <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"546": {"data": {"text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine, it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [137, 148], "span2": [192, 210]}, "bert_text": "Third, although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to <e1> pilocarpine </e1>, it is more difficult to terminate ongoing <e2> status epilepticus </e2> and block the lethality of the seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"547": {"data": {"text": "This study was done to assess the influence of a high intracoronary cocaine concentration on LV systolic and diastolic function in humans.", "entity1": "cocaine", "entity2": "LV", "span1": [68, 75], "span2": [93, 95]}, "bert_text": "This study was done to assess the influence of a high intracoronary <e1> cocaine </e1> concentration on <e2> LV </e2> systolic and diastolic function in humans.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"548": {"data": {"text": "METHODS: We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin.", "entity1": "carboplatin", "entity2": "abnormal ocular motility", "span1": [116, 127], "span2": [18, 42]}, "bert_text": "METHODS: We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon <e1> carboplatin </e1> <e2> abnormal ocular motility </e2> in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"549": {"data": {"text": "METHODS: We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin.", "entity1": "carboplatin", "entity2": "retinoblastoma", "span1": [116, 127], "span2": [75, 89]}, "bert_text": "METHODS: We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon <e1> carboplatin </e1> <e2> retinoblastoma </e2> who had received subtenon carboplatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"550": {"data": {"text": "Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.", "entity1": "losartan", "entity2": "tubular atrophy", "span1": [37, 45], "span2": [60, 75]}, "bert_text": "Histological examination showed that <e1> losartan </e1> could prevent <e2> tubular atrophy </e2>, interstitial infiltration and fibrosis in ADR nephropathy.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"551": {"data": {"text": "Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.", "entity1": "losartan", "entity2": "fibrosis", "span1": [37, 45], "span2": [107, 115]}, "bert_text": "Histological examination showed that <e1> losartan </e1> could prevent tubular atrophy, interstitial infiltration and <e2> fibrosis </e2> in ADR nephropathy.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"552": {"data": {"text": "Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.", "entity1": "losartan", "entity2": "nephropathy", "span1": [37, 45], "span2": [123, 134]}, "bert_text": "Histological examination showed that <e1> losartan </e1> could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"553": {"data": {"text": "Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.", "entity1": "ADR", "entity2": "tubular atrophy", "span1": [119, 122], "span2": [60, 75]}, "bert_text": "Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in <e1> ADR </e1> <e2> tubular atrophy </e2>, interstitial infiltration and fibrosis in ADR nephropathy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"554": {"data": {"text": "Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.", "entity1": "ADR", "entity2": "fibrosis", "span1": [119, 122], "span2": [107, 115]}, "bert_text": "Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in <e1> ADR </e1> <e2> fibrosis </e2> in ADR nephropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"555": {"data": {"text": "Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in ADR nephropathy.", "entity1": "ADR", "entity2": "nephropathy", "span1": [119, 122], "span2": [123, 134]}, "bert_text": "Histological examination showed that losartan could prevent tubular atrophy, interstitial infiltration and fibrosis in <e1> ADR </e1> <e2> nephropathy </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"556": {"data": {"text": "Experimental studies in healthy human volunteers indicate aminoglycosides cause proximal tubular damage in most patients, but rarely, if ever, cause glomerular or tubular dysfunction.", "entity1": "aminoglycosides", "entity2": "glomerular or tubular dysfunction", "span1": [58, 73], "span2": [149, 182]}, "bert_text": "Experimental studies in healthy human volunteers indicate <e1> aminoglycosides </e1> cause proximal tubular damage in most patients, but rarely, if ever, cause <e2> glomerular or tubular dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"557": {"data": {"text": "Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.", "entity1": "aminoglycoside", "entity2": "liver disease", "span1": [77, 91], "span2": [100, 113]}, "bert_text": "Further analysis of these data suggests that the duration of therapy, plasma <e1> aminoglycoside </e1> levels, <e2> liver disease </e2>, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0], "label": 0},
+	"558": {"data": {"text": "Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.", "entity1": "aminoglycoside", "entity2": "nephrotoxicity", "span1": [77, 91], "span2": [228, 242]}, "bert_text": "Further analysis of these data suggests that the duration of therapy, plasma <e1> aminoglycoside </e1> levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0], "label": 1},
+	"559": {"data": {"text": "Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.", "entity1": "creatinine", "entity2": "liver disease", "span1": [152, 162], "span2": [100, 113]}, "bert_text": "Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated <e1> creatinine </e1> <e2> liver disease </e2>, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"560": {"data": {"text": "Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated creatinine clearance and, possibly, female gender all increase the risk for nephrotoxicity.", "entity1": "creatinine", "entity2": "nephrotoxicity", "span1": [152, 162], "span2": [228, 242]}, "bert_text": "Further analysis of these data suggests that the duration of therapy, plasma aminoglycoside levels, liver disease, advanced age, high initial estimated <e1> creatinine </e1> clearance and, possibly, female gender all increase the risk for <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"561": {"data": {"text": "After the addition of clonidine 0.15 mg bid she developed complete AV block, which resolved after all therapy was stopped.", "entity1": "clonidine", "entity2": "AV block", "span1": [22, 31], "span2": [67, 75]}, "bert_text": "After the addition of <e1> clonidine </e1> 0.15 mg bid she developed complete <e2> AV block </e2>, which resolved after all therapy was stopped.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"562": {"data": {"text": "In conclusion, clentiazem attenuated epinephrine-induced cardiac injury, possibly through its effect on the adrenergic pathway.", "entity1": "clentiazem", "entity2": "cardiac injury", "span1": [15, 25], "span2": [57, 71]}, "bert_text": "In conclusion, <e1> clentiazem </e1> attenuated epinephrine-induced <e2> cardiac injury </e2>, possibly through its effect on the adrenergic pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"563": {"data": {"text": "In conclusion, clentiazem attenuated epinephrine-induced cardiac injury, possibly through its effect on the adrenergic pathway.", "entity1": "epinephrine", "entity2": "cardiac injury", "span1": [37, 48], "span2": [57, 71]}, "bert_text": "In conclusion, clentiazem attenuated <e1> epinephrine </e1>-induced <e2> cardiac injury </e2>, possibly through its effect on the adrenergic pathway.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"564": {"data": {"text": "PURPOSE: To demonstrate the association between ethambutol and optic neuropathy.", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [48, 58], "span2": [63, 79]}, "bert_text": "PURPOSE: To demonstrate the association between <e1> ethambutol </e1> and <e2> optic neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"565": {"data": {"text": "In our case the therapy with zinc acetate represented an effective treatment for a Wilson's disease patient in which penicillamine-related side effects appeared.", "entity1": "zinc acetate", "entity2": "Wilson's disease", "span1": [29, 41], "span2": [83, 99]}, "bert_text": "In our case the therapy with <e1> zinc acetate </e1> represented an effective treatment for a <e2> Wilson's disease </e2> patient in which penicillamine-related side effects appeared.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"566": {"data": {"text": "In our case the therapy with zinc acetate represented an effective treatment for a Wilson's disease patient in which penicillamine-related side effects appeared.", "entity1": "penicillamine", "entity2": "Wilson's disease", "span1": [117, 130], "span2": [83, 99]}, "bert_text": "In our case the therapy with zinc acetate represented an effective treatment for a Wilson's disease patient in which <e1> penicillamine </e1> <e2> Wilson's disease </e2> patient in which penicillamine-related side effects appeared.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"567": {"data": {"text": "PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (CYP)-induced cystitis in rats.", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [102, 118], "span2": [133, 141]}, "bert_text": "PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on <e1> cyclophosphamide </e1> (CYP)-induced <e2> cystitis </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"568": {"data": {"text": "PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (CYP)-induced cystitis in rats.", "entity1": "CYP)-induced", "entity2": "cystitis", "span1": [120, 132], "span2": [133, 141]}, "bert_text": "PURPOSE: The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide (<e1> CYP)-induced </e1> <e2> cystitis </e2> in rats.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"569": {"data": {"text": "Amiodarone, an efficacious and widely used antiarrhythmic agent, has been reported to cause hepatotoxicity in some patients.", "entity1": "Amiodarone", "entity2": "hepatotoxicity", "span1": [0, 10], "span2": [92, 106]}, "bert_text": "<e1> Amiodarone </e1>, an efficacious and widely used antiarrhythmic agent, has been reported to cause <e2> hepatotoxicity </e2> in some patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"570": {"data": {"text": "Major bleeding with argatroban is 0-10% in the non-interventional setting and 0-5.8% periprocedurally.", "entity1": "argatroban", "entity2": "bleeding", "span1": [20, 30], "span2": [6, 14]}, "bert_text": "Major bleeding with <e1> argatroban </e1> <e2> bleeding </e2> with argatroban is 0-10% in the non-interventional setting and 0-5.8% periprocedurally.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"571": {"data": {"text": "Quinine-induced arrhythmia in a patient with severe malaria.\n", "entity1": "Quinine", "entity2": "arrhythmia", "span1": [0, 7], "span2": [16, 26]}, "bert_text": "<e1> Quinine </e1>-induced <e2> arrhythmia </e2> in a patient with severe malaria.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"572": {"data": {"text": "Quinine-induced arrhythmia in a patient with severe malaria.\n", "entity1": "Quinine", "entity2": "malaria", "span1": [0, 7], "span2": [52, 59]}, "bert_text": "<e1> Quinine </e1>-induced arrhythmia in a patient with severe <e2> malaria </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"573": {"data": {"text": "At detection of reduction in sural nerve SAP amplitude, the median thalidomide cumulative dose was 21.4 g. The threshold neurotoxic dosage is lower than previously reported.", "entity1": "thalidomide", "entity2": "neurotoxic", "span1": [67, 78], "span2": [121, 131]}, "bert_text": "At detection of reduction in sural nerve SAP amplitude, the median <e1> thalidomide </e1> cumulative dose was 21.4 g. The threshold <e2> neurotoxic </e2> dosage is lower than previously reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"574": {"data": {"text": "However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of tetracycline on depression of output of triglyceride under these experimental conditions.", "entity1": "tetracycline", "entity2": "depression", "span1": [110, 122], "span2": [126, 136]}, "bert_text": "However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of <e1> tetracycline </e1> on <e2> depression </e2> of output of triglyceride under these experimental conditions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"575": {"data": {"text": "However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of tetracycline on depression of output of triglyceride under these experimental conditions.", "entity1": "triglyceride", "entity2": "depression", "span1": [150, 162], "span2": [126, 136]}, "bert_text": "However, livers from female, and especially pregnant female rats, were strikingly resistant to the effects of tetracycline on depression of output of <e1> triglyceride </e1> <e2> depression </e2> of output of triglyceride under these experimental conditions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"576": {"data": {"text": "BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "entity1": "carboplatin", "entity2": "toxicity", "span1": [27, 38], "span2": [90, 98]}, "bert_text": "BACKGROUND: Focal subtenon <e1> carboplatin </e1> injections have recently been used as a presumably <e2> toxicity </e2>-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"577": {"data": {"text": "BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "entity1": "carboplatin", "entity2": "intraocular retinoblastoma", "span1": [27, 38], "span2": [141, 167]}, "bert_text": "BACKGROUND: Focal subtenon <e1> carboplatin </e1> injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for <e2> intraocular retinoblastoma </e2>. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"578": {"data": {"text": "BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "entity1": "carboplatin", "entity2": "abnormal ocular motility", "span1": [27, 38], "span2": [219, 243]}, "bert_text": "BACKGROUND: Focal subtenon <e1> carboplatin </e1> injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with <e2> abnormal ocular motility </e2> in patients treated with subtenon carboplatin chemotherapy.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"579": {"data": {"text": "BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "entity1": "carboplatin", "entity2": "toxicity", "span1": [278, 289], "span2": [90, 98]}, "bert_text": "BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon <e1> carboplatin </e1> <e2> toxicity </e2>-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"580": {"data": {"text": "BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "entity1": "carboplatin", "entity2": "intraocular retinoblastoma", "span1": [278, 289], "span2": [141, 167]}, "bert_text": "BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon <e1> carboplatin </e1> <e2> intraocular retinoblastoma </e2>. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"581": {"data": {"text": "BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.", "entity1": "carboplatin", "entity2": "abnormal ocular motility", "span1": [278, 289], "span2": [219, 243]}, "bert_text": "BACKGROUND: Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma. OBJECTIVE: To report our clinical experience with abnormal ocular motility in patients treated with subtenon <e1> carboplatin </e1> <e2> abnormal ocular motility </e2> in patients treated with subtenon carboplatin chemotherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"582": {"data": {"text": "CONCLUSION: Verapamil responsiveness is not a reliable finding for the differential diagnosis of hyperprolactinemia.", "entity1": "Verapamil", "entity2": "hyperprolactinemia", "span1": [12, 21], "span2": [97, 115]}, "bert_text": "CONCLUSION: <e1> Verapamil </e1> responsiveness is not a reliable finding for the differential diagnosis of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"583": {"data": {"text": "We report a case of acute interstitial nephritis (AIN) due to nicergoline (Sermion).", "entity1": "nicergoline", "entity2": "interstitial nephritis", "span1": [62, 73], "span2": [26, 48]}, "bert_text": "We report a case of acute interstitial nephritis (AIN) due to <e1> nicergoline </e1> <e2> interstitial nephritis </e2> (AIN) due to nicergoline (Sermion).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"584": {"data": {"text": "We report a case of acute interstitial nephritis (AIN) due to nicergoline (Sermion).", "entity1": "nicergoline", "entity2": "AIN", "span1": [62, 73], "span2": [50, 53]}, "bert_text": "We report a case of acute interstitial nephritis (AIN) due to <e1> nicergoline </e1> <e2> AIN </e2>) due to nicergoline (Sermion).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"585": {"data": {"text": "This case demonstrates the selective vulnerability of the anterior visual pathways and peripheral nerves to ethambutol toxicity.", "entity1": "ethambutol", "entity2": "toxicity", "span1": [108, 118], "span2": [119, 127]}, "bert_text": "This case demonstrates the selective vulnerability of the anterior visual pathways and peripheral nerves to <e1> ethambutol </e1> <e2> toxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"586": {"data": {"text": "The results demonstrate that the threshold for pilocarpine-induced seizures in rats is subjected to the regulation of the GABA-mediated synaptic inhibition within the substantia nigra.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [47, 58], "span2": [67, 75]}, "bert_text": "The results demonstrate that the threshold for <e1> pilocarpine </e1>-induced <e2> seizures </e2> in rats is subjected to the regulation of the GABA-mediated synaptic inhibition within the substantia nigra.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"587": {"data": {"text": "The results demonstrate that the threshold for pilocarpine-induced seizures in rats is subjected to the regulation of the GABA-mediated synaptic inhibition within the substantia nigra.", "entity1": "GABA", "entity2": "seizures", "span1": [122, 126], "span2": [67, 75]}, "bert_text": "The results demonstrate that the threshold for pilocarpine-induced seizures in rats is subjected to the regulation of the <e1> GABA </e1> <e2> seizures </e2> in rats is subjected to the regulation of the GABA-mediated synaptic inhibition within the substantia nigra.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"588": {"data": {"text": "LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/-", "entity1": "Iso", "entity2": "LV hypertrophy", "span1": [26, 29], "span2": [0, 14]}, "bert_text": "LV hypertrophy induced by <e1> Iso </e1> <e2> LV hypertrophy </e2> induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"589": {"data": {"text": "LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/-", "entity1": "Iso", "entity2": "LV", "span1": [26, 29], "span2": [94, 96]}, "bert_text": "LV hypertrophy induced by <e1> Iso </e1> treatment was significantly higher in TGR than in SD rats (in g <e2> LV </e2> wt/100 g body wt, 0.28 +/-", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"590": {"data": {"text": "Tacrolimus-related seizure after pediatric liver transplantation--a single-center experience.\n", "entity1": "Tacrolimus", "entity2": "seizure", "span1": [0, 10], "span2": [19, 26]}, "bert_text": "<e1> Tacrolimus </e1>-related <e2> seizure </e2> after pediatric liver transplantation--a single-center experience.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"591": {"data": {"text": "was observed in a 57-year-old woman, under treatment for angina with 80 mg propranolol daily.", "entity1": "propranolol", "entity2": "angina", "span1": [75, 86], "span2": [57, 63]}, "bert_text": "was observed in a 57-year-old woman, under treatment for angina with 80 mg <e1> propranolol </e1> <e2> angina </e2> with 80 mg propranolol daily.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"592": {"data": {"text": "Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.\n", "entity1": "Metformin", "entity2": "seizures", "span1": [0, 9], "span2": [27, 35]}, "bert_text": "<e1> Metformin </e1> protects against <e2> seizures </e2>, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"593": {"data": {"text": "Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.\n", "entity1": "Metformin", "entity2": "learning and memory impairments", "span1": [0, 9], "span2": [37, 68]}, "bert_text": "<e1> Metformin </e1> protects against seizures, <e2> learning and memory impairments </e2> and oxidative damage induced by pentylenetetrazole-induced kindling in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"594": {"data": {"text": "Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.\n", "entity1": "pentylenetetrazole", "entity2": "seizures", "span1": [101, 119], "span2": [27, 35]}, "bert_text": "Metformin protects against seizures, learning and memory impairments and oxidative damage induced by <e1> pentylenetetrazole </e1> <e2> seizures </e2>, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"595": {"data": {"text": "Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice.\n", "entity1": "pentylenetetrazole", "entity2": "learning and memory impairments", "span1": [101, 119], "span2": [37, 68]}, "bert_text": "Metformin protects against seizures, learning and memory impairments and oxidative damage induced by <e1> pentylenetetrazole </e1> <e2> learning and memory impairments </e2> and oxidative damage induced by pentylenetetrazole-induced kindling in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"596": {"data": {"text": "Evidence for a cholinergic role in haloperidol-induced catalepsy.\n", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [35, 46], "span2": [55, 64]}, "bert_text": "Evidence for a cholinergic role in <e1> haloperidol </e1>-induced <e2> catalepsy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"597": {"data": {"text": "Isradipine treatment for hypertension in general practice in Hong Kong.\n", "entity1": "Isradipine", "entity2": "hypertension", "span1": [0, 10], "span2": [25, 37]}, "bert_text": "<e1> Isradipine </e1> treatment for <e2> hypertension </e2> in general practice in Hong Kong.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"598": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "caffeine", "entity2": "agoraphobia", "span1": [38, 46], "span2": [277, 288]}, "bert_text": "The effects of oral administration of <e1> caffeine </e1> (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for <e2> agoraphobia </e2> with panic attacks or panic disorder.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"599": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "caffeine", "entity2": "panic attacks", "span1": [38, 46], "span2": [294, 307]}, "bert_text": "The effects of oral administration of <e1> caffeine </e1> (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with <e2> panic attacks </e2> or panic disorder.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"600": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "caffeine", "entity2": "panic disorder", "span1": [38, 46], "span2": [311, 325]}, "bert_text": "The effects of oral administration of <e1> caffeine </e1> (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or <e2> panic disorder </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"601": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "3-methoxy-4-hydroxyphenethyleneglycol", "entity2": "agoraphobia", "span1": [135, 172], "span2": [277, 288]}, "bert_text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of <e1> 3-methoxy-4-hydroxyphenethyleneglycol </e1> (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for <e2> agoraphobia </e2> with panic attacks or panic disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"602": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "3-methoxy-4-hydroxyphenethyleneglycol", "entity2": "panic attacks", "span1": [135, 172], "span2": [294, 307]}, "bert_text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of <e1> 3-methoxy-4-hydroxyphenethyleneglycol </e1> (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with <e2> panic attacks </e2> or panic disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"603": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "3-methoxy-4-hydroxyphenethyleneglycol", "entity2": "panic disorder", "span1": [135, 172], "span2": [311, 325]}, "bert_text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of <e1> 3-methoxy-4-hydroxyphenethyleneglycol </e1> (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or <e2> panic disorder </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"604": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "MHPG", "entity2": "agoraphobia", "span1": [174, 178], "span2": [277, 288]}, "bert_text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (<e1> MHPG </e1>) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for <e2> agoraphobia </e2> with panic attacks or panic disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"605": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "MHPG", "entity2": "panic attacks", "span1": [174, 178], "span2": [294, 307]}, "bert_text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (<e1> MHPG </e1>) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with <e2> panic attacks </e2> or panic disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"606": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "MHPG", "entity2": "panic disorder", "span1": [174, 178], "span2": [311, 325]}, "bert_text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (<e1> MHPG </e1>) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or <e2> panic disorder </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"607": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "cortisol", "entity2": "agoraphobia", "span1": [184, 192], "span2": [277, 288]}, "bert_text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and <e1> cortisol </e1> were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for <e2> agoraphobia </e2> with panic attacks or panic disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"608": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "cortisol", "entity2": "panic attacks", "span1": [184, 192], "span2": [294, 307]}, "bert_text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and <e1> cortisol </e1> were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with <e2> panic attacks </e2> or panic disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"609": {"data": {"text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or panic disorder.", "entity1": "cortisol", "entity2": "panic disorder", "span1": [184, 192], "span2": [311, 325]}, "bert_text": "The effects of oral administration of caffeine (10 mg/kg) on behavioral ratings, somatic symptoms, blood pressure and plasma levels of 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) and <e1> cortisol </e1> were determined in 17 healthy subjects and 21 patients meeting DSM-III criteria for agoraphobia with panic attacks or <e2> panic disorder </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"610": {"data": {"text": "Non-invasive detection of coronary artery disease by body surface electrocardiographic mapping after dipyridamole infusion.\n", "entity1": "dipyridamole", "entity2": "coronary artery disease", "span1": [101, 113], "span2": [26, 49]}, "bert_text": "Non-invasive detection of coronary artery disease by body surface electrocardiographic mapping after <e1> dipyridamole </e1> <e2> coronary artery disease </e2> by body surface electrocardiographic mapping after dipyridamole infusion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"611": {"data": {"text": "These results may be relevant to the use of FZP in clinical situations in which there is increased neural excitability, such as epilepsy or sedative-hypnotic drug withdrawal.", "entity1": "FZP", "entity2": "epilepsy", "span1": [44, 47], "span2": [128, 136]}, "bert_text": "These results may be relevant to the use of <e1> FZP </e1> in clinical situations in which there is increased neural excitability, such as <e2> epilepsy </e2> or sedative-hypnotic drug withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"612": {"data": {"text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "entity1": "doxorubicin", "entity2": "toxicity", "span1": [99, 110], "span2": [51, 59]}, "bert_text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg <e1> doxorubicin </e1> <e2> toxicity </e2> and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"613": {"data": {"text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [99, 110], "span2": [73, 87]}, "bert_text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"614": {"data": {"text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "entity1": "DOX", "entity2": "toxicity", "span1": [112, 115], "span2": [51, 59]}, "bert_text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (<e1> DOX </e1> <e2> toxicity </e2> and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"615": {"data": {"text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [112, 115], "span2": [73, 87]}, "bert_text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (<e1> DOX </e1> <e2> cardiotoxicity </e2> of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"616": {"data": {"text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "entity1": "N-(2-hydroxypropyl)methacrylamide", "entity2": "toxicity", "span1": [167, 200], "span2": [51, 59]}, "bert_text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three <e1> N-(2-hydroxypropyl)methacrylamide </e1> <e2> toxicity </e2> and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"617": {"data": {"text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "entity1": "N-(2-hydroxypropyl)methacrylamide", "entity2": "cardiotoxicity", "span1": [167, 200], "span2": [73, 87]}, "bert_text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three <e1> N-(2-hydroxypropyl)methacrylamide </e1> <e2> cardiotoxicity </e2> of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"618": {"data": {"text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "entity1": "HPMA", "entity2": "toxicity", "span1": [202, 206], "span2": [51, 59]}, "bert_text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (<e1> HPMA </e1> <e2> toxicity </e2> and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"619": {"data": {"text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "entity1": "HPMA", "entity2": "cardiotoxicity", "span1": [202, 206], "span2": [73, 87]}, "bert_text": "A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (<e1> HPMA </e1> <e2> cardiotoxicity </e2> of 4 mg/kg doxorubicin (DOX) given either as free drug or in the form of three N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer conjugates.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"620": {"data": {"text": "No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.", "entity1": "oxitropium", "entity2": "nausea", "span1": [36, 46], "span2": [88, 94]}, "bert_text": "No subject reported side effects of <e1> oxitropium </e1>, as compared to three subjects reporting <e2> nausea </e2>, vomiting and tremors after theophylline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"621": {"data": {"text": "No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.", "entity1": "oxitropium", "entity2": "vomiting", "span1": [36, 46], "span2": [96, 104]}, "bert_text": "No subject reported side effects of <e1> oxitropium </e1>, as compared to three subjects reporting nausea, <e2> vomiting </e2> and tremors after theophylline.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"622": {"data": {"text": "No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.", "entity1": "oxitropium", "entity2": "tremors", "span1": [36, 46], "span2": [109, 116]}, "bert_text": "No subject reported side effects of <e1> oxitropium </e1>, as compared to three subjects reporting nausea, vomiting and <e2> tremors </e2> after theophylline.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"623": {"data": {"text": "No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.", "entity1": "theophylline", "entity2": "nausea", "span1": [123, 135], "span2": [88, 94]}, "bert_text": "No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after <e1> theophylline </e1> <e2> nausea </e2>, vomiting and tremors after theophylline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"624": {"data": {"text": "No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.", "entity1": "theophylline", "entity2": "vomiting", "span1": [123, 135], "span2": [96, 104]}, "bert_text": "No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after <e1> theophylline </e1> <e2> vomiting </e2> and tremors after theophylline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"625": {"data": {"text": "No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after theophylline.", "entity1": "theophylline", "entity2": "tremors", "span1": [123, 135], "span2": [109, 116]}, "bert_text": "No subject reported side effects of oxitropium, as compared to three subjects reporting nausea, vomiting and tremors after <e1> theophylline </e1> <e2> tremors </e2> after theophylline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"626": {"data": {"text": "Before admission, he had been taking nicergoline and bendazac lysine due to retinal vein occlusion at ophthalmologic department.", "entity1": "nicergoline", "entity2": "retinal vein occlusion", "span1": [37, 48], "span2": [76, 98]}, "bert_text": "Before admission, he had been taking <e1> nicergoline </e1> and bendazac lysine due to <e2> retinal vein occlusion </e2> at ophthalmologic department.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"627": {"data": {"text": "Before admission, he had been taking nicergoline and bendazac lysine due to retinal vein occlusion at ophthalmologic department.", "entity1": "bendazac lysine", "entity2": "retinal vein occlusion", "span1": [53, 68], "span2": [76, 98]}, "bert_text": "Before admission, he had been taking nicergoline and <e1> bendazac lysine </e1> due to <e2> retinal vein occlusion </e2> at ophthalmologic department.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"628": {"data": {"text": "The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with androgens, corticosteroids and transfusions.", "entity1": "androgens", "entity2": "Fanconi's anemia", "span1": [115, 124], "span2": [65, 81]}, "bert_text": "The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with <e1> androgens </e1> <e2> Fanconi's anemia </e2> for 3 years and was treated with androgens, corticosteroids and transfusions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"629": {"data": {"text": "The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with androgens, corticosteroids and transfusions.", "entity1": "corticosteroids", "entity2": "Fanconi's anemia", "span1": [126, 141], "span2": [65, 81]}, "bert_text": "The case of an 11-year-old boy is reported who was known to have Fanconi's anemia for 3 years and was treated with androgens, <e1> corticosteroids </e1> <e2> Fanconi's anemia </e2> for 3 years and was treated with androgens, corticosteroids and transfusions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"630": {"data": {"text": "In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than HCTZ alone.", "entity1": "VAL", "entity2": "hypokalemia", "span1": [53, 56], "span2": [204, 215]}, "bert_text": "In this study population, combination therapies with <e1> VAL </e1>/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less <e2> hypokalemia </e2> than HCTZ alone.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"631": {"data": {"text": "In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than HCTZ alone.", "entity1": "HCTZ", "entity2": "hypokalemia", "span1": [57, 61], "span2": [204, 215]}, "bert_text": "In this study population, combination therapies with VAL/<e1> HCTZ </e1> were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less <e2> hypokalemia </e2> than HCTZ alone.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"632": {"data": {"text": "In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than HCTZ alone.", "entity1": "HCTZ", "entity2": "hypokalemia", "span1": [221, 225], "span2": [204, 215]}, "bert_text": "In this study population, combination therapies with VAL/HCTZ were associated with significantly greater BP reductions compared with either monotherapy, were well tolerated, and were associated with less hypokalemia than <e1> HCTZ </e1> <e2> hypokalemia </e2> than HCTZ alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"633": {"data": {"text": "Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.", "entity1": "propranolol", "entity2": "ventricular tachycardia", "span1": [16, 27], "span2": [59, 82]}, "bert_text": "Both isomers of <e1> propranolol </e1> were also capable of reversing <e2> ventricular tachycardia </e2> caused by ouabain in anaesthetized cats and dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"634": {"data": {"text": "Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs.", "entity1": "ouabain", "entity2": "ventricular tachycardia", "span1": [93, 100], "span2": [59, 82]}, "bert_text": "Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by <e1> ouabain </e1> <e2> ventricular tachycardia </e2> caused by ouabain in anaesthetized cats and dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"635": {"data": {"text": "Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced amnesia.", "entity1": "naloxone", "entity2": "amnesia", "span1": [32, 40], "span2": [122, 129]}, "bert_text": "Post-training administration of <e1> naloxone </e1> (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"636": {"data": {"text": "Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the scopolamine-induced amnesia.", "entity1": "scopolamine", "entity2": "amnesia", "span1": [102, 113], "span2": [122, 129]}, "bert_text": "Post-training administration of naloxone (3 mg/kg) as a single or as a split dose also attenuated the <e1> scopolamine </e1>-induced <e2> amnesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"637": {"data": {"text": "The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide-induced cystitis in rats.\n", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [62, 78], "span2": [87, 95]}, "bert_text": "The function of P2X3 receptor and NK1 receptor antagonists on <e1> cyclophosphamide </e1>-induced <e2> cystitis </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"638": {"data": {"text": "The association of the tumor with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to cyclophosphamide.", "entity1": "cyclophosphamide", "entity2": "tumor", "span1": [161, 177], "span2": [23, 28]}, "bert_text": "The association of the tumor with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to <e1> cyclophosphamide </e1> <e2> tumor </e2> with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to cyclophosphamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"639": {"data": {"text": "Bpd was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 AFL cases.", "entity1": "Bpd", "entity2": "AF", "span1": [0, 3], "span2": [83, 85]}, "bert_text": "<e1> Bpd </e1> was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 <e2> AF </e2> and 81 AFL cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"640": {"data": {"text": "Bpd was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 AFL cases.", "entity1": "Bpd", "entity2": "AFL", "span1": [0, 3], "span2": [93, 96]}, "bert_text": "<e1> Bpd </e1> was administered to 459 patients (361 males, 63+/-12 years old) comprising 378 AF and 81 <e2> AFL </e2> cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"641": {"data": {"text": "After 6 months of hyperprolactinemia, dopamine (DA) concentrations in the median eminence (ME) increased by 84% over the control group.", "entity1": "dopamine", "entity2": "hyperprolactinemia", "span1": [38, 46], "span2": [18, 36]}, "bert_text": "After 6 months of hyperprolactinemia, <e1> dopamine </e1> <e2> hyperprolactinemia </e2>, dopamine (DA) concentrations in the median eminence (ME) increased by 84% over the control group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"642": {"data": {"text": "After 6 months of hyperprolactinemia, dopamine (DA) concentrations in the median eminence (ME) increased by 84% over the control group.", "entity1": "DA", "entity2": "hyperprolactinemia", "span1": [48, 50], "span2": [18, 36]}, "bert_text": "After 6 months of hyperprolactinemia, dopamine (<e1> DA </e1> <e2> hyperprolactinemia </e2>, dopamine (DA) concentrations in the median eminence (ME) increased by 84% over the control group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"643": {"data": {"text": "In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.", "entity1": "chlorpromazine", "entity2": "EPS", "span1": [50, 64], "span2": [73, 76]}, "bert_text": "In this study, we evaluate the role DRD2 plays in <e1> chlorpromazine </e1>-induced <e2> EPS </e2> in schizophrenic patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"644": {"data": {"text": "In this study, we evaluate the role DRD2 plays in chlorpromazine-induced EPS in schizophrenic patients.", "entity1": "chlorpromazine", "entity2": "schizophrenic", "span1": [50, 64], "span2": [80, 93]}, "bert_text": "In this study, we evaluate the role DRD2 plays in <e1> chlorpromazine </e1>-induced EPS in <e2> schizophrenic </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"645": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "DA", "entity2": "hyperprolactinemia", "span1": [37, 39], "span2": [315, 333]}, "bert_text": "There was no change in the levels of <e1> DA </e1>, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of <e2> hyperprolactinemia </e2> and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"646": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "DA", "entity2": "hyperprolactinemia", "span1": [37, 39], "span2": [399, 417]}, "bert_text": "There was no change in the levels of <e1> DA </e1>, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"647": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "DA", "entity2": "hyperprolactinemia", "span1": [353, 355], "span2": [315, 333]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in <e1> DA </e1> <e2> hyperprolactinemia </e2> and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"648": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "DA", "entity2": "hyperprolactinemia", "span1": [353, 355], "span2": [399, 417]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in <e1> DA </e1> concentrations in the AN after 9-months of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"649": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "norepinephrine", "entity2": "hyperprolactinemia", "span1": [41, 55], "span2": [315, 333]}, "bert_text": "There was no change in the levels of DA, <e1> norepinephrine </e1> (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of <e2> hyperprolactinemia </e2> and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"650": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "norepinephrine", "entity2": "hyperprolactinemia", "span1": [41, 55], "span2": [399, 417]}, "bert_text": "There was no change in the levels of DA, <e1> norepinephrine </e1> (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"651": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "NE", "entity2": "hyperprolactinemia", "span1": [57, 59], "span2": [315, 333]}, "bert_text": "There was no change in the levels of DA, norepinephrine (<e1> NE </e1>), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of <e2> hyperprolactinemia </e2> and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"652": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "NE", "entity2": "hyperprolactinemia", "span1": [57, 59], "span2": [399, 417]}, "bert_text": "There was no change in the levels of DA, norepinephrine (<e1> NE </e1>), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"653": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "serotonin", "entity2": "hyperprolactinemia", "span1": [62, 71], "span2": [315, 333]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), <e1> serotonin </e1> (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of <e2> hyperprolactinemia </e2> and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"654": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "serotonin", "entity2": "hyperprolactinemia", "span1": [62, 71], "span2": [399, 417]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), <e1> serotonin </e1> (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"655": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "5-HT", "entity2": "hyperprolactinemia", "span1": [73, 77], "span2": [315, 333]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (<e1> 5-HT </e1>), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of <e2> hyperprolactinemia </e2> and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"656": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "5-HT", "entity2": "hyperprolactinemia", "span1": [73, 77], "span2": [399, 417]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (<e1> 5-HT </e1>), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"657": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "MPA", "entity2": "hyperprolactinemia", "span1": [152, 155], "span2": [315, 333]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (<e1> MPA </e1>), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of <e2> hyperprolactinemia </e2> and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"658": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "MPA", "entity2": "hyperprolactinemia", "span1": [152, 155], "span2": [399, 417]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (<e1> MPA </e1>), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"659": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "5-hydroxyindoleacetic acid", "entity2": "hyperprolactinemia", "span1": [251, 277], "span2": [315, 333]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in <e1> 5-hydroxyindoleacetic acid </e1> (5-HIAA) in the AN after 6-months of <e2> hyperprolactinemia </e2> and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"660": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "5-hydroxyindoleacetic acid", "entity2": "hyperprolactinemia", "span1": [251, 277], "span2": [399, 417]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in <e1> 5-hydroxyindoleacetic acid </e1> (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"661": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "5-HIAA", "entity2": "hyperprolactinemia", "span1": [279, 285], "span2": [315, 333]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (<e1> 5-HIAA </e1>) in the AN after 6-months of <e2> hyperprolactinemia </e2> and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"662": {"data": {"text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (5-HIAA) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of hyperprolactinemia.", "entity1": "5-HIAA", "entity2": "hyperprolactinemia", "span1": [279, 285], "span2": [399, 417]}, "bert_text": "There was no change in the levels of DA, norepinephrine (NE), serotonin (5-HT), or their metabolites in the arcuate nucleus (AN), medial preoptic area (MPA), caudate putamen (CP), substantia nigra (SN), and zona incerta (ZI), except for a decrease in 5-hydroxyindoleacetic acid (<e1> 5-HIAA </e1>) in the AN after 6-months of hyperprolactinemia and an increase in DA concentrations in the AN after 9-months of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"663": {"data": {"text": "A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial.\n", "entity1": "glyceryl trinitrate", "entity2": "primary dysmenorrhea", "span1": [16, 35], "span2": [73, 93]}, "bert_text": "A comparison of <e1> glyceryl trinitrate </e1> with diclofenac for the treatment of <e2> primary dysmenorrhea </e2>: an open, randomized, cross-over trial.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"664": {"data": {"text": "A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial.\n", "entity1": "diclofenac", "entity2": "primary dysmenorrhea", "span1": [41, 51], "span2": [73, 93]}, "bert_text": "A comparison of glyceryl trinitrate with <e1> diclofenac </e1> for the treatment of <e2> primary dysmenorrhea </e2>: an open, randomized, cross-over trial.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"665": {"data": {"text": "We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.", "entity1": "bupivacaine", "entity2": "dysrhythmia", "span1": [184, 195], "span2": [26, 37]}, "bert_text": "We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of <e1> bupivacaine </e1> <e2> dysrhythmia </e2> occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"666": {"data": {"text": "We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption.", "entity1": "bupivacaine", "entity2": "asystole", "span1": [184, 195], "span2": [155, 163]}, "bert_text": "We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of <e1> bupivacaine </e1> <e2> asystole </e2> and total amount of bupivacaine consumption.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"667": {"data": {"text": "Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial prostaglandins; non-steroidal anti-inflammatory drugs are the first choice for its treatment.", "entity1": "prostaglandins", "entity2": "Primary dysmenorrhea", "span1": [124, 138], "span2": [0, 20]}, "bert_text": "Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial <e1> prostaglandins </e1> <e2> Primary dysmenorrhea </e2> is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial prostaglandins; non-steroidal anti-inflammatory drugs are the first choice for its treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"668": {"data": {"text": "Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial prostaglandins; non-steroidal anti-inflammatory drugs are the first choice for its treatment.", "entity1": "prostaglandins", "entity2": "painful", "span1": [124, 138], "span2": [52, 59]}, "bert_text": "Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial <e1> prostaglandins </e1> <e2> painful </e2> uterine contractility caused by a hypersecretion of endometrial prostaglandins; non-steroidal anti-inflammatory drugs are the first choice for its treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"669": {"data": {"text": "Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial prostaglandins; non-steroidal anti-inflammatory drugs are the first choice for its treatment.", "entity1": "prostaglandins", "entity2": "endometrial", "span1": [124, 138], "span2": [112, 123]}, "bert_text": "Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial <e1> prostaglandins </e1> <e2> endometrial </e2> prostaglandins; non-steroidal anti-inflammatory drugs are the first choice for its treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"670": {"data": {"text": "High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%).", "entity1": "5-FU", "entity2": "AGC", "span1": [10, 14], "span2": [80, 83]}, "bert_text": "High-dose <e1> 5-FU </e1>/FA/MMC is an effective and well-tolerated outpatient regimen for <e2> AGC </e2> (objective response rate 54.6%).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"671": {"data": {"text": "High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%).", "entity1": "FA", "entity2": "AGC", "span1": [15, 17], "span2": [80, 83]}, "bert_text": "High-dose 5-FU/<e1> FA </e1>/MMC is an effective and well-tolerated outpatient regimen for <e2> AGC </e2> (objective response rate 54.6%).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"672": {"data": {"text": "High-dose 5-FU/FA/MMC is an effective and well-tolerated outpatient regimen for AGC (objective response rate 54.6%).", "entity1": "MMC", "entity2": "AGC", "span1": [18, 21], "span2": [80, 83]}, "bert_text": "High-dose 5-FU/FA/<e1> MMC </e1> is an effective and well-tolerated outpatient regimen for <e2> AGC </e2> (objective response rate 54.6%).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"673": {"data": {"text": "Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function.", "entity1": "cisplatin", "entity2": "acute kidney injury", "span1": [65, 74], "span2": [83, 102]}, "bert_text": "Thus, our data suggest that the kinin B2 receptor is involved in <e1> cisplatin </e1>-induced <e2> acute kidney injury </e2> by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"674": {"data": {"text": "Thus, our data suggest that the kinin B2 receptor is involved in cisplatin-induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines, thus resulting in declined renal function.", "entity1": "cisplatin", "entity2": "necrotic", "span1": [65, 74], "span2": [120, 128]}, "bert_text": "Thus, our data suggest that the kinin B2 receptor is involved in <e1> cisplatin </e1>-induced acute kidney injury by mediating the <e2> necrotic </e2> process and the expression of inflammatory cytokines, thus resulting in declined renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"675": {"data": {"text": "We describe a female patient with stable Parkinson's disease who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with veralipride, as well as the improvement of her symptoms back to baseline after discontinuation of the drug.", "entity1": "veralipride", "entity2": "Parkinson's disease", "span1": [170, 181], "span2": [41, 60]}, "bert_text": "We describe a female patient with stable Parkinson's disease who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with <e1> veralipride </e1> <e2> Parkinson's disease </e2> who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with veralipride, as well as the improvement of her symptoms back to baseline after discontinuation of the drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"676": {"data": {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity1": "remoxipride", "entity2": "aplastic anemia", "span1": [16, 27], "span2": [51, 66]}, "bert_text": "We propose that <e1> remoxipride </e1> and benzene may induce <e2> aplastic anemia </e2> via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"677": {"data": {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity1": "remoxipride", "entity2": "aplastic anemia", "span1": [16, 27], "span2": [242, 257]}, "bert_text": "We propose that <e1> remoxipride </e1> and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired <e2> aplastic anemia </e2> that has been associated with remoxipride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"678": {"data": {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity1": "remoxipride", "entity2": "aplastic anemia", "span1": [288, 299], "span2": [51, 66]}, "bert_text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with <e1> remoxipride </e1> <e2> aplastic anemia </e2> via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"679": {"data": {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity1": "remoxipride", "entity2": "aplastic anemia", "span1": [288, 299], "span2": [242, 257]}, "bert_text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with <e1> remoxipride </e1> <e2> aplastic anemia </e2> that has been associated with remoxipride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"680": {"data": {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity1": "benzene", "entity2": "aplastic anemia", "span1": [32, 39], "span2": [51, 66]}, "bert_text": "We propose that remoxipride and <e1> benzene </e1> may induce <e2> aplastic anemia </e2> via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"681": {"data": {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity1": "benzene", "entity2": "aplastic anemia", "span1": [32, 39], "span2": [242, 257]}, "bert_text": "We propose that remoxipride and <e1> benzene </e1> may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired <e2> aplastic anemia </e2> that has been associated with remoxipride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"682": {"data": {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity1": "NCQ436", "entity2": "aplastic anemia", "span1": [138, 144], "span2": [51, 66]}, "bert_text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of <e1> NCQ436 </e1> <e2> aplastic anemia </e2> via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"683": {"data": {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity1": "NCQ436", "entity2": "aplastic anemia", "span1": [138, 144], "span2": [242, 257]}, "bert_text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of <e1> NCQ436 </e1> and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired <e2> aplastic anemia </e2> that has been associated with remoxipride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"684": {"data": {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity1": "NCQ344", "entity2": "aplastic anemia", "span1": [149, 155], "span2": [51, 66]}, "bert_text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and <e1> NCQ344 </e1> <e2> aplastic anemia </e2> via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"685": {"data": {"text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride.", "entity1": "NCQ344", "entity2": "aplastic anemia", "span1": [149, 155], "span2": [242, 257]}, "bert_text": "We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and <e1> NCQ344 </e1> to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired <e2> aplastic anemia </e2> that has been associated with remoxipride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"686": {"data": {"text": "Oral pre-treatment with PK (80 mg kg(-1) day(-1) for 15 days) significantly prevented the isoproterenol-induced myocardial infarction and maintained the rats at near normal status.", "entity1": "PK", "entity2": "myocardial infarction", "span1": [24, 26], "span2": [112, 133]}, "bert_text": "Oral pre-treatment with <e1> PK </e1> (80 mg kg(-1) day(-1) for 15 days) significantly prevented the isoproterenol-induced <e2> myocardial infarction </e2> and maintained the rats at near normal status.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"687": {"data": {"text": "Oral pre-treatment with PK (80 mg kg(-1) day(-1) for 15 days) significantly prevented the isoproterenol-induced myocardial infarction and maintained the rats at near normal status.", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [90, 103], "span2": [112, 133]}, "bert_text": "Oral pre-treatment with PK (80 mg kg(-1) day(-1) for 15 days) significantly prevented the <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2> and maintained the rats at near normal status.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"688": {"data": {"text": "Single dose of DOX was associated with increased cardiac disarrangement, necrosis, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP.", "entity1": "DOX", "entity2": "necrosis", "span1": [15, 18], "span2": [73, 81]}, "bert_text": "Single dose of <e1> DOX </e1> was associated with increased cardiac disarrangement, <e2> necrosis </e2>, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"689": {"data": {"text": "Single dose of DOX was associated with increased cardiac disarrangement, necrosis, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP.", "entity1": "pyrimidines", "entity2": "necrosis", "span1": [132, 143], "span2": [73, 81]}, "bert_text": "Single dose of DOX was associated with increased cardiac disarrangement, necrosis, and DNA damage (strand breaks (SBs) and oxidized <e1> pyrimidines </e1> <e2> necrosis </e2>, and DNA damage (strand breaks (SBs) and oxidized pyrimidines) and decreased TAP.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"690": {"data": {"text": "Those patients in whom d,l-sotalol prevented induction of ventricular tachycardia or ventricular fibrillation were discharged with the drug and followed up on an outpatient basis for 21 +/-", "entity1": "l-sotalol", "entity2": "ventricular tachycardia", "span1": [25, 34], "span2": [58, 81]}, "bert_text": "Those patients in whom d,<e1> l-sotalol </e1> prevented induction of <e2> ventricular tachycardia </e2> or ventricular fibrillation were discharged with the drug and followed up on an outpatient basis for 21 +/-", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"691": {"data": {"text": "Those patients in whom d,l-sotalol prevented induction of ventricular tachycardia or ventricular fibrillation were discharged with the drug and followed up on an outpatient basis for 21 +/-", "entity1": "l-sotalol", "entity2": "ventricular fibrillation", "span1": [25, 34], "span2": [85, 109]}, "bert_text": "Those patients in whom d,<e1> l-sotalol </e1> prevented induction of ventricular tachycardia or <e2> ventricular fibrillation </e2> were discharged with the drug and followed up on an outpatient basis for 21 +/-", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"692": {"data": {"text": "It may serve as an alternative to cisplatin-containing regimens; however, it has to be considered that possibly HUS may occur.", "entity1": "cisplatin", "entity2": "HUS", "span1": [34, 43], "span2": [112, 115]}, "bert_text": "It may serve as an alternative to <e1> cisplatin </e1>-containing regimens; however, it has to be considered that possibly <e2> HUS </e2> may occur.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"693": {"data": {"text": "OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "entity1": "methicillin", "entity2": "bacteremia", "span1": [31, 42], "span2": [82, 92]}, "bert_text": "OBJECTIVE: To report a case of <e1> methicillin </e1>-sensitive Staphylococcus aureus (MSSA) <e2> bacteremia </e2> with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"694": {"data": {"text": "OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "entity1": "methicillin", "entity2": "meningitis", "span1": [31, 42], "span2": [113, 123]}, "bert_text": "OBJECTIVE: To report a case of <e1> methicillin </e1>-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA <e2> meningitis </e2> treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"695": {"data": {"text": "OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "entity1": "MSSA", "entity2": "bacteremia", "span1": [108, 112], "span2": [82, 92]}, "bert_text": "OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected <e1> MSSA </e1> <e2> bacteremia </e2> with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"696": {"data": {"text": "OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "entity1": "MSSA", "entity2": "meningitis", "span1": [108, 112], "span2": [113, 123]}, "bert_text": "OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected <e1> MSSA </e1> <e2> meningitis </e2> treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"697": {"data": {"text": "OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "entity1": "daptomycin", "entity2": "bacteremia", "span1": [147, 157], "span2": [82, 92]}, "bert_text": "OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose <e1> daptomycin </e1> <e2> bacteremia </e2> with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"698": {"data": {"text": "OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "entity1": "daptomycin", "entity2": "meningitis", "span1": [147, 157], "span2": [113, 123]}, "bert_text": "OBJECTIVE: To report a case of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia with suspected MSSA meningitis treated with high-dose <e1> daptomycin </e1> <e2> meningitis </e2> treated with high-dose daptomycin assessed with concurrent serum and cerebrospinal fluid (CSF) concentrations.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"699": {"data": {"text": "PURPOSE: Prenatal cocaine exposure has been linked with subependymal hemorrhage and the formation of cysts that are detectable on cranial sonography in neonates born at term.", "entity1": "cocaine", "entity2": "subependymal hemorrhage", "span1": [18, 25], "span2": [56, 79]}, "bert_text": "PURPOSE: Prenatal <e1> cocaine </e1> exposure has been linked with <e2> subependymal hemorrhage </e2> and the formation of cysts that are detectable on cranial sonography in neonates born at term.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"700": {"data": {"text": "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.\n", "entity1": "Lamivudine", "entity2": "hepatitis B", "span1": [0, 10], "span2": [39, 50]}, "bert_text": "<e1> Lamivudine </e1> is effective in suppressing <e2> hepatitis B </e2> virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"701": {"data": {"text": "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.\n", "entity1": "Lamivudine", "entity2": "hepatitis B", "span1": [0, 10], "span2": [72, 83]}, "bert_text": "<e1> Lamivudine </e1> is effective in suppressing hepatitis B virus DNA in Chinese <e2> hepatitis B </e2> surface antigen carriers: a placebo-controlled trial.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"702": {"data": {"text": "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.\n", "entity1": "surface antigen", "entity2": "hepatitis B", "span1": [84, 99], "span2": [39, 50]}, "bert_text": "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B <e1> surface antigen </e1> <e2> hepatitis B </e2> virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"703": {"data": {"text": "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.\n", "entity1": "surface antigen", "entity2": "hepatitis B", "span1": [84, 99], "span2": [72, 83]}, "bert_text": "Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B <e1> surface antigen </e1> <e2> hepatitis B </e2> surface antigen carriers: a placebo-controlled trial.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"704": {"data": {"text": "Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\n", "entity1": "methadone", "entity2": "long QT syndrome", "span1": [64, 73], "span2": [13, 29]}, "bert_text": "Drug-induced long QT syndrome in injection drug users receiving <e1> methadone </e1> <e2> long QT syndrome </e2> in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"705": {"data": {"text": "Delirium during fluoxetine treatment.", "entity1": "fluoxetine", "entity2": "Delirium", "span1": [16, 26], "span2": [0, 8]}, "bert_text": "Delirium during <e1> fluoxetine </e1> <e2> Delirium </e2> during fluoxetine treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"706": {"data": {"text": "Binasal visual field defects are not specific to vigabatrin.\n", "entity1": "vigabatrin", "entity2": "visual field defects", "span1": [49, 59], "span2": [8, 28]}, "bert_text": "Binasal visual field defects are not specific to <e1> vigabatrin </e1> <e2> visual field defects </e2> are not specific to vigabatrin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"707": {"data": {"text": "CONCLUSIONS: Precurarization with 0.04 mg/kg rocuronium was the optimal dose considering the reduction in the incidence and severity of fasciculation and myalgia with acceptable onset time, and the safe and effective precurarization.", "entity1": "rocuronium", "entity2": "fasciculation", "span1": [45, 55], "span2": [136, 149]}, "bert_text": "CONCLUSIONS: Precurarization with 0.04 mg/kg <e1> rocuronium </e1> was the optimal dose considering the reduction in the incidence and severity of <e2> fasciculation </e2> and myalgia with acceptable onset time, and the safe and effective precurarization.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"708": {"data": {"text": "CONCLUSIONS: Precurarization with 0.04 mg/kg rocuronium was the optimal dose considering the reduction in the incidence and severity of fasciculation and myalgia with acceptable onset time, and the safe and effective precurarization.", "entity1": "rocuronium", "entity2": "myalgia", "span1": [45, 55], "span2": [154, 161]}, "bert_text": "CONCLUSIONS: Precurarization with 0.04 mg/kg <e1> rocuronium </e1> was the optimal dose considering the reduction in the incidence and severity of fasciculation and <e2> myalgia </e2> with acceptable onset time, and the safe and effective precurarization.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"709": {"data": {"text": "Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.", "entity1": "Caffeine", "entity2": "anxiety", "span1": [0, 8], "span2": [67, 74]}, "bert_text": "<e1> Caffeine </e1> produced significantly greater increases in subject-rated <e2> anxiety </e2>, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"710": {"data": {"text": "Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.", "entity1": "Caffeine", "entity2": "nausea", "span1": [0, 8], "span2": [95, 101]}, "bert_text": "<e1> Caffeine </e1> produced significantly greater increases in subject-rated anxiety, nervousness, fear, <e2> nausea </e2>, palpitations, restlessness, and tremors in the patients compared with healthy subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"711": {"data": {"text": "Caffeine produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and tremors in the patients compared with healthy subjects.", "entity1": "Caffeine", "entity2": "tremors", "span1": [0, 8], "span2": [135, 142]}, "bert_text": "<e1> Caffeine </e1> produced significantly greater increases in subject-rated anxiety, nervousness, fear, nausea, palpitations, restlessness, and <e2> tremors </e2> in the patients compared with healthy subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"712": {"data": {"text": "Reversible valproic acid-induced dementia: a case report.\n", "entity1": "valproic acid", "entity2": "dementia", "span1": [11, 24], "span2": [33, 41]}, "bert_text": "Reversible <e1> valproic acid </e1>-induced <e2> dementia </e2>: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"713": {"data": {"text": "Patients exhibiting signs of continuing cocaine toxicity were excluded from the study.", "entity1": "cocaine", "entity2": "toxicity", "span1": [40, 47], "span2": [48, 56]}, "bert_text": "Patients exhibiting signs of continuing <e1> cocaine </e1> <e2> toxicity </e2> were excluded from the study.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"714": {"data": {"text": "Overall, galantamine was well-tolerated, with no significant adverse effects apart from headaches in one patient.", "entity1": "galantamine", "entity2": "headaches", "span1": [9, 20], "span2": [88, 97]}, "bert_text": "Overall, <e1> galantamine </e1> was well-tolerated, with no significant adverse effects apart from <e2> headaches </e2> in one patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"715": {"data": {"text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "entity1": "caffeine", "entity2": "panic disorder", "span1": [271, 279], "span2": [40, 54]}, "bert_text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e1> caffeine </e1> <e2> panic disorder </e2> (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"716": {"data": {"text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "entity1": "caffeine", "entity2": "PD", "span1": [271, 279], "span2": [56, 58]}, "bert_text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e1> caffeine </e1> <e2> PD </e2>) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"717": {"data": {"text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "entity1": "caffeine", "entity2": "panic attacks", "span1": [271, 279], "span2": [100, 113]}, "bert_text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e1> caffeine </e1> <e2> panic attacks </e2> (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"718": {"data": {"text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "entity1": "caffeine", "entity2": "panic attacks", "span1": [271, 279], "span2": [246, 259]}, "bert_text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e1> caffeine </e1> <e2> panic attacks </e2> by an oral caffeine challenge test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"719": {"data": {"text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "entity1": "caffeine", "entity2": "major depression", "span1": [271, 279], "span2": [78, 94]}, "bert_text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e1> caffeine </e1> <e2> major depression </e2> with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"720": {"data": {"text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "entity1": "caffeine", "entity2": "MDP", "span1": [271, 279], "span2": [115, 118]}, "bert_text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e1> caffeine </e1> <e2> MDP </e2>) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"721": {"data": {"text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "entity1": "caffeine", "entity2": "Mental Disorders", "span1": [271, 279], "span2": [158, 174]}, "bert_text": "Our aim was to observe if patients with panic disorder (PD) and patients with major depression with panic attacks (MDP) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral <e1> caffeine </e1> <e2> Mental Disorders </e2>, Fourth Edition criteria) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"722": {"data": {"text": "METHODS: Marmosets were administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (2.0 mg/kg s.c.) for five days, resulting in stable parkinsonism.", "entity1": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "entity2": "parkinsonism", "span1": [37, 81], "span2": [134, 146]}, "bert_text": "METHODS: Marmosets were administered <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> (2.0 mg/kg s.c.) for five days, resulting in stable <e2> parkinsonism </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"723": {"data": {"text": "Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy.\n", "entity1": "streptozotocin", "entity2": "diabetic nephropathy", "span1": [100, 114], "span2": [123, 143]}, "bert_text": "Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of <e1> streptozotocin </e1>-induced <e2> diabetic nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"724": {"data": {"text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "entity1": "ribavirin", "entity2": "anemia", "span1": [24, 33], "span2": [42, 48]}, "bert_text": "Factors contributing to <e1> ribavirin </e1>-induced <e2> anemia </e2>.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"725": {"data": {"text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "entity1": "ribavirin", "entity2": "chronic hepatitis C", "span1": [24, 33], "span2": [119, 138]}, "bert_text": "Factors contributing to <e1> ribavirin </e1>-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for <e2> chronic hepatitis C </e2> produces hemolytic anemia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"726": {"data": {"text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "entity1": "ribavirin", "entity2": "hemolytic anemia", "span1": [24, 33], "span2": [148, 164]}, "bert_text": "Factors contributing to <e1> ribavirin </e1>-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces <e2> hemolytic anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"727": {"data": {"text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "entity1": "ribavirin", "entity2": "anemia", "span1": [85, 94], "span2": [42, 48]}, "bert_text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and <e1> ribavirin </e1> <e2> anemia </e2>.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"728": {"data": {"text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "entity1": "ribavirin", "entity2": "chronic hepatitis C", "span1": [85, 94], "span2": [119, 138]}, "bert_text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and <e1> ribavirin </e1> combination therapy for <e2> chronic hepatitis C </e2> produces hemolytic anemia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"729": {"data": {"text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "entity1": "ribavirin", "entity2": "hemolytic anemia", "span1": [85, 94], "span2": [148, 164]}, "bert_text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and <e1> ribavirin </e1> combination therapy for chronic hepatitis C produces <e2> hemolytic anemia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"730": {"data": {"text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "entity1": "Interferon", "entity2": "anemia", "span1": [70, 80], "span2": [42, 48]}, "bert_text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: <e1> Interferon </e1> <e2> anemia </e2>.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"731": {"data": {"text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "entity1": "Interferon", "entity2": "chronic hepatitis C", "span1": [70, 80], "span2": [119, 138]}, "bert_text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: <e1> Interferon </e1> and ribavirin combination therapy for <e2> chronic hepatitis C </e2> produces hemolytic anemia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"732": {"data": {"text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia.", "entity1": "Interferon", "entity2": "hemolytic anemia", "span1": [70, 80], "span2": [148, 164]}, "bert_text": "Factors contributing to ribavirin-induced anemia.\nBACKGROUND AND AIM: <e1> Interferon </e1> and ribavirin combination therapy for chronic hepatitis C produces <e2> hemolytic anemia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"733": {"data": {"text": "CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.", "entity1": "dexmedetomidine", "entity2": "hypotension", "span1": [119, 134], "span2": [20, 31]}, "bert_text": "CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive <e1> dexmedetomidine </e1> <e2> hypotension </e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"734": {"data": {"text": "CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.", "entity1": "dexmedetomidine", "entity2": "bradycardia", "span1": [119, 134], "span2": [36, 47]}, "bert_text": "CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive <e1> dexmedetomidine </e1> <e2> bradycardia </e2> occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"735": {"data": {"text": "CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.", "entity1": "propofol", "entity2": "hypotension", "span1": [138, 146], "span2": [20, 31]}, "bert_text": "CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1> propofol </e1> <e2> hypotension </e2> and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"736": {"data": {"text": "CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.", "entity1": "propofol", "entity2": "bradycardia", "span1": [138, 146], "span2": [36, 47]}, "bert_text": "CONCLUSIONS: Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or <e1> propofol </e1> <e2> bradycardia </e2> occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"737": {"data": {"text": "Downbeat nystagmus associated with intravenous patient-controlled administration of morphine.\n", "entity1": "morphine", "entity2": "nystagmus", "span1": [84, 92], "span2": [9, 18]}, "bert_text": "Downbeat nystagmus associated with intravenous patient-controlled administration of <e1> morphine </e1> <e2> nystagmus </e2> associated with intravenous patient-controlled administration of morphine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"738": {"data": {"text": "CONCLUSION: In this open trial, galantamine was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and inattention.", "entity1": "galantamine", "entity2": "autism", "span1": [32, 43], "span2": [153, 159]}, "bert_text": "CONCLUSION: In this open trial, <e1> galantamine </e1> was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with <e2> autism </e2>, particularly aggression, behavioral dyscontrol, and inattention.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"739": {"data": {"text": "CONCLUSION: In this open trial, galantamine was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly aggression, behavioral dyscontrol, and inattention.", "entity1": "galantamine", "entity2": "aggression", "span1": [32, 43], "span2": [174, 184]}, "bert_text": "CONCLUSION: In this open trial, <e1> galantamine </e1> was well-tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism, particularly <e2> aggression </e2>, behavioral dyscontrol, and inattention.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"740": {"data": {"text": "Branch retinal vein occlusion and fluoxetine.\n", "entity1": "fluoxetine", "entity2": "Branch retinal vein occlusion", "span1": [34, 44], "span2": [0, 29]}, "bert_text": "Branch retinal vein occlusion and <e1> fluoxetine </e1> <e2> Branch retinal vein occlusion </e2> and fluoxetine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"741": {"data": {"text": "We conclude that: 1) administration of rhIGF-I improves growth and GFR in rats with chronic PAN nephropathy and 2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and structural injury in this disease model.", "entity1": "PAN", "entity2": "nephropathy", "span1": [92, 95], "span2": [96, 107]}, "bert_text": "We conclude that: 1) administration of rhIGF-I improves growth and GFR in rats with chronic <e1> PAN </e1> <e2> nephropathy </e2> and 2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and structural injury in this disease model.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"742": {"data": {"text": "We conclude that: 1) administration of rhIGF-I improves growth and GFR in rats with chronic PAN nephropathy and 2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and structural injury in this disease model.", "entity1": "PAN", "entity2": "structural injury", "span1": [92, 95], "span2": [190, 207]}, "bert_text": "We conclude that: 1) administration of rhIGF-I improves growth and GFR in rats with chronic <e1> PAN </e1> nephropathy and 2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and <e2> structural injury </e2> in this disease model.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"743": {"data": {"text": "Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.\n", "entity1": "melphalan", "entity2": "Acute renal insufficiency", "span1": [42, 51], "span2": [0, 25]}, "bert_text": "Acute renal insufficiency after high-dose <e1> melphalan </e1> <e2> Acute renal insufficiency </e2> after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"744": {"data": {"text": "Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.\n", "entity1": "melphalan", "entity2": "amyloidosis", "span1": [42, 51], "span2": [86, 97]}, "bert_text": "Acute renal insufficiency after high-dose <e1> melphalan </e1> in patients with primary systemic <e2> amyloidosis </e2> during stem cell transplantation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"745": {"data": {"text": "The purpose of this study was to determine if PAP formation is a requisite step in APAP-induced nephrotoxicity.", "entity1": "PAP", "entity2": "nephrotoxicity", "span1": [46, 49], "span2": [96, 110]}, "bert_text": "The purpose of this study was to determine if <e1> PAP </e1> formation is a requisite step in APAP-induced <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"746": {"data": {"text": "The purpose of this study was to determine if PAP formation is a requisite step in APAP-induced nephrotoxicity.", "entity1": "APAP", "entity2": "nephrotoxicity", "span1": [83, 87], "span2": [96, 110]}, "bert_text": "The purpose of this study was to determine if PAP formation is a requisite step in <e1> APAP </e1>-induced <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"747": {"data": {"text": "Her delirium significantly improved after misoprostol was discontinued and her mental status returned to normal within a week.", "entity1": "misoprostol", "entity2": "delirium", "span1": [42, 53], "span2": [4, 12]}, "bert_text": "Her delirium significantly improved after <e1> misoprostol </e1> <e2> delirium </e2> significantly improved after misoprostol was discontinued and her mental status returned to normal within a week.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"748": {"data": {"text": "In ethacrynic acid-induced convulsions, these neurotransmitter systems may be differentially modulated, probably through activation of glutaminergic neurons in the brain.", "entity1": "ethacrynic acid", "entity2": "convulsions", "span1": [3, 18], "span2": [27, 38]}, "bert_text": "In <e1> ethacrynic acid </e1>-induced <e2> convulsions </e2>, these neurotransmitter systems may be differentially modulated, probably through activation of glutaminergic neurons in the brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"749": {"data": {"text": "Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy.\n", "entity1": "indinavir", "entity2": "ureteric obstruction", "span1": [90, 99], "span2": [37, 57]}, "bert_text": "Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing <e1> indinavir </e1> <e2> ureteric obstruction </e2> in patients with HIV undergoing indinavir therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"750": {"data": {"text": "Bradycardia after high-dose intravenous methylprednisolone therapy.\n", "entity1": "methylprednisolone", "entity2": "Bradycardia", "span1": [40, 58], "span2": [0, 11]}, "bert_text": "Bradycardia after high-dose intravenous <e1> methylprednisolone </e1> <e2> Bradycardia </e2> after high-dose intravenous methylprednisolone therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"751": {"data": {"text": "This study was conducted to identify the factors contributing to ribavirin-induced anemia.", "entity1": "ribavirin", "entity2": "anemia", "span1": [65, 74], "span2": [83, 89]}, "bert_text": "This study was conducted to identify the factors contributing to <e1> ribavirin </e1>-induced <e2> anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"752": {"data": {"text": "In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated.", "entity1": "gamma-aminobutyric acid", "entity2": "seizures", "span1": [70, 93], "span2": [161, 169]}, "bert_text": "In the present study, the effects of manipulating the activity of the <e1> gamma-aminobutyric acid </e1> (GABA)-mediated synaptic inhibition within the substantia nigra on <e2> seizures </e2> produced by pilocarpine in rats, were investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"753": {"data": {"text": "In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated.", "entity1": "GABA)-mediated", "entity2": "seizures", "span1": [95, 109], "span2": [161, 169]}, "bert_text": "In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (<e1> GABA)-mediated </e1> synaptic inhibition within the substantia nigra on <e2> seizures </e2> produced by pilocarpine in rats, were investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"754": {"data": {"text": "In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats, were investigated.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [182, 193], "span2": [161, 169]}, "bert_text": "In the present study, the effects of manipulating the activity of the gamma-aminobutyric acid (GABA)-mediated synaptic inhibition within the substantia nigra on seizures produced by <e1> pilocarpine </e1> <e2> seizures </e2> produced by pilocarpine in rats, were investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"755": {"data": {"text": "Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.", "entity1": "Indinavir", "entity2": "nephrotoxicity", "span1": [0, 9], "span2": [21, 35]}, "bert_text": "<e1> Indinavir </e1>-associated <e2> nephrotoxicity </e2> must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"756": {"data": {"text": "Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.", "entity1": "Indinavir", "entity2": "sterile leukocyturia", "span1": [0, 9], "span2": [123, 143]}, "bert_text": "<e1> Indinavir </e1>-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent <e2> sterile leukocyturia </e2>, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"757": {"data": {"text": "Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.", "entity1": "indinavir", "entity2": "nephrotoxicity", "span1": [188, 197], "span2": [21, 35]}, "bert_text": "Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of <e1> indinavir </e1> <e2> nephrotoxicity </e2> must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"758": {"data": {"text": "Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.", "entity1": "indinavir", "entity2": "sterile leukocyturia", "span1": [188, 197], "span2": [123, 143]}, "bert_text": "Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age <5.6 years, an area under the curve of <e1> indinavir </e1> <e2> sterile leukocyturia </e2>, age <5.6 years, an area under the curve of indinavir >19 mg/L x h, and a C(max) >12 mg/L.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"759": {"data": {"text": "Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg.", "entity1": "GABA", "entity2": "seizures", "span1": [44, 48], "span2": [212, 220]}, "bert_text": "Application of an irreversible inhibitor of <e1> GABA </e1> transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral <e2> seizures </e2> produced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"760": {"data": {"text": "Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg.", "entity1": "gamma-vinyl-GABA", "entity2": "seizures", "span1": [63, 79], "span2": [212, 220]}, "bert_text": "Application of an irreversible inhibitor of GABA transaminase, <e1> gamma-vinyl-GABA </e1> (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral <e2> seizures </e2> produced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"761": {"data": {"text": "Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg.", "entity1": "D,L-4-amino-hex-5-enoic acid", "entity2": "seizures", "span1": [81, 109], "span2": [212, 220]}, "bert_text": "Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (<e1> D,L-4-amino-hex-5-enoic acid </e1>), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral <e2> seizures </e2> produced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"762": {"data": {"text": "Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine, 380 mg/kg.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [233, 244], "span2": [212, 220]}, "bert_text": "Application of an irreversible inhibitor of GABA transaminase, gamma-vinyl-GABA (D,L-4-amino-hex-5-enoic acid), 5 micrograms, into the SNR, bilaterally, suppressed the appearance of electrographic and behavioral seizures produced by <e1> pilocarpine </e1> <e2> seizures </e2> produced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"763": {"data": {"text": "We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.", "entity1": "5-FU", "entity2": "cardiotoxicity", "span1": [52, 56], "span2": [65, 79]}, "bert_text": "We herein report the case of a 70-year-old man with <e1> 5-FU </e1>-induced <e2> cardiotoxicity </e2>, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"764": {"data": {"text": "We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.", "entity1": "alpha-fluoro-beta-alanine", "entity2": "cardiotoxicity", "span1": [111, 136], "span2": [65, 79]}, "bert_text": "We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of <e1> alpha-fluoro-beta-alanine </e1> <e2> cardiotoxicity </e2>, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"765": {"data": {"text": "We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.", "entity1": "FBAL", "entity2": "cardiotoxicity", "span1": [138, 142], "span2": [65, 79]}, "bert_text": "We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (<e1> FBAL </e1> <e2> cardiotoxicity </e2>, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"766": {"data": {"text": "METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of chest pain, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10).", "entity1": "cocaine hydrochloride", "entity2": "chest pain", "span1": [402, 423], "span2": [136, 146]}, "bert_text": "METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of chest pain, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or <e1> cocaine hydrochloride </e1> <e2> chest pain </e2>, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"767": {"data": {"text": "METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of chest pain, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10).", "entity1": "cocaine hydrochloride", "entity2": "LV", "span1": [402, 423], "span2": [200, 202]}, "bert_text": "METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of chest pain, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or <e1> cocaine hydrochloride </e1> <e2> LV </e2> pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"768": {"data": {"text": "METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of chest pain, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10).", "entity1": "cocaine hydrochloride", "entity2": "LV", "span1": [402, 423], "span2": [250, 252]}, "bert_text": "METHODS AND RESULTS: In 20 patients (14 men and 6 women aged 39 to 72 years) referred for cardiac catheterization for the evaluation of chest pain, we measured heart rate, systemic arterial pressure, LV pressure and its first derivative (dP/dt), and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or <e1> cocaine hydrochloride </e1> <e2> LV </e2> volumes and ejection fraction before and during the final 2 to 3 minutes of a 15-minute intracoronary infusion of saline (n=10, control subjects) or cocaine hydrochloride 1 mg/min (n=10).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"769": {"data": {"text": "Intravascular hemolysis and acute renal failure following intermittent rifampin therapy.\n", "entity1": "rifampin", "entity2": "hemolysis", "span1": [71, 79], "span2": [14, 23]}, "bert_text": "Intravascular hemolysis and acute renal failure following intermittent <e1> rifampin </e1> <e2> hemolysis </e2> and acute renal failure following intermittent rifampin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"770": {"data": {"text": "Intravascular hemolysis and acute renal failure following intermittent rifampin therapy.\n", "entity1": "rifampin", "entity2": "acute renal failure", "span1": [71, 79], "span2": [28, 47]}, "bert_text": "Intravascular hemolysis and acute renal failure following intermittent <e1> rifampin </e1> <e2> acute renal failure </e2> following intermittent rifampin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"771": {"data": {"text": "A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here.", "entity1": "quetiapine", "entity2": "hepatocellular carcinoma", "span1": [98, 108], "span2": [25, 49]}, "bert_text": "A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with <e1> quetiapine </e1> <e2> hepatocellular carcinoma </e2> that developed neutropenia after treatment with quetiapine is described here.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"772": {"data": {"text": "A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here.", "entity1": "quetiapine", "entity2": "neutropenia", "span1": [98, 108], "span2": [65, 76]}, "bert_text": "A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with <e1> quetiapine </e1> <e2> neutropenia </e2> after treatment with quetiapine is described here.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"773": {"data": {"text": "7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [52, 63], "span2": [31, 40]}, "bert_text": "7e exhibits a high reversal of catalepsy induced by <e1> haloperidol </e1> <e2> catalepsy </e2> induced by haloperidol indicating its atypical antipsychotic nature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"774": {"data": {"text": "CONCLUSIONS: We found an increased incidence of subependymal cyst formation in preterm infants who were exposed to cocaine prenatally.", "entity1": "cocaine", "entity2": "subependymal cyst", "span1": [115, 122], "span2": [48, 65]}, "bert_text": "CONCLUSIONS: We found an increased incidence of subependymal cyst formation in preterm infants who were exposed to <e1> cocaine </e1> <e2> subependymal cyst </e2> formation in preterm infants who were exposed to cocaine prenatally.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"775": {"data": {"text": "Chronic progesterone pretreatment (5 mg/kg/day for 21 days) caused a significant increase in bupivacaine arrhythmogenicity in intact pentobarbital-anesthetized rats.", "entity1": "progesterone", "entity2": "arrhythmogenicity", "span1": [8, 20], "span2": [105, 122]}, "bert_text": "Chronic <e1> progesterone </e1> pretreatment (5 mg/kg/day for 21 days) caused a significant increase in bupivacaine <e2> arrhythmogenicity </e2> in intact pentobarbital-anesthetized rats.", "weak_labels": [1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"776": {"data": {"text": "Chronic progesterone pretreatment (5 mg/kg/day for 21 days) caused a significant increase in bupivacaine arrhythmogenicity in intact pentobarbital-anesthetized rats.", "entity1": "bupivacaine", "entity2": "arrhythmogenicity", "span1": [93, 104], "span2": [105, 122]}, "bert_text": "Chronic progesterone pretreatment (5 mg/kg/day for 21 days) caused a significant increase in <e1> bupivacaine </e1> <e2> arrhythmogenicity </e2> in intact pentobarbital-anesthetized rats.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"777": {"data": {"text": "Chronic progesterone pretreatment (5 mg/kg/day for 21 days) caused a significant increase in bupivacaine arrhythmogenicity in intact pentobarbital-anesthetized rats.", "entity1": "pentobarbital", "entity2": "arrhythmogenicity", "span1": [133, 146], "span2": [105, 122]}, "bert_text": "Chronic progesterone pretreatment (5 mg/kg/day for 21 days) caused a significant increase in bupivacaine arrhythmogenicity in intact <e1> pentobarbital </e1> <e2> arrhythmogenicity </e2> in intact pentobarbital-anesthetized rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"778": {"data": {"text": "These data show that inhibition of NF-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin.", "entity1": "gentamicin", "entity2": "tubulointerstitial nephritis", "span1": [107, 117], "span2": [67, 95]}, "bert_text": "These data show that inhibition of NF-kappaB activation attenuates tubulointerstitial nephritis induced by <e1> gentamicin </e1> <e2> tubulointerstitial nephritis </e2> induced by gentamicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"779": {"data": {"text": "RESULTS: L-NOARG sub-chronic administration produced tolerance of L-NOARG and of haloperidol-induced catalepsy.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [81, 92], "span2": [101, 110]}, "bert_text": "RESULTS: L-NOARG sub-chronic administration produced tolerance of L-NOARG and of <e1> haloperidol </e1>-induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"780": {"data": {"text": "Children with persistent sterile leukocyturia more frequently had serum creatinine levels of 50% above normal than those children without persistent sterile leukocyturia.", "entity1": "creatinine", "entity2": "sterile leukocyturia", "span1": [72, 82], "span2": [25, 45]}, "bert_text": "Children with persistent sterile leukocyturia more frequently had serum <e1> creatinine </e1> <e2> sterile leukocyturia </e2> more frequently had serum creatinine levels of 50% above normal than those children without persistent sterile leukocyturia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"781": {"data": {"text": "Children with persistent sterile leukocyturia more frequently had serum creatinine levels of 50% above normal than those children without persistent sterile leukocyturia.", "entity1": "creatinine", "entity2": "sterile leukocyturia", "span1": [72, 82], "span2": [149, 169]}, "bert_text": "Children with persistent sterile leukocyturia more frequently had serum <e1> creatinine </e1> levels of 50% above normal than those children without persistent <e2> sterile leukocyturia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"782": {"data": {"text": "Although the oral administration of class IC drugs, including pilsicainide, is effective to terminate atrial fibrillation, careful consideration must be taken before giving these drugs to octogenarians.", "entity1": "pilsicainide", "entity2": "atrial fibrillation", "span1": [62, 74], "span2": [102, 121]}, "bert_text": "Although the oral administration of class IC drugs, including <e1> pilsicainide </e1>, is effective to terminate <e2> atrial fibrillation </e2>, careful consideration must be taken before giving these drugs to octogenarians.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"783": {"data": {"text": "A rat model of IUGR was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized.", "entity1": "PCE", "entity2": "IUGR", "span1": [39, 42], "span2": [15, 19]}, "bert_text": "A rat model of IUGR was established by <e1> PCE </e1> <e2> IUGR </e2> was established by PCE, male fetuses and adult offspring at the age of postnatal week 24 were euthanized.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"784": {"data": {"text": "Thus, two control groups were generated: group C1, which included age- and sex-comparable lithium-treated bipolar normocalcemic patients, and group C2, which included bipolar normocalcemic patients treated with anticonvulsant mood stabilizers.", "entity1": "lithium", "entity2": "bipolar normocalcemic", "span1": [90, 97], "span2": [106, 127]}, "bert_text": "Thus, two control groups were generated: group C1, which included age- and sex-comparable <e1> lithium </e1>-treated <e2> bipolar normocalcemic </e2> patients, and group C2, which included bipolar normocalcemic patients treated with anticonvulsant mood stabilizers.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"785": {"data": {"text": "Thus, two control groups were generated: group C1, which included age- and sex-comparable lithium-treated bipolar normocalcemic patients, and group C2, which included bipolar normocalcemic patients treated with anticonvulsant mood stabilizers.", "entity1": "lithium", "entity2": "bipolar normocalcemic", "span1": [90, 97], "span2": [167, 188]}, "bert_text": "Thus, two control groups were generated: group C1, which included age- and sex-comparable <e1> lithium </e1>-treated bipolar normocalcemic patients, and group C2, which included <e2> bipolar normocalcemic </e2> patients treated with anticonvulsant mood stabilizers.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"786": {"data": {"text": "Bromocriptine has been implicated in several previous case reports of myocardial infarction in the puerperium.", "entity1": "Bromocriptine", "entity2": "myocardial infarction", "span1": [0, 13], "span2": [70, 91]}, "bert_text": "<e1> Bromocriptine </e1> has been implicated in several previous case reports of <e2> myocardial infarction </e2> in the puerperium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"787": {"data": {"text": "Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.", "entity1": "CsA", "entity2": "renal damage", "span1": [10, 13], "span2": [34, 46]}, "bert_text": "Prolonged <e1> CsA </e1> exposure aggravated <e2> renal damage </e2>, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"788": {"data": {"text": "Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.", "entity1": "TBARs", "entity2": "renal damage", "span1": [142, 147], "span2": [34, 46]}, "bert_text": "Prolonged CsA exposure aggravated renal damage, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, <e1> TBARs </e1> <e2> renal damage </e2>, without clear changes on the traditional markers, but with changes in serums TGF- b and IL-7, TBARs clearance, and kidney TGF-b and mTOR.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"789": {"data": {"text": "Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course.\n", "entity1": "capsaicin", "entity2": "neuralgia", "span1": [15, 24], "span2": [50, 59]}, "bert_text": "Topical 0.025% <e1> capsaicin </e1> in chronic post-herpetic <e2> neuralgia </e2>: efficacy, predictors of response and long-term course.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"790": {"data": {"text": "Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine-induced convulsions.", "entity1": "pilocarpine", "entity2": "convulsions", "span1": [101, 112], "span2": [121, 132]}, "bert_text": "Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for <e1> pilocarpine </e1>-induced <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"791": {"data": {"text": "0.06 mL/min/100 g of body weight in untreated PAN nephropathy animals, p < 0.05.", "entity1": "PAN", "entity2": "nephropathy", "span1": [46, 49], "span2": [50, 61]}, "bert_text": "0.06 mL/min/100 g of body weight in untreated <e1> PAN </e1> <e2> nephropathy </e2> animals, p < 0.05.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"792": {"data": {"text": "Rats were divided into three groups: sham, VCM and VCM plus erdosteine.", "entity1": "VCM", "entity2": "VCM plus erdosteine", "span1": [43, 46], "span2": [51, 70]}, "bert_text": "Rats were divided into three groups: sham, <e1> VCM </e1> and <e2> VCM plus erdosteine </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"793": {"data": {"text": "We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction.", "entity1": "cocaine", "entity2": "left ventricular dysfunction", "span1": [21, 28], "span2": [101, 129]}, "bert_text": "We hypothesized that <e1> cocaine </e1> abuse may lead to altered mitochondrial function that in turn may cause <e2> left ventricular dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"794": {"data": {"text": "51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias.", "entity1": "L-DOPA", "entity2": "Parkinson's disease", "span1": [190, 196], "span2": [38, 57]}, "bert_text": "51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and <e1> L-DOPA </e1> <e2> Parkinson's disease </e2> underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"795": {"data": {"text": "51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias.", "entity1": "L-DOPA", "entity2": "bradykinesia", "span1": [190, 196], "span2": [162, 174]}, "bert_text": "51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and <e1> L-DOPA </e1> <e2> bradykinesia </e2>, rigidity, and L-DOPA-induced dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"796": {"data": {"text": "51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias.", "entity1": "L-DOPA", "entity2": "rigidity", "span1": [190, 196], "span2": [176, 184]}, "bert_text": "51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and <e1> L-DOPA </e1> <e2> rigidity </e2>, and L-DOPA-induced dyskinesias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"797": {"data": {"text": "51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and L-DOPA-induced dyskinesias.", "entity1": "L-DOPA", "entity2": "dyskinesias", "span1": [190, 196], "span2": [205, 216]}, "bert_text": "51 patients with medically refractory Parkinson's disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia, rigidity, and <e1> L-DOPA </e1>-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"798": {"data": {"text": "The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced epilepsy in male Wistar albino rats.", "entity1": "NO", "entity2": "epilepsy", "span1": [61, 63], "span2": [125, 133]}, "bert_text": "The aim of the current study was to determine the effects of <e1> NO </e1> on the behavioral and EEG characteristics of lindane-induced <e2> epilepsy </e2> in male Wistar albino rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"799": {"data": {"text": "The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane-induced epilepsy in male Wistar albino rats.", "entity1": "lindane", "entity2": "epilepsy", "span1": [109, 116], "span2": [125, 133]}, "bert_text": "The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of <e1> lindane </e1>-induced <e2> epilepsy </e2> in male Wistar albino rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"800": {"data": {"text": "A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.", "entity1": "amiodarone", "entity2": "bradycardia", "span1": [113, 123], "span2": [36, 47]}, "bert_text": "A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of <e1> amiodarone </e1> <e2> bradycardia </e2>, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"801": {"data": {"text": "A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.", "entity1": "amiodarone", "entity2": "hypothermia", "span1": [113, 123], "span2": [49, 60]}, "bert_text": "A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of <e1> amiodarone </e1> <e2> hypothermia </e2> and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"802": {"data": {"text": "A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.", "entity1": "amiodarone", "entity2": "respiratory failure", "span1": [113, 123], "span2": [65, 84]}, "bert_text": "A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of <e1> amiodarone </e1> <e2> respiratory failure </e2> 3 weeks after initiation of amiodarone therapy for atrial fibrillation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"803": {"data": {"text": "A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation.", "entity1": "amiodarone", "entity2": "atrial fibrillation", "span1": [113, 123], "span2": [136, 155]}, "bert_text": "A 62-year-old man was found to have bradycardia, hypothermia and respiratory failure 3 weeks after initiation of <e1> amiodarone </e1> therapy for <e2> atrial fibrillation </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"804": {"data": {"text": "Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.", "entity1": "cromakalim", "entity2": "hypotension", "span1": [76, 86], "span2": [53, 64]}, "bert_text": "Vasodilation of large and small coronary vessels and hypotension induced by <e1> cromakalim </e1> <e2> hypotension </e2> induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"805": {"data": {"text": "Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.", "entity1": "cromakalim", "entity2": "tachycardia", "span1": [76, 86], "span2": [204, 215]}, "bert_text": "Vasodilation of large and small coronary vessels and hypotension induced by <e1> cromakalim </e1> and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced <e2> tachycardia </e2> was abolished.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"806": {"data": {"text": "Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.", "entity1": "pinacidil", "entity2": "hypotension", "span1": [91, 100], "span2": [53, 64]}, "bert_text": "Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and <e1> pinacidil </e1> <e2> hypotension </e2> induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"807": {"data": {"text": "Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced tachycardia was abolished.", "entity1": "pinacidil", "entity2": "tachycardia", "span1": [91, 100], "span2": [204, 215]}, "bert_text": "Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and <e1> pinacidil </e1> were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug-induced <e2> tachycardia </e2> was abolished.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"808": {"data": {"text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.", "entity1": "BNPP", "entity2": "nephrotoxicity", "span1": [29, 33], "span2": [119, 133]}, "bert_text": "Pretreatment of animals with <e1> BNPP </e1> prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) <e2> nephrotoxicity </e2> but not PAP nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"809": {"data": {"text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.", "entity1": "BNPP", "entity2": "nephrotoxicity", "span1": [29, 33], "span2": [146, 160]}, "bert_text": "Pretreatment of animals with <e1> BNPP </e1> prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"810": {"data": {"text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.", "entity1": "APAP", "entity2": "nephrotoxicity", "span1": [43, 47], "span2": [119, 133]}, "bert_text": "Pretreatment of animals with BNPP prior to <e1> APAP </e1> or PAP administration resulted in marked reduction of APAP (900 mg/kg) <e2> nephrotoxicity </e2> but not PAP nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"811": {"data": {"text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.", "entity1": "APAP", "entity2": "nephrotoxicity", "span1": [43, 47], "span2": [146, 160]}, "bert_text": "Pretreatment of animals with BNPP prior to <e1> APAP </e1> or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"812": {"data": {"text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.", "entity1": "APAP", "entity2": "nephrotoxicity", "span1": [102, 106], "span2": [119, 133]}, "bert_text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of <e1> APAP </e1> (900 mg/kg) <e2> nephrotoxicity </e2> but not PAP nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"813": {"data": {"text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.", "entity1": "APAP", "entity2": "nephrotoxicity", "span1": [102, 106], "span2": [146, 160]}, "bert_text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of <e1> APAP </e1> (900 mg/kg) nephrotoxicity but not PAP <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"814": {"data": {"text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.", "entity1": "PAP", "entity2": "nephrotoxicity", "span1": [51, 54], "span2": [119, 133]}, "bert_text": "Pretreatment of animals with BNPP prior to APAP or <e1> PAP </e1> administration resulted in marked reduction of APAP (900 mg/kg) <e2> nephrotoxicity </e2> but not PAP nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"815": {"data": {"text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.", "entity1": "PAP", "entity2": "nephrotoxicity", "span1": [51, 54], "span2": [146, 160]}, "bert_text": "Pretreatment of animals with BNPP prior to APAP or <e1> PAP </e1> administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"816": {"data": {"text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.", "entity1": "PAP", "entity2": "nephrotoxicity", "span1": [142, 145], "span2": [119, 133]}, "bert_text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not <e1> PAP </e1> <e2> nephrotoxicity </e2> but not PAP nephrotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"817": {"data": {"text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not PAP nephrotoxicity.", "entity1": "PAP", "entity2": "nephrotoxicity", "span1": [142, 145], "span2": [146, 160]}, "bert_text": "Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP (900 mg/kg) nephrotoxicity but not <e1> PAP </e1> <e2> nephrotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"818": {"data": {"text": "We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease.", "entity1": "tiapride", "entity2": "neuroleptic malignant syndrome", "span1": [168, 176], "span2": [66, 96]}, "bert_text": "We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with <e1> tiapride </e1> <e2> neuroleptic malignant syndrome </e2> that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"819": {"data": {"text": "We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease.", "entity1": "tiapride", "entity2": "Huntington's disease", "span1": [168, 176], "span2": [225, 245]}, "bert_text": "We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with <e1> tiapride </e1> (75 mg/day) and tetrabenazine (12.5 mg/day) for <e2> Huntington's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"820": {"data": {"text": "We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease.", "entity1": "tetrabenazine", "entity2": "neuroleptic malignant syndrome", "span1": [193, 206], "span2": [66, 96]}, "bert_text": "We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and <e1> tetrabenazine </e1> <e2> neuroleptic malignant syndrome </e2> that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"821": {"data": {"text": "We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and tetrabenazine (12.5 mg/day) for Huntington's disease.", "entity1": "tetrabenazine", "entity2": "Huntington's disease", "span1": [193, 206], "span2": [225, 245]}, "bert_text": "We herein describe the case of an 81-year-old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride (75 mg/day) and <e1> tetrabenazine </e1> (12.5 mg/day) for <e2> Huntington's disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"822": {"data": {"text": "Hyperosmolar nonketotic coma precipitated by lithium-induced nephrogenic diabetes insipidus.\n", "entity1": "lithium", "entity2": "Hyperosmolar nonketotic coma", "span1": [45, 52], "span2": [0, 28]}, "bert_text": "Hyperosmolar nonketotic coma precipitated by <e1> lithium </e1> <e2> Hyperosmolar nonketotic coma </e2> precipitated by lithium-induced nephrogenic diabetes insipidus.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"823": {"data": {"text": "Hyperosmolar nonketotic coma precipitated by lithium-induced nephrogenic diabetes insipidus.\n", "entity1": "lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [45, 52], "span2": [61, 91]}, "bert_text": "Hyperosmolar nonketotic coma precipitated by <e1> lithium </e1>-induced <e2> nephrogenic diabetes insipidus </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"824": {"data": {"text": "Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [78, 86], "span2": [14, 24]}, "bert_text": "Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of <e1> levodopa </e1> <e2> dyskinesia </e2> had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"825": {"data": {"text": "Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [166, 174], "span2": [14, 24]}, "bert_text": "Patients with dyskinesia had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily <e1> levodopa </e1> <e2> dyskinesia </e2> had lower onset age ( p < 0.001), longer duration of levodopa therapy ( p < 0.001), longer disease duration ( p < 0.001), higher total daily levodopa dose ( p", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"826": {"data": {"text": "The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical malondialdehyde content.", "entity1": "malondialdehyde", "entity2": "glomerular hypertrophy", "span1": [167, 182], "span2": [56, 78]}, "bert_text": "The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical <e1> malondialdehyde </e1> <e2> glomerular hypertrophy </e2> or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical malondialdehyde content.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"827": {"data": {"text": "The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical malondialdehyde content.", "entity1": "malondialdehyde", "entity2": "glomerulosclerosis", "span1": [167, 182], "span2": [102, 120]}, "bert_text": "The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical <e1> malondialdehyde </e1> <e2> glomerulosclerosis </e2>, tubulointerstitial injury, or renal cortical malondialdehyde content.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"828": {"data": {"text": "Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU.", "entity1": "5-FU", "entity2": "pain", "span1": [117, 121], "span2": [20, 24]}, "bert_text": "Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of <e1> 5-FU </e1> <e2> pain </e2> and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"829": {"data": {"text": "Antitumor activity, cardiotoxicity, and nephrotoxicity induced by doxorubicin were studied in LOU/M/WSL inbred rats each bearing a transplantable solid IgM immunocytoma.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [66, 77], "span2": [20, 34]}, "bert_text": "Antitumor activity, cardiotoxicity, and nephrotoxicity induced by <e1> doxorubicin </e1> <e2> cardiotoxicity </e2>, and nephrotoxicity induced by doxorubicin were studied in LOU/M/WSL inbred rats each bearing a transplantable solid IgM immunocytoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"830": {"data": {"text": "Antitumor activity, cardiotoxicity, and nephrotoxicity induced by doxorubicin were studied in LOU/M/WSL inbred rats each bearing a transplantable solid IgM immunocytoma.", "entity1": "doxorubicin", "entity2": "nephrotoxicity", "span1": [66, 77], "span2": [40, 54]}, "bert_text": "Antitumor activity, cardiotoxicity, and nephrotoxicity induced by <e1> doxorubicin </e1> <e2> nephrotoxicity </e2> induced by doxorubicin were studied in LOU/M/WSL inbred rats each bearing a transplantable solid IgM immunocytoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"831": {"data": {"text": "Antitumor activity, cardiotoxicity, and nephrotoxicity induced by doxorubicin were studied in LOU/M/WSL inbred rats each bearing a transplantable solid IgM immunocytoma.", "entity1": "doxorubicin", "entity2": "IgM immunocytoma", "span1": [66, 77], "span2": [152, 168]}, "bert_text": "Antitumor activity, cardiotoxicity, and nephrotoxicity induced by <e1> doxorubicin </e1> were studied in LOU/M/WSL inbred rats each bearing a transplantable solid <e2> IgM immunocytoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"832": {"data": {"text": "Doxorubicin causes significant cardiotoxicity characterized by marked increases in oxidative stress and mitochondrial dysfunction.", "entity1": "Doxorubicin", "entity2": "cardiotoxicity", "span1": [0, 11], "span2": [31, 45]}, "bert_text": "<e1> Doxorubicin </e1> causes significant <e2> cardiotoxicity </e2> characterized by marked increases in oxidative stress and mitochondrial dysfunction.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"833": {"data": {"text": "Doxorubicin causes significant cardiotoxicity characterized by marked increases in oxidative stress and mitochondrial dysfunction.", "entity1": "Doxorubicin", "entity2": "mitochondrial dysfunction", "span1": [0, 11], "span2": [104, 129]}, "bert_text": "<e1> Doxorubicin </e1> causes significant cardiotoxicity characterized by marked increases in oxidative stress and <e2> mitochondrial dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"834": {"data": {"text": "A 69-year-old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis.", "entity1": "methoxyflurane", "entity2": "acute cholecystitis", "span1": [57, 71], "span2": [31, 50]}, "bert_text": "A 69-year-old man operated for acute cholecystitis under <e1> methoxyflurane </e1> <e2> acute cholecystitis </e2> under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"835": {"data": {"text": "A 69-year-old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis.", "entity1": "methoxyflurane", "entity2": "hepatic insufficiency syndrome", "span1": [57, 71], "span2": [111, 141]}, "bert_text": "A 69-year-old man operated for acute cholecystitis under <e1> methoxyflurane </e1> anesthesia developed postoperatively a <e2> hepatic insufficiency syndrome </e2> and renal tubular acidosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"836": {"data": {"text": "A 69-year-old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis.", "entity1": "methoxyflurane", "entity2": "renal tubular acidosis", "span1": [57, 71], "span2": [146, 168]}, "bert_text": "A 69-year-old man operated for acute cholecystitis under <e1> methoxyflurane </e1> anesthesia developed postoperatively a hepatic insufficiency syndrome and <e2> renal tubular acidosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"837": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "adenosine", "entity2": "hyperactivity", "span1": [32, 41], "span2": [165, 178]}, "bert_text": "Our results have shown that all <e1> adenosine </e1> receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced <e2> hyperactivity </e2> is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"838": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "adenosine", "entity2": "hyperactivity", "span1": [32, 41], "span2": [282, 295]}, "bert_text": "Our results have shown that all <e1> adenosine </e1> receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"839": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "adenosine", "entity2": "hyperactivity", "span1": [201, 210], "span2": [165, 178]}, "bert_text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by <e1> adenosine </e1> <e2> hyperactivity </e2> is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"840": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "adenosine", "entity2": "hyperactivity", "span1": [201, 210], "span2": [282, 295]}, "bert_text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by <e1> adenosine </e1> receptor agonists (particularly A1 receptors) than amphetamine-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"841": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "cocaine-", "entity2": "hyperactivity", "span1": [79, 87], "span2": [165, 178]}, "bert_text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce <e1> cocaine- </e1> and amphetamine-induced locomotor activity and indicate that cocaine-induced <e2> hyperactivity </e2> is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"842": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "cocaine-", "entity2": "hyperactivity", "span1": [79, 87], "span2": [282, 295]}, "bert_text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce <e1> cocaine- </e1> and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"843": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "cocaine", "entity2": "hyperactivity", "span1": [149, 156], "span2": [165, 178]}, "bert_text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that <e1> cocaine </e1>-induced <e2> hyperactivity </e2> is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"844": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "cocaine", "entity2": "hyperactivity", "span1": [149, 156], "span2": [282, 295]}, "bert_text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that <e1> cocaine </e1>-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"845": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [92, 103], "span2": [165, 178]}, "bert_text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and <e1> amphetamine </e1>-induced locomotor activity and indicate that cocaine-induced <e2> hyperactivity </e2> is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"846": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [92, 103], "span2": [282, 295]}, "bert_text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and <e1> amphetamine </e1>-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"847": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [262, 273], "span2": [165, 178]}, "bert_text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than <e1> amphetamine </e1> <e2> hyperactivity </e2> is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"848": {"data": {"text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than amphetamine-induced hyperactivity.", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [262, 273], "span2": [282, 295]}, "bert_text": "Our results have shown that all adenosine receptor agonists (A1 and A2) reduce cocaine- and amphetamine-induced locomotor activity and indicate that cocaine-induced hyperactivity is more influenced by adenosine receptor agonists (particularly A1 receptors) than <e1> amphetamine </e1>-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"849": {"data": {"text": "For capsaicin, secondary pinprick hyperalgesia was detected with all von Frey gauges (P < 0.001).", "entity1": "capsaicin", "entity2": "pinprick hyperalgesia", "span1": [4, 13], "span2": [25, 46]}, "bert_text": "For <e1> capsaicin </e1>, secondary <e2> pinprick hyperalgesia </e2> was detected with all von Frey gauges (P < 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"850": {"data": {"text": "Aspirin use increases the risk for serious bleeding events.", "entity1": "Aspirin", "entity2": "bleeding", "span1": [0, 7], "span2": [43, 51]}, "bert_text": "<e1> Aspirin </e1> use increases the risk for serious <e2> bleeding </e2> events.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"851": {"data": {"text": "Pronounced changes in the surface ECG (cycle length, QT, and QTc) in relation to the dose of oral d,l-sotalol might identify a subgroup of patients with an increased risk for torsades de pointes.", "entity1": "l-sotalol", "entity2": "torsades de pointes", "span1": [100, 109], "span2": [175, 194]}, "bert_text": "Pronounced changes in the surface ECG (cycle length, QT, and QTc) in relation to the dose of oral d,<e1> l-sotalol </e1> might identify a subgroup of patients with an increased risk for <e2> torsades de pointes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"852": {"data": {"text": "The authors present a case of early (within 4 days) development of torsade de pointes (TdP) associated with oral amiodarone therapy.", "entity1": "amiodarone", "entity2": "torsade de pointes", "span1": [113, 123], "span2": [67, 85]}, "bert_text": "The authors present a case of early (within 4 days) development of torsade de pointes (TdP) associated with oral <e1> amiodarone </e1> <e2> torsade de pointes </e2> (TdP) associated with oral amiodarone therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"853": {"data": {"text": "The authors present a case of early (within 4 days) development of torsade de pointes (TdP) associated with oral amiodarone therapy.", "entity1": "amiodarone", "entity2": "TdP", "span1": [113, 123], "span2": [87, 90]}, "bert_text": "The authors present a case of early (within 4 days) development of torsade de pointes (TdP) associated with oral <e1> amiodarone </e1> <e2> TdP </e2>) associated with oral amiodarone therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"854": {"data": {"text": "Ethacrynic acid-induced convulsions and brain neurotransmitters in mice.\n", "entity1": "Ethacrynic acid", "entity2": "convulsions", "span1": [0, 15], "span2": [24, 35]}, "bert_text": "<e1> Ethacrynic acid </e1>-induced <e2> convulsions </e2> and brain neurotransmitters in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"855": {"data": {"text": "A prospective, open-label trial of galantamine in autistic disorder.\n", "entity1": "galantamine", "entity2": "autistic disorder", "span1": [35, 46], "span2": [50, 67]}, "bert_text": "A prospective, open-label trial of <e1> galantamine </e1> in <e2> autistic disorder </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"856": {"data": {"text": "The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.", "entity1": "AMI", "entity2": "GI toxicity", "span1": [4, 7], "span2": [8, 19]}, "bert_text": "The <e1> AMI </e1>/<e2> GI toxicity </e2> of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"857": {"data": {"text": "The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.", "entity1": "celecoxib", "entity2": "GI toxicity", "span1": [23, 32], "span2": [8, 19]}, "bert_text": "The AMI/GI toxicity of <e1> celecoxib </e1> <e2> GI toxicity </e2> of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"858": {"data": {"text": "The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.", "entity1": "acetaminophen", "entity2": "GI toxicity", "span1": [56, 69], "span2": [8, 19]}, "bert_text": "The AMI/GI toxicity of celecoxib was similar to that of <e1> acetaminophen </e1> <e2> GI toxicity </e2> of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"859": {"data": {"text": "The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.", "entity1": "rofecoxib", "entity2": "GI toxicity", "span1": [108, 117], "span2": [8, 19]}, "bert_text": "The AMI/GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of <e1> rofecoxib </e1> <e2> GI toxicity </e2> of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS-NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"860": {"data": {"text": "Mania associated with fluoxetine treatment in adolescents.\n", "entity1": "fluoxetine", "entity2": "Mania", "span1": [22, 32], "span2": [0, 5]}, "bert_text": "Mania associated with <e1> fluoxetine </e1> <e2> Mania </e2> associated with fluoxetine treatment in adolescents.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"861": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "dihydropyridine", "entity2": "headache", "span1": [16, 31], "span2": [90, 98]}, "bert_text": "In general, the <e1> dihydropyridine </e1> calcium channel blockers are usually well tolerated, with <e2> headache </e2>, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"862": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "dihydropyridine", "entity2": "facial flushing", "span1": [16, 31], "span2": [100, 115]}, "bert_text": "In general, the <e1> dihydropyridine </e1> calcium channel blockers are usually well tolerated, with headache, <e2> facial flushing </e2>, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"863": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "dihydropyridine", "entity2": "edema", "span1": [16, 31], "span2": [131, 136]}, "bert_text": "In general, the <e1> dihydropyridine </e1> calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, <e2> edema </e2>, nausea, anorexia, and dizziness being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"864": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "dihydropyridine", "entity2": "nausea", "span1": [16, 31], "span2": [138, 144]}, "bert_text": "In general, the <e1> dihydropyridine </e1> calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, <e2> nausea </e2>, anorexia, and dizziness being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"865": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "dihydropyridine", "entity2": "anorexia", "span1": [16, 31], "span2": [146, 154]}, "bert_text": "In general, the <e1> dihydropyridine </e1> calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, <e2> anorexia </e2>, and dizziness being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"866": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "dihydropyridine", "entity2": "dizziness", "span1": [16, 31], "span2": [160, 169]}, "bert_text": "In general, the <e1> dihydropyridine </e1> calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and <e2> dizziness </e2> being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"867": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "calcium", "entity2": "headache", "span1": [32, 39], "span2": [90, 98]}, "bert_text": "In general, the dihydropyridine <e1> calcium </e1> channel blockers are usually well tolerated, with <e2> headache </e2>, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"868": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "calcium", "entity2": "facial flushing", "span1": [32, 39], "span2": [100, 115]}, "bert_text": "In general, the dihydropyridine <e1> calcium </e1> channel blockers are usually well tolerated, with headache, <e2> facial flushing </e2>, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"869": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "calcium", "entity2": "edema", "span1": [32, 39], "span2": [131, 136]}, "bert_text": "In general, the dihydropyridine <e1> calcium </e1> channel blockers are usually well tolerated, with headache, facial flushing, palpitations, <e2> edema </e2>, nausea, anorexia, and dizziness being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"870": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "calcium", "entity2": "nausea", "span1": [32, 39], "span2": [138, 144]}, "bert_text": "In general, the dihydropyridine <e1> calcium </e1> channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, <e2> nausea </e2>, anorexia, and dizziness being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"871": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "calcium", "entity2": "anorexia", "span1": [32, 39], "span2": [146, 154]}, "bert_text": "In general, the dihydropyridine <e1> calcium </e1> channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, <e2> anorexia </e2>, and dizziness being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"872": {"data": {"text": "In general, the dihydropyridine calcium channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and dizziness being the more common adverse effects.", "entity1": "calcium", "entity2": "dizziness", "span1": [32, 39], "span2": [160, 169]}, "bert_text": "In general, the dihydropyridine <e1> calcium </e1> channel blockers are usually well tolerated, with headache, facial flushing, palpitations, edema, nausea, anorexia, and <e2> dizziness </e2> being the more common adverse effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"873": {"data": {"text": "Delirium in an elderly woman possibly associated with administration of misoprostol.\n", "entity1": "misoprostol", "entity2": "Delirium", "span1": [72, 83], "span2": [0, 8]}, "bert_text": "Delirium in an elderly woman possibly associated with administration of <e1> misoprostol </e1> <e2> Delirium </e2> in an elderly woman possibly associated with administration of misoprostol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"874": {"data": {"text": "These findings are strong support for the adrenaline-hypertension hypothesis in man.", "entity1": "adrenaline", "entity2": "hypertension hypothesis", "span1": [42, 52], "span2": [53, 76]}, "bert_text": "These findings are strong support for the <e1> adrenaline </e1>-<e2> hypertension hypothesis </e2> in man.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"875": {"data": {"text": "Our data suggested that the ginsenoside Re, but not Rg1 or Rb1, may contribute toward reversal of OIH.", "entity1": "ginsenoside Re", "entity2": "OIH", "span1": [28, 42], "span2": [98, 101]}, "bert_text": "Our data suggested that the <e1> ginsenoside Re </e1>, but not Rg1 or Rb1, may contribute toward reversal of <e2> OIH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"876": {"data": {"text": "Our data suggested that the ginsenoside Re, but not Rg1 or Rb1, may contribute toward reversal of OIH.", "entity1": "Rg1", "entity2": "OIH", "span1": [52, 55], "span2": [98, 101]}, "bert_text": "Our data suggested that the ginsenoside Re, but not <e1> Rg1 </e1> or Rb1, may contribute toward reversal of <e2> OIH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"877": {"data": {"text": "There was a significant decrease in the time to onset of arrhythmia as compared with control nonprogesterone-treated rats (6.2 +/-", "entity1": "control nonprogesterone", "entity2": "arrhythmia", "span1": [85, 108], "span2": [57, 67]}, "bert_text": "There was a significant decrease in the time to onset of arrhythmia as compared with <e1> control nonprogesterone </e1> <e2> arrhythmia </e2> as compared with control nonprogesterone-treated rats (6.2 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"878": {"data": {"text": "Reported cases of decreased dark adaptation are under investigation. Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia).", "entity1": "Isotretinoin", "entity2": "congenital abnormalities", "span1": [69, 81], "span2": [143, 167]}, "bert_text": "Reported cases of decreased dark adaptation are under investigation. <e1> Isotretinoin </e1> is contraindicated in pregnancy because of the many reported <e2> congenital abnormalities </e2> after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"879": {"data": {"text": "Reported cases of decreased dark adaptation are under investigation. Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia).", "entity1": "Isotretinoin", "entity2": "orbital hypertelorism", "span1": [69, 81], "span2": [214, 235]}, "bert_text": "Reported cases of decreased dark adaptation are under investigation. <e1> Isotretinoin </e1> is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, <e2> orbital hypertelorism </e2>, and optic nerve hypoplasia).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"880": {"data": {"text": "Reported cases of decreased dark adaptation are under investigation. Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and optic nerve hypoplasia).", "entity1": "Isotretinoin", "entity2": "optic nerve hypoplasia", "span1": [69, 81], "span2": [241, 263]}, "bert_text": "Reported cases of decreased dark adaptation are under investigation. <e1> Isotretinoin </e1> is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use (including microphthalmos, orbital hypertelorism, and <e2> optic nerve hypoplasia </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"881": {"data": {"text": "PATIENTS AND METHODS: A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [95, 105], "span2": [44, 55]}, "bert_text": "PATIENTS AND METHODS: A total of 77 chronic hepatitis B patients who had not been treated with <e1> lamivudine </e1> <e2> hepatitis B </e2> patients who had not been treated with lamivudine were included in the study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"882": {"data": {"text": "The authors have noted the development of acute renal insufficiency immediately after melphalan conditioning.", "entity1": "melphalan", "entity2": "acute renal insufficiency", "span1": [86, 95], "span2": [42, 67]}, "bert_text": "The authors have noted the development of acute renal insufficiency immediately after <e1> melphalan </e1> <e2> acute renal insufficiency </e2> immediately after melphalan conditioning.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"883": {"data": {"text": "Administration of aprotinin should be avoided in coronary artery bypass graft and high risk patients, whereas administration of tranexamic acid is not recommended in valve surgery.", "entity1": "tranexamic acid", "entity2": "coronary artery", "span1": [128, 143], "span2": [49, 64]}, "bert_text": "Administration of aprotinin should be avoided in coronary artery bypass graft and high risk patients, whereas administration of <e1> tranexamic acid </e1> <e2> coronary artery </e2> bypass graft and high risk patients, whereas administration of tranexamic acid is not recommended in valve surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"884": {"data": {"text": "Val204Asp) causes loss of activity and prolonged apnea with suxamethonium.\n", "entity1": "suxamethonium", "entity2": "apnea", "span1": [60, 73], "span2": [49, 54]}, "bert_text": "Val204Asp) causes loss of activity and prolonged apnea with <e1> suxamethonium </e1> <e2> apnea </e2> with suxamethonium.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"885": {"data": {"text": "Chronic hyperprolactinemia and changes in dopamine neurons.\n", "entity1": "dopamine", "entity2": "hyperprolactinemia", "span1": [42, 50], "span2": [8, 26]}, "bert_text": "Chronic hyperprolactinemia and changes in <e1> dopamine </e1> <e2> hyperprolactinemia </e2> and changes in dopamine neurons.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"886": {"data": {"text": "Prednisone induces anxiety and glial cerebral changes in rats.\n", "entity1": "Prednisone", "entity2": "anxiety", "span1": [0, 10], "span2": [19, 26]}, "bert_text": "<e1> Prednisone </e1> induces <e2> anxiety </e2> and glial cerebral changes in rats.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"887": {"data": {"text": "Dyskinesia was present in 44% (n = 42) with median levodopa therapy of 3 years.", "entity1": "levodopa", "entity2": "Dyskinesia", "span1": [51, 59], "span2": [0, 10]}, "bert_text": "Dyskinesia was present in 44% (n = 42) with median <e1> levodopa </e1> <e2> Dyskinesia </e2> was present in 44% (n = 42) with median levodopa therapy of 3 years.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"888": {"data": {"text": "Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.", "entity1": "olanzapine", "entity2": "weight gain", "span1": [45, 55], "span2": [19, 30]}, "bert_text": "Significantly more weight gain occurred with <e1> olanzapine </e1> <e2> weight gain </e2> occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"889": {"data": {"text": "Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.", "entity1": "olanzapine", "entity2": "weight gain", "span1": [178, 188], "span2": [19, 30]}, "bert_text": "Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with <e1> olanzapine </e1> <e2> weight gain </e2> occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"890": {"data": {"text": "Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.", "entity1": "risperidone", "entity2": "weight gain", "span1": [66, 77], "span2": [19, 30]}, "bert_text": "Significantly more weight gain occurred with olanzapine than with <e1> risperidone </e1> <e2> weight gain </e2> occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"891": {"data": {"text": "Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.", "entity1": "risperidone", "entity2": "weight gain", "span1": [224, 235], "span2": [19, 30]}, "bert_text": "Significantly more weight gain occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with <e1> risperidone </e1> <e2> weight gain </e2> occurred with olanzapine than with risperidone: the increase in weight at 4 months relative to baseline weight was 17.3% (95% CI=14.2%-20.5%) with olanzapine and 11.3% (95% CI=8.4%-14.3%) with risperidone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"892": {"data": {"text": "The protective role of betaine on myocardial damage was further confirmed by histopathological examination.", "entity1": "betaine", "entity2": "myocardial damage", "span1": [23, 30], "span2": [34, 51]}, "bert_text": "The protective role of <e1> betaine </e1> on <e2> myocardial damage </e2> was further confirmed by histopathological examination.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"893": {"data": {"text": "Subsequent HD-MTX therapy caused acute renal failure that required continuous hemodialysis.", "entity1": "MTX", "entity2": "HD", "span1": [14, 17], "span2": [11, 13]}, "bert_text": "Subsequent HD-<e1> MTX </e1> <e2> HD </e2>-MTX therapy caused acute renal failure that required continuous hemodialysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"894": {"data": {"text": "Subsequent HD-MTX therapy caused acute renal failure that required continuous hemodialysis.", "entity1": "MTX", "entity2": "acute renal failure", "span1": [14, 17], "span2": [33, 52]}, "bert_text": "Subsequent HD-<e1> MTX </e1> therapy caused <e2> acute renal failure </e2> that required continuous hemodialysis.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"895": {"data": {"text": "The possible aetiologies of valproate-induced encephalopathy and NMDA receptor-associated encephalitis present a diagnostic dilemma.", "entity1": "valproate", "entity2": "encephalopathy", "span1": [28, 37], "span2": [46, 60]}, "bert_text": "The possible aetiologies of <e1> valproate </e1>-induced <e2> encephalopathy </e2> and NMDA receptor-associated encephalitis present a diagnostic dilemma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"896": {"data": {"text": "The possible aetiologies of valproate-induced encephalopathy and NMDA receptor-associated encephalitis present a diagnostic dilemma.", "entity1": "valproate", "entity2": "encephalitis", "span1": [28, 37], "span2": [90, 102]}, "bert_text": "The possible aetiologies of <e1> valproate </e1>-induced encephalopathy and NMDA receptor-associated <e2> encephalitis </e2> present a diagnostic dilemma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"897": {"data": {"text": "Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication.", "entity1": "potassium", "entity2": "diabetes mellitus", "span1": [40, 49], "span2": [177, 194]}, "bert_text": "Careful attention to renal function and <e1> potassium </e1> balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with <e2> diabetes mellitus </e2> or preexisting renal disease, will help prevent this potentially serious complication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"898": {"data": {"text": "Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication.", "entity1": "potassium", "entity2": "renal disease", "span1": [40, 49], "span2": [210, 223]}, "bert_text": "Careful attention to renal function and <e1> potassium </e1> balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting <e2> renal disease </e2>, will help prevent this potentially serious complication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"899": {"data": {"text": "Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication.", "entity1": "indomethacin", "entity2": "diabetes mellitus", "span1": [80, 92], "span2": [177, 194]}, "bert_text": "Careful attention to renal function and potassium balance in patients receiving <e1> indomethacin </e1> or other nonsteroidal anti-inflammatory agents, particularly in those patients with <e2> diabetes mellitus </e2> or preexisting renal disease, will help prevent this potentially serious complication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"900": {"data": {"text": "Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting renal disease, will help prevent this potentially serious complication.", "entity1": "indomethacin", "entity2": "renal disease", "span1": [80, 92], "span2": [210, 223]}, "bert_text": "Careful attention to renal function and potassium balance in patients receiving <e1> indomethacin </e1> or other nonsteroidal anti-inflammatory agents, particularly in those patients with diabetes mellitus or preexisting <e2> renal disease </e2>, will help prevent this potentially serious complication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"901": {"data": {"text": "In order to evaluate the efficacy, time-course of action and predictors of response to topical capsaicin, 39 patients with chronic post-herpetic neuralgia (PHN), median duration 24 months, were treated with 0.025% capsaicin cream for 8 weeks.", "entity1": "capsaicin", "entity2": "neuralgia", "span1": [95, 104], "span2": [145, 154]}, "bert_text": "In order to evaluate the efficacy, time-course of action and predictors of response to topical <e1> capsaicin </e1>, 39 patients with chronic post-herpetic <e2> neuralgia </e2> (PHN), median duration 24 months, were treated with 0.025% capsaicin cream for 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"902": {"data": {"text": "In order to evaluate the efficacy, time-course of action and predictors of response to topical capsaicin, 39 patients with chronic post-herpetic neuralgia (PHN), median duration 24 months, were treated with 0.025% capsaicin cream for 8 weeks.", "entity1": "capsaicin cream", "entity2": "neuralgia", "span1": [214, 229], "span2": [145, 154]}, "bert_text": "In order to evaluate the efficacy, time-course of action and predictors of response to topical capsaicin, 39 patients with chronic post-herpetic neuralgia (PHN), median duration 24 months, were treated with 0.025% <e1> capsaicin cream </e1> <e2> neuralgia </e2> (PHN), median duration 24 months, were treated with 0.025% capsaicin cream for 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"903": {"data": {"text": "Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.\n", "entity1": "Cyclophosphamide", "entity2": "cardiotoxicity", "span1": [0, 16], "span2": [17, 31]}, "bert_text": "<e1> Cyclophosphamide </e1> <e2> cardiotoxicity </e2>: an analysis of dosing as a risk factor.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"904": {"data": {"text": "In the current study, dyskinetic patients performed better in swallowing function, which could be explained on the basis of a greater levodopa dose.", "entity1": "levodopa", "entity2": "dyskinetic", "span1": [134, 142], "span2": [22, 32]}, "bert_text": "In the current study, dyskinetic patients performed better in swallowing function, which could be explained on the basis of a greater <e1> levodopa </e1> <e2> dyskinetic </e2> patients performed better in swallowing function, which could be explained on the basis of a greater levodopa dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"905": {"data": {"text": "The effects of a new inhaled antimuscarinic drug, oxitropium bromide, and of a slow-release theophylline preparation upon nocturnal asthma were compared in a placebo-controlled double-blind study.", "entity1": "oxitropium bromide", "entity2": "nocturnal asthma", "span1": [50, 68], "span2": [122, 138]}, "bert_text": "The effects of a new inhaled antimuscarinic drug, <e1> oxitropium bromide </e1>, and of a slow-release theophylline preparation upon <e2> nocturnal asthma </e2> were compared in a placebo-controlled double-blind study.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"906": {"data": {"text": "The effects of a new inhaled antimuscarinic drug, oxitropium bromide, and of a slow-release theophylline preparation upon nocturnal asthma were compared in a placebo-controlled double-blind study.", "entity1": "theophylline", "entity2": "nocturnal asthma", "span1": [92, 104], "span2": [122, 138]}, "bert_text": "The effects of a new inhaled antimuscarinic drug, oxitropium bromide, and of a slow-release <e1> theophylline </e1> preparation upon <e2> nocturnal asthma </e2> were compared in a placebo-controlled double-blind study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"907": {"data": {"text": "RESULTS: Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria.", "entity1": "losartan", "entity2": "glomerulosclerosis", "span1": [20, 28], "span2": [125, 143]}, "bert_text": "RESULTS: Short-term <e1> losartan </e1> treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated <e2> glomerulosclerosis </e2> resulting in decreased proteinuria.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"908": {"data": {"text": "RESULTS: Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria.", "entity1": "losartan", "entity2": "proteinuria", "span1": [20, 28], "span2": [167, 178]}, "bert_text": "RESULTS: Short-term <e1> losartan </e1> treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased <e2> proteinuria </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"909": {"data": {"text": "The results warrant clinical trials of denopamine in the treatment of cardiac failure.", "entity1": "denopamine", "entity2": "cardiac failure", "span1": [39, 49], "span2": [70, 85]}, "bert_text": "The results warrant clinical trials of <e1> denopamine </e1> in the treatment of <e2> cardiac failure </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"910": {"data": {"text": "Peak serum cocaethylene concentrations were associated with prolonged myocardial depression.", "entity1": "cocaethylene", "entity2": "myocardial depression", "span1": [11, 23], "span2": [70, 91]}, "bert_text": "Peak serum <e1> cocaethylene </e1> concentrations were associated with prolonged <e2> myocardial depression </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"911": {"data": {"text": "Intravenous or intratracheal inoculation of 2.0 to 2.5 mg of vincristine sulfate was followed by leukopenia in 4 to 5 days.", "entity1": "vincristine sulfate", "entity2": "leukopenia", "span1": [61, 80], "span2": [97, 107]}, "bert_text": "Intravenous or intratracheal inoculation of 2.0 to 2.5 mg of <e1> vincristine sulfate </e1> was followed by <e2> leukopenia </e2> in 4 to 5 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"912": {"data": {"text": "However, the oral dose of d,l-sotalol was significantly lower in patients with torsades de pointes (200 +/-", "entity1": "l-sotalol", "entity2": "torsades de pointes", "span1": [28, 37], "span2": [79, 98]}, "bert_text": "However, the oral dose of d,<e1> l-sotalol </e1> was significantly lower in patients with <e2> torsades de pointes </e2> (200 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"913": {"data": {"text": "We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a behavior disorder.", "entity1": "Imipramine", "entity2": "hypertension", "span1": [127, 137], "span2": [35, 47]}, "bert_text": "We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given <e1> Imipramine </e1> <e2> hypertension </e2> (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a behavior disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"914": {"data": {"text": "We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a behavior disorder.", "entity1": "Imipramine", "entity2": "neuroblastoma", "span1": [127, 137], "span2": [99, 112]}, "bert_text": "We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given <e1> Imipramine </e1> <e2> neuroblastoma </e2> who was given Imipramine to control a behavior disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"915": {"data": {"text": "We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given Imipramine to control a behavior disorder.", "entity1": "Imipramine", "entity2": "behavior disorder", "span1": [127, 137], "span2": [151, 168]}, "bert_text": "We report the occurrence of severe hypertension (blood pressure 190/160) in a 4-year-old girl with neuroblastoma who was given <e1> Imipramine </e1> to control a <e2> behavior disorder </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"916": {"data": {"text": "BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).", "entity1": "Bepridil hydrochloride", "entity2": "atrial fibrillation", "span1": [12, 34], "span2": [90, 109]}, "bert_text": "BACKGROUND: <e1> Bepridil hydrochloride </e1> (Bpd) has attracted attention as an effective drug for <e2> atrial fibrillation </e2> (AF) and atrial flutter (AFL).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"917": {"data": {"text": "BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).", "entity1": "Bepridil hydrochloride", "entity2": "AF", "span1": [12, 34], "span2": [111, 113]}, "bert_text": "BACKGROUND: <e1> Bepridil hydrochloride </e1> (Bpd) has attracted attention as an effective drug for atrial fibrillation (<e2> AF </e2>) and atrial flutter (AFL).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"918": {"data": {"text": "BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).", "entity1": "Bepridil hydrochloride", "entity2": "atrial flutter", "span1": [12, 34], "span2": [119, 133]}, "bert_text": "BACKGROUND: <e1> Bepridil hydrochloride </e1> (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and <e2> atrial flutter </e2> (AFL).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"919": {"data": {"text": "BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).", "entity1": "Bepridil hydrochloride", "entity2": "AFL", "span1": [12, 34], "span2": [135, 138]}, "bert_text": "BACKGROUND: <e1> Bepridil hydrochloride </e1> (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (<e2> AFL </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"920": {"data": {"text": "BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).", "entity1": "Bpd", "entity2": "atrial fibrillation", "span1": [36, 39], "span2": [90, 109]}, "bert_text": "BACKGROUND: Bepridil hydrochloride (<e1> Bpd </e1>) has attracted attention as an effective drug for <e2> atrial fibrillation </e2> (AF) and atrial flutter (AFL).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"921": {"data": {"text": "BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).", "entity1": "Bpd", "entity2": "AF", "span1": [36, 39], "span2": [111, 113]}, "bert_text": "BACKGROUND: Bepridil hydrochloride (<e1> Bpd </e1>) has attracted attention as an effective drug for atrial fibrillation (<e2> AF </e2>) and atrial flutter (AFL).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"922": {"data": {"text": "BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).", "entity1": "Bpd", "entity2": "atrial flutter", "span1": [36, 39], "span2": [119, 133]}, "bert_text": "BACKGROUND: Bepridil hydrochloride (<e1> Bpd </e1>) has attracted attention as an effective drug for atrial fibrillation (AF) and <e2> atrial flutter </e2> (AFL).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"923": {"data": {"text": "BACKGROUND: Bepridil hydrochloride (Bpd) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (AFL).", "entity1": "Bpd", "entity2": "AFL", "span1": [36, 39], "span2": [135, 138]}, "bert_text": "BACKGROUND: Bepridil hydrochloride (<e1> Bpd </e1>) has attracted attention as an effective drug for atrial fibrillation (AF) and atrial flutter (<e2> AFL </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"924": {"data": {"text": "BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "entity1": "S-53482", "entity2": "ventricular septal defects", "span1": [12, 19], "span2": [114, 140]}, "bert_text": "BACKGROUND: <e1> S-53482 </e1> and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly <e2> ventricular septal defects </e2> and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"925": {"data": {"text": "BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "entity1": "S-53482", "entity2": "growth retardation", "span1": [12, 19], "span2": [161, 179]}, "bert_text": "BACKGROUND: <e1> S-53482 </e1> and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and <e2> growth retardation </e2> in rats in conventional oral developmental toxicity studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"926": {"data": {"text": "BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "entity1": "S-53482", "entity2": "toxicity", "span1": [12, 19], "span2": [223, 231]}, "bert_text": "BACKGROUND: <e1> S-53482 </e1> and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental <e2> toxicity </e2> studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"927": {"data": {"text": "BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "entity1": "S-23121", "entity2": "ventricular septal defects", "span1": [24, 31], "span2": [114, 140]}, "bert_text": "BACKGROUND: S-53482 and <e1> S-23121 </e1> are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly <e2> ventricular septal defects </e2> and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"928": {"data": {"text": "BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "entity1": "S-23121", "entity2": "growth retardation", "span1": [24, 31], "span2": [161, 179]}, "bert_text": "BACKGROUND: S-53482 and <e1> S-23121 </e1> are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and <e2> growth retardation </e2> in rats in conventional oral developmental toxicity studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"929": {"data": {"text": "BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "entity1": "S-23121", "entity2": "toxicity", "span1": [24, 31], "span2": [223, 231]}, "bert_text": "BACKGROUND: S-53482 and <e1> S-23121 </e1> are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental <e2> toxicity </e2> studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"930": {"data": {"text": "BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "entity1": "N-phenylimide herbicides", "entity2": "ventricular septal defects", "span1": [36, 60], "span2": [114, 140]}, "bert_text": "BACKGROUND: S-53482 and S-23121 are <e1> N-phenylimide herbicides </e1> and produced embryolethality, teratogenicity (mainly <e2> ventricular septal defects </e2> and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"931": {"data": {"text": "BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "entity1": "N-phenylimide herbicides", "entity2": "growth retardation", "span1": [36, 60], "span2": [161, 179]}, "bert_text": "BACKGROUND: S-53482 and S-23121 are <e1> N-phenylimide herbicides </e1> and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and <e2> growth retardation </e2> in rats in conventional oral developmental toxicity studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"932": {"data": {"text": "BACKGROUND: S-53482 and S-23121 are N-phenylimide herbicides and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental toxicity studies.", "entity1": "N-phenylimide herbicides", "entity2": "toxicity", "span1": [36, 60], "span2": [223, 231]}, "bert_text": "BACKGROUND: S-53482 and S-23121 are <e1> N-phenylimide herbicides </e1> and produced embryolethality, teratogenicity (mainly ventricular septal defects and wavy ribs), and growth retardation in rats in conventional oral developmental <e2> toxicity </e2> studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"933": {"data": {"text": "A 45-year-old man, with a 10-year history of manic depression treated with lithium, was admitted with hyperosmolar, nonketotic coma.", "entity1": "lithium", "entity2": "manic depression", "span1": [75, 82], "span2": [45, 61]}, "bert_text": "A 45-year-old man, with a 10-year history of manic depression treated with <e1> lithium </e1> <e2> manic depression </e2> treated with lithium, was admitted with hyperosmolar, nonketotic coma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"934": {"data": {"text": "A 45-year-old man, with a 10-year history of manic depression treated with lithium, was admitted with hyperosmolar, nonketotic coma.", "entity1": "lithium", "entity2": "coma", "span1": [75, 82], "span2": [127, 131]}, "bert_text": "A 45-year-old man, with a 10-year history of manic depression treated with <e1> lithium </e1>, was admitted with hyperosmolar, nonketotic <e2> coma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"935": {"data": {"text": "These data indicate that adult mouse atrial and ventricular cardiomyocytes do not synthesize DNA in response to isoproterenol-induced cardiac hypertrophy.", "entity1": "isoproterenol", "entity2": "cardiac hypertrophy", "span1": [112, 125], "span2": [134, 153]}, "bert_text": "These data indicate that adult mouse atrial and ventricular cardiomyocytes do not synthesize DNA in response to <e1> isoproterenol </e1>-induced <e2> cardiac hypertrophy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"936": {"data": {"text": "1,3-Butadiene, CML and the t(9:22) translocation: A reality check.\n", "entity1": "1,3-Butadiene", "entity2": "CML", "span1": [0, 13], "span2": [15, 18]}, "bert_text": "<e1> 1,3-Butadiene </e1>, <e2> CML </e2> and the t(9:22) translocation: A reality check.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"937": {"data": {"text": "Haloperidol decreased the incidence of cocaine-induced seizures at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose.", "entity1": "Haloperidol", "entity2": "seizures", "span1": [0, 11], "span2": [55, 63]}, "bert_text": "<e1> Haloperidol </e1> decreased the incidence of cocaine-induced <e2> seizures </e2> at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"938": {"data": {"text": "Haloperidol decreased the incidence of cocaine-induced seizures at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose.", "entity1": "cocaine", "entity2": "seizures", "span1": [39, 46], "span2": [55, 63]}, "bert_text": "Haloperidol decreased the incidence of <e1> cocaine </e1>-induced <e2> seizures </e2> at the two highest doses, but the lowering of the mortality rate did not reach statistical significance at any dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"939": {"data": {"text": "An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.\n", "entity1": "thalidomide", "entity2": "prostate cancer", "span1": [41, 52], "span2": [77, 92]}, "bert_text": "An open-label phase II study of low-dose <e1> thalidomide </e1> in androgen-independent <e2> prostate cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"940": {"data": {"text": "Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [117, 127], "span2": [59, 70]}, "bert_text": "Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in <e1> lamivudine </e1> <e2> hepatitis B </e2> virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"941": {"data": {"text": "Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [117, 127], "span2": [146, 157]}, "bert_text": "Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in <e1> lamivudine </e1>-untreated chronic <e2> hepatitis B </e2> patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"942": {"data": {"text": "We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed visual loss and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ethambutol.", "entity1": "ethambutol", "entity2": "visual loss", "span1": [197, 207], "span2": [111, 122]}, "bert_text": "We characterize the clinical, neurophysiological, and neuroimaging findings in a 72-year-old man who developed visual loss and paresthesias after 11 weeks of exposure to a supratherapeutic dose of <e1> ethambutol </e1> <e2> visual loss </e2> and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ethambutol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"943": {"data": {"text": "Propranolol antagonism of phenylpropanolamine-induced hypertension.\n", "entity1": "Propranolol", "entity2": "hypertension", "span1": [0, 11], "span2": [54, 66]}, "bert_text": "<e1> Propranolol </e1> antagonism of phenylpropanolamine-induced <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"944": {"data": {"text": "Propranolol antagonism of phenylpropanolamine-induced hypertension.\n", "entity1": "phenylpropanolamine", "entity2": "hypertension", "span1": [26, 45], "span2": [54, 66]}, "bert_text": "Propranolol antagonism of <e1> phenylpropanolamine </e1>-induced <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"945": {"data": {"text": "All 36 patients receiving lamivudine had a decrease in hepatitis B virus (HBV) DNA values of >90% (P < .001 compared with placebo).", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [26, 36], "span2": [55, 66]}, "bert_text": "All 36 patients receiving <e1> lamivudine </e1> had a decrease in <e2> hepatitis B </e2> virus (HBV) DNA values of >90% (P < .001 compared with placebo).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"946": {"data": {"text": "Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.\n", "entity1": "lomustine", "entity2": "lymphoma", "span1": [16, 25], "span2": [76, 84]}, "bert_text": "Tolerability of <e1> lomustine </e1> in combination with cyclophosphamide in dogs with <e2> lymphoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"947": {"data": {"text": "Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.\n", "entity1": "cyclophosphamide", "entity2": "lymphoma", "span1": [46, 62], "span2": [76, 84]}, "bert_text": "Tolerability of lomustine in combination with <e1> cyclophosphamide </e1> in dogs with <e2> lymphoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"948": {"data": {"text": "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH).", "entity1": "Epsilon aminocaproic acid", "entity2": "subarachnoid hemorrhage", "span1": [0, 25], "span2": [86, 109]}, "bert_text": "<e1> Epsilon aminocaproic acid </e1> (EACA) has been used to prevent rebleeding in patients with <e2> subarachnoid hemorrhage </e2> (SAH).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"949": {"data": {"text": "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH).", "entity1": "Epsilon aminocaproic acid", "entity2": "SAH", "span1": [0, 25], "span2": [111, 114]}, "bert_text": "<e1> Epsilon aminocaproic acid </e1> (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (<e2> SAH </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"950": {"data": {"text": "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH).", "entity1": "EACA", "entity2": "subarachnoid hemorrhage", "span1": [27, 31], "span2": [86, 109]}, "bert_text": "Epsilon aminocaproic acid (<e1> EACA </e1>) has been used to prevent rebleeding in patients with <e2> subarachnoid hemorrhage </e2> (SAH).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"951": {"data": {"text": "Epsilon aminocaproic acid (EACA) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (SAH).", "entity1": "EACA", "entity2": "SAH", "span1": [27, 31], "span2": [111, 114]}, "bert_text": "Epsilon aminocaproic acid (<e1> EACA </e1>) has been used to prevent rebleeding in patients with subarachnoid hemorrhage (<e2> SAH </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"952": {"data": {"text": "Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine.", "entity1": "caffeine", "entity2": "panic disorder", "span1": [8, 16], "span2": [86, 100]}, "bert_text": "Because <e1> caffeine </e1> is an adenosine receptor antagonist, these results suggest that some <e2> panic disorder </e2> patients may have abnormalities in neuronal systems involving adenosine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"953": {"data": {"text": "Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine.", "entity1": "adenosine", "entity2": "panic disorder", "span1": [23, 32], "span2": [86, 100]}, "bert_text": "Because caffeine is an <e1> adenosine </e1> receptor antagonist, these results suggest that some <e2> panic disorder </e2> patients may have abnormalities in neuronal systems involving adenosine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"954": {"data": {"text": "Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine.", "entity1": "adenosine", "entity2": "panic disorder", "span1": [163, 172], "span2": [86, 100]}, "bert_text": "Because caffeine is an adenosine receptor antagonist, these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving <e1> adenosine </e1> <e2> panic disorder </e2> patients may have abnormalities in neuronal systems involving adenosine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"955": {"data": {"text": "In 5 consecutive patients with rheumatoid arthritis who received intravenous high-dose methylprednisolone (MP) therapy (1 g daily for 2 or 3 consecutive days), a decline in pulse rate was observed, most pronounced on day 4.", "entity1": "methylprednisolone", "entity2": "rheumatoid arthritis", "span1": [87, 105], "span2": [31, 51]}, "bert_text": "In 5 consecutive patients with rheumatoid arthritis who received intravenous high-dose <e1> methylprednisolone </e1> <e2> rheumatoid arthritis </e2> who received intravenous high-dose methylprednisolone (MP) therapy (1 g daily for 2 or 3 consecutive days), a decline in pulse rate was observed, most pronounced on day 4.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"956": {"data": {"text": "In 5 consecutive patients with rheumatoid arthritis who received intravenous high-dose methylprednisolone (MP) therapy (1 g daily for 2 or 3 consecutive days), a decline in pulse rate was observed, most pronounced on day 4.", "entity1": "MP", "entity2": "rheumatoid arthritis", "span1": [107, 109], "span2": [31, 51]}, "bert_text": "In 5 consecutive patients with rheumatoid arthritis who received intravenous high-dose methylprednisolone (<e1> MP </e1> <e2> rheumatoid arthritis </e2> who received intravenous high-dose methylprednisolone (MP) therapy (1 g daily for 2 or 3 consecutive days), a decline in pulse rate was observed, most pronounced on day 4.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"957": {"data": {"text": "OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.", "entity1": "nicotine", "entity2": "anxiety", "span1": [58, 66], "span2": [70, 77]}, "bert_text": "OBJECTIVES: The present study investigates the effects of <e1> nicotine </e1> on <e2> anxiety </e2> induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"958": {"data": {"text": "OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.", "entity1": "caffeine", "entity2": "anxiety", "span1": [89, 97], "span2": [70, 77]}, "bert_text": "OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by <e1> caffeine </e1> <e2> anxiety </e2> induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"959": {"data": {"text": "OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.", "entity1": "pentylenetetrazole", "entity2": "anxiety", "span1": [127, 145], "span2": [70, 77]}, "bert_text": "OBJECTIVES: The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug, <e1> pentylenetetrazole </e1> <e2> anxiety </e2> induced by caffeine and another anxiogenic drug, pentylenetetrazole, in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"960": {"data": {"text": "Intravenous inoculation of 4.2 x 10(10) to 7.8 x 10(10) pyocin type 6 Pseudomonas organisms in monkeys given vincristine sulfate 4 days previously resulted in fatal infection in 11 of 14 monkeys, whereas none of four receiving Pseudomonas alone died.", "entity1": "vincristine sulfate", "entity2": "infection", "span1": [109, 128], "span2": [165, 174]}, "bert_text": "Intravenous inoculation of 4.2 x 10(10) to 7.8 x 10(10) pyocin type 6 Pseudomonas organisms in monkeys given <e1> vincristine sulfate </e1> 4 days previously resulted in fatal <e2> infection </e2> in 11 of 14 monkeys, whereas none of four receiving Pseudomonas alone died.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"961": {"data": {"text": "BACKGROUND: We compared the efficacy and safety of olanzapine vs placebo for the treatment of acute bipolar mania.", "entity1": "olanzapine", "entity2": "bipolar mania", "span1": [51, 61], "span2": [100, 113]}, "bert_text": "BACKGROUND: We compared the efficacy and safety of <e1> olanzapine </e1> vs placebo for the treatment of acute <e2> bipolar mania </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"962": {"data": {"text": "Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.", "entity1": "quinacrine hydrochloride", "entity2": "thrombosis", "span1": [38, 62], "span2": [123, 133]}, "bert_text": "Seventy percent of rats given 250 ppm <e1> quinacrine hydrochloride </e1> and 1,000 ppm sodium nitrite simultaneously in the diet had <e2> thrombosis </e2> of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"963": {"data": {"text": "Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.", "entity1": "quinacrine hydrochloride", "entity2": "atrial thrombosis", "span1": [38, 62], "span2": [222, 239]}, "bert_text": "Seventy percent of rats given 250 ppm <e1> quinacrine hydrochloride </e1> and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have <e2> atrial thrombosis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"964": {"data": {"text": "Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.", "entity1": "sodium nitrite", "entity2": "thrombosis", "span1": [77, 91], "span2": [123, 133]}, "bert_text": "Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm <e1> sodium nitrite </e1> simultaneously in the diet had <e2> thrombosis </e2> of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"965": {"data": {"text": "Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have atrial thrombosis.", "entity1": "sodium nitrite", "entity2": "atrial thrombosis", "span1": [77, 91], "span2": [222, 239]}, "bert_text": "Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1,000 ppm <e1> sodium nitrite </e1> simultaneously in the diet had thrombosis of the atria of the heart, while untreated control rats in this laboratory did not have <e2> atrial thrombosis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"966": {"data": {"text": "METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema.", "entity1": "acetaminophen", "entity2": "FHF", "span1": [140, 153], "span2": [131, 134]}, "bert_text": "METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from <e1> acetaminophen </e1> <e2> FHF </e2> from acetaminophen and resultant cerebral edema.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"967": {"data": {"text": "METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema.", "entity1": "acetaminophen", "entity2": "cerebral edema", "span1": [140, 153], "span2": [168, 182]}, "bert_text": "METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from <e1> acetaminophen </e1> and resultant <e2> cerebral edema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"968": {"data": {"text": "In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.", "entity1": "CCL2", "entity2": "status epilepticus", "span1": [22, 26], "span2": [62, 80]}, "bert_text": "In this work CCR2 and <e1> CCL2 </e1> expression were examined following <e2> status epilepticus </e2> (SE) induced by pilocarpine injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"969": {"data": {"text": "In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.", "entity1": "CCL2", "entity2": "SE", "span1": [22, 26], "span2": [82, 84]}, "bert_text": "In this work CCR2 and <e1> CCL2 </e1> expression were examined following status epilepticus (<e2> SE </e2>) induced by pilocarpine injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"970": {"data": {"text": "In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [97, 108], "span2": [62, 80]}, "bert_text": "In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by <e1> pilocarpine </e1> <e2> status epilepticus </e2> (SE) induced by pilocarpine injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"971": {"data": {"text": "In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by pilocarpine injection.", "entity1": "pilocarpine", "entity2": "SE", "span1": [97, 108], "span2": [82, 84]}, "bert_text": "In this work CCR2 and CCL2 expression were examined following status epilepticus (SE) induced by <e1> pilocarpine </e1> <e2> SE </e2>) induced by pilocarpine injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"972": {"data": {"text": "Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report.\n", "entity1": "veralipride", "entity2": "Parkinsonism", "span1": [43, 54], "span2": [13, 25]}, "bert_text": "Worsening of Parkinsonism after the use of <e1> veralipride </e1> <e2> Parkinsonism </e2> after the use of veralipride for treatment of menopause: case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"973": {"data": {"text": "In the presence of coronary artery stenosis, 3-min periods of intracoronary ISO infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram.", "entity1": "ISO", "entity2": "coronary artery stenosis", "span1": [76, 79], "span2": [19, 43]}, "bert_text": "In the presence of coronary artery stenosis, 3-min periods of intracoronary <e1> ISO </e1> <e2> coronary artery stenosis </e2>, 3-min periods of intracoronary ISO infusion (10 ng/kg/min) increased heart rate and maximal rate of left ventricular pressure rise, which resulted in a decrease in percentage segmental shortening and ST-segment elevation of the epicardial electrocardiogram.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"974": {"data": {"text": "This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced seizures model.", "entity1": "lithium", "entity2": "seizures", "span1": [91, 98], "span2": [145, 153]}, "bert_text": "This study shows that MIP synthase inhibition does not replicate or augment the effects of <e1> lithium </e1> in the inositol sensitive pilocarpine-induced <e2> seizures </e2> model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"975": {"data": {"text": "This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine-induced seizures model.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [125, 136], "span2": [145, 153]}, "bert_text": "This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive <e1> pilocarpine </e1>-induced <e2> seizures </e2> model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"976": {"data": {"text": "Ischemic colitis and sumatriptan use.\n", "entity1": "sumatriptan", "entity2": "Ischemic colitis", "span1": [21, 32], "span2": [0, 16]}, "bert_text": "Ischemic colitis and <e1> sumatriptan </e1> <e2> Ischemic colitis </e2> and sumatriptan use.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"977": {"data": {"text": "PURPOSE: To report a case of bilateral optic neuropathy in a patient receiving tacrolimus (FK 506, Prograf; Fujisawa USA, Inc, Deerfield, Illinois) for immunosuppression after orthotropic liver transplantation.", "entity1": "tacrolimus", "entity2": "optic neuropathy", "span1": [79, 89], "span2": [39, 55]}, "bert_text": "PURPOSE: To report a case of bilateral optic neuropathy in a patient receiving <e1> tacrolimus </e1> <e2> optic neuropathy </e2> in a patient receiving tacrolimus (FK 506, Prograf; Fujisawa USA, Inc, Deerfield, Illinois) for immunosuppression after orthotropic liver transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"978": {"data": {"text": "PURPOSE: To report a case of bilateral optic neuropathy in a patient receiving tacrolimus (FK 506, Prograf; Fujisawa USA, Inc, Deerfield, Illinois) for immunosuppression after orthotropic liver transplantation.", "entity1": "FK 506", "entity2": "optic neuropathy", "span1": [91, 97], "span2": [39, 55]}, "bert_text": "PURPOSE: To report a case of bilateral optic neuropathy in a patient receiving tacrolimus (<e1> FK 506 </e1> <e2> optic neuropathy </e2> in a patient receiving tacrolimus (FK 506, Prograf; Fujisawa USA, Inc, Deerfield, Illinois) for immunosuppression after orthotropic liver transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"979": {"data": {"text": "Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.\n", "entity1": "Temocapril", "entity2": "glomerular injury", "span1": [0, 10], "span2": [90, 107]}, "bert_text": "<e1> Temocapril </e1>, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates <e2> glomerular injury </e2> in chronic puromycin aminonucleoside nephrosis.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"980": {"data": {"text": "Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.\n", "entity1": "Temocapril", "entity2": "nephrosis", "span1": [0, 10], "span2": [145, 154]}, "bert_text": "<e1> Temocapril </e1>, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside <e2> nephrosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"981": {"data": {"text": "Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.\n", "entity1": "angiotensin", "entity2": "glomerular injury", "span1": [39, 50], "span2": [90, 107]}, "bert_text": "Temocapril, a long-acting non-SH group <e1> angiotensin </e1> converting enzyme inhibitor, modulates <e2> glomerular injury </e2> in chronic puromycin aminonucleoside nephrosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"982": {"data": {"text": "Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.\n", "entity1": "angiotensin", "entity2": "nephrosis", "span1": [39, 50], "span2": [145, 154]}, "bert_text": "Temocapril, a long-acting non-SH group <e1> angiotensin </e1> converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside <e2> nephrosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"983": {"data": {"text": "Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.\n", "entity1": "puromycin aminonucleoside", "entity2": "glomerular injury", "span1": [119, 144], "span2": [90, 107]}, "bert_text": "Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic <e1> puromycin aminonucleoside </e1> <e2> glomerular injury </e2> in chronic puromycin aminonucleoside nephrosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"984": {"data": {"text": "Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic puromycin aminonucleoside nephrosis.\n", "entity1": "puromycin aminonucleoside", "entity2": "nephrosis", "span1": [119, 144], "span2": [145, 154]}, "bert_text": "Temocapril, a long-acting non-SH group angiotensin converting enzyme inhibitor, modulates glomerular injury in chronic <e1> puromycin aminonucleoside </e1> <e2> nephrosis </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"985": {"data": {"text": "Percutaneous absorption of warfarin causing coagulopathy, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "entity1": "warfarin", "entity2": "coagulopathy", "span1": [27, 35], "span2": [44, 56]}, "bert_text": "Percutaneous absorption of <e1> warfarin </e1> causing <e2> coagulopathy </e2>, reported three times in the past, is a significant risk if protective measures, such as gloves, are not used.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"986": {"data": {"text": "Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of EACA therapy.", "entity1": "EACA", "entity2": "thrombotic", "span1": [122, 126], "span2": [94, 104]}, "bert_text": "Although this agent does decrease the frequency of rebleeding, several reports have described thrombotic complications of <e1> EACA </e1> <e2> thrombotic </e2> complications of EACA therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"987": {"data": {"text": "Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.\n", "entity1": "nifedipine", "entity2": "hypertension", "span1": [40, 50], "span2": [103, 115]}, "bert_text": "Long-term efficacy and adverse event of <e1> nifedipine </e1> sustained-release tablets for cyclosporin A-induced <e2> hypertension </e2> in patients with psoriasis.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"988": {"data": {"text": "Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.\n", "entity1": "nifedipine", "entity2": "psoriasis", "span1": [40, 50], "span2": [133, 142]}, "bert_text": "Long-term efficacy and adverse event of <e1> nifedipine </e1> sustained-release tablets for cyclosporin A-induced hypertension in patients with <e2> psoriasis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"989": {"data": {"text": "Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.\n", "entity1": "cyclosporin A", "entity2": "hypertension", "span1": [81, 94], "span2": [103, 115]}, "bert_text": "Long-term efficacy and adverse event of nifedipine sustained-release tablets for <e1> cyclosporin A </e1>-induced <e2> hypertension </e2> in patients with psoriasis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"990": {"data": {"text": "Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.\n", "entity1": "cyclosporin A", "entity2": "psoriasis", "span1": [81, 94], "span2": [133, 142]}, "bert_text": "Long-term efficacy and adverse event of nifedipine sustained-release tablets for <e1> cyclosporin A </e1>-induced hypertension in patients with <e2> psoriasis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"991": {"data": {"text": "Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.", "entity1": "VAL", "entity2": "hypertension", "span1": [148, 151], "span2": [24, 36]}, "bert_text": "Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: <e1> VAL </e1> <e2> hypertension </e2> (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"992": {"data": {"text": "Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.", "entity1": "VAL", "entity2": "hypertension", "span1": [187, 190], "span2": [24, 36]}, "bert_text": "Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; <e1> VAL </e1> <e2> hypertension </e2> (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"993": {"data": {"text": "Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.", "entity1": "HCTZ", "entity2": "hypertension", "span1": [167, 171], "span2": [24, 36]}, "bert_text": "Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; <e1> HCTZ </e1> <e2> hypertension </e2> (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"994": {"data": {"text": "Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.", "entity1": "HCTZ", "entity2": "hypertension", "span1": [191, 195], "span2": [24, 36]}, "bert_text": "Patients with essential hypertension (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/<e1> HCTZ </e1> <e2> hypertension </e2> (mean sitting diastolic BP [MSDBP], > or =95 mm Hg and <110 mm Hg) were randomized to 1 of 8 treatment groups: VAL 160 or 320 mg; HCTZ 12.5 or 25 mg; VAL/HCTZ 160/12.5, 320/12.5, or 320/25 mg; or placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"995": {"data": {"text": "Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study.", "entity1": "olanzapine", "entity2": "bipolar mania", "span1": [12, 22], "span2": [32, 45]}, "bert_text": "Efficacy of <e1> olanzapine </e1> in acute <e2> bipolar mania </e2>: a double-blind, placebo-controlled study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"996": {"data": {"text": "Prophylactic lidocaine in the early phase of suspected myocardial infarction.\n", "entity1": "lidocaine", "entity2": "myocardial infarction", "span1": [13, 22], "span2": [55, 76]}, "bert_text": "Prophylactic <e1> lidocaine </e1> in the early phase of suspected <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"997": {"data": {"text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.", "entity1": "amiodarone", "entity2": "hepatotoxic", "span1": [97, 107], "span2": [74, 85]}, "bert_text": "These results provide important new mechanistic information regarding the hepatotoxic effects of <e1> amiodarone </e1> <e2> hepatotoxic </e2> effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"998": {"data": {"text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.", "entity1": "amiodarone", "entity2": "hepatotoxicity", "span1": [97, 107], "span2": [172, 186]}, "bert_text": "These results provide important new mechanistic information regarding the hepatotoxic effects of <e1> amiodarone </e1> and indicate that PPARalpha protects against amiodarone-induced <e2> hepatotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"999": {"data": {"text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.", "entity1": "amiodarone", "entity2": "hepatotoxic", "span1": [153, 163], "span2": [74, 85]}, "bert_text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against <e1> amiodarone </e1> <e2> hepatotoxic </e2> effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1000": {"data": {"text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.", "entity1": "amiodarone", "entity2": "hepatotoxicity", "span1": [153, 163], "span2": [172, 186]}, "bert_text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against <e1> amiodarone </e1>-induced <e2> hepatotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1001": {"data": {"text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.", "entity1": "PPARalpha", "entity2": "hepatotoxic", "span1": [126, 135], "span2": [74, 85]}, "bert_text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that <e1> PPARalpha </e1> <e2> hepatotoxic </e2> effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1002": {"data": {"text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone-induced hepatotoxicity.", "entity1": "PPARalpha", "entity2": "hepatotoxicity", "span1": [126, 135], "span2": [172, 186]}, "bert_text": "These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that <e1> PPARalpha </e1> protects against amiodarone-induced <e2> hepatotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1003": {"data": {"text": "Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and trimetaphan (TMP) deliberate hypotension (20% and 40% mean pressure decrease from baseline).", "entity1": "sodium nitroprusside", "entity2": "hypotension", "span1": [76, 96], "span2": [136, 147]}, "bert_text": "Coronary blood flow, cardiac work and metabolism were studied in dogs under <e1> sodium nitroprusside </e1> (SNP) and trimetaphan (TMP) deliberate <e2> hypotension </e2> (20% and 40% mean pressure decrease from baseline).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1004": {"data": {"text": "Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and trimetaphan (TMP) deliberate hypotension (20% and 40% mean pressure decrease from baseline).", "entity1": "SNP", "entity2": "hypotension", "span1": [98, 101], "span2": [136, 147]}, "bert_text": "Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (<e1> SNP </e1>) and trimetaphan (TMP) deliberate <e2> hypotension </e2> (20% and 40% mean pressure decrease from baseline).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1005": {"data": {"text": "Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and trimetaphan (TMP) deliberate hypotension (20% and 40% mean pressure decrease from baseline).", "entity1": "trimetaphan", "entity2": "hypotension", "span1": [107, 118], "span2": [136, 147]}, "bert_text": "Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and <e1> trimetaphan </e1> (TMP) deliberate <e2> hypotension </e2> (20% and 40% mean pressure decrease from baseline).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1006": {"data": {"text": "Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and trimetaphan (TMP) deliberate hypotension (20% and 40% mean pressure decrease from baseline).", "entity1": "TMP", "entity2": "hypotension", "span1": [120, 123], "span2": [136, 147]}, "bert_text": "Coronary blood flow, cardiac work and metabolism were studied in dogs under sodium nitroprusside (SNP) and trimetaphan (<e1> TMP </e1>) deliberate <e2> hypotension </e2> (20% and 40% mean pressure decrease from baseline).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1007": {"data": {"text": "He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for glucose.", "entity1": "glucose", "entity2": "polyuria", "span1": [107, 114], "span2": [31, 39]}, "bert_text": "He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for <e1> glucose </e1> <e2> polyuria </e2> and polydipsia, during which time urinalysis had been negative for glucose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1008": {"data": {"text": "He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for glucose.", "entity1": "glucose", "entity2": "polydipsia", "span1": [107, 114], "span2": [44, 54]}, "bert_text": "He gave a five-year history of polyuria and polydipsia, during which time urinalysis had been negative for <e1> glucose </e1> <e2> polydipsia </e2>, during which time urinalysis had been negative for glucose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1009": {"data": {"text": "Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.", "entity1": "Amiodarone", "entity2": "hepatomegaly", "span1": [0, 10], "span2": [19, 31]}, "bert_text": "<e1> Amiodarone </e1> induced <e2> hepatomegaly </e2>, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1010": {"data": {"text": "Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.", "entity1": "triglycerides", "entity2": "hepatomegaly", "span1": [115, 128], "span2": [19, 31]}, "bert_text": "Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum <e1> triglycerides </e1> <e2> hepatomegaly </e2>, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1011": {"data": {"text": "Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.", "entity1": "glucose", "entity2": "hepatomegaly", "span1": [133, 140], "span2": [19, 31]}, "bert_text": "Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and <e1> glucose </e1> <e2> hepatomegaly </e2>, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1012": {"data": {"text": "Our results suggest a role for levodopa in the oral phase of deglutition and confirm that dysphagia is not a good predictor of deglutition alterations in PD.", "entity1": "levodopa", "entity2": "dysphagia", "span1": [31, 39], "span2": [90, 99]}, "bert_text": "Our results suggest a role for <e1> levodopa </e1> in the oral phase of deglutition and confirm that <e2> dysphagia </e2> is not a good predictor of deglutition alterations in PD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1013": {"data": {"text": "Our results suggest a role for levodopa in the oral phase of deglutition and confirm that dysphagia is not a good predictor of deglutition alterations in PD.", "entity1": "levodopa", "entity2": "PD", "span1": [31, 39], "span2": [154, 156]}, "bert_text": "Our results suggest a role for <e1> levodopa </e1> in the oral phase of deglutition and confirm that dysphagia is not a good predictor of deglutition alterations in <e2> PD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1014": {"data": {"text": "CONCLUSIONS: When limited quantities of mannitol are available, it should preferentially be given to patients at particularly high risk of nephrotoxicity.", "entity1": "mannitol", "entity2": "nephrotoxicity", "span1": [40, 48], "span2": [139, 153]}, "bert_text": "CONCLUSIONS: When limited quantities of <e1> mannitol </e1> are available, it should preferentially be given to patients at particularly high risk of <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1015": {"data": {"text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.", "entity1": "sodium pentobarbital", "entity2": "myocardial metabolic disturbances", "span1": [173, 193], "span2": [81, 114]}, "bert_text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to <e1> sodium pentobarbital </e1> <e2> myocardial metabolic disturbances </e2>, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1016": {"data": {"text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.", "entity1": "sodium pentobarbital", "entity2": "hypersensitivity", "span1": [173, 193], "span2": [124, 140]}, "bert_text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to <e1> sodium pentobarbital </e1> <e2> hypersensitivity </e2> of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1017": {"data": {"text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.", "entity1": "sodium pentobarbital", "entity2": "cardiomyopathic disorder", "span1": [173, 193], "span2": [244, 268]}, "bert_text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to <e1> sodium pentobarbital </e1> suggest the existence of a heretofore undescribed <e2> cardiomyopathic disorder </e2> induced by chronic barium exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1018": {"data": {"text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.", "entity1": "barium", "entity2": "myocardial metabolic disturbances", "span1": [288, 294], "span2": [81, 114]}, "bert_text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic <e1> barium </e1> <e2> myocardial metabolic disturbances </e2>, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1019": {"data": {"text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.", "entity1": "barium", "entity2": "hypersensitivity", "span1": [288, 294], "span2": [124, 140]}, "bert_text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic <e1> barium </e1> <e2> hypersensitivity </e2> of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1020": {"data": {"text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure.", "entity1": "barium", "entity2": "cardiomyopathic disorder", "span1": [288, 294], "span2": [244, 268]}, "bert_text": "Overall, the altered cardiac contractility and excitability characteristics, the myocardial metabolic disturbances, and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic <e1> barium </e1> <e2> cardiomyopathic disorder </e2> induced by chronic barium exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1021": {"data": {"text": "In this study we aimed to determine the rate of YMDD motif mutants in lamivudine-untreated chronic hepatitis B patients in Iran.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [70, 80], "span2": [99, 110]}, "bert_text": "In this study we aimed to determine the rate of YMDD motif mutants in <e1> lamivudine </e1>-untreated chronic <e2> hepatitis B </e2> patients in Iran.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1022": {"data": {"text": "Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC.", "entity1": "corticosteroid", "entity2": "SRC", "span1": [22, 36], "span2": [82, 85]}, "bert_text": "Moderate to high dose <e1> corticosteroid </e1> use is recognized as a major risk factor for <e2> SRC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1023": {"data": {"text": "The NMS-like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects.", "entity1": "antidepressants", "entity2": "NMS", "span1": [73, 88], "span2": [4, 7]}, "bert_text": "The NMS-like encephalopathy that develops in association with the use of <e1> antidepressants </e1> <e2> NMS </e2>-like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1024": {"data": {"text": "The NMS-like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects.", "entity1": "antidepressants", "entity2": "NMS", "span1": [73, 88], "span2": [104, 107]}, "bert_text": "The NMS-like encephalopathy that develops in association with the use of <e1> antidepressants </e1> indicates that <e2> NMS </e2> and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1025": {"data": {"text": "The NMS-like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects.", "entity1": "antidepressants", "entity2": "encephalopathy", "span1": [73, 88], "span2": [13, 27]}, "bert_text": "The NMS-like encephalopathy that develops in association with the use of <e1> antidepressants </e1> <e2> encephalopathy </e2> that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1026": {"data": {"text": "The NMS-like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects.", "entity1": "antidepressants", "entity2": "SS", "span1": [73, 88], "span2": [112, 114]}, "bert_text": "The NMS-like encephalopathy that develops in association with the use of <e1> antidepressants </e1> indicates that NMS and <e2> SS </e2> are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1027": {"data": {"text": "The NMS-like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects.", "entity1": "antidepressants", "entity2": "disorders", "span1": [73, 88], "span2": [128, 137]}, "bert_text": "The NMS-like encephalopathy that develops in association with the use of <e1> antidepressants </e1> indicates that NMS and SS are spectrum <e2> disorders </e2> induced by drugs with both antidopaminergic and serotonergic effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1028": {"data": {"text": "levodopa were examined in parkinsonian patients with stable and fluctuating responses to levodopa.", "entity1": "levodopa", "entity2": "parkinsonian", "span1": [0, 8], "span2": [26, 38]}, "bert_text": "<e1> levodopa </e1> were examined in <e2> parkinsonian </e2> patients with stable and fluctuating responses to levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1029": {"data": {"text": "levodopa were examined in parkinsonian patients with stable and fluctuating responses to levodopa.", "entity1": "levodopa", "entity2": "parkinsonian", "span1": [89, 97], "span2": [26, 38]}, "bert_text": "levodopa were examined in parkinsonian patients with stable and fluctuating responses to <e1> levodopa </e1> <e2> parkinsonian </e2> patients with stable and fluctuating responses to levodopa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1030": {"data": {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity1": "flutamide", "entity2": "impaired the memory", "span1": [18, 27], "span2": [66, 85]}, "bert_text": "Administration of <e1> flutamide </e1>, letrozole or tamoxifen significantly <e2> impaired the memory </e2> in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1031": {"data": {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity1": "flutamide", "entity2": "memory impairment", "span1": [18, 27], "span2": [201, 218]}, "bert_text": "Administration of <e1> flutamide </e1>, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced <e2> memory impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1032": {"data": {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity1": "letrozole", "entity2": "impaired the memory", "span1": [29, 38], "span2": [66, 85]}, "bert_text": "Administration of flutamide, <e1> letrozole </e1> or tamoxifen significantly <e2> impaired the memory </e2> in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1033": {"data": {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity1": "letrozole", "entity2": "memory impairment", "span1": [29, 38], "span2": [201, 218]}, "bert_text": "Administration of flutamide, <e1> letrozole </e1> or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced <e2> memory impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1034": {"data": {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity1": "tamoxifen", "entity2": "impaired the memory", "span1": [42, 51], "span2": [66, 85]}, "bert_text": "Administration of flutamide, letrozole or <e1> tamoxifen </e1> significantly <e2> impaired the memory </e2> in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1035": {"data": {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity1": "tamoxifen", "entity2": "memory impairment", "span1": [42, 51], "span2": [201, 218]}, "bert_text": "Administration of flutamide, letrozole or <e1> tamoxifen </e1> significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced <e2> memory impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1036": {"data": {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity1": "testosterone", "entity2": "impaired the memory", "span1": [135, 147], "span2": [66, 85]}, "bert_text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the <e1> testosterone </e1> <e2> impaired the memory </e2> in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1037": {"data": {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity1": "testosterone", "entity2": "memory impairment", "span1": [135, 147], "span2": [201, 218]}, "bert_text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the <e1> testosterone </e1> replacement in improving STZ- and castration-induced <e2> memory impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1038": {"data": {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity1": "STZ-", "entity2": "impaired the memory", "span1": [173, 177], "span2": [66, 85]}, "bert_text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving <e1> STZ- </e1> <e2> impaired the memory </e2> in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1039": {"data": {"text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving STZ- and castration-induced memory impairment.", "entity1": "STZ-", "entity2": "memory impairment", "span1": [173, 177], "span2": [201, 218]}, "bert_text": "Administration of flutamide, letrozole or tamoxifen significantly impaired the memory in intact rats, and significantly attenuated the testosterone replacement in improving <e1> STZ- </e1> and castration-induced <e2> memory impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1040": {"data": {"text": "However, the role of vasopressin remains to be determined in human essential hypertension.", "entity1": "vasopressin", "entity2": "hypertension", "span1": [21, 32], "span2": [77, 89]}, "bert_text": "However, the role of <e1> vasopressin </e1> remains to be determined in human essential <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1041": {"data": {"text": "This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,l-sotalol for sustained ventricular tachyarrhythmias.", "entity1": "l-sotalol", "entity2": "torsades de pointes", "span1": [179, 188], "span2": [75, 94]}, "bert_text": "This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,<e1> l-sotalol </e1> <e2> torsades de pointes </e2>, and the presumable risk factors for torsades de pointes in patients treated with d,l-sotalol for sustained ventricular tachyarrhythmias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1042": {"data": {"text": "This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,l-sotalol for sustained ventricular tachyarrhythmias.", "entity1": "l-sotalol", "entity2": "torsades de pointes", "span1": [179, 188], "span2": [132, 151]}, "bert_text": "This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,<e1> l-sotalol </e1> <e2> torsades de pointes </e2> in patients treated with d,l-sotalol for sustained ventricular tachyarrhythmias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1043": {"data": {"text": "This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,l-sotalol for sustained ventricular tachyarrhythmias.", "entity1": "l-sotalol", "entity2": "ventricular tachyarrhythmias", "span1": [179, 188], "span2": [203, 231]}, "bert_text": "This study prospectively evaluated the clinical efficacy, the incidence of torsades de pointes, and the presumable risk factors for torsades de pointes in patients treated with d,<e1> l-sotalol </e1> for sustained <e2> ventricular tachyarrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1044": {"data": {"text": "In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of renal disease.", "entity1": "calcium", "entity2": "hypercalcemia", "span1": [118, 125], "span2": [69, 82]}, "bert_text": "In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal <e1> calcium </e1> <e2> hypercalcemia </e2>, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of renal disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1045": {"data": {"text": "In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of renal disease.", "entity1": "calcium", "entity2": "renal disease", "span1": [118, 125], "span2": [302, 315]}, "bert_text": "In order to identify risk factors associated with the development of hypercalcemia, indirect parameters of intestinal <e1> calcium </e1> reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age, sex, length of time on dialysis, and etiology of <e2> renal disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1046": {"data": {"text": "We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.", "entity1": "propranolol", "entity2": "hypoglycemia", "span1": [188, 199], "span2": [37, 49]}, "bert_text": "We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic <e1> propranolol </e1> <e2> hypoglycemia </e2>, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1047": {"data": {"text": "We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.", "entity1": "propranolol", "entity2": "hyperbilirubinemia", "span1": [188, 199], "span2": [51, 69]}, "bert_text": "We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic <e1> propranolol </e1> <e2> hyperbilirubinemia </e2>, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1048": {"data": {"text": "We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.", "entity1": "propranolol", "entity2": "polycythemia", "span1": [188, 199], "span2": [71, 83]}, "bert_text": "We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic <e1> propranolol </e1> <e2> polycythemia </e2>, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1049": {"data": {"text": "We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.", "entity1": "propranolol", "entity2": "apnea", "span1": [188, 199], "span2": [94, 99]}, "bert_text": "We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic <e1> propranolol </e1> <e2> apnea </e2>, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1050": {"data": {"text": "We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy.", "entity1": "propranolol", "entity2": "bradycardia", "span1": [188, 199], "span2": [105, 116]}, "bert_text": "We conclude that previously reported hypoglycemia, hyperbilirubinemia, polycythemia, neonatal apnea, and bradycardia are not invariable and cannot be statistically correlated with chronic <e1> propranolol </e1> <e2> bradycardia </e2> are not invariable and cannot be statistically correlated with chronic propranolol therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1051": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "temocapril", "entity2": "proteinuria", "span1": [84, 94], "span2": [178, 189]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of <e1> temocapril </e1>, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced <e2> proteinuria </e2>, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1052": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "temocapril", "entity2": "glomerular hypertrophy", "span1": [84, 94], "span2": [201, 223]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of <e1> temocapril </e1>, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited <e2> glomerular hypertrophy </e2> and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1053": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "temocapril", "entity2": "glomerulosclerosis", "span1": [84, 94], "span2": [238, 256]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of <e1> temocapril </e1>, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented <e2> glomerulosclerosis </e2> in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1054": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "temocapril", "entity2": "nephrotic", "span1": [84, 94], "span2": [310, 319]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of <e1> temocapril </e1>, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced <e2> nephrotic </e2> rats.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1055": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "angiotensin", "entity2": "proteinuria", "span1": [123, 134], "span2": [178, 189]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group <e1> angiotensin </e1> converting enzyme (ACE) inhibitor, reduced <e2> proteinuria </e2>, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1056": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "angiotensin", "entity2": "glomerular hypertrophy", "span1": [123, 134], "span2": [201, 223]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group <e1> angiotensin </e1> converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited <e2> glomerular hypertrophy </e2> and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1057": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "angiotensin", "entity2": "glomerulosclerosis", "span1": [123, 134], "span2": [238, 256]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group <e1> angiotensin </e1> converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented <e2> glomerulosclerosis </e2> in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1058": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "angiotensin", "entity2": "nephrotic", "span1": [123, 134], "span2": [310, 319]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group <e1> angiotensin </e1> converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced <e2> nephrotic </e2> rats.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1059": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "puromycin aminonucleoside", "entity2": "proteinuria", "span1": [268, 293], "span2": [178, 189]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic <e1> puromycin aminonucleoside </e1> <e2> proteinuria </e2>, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1060": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "puromycin aminonucleoside", "entity2": "glomerular hypertrophy", "span1": [268, 293], "span2": [201, 223]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic <e1> puromycin aminonucleoside </e1> <e2> glomerular hypertrophy </e2> and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1061": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "puromycin aminonucleoside", "entity2": "glomerulosclerosis", "span1": [268, 293], "span2": [238, 256]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic <e1> puromycin aminonucleoside </e1> <e2> glomerulosclerosis </e2> in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1062": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "puromycin aminonucleoside", "entity2": "nephrotic", "span1": [268, 293], "span2": [310, 319]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic <e1> puromycin aminonucleoside </e1> (PAN) - induced <e2> nephrotic </e2> rats.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1063": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "PAN", "entity2": "proteinuria", "span1": [295, 298], "span2": [178, 189]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (<e1> PAN </e1> <e2> proteinuria </e2>, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1064": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "PAN", "entity2": "glomerular hypertrophy", "span1": [295, 298], "span2": [201, 223]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (<e1> PAN </e1> <e2> glomerular hypertrophy </e2> and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1065": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "PAN", "entity2": "glomerulosclerosis", "span1": [295, 298], "span2": [238, 256]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (<e1> PAN </e1> <e2> glomerulosclerosis </e2> in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1066": {"data": {"text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (PAN) - induced nephrotic rats.", "entity1": "PAN", "entity2": "nephrotic", "span1": [295, 298], "span2": [310, 319]}, "bert_text": "The purpose of the present study was to determine whether chronic administration of temocapril, a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, reduced proteinuria, inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside (<e1> PAN </e1>) - induced <e2> nephrotic </e2> rats.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1067": {"data": {"text": "RESULTS: Cyclophosphamide treatment increased the spontaneous pain behaviors scores.", "entity1": "Cyclophosphamide", "entity2": "pain", "span1": [9, 25], "span2": [62, 66]}, "bert_text": "RESULTS: <e1> Cyclophosphamide </e1> treatment increased the spontaneous <e2> pain </e2> behaviors scores.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1068": {"data": {"text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "entity1": "piperacillin/tazobactam", "entity2": "end-stage renal disease", "span1": [280, 303], "span2": [35, 58]}, "bert_text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <e1> piperacillin/tazobactam </e1> <e2> end-stage renal disease </e2> receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1069": {"data": {"text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "entity1": "piperacillin/tazobactam", "entity2": "tremor", "span1": [280, 303], "span2": [149, 155]}, "bert_text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <e1> piperacillin/tazobactam </e1> <e2> tremor </e2>, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1070": {"data": {"text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "entity1": "piperacillin/tazobactam", "entity2": "mental confusion", "span1": [280, 303], "span2": [187, 203]}, "bert_text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <e1> piperacillin/tazobactam </e1> <e2> mental confusion </e2>, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1071": {"data": {"text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "entity1": "piperacillin/tazobactam", "entity2": "tonic-clonic seizure", "span1": [280, 303], "span2": [235, 255]}, "bert_text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <e1> piperacillin/tazobactam </e1> <e2> tonic-clonic seizure </e2> (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1072": {"data": {"text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "entity1": "piperacillin/tazobactam", "entity2": "bronchiectasis", "span1": [280, 303], "span2": [332, 346]}, "bert_text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <e1> piperacillin/tazobactam </e1> (2 g/250 mg) were given for <e2> bronchiectasis </e2> with secondary infection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1073": {"data": {"text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of piperacillin/tazobactam (2 g/250 mg) were given for bronchiectasis with secondary infection.", "entity1": "piperacillin/tazobactam", "entity2": "infection", "span1": [280, 303], "span2": [362, 371]}, "bert_text": "We report a 57-year-old woman with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD), who developed slurred speech, tremor, bizarre behavior, progressive mental confusion, and 2 episodes of generalized tonic-clonic seizure (GTCS) after 5 doses of <e1> piperacillin/tazobactam </e1> (2 g/250 mg) were given for bronchiectasis with secondary <e2> infection </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1074": {"data": {"text": "Myoclonic movements are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection.", "entity1": "etomidate", "entity2": "Myoclonic movements", "span1": [124, 133], "span2": [0, 19]}, "bert_text": "Myoclonic movements are evaluated, which were observed and graded according to clinical severity during the 2 minutes after <e1> etomidate </e1> <e2> Myoclonic movements </e2> are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1075": {"data": {"text": "Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use.", "entity1": "sumatriptan", "entity2": "coronary vasospasm", "span1": [112, 123], "span2": [29, 47]}, "bert_text": "Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after <e1> sumatriptan </e1> <e2> coronary vasospasm </e2>, myocardial ischemia, and myocardial infarction occurring after sumatriptan use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1076": {"data": {"text": "Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use.", "entity1": "sumatriptan", "entity2": "myocardial ischemia", "span1": [112, 123], "span2": [49, 68]}, "bert_text": "Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after <e1> sumatriptan </e1> <e2> myocardial ischemia </e2>, and myocardial infarction occurring after sumatriptan use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1077": {"data": {"text": "Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use.", "entity1": "sumatriptan", "entity2": "myocardial infarction", "span1": [112, 123], "span2": [74, 95]}, "bert_text": "Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after <e1> sumatriptan </e1> <e2> myocardial infarction </e2> occurring after sumatriptan use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1078": {"data": {"text": "CONCLUSION: Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats.", "entity1": "Testosterone", "entity2": "memory impairment", "span1": [12, 24], "span2": [80, 97]}, "bert_text": "CONCLUSION: <e1> Testosterone </e1> administration ameliorates STZ- and castration-induced <e2> memory impairment </e2> in male Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1079": {"data": {"text": "CONCLUSION: Testosterone administration ameliorates STZ- and castration-induced memory impairment in male Wistar rats.", "entity1": "STZ-", "entity2": "memory impairment", "span1": [52, 56], "span2": [80, 97]}, "bert_text": "CONCLUSION: Testosterone administration ameliorates <e1> STZ- </e1> and castration-induced <e2> memory impairment </e2> in male Wistar rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1080": {"data": {"text": "PURPOSE: To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions, strokes, and death.", "entity1": "aspirin", "entity2": "myocardial infarctions", "span1": [55, 62], "span2": [93, 115]}, "bert_text": "PURPOSE: To determine the benefits and harms of taking <e1> aspirin </e1> for the primary prevention of <e2> myocardial infarctions </e2>, strokes, and death.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1081": {"data": {"text": "PURPOSE: To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions, strokes, and death.", "entity1": "aspirin", "entity2": "strokes", "span1": [55, 62], "span2": [117, 124]}, "bert_text": "PURPOSE: To determine the benefits and harms of taking <e1> aspirin </e1> for the primary prevention of myocardial infarctions, <e2> strokes </e2>, and death.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1082": {"data": {"text": "PURPOSE: To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions, strokes, and death.", "entity1": "aspirin", "entity2": "death", "span1": [55, 62], "span2": [130, 135]}, "bert_text": "PURPOSE: To determine the benefits and harms of taking <e1> aspirin </e1> for the primary prevention of myocardial infarctions, strokes, and <e2> death </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1083": {"data": {"text": "In six dogs with doxorubicin-induced heart failure, VIP decreased from 31 +/-", "entity1": "doxorubicin", "entity2": "heart failure", "span1": [17, 28], "span2": [37, 50]}, "bert_text": "In six dogs with <e1> doxorubicin </e1>-induced <e2> heart failure </e2>, VIP decreased from 31 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1084": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "lidocaine", "entity2": "toxicity", "span1": [46, 55], "span2": [76, 84]}, "bert_text": "CONCLUSION: Despite theoretical concerns that <e1> lidocaine </e1> may enhance cocaine <e2> toxicity </e2>, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1085": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "lidocaine", "entity2": "toxicity", "span1": [46, 55], "span2": [223, 231]}, "bert_text": "CONCLUSION: Despite theoretical concerns that <e1> lidocaine </e1> may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1086": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "lidocaine", "entity2": "MI", "span1": [46, 55], "span2": [143, 145]}, "bert_text": "CONCLUSION: Despite theoretical concerns that <e1> lidocaine </e1> may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated <e2> MI </e2> was not associated with significant cardiovascular or central nervous system toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1087": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "lidocaine", "entity2": "toxicity", "span1": [97, 106], "span2": [76, 84]}, "bert_text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of <e1> lidocaine </e1> <e2> toxicity </e2>, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1088": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "lidocaine", "entity2": "toxicity", "span1": [97, 106], "span2": [223, 231]}, "bert_text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of <e1> lidocaine </e1> in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1089": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "lidocaine", "entity2": "MI", "span1": [97, 106], "span2": [143, 145]}, "bert_text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of <e1> lidocaine </e1> in patients with cocaine-associated <e2> MI </e2> was not associated with significant cardiovascular or central nervous system toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1090": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "cocaine", "entity2": "toxicity", "span1": [68, 75], "span2": [76, 84]}, "bert_text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance <e1> cocaine </e1> <e2> toxicity </e2>, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1091": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "cocaine", "entity2": "toxicity", "span1": [68, 75], "span2": [223, 231]}, "bert_text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance <e1> cocaine </e1> toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1092": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "cocaine", "entity2": "MI", "span1": [68, 75], "span2": [143, 145]}, "bert_text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance <e1> cocaine </e1> toxicity, the use of lidocaine in patients with cocaine-associated <e2> MI </e2> was not associated with significant cardiovascular or central nervous system toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1093": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "cocaine", "entity2": "toxicity", "span1": [124, 131], "span2": [76, 84]}, "bert_text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with <e1> cocaine </e1> <e2> toxicity </e2>, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1094": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "cocaine", "entity2": "toxicity", "span1": [124, 131], "span2": [223, 231]}, "bert_text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with <e1> cocaine </e1>-associated MI was not associated with significant cardiovascular or central nervous system <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1095": {"data": {"text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with cocaine-associated MI was not associated with significant cardiovascular or central nervous system toxicity.", "entity1": "cocaine", "entity2": "MI", "span1": [124, 131], "span2": [143, 145]}, "bert_text": "CONCLUSION: Despite theoretical concerns that lidocaine may enhance cocaine toxicity, the use of lidocaine in patients with <e1> cocaine </e1>-associated <e2> MI </e2> was not associated with significant cardiovascular or central nervous system toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1096": {"data": {"text": "Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.", "entity1": "PS", "entity2": "toxicity", "span1": [54, 56], "span2": [70, 78]}, "bert_text": "Therefore, it is suggested that the administration of <e1> PS </e1> enhances the <e2> toxicity </e2> of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1097": {"data": {"text": "Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.", "entity1": "PS", "entity2": "end-stage renal disease", "span1": [54, 56], "span2": [168, 191]}, "bert_text": "Therefore, it is suggested that the administration of <e1> PS </e1> enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the <e2> end-stage renal disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1098": {"data": {"text": "Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.", "entity1": "AMNS", "entity2": "toxicity", "span1": [82, 86], "span2": [70, 78]}, "bert_text": "Therefore, it is suggested that the administration of PS enhances the toxicity of <e1> AMNS </e1> <e2> toxicity </e2> of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1099": {"data": {"text": "Therefore, it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end-stage renal disease.", "entity1": "AMNS", "entity2": "end-stage renal disease", "span1": [82, 86], "span2": [168, 191]}, "bert_text": "Therefore, it is suggested that the administration of PS enhances the toxicity of <e1> AMNS </e1> on the glomerulus and readily produces progressive FSGS in rats resulting in the <e2> end-stage renal disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1100": {"data": {"text": "In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).", "entity1": "adenosine", "entity2": "acute renal failure", "span1": [86, 95], "span2": [194, 213]}, "bert_text": "In the present study, the effects of three alkylxanthines with different potencies as <e1> adenosine </e1> antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing <e2> acute renal failure </e2> after 4 daily injections of gentamicin (200 mg kg-1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1101": {"data": {"text": "In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).", "entity1": "8-phenyltheophylline", "entity2": "acute renal failure", "span1": [108, 128], "span2": [194, 213]}, "bert_text": "In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists <e1> 8-phenyltheophylline </e1>, theophylline and enprofylline, were examined in rats developing <e2> acute renal failure </e2> after 4 daily injections of gentamicin (200 mg kg-1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1102": {"data": {"text": "In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).", "entity1": "theophylline", "entity2": "acute renal failure", "span1": [130, 142], "span2": [194, 213]}, "bert_text": "In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, <e1> theophylline </e1> and enprofylline, were examined in rats developing <e2> acute renal failure </e2> after 4 daily injections of gentamicin (200 mg kg-1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1103": {"data": {"text": "In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).", "entity1": "enprofylline", "entity2": "acute renal failure", "span1": [147, 159], "span2": [194, 213]}, "bert_text": "In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and <e1> enprofylline </e1>, were examined in rats developing <e2> acute renal failure </e2> after 4 daily injections of gentamicin (200 mg kg-1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1104": {"data": {"text": "In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of gentamicin (200 mg kg-1).", "entity1": "gentamicin", "entity2": "acute renal failure", "span1": [242, 252], "span2": [194, 213]}, "bert_text": "In the present study, the effects of three alkylxanthines with different potencies as adenosine antagonists 8-phenyltheophylline, theophylline and enprofylline, were examined in rats developing acute renal failure after 4 daily injections of <e1> gentamicin </e1> <e2> acute renal failure </e2> after 4 daily injections of gentamicin (200 mg kg-1).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1105": {"data": {"text": "CONCLUSION: In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients.", "entity1": "PTRA", "entity2": "renal damage", "span1": [60, 64], "span2": [98, 110]}, "bert_text": "CONCLUSION: In this preliminary study patients submitted to <e1> PTRA </e1> showed a lower susceptibility to <e2> renal damage </e2> induced by CM administration than PCI patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1106": {"data": {"text": "CONCLUSION: In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients.", "entity1": "PTRA", "entity2": "CM", "span1": [60, 64], "span2": [122, 124]}, "bert_text": "CONCLUSION: In this preliminary study patients submitted to <e1> PTRA </e1> showed a lower susceptibility to renal damage induced by <e2> CM </e2> administration than PCI patients.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1107": {"data": {"text": "Fourteen of 84 (17%) patients had symptoms and signs consistent with CYA cardiotoxicity within ten days of receiving 1 to 4 doses of CYA.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [69, 72], "span2": [73, 87]}, "bert_text": "Fourteen of 84 (17%) patients had symptoms and signs consistent with <e1> CYA </e1> <e2> cardiotoxicity </e2> within ten days of receiving 1 to 4 doses of CYA.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1108": {"data": {"text": "Fourteen of 84 (17%) patients had symptoms and signs consistent with CYA cardiotoxicity within ten days of receiving 1 to 4 doses of CYA.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [133, 136], "span2": [73, 87]}, "bert_text": "Fourteen of 84 (17%) patients had symptoms and signs consistent with CYA cardiotoxicity within ten days of receiving 1 to 4 doses of <e1> CYA </e1> <e2> cardiotoxicity </e2> within ten days of receiving 1 to 4 doses of CYA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1109": {"data": {"text": "After the withdrawal of VPA therapy, our patient showed a significant weight loss, a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization.", "entity1": "VPA", "entity2": "weight loss", "span1": [24, 27], "span2": [70, 81]}, "bert_text": "After the withdrawal of <e1> VPA </e1> therapy, our patient showed a significant <e2> weight loss </e2>, a decrease of body mass index, and normalization of metabolic and endocrine parameters; moreover, ultrasound measurements showed a complete normalization.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1110": {"data": {"text": "RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "entity1": "Verapamil", "entity2": "macroprolactinoma", "span1": [9, 18], "span2": [93, 110]}, "bert_text": "RESULTS: <e1> Verapamil </e1> significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), <e2> macroprolactinoma </e2> (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1111": {"data": {"text": "RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "entity1": "Verapamil", "entity2": "microprolactinoma", "span1": [9, 18], "span2": [128, 145]}, "bert_text": "RESULTS: <e1> Verapamil </e1> significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), <e2> microprolactinoma </e2> (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1112": {"data": {"text": "RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "entity1": "Verapamil", "entity2": "hyperprolactinemia", "span1": [9, 18], "span2": [277, 295]}, "bert_text": "RESULTS: <e1> Verapamil </e1> significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced <e2> hyperprolactinemia </e2> (N. 7, PRL: 3%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1113": {"data": {"text": "RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "entity1": "risperidone", "entity2": "macroprolactinoma", "span1": [257, 268], "span2": [93, 110]}, "bert_text": "RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and <e1> risperidone </e1> <e2> macroprolactinoma </e2> (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1114": {"data": {"text": "RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "entity1": "risperidone", "entity2": "microprolactinoma", "span1": [257, 268], "span2": [128, 145]}, "bert_text": "RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and <e1> risperidone </e1> <e2> microprolactinoma </e2> (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1115": {"data": {"text": "RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and risperidone-induced hyperprolactinemia (N. 7, PRL: 3%).", "entity1": "risperidone", "entity2": "hyperprolactinemia", "span1": [257, 268], "span2": [277, 295]}, "bert_text": "RESULTS: Verapamil significantly increased PRL levels in healthy controls (N. 8, PRL: 183%), macroprolactinoma (N. 8, PRL: 7%), microprolactinoma (N. 19, PRL: 21%), macroprolactinemia (N. 23, PRL: 126%), but not in pseudoprolactinoma (N. 8, PRL: 0.8%), and <e1> risperidone </e1>-induced <e2> hyperprolactinemia </e2> (N. 7, PRL: 3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1116": {"data": {"text": "An alternate class III agent, sotalol, was also effective for the prevention of VT.", "entity1": "sotalol", "entity2": "VT", "span1": [30, 37], "span2": [80, 82]}, "bert_text": "An alternate class III agent, <e1> sotalol </e1>, was also effective for the prevention of <e2> VT </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1117": {"data": {"text": "Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the cardiotoxicity of aconitine.", "entity1": "Na(+", "entity2": "cardiotoxicity", "span1": [51, 55], "span2": [92, 106]}, "bert_text": "Emerging evidence indicates that voltage-dependent <e1> Na(+ </e1>) channels have pivotal roles in the <e2> cardiotoxicity </e2> of aconitine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1118": {"data": {"text": "Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the cardiotoxicity of aconitine.", "entity1": "aconitine", "entity2": "cardiotoxicity", "span1": [110, 119], "span2": [92, 106]}, "bert_text": "Emerging evidence indicates that voltage-dependent Na(+) channels have pivotal roles in the cardiotoxicity of <e1> aconitine </e1> <e2> cardiotoxicity </e2> of aconitine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1119": {"data": {"text": "CONCLUSION: The data suggest that fluocinolone acetonide implant (0.59 mg) helps to control inflammation in otherwise treatment-refractory cases of birdshot retinochoroidopathy.", "entity1": "fluocinolone acetonide", "entity2": "inflammation", "span1": [34, 56], "span2": [92, 104]}, "bert_text": "CONCLUSION: The data suggest that <e1> fluocinolone acetonide </e1> implant (0.59 mg) helps to control <e2> inflammation </e2> in otherwise treatment-refractory cases of birdshot retinochoroidopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1120": {"data": {"text": "CONCLUSION: The data suggest that fluocinolone acetonide implant (0.59 mg) helps to control inflammation in otherwise treatment-refractory cases of birdshot retinochoroidopathy.", "entity1": "fluocinolone acetonide", "entity2": "birdshot retinochoroidopathy", "span1": [34, 56], "span2": [148, 176]}, "bert_text": "CONCLUSION: The data suggest that <e1> fluocinolone acetonide </e1> implant (0.59 mg) helps to control inflammation in otherwise treatment-refractory cases of <e2> birdshot retinochoroidopathy </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1121": {"data": {"text": "He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation.", "entity1": "aspirin", "entity2": "fever", "span1": [14, 21], "span2": [63, 68]}, "bert_text": "He was put on <e1> aspirin </e1> following surgery and took ibuprofen for <e2> fever </e2> for nearly a week prior to presentation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1122": {"data": {"text": "He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation.", "entity1": "ibuprofen", "entity2": "fever", "span1": [49, 58], "span2": [63, 68]}, "bert_text": "He was put on aspirin following surgery and took <e1> ibuprofen </e1> for <e2> fever </e2> for nearly a week prior to presentation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1123": {"data": {"text": "CONCLUSIONS: The combination of carboplatin and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma.", "entity1": "carboplatin", "entity2": "carcinoma", "span1": [32, 43], "span2": [126, 135]}, "bert_text": "CONCLUSIONS: The combination of <e1> carboplatin </e1> and liposomal doxorubicin has modest activity in patients with recurrent cervical <e2> carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1124": {"data": {"text": "CONCLUSIONS: The combination of carboplatin and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma.", "entity1": "doxorubicin", "entity2": "carcinoma", "span1": [58, 69], "span2": [126, 135]}, "bert_text": "CONCLUSIONS: The combination of carboplatin and liposomal <e1> doxorubicin </e1> has modest activity in patients with recurrent cervical <e2> carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1125": {"data": {"text": "BACKGROUND: Lamivudine is used for the treatment of chronic hepatitis B patients.", "entity1": "Lamivudine", "entity2": "hepatitis B", "span1": [12, 22], "span2": [60, 71]}, "bert_text": "BACKGROUND: <e1> Lamivudine </e1> is used for the treatment of chronic <e2> hepatitis B </e2> patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1126": {"data": {"text": "CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced anemia.", "entity1": "Azathioprine", "entity2": "death", "span1": [13, 25], "span2": [56, 61]}, "bert_text": "CONCLUSIONS: <e1> Azathioprine </e1> triggers suicidal erythrocyte <e2> death </e2>, an effect presumably contributing to azathioprine-induced anemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1127": {"data": {"text": "CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced anemia.", "entity1": "Azathioprine", "entity2": "anemia", "span1": [13, 25], "span2": [121, 127]}, "bert_text": "CONCLUSIONS: <e1> Azathioprine </e1> triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced <e2> anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1128": {"data": {"text": "CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced anemia.", "entity1": "azathioprine", "entity2": "death", "span1": [100, 112], "span2": [56, 61]}, "bert_text": "CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to <e1> azathioprine </e1> <e2> death </e2>, an effect presumably contributing to azathioprine-induced anemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1129": {"data": {"text": "CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to azathioprine-induced anemia.", "entity1": "azathioprine", "entity2": "anemia", "span1": [100, 112], "span2": [121, 127]}, "bert_text": "CONCLUSIONS: Azathioprine triggers suicidal erythrocyte death, an effect presumably contributing to <e1> azathioprine </e1>-induced <e2> anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1130": {"data": {"text": "Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.", "entity1": "serotonin", "entity2": "depressive disorders", "span1": [258, 267], "span2": [12, 32]}, "bert_text": "Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with <e1> serotonin </e1> <e2> depressive disorders </e2> (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1131": {"data": {"text": "Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.", "entity1": "serotonin", "entity2": "psychosis", "span1": [258, 267], "span2": [98, 107]}, "bert_text": "Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with <e1> serotonin </e1> <e2> psychosis </e2>, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1132": {"data": {"text": "Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.", "entity1": "serotonin", "entity2": "psychosis", "span1": [258, 267], "span2": [168, 177]}, "bert_text": "Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with <e1> serotonin </e1> <e2> psychosis </e2>) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1133": {"data": {"text": "Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.", "entity1": "serotonin", "entity2": "bipolarity", "span1": [258, 267], "span2": [109, 119]}, "bert_text": "Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with <e1> serotonin </e1> <e2> bipolarity </e2>, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1134": {"data": {"text": "Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors.", "entity1": "serotonin", "entity2": "paranoid", "span1": [258, 267], "span2": [219, 227]}, "bert_text": "Complicated depressive disorders (including atypicality of course and symptomatology, chronicity, psychosis, bipolarity, and secondary onset in the course of a primary psychosis) may present particular vulnerability to paranoid exacerbations associated with <e1> serotonin </e1> <e2> paranoid </e2> exacerbations associated with serotonin reuptake inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1135": {"data": {"text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "entity1": "glucose", "entity2": "dementia", "span1": [191, 198], "span2": [50, 58]}, "bert_text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased <e1> glucose </e1> <e2> dementia </e2> of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1136": {"data": {"text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "entity1": "glucose", "entity2": "Alzheimer's disease", "span1": [191, 198], "span2": [71, 90]}, "bert_text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased <e1> glucose </e1> <e2> Alzheimer's disease </e2> (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1137": {"data": {"text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "entity1": "glucose", "entity2": "dementia", "span1": [213, 220], "span2": [50, 58]}, "bert_text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via <e1> glucose </e1> <e2> dementia </e2> of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1138": {"data": {"text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "entity1": "glucose", "entity2": "Alzheimer's disease", "span1": [213, 220], "span2": [71, 90]}, "bert_text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via <e1> glucose </e1> <e2> Alzheimer's disease </e2> (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1139": {"data": {"text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "entity1": "glucose", "entity2": "dementia", "span1": [253, 260], "span2": [50, 58]}, "bert_text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased <e1> glucose </e1> <e2> dementia </e2> of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1140": {"data": {"text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "entity1": "glucose", "entity2": "Alzheimer's disease", "span1": [253, 260], "span2": [71, 90]}, "bert_text": "Basic and clinical research has demonstrated that dementia of sporadic Alzheimer's disease (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased <e1> glucose </e1> <e2> Alzheimer's disease </e2> (sAD) type is associated with dysfunction of the insulin-receptor (IR) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1141": {"data": {"text": "In some cases, a high serum concentration of citalopram (> 600 nmol/L) in elderly patients has been associated with increased somnolence and movement difficulties.", "entity1": "citalopram", "entity2": "somnolence", "span1": [45, 55], "span2": [126, 136]}, "bert_text": "In some cases, a high serum concentration of <e1> citalopram </e1> (> 600 nmol/L) in elderly patients has been associated with increased <e2> somnolence </e2> and movement difficulties.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1142": {"data": {"text": "In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.", "entity1": "betaine", "entity2": "myocardial ischemia", "span1": [36, 43], "span2": [96, 115]}, "bert_text": "In summary, our results showed that <e1> betaine </e1> pretreatment attenuated isoproterenol-induced acute <e2> myocardial ischemia </e2> via the regulation of STAT3 and apoptotic pathways.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1143": {"data": {"text": "In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.", "entity1": "isoproterenol", "entity2": "myocardial ischemia", "span1": [68, 81], "span2": [96, 115]}, "bert_text": "In summary, our results showed that betaine pretreatment attenuated <e1> isoproterenol </e1>-induced acute <e2> myocardial ischemia </e2> via the regulation of STAT3 and apoptotic pathways.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1144": {"data": {"text": "Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced ocular hypertension.", "entity1": "Dexamethasone", "entity2": "ocular hypertension", "span1": [0, 13], "span2": [209, 228]}, "bert_text": "<e1> Dexamethasone </e1> induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced <e2> ocular hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1145": {"data": {"text": "Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented dexamethasone-induced ocular hypertension.", "entity1": "dexamethasone", "entity2": "ocular hypertension", "span1": [187, 200], "span2": [209, 228]}, "bert_text": "Dexamethasone induced the transcriptional factor CHOP, a marker for chronic ER stress, in the anterior segment tissues, and Chop deletion reduced ER stress in these tissues and prevented <e1> dexamethasone </e1>-induced <e2> ocular hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1146": {"data": {"text": "Acute hepatitis associated with clopidogrel: a case report and review of the literature.\n", "entity1": "clopidogrel", "entity2": "hepatitis", "span1": [32, 43], "span2": [6, 15]}, "bert_text": "Acute hepatitis associated with <e1> clopidogrel </e1> <e2> hepatitis </e2> associated with clopidogrel: a case report and review of the literature.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1147": {"data": {"text": "Carvedilol also prevented the decrease in mitochondrial Ca(2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin.", "entity1": "Carvedilol", "entity2": "heart mitochondria", "span1": [0, 10], "span2": [131, 149]}, "bert_text": "<e1> Carvedilol </e1> also prevented the decrease in mitochondrial Ca(2+) loading capacity and the inhibition of the respiratory complexes of <e2> heart mitochondria </e2> caused by doxorubicin.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1148": {"data": {"text": "Carvedilol also prevented the decrease in mitochondrial Ca(2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin.", "entity1": "Ca(2", "entity2": "heart mitochondria", "span1": [56, 60], "span2": [131, 149]}, "bert_text": "Carvedilol also prevented the decrease in mitochondrial <e1> Ca(2 </e1>+) loading capacity and the inhibition of the respiratory complexes of <e2> heart mitochondria </e2> caused by doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1149": {"data": {"text": "Carvedilol also prevented the decrease in mitochondrial Ca(2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by doxorubicin.", "entity1": "doxorubicin", "entity2": "heart mitochondria", "span1": [160, 171], "span2": [131, 149]}, "bert_text": "Carvedilol also prevented the decrease in mitochondrial Ca(2+) loading capacity and the inhibition of the respiratory complexes of heart mitochondria caused by <e1> doxorubicin </e1> <e2> heart mitochondria </e2> caused by doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1150": {"data": {"text": "Nasal hypoplasia with or without stippled epiphyses has now been reported in 11 infants born to mothers treated with warfarin during the first trimester, and a causal association is probable.", "entity1": "warfarin", "entity2": "Nasal hypoplasia", "span1": [117, 125], "span2": [0, 16]}, "bert_text": "Nasal hypoplasia with or without stippled epiphyses has now been reported in 11 infants born to mothers treated with <e1> warfarin </e1> <e2> Nasal hypoplasia </e2> with or without stippled epiphyses has now been reported in 11 infants born to mothers treated with warfarin during the first trimester, and a causal association is probable.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1151": {"data": {"text": "Administration of MK-801 30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate.", "entity1": "MK-801", "entity2": "status epilepticus", "span1": [18, 24], "span2": [70, 88]}, "bert_text": "Administration of <e1> MK-801 </e1> 30 or 60 min after pilocarpine, i.e., during <e2> status epilepticus </e2>, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1152": {"data": {"text": "Administration of MK-801 30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate.", "entity1": "MK-801", "entity2": "seizure", "span1": [18, 24], "span2": [134, 141]}, "bert_text": "Administration of <e1> MK-801 </e1> 30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral <e2> seizure </e2> activity and greatly enhanced the survival rate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1153": {"data": {"text": "Administration of MK-801 30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [44, 55], "span2": [70, 88]}, "bert_text": "Administration of MK-801 30 or 60 min after <e1> pilocarpine </e1>, i.e., during <e2> status epilepticus </e2>, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1154": {"data": {"text": "Administration of MK-801 30 or 60 min after pilocarpine, i.e., during status epilepticus, gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [44, 55], "span2": [134, 141]}, "bert_text": "Administration of MK-801 30 or 60 min after <e1> pilocarpine </e1>, i.e., during status epilepticus, gradually reduced electrical and behavioral <e2> seizure </e2> activity and greatly enhanced the survival rate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1155": {"data": {"text": "In SHR but not in WKY administration of ANP, AVP and ANP + AVP decreased CCB during Phe-induced MAP elevation.", "entity1": "AVP", "entity2": "SHR", "span1": [45, 48], "span2": [3, 6]}, "bert_text": "In SHR but not in WKY administration of ANP, <e1> AVP </e1> <e2> SHR </e2> but not in WKY administration of ANP, AVP and ANP + AVP decreased CCB during Phe-induced MAP elevation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1156": {"data": {"text": "In SHR but not in WKY administration of ANP, AVP and ANP + AVP decreased CCB during Phe-induced MAP elevation.", "entity1": "AVP", "entity2": "SHR", "span1": [59, 62], "span2": [3, 6]}, "bert_text": "In SHR but not in WKY administration of ANP, AVP and ANP + <e1> AVP </e1> <e2> SHR </e2> but not in WKY administration of ANP, AVP and ANP + AVP decreased CCB during Phe-induced MAP elevation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1157": {"data": {"text": "In SHR but not in WKY administration of ANP, AVP and ANP + AVP decreased CCB during Phe-induced MAP elevation.", "entity1": "CCB", "entity2": "SHR", "span1": [73, 76], "span2": [3, 6]}, "bert_text": "In SHR but not in WKY administration of ANP, AVP and ANP + AVP decreased <e1> CCB </e1> <e2> SHR </e2> but not in WKY administration of ANP, AVP and ANP + AVP decreased CCB during Phe-induced MAP elevation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1158": {"data": {"text": "In SHR but not in WKY administration of ANP, AVP and ANP + AVP decreased CCB during Phe-induced MAP elevation.", "entity1": "Phe", "entity2": "SHR", "span1": [84, 87], "span2": [3, 6]}, "bert_text": "In SHR but not in WKY administration of ANP, AVP and ANP + AVP decreased CCB during <e1> Phe </e1> <e2> SHR </e2> but not in WKY administration of ANP, AVP and ANP + AVP decreased CCB during Phe-induced MAP elevation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1159": {"data": {"text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "entity1": "VPA", "entity2": "obesity", "span1": [107, 110], "span2": [31, 38]}, "bert_text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with <e1> VPA </e1> <e2> obesity </e2>, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1160": {"data": {"text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "entity1": "VPA", "entity2": "hyperinsulinemia", "span1": [107, 110], "span2": [40, 56]}, "bert_text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with <e1> VPA </e1> <e2> hyperinsulinemia </e2>, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1161": {"data": {"text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "entity1": "VPA", "entity2": "NAFLD", "span1": [107, 110], "span2": [157, 162]}, "bert_text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with <e1> VPA </e1> may be all associated with the development of <e2> NAFLD </e2>; this side effect is reversible after VPA withdrawal.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1162": {"data": {"text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "entity1": "VPA", "entity2": "obesity", "span1": [201, 204], "span2": [31, 38]}, "bert_text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after <e1> VPA </e1> <e2> obesity </e2>, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1163": {"data": {"text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "entity1": "VPA", "entity2": "hyperinsulinemia", "span1": [201, 204], "span2": [40, 56]}, "bert_text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after <e1> VPA </e1> <e2> hyperinsulinemia </e2>, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1164": {"data": {"text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after VPA withdrawal.", "entity1": "VPA", "entity2": "NAFLD", "span1": [201, 204], "span2": [157, 162]}, "bert_text": "The present case suggests that obesity, hyperinsulinemia, insulin resistance, and long-term treatment with VPA may be all associated with the development of NAFLD; this side effect is reversible after <e1> VPA </e1> <e2> NAFLD </e2>; this side effect is reversible after VPA withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1165": {"data": {"text": "OBJECTIVES: To investigate the effects of subchronic L-NOARG treatment in haloperidol-induced catalepsy and the number of NOS neurons in areas related to motor control.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [74, 85], "span2": [94, 103]}, "bert_text": "OBJECTIVES: To investigate the effects of subchronic L-NOARG treatment in <e1> haloperidol </e1>-induced <e2> catalepsy </e2> and the number of NOS neurons in areas related to motor control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1166": {"data": {"text": "It is the third urinary tract cancer reported in association with cyclophosphamide treatment for nonmalignant disease.", "entity1": "cyclophosphamide", "entity2": "cancer", "span1": [66, 82], "span2": [30, 36]}, "bert_text": "It is the third urinary tract cancer reported in association with <e1> cyclophosphamide </e1> <e2> cancer </e2> reported in association with cyclophosphamide treatment for nonmalignant disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1167": {"data": {"text": "Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation OCs.", "entity1": "OCs", "entity2": "VTE", "span1": [128, 131], "span2": [68, 71]}, "bert_text": "Logistic regression showed no significant difference in the risk of VTE between users of third-generation and second-generation <e1> OCs </e1> <e2> VTE </e2> between users of third-generation and second-generation OCs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"1168": {"data": {"text": "Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed cortical dysplasia group.", "entity1": "BCNU", "entity2": "cortical dysplasia", "span1": [169, 173], "span2": [182, 200]}, "bert_text": "Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in <e1> BCNU </e1>-exposed <e2> cortical dysplasia </e2> group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1169": {"data": {"text": "Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate.\n", "entity1": "glycopyrrolate", "entity2": "hyperhidrosis", "span1": [63, 77], "span2": [36, 49]}, "bert_text": "Treatment of compensatory gustatory hyperhidrosis with topical <e1> glycopyrrolate </e1> <e2> hyperhidrosis </e2> with topical glycopyrrolate.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1170": {"data": {"text": "Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.\n", "entity1": "bortezomib", "entity2": "multiple myeloma", "span1": [15, 25], "span2": [150, 166]}, "bert_text": "Combination of <e1> bortezomib </e1>, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic <e2> multiple myeloma </e2> in Japanese patients.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1171": {"data": {"text": "Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.\n", "entity1": "thalidomide", "entity2": "multiple myeloma", "span1": [27, 38], "span2": [150, 166]}, "bert_text": "Combination of bortezomib, <e1> thalidomide </e1>, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic <e2> multiple myeloma </e2> in Japanese patients.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1172": {"data": {"text": "Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.\n", "entity1": "dexamethasone", "entity2": "multiple myeloma", "span1": [44, 57], "span2": [150, 166]}, "bert_text": "Combination of bortezomib, thalidomide, and <e1> dexamethasone </e1> (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic <e2> multiple myeloma </e2> in Japanese patients.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1173": {"data": {"text": "Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia.\n", "entity1": "haloperidol", "entity2": "hyperprolactinemia", "span1": [67, 78], "span2": [87, 105]}, "bert_text": "Pituitary response to luteinizing hormone-releasing hormone during <e1> haloperidol </e1>-induced <e2> hyperprolactinemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1174": {"data": {"text": "Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.", "entity1": "l-sotalol", "entity2": "coronary artery disease", "span1": [195, 204], "span2": [41, 64]}, "bert_text": "Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,<e1> l-sotalol </e1> <e2> coronary artery disease </e2>, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1175": {"data": {"text": "Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.", "entity1": "l-sotalol", "entity2": "dilated cardiomyopathy", "span1": [195, 204], "span2": [78, 100]}, "bert_text": "Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,<e1> l-sotalol </e1> <e2> dilated cardiomyopathy </e2>) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1176": {"data": {"text": "Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.", "entity1": "l-sotalol", "entity2": "ventricular tachycardia", "span1": [195, 204], "span2": [127, 150]}, "bert_text": "Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,<e1> l-sotalol </e1> <e2> ventricular tachycardia </e2> or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1177": {"data": {"text": "Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.", "entity1": "l-sotalol", "entity2": "ventricular tachyarrhythmia", "span1": [195, 204], "span2": [233, 260]}, "bert_text": "Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,<e1> l-sotalol </e1> to prevent induction of the <e2> ventricular tachyarrhythmia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1178": {"data": {"text": "Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.", "entity1": "l-sotalol", "entity2": "ventricular fibrillation", "span1": [195, 204], "span2": [154, 178]}, "bert_text": "Eighty-one consecutive patients (54 with coronary artery disease, and 20 with dilated cardiomyopathy) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d,<e1> l-sotalol </e1> <e2> ventricular fibrillation </e2> received oral d,l-sotalol to prevent induction of the ventricular tachyarrhythmia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1179": {"data": {"text": "Using magnetic resonance imaging (MRI) and new computational brain-mapping techniques, we determined the pattern of structural brain alterations associated with chronic MA abuse in human subjects and related these deficits to cognitive impairment.", "entity1": "MA", "entity2": "deficits", "span1": [169, 171], "span2": [214, 222]}, "bert_text": "Using magnetic resonance imaging (MRI) and new computational brain-mapping techniques, we determined the pattern of structural brain alterations associated with chronic <e1> MA </e1> abuse in human subjects and related these <e2> deficits </e2> to cognitive impairment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1180": {"data": {"text": "Using magnetic resonance imaging (MRI) and new computational brain-mapping techniques, we determined the pattern of structural brain alterations associated with chronic MA abuse in human subjects and related these deficits to cognitive impairment.", "entity1": "MA", "entity2": "cognitive impairment", "span1": [169, 171], "span2": [226, 246]}, "bert_text": "Using magnetic resonance imaging (MRI) and new computational brain-mapping techniques, we determined the pattern of structural brain alterations associated with chronic <e1> MA </e1> abuse in human subjects and related these deficits to <e2> cognitive impairment </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1181": {"data": {"text": "Data were collected on adult cancer patients receiving single-agent cisplatin as an outpatient from January 2011 to September 2012.", "entity1": "cisplatin", "entity2": "cancer", "span1": [68, 77], "span2": [29, 35]}, "bert_text": "Data were collected on adult cancer patients receiving single-agent <e1> cisplatin </e1> <e2> cancer </e2> patients receiving single-agent cisplatin as an outpatient from January 2011 to September 2012.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1182": {"data": {"text": "The worst toxicities (%) observed were (CTC-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "entity1": "CTC", "entity2": "toxicities", "span1": [40, 43], "span2": [10, 20]}, "bert_text": "The worst toxicities (%) observed were (<e1> CTC </e1> <e2> toxicities </e2> (%) observed were (CTC-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1183": {"data": {"text": "The worst toxicities (%) observed were (CTC-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "entity1": "CTC", "entity2": "leukopenia", "span1": [40, 43], "span2": [56, 66]}, "bert_text": "The worst toxicities (%) observed were (<e1> CTC </e1>-NCI 1/2/3): <e2> leukopenia </e2> 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1184": {"data": {"text": "The worst toxicities (%) observed were (CTC-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "entity1": "CTC", "entity2": "thrombocytopenia", "span1": [40, 43], "span2": [82, 98]}, "bert_text": "The worst toxicities (%) observed were (<e1> CTC </e1>-NCI 1/2/3): leukopenia 45.5/18.2/6.1, <e2> thrombocytopenia </e2> 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1185": {"data": {"text": "The worst toxicities (%) observed were (CTC-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "entity1": "CTC", "entity2": "diarrhea", "span1": [40, 43], "span2": [133, 141]}, "bert_text": "The worst toxicities (%) observed were (<e1> CTC </e1>-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, <e2> diarrhea </e2> 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1186": {"data": {"text": "The worst toxicities (%) observed were (CTC-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "entity1": "CTC", "entity2": "stomatitis", "span1": [40, 43], "span2": [156, 166]}, "bert_text": "The worst toxicities (%) observed were (<e1> CTC </e1>-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, <e2> stomatitis </e2> 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1187": {"data": {"text": "The worst toxicities (%) observed were (CTC-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, hand-foot syndrome 12.1/0/0.", "entity1": "CTC", "entity2": "hand-foot syndrome", "span1": [40, 43], "span2": [179, 197]}, "bert_text": "The worst toxicities (%) observed were (<e1> CTC </e1>-NCI 1/2/3): leukopenia 45.5/18.2/6.1, thrombocytopenia 33.3/9.1/6.1, vomitus 24.2/9.1/0, diarrhea 36.4/6.1/3.0, stomatitis 18.2/9.1/0, <e2> hand-foot syndrome </e2> 12.1/0/0.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1188": {"data": {"text": "Our findings demonstrated that ouabain at 10(-2) and 10(-3)M induced hyperlocomotion in rats, and this response remained up to 7 days following a single ICV injection.", "entity1": "ouabain", "entity2": "hyperlocomotion", "span1": [31, 38], "span2": [69, 84]}, "bert_text": "Our findings demonstrated that <e1> ouabain </e1> at 10(-2) and 10(-3)M induced <e2> hyperlocomotion </e2> in rats, and this response remained up to 7 days following a single ICV injection.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1189": {"data": {"text": "On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs.", "entity1": "CCNU", "entity2": "tumor", "span1": [70, 74], "span2": [153, 158]}, "bert_text": "On the basis of the findings reported herein, a dose of 60 mg/m(2) of <e1> CCNU </e1> combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in <e2> tumor </e2>-bearing dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1190": {"data": {"text": "On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs.", "entity1": "CTX", "entity2": "tumor", "span1": [104, 107], "span2": [153, 158]}, "bert_text": "On the basis of the findings reported herein, a dose of 60 mg/m(2) of CCNU combined with 250 mg/m(2) of <e1> CTX </e1> (divided over 5 days) q 4 wk is tolerable in <e2> tumor </e2>-bearing dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1191": {"data": {"text": "Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients.\n", "entity1": "tobramycin", "entity2": "infections", "span1": [20, 30], "span2": [63, 73]}, "bert_text": "Continuous infusion <e1> tobramycin </e1> combined with carbenicillin for <e2> infections </e2> in cancer patients.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1192": {"data": {"text": "Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients.\n", "entity1": "tobramycin", "entity2": "cancer", "span1": [20, 30], "span2": [77, 83]}, "bert_text": "Continuous infusion <e1> tobramycin </e1> combined with carbenicillin for infections in <e2> cancer </e2> patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1193": {"data": {"text": "Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients.\n", "entity1": "carbenicillin", "entity2": "infections", "span1": [45, 58], "span2": [63, 73]}, "bert_text": "Continuous infusion tobramycin combined with <e1> carbenicillin </e1> for <e2> infections </e2> in cancer patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1194": {"data": {"text": "Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients.\n", "entity1": "carbenicillin", "entity2": "cancer", "span1": [45, 58], "span2": [77, 83]}, "bert_text": "Continuous infusion tobramycin combined with <e1> carbenicillin </e1> for infections in <e2> cancer </e2> patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1195": {"data": {"text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "entity1": "linezolid", "entity2": "tuberculous", "span1": [107, 116], "span2": [79, 90]}, "bert_text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including <e1> linezolid </e1> <e2> tuberculous </e2> drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1196": {"data": {"text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "entity1": "linezolid", "entity2": "tuberculosis", "span1": [107, 116], "span2": [163, 175]}, "bert_text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including <e1> linezolid </e1> and ethambutol for extensively drug-resistant <e2> tuberculosis </e2> (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1197": {"data": {"text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "entity1": "linezolid", "entity2": "painless progressive loss of vision", "span1": [107, 116], "span2": [206, 241]}, "bert_text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including <e1> linezolid </e1> and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with <e2> painless progressive loss of vision </e2> in both eyes.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1198": {"data": {"text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "entity1": "ethambutol", "entity2": "tuberculous", "span1": [121, 131], "span2": [79, 90]}, "bert_text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and <e1> ethambutol </e1> <e2> tuberculous </e2> drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1199": {"data": {"text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "entity1": "ethambutol", "entity2": "tuberculosis", "span1": [121, 131], "span2": [163, 175]}, "bert_text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and <e1> ethambutol </e1> for extensively drug-resistant <e2> tuberculosis </e2> (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1200": {"data": {"text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "entity1": "ethambutol", "entity2": "painless progressive loss of vision", "span1": [121, 131], "span2": [206, 241]}, "bert_text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and <e1> ethambutol </e1> for extensively drug-resistant tuberculosis (XDR-TB) presented to us with <e2> painless progressive loss of vision </e2> in both eyes.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1201": {"data": {"text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "entity1": "XDR-TB", "entity2": "tuberculous", "span1": [177, 183], "span2": [79, 90]}, "bert_text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (<e1> XDR-TB </e1> <e2> tuberculous </e2> drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1202": {"data": {"text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "entity1": "XDR-TB", "entity2": "tuberculosis", "span1": [177, 183], "span2": [163, 175]}, "bert_text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (<e1> XDR-TB </e1> <e2> tuberculosis </e2> (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1203": {"data": {"text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (XDR-TB) presented to us with painless progressive loss of vision in both eyes.", "entity1": "XDR-TB", "entity2": "painless progressive loss of vision", "span1": [177, 183], "span2": [206, 241]}, "bert_text": "A 45-year-old male patient who was on treatment with multiple second-line anti-tuberculous drugs including linezolid and ethambutol for extensively drug-resistant tuberculosis (<e1> XDR-TB </e1>) presented to us with <e2> painless progressive loss of vision </e2> in both eyes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1204": {"data": {"text": "Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder.\n", "entity1": "quetiapine", "entity2": "agitation", "span1": [58, 68], "span2": [19, 28]}, "bert_text": "Paradoxical severe agitation induced by add-on high-doses <e1> quetiapine </e1> <e2> agitation </e2> induced by add-on high-doses quetiapine in schizo-affective disorder.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1205": {"data": {"text": "Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism.", "entity1": "apomorphine", "entity2": "amnesia", "span1": [11, 22], "span2": [185, 192]}, "bert_text": "Given that <e1> apomorphine </e1> inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate <e2> amnesia </e2> induced by dopaminergic agonism.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1206": {"data": {"text": "Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism.", "entity1": "nefiracetam", "entity2": "amnesia", "span1": [160, 171], "span2": [185, 192]}, "bert_text": "Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10-12h post-training period, we evaluated the ability of <e1> nefiracetam </e1> to attenuate <e2> amnesia </e2> induced by dopaminergic agonism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1207": {"data": {"text": "OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.", "entity1": "indinavir", "entity2": "ureteric calculi", "span1": [105, 114], "span2": [49, 65]}, "bert_text": "OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving <e1> indinavir </e1> <e2> ureteric calculi </e2> in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1208": {"data": {"text": "OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.", "entity1": "indinavir", "entity2": "HIV-infected", "span1": [105, 114], "span2": [73, 85]}, "bert_text": "OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving <e1> indinavir </e1> <e2> HIV-infected </e2> patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1209": {"data": {"text": "OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving indinavir, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of urolithiasis.", "entity1": "indinavir", "entity2": "urolithiasis", "span1": [105, 114], "span2": [214, 226]}, "bert_text": "OBJECTIVE: We describe the unique CT features of ureteric calculi in six HIV-infected patients receiving <e1> indinavir </e1>, the most commonly used HIV protease inhibitor, which is associated with an increased incidence of <e2> urolithiasis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1210": {"data": {"text": "CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.", "entity1": "levobupivacaine", "entity2": "cardiac toxicity", "span1": [22, 37], "span2": [55, 71]}, "bert_text": "CONCLUSIONS: Although <e1> levobupivacaine </e1> may have a safer <e2> cardiac toxicity </e2> profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1211": {"data": {"text": "CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.", "entity1": "levobupivacaine", "entity2": "convulsions", "span1": [22, 37], "span2": [186, 197]}, "bert_text": "CONCLUSIONS: Although <e1> levobupivacaine </e1> may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1212": {"data": {"text": "CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.", "entity1": "levobupivacaine", "entity2": "cardiac toxicity", "span1": [129, 144], "span2": [55, 71]}, "bert_text": "CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of <e1> levobupivacaine </e1> <e2> cardiac toxicity </e2> profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1213": {"data": {"text": "CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.", "entity1": "levobupivacaine", "entity2": "convulsions", "span1": [129, 144], "span2": [186, 197]}, "bert_text": "CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of <e1> levobupivacaine </e1> reach the circulation, it will result in <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1214": {"data": {"text": "CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.", "entity1": "bupivacaine", "entity2": "cardiac toxicity", "span1": [93, 104], "span2": [55, 71]}, "bert_text": "CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic <e1> bupivacaine </e1> <e2> cardiac toxicity </e2> profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1215": {"data": {"text": "CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine, if adequate amounts of levobupivacaine reach the circulation, it will result in convulsions.", "entity1": "bupivacaine", "entity2": "convulsions", "span1": [93, 104], "span2": [186, 197]}, "bert_text": "CONCLUSIONS: Although levobupivacaine may have a safer cardiac toxicity profile than racemic <e1> bupivacaine </e1>, if adequate amounts of levobupivacaine reach the circulation, it will result in <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1216": {"data": {"text": "Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury.\n", "entity1": "adriamycin", "entity2": "cardiac mitochondrial injury", "span1": [46, 56], "span2": [65, 93]}, "bert_text": "Oxidative damage precedes nitrative damage in <e1> adriamycin </e1>-induced <e2> cardiac mitochondrial injury </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1217": {"data": {"text": "A 27-year-old male patient presented with a maculopapular eruption on the flexural areas and buttocks after using oral ketoconazole.", "entity1": "ketoconazole", "entity2": "maculopapular eruption", "span1": [119, 131], "span2": [44, 66]}, "bert_text": "A 27-year-old male patient presented with a maculopapular eruption on the flexural areas and buttocks after using oral <e1> ketoconazole </e1> <e2> maculopapular eruption </e2> on the flexural areas and buttocks after using oral ketoconazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1218": {"data": {"text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.", "entity1": "isoniazid", "entity2": "seizures", "span1": [46, 55], "span2": [312, 320]}, "bert_text": "In animals pretreated with microinjections of <e1> isoniazid </e1>, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic <e2> seizures </e2> and status epilepticus.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1219": {"data": {"text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.", "entity1": "isoniazid", "entity2": "status epilepticus", "span1": [46, 55], "span2": [325, 343]}, "bert_text": "In animals pretreated with microinjections of <e1> isoniazid </e1>, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and <e2> status epilepticus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1220": {"data": {"text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.", "entity1": "GABA", "entity2": "seizures", "span1": [105, 109], "span2": [312, 320]}, "bert_text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the <e1> GABA </e1>-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic <e2> seizures </e2> and status epilepticus.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1221": {"data": {"text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.", "entity1": "GABA", "entity2": "status epilepticus", "span1": [105, 109], "span2": [325, 343]}, "bert_text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the <e1> GABA </e1>-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and <e2> status epilepticus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1222": {"data": {"text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [248, 259], "span2": [312, 320]}, "bert_text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of <e1> pilocarpine </e1>, 100 and 200 mg/kg, resulted in severe motor limbic <e2> seizures </e2> and status epilepticus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1223": {"data": {"text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of pilocarpine, 100 and 200 mg/kg, resulted in severe motor limbic seizures and status epilepticus.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [248, 259], "span2": [325, 343]}, "bert_text": "In animals pretreated with microinjections of isoniazid, 150 micrograms, an inhibitor of activity of the GABA-synthesizing enzyme, L-glutamic acid decarboxylase, into the substantia nigra pars reticulata (SNR), bilaterally, non-convulsant doses of <e1> pilocarpine </e1>, 100 and 200 mg/kg, resulted in severe motor limbic seizures and <e2> status epilepticus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1224": {"data": {"text": "The efficacy of denopamine, an orally active beta 1-adrenoceptor agonist, in improving cardiac failure was assessed in dog heart-lung preparations.", "entity1": "denopamine", "entity2": "cardiac failure", "span1": [16, 26], "span2": [87, 102]}, "bert_text": "The efficacy of <e1> denopamine </e1>, an orally active beta 1-adrenoceptor agonist, in improving <e2> cardiac failure </e2> was assessed in dog heart-lung preparations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1225": {"data": {"text": "Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas.\n", "entity1": "estrogen", "entity2": "hamster renal carcinomas", "span1": [29, 37], "span2": [93, 117]}, "bert_text": "Autoradiographic evidence of <e1> estrogen </e1> binding sites in nuclei of diethylstilbesterol induced <e2> hamster renal carcinomas </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1226": {"data": {"text": "Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas.\n", "entity1": "diethylstilbesterol", "entity2": "hamster renal carcinomas", "span1": [65, 84], "span2": [93, 117]}, "bert_text": "Autoradiographic evidence of estrogen binding sites in nuclei of <e1> diethylstilbesterol </e1> induced <e2> hamster renal carcinomas </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1227": {"data": {"text": "It is concluded that anticholinesterases are only partially effective in restoring neuromuscular function in succinylcholine apnoea despite muscle twitch activity typical of phase II block.", "entity1": "succinylcholine", "entity2": "apnoea", "span1": [109, 124], "span2": [125, 131]}, "bert_text": "It is concluded that anticholinesterases are only partially effective in restoring neuromuscular function in <e1> succinylcholine </e1> <e2> apnoea </e2> despite muscle twitch activity typical of phase II block.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1228": {"data": {"text": "Nineteen patients (48.7%) substantially improved after the 8-week trial; 5 (12.8%) discontinued therapy due to side-effects such as intolerable capsaicin-induced burning sensations (4) or mastitis (1); 15 (38.5%) reported no benefit.", "entity1": "capsaicin", "entity2": "mastitis", "span1": [144, 153], "span2": [188, 196]}, "bert_text": "Nineteen patients (48.7%) substantially improved after the 8-week trial; 5 (12.8%) discontinued therapy due to side-effects such as intolerable <e1> capsaicin </e1>-induced burning sensations (4) or <e2> mastitis </e2> (1); 15 (38.5%) reported no benefit.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1229": {"data": {"text": "The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [55, 66], "span2": [128, 142]}, "bert_text": "The influence of the time interval between monoHER and <e1> doxorubicin </e1> administration on the protection against doxorubicin-induced <e2> cardiotoxicity </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1230": {"data": {"text": "The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [108, 119], "span2": [128, 142]}, "bert_text": "The influence of the time interval between monoHER and doxorubicin administration on the protection against <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1231": {"data": {"text": "First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the lithium-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control seizures in these two models.", "entity1": "MK-801", "entity2": "seizures", "span1": [25, 31], "span2": [237, 245]}, "bert_text": "First, pretreatment with <e1> MK-801 </e1> produced an effective and dose-dependent anticonvulsant action with the lithium-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control <e2> seizures </e2> in these two models.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1232": {"data": {"text": "First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the lithium-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control seizures in these two models.", "entity1": "lithium", "entity2": "seizures", "span1": [104, 111], "span2": [237, 245]}, "bert_text": "First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the <e1> lithium </e1>-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control <e2> seizures </e2> in these two models.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1233": {"data": {"text": "First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the lithium-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control seizures in these two models.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [112, 123], "span2": [237, 245]}, "bert_text": "First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the lithium-<e1> pilocarpine </e1> model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control <e2> seizures </e2> in these two models.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1234": {"data": {"text": "First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the lithium-pilocarpine model but not with rats treated with pilocarpine alone, suggesting that different biochemical mechanisms control seizures in these two models.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [161, 172], "span2": [237, 245]}, "bert_text": "First, pretreatment with MK-801 produced an effective and dose-dependent anticonvulsant action with the lithium-pilocarpine model but not with rats treated with <e1> pilocarpine </e1> alone, suggesting that different biochemical mechanisms control <e2> seizures </e2> in these two models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1235": {"data": {"text": "This is the first reported patient with neuroleptic malignant syndrome probably caused by methylphenidate.", "entity1": "methylphenidate", "entity2": "neuroleptic malignant syndrome", "span1": [90, 105], "span2": [40, 70]}, "bert_text": "This is the first reported patient with neuroleptic malignant syndrome probably caused by <e1> methylphenidate </e1> <e2> neuroleptic malignant syndrome </e2> probably caused by methylphenidate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1236": {"data": {"text": "PURPOSE: Despite its well-known cardiotoxicity, the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent.", "entity1": "anthracyclin doxorubicin", "entity2": "cardiotoxicity", "span1": [52, 76], "span2": [32, 46]}, "bert_text": "PURPOSE: Despite its well-known cardiotoxicity, the <e1> anthracyclin doxorubicin </e1> <e2> cardiotoxicity </e2>, the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1237": {"data": {"text": "PURPOSE: Despite its well-known cardiotoxicity, the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [78, 81], "span2": [32, 46]}, "bert_text": "PURPOSE: Despite its well-known cardiotoxicity, the anthracyclin doxorubicin (<e1> DOX </e1> <e2> cardiotoxicity </e2>, the anthracyclin doxorubicin (DOX) continues to be an effective and widely used chemotherapeutic agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1238": {"data": {"text": "We report a case about a female with essential hypertension on drug treatment with amlodipine developed loss of taste sensation.", "entity1": "amlodipine", "entity2": "hypertension", "span1": [83, 93], "span2": [47, 59]}, "bert_text": "We report a case about a female with essential hypertension on drug treatment with <e1> amlodipine </e1> <e2> hypertension </e2> on drug treatment with amlodipine developed loss of taste sensation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1239": {"data": {"text": "We report a case about a female with essential hypertension on drug treatment with amlodipine developed loss of taste sensation.", "entity1": "amlodipine", "entity2": "loss of taste sensation", "span1": [83, 93], "span2": [104, 127]}, "bert_text": "We report a case about a female with essential hypertension on drug treatment with <e1> amlodipine </e1> developed <e2> loss of taste sensation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1240": {"data": {"text": "Thus, the investigations did not provide any evidence that the beta-receptor blockers propranolol and B 24/76 have the potency to prevent isoproterenol from producing heart hypertrophy.", "entity1": "propranolol", "entity2": "hypertrophy", "span1": [86, 97], "span2": [173, 184]}, "bert_text": "Thus, the investigations did not provide any evidence that the beta-receptor blockers <e1> propranolol </e1> and B 24/76 have the potency to prevent isoproterenol from producing heart <e2> hypertrophy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1241": {"data": {"text": "Thus, the investigations did not provide any evidence that the beta-receptor blockers propranolol and B 24/76 have the potency to prevent isoproterenol from producing heart hypertrophy.", "entity1": "isoproterenol", "entity2": "hypertrophy", "span1": [138, 151], "span2": [173, 184]}, "bert_text": "Thus, the investigations did not provide any evidence that the beta-receptor blockers propranolol and B 24/76 have the potency to prevent <e1> isoproterenol </e1> from producing heart <e2> hypertrophy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1242": {"data": {"text": "Brain injury (percentage of the ischemic hemisphere) was less in the 15/HTN group (16 +/-", "entity1": "15/HTN", "entity2": "Brain injury", "span1": [69, 75], "span2": [0, 12]}, "bert_text": "Brain injury (percentage of the ischemic hemisphere) was less in the <e1> 15/HTN </e1> <e2> Brain injury </e2> (percentage of the ischemic hemisphere) was less in the 15/HTN group (16 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1243": {"data": {"text": "Brain injury (percentage of the ischemic hemisphere) was less in the 15/HTN group (16 +/-", "entity1": "15/HTN", "entity2": "ischemic", "span1": [69, 75], "span2": [32, 40]}, "bert_text": "Brain injury (percentage of the ischemic hemisphere) was less in the <e1> 15/HTN </e1> <e2> ischemic </e2> hemisphere) was less in the 15/HTN group (16 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1244": {"data": {"text": "The myocardial content of catecholamines was estimated in these 8 day diabetic rats.", "entity1": "catecholamines", "entity2": "diabetic", "span1": [26, 40], "span2": [70, 78]}, "bert_text": "The myocardial content of <e1> catecholamines </e1> was estimated in these 8 day <e2> diabetic </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1245": {"data": {"text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "entity1": "trazodone", "entity2": "catalepsy", "span1": [41, 50], "span2": [116, 125]}, "bert_text": "METHODS: The effect of pretreatment with <e1> trazodone </e1> on dexamphetamine- and apomorphine-induced oral stereotypies, on <e2> catalepsy </e2> induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1246": {"data": {"text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "entity1": "dexamphetamine-", "entity2": "catalepsy", "span1": [54, 69], "span2": [116, 125]}, "bert_text": "METHODS: The effect of pretreatment with trazodone on <e1> dexamphetamine- </e1> and apomorphine-induced oral stereotypies, on <e2> catalepsy </e2> induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1247": {"data": {"text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [74, 85], "span2": [116, 125]}, "bert_text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and <e1> apomorphine </e1>-induced oral stereotypies, on <e2> catalepsy </e2> induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1248": {"data": {"text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [153, 164], "span2": [116, 125]}, "bert_text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and <e1> apomorphine </e1> <e2> catalepsy </e2> induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1249": {"data": {"text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [137, 148], "span2": [116, 125]}, "bert_text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by <e1> haloperidol </e1> <e2> catalepsy </e2> induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1250": {"data": {"text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "entity1": "ergometrine", "entity2": "catalepsy", "span1": [188, 199], "span2": [116, 125]}, "bert_text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on <e1> ergometrine </e1> <e2> catalepsy </e2> induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1251": {"data": {"text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "entity1": "fluoxetine", "entity2": "catalepsy", "span1": [241, 251], "span2": [116, 125]}, "bert_text": "METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and <e1> fluoxetine </e1> <e2> catalepsy </e2> induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1252": {"data": {"text": "On day 8, the patient developed acute renal failure (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission).", "entity1": "creatinine", "entity2": "acute renal failure", "span1": [59, 69], "span2": [32, 51]}, "bert_text": "On day 8, the patient developed acute renal failure (serum <e1> creatinine </e1> <e2> acute renal failure </e2> (serum creatinine 1.9 mg/dL, increased from 1.2 mg/dL the previous day and 0.8 mg/dL on admission).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1253": {"data": {"text": "The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine-induced hypotension and bradycardia.", "entity1": "clonidine", "entity2": "hypotension", "span1": [88, 97], "span2": [106, 117]}, "bert_text": "The data indicate that a bulbospinal serotonergic pathway is involved in development of <e1> clonidine </e1>-induced <e2> hypotension </e2> and bradycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1254": {"data": {"text": "The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine-induced hypotension and bradycardia.", "entity1": "clonidine", "entity2": "bradycardia", "span1": [88, 97], "span2": [122, 133]}, "bert_text": "The data indicate that a bulbospinal serotonergic pathway is involved in development of <e1> clonidine </e1>-induced hypotension and <e2> bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1255": {"data": {"text": "An increase in TDR by dl-sotalol facilitated transmural propagation of EADs that initiated multiple episodes of spontaneous TdP in 3 of 6 rabbit left ventricles.", "entity1": "dl-sotalol", "entity2": "TdP", "span1": [22, 32], "span2": [124, 127]}, "bert_text": "An increase in TDR by <e1> dl-sotalol </e1> facilitated transmural propagation of EADs that initiated multiple episodes of spontaneous <e2> TdP </e2> in 3 of 6 rabbit left ventricles.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1256": {"data": {"text": "Pubertal exposure to Bisphenol A increases anxiety-like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice.\n", "entity1": "Bisphenol A", "entity2": "anxiety", "span1": [21, 32], "span2": [43, 50]}, "bert_text": "Pubertal exposure to <e1> Bisphenol A </e1> increases <e2> anxiety </e2>-like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1257": {"data": {"text": "Two hundred four people with epilepsy were grouped on the basis of antiepileptic drug therapy (current, previous, or no exposure to VGB).", "entity1": "VGB", "entity2": "epilepsy", "span1": [132, 135], "span2": [29, 37]}, "bert_text": "Two hundred four people with epilepsy were grouped on the basis of antiepileptic drug therapy (current, previous, or no exposure to <e1> VGB </e1> <e2> epilepsy </e2> were grouped on the basis of antiepileptic drug therapy (current, previous, or no exposure to VGB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1258": {"data": {"text": "Fluoxetine, a selective serotonin reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression.", "entity1": "Fluoxetine", "entity2": "depression", "span1": [0, 10], "span2": [117, 127]}, "bert_text": "<e1> Fluoxetine </e1>, a selective serotonin reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent <e2> depression </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1259": {"data": {"text": "Fluoxetine, a selective serotonin reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent depression.", "entity1": "serotonin", "entity2": "depression", "span1": [24, 33], "span2": [117, 127]}, "bert_text": "Fluoxetine, a selective <e1> serotonin </e1> reuptake inhibitor, is gaining increased acceptance in the treatment of adolescent <e2> depression </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1260": {"data": {"text": "Hyperprolactinemia was induced by treatment with haloperidol, a dopamine receptor antagonist, and Palkovits' microdissection technique in combination with high-performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain.", "entity1": "haloperidol", "entity2": "Hyperprolactinemia", "span1": [49, 60], "span2": [0, 18]}, "bert_text": "Hyperprolactinemia was induced by treatment with <e1> haloperidol </e1> <e2> Hyperprolactinemia </e2> was induced by treatment with haloperidol, a dopamine receptor antagonist, and Palkovits' microdissection technique in combination with high-performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1261": {"data": {"text": "Hyperprolactinemia was induced by treatment with haloperidol, a dopamine receptor antagonist, and Palkovits' microdissection technique in combination with high-performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain.", "entity1": "dopamine", "entity2": "Hyperprolactinemia", "span1": [64, 72], "span2": [0, 18]}, "bert_text": "Hyperprolactinemia was induced by treatment with haloperidol, a <e1> dopamine </e1> <e2> Hyperprolactinemia </e2> was induced by treatment with haloperidol, a dopamine receptor antagonist, and Palkovits' microdissection technique in combination with high-performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1262": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "all-trans-retinoic acid", "entity2": "acute renal failure", "span1": [131, 154], "span2": [10, 29]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with <e1> all-trans-retinoic acid </e1> <e2> acute renal failure </e2>, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1263": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "all-trans-retinoic acid", "entity2": "occlusion of renal vessels", "span1": [131, 154], "span2": [38, 64]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with <e1> all-trans-retinoic acid </e1> <e2> occlusion of renal vessels </e2> in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1264": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "all-trans-retinoic acid", "entity2": "acute promyelocytic leukemia", "span1": [131, 154], "span2": [83, 111]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with <e1> all-trans-retinoic acid </e1> <e2> acute promyelocytic leukemia </e2> (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1265": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "all-trans-retinoic acid", "entity2": "APL", "span1": [131, 154], "span2": [113, 116]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with <e1> all-trans-retinoic acid </e1> <e2> APL </e2>) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1266": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "ATRA", "entity2": "acute renal failure", "span1": [156, 160], "span2": [10, 29]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (<e1> ATRA </e1> <e2> acute renal failure </e2>, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1267": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "ATRA", "entity2": "occlusion of renal vessels", "span1": [156, 160], "span2": [38, 64]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (<e1> ATRA </e1> <e2> occlusion of renal vessels </e2> in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1268": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "ATRA", "entity2": "acute promyelocytic leukemia", "span1": [156, 160], "span2": [83, 111]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (<e1> ATRA </e1> <e2> acute promyelocytic leukemia </e2> (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1269": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "ATRA", "entity2": "APL", "span1": [156, 160], "span2": [113, 116]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (<e1> ATRA </e1> <e2> APL </e2>) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1270": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "tranexamic acid", "entity2": "acute renal failure", "span1": [166, 181], "span2": [10, 29]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and <e1> tranexamic acid </e1> <e2> acute renal failure </e2>, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1271": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "tranexamic acid", "entity2": "occlusion of renal vessels", "span1": [166, 181], "span2": [38, 64]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and <e1> tranexamic acid </e1> <e2> occlusion of renal vessels </e2> in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1272": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "tranexamic acid", "entity2": "acute promyelocytic leukemia", "span1": [166, 181], "span2": [83, 111]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and <e1> tranexamic acid </e1> <e2> acute promyelocytic leukemia </e2> (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1273": {"data": {"text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "entity1": "tranexamic acid", "entity2": "APL", "span1": [166, 181], "span2": [113, 116]}, "bert_text": "A case of acute renal failure, due to occlusion of renal vessels in a patient with acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and <e1> tranexamic acid </e1> <e2> APL </e2>) treated with all-trans-retinoic acid (ATRA) and tranexamic acid has been described recently.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1274": {"data": {"text": "Damage of substantia nigra pars reticulata during pilocarpine-induced status epilepticus in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation.\n", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [50, 61], "span2": [70, 88]}, "bert_text": "Damage of substantia nigra pars reticulata during <e1> pilocarpine </e1>-induced <e2> status epilepticus </e2> in the rat: immunohistochemical study of neurons, astrocytes and serum-protein extravasation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1275": {"data": {"text": "Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy.\n", "entity1": "all-trans-retinoic acid", "entity2": "Thrombotic complications", "span1": [64, 87], "span2": [0, 24]}, "bert_text": "Thrombotic complications in acute promyelocytic leukemia during <e1> all-trans-retinoic acid </e1> <e2> Thrombotic complications </e2> in acute promyelocytic leukemia during all-trans-retinoic acid therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1276": {"data": {"text": "Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy.\n", "entity1": "all-trans-retinoic acid", "entity2": "acute promyelocytic leukemia", "span1": [64, 87], "span2": [28, 56]}, "bert_text": "Thrombotic complications in acute promyelocytic leukemia during <e1> all-trans-retinoic acid </e1> <e2> acute promyelocytic leukemia </e2> during all-trans-retinoic acid therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1277": {"data": {"text": "Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.\n", "entity1": "temsirolimus", "entity2": "mantle cell lymphoma", "span1": [42, 54], "span2": [69, 89]}, "bert_text": "Cytostatic and anti-angiogenic effects of <e1> temsirolimus </e1> in refractory <e2> mantle cell lymphoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1278": {"data": {"text": "This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.", "entity1": "bort", "entity2": "MM", "span1": [57, 61], "span2": [212, 214]}, "bert_text": "This retrospective study investigated the combination of <e1> bort </e1> (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R <e2> MM </e2> after prior autologous stem cell transplantation or conventional chemotherapy.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1279": {"data": {"text": "This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.", "entity1": "bort", "entity2": "MM", "span1": [161, 165], "span2": [212, 214]}, "bert_text": "This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after <e1> bort </e1>) as salvage treatment in 85 patients with R/R <e2> MM </e2> after prior autologous stem cell transplantation or conventional chemotherapy.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1280": {"data": {"text": "This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and dex (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R MM after prior autologous stem cell transplantation or conventional chemotherapy.", "entity1": "dex", "entity2": "MM", "span1": [118, 121], "span2": [212, 214]}, "bert_text": "This retrospective study investigated the combination of bort (1.3 mg/m(2) on days 1, 4, 8, and 11 every 3 weeks) and <e1> dex </e1> (20 mg on the day of and the day after bort) as salvage treatment in 85 patients with R/R <e2> MM </e2> after prior autologous stem cell transplantation or conventional chemotherapy.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1281": {"data": {"text": "Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [33, 49], "span2": [9, 17]}, "bert_text": "Chemical cystitis was induced by <e1> cyclophosphamide </e1> <e2> cystitis </e2> was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1282": {"data": {"text": "Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.", "entity1": "CYP", "entity2": "cystitis", "span1": [51, 54], "span2": [9, 17]}, "bert_text": "Chemical cystitis was induced by cyclophosphamide (<e1> CYP </e1> <e2> cystitis </e2> was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1283": {"data": {"text": "Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.", "entity1": "acrolein", "entity2": "cystitis", "span1": [80, 88], "span2": [9, 17]}, "bert_text": "Chemical cystitis was induced by cyclophosphamide (CYP) which is metabolized to <e1> acrolein </e1> <e2> cystitis </e2> was induced by cyclophosphamide (CYP) which is metabolized to acrolein, an irritant eliminated in the urine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1284": {"data": {"text": "These cases call attention to possible paranoid exacerbations with serotonin reuptake blockers in select patients and raise neurobiological considerations regarding paranoia.", "entity1": "serotonin", "entity2": "paranoid", "span1": [67, 76], "span2": [39, 47]}, "bert_text": "These cases call attention to possible paranoid exacerbations with <e1> serotonin </e1> <e2> paranoid </e2> exacerbations with serotonin reuptake blockers in select patients and raise neurobiological considerations regarding paranoia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1285": {"data": {"text": "These cases call attention to possible paranoid exacerbations with serotonin reuptake blockers in select patients and raise neurobiological considerations regarding paranoia.", "entity1": "serotonin", "entity2": "paranoia", "span1": [67, 76], "span2": [165, 173]}, "bert_text": "These cases call attention to possible paranoid exacerbations with <e1> serotonin </e1> reuptake blockers in select patients and raise neurobiological considerations regarding <e2> paranoia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1286": {"data": {"text": "Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.\n", "entity1": "sodium pentobarbital", "entity2": "Cardiovascular dysfunction", "span1": [51, 71], "span2": [0, 26]}, "bert_text": "Cardiovascular dysfunction and hypersensitivity to <e1> sodium pentobarbital </e1> <e2> Cardiovascular dysfunction </e2> and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1287": {"data": {"text": "Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.\n", "entity1": "sodium pentobarbital", "entity2": "hypersensitivity", "span1": [51, 71], "span2": [31, 47]}, "bert_text": "Cardiovascular dysfunction and hypersensitivity to <e1> sodium pentobarbital </e1> <e2> hypersensitivity </e2> to sodium pentobarbital induced by chronic barium chloride ingestion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1288": {"data": {"text": "Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.\n", "entity1": "barium chloride", "entity2": "Cardiovascular dysfunction", "span1": [91, 106], "span2": [0, 26]}, "bert_text": "Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic <e1> barium chloride </e1> <e2> Cardiovascular dysfunction </e2> and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1289": {"data": {"text": "Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion.\n", "entity1": "barium chloride", "entity2": "hypersensitivity", "span1": [91, 106], "span2": [31, 47]}, "bert_text": "Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic <e1> barium chloride </e1> <e2> hypersensitivity </e2> to sodium pentobarbital induced by chronic barium chloride ingestion.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1290": {"data": {"text": "The abolition of muscle fasciculations (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain.", "entity1": "Fazadinium", "entity2": "muscle fasciculations", "span1": [62, 72], "span2": [17, 38]}, "bert_text": "The abolition of muscle fasciculations (by 0.075mg/kg dose of <e1> Fazadinium </e1> <e2> muscle fasciculations </e2> (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1291": {"data": {"text": "The abolition of muscle fasciculations (by 0.075mg/kg dose of Fazadinium) did not influence the occurrence of scoline pain.", "entity1": "Fazadinium", "entity2": "pain", "span1": [62, 72], "span2": [118, 122]}, "bert_text": "The abolition of muscle fasciculations (by 0.075mg/kg dose of <e1> Fazadinium </e1>) did not influence the occurrence of scoline <e2> pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1292": {"data": {"text": "infusion of clonazepam; none had any neurological symptoms.", "entity1": "clonazepam", "entity2": "neurological symptoms", "span1": [12, 22], "span2": [37, 58]}, "bert_text": "infusion of <e1> clonazepam </e1>; none had any <e2> neurological symptoms </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"1293": {"data": {"text": "OBJECTIVE: We wanted to test whether assessment of both a central pain-related signal (chemo-somatosensory evoked potential, CSSEP) and a concomitantly recorded peripheral signal (negative mucosal potential, NMP) allows for separation of central and peripheral effects of NSAIDs.", "entity1": "NMP", "entity2": "pain", "span1": [208, 211], "span2": [66, 70]}, "bert_text": "OBJECTIVE: We wanted to test whether assessment of both a central pain-related signal (chemo-somatosensory evoked potential, CSSEP) and a concomitantly recorded peripheral signal (negative mucosal potential, <e1> NMP </e1> <e2> pain </e2>-related signal (chemo-somatosensory evoked potential, CSSEP) and a concomitantly recorded peripheral signal (negative mucosal potential, NMP) allows for separation of central and peripheral effects of NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1294": {"data": {"text": "We describe 2 cases of grand mal seizures following accidental intravascular injection of levobupivacaine.", "entity1": "levobupivacaine", "entity2": "seizures", "span1": [90, 105], "span2": [33, 41]}, "bert_text": "We describe 2 cases of grand mal seizures following accidental intravascular injection of <e1> levobupivacaine </e1> <e2> seizures </e2> following accidental intravascular injection of levobupivacaine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1295": {"data": {"text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "entity1": "SNP(single", "entity2": "schizophrenic", "span1": [29, 39], "span2": [155, 168]}, "bert_text": "METHODS: We identified seven <e1> SNP(single </e1> nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 <e2> schizophrenic </e2> inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1296": {"data": {"text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "entity1": "SNP(single", "entity2": "EPS", "span1": [29, 39], "span2": [189, 192]}, "bert_text": "METHODS: We identified seven <e1> SNP(single </e1> nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with <e2> EPS </e2> and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1297": {"data": {"text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "entity1": "SNP(single", "entity2": "EPS", "span1": [29, 39], "span2": [208, 211]}, "bert_text": "METHODS: We identified seven <e1> SNP(single </e1> nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without <e2> EPS </e2> according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1298": {"data": {"text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "entity1": "nucleotide", "entity2": "schizophrenic", "span1": [40, 50], "span2": [155, 168]}, "bert_text": "METHODS: We identified seven SNP(single <e1> nucleotide </e1> polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 <e2> schizophrenic </e2> inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1299": {"data": {"text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "entity1": "nucleotide", "entity2": "EPS", "span1": [40, 50], "span2": [189, 192]}, "bert_text": "METHODS: We identified seven SNP(single <e1> nucleotide </e1> polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with <e2> EPS </e2> and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1300": {"data": {"text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "entity1": "nucleotide", "entity2": "EPS", "span1": [40, 50], "span2": [208, 211]}, "bert_text": "METHODS: We identified seven SNP(single <e1> nucleotide </e1> polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without <e2> EPS </e2> according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1301": {"data": {"text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "entity1": "chlorpromazine", "entity2": "schizophrenic", "span1": [263, 277], "span2": [155, 168]}, "bert_text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with <e1> chlorpromazine </e1> <e2> schizophrenic </e2> inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1302": {"data": {"text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "entity1": "chlorpromazine", "entity2": "EPS", "span1": [263, 277], "span2": [189, 192]}, "bert_text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with <e1> chlorpromazine </e1> <e2> EPS </e2> and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1303": {"data": {"text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "entity1": "chlorpromazine", "entity2": "EPS", "span1": [263, 277], "span2": [208, 211]}, "bert_text": "METHODS: We identified seven SNP(single nucleotide polymorphism) (-141Cins>del, TaqIB, TaqID, Ser311Cys, rs6275, rs6277 and TaqIA) in the DRD2 gene in 146 schizophrenic inpatients (59 with EPS and 87 without EPS according to the Simpson-Angus Scale) treated with <e1> chlorpromazine </e1> <e2> EPS </e2> according to the Simpson-Angus Scale) treated with chlorpromazine after 8 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1304": {"data": {"text": "Bortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies.", "entity1": "Bortezomib", "entity2": "infections", "span1": [0, 10], "span2": [126, 136]}, "bert_text": "<e1> Bortezomib </e1> and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial <e2> infections </e2> in patients with B-cell malignancies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1305": {"data": {"text": "Bortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies.", "entity1": "Bortezomib", "entity2": "malignancies", "span1": [0, 10], "span2": [161, 173]}, "bert_text": "<e1> Bortezomib </e1> and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell <e2> malignancies </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1306": {"data": {"text": "Bortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies.", "entity1": "dexamethasone", "entity2": "infections", "span1": [25, 38], "span2": [126, 136]}, "bert_text": "Bortezomib and high-dose <e1> dexamethasone </e1>-containing regimens are considered to be generally tolerable with few severe bacterial <e2> infections </e2> in patients with B-cell malignancies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1307": {"data": {"text": "Bortezomib and high-dose dexamethasone-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell malignancies.", "entity1": "dexamethasone", "entity2": "malignancies", "span1": [25, 38], "span2": [161, 173]}, "bert_text": "Bortezomib and high-dose <e1> dexamethasone </e1>-containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B-cell <e2> malignancies </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1308": {"data": {"text": "In order to quantify the incidence of these cardiac events, we performed a meta-analysis of clinical trials comparing VNR with other chemotherapeutic agents in the treatment of various malignancies.", "entity1": "VNR", "entity2": "malignancies", "span1": [118, 121], "span2": [185, 197]}, "bert_text": "In order to quantify the incidence of these cardiac events, we performed a meta-analysis of clinical trials comparing <e1> VNR </e1> with other chemotherapeutic agents in the treatment of various <e2> malignancies </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1309": {"data": {"text": "Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and niacin extended-release/lovastatin.", "entity1": "niacin", "entity2": "dyslipidemia", "span1": [162, 168], "span2": [145, 157]}, "bert_text": "Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and <e1> niacin </e1> <e2> dyslipidemia </e2> and niacin extended-release/lovastatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1310": {"data": {"text": "Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and niacin extended-release/lovastatin.", "entity1": "lovastatin", "entity2": "dyslipidemia", "span1": [186, 196], "span2": [145, 157]}, "bert_text": "Patients also received dietary counseling, educational materials, and reminders to call a toll-free number that provided further education about dyslipidemia and niacin extended-release/<e1> lovastatin </e1> <e2> dyslipidemia </e2> and niacin extended-release/lovastatin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1311": {"data": {"text": "We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of suxamethonium.", "entity1": "suxamethonium", "entity2": "muscle spasm", "span1": [174, 187], "span2": [84, 96]}, "bert_text": "We describe a previously healthy 32-year-old woman who developed a life-threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of <e1> suxamethonium </e1> <e2> muscle spasm </e2> and secondary ventilation difficulties following a preoperative injection of suxamethonium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1312": {"data": {"text": "RESULTS: Acetaminophen-induced ALF patients undergoing LT had a greater severity of pre-LT illness reflected by higher Acute Physiology and Chronic Health Evaluation II scores and requirement for organ support compared with the other two groups.", "entity1": "Acetaminophen", "entity2": "ALF", "span1": [9, 22], "span2": [31, 34]}, "bert_text": "RESULTS: <e1> Acetaminophen </e1>-induced <e2> ALF </e2> patients undergoing LT had a greater severity of pre-LT illness reflected by higher Acute Physiology and Chronic Health Evaluation II scores and requirement for organ support compared with the other two groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1313": {"data": {"text": "A flurothyl ether seizure screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g).", "entity1": "flurothyl", "entity2": "seizure", "span1": [2, 11], "span2": [18, 25]}, "bert_text": "A <e1> flurothyl </e1> ether <e2> seizure </e2> screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1314": {"data": {"text": "A flurothyl ether seizure screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g).", "entity1": "flurothyl", "entity2": "seizure", "span1": [2, 11], "span2": [67, 74]}, "bert_text": "A <e1> flurothyl </e1> ether seizure screening technique was used to evaluate <e2> seizure </e2> susceptibility in adult mice that received neonatal injections of MSG (4 mg/g and 1 mg/g).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1315": {"data": {"text": "It is concluded that PAP formation, in vivo, accounts, at least in part, for APAP-induced renal tubular necrosis.", "entity1": "PAP", "entity2": "renal tubular necrosis", "span1": [21, 24], "span2": [90, 112]}, "bert_text": "It is concluded that <e1> PAP </e1> formation, in vivo, accounts, at least in part, for APAP-induced <e2> renal tubular necrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1316": {"data": {"text": "It is concluded that PAP formation, in vivo, accounts, at least in part, for APAP-induced renal tubular necrosis.", "entity1": "APAP", "entity2": "renal tubular necrosis", "span1": [77, 81], "span2": [90, 112]}, "bert_text": "It is concluded that PAP formation, in vivo, accounts, at least in part, for <e1> APAP </e1>-induced <e2> renal tubular necrosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1317": {"data": {"text": "Generally safe and well tolerated by adults, fluoxetine has been reported to induce mania.", "entity1": "fluoxetine", "entity2": "mania", "span1": [45, 55], "span2": [84, 89]}, "bert_text": "Generally safe and well tolerated by adults, <e1> fluoxetine </e1> has been reported to induce <e2> mania </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1318": {"data": {"text": "Valproate-induced hyperammonemic encephalopathy in a renal transplanted patient.\n", "entity1": "Valproate", "entity2": "hyperammonemic encephalopathy", "span1": [0, 9], "span2": [18, 47]}, "bert_text": "<e1> Valproate </e1>-induced <e2> hyperammonemic encephalopathy </e2> in a renal transplanted patient.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1319": {"data": {"text": "Progressive bile duct injury after thiabendazole administration.\n", "entity1": "thiabendazole", "entity2": "bile duct injury", "span1": [35, 48], "span2": [12, 28]}, "bert_text": "Progressive bile duct injury after <e1> thiabendazole </e1> <e2> bile duct injury </e2> after thiabendazole administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1320": {"data": {"text": "Amoxicillin-clavulanate stands out as the most common drug related to DILI.", "entity1": "Amoxicillin-clavulanate", "entity2": "DILI", "span1": [0, 23], "span2": [70, 74]}, "bert_text": "<e1> Amoxicillin-clavulanate </e1> stands out as the most common drug related to <e2> DILI </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1321": {"data": {"text": "Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.\n", "entity1": "Amiodarone", "entity2": "bradyarrhythmia", "span1": [0, 10], "span2": [27, 42]}, "bert_text": "<e1> Amiodarone </e1> and the risk of <e2> bradyarrhythmia </e2> requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1322": {"data": {"text": "Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.\n", "entity1": "Amiodarone", "entity2": "atrial fibrillation", "span1": [0, 10], "span2": [98, 117]}, "bert_text": "<e1> Amiodarone </e1> and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with <e2> atrial fibrillation </e2> and prior myocardial infarction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1323": {"data": {"text": "Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.\n", "entity1": "Amiodarone", "entity2": "myocardial infarction", "span1": [0, 10], "span2": [128, 149]}, "bert_text": "<e1> Amiodarone </e1> and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1324": {"data": {"text": "Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.", "entity1": "losartan", "entity2": "glomerulosclerosis", "span1": [25, 33], "span2": [62, 80]}, "bert_text": "Prolonged treatment with <e1> losartan </e1> showed further reduction of <e2> glomerulosclerosis </e2> associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1325": {"data": {"text": "Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.", "entity1": "losartan", "entity2": "tubular atrophy", "span1": [25, 33], "span2": [120, 135]}, "bert_text": "Prolonged treatment with <e1> losartan </e1> showed further reduction of glomerulosclerosis associated with reduced progression of <e2> tubular atrophy </e2> and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1326": {"data": {"text": "Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.", "entity1": "losartan", "entity2": "fibrosis", "span1": [25, 33], "span2": [153, 161]}, "bert_text": "Prolonged treatment with <e1> losartan </e1> showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial <e2> fibrosis </e2>, thus preventing heavy proteinuria and chronic renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1327": {"data": {"text": "Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.", "entity1": "losartan", "entity2": "proteinuria", "span1": [25, 33], "span2": [185, 196]}, "bert_text": "Prolonged treatment with <e1> losartan </e1> showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy <e2> proteinuria </e2> and chronic renal failure.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1328": {"data": {"text": "Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and chronic renal failure.", "entity1": "losartan", "entity2": "chronic renal failure", "span1": [25, 33], "span2": [201, 222]}, "bert_text": "Prolonged treatment with <e1> losartan </e1> showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis, thus preventing heavy proteinuria and <e2> chronic renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1329": {"data": {"text": "METHODS: This is a cross-sectional study involving 95 patients with PD on uninterrupted levodopa therapy for at least 6 months.", "entity1": "levodopa", "entity2": "PD", "span1": [88, 96], "span2": [68, 70]}, "bert_text": "METHODS: This is a cross-sectional study involving 95 patients with PD on uninterrupted <e1> levodopa </e1> <e2> PD </e2> on uninterrupted levodopa therapy for at least 6 months.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1330": {"data": {"text": "To our knowledge, this is the first published case report of severe neurotoxicity caused by nelarabine in a patient who received concurrent IT chemotherapy.", "entity1": "nelarabine", "entity2": "neurotoxicity", "span1": [92, 102], "span2": [68, 81]}, "bert_text": "To our knowledge, this is the first published case report of severe neurotoxicity caused by <e1> nelarabine </e1> <e2> neurotoxicity </e2> caused by nelarabine in a patient who received concurrent IT chemotherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1331": {"data": {"text": "Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report.\n", "entity1": "tacrolimus", "entity2": "scleroderma renal crisis", "span1": [47, 57], "span2": [11, 35]}, "bert_text": "Late-onset scleroderma renal crisis induced by <e1> tacrolimus </e1> <e2> scleroderma renal crisis </e2> induced by tacrolimus and prednisolone: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1332": {"data": {"text": "Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report.\n", "entity1": "prednisolone", "entity2": "scleroderma renal crisis", "span1": [62, 74], "span2": [11, 35]}, "bert_text": "Late-onset scleroderma renal crisis induced by tacrolimus and <e1> prednisolone </e1> <e2> scleroderma renal crisis </e2> induced by tacrolimus and prednisolone: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1333": {"data": {"text": "Light microscopic evidence of renal damage was seen above a dose of 0.5 mg doxorubicin/kg, which resulted in albuminuria and very low serum albumin levels.", "entity1": "doxorubicin", "entity2": "renal damage", "span1": [75, 86], "span2": [30, 42]}, "bert_text": "Light microscopic evidence of renal damage was seen above a dose of 0.5 mg <e1> doxorubicin </e1> <e2> renal damage </e2> was seen above a dose of 0.5 mg doxorubicin/kg, which resulted in albuminuria and very low serum albumin levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1334": {"data": {"text": "Light microscopic evidence of renal damage was seen above a dose of 0.5 mg doxorubicin/kg, which resulted in albuminuria and very low serum albumin levels.", "entity1": "doxorubicin", "entity2": "albuminuria", "span1": [75, 86], "span2": [109, 120]}, "bert_text": "Light microscopic evidence of renal damage was seen above a dose of 0.5 mg <e1> doxorubicin </e1>/kg, which resulted in <e2> albuminuria </e2> and very low serum albumin levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1335": {"data": {"text": "At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug-drug interaction was suspected.", "entity1": "simvastatin", "entity2": "toxicity", "span1": [13, 24], "span2": [75, 83]}, "bert_text": "At admission <e1> simvastatin </e1> and all antiviral drugs were discontinued because <e2> toxicity </e2> due to a drug-drug interaction was suspected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1336": {"data": {"text": "IMPLICATIONS: This case documents a patient who developed dizziness with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia morphine.", "entity1": "morphine", "entity2": "dizziness", "span1": [170, 178], "span2": [58, 67]}, "bert_text": "IMPLICATIONS: This case documents a patient who developed dizziness with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia <e1> morphine </e1> <e2> dizziness </e2> with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia morphine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1337": {"data": {"text": "IMPLICATIONS: This case documents a patient who developed dizziness with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia morphine.", "entity1": "morphine", "entity2": "nystagmus", "span1": [170, 178], "span2": [85, 94]}, "bert_text": "IMPLICATIONS: This case documents a patient who developed dizziness with downbeating nystagmus while receiving a relatively large dose of IV patient-controlled analgesia <e1> morphine </e1> <e2> nystagmus </e2> while receiving a relatively large dose of IV patient-controlled analgesia morphine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1338": {"data": {"text": "After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become arrhythmic), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.", "entity1": "bupivacaine", "entity2": "arrhythmic", "span1": [22, 33], "span2": [141, 151]}, "bert_text": "After determining the <e1> bupivacaine </e1> AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become <e2> arrhythmic </e2>), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1339": {"data": {"text": "After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become arrhythmic), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.", "entity1": "bupivacaine", "entity2": "arrhythmic", "span1": [61, 72], "span2": [141, 151]}, "bert_text": "After determining the bupivacaine AD50 (the concentration of <e1> bupivacaine </e1> that caused 50% of all beating rat heart myocyte cultures to become <e2> arrhythmic </e2>), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1340": {"data": {"text": "After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become arrhythmic), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.", "entity1": "progesterone HCl", "entity2": "arrhythmic", "span1": [189, 205], "span2": [141, 151]}, "bert_text": "After determining the bupivacaine AD50 (the concentration of bupivacaine that caused 50% of all beating rat heart myocyte cultures to become arrhythmic), we determined the effect of 1-hour <e1> progesterone HCl </e1> <e2> arrhythmic </e2>), we determined the effect of 1-hour progesterone HCl exposure on myocyte contractile rhythm.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1341": {"data": {"text": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "entity1": "Simvastatin", "entity2": "muscle toxicity", "span1": [0, 11], "span2": [87, 102]}, "bert_text": "<e1> Simvastatin </e1> plasma concentration increased 30 times in this patient and statin induced <e2> muscle toxicity </e2> is related to the concentration of the statin in blood.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1342": {"data": {"text": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "entity1": "statin", "entity2": "muscle toxicity", "span1": [72, 78], "span2": [87, 102]}, "bert_text": "Simvastatin plasma concentration increased 30 times in this patient and <e1> statin </e1> induced <e2> muscle toxicity </e2> is related to the concentration of the statin in blood.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1343": {"data": {"text": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood.", "entity1": "statin", "entity2": "muscle toxicity", "span1": [142, 148], "span2": [87, 102]}, "bert_text": "Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the <e1> statin </e1> <e2> muscle toxicity </e2> is related to the concentration of the statin in blood.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1344": {"data": {"text": "Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during Ara-C infusion to ten patients, including the four who developed the syndrome.", "entity1": "Ara", "entity2": "TNF", "span1": [78, 81], "span2": [44, 47]}, "bert_text": "Sequential biological assays of IL-1, IL-2, TNF and PAF were performed during <e1> Ara </e1> <e2> TNF </e2> and PAF were performed during Ara-C infusion to ten patients, including the four who developed the syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1345": {"data": {"text": "Neuroleptic drugs such as haloperidol, which block dopamine receptors, also cause catalepsy in rodents.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [26, 37], "span2": [82, 91]}, "bert_text": "Neuroleptic drugs such as <e1> haloperidol </e1>, which block dopamine receptors, also cause <e2> catalepsy </e2> in rodents.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1346": {"data": {"text": "Neuroleptic drugs such as haloperidol, which block dopamine receptors, also cause catalepsy in rodents.", "entity1": "dopamine", "entity2": "catalepsy", "span1": [51, 59], "span2": [82, 91]}, "bert_text": "Neuroleptic drugs such as haloperidol, which block <e1> dopamine </e1> receptors, also cause <e2> catalepsy </e2> in rodents.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1347": {"data": {"text": "Phenytoin encephalopathy as probable idiosyncratic reaction: case report.\n", "entity1": "Phenytoin", "entity2": "encephalopathy", "span1": [0, 9], "span2": [10, 24]}, "bert_text": "<e1> Phenytoin </e1> <e2> encephalopathy </e2> as probable idiosyncratic reaction: case report.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1348": {"data": {"text": "Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels.", "entity1": "paclitaxel", "entity2": "Toxicities", "span1": [73, 83], "span2": [0, 10]}, "bert_text": "Toxicities were compared with a cohort of patients in a phase I trial of <e1> paclitaxel </e1> <e2> Toxicities </e2> were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1349": {"data": {"text": "Similarly, significant disturbances in myocardial energy metabolism were detected in the barium-exposed rats which were consistent with the reduced contractile element shortening velocity.", "entity1": "barium", "entity2": "disturbances in myocardial energy metabolism", "span1": [89, 95], "span2": [23, 67]}, "bert_text": "Similarly, significant disturbances in myocardial energy metabolism were detected in the <e1> barium </e1> <e2> disturbances in myocardial energy metabolism </e2> were detected in the barium-exposed rats which were consistent with the reduced contractile element shortening velocity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1350": {"data": {"text": "Procaterol and terbutaline in bronchial asthma.", "entity1": "Procaterol", "entity2": "bronchial asthma", "span1": [0, 10], "span2": [30, 46]}, "bert_text": "<e1> Procaterol </e1> and terbutaline in <e2> bronchial asthma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1351": {"data": {"text": "Procaterol and terbutaline in bronchial asthma.", "entity1": "terbutaline", "entity2": "bronchial asthma", "span1": [15, 26], "span2": [30, 46]}, "bert_text": "Procaterol and <e1> terbutaline </e1> in <e2> bronchial asthma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1352": {"data": {"text": "BACKGROUND: Studies on the association between the long-term use of aspirin and other analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs) and end-stage renal disease (ESRD) have given conflicting results.", "entity1": "aspirin", "entity2": "end-stage renal disease", "span1": [68, 75], "span2": [150, 173]}, "bert_text": "BACKGROUND: Studies on the association between the long-term use of <e1> aspirin </e1> and other analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs) and <e2> end-stage renal disease </e2> (ESRD) have given conflicting results.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1353": {"data": {"text": "BACKGROUND: Studies on the association between the long-term use of aspirin and other analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs) and end-stage renal disease (ESRD) have given conflicting results.", "entity1": "aspirin", "entity2": "ESRD", "span1": [68, 75], "span2": [175, 179]}, "bert_text": "BACKGROUND: Studies on the association between the long-term use of <e1> aspirin </e1> and other analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs) and end-stage renal disease (<e2> ESRD </e2>) have given conflicting results.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1354": {"data": {"text": "Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors.", "entity1": "flecainide", "entity2": "toxicity", "span1": [32, 42], "span2": [8, 16]}, "bert_text": "Because toxicity may occur when <e1> flecainide </e1> <e2> toxicity </e2> may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1355": {"data": {"text": "Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors.", "entity1": "flecainide", "entity2": "toxicity", "span1": [109, 119], "span2": [8, 16]}, "bert_text": "Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, <e1> flecainide </e1> <e2> toxicity </e2> may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1356": {"data": {"text": "Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors.", "entity1": "paroxetine", "entity2": "toxicity", "span1": [62, 72], "span2": [8, 16]}, "bert_text": "Because toxicity may occur when flecainide is prescribed with <e1> paroxetine </e1> <e2> toxicity </e2> may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors, flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1357": {"data": {"text": "Tranexamic acid overdosage-induced generalized seizure in renal failure.\nWe report a 45-year-old lady with chronic kidney disease stage 4 due to chronic tubulointerstial disease.", "entity1": "Tranexamic acid", "entity2": "seizure", "span1": [0, 15], "span2": [47, 54]}, "bert_text": "<e1> Tranexamic acid </e1> overdosage-induced generalized <e2> seizure </e2> in renal failure.\nWe report a 45-year-old lady with chronic kidney disease stage 4 due to chronic tubulointerstial disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1358": {"data": {"text": "Tranexamic acid overdosage-induced generalized seizure in renal failure.\nWe report a 45-year-old lady with chronic kidney disease stage 4 due to chronic tubulointerstial disease.", "entity1": "Tranexamic acid", "entity2": "renal failure", "span1": [0, 15], "span2": [58, 71]}, "bert_text": "<e1> Tranexamic acid </e1> overdosage-induced generalized seizure in <e2> renal failure </e2>.\nWe report a 45-year-old lady with chronic kidney disease stage 4 due to chronic tubulointerstial disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1359": {"data": {"text": "Tranexamic acid overdosage-induced generalized seizure in renal failure.\nWe report a 45-year-old lady with chronic kidney disease stage 4 due to chronic tubulointerstial disease.", "entity1": "Tranexamic acid", "entity2": "chronic kidney disease", "span1": [0, 15], "span2": [107, 129]}, "bert_text": "<e1> Tranexamic acid </e1> overdosage-induced generalized seizure in renal failure.\nWe report a 45-year-old lady with <e2> chronic kidney disease </e2> stage 4 due to chronic tubulointerstial disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1360": {"data": {"text": "These findings demonstrate that ACE inhibitor therapy in most patients with CHF can be successfully titrated to and maintained at high doses, and that more aggressive use of these agents is warranted.", "entity1": "ACE inhibitor", "entity2": "CHF", "span1": [32, 45], "span2": [76, 79]}, "bert_text": "These findings demonstrate that <e1> ACE inhibitor </e1> therapy in most patients with <e2> CHF </e2> can be successfully titrated to and maintained at high doses, and that more aggressive use of these agents is warranted.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1361": {"data": {"text": "Renal failure is a rare complication associated with the use of rifampin.", "entity1": "rifampin", "entity2": "Renal failure", "span1": [64, 72], "span2": [0, 13]}, "bert_text": "Renal failure is a rare complication associated with the use of <e1> rifampin </e1> <e2> Renal failure </e2> is a rare complication associated with the use of rifampin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1362": {"data": {"text": "High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer.", "entity1": "5-fluorouracil", "entity2": "gastric cancer", "span1": [10, 24], "span2": [114, 128]}, "bert_text": "High-dose <e1> 5-fluorouracil </e1> / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced <e2> gastric cancer </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1363": {"data": {"text": "High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer.", "entity1": "folinic acid", "entity2": "gastric cancer", "span1": [27, 39], "span2": [114, 128]}, "bert_text": "High-dose 5-fluorouracil / <e1> folinic acid </e1> in combination with three-weekly mitomycin C in the treatment of advanced <e2> gastric cancer </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1364": {"data": {"text": "High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer.", "entity1": "mitomycin C", "entity2": "gastric cancer", "span1": [73, 84], "span2": [114, 128]}, "bert_text": "High-dose 5-fluorouracil / folinic acid in combination with three-weekly <e1> mitomycin C </e1> in the treatment of advanced <e2> gastric cancer </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1365": {"data": {"text": "Renal patients on cyclosporine had the fewest bacteremias.", "entity1": "cyclosporine", "entity2": "bacteremias", "span1": [18, 30], "span2": [46, 57]}, "bert_text": "Renal patients on <e1> cyclosporine </e1> had the fewest <e2> bacteremias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1366": {"data": {"text": "One woman, however, developed worsened psychiatric symptoms while taking bromocriptine, and it was discontinued.", "entity1": "bromocriptine", "entity2": "psychiatric", "span1": [73, 86], "span2": [39, 50]}, "bert_text": "One woman, however, developed worsened psychiatric symptoms while taking <e1> bromocriptine </e1> <e2> psychiatric </e2> symptoms while taking bromocriptine, and it was discontinued.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1367": {"data": {"text": "Long QT syndrome can occur with low doses of methadone.", "entity1": "methadone", "entity2": "Long QT syndrome", "span1": [45, 54], "span2": [0, 16]}, "bert_text": "Long QT syndrome can occur with low doses of <e1> methadone </e1> <e2> Long QT syndrome </e2> can occur with low doses of methadone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1368": {"data": {"text": "BACKGROUND: The optimal dosing regimens of lipid emulsion, epinephrine, or both are not yet determined in neonates in cases of local anaesthetic systemic toxicity (LAST). METHODS: Newborn piglets received levobupivacaine until cardiovascular collapse occurred.", "entity1": "epinephrine", "entity2": "toxicity", "span1": [59, 70], "span2": [154, 162]}, "bert_text": "BACKGROUND: The optimal dosing regimens of lipid emulsion, <e1> epinephrine </e1>, or both are not yet determined in neonates in cases of local anaesthetic systemic <e2> toxicity </e2> (LAST). METHODS: Newborn piglets received levobupivacaine until cardiovascular collapse occurred.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1369": {"data": {"text": "BACKGROUND: The optimal dosing regimens of lipid emulsion, epinephrine, or both are not yet determined in neonates in cases of local anaesthetic systemic toxicity (LAST). METHODS: Newborn piglets received levobupivacaine until cardiovascular collapse occurred.", "entity1": "levobupivacaine", "entity2": "toxicity", "span1": [205, 220], "span2": [154, 162]}, "bert_text": "BACKGROUND: The optimal dosing regimens of lipid emulsion, epinephrine, or both are not yet determined in neonates in cases of local anaesthetic systemic toxicity (LAST). METHODS: Newborn piglets received <e1> levobupivacaine </e1> <e2> toxicity </e2> (LAST). METHODS: Newborn piglets received levobupivacaine until cardiovascular collapse occurred.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1370": {"data": {"text": "Emergency physicians should be aware of oral penicillin anaphylaxis in order to prevent its occurrence by prescribing the antibiotic judiciously and knowledgeably and to offer optimal medical therapy once this life-threatening reaction has begun.", "entity1": "penicillin", "entity2": "anaphylaxis", "span1": [45, 55], "span2": [56, 67]}, "bert_text": "Emergency physicians should be aware of oral <e1> penicillin </e1> <e2> anaphylaxis </e2> in order to prevent its occurrence by prescribing the antibiotic judiciously and knowledgeably and to offer optimal medical therapy once this life-threatening reaction has begun.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1371": {"data": {"text": "ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ventricular tachycardia in anesthetized dogs.", "entity1": "ACC-9653", "entity2": "ventricular tachycardia", "span1": [0, 8], "span2": [91, 114]}, "bert_text": "<e1> ACC-9653 </e1> and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced <e2> ventricular tachycardia </e2> in anesthetized dogs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1372": {"data": {"text": "ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ventricular tachycardia in anesthetized dogs.", "entity1": "phenytoin sodium", "entity2": "ventricular tachycardia", "span1": [13, 29], "span2": [91, 114]}, "bert_text": "ACC-9653 and <e1> phenytoin sodium </e1> have similar antiarrhythmic activity against ouabain-induced <e2> ventricular tachycardia </e2> in anesthetized dogs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1373": {"data": {"text": "ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain-induced ventricular tachycardia in anesthetized dogs.", "entity1": "ouabain", "entity2": "ventricular tachycardia", "span1": [75, 82], "span2": [91, 114]}, "bert_text": "ACC-9653 and phenytoin sodium have similar antiarrhythmic activity against <e1> ouabain </e1>-induced <e2> ventricular tachycardia </e2> in anesthetized dogs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1374": {"data": {"text": "Subacute effects of propranolol and B 24/76 on isoproterenol-induced rat heart hypertrophy in correlation with blood pressure.\n", "entity1": "propranolol", "entity2": "hypertrophy", "span1": [20, 31], "span2": [79, 90]}, "bert_text": "Subacute effects of <e1> propranolol </e1> and B 24/76 on isoproterenol-induced rat heart <e2> hypertrophy </e2> in correlation with blood pressure.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1375": {"data": {"text": "Subacute effects of propranolol and B 24/76 on isoproterenol-induced rat heart hypertrophy in correlation with blood pressure.\n", "entity1": "isoproterenol", "entity2": "hypertrophy", "span1": [47, 60], "span2": [79, 90]}, "bert_text": "Subacute effects of propranolol and B 24/76 on <e1> isoproterenol </e1>-induced rat heart <e2> hypertrophy </e2> in correlation with blood pressure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1376": {"data": {"text": "The participants had physical examination, medical record extraction, and venipuncture, CD4+T-cell counts determination, measurement of depression symptoms (using the self-report Center for Epidemiological Studies-Depression Scale), and alcohol use assessment at enrollment, and semiannually until March 2000.", "entity1": "alcohol", "entity2": "depression symptoms", "span1": [237, 244], "span2": [136, 155]}, "bert_text": "The participants had physical examination, medical record extraction, and venipuncture, CD4+T-cell counts determination, measurement of depression symptoms (using the self-report Center for Epidemiological Studies-Depression Scale), and <e1> alcohol </e1> <e2> depression symptoms </e2> (using the self-report Center for Epidemiological Studies-Depression Scale), and alcohol use assessment at enrollment, and semiannually until March 2000.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1377": {"data": {"text": "The participants had physical examination, medical record extraction, and venipuncture, CD4+T-cell counts determination, measurement of depression symptoms (using the self-report Center for Epidemiological Studies-Depression Scale), and alcohol use assessment at enrollment, and semiannually until March 2000.", "entity1": "alcohol", "entity2": "Depression", "span1": [237, 244], "span2": [214, 224]}, "bert_text": "The participants had physical examination, medical record extraction, and venipuncture, CD4+T-cell counts determination, measurement of depression symptoms (using the self-report Center for Epidemiological Studies-Depression Scale), and <e1> alcohol </e1> <e2> Depression </e2> Scale), and alcohol use assessment at enrollment, and semiannually until March 2000.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1378": {"data": {"text": "With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and fibrosis of the left ventricles were observed.", "entity1": "epinephrine", "entity2": "ischemic lesions", "span1": [20, 31], "span2": [87, 103]}, "bert_text": "With 2-week chronic <e1> epinephrine </e1> infusion, 16 of 30 rats died within 4 days, and severe <e2> ischemic lesions </e2> and fibrosis of the left ventricles were observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1379": {"data": {"text": "With 2-week chronic epinephrine infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and fibrosis of the left ventricles were observed.", "entity1": "epinephrine", "entity2": "fibrosis", "span1": [20, 31], "span2": [108, 116]}, "bert_text": "With 2-week chronic <e1> epinephrine </e1> infusion, 16 of 30 rats died within 4 days, and severe ischemic lesions and <e2> fibrosis </e2> of the left ventricles were observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1380": {"data": {"text": "OBJECTIVE: To highlight the role of electroencephalogram (EEG) in the early detection and management of ifosfamide related encephalopathy.", "entity1": "ifosfamide", "entity2": "encephalopathy", "span1": [104, 114], "span2": [123, 137]}, "bert_text": "OBJECTIVE: To highlight the role of electroencephalogram (EEG) in the early detection and management of <e1> ifosfamide </e1> related <e2> encephalopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1381": {"data": {"text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.", "entity1": "VCM", "entity2": "nephrotoxicity", "span1": [77, 80], "span2": [89, 103]}, "bert_text": "It is concluded that oxidative tubular damage plays an important role in the <e1> VCM </e1>-induced <e2> nephrotoxicity </e2> and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1382": {"data": {"text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.", "entity1": "VCM", "entity2": "kidney damage", "span1": [77, 80], "span2": [183, 196]}, "bert_text": "It is concluded that oxidative tubular damage plays an important role in the <e1> VCM </e1>-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced <e2> kidney damage </e2> both at the biochemical and histological levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1383": {"data": {"text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.", "entity1": "VCM", "entity2": "nephrotoxicity", "span1": [171, 174], "span2": [89, 103]}, "bert_text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the <e1> VCM </e1> <e2> nephrotoxicity </e2> and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1384": {"data": {"text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.", "entity1": "VCM", "entity2": "kidney damage", "span1": [171, 174], "span2": [183, 196]}, "bert_text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the <e1> VCM </e1>-induced <e2> kidney damage </e2> both at the biochemical and histological levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1385": {"data": {"text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.", "entity1": "erdosteine", "entity2": "nephrotoxicity", "span1": [148, 158], "span2": [89, 103]}, "bert_text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with <e1> erdosteine </e1> <e2> nephrotoxicity </e2> and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1386": {"data": {"text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM-induced kidney damage both at the biochemical and histological levels.", "entity1": "erdosteine", "entity2": "kidney damage", "span1": [148, 158], "span2": [183, 196]}, "bert_text": "It is concluded that oxidative tubular damage plays an important role in the VCM-induced nephrotoxicity and the modulation of oxidative stress with <e1> erdosteine </e1> reduces the VCM-induced <e2> kidney damage </e2> both at the biochemical and histological levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1387": {"data": {"text": "Niacin extended-release/lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia.", "entity1": "Niacin", "entity2": "primary hypercholesterolemia", "span1": [0, 6], "span2": [90, 118]}, "bert_text": "<e1> Niacin </e1> extended-release/lovastatin is a new combination product approved for treatment of <e2> primary hypercholesterolemia </e2> and mixed dyslipidemia.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1388": {"data": {"text": "Niacin extended-release/lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia.", "entity1": "Niacin", "entity2": "dyslipidemia", "span1": [0, 6], "span2": [129, 141]}, "bert_text": "<e1> Niacin </e1> extended-release/lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed <e2> dyslipidemia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1389": {"data": {"text": "Niacin extended-release/lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia.", "entity1": "lovastatin", "entity2": "primary hypercholesterolemia", "span1": [24, 34], "span2": [90, 118]}, "bert_text": "Niacin extended-release/<e1> lovastatin </e1> is a new combination product approved for treatment of <e2> primary hypercholesterolemia </e2> and mixed dyslipidemia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1390": {"data": {"text": "Niacin extended-release/lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia.", "entity1": "lovastatin", "entity2": "dyslipidemia", "span1": [24, 34], "span2": [129, 141]}, "bert_text": "Niacin extended-release/<e1> lovastatin </e1> is a new combination product approved for treatment of primary hypercholesterolemia and mixed <e2> dyslipidemia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1391": {"data": {"text": "The total doses of ACC-9653 or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 +/-", "entity1": "ACC-9653", "entity2": "arrhythmia", "span1": [19, 27], "span2": [73, 83]}, "bert_text": "The total doses of <e1> ACC-9653 </e1> or phenytoin sodium necessary to convert the <e2> arrhythmia </e2> to a normal sinus rhythm were 24 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1392": {"data": {"text": "The total doses of ACC-9653 or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 +/-", "entity1": "phenytoin sodium", "entity2": "arrhythmia", "span1": [31, 47], "span2": [73, 83]}, "bert_text": "The total doses of ACC-9653 or <e1> phenytoin sodium </e1> necessary to convert the <e2> arrhythmia </e2> to a normal sinus rhythm were 24 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1393": {"data": {"text": "Intravascular hemolysis leading to acute renal failure following rifampin therapy is extremely rare.", "entity1": "rifampin", "entity2": "hemolysis", "span1": [65, 73], "span2": [14, 23]}, "bert_text": "Intravascular hemolysis leading to acute renal failure following <e1> rifampin </e1> <e2> hemolysis </e2> leading to acute renal failure following rifampin therapy is extremely rare.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1394": {"data": {"text": "Intravascular hemolysis leading to acute renal failure following rifampin therapy is extremely rare.", "entity1": "rifampin", "entity2": "acute renal failure", "span1": [65, 73], "span2": [35, 54]}, "bert_text": "Intravascular hemolysis leading to acute renal failure following <e1> rifampin </e1> <e2> acute renal failure </e2> following rifampin therapy is extremely rare.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1395": {"data": {"text": "The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed myocardial infarction.", "entity1": "dronedarone", "entity2": "myocardial infarction", "span1": [46, 57], "span2": [275, 296]}, "bert_text": "The hemodynamic and antiadrenergic effects of <e1> dronedarone </e1>, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1396": {"data": {"text": "The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed myocardial infarction.", "entity1": "amiodarone", "entity2": "myocardial infarction", "span1": [107, 117], "span2": [275, 296]}, "bert_text": "The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to <e1> amiodarone </e1>, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1397": {"data": {"text": "The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of amiodarone after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed myocardial infarction.", "entity1": "amiodarone", "entity2": "myocardial infarction", "span1": [147, 157], "span2": [275, 296]}, "bert_text": "The hemodynamic and antiadrenergic effects of dronedarone, a noniodinated compound structurally related to amiodarone, were compared with those of <e1> amiodarone </e1> after prolonged oral administration, both at rest and during sympathetic stimulation in conscious dogs with a healed <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1398": {"data": {"text": "It is unclear whether a coronary CTA strategy would be efficacious in cocaine-associated chest pain, as coronary vasospasm may account for some of the ischemia.", "entity1": "cocaine", "entity2": "chest pain", "span1": [70, 77], "span2": [89, 99]}, "bert_text": "It is unclear whether a coronary CTA strategy would be efficacious in <e1> cocaine </e1>-associated <e2> chest pain </e2>, as coronary vasospasm may account for some of the ischemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1399": {"data": {"text": "It is unclear whether a coronary CTA strategy would be efficacious in cocaine-associated chest pain, as coronary vasospasm may account for some of the ischemia.", "entity1": "cocaine", "entity2": "coronary vasospasm", "span1": [70, 77], "span2": [104, 122]}, "bert_text": "It is unclear whether a coronary CTA strategy would be efficacious in <e1> cocaine </e1>-associated chest pain, as <e2> coronary vasospasm </e2> may account for some of the ischemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1400": {"data": {"text": "It is unclear whether a coronary CTA strategy would be efficacious in cocaine-associated chest pain, as coronary vasospasm may account for some of the ischemia.", "entity1": "cocaine", "entity2": "ischemia", "span1": [70, 77], "span2": [151, 159]}, "bert_text": "It is unclear whether a coronary CTA strategy would be efficacious in <e1> cocaine </e1>-associated chest pain, as coronary vasospasm may account for some of the <e2> ischemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1401": {"data": {"text": "In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH.", "entity1": "Rg1", "entity2": "OIH", "span1": [50, 53], "span2": [117, 120]}, "bert_text": "In this study, we investigated the effects of Re, <e1> Rg1 </e1>, and Rb1 ginsenosides, the bioactive components of ginseng, on <e2> OIH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1402": {"data": {"text": "In this study, we investigated the effects of Re, Rg1, and Rb1 ginsenosides, the bioactive components of ginseng, on OIH.", "entity1": "Rb1 ginsenosides", "entity2": "OIH", "span1": [59, 75], "span2": [117, 120]}, "bert_text": "In this study, we investigated the effects of Re, Rg1, and <e1> Rb1 ginsenosides </e1>, the bioactive components of ginseng, on <e2> OIH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1403": {"data": {"text": "Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days.", "entity1": "isoproterenol", "entity2": "myocardial ischemic injury", "span1": [82, 95], "span2": [6, 32]}, "bert_text": "Acute myocardial ischemic injury was induced in rats by subcutaneous injection of <e1> isoproterenol </e1> <e2> myocardial ischemic injury </e2> was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1404": {"data": {"text": "An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).", "entity1": "puromycin-aminonucleoside", "entity2": "glomerular sclerosis", "span1": [125, 150], "span2": [41, 61]}, "bert_text": "An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of <e1> puromycin-aminonucleoside </e1> <e2> glomerular sclerosis </e2> (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1405": {"data": {"text": "An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).", "entity1": "AMNS", "entity2": "glomerular sclerosis", "span1": [152, 156], "span2": [41, 61]}, "bert_text": "An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (<e1> AMNS </e1> <e2> glomerular sclerosis </e2> (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1406": {"data": {"text": "An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).", "entity1": "protamine sulfate", "entity2": "glomerular sclerosis", "span1": [162, 179], "span2": [41, 61]}, "bert_text": "An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and <e1> protamine sulfate </e1> <e2> glomerular sclerosis </e2> (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1407": {"data": {"text": "An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).", "entity1": "PS", "entity2": "glomerular sclerosis", "span1": [181, 183], "span2": [41, 61]}, "bert_text": "An experimental model of focal segmental glomerular sclerosis (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (<e1> PS </e1> <e2> glomerular sclerosis </e2> (FSGS) was developed in rats by the combined administration of puromycin-aminonucleoside (AMNS) and protamine sulfate (PS).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1408": {"data": {"text": "Levodopa-induced ocular dyskinesias in Parkinson's disease.\n", "entity1": "Levodopa", "entity2": "ocular dyskinesias", "span1": [0, 8], "span2": [17, 35]}, "bert_text": "<e1> Levodopa </e1>-induced <e2> ocular dyskinesias </e2> in Parkinson's disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1409": {"data": {"text": "Levodopa-induced ocular dyskinesias in Parkinson's disease.\n", "entity1": "Levodopa", "entity2": "Parkinson's disease", "span1": [0, 8], "span2": [39, 58]}, "bert_text": "<e1> Levodopa </e1>-induced ocular dyskinesias in <e2> Parkinson's disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1410": {"data": {"text": "Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors", "entity1": "everolimus", "entity2": "NSCLC", "span1": [12, 22], "span2": [58, 63]}, "bert_text": "Efficacy of <e1> everolimus </e1> (RAD001) in patients with advanced <e2> NSCLC </e2> previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1411": {"data": {"text": "Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors", "entity1": "RAD001", "entity2": "NSCLC", "span1": [24, 30], "span2": [58, 63]}, "bert_text": "Efficacy of everolimus (<e1> RAD001 </e1>) in patients with advanced <e2> NSCLC </e2> previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1412": {"data": {"text": "Hypotheses of heroin-related rhabdomyolysis and stroke in heroin abusers are discussed.", "entity1": "heroin", "entity2": "rhabdomyolysis", "span1": [14, 20], "span2": [29, 43]}, "bert_text": "Hypotheses of <e1> heroin </e1>-related <e2> rhabdomyolysis </e2> and stroke in heroin abusers are discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1413": {"data": {"text": "Hypotheses of heroin-related rhabdomyolysis and stroke in heroin abusers are discussed.", "entity1": "heroin", "entity2": "stroke", "span1": [14, 20], "span2": [48, 54]}, "bert_text": "Hypotheses of <e1> heroin </e1>-related rhabdomyolysis and <e2> stroke </e2> in heroin abusers are discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1414": {"data": {"text": "Hypotheses of heroin-related rhabdomyolysis and stroke in heroin abusers are discussed.", "entity1": "heroin", "entity2": "rhabdomyolysis", "span1": [58, 64], "span2": [29, 43]}, "bert_text": "Hypotheses of heroin-related rhabdomyolysis and stroke in <e1> heroin </e1> <e2> rhabdomyolysis </e2> and stroke in heroin abusers are discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1415": {"data": {"text": "Hypotheses of heroin-related rhabdomyolysis and stroke in heroin abusers are discussed.", "entity1": "heroin", "entity2": "stroke", "span1": [58, 64], "span2": [48, 54]}, "bert_text": "Hypotheses of heroin-related rhabdomyolysis and stroke in <e1> heroin </e1> <e2> stroke </e2> in heroin abusers are discussed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1416": {"data": {"text": "All-trans retinoic acid (ATRA), a component of standard therapy for acute promyelocytic leukemia (APL), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement.", "entity1": "All-trans retinoic acid", "entity2": "acute promyelocytic leukemia", "span1": [0, 23], "span2": [68, 96]}, "bert_text": "<e1> All-trans retinoic acid </e1> (ATRA), a component of standard therapy for <e2> acute promyelocytic leukemia </e2> (APL), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1417": {"data": {"text": "All-trans retinoic acid (ATRA), a component of standard therapy for acute promyelocytic leukemia (APL), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement.", "entity1": "All-trans retinoic acid", "entity2": "APL", "span1": [0, 23], "span2": [98, 101]}, "bert_text": "<e1> All-trans retinoic acid </e1> (ATRA), a component of standard therapy for acute promyelocytic leukemia (<e2> APL </e2>), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1418": {"data": {"text": "All-trans retinoic acid (ATRA), a component of standard therapy for acute promyelocytic leukemia (APL), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement.", "entity1": "ATRA", "entity2": "acute promyelocytic leukemia", "span1": [25, 29], "span2": [68, 96]}, "bert_text": "All-trans retinoic acid (<e1> ATRA </e1>), a component of standard therapy for <e2> acute promyelocytic leukemia </e2> (APL), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1419": {"data": {"text": "All-trans retinoic acid (ATRA), a component of standard therapy for acute promyelocytic leukemia (APL), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement.", "entity1": "ATRA", "entity2": "APL", "span1": [25, 29], "span2": [98, 101]}, "bert_text": "All-trans retinoic acid (<e1> ATRA </e1>), a component of standard therapy for acute promyelocytic leukemia (<e2> APL </e2>), is associated with potentially serious but treatable adverse effects involving numerous organ systems, including rare skeletal muscle involvement.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1420": {"data": {"text": "We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by trimethoprim-sulfomethoxazole, resulting in cerebral anoxia leading to permanent damage.", "entity1": "trimethoprim-sulfomethoxazole", "entity2": "hemolytic anemia", "span1": [132, 161], "span2": [97, 113]}, "bert_text": "We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by <e1> trimethoprim-sulfomethoxazole </e1> <e2> hemolytic anemia </e2> crisis induced by trimethoprim-sulfomethoxazole, resulting in cerebral anoxia leading to permanent damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1421": {"data": {"text": "We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by trimethoprim-sulfomethoxazole, resulting in cerebral anoxia leading to permanent damage.", "entity1": "trimethoprim-sulfomethoxazole", "entity2": "cerebral anoxia", "span1": [132, 161], "span2": [176, 191]}, "bert_text": "We present magnetic resonance imaging findings of a 5-year-old girl who had a rapidly installing hemolytic anemia crisis induced by <e1> trimethoprim-sulfomethoxazole </e1>, resulting in <e2> cerebral anoxia </e2> leading to permanent damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1422": {"data": {"text": "Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.\n", "entity1": "angiotensin", "entity2": "Syncope", "span1": [73, 84], "span2": [0, 7]}, "bert_text": "Syncope caused by hyperkalemia during use of a combined therapy with the <e1> angiotensin </e1> <e2> Syncope </e2> caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1423": {"data": {"text": "Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.\n", "entity1": "angiotensin", "entity2": "hyperkalemia", "span1": [73, 84], "span2": [18, 30]}, "bert_text": "Syncope caused by hyperkalemia during use of a combined therapy with the <e1> angiotensin </e1> <e2> hyperkalemia </e2> during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1424": {"data": {"text": "Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.\n", "entity1": "spironolactone", "entity2": "Syncope", "span1": [117, 131], "span2": [0, 7]}, "bert_text": "Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and <e1> spironolactone </e1> <e2> Syncope </e2> caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1425": {"data": {"text": "Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.\n", "entity1": "spironolactone", "entity2": "hyperkalemia", "span1": [117, 131], "span2": [18, 30]}, "bert_text": "Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and <e1> spironolactone </e1> <e2> hyperkalemia </e2> during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1426": {"data": {"text": "The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.", "entity1": "GFC", "entity2": "status epilepticus", "span1": [26, 29], "span2": [128, 146]}, "bert_text": "The results indicate that <e1> GFC </e1> can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced <e2> status epilepticus </e2>, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1427": {"data": {"text": "The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.", "entity1": "GFC", "entity2": "seizure", "span1": [26, 29], "span2": [196, 203]}, "bert_text": "The results indicate that <e1> GFC </e1> can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first <e2> seizure </e2> and decrease in mortality rate of animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1428": {"data": {"text": "The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [108, 119], "span2": [128, 146]}, "bert_text": "The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of <e1> pilocarpine </e1>-induced <e2> status epilepticus </e2>, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1429": {"data": {"text": "The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine-induced status epilepticus, as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [108, 119], "span2": [196, 203]}, "bert_text": "The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of <e1> pilocarpine </e1>-induced status epilepticus, as demonstrated by increase in latency to first <e2> seizure </e2> and decrease in mortality rate of animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1430": {"data": {"text": "Famotidine-associated delirium.", "entity1": "Famotidine", "entity2": "delirium", "span1": [0, 10], "span2": [22, 30]}, "bert_text": "<e1> Famotidine </e1>-associated <e2> delirium </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1431": {"data": {"text": "Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0.5 mg/kg) did not.", "entity1": "Scopolamine", "entity2": "seizure", "span1": [0, 11], "span2": [107, 114]}, "bert_text": "<e1> Scopolamine </e1> (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral <e2> seizure </e2> but MK-801 (0.5 mg/kg) did not.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1432": {"data": {"text": "Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0.5 mg/kg) did not.", "entity1": "pentobarbital", "entity2": "seizure", "span1": [27, 40], "span2": [107, 114]}, "bert_text": "Scopolamine (10 mg/kg) and <e1> pentobarbital </e1> (5 mg/kg) prevented development of pilocarpine-induced behavioral <e2> seizure </e2> but MK-801 (0.5 mg/kg) did not.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1433": {"data": {"text": "Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0.5 mg/kg) did not.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [76, 87], "span2": [107, 114]}, "bert_text": "Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of <e1> pilocarpine </e1>-induced behavioral <e2> seizure </e2> but MK-801 (0.5 mg/kg) did not.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1434": {"data": {"text": "Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but MK-801 (0.5 mg/kg) did not.", "entity1": "MK-801", "entity2": "seizure", "span1": [119, 125], "span2": [107, 114]}, "bert_text": "Scopolamine (10 mg/kg) and pentobarbital (5 mg/kg) prevented development of pilocarpine-induced behavioral seizure but <e1> MK-801 </e1> <e2> seizure </e2> but MK-801 (0.5 mg/kg) did not.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"1435": {"data": {"text": "Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training naloxone.\n", "entity1": "scopolamine", "entity2": "amnesia", "span1": [12, 23], "span2": [32, 39]}, "bert_text": "Reversal of <e1> scopolamine </e1>-induced <e2> amnesia </e2> of passive avoidance by pre- and post-training naloxone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1436": {"data": {"text": "Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training naloxone.\n", "entity1": "naloxone", "entity2": "amnesia", "span1": [87, 95], "span2": [32, 39]}, "bert_text": "Reversal of scopolamine-induced amnesia of passive avoidance by pre- and post-training <e1> naloxone </e1> <e2> amnesia </e2> of passive avoidance by pre- and post-training naloxone.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1437": {"data": {"text": "However, DCF continued to be effective in reducing pelvic pain for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/-", "entity1": "DCF", "entity2": "pelvic pain", "span1": [9, 12], "span2": [51, 62]}, "bert_text": "However, <e1> DCF </e1> continued to be effective in reducing <e2> pelvic pain </e2> for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/-", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1438": {"data": {"text": "However, DCF continued to be effective in reducing pelvic pain for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/-", "entity1": "GTN", "entity2": "pelvic pain", "span1": [86, 89], "span2": [51, 62]}, "bert_text": "However, DCF continued to be effective in reducing pelvic pain for two hours, whereas <e1> GTN </e1> <e2> pelvic pain </e2> for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1439": {"data": {"text": "However, DCF continued to be effective in reducing pelvic pain for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/-", "entity1": "GTN", "entity2": "pelvic pain", "span1": [200, 203], "span2": [51, 62]}, "bert_text": "However, DCF continued to be effective in reducing pelvic pain for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: <e1> GTN </e1> <e2> pelvic pain </e2> for two hours, whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC (after one hour: GTN, -12.8 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1440": {"data": {"text": "METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson Cancer Center between years 2009 and 2012, who developed ifosfamide related acute encephalopathy.", "entity1": "ifosfamide", "entity2": "MD Anderson Cancer", "span1": [187, 197], "span2": [118, 136]}, "bert_text": "METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson Cancer Center between years 2009 and 2012, who developed <e1> ifosfamide </e1> <e2> MD Anderson Cancer </e2> Center between years 2009 and 2012, who developed ifosfamide related acute encephalopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1441": {"data": {"text": "METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson Cancer Center between years 2009 and 2012, who developed ifosfamide related acute encephalopathy.", "entity1": "ifosfamide", "entity2": "encephalopathy", "span1": [187, 197], "span2": [212, 226]}, "bert_text": "METHODS: Retrospective chart review including clinical data and EEG recordings was done on five patients, admitted to MD Anderson Cancer Center between years 2009 and 2012, who developed <e1> ifosfamide </e1> related acute <e2> encephalopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1442": {"data": {"text": "We found that metformin suppressed the progression of kindling, ameliorated the cognitive impairment and decreased brain oxidative stress.", "entity1": "metformin", "entity2": "cognitive impairment", "span1": [14, 23], "span2": [80, 100]}, "bert_text": "We found that <e1> metformin </e1> suppressed the progression of kindling, ameliorated the <e2> cognitive impairment </e2> and decreased brain oxidative stress.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1443": {"data": {"text": "Of the cyclosporine patients, 15% had symptoms related to CMV infection.", "entity1": "cyclosporine", "entity2": "CMV infection", "span1": [7, 19], "span2": [58, 71]}, "bert_text": "Of the <e1> cyclosporine </e1> patients, 15% had symptoms related to <e2> CMV infection </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1444": {"data": {"text": "Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.", "entity1": "cyclosporin A", "entity2": "hypertension", "span1": [67, 80], "span2": [33, 45]}, "bert_text": "Thirteen psoriatic patients with hypertension during the course of <e1> cyclosporin A </e1> <e2> hypertension </e2> during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1445": {"data": {"text": "Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.", "entity1": "calcium", "entity2": "hypertension", "span1": [123, 130], "span2": [33, 45]}, "bert_text": "Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a <e1> calcium </e1> <e2> hypertension </e2> during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1446": {"data": {"text": "Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.", "entity1": "nifedipine", "entity2": "hypertension", "span1": [166, 176], "span2": [33, 45]}, "bert_text": "Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release <e1> nifedipine </e1> <e2> hypertension </e2> during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker, sustained-release nifedipine, to study the clinical antihypertensive effects and adverse events during treatment with both drugs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1447": {"data": {"text": "Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain.", "entity1": "Pilocarpine", "entity2": "temporal lobe epilepsy", "span1": [0, 11], "span2": [91, 113]}, "bert_text": "<e1> Pilocarpine </e1>, given intraperitoneally to rats, reproduces the neuropathological sequelae of <e2> temporal lobe epilepsy </e2> and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1448": {"data": {"text": "Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain.", "entity1": "Pilocarpine", "entity2": "convulsive", "span1": [0, 11], "span2": [189, 199]}, "bert_text": "<e1> Pilocarpine </e1>, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of <e2> convulsive </e2> activity and pathways operative in the generalization and propagation of seizures within the forebrain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1449": {"data": {"text": "Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain.", "entity1": "Pilocarpine", "entity2": "seizures", "span1": [0, 11], "span2": [273, 281]}, "bert_text": "<e1> Pilocarpine </e1>, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of <e2> seizures </e2> within the forebrain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1450": {"data": {"text": "Postthrombectomy continuous CDT with alteplase was commenced while argatroban was withheld, and complete patency of the SVC and central veins was achieved after three days of therapy.", "entity1": "argatroban", "entity2": "SVC", "span1": [67, 77], "span2": [120, 123]}, "bert_text": "Postthrombectomy continuous CDT with alteplase was commenced while <e1> argatroban </e1> was withheld, and complete patency of the <e2> SVC </e2> and central veins was achieved after three days of therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1451": {"data": {"text": "However, the chronic use of aspirin may increase the risk of ESRD.", "entity1": "aspirin", "entity2": "ESRD", "span1": [28, 35], "span2": [61, 65]}, "bert_text": "However, the chronic use of <e1> aspirin </e1> may increase the risk of <e2> ESRD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1452": {"data": {"text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.", "entity1": "pilocarpine nitrate", "entity2": "bradycardia", "span1": [57, 76], "span2": [120, 131]}, "bert_text": "A 69-yr-old man, who was concurrently being treated with <e1> pilocarpine nitrate </e1> and timolol maleate eye drops, developed a <e2> bradycardia </e2> and became hypotensive during halothane anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1453": {"data": {"text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.", "entity1": "pilocarpine nitrate", "entity2": "hypotensive", "span1": [57, 76], "span2": [143, 154]}, "bert_text": "A 69-yr-old man, who was concurrently being treated with <e1> pilocarpine nitrate </e1> and timolol maleate eye drops, developed a bradycardia and became <e2> hypotensive </e2> during halothane anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1454": {"data": {"text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.", "entity1": "timolol", "entity2": "bradycardia", "span1": [81, 88], "span2": [120, 131]}, "bert_text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and <e1> timolol </e1> maleate eye drops, developed a <e2> bradycardia </e2> and became hypotensive during halothane anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1455": {"data": {"text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.", "entity1": "timolol", "entity2": "hypotensive", "span1": [81, 88], "span2": [143, 154]}, "bert_text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and <e1> timolol </e1> maleate eye drops, developed a bradycardia and became <e2> hypotensive </e2> during halothane anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1456": {"data": {"text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.", "entity1": "halothane", "entity2": "bradycardia", "span1": [162, 171], "span2": [120, 131]}, "bert_text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during <e1> halothane </e1> <e2> bradycardia </e2> and became hypotensive during halothane anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1457": {"data": {"text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during halothane anaesthesia.", "entity1": "halothane", "entity2": "hypotensive", "span1": [162, 171], "span2": [143, 154]}, "bert_text": "A 69-yr-old man, who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops, developed a bradycardia and became hypotensive during <e1> halothane </e1> <e2> hypotensive </e2> during halothane anaesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1458": {"data": {"text": "We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures.", "entity1": "lindane", "entity2": "seizures", "span1": [25, 32], "span2": [189, 197]}, "bert_text": "We studied the effect of <e1> lindane </e1> (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1459": {"data": {"text": "We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures.", "entity1": "GABA", "entity2": "seizures", "span1": [121, 125], "span2": [189, 197]}, "bert_text": "We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of <e1> GABA </e1>, dopamine and its metabolites in 7 brain areas at the onset of <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"1460": {"data": {"text": "We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, dopamine and its metabolites in 7 brain areas at the onset of seizures.", "entity1": "dopamine", "entity2": "seizures", "span1": [127, 135], "span2": [189, 197]}, "bert_text": "We studied the effect of lindane (150 mg/kg) on the GABAergic and dopaminergic systems by measuring the concentration of GABA, <e1> dopamine </e1> and its metabolites in 7 brain areas at the onset of <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"1461": {"data": {"text": "Despite popular use of piperacillin, the dire neurotoxicity associated with piperacillin still goes unrecognized, leading to a delay in appropriate management.", "entity1": "piperacillin", "entity2": "neurotoxicity", "span1": [23, 35], "span2": [46, 59]}, "bert_text": "Despite popular use of <e1> piperacillin </e1>, the dire <e2> neurotoxicity </e2> associated with piperacillin still goes unrecognized, leading to a delay in appropriate management.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1462": {"data": {"text": "Despite popular use of piperacillin, the dire neurotoxicity associated with piperacillin still goes unrecognized, leading to a delay in appropriate management.", "entity1": "piperacillin", "entity2": "neurotoxicity", "span1": [76, 88], "span2": [46, 59]}, "bert_text": "Despite popular use of piperacillin, the dire neurotoxicity associated with <e1> piperacillin </e1> <e2> neurotoxicity </e2> associated with piperacillin still goes unrecognized, leading to a delay in appropriate management.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1463": {"data": {"text": "Seizure frequencies before and after initiation of levetiracetam treatment were compared, and adverse effects were recorded.", "entity1": "levetiracetam", "entity2": "Seizure", "span1": [51, 64], "span2": [0, 7]}, "bert_text": "Seizure frequencies before and after initiation of <e1> levetiracetam </e1> <e2> Seizure </e2> frequencies before and after initiation of levetiracetam treatment were compared, and adverse effects were recorded.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1464": {"data": {"text": "This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.", "entity1": "corticosteroid", "entity2": "hepatic neoplasms", "span1": [148, 162], "span2": [74, 91]}, "bert_text": "This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and <e1> corticosteroid </e1> <e2> hepatic neoplasms </e2> and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1465": {"data": {"text": "This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and corticosteroid-treated Fanconi's anemia.", "entity1": "corticosteroid", "entity2": "Fanconi's anemia", "span1": [148, 162], "span2": [171, 187]}, "bert_text": "This case contributes to the previous observations that non-metastasizing hepatic neoplasms and peliosis can develop in patients with androgen- and <e1> corticosteroid </e1>-treated <e2> Fanconi's anemia </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1466": {"data": {"text": "Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.", "entity1": "SRL", "entity2": "renal damage", "span1": [14, 17], "span2": [40, 52]}, "bert_text": "Conversion to <e1> SRL </e1> prevented CsA-induced <e2> renal damage </e2> evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1467": {"data": {"text": "Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.", "entity1": "SRL", "entity2": "renal damage", "span1": [179, 182], "span2": [40, 52]}, "bert_text": "Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to <e1> SRL </e1> <e2> renal damage </e2> evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"1468": {"data": {"text": "Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.", "entity1": "CsA", "entity2": "renal damage", "span1": [28, 31], "span2": [40, 52]}, "bert_text": "Conversion to SRL prevented <e1> CsA </e1>-induced <e2> renal damage </e2> evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1469": {"data": {"text": "Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.", "entity1": "CsA", "entity2": "renal damage", "span1": [160, 163], "span2": [40, 52]}, "bert_text": "Conversion to SRL prevented CsA-induced renal damage evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of <e1> CsA </e1> <e2> renal damage </e2> evolution (absent/mild grade lesions), while NGAL (serum versus urine) seems to be a feasible biomarker of CsA replacement to SRL.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 1},
+	"1470": {"data": {"text": "CONCLUSION: Flumazenil can unmask seizures and increase the incidence of death in a model of combined cocaine-diazepam intoxications.", "entity1": "Flumazenil", "entity2": "seizures", "span1": [12, 22], "span2": [34, 42]}, "bert_text": "CONCLUSION: <e1> Flumazenil </e1> can unmask <e2> seizures </e2> and increase the incidence of death in a model of combined cocaine-diazepam intoxications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1471": {"data": {"text": "CONCLUSION: Flumazenil can unmask seizures and increase the incidence of death in a model of combined cocaine-diazepam intoxications.", "entity1": "Flumazenil", "entity2": "death", "span1": [12, 22], "span2": [73, 78]}, "bert_text": "CONCLUSION: <e1> Flumazenil </e1> can unmask seizures and increase the incidence of <e2> death </e2> in a model of combined cocaine-diazepam intoxications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1472": {"data": {"text": "CONCLUSION: Flumazenil can unmask seizures and increase the incidence of death in a model of combined cocaine-diazepam intoxications.", "entity1": "cocaine-diazepam", "entity2": "seizures", "span1": [102, 118], "span2": [34, 42]}, "bert_text": "CONCLUSION: Flumazenil can unmask seizures and increase the incidence of death in a model of combined <e1> cocaine-diazepam </e1> <e2> seizures </e2> and increase the incidence of death in a model of combined cocaine-diazepam intoxications.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1473": {"data": {"text": "CONCLUSION: Flumazenil can unmask seizures and increase the incidence of death in a model of combined cocaine-diazepam intoxications.", "entity1": "cocaine-diazepam", "entity2": "death", "span1": [102, 118], "span2": [73, 78]}, "bert_text": "CONCLUSION: Flumazenil can unmask seizures and increase the incidence of death in a model of combined <e1> cocaine-diazepam </e1> <e2> death </e2> in a model of combined cocaine-diazepam intoxications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1474": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "K(+)-channels", "entity2": "hypoactivity", "span1": [42, 55], "span2": [130, 142]}, "bert_text": "It is also suggested that the blockade of <e1> K(+)-channels </e1> sensitive to these blockers is not sufficient to prevent morphine-induced <e2> hypoactivity </e2> whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1475": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "K(+)-channels", "entity2": "hyperactivity", "span1": [42, 55], "span2": [168, 181]}, "bert_text": "It is also suggested that the blockade of <e1> K(+)-channels </e1> sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced <e2> hyperactivity </e2> seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1476": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "K(+)-channels", "entity2": "hypoactivity", "span1": [251, 264], "span2": [130, 142]}, "bert_text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive <e1> K(+)-channels </e1> <e2> hypoactivity </e2> whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"1477": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "K(+)-channels", "entity2": "hyperactivity", "span1": [251, 264], "span2": [168, 181]}, "bert_text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive <e1> K(+)-channels </e1> <e2> hyperactivity </e2> seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1478": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "morphine", "entity2": "hypoactivity", "span1": [113, 121], "span2": [130, 142]}, "bert_text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent <e1> morphine </e1>-induced <e2> hypoactivity </e2> whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1479": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "morphine", "entity2": "hyperactivity", "span1": [113, 121], "span2": [168, 181]}, "bert_text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent <e1> morphine </e1>-induced hypoactivity whereas morphine-induced <e2> hyperactivity </e2> seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1480": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "morphine", "entity2": "hypoactivity", "span1": [151, 159], "span2": [130, 142]}, "bert_text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas <e1> morphine </e1> <e2> hypoactivity </e2> whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"1481": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "morphine", "entity2": "hyperactivity", "span1": [151, 159], "span2": [168, 181]}, "bert_text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas <e1> morphine </e1>-induced <e2> hyperactivity </e2> seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1482": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "quinine-", "entity2": "hypoactivity", "span1": [212, 220], "span2": [130, 142]}, "bert_text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both <e1> quinine- </e1> <e2> hypoactivity </e2> whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"1483": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "quinine-", "entity2": "hyperactivity", "span1": [212, 220], "span2": [168, 181]}, "bert_text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both <e1> quinine- </e1> <e2> hyperactivity </e2> seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1484": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "4-aminopyridine", "entity2": "hypoactivity", "span1": [225, 240], "span2": [130, 142]}, "bert_text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and <e1> 4-aminopyridine </e1> <e2> hypoactivity </e2> whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"1485": {"data": {"text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "entity1": "4-aminopyridine", "entity2": "hyperactivity", "span1": [225, 240], "span2": [168, 181]}, "bert_text": "It is also suggested that the blockade of K(+)-channels sensitive to these blockers is not sufficient to prevent morphine-induced hypoactivity whereas morphine-induced hyperactivity seems to be connected to both quinine- and <e1> 4-aminopyridine </e1> <e2> hyperactivity </e2> seems to be connected to both quinine- and 4-aminopyridine-sensitive K(+)-channels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1486": {"data": {"text": "In spite of the fact that TSPA is a useful IT agent, its combination with MTX, ara-C and radiotherapy could cause severe neurotoxicity.", "entity1": "MTX", "entity2": "neurotoxicity", "span1": [74, 77], "span2": [121, 134]}, "bert_text": "In spite of the fact that TSPA is a useful IT agent, its combination with <e1> MTX </e1>, ara-C and radiotherapy could cause severe <e2> neurotoxicity </e2>.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1487": {"data": {"text": "In spite of the fact that TSPA is a useful IT agent, its combination with MTX, ara-C and radiotherapy could cause severe neurotoxicity.", "entity1": "ara", "entity2": "neurotoxicity", "span1": [79, 82], "span2": [121, 134]}, "bert_text": "In spite of the fact that TSPA is a useful IT agent, its combination with MTX, <e1> ara </e1>-C and radiotherapy could cause severe <e2> neurotoxicity </e2>.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1488": {"data": {"text": "Piperacillin-induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations.", "entity1": "Piperacillin", "entity2": "encephalopathy", "span1": [0, 12], "span2": [21, 35]}, "bert_text": "<e1> Piperacillin </e1>-induced <e2> encephalopathy </e2> should be considered in any uremic patients with unexplained neurological manifestations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1489": {"data": {"text": "Piperacillin-induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations.", "entity1": "Piperacillin", "entity2": "uremic", "span1": [0, 12], "span2": [64, 70]}, "bert_text": "<e1> Piperacillin </e1>-induced encephalopathy should be considered in any <e2> uremic </e2> patients with unexplained neurological manifestations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1490": {"data": {"text": "The experience of this case, together with a review of the literature, suggests that FBAL is related to 5-FU-induced cardiotoxicity.", "entity1": "FBAL", "entity2": "cardiotoxicity", "span1": [85, 89], "span2": [117, 131]}, "bert_text": "The experience of this case, together with a review of the literature, suggests that <e1> FBAL </e1> is related to 5-FU-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1491": {"data": {"text": "The experience of this case, together with a review of the literature, suggests that FBAL is related to 5-FU-induced cardiotoxicity.", "entity1": "5-FU", "entity2": "cardiotoxicity", "span1": [104, 108], "span2": [117, 131]}, "bert_text": "The experience of this case, together with a review of the literature, suggests that FBAL is related to <e1> 5-FU </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1492": {"data": {"text": "From the results obtained, haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive acute renal failure caused by desferrioxamine.", "entity1": "desferrioxamine", "entity2": "acute renal failure", "span1": [147, 162], "span2": [117, 136]}, "bert_text": "From the results obtained, haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive acute renal failure caused by <e1> desferrioxamine </e1> <e2> acute renal failure </e2> caused by desferrioxamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1493": {"data": {"text": "Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing.\n", "entity1": "Flurothyl", "entity2": "seizure", "span1": [0, 9], "span2": [10, 17]}, "bert_text": "<e1> Flurothyl </e1> <e2> seizure </e2> thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1494": {"data": {"text": "Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing.\n", "entity1": "Flurothyl", "entity2": "seizure", "span1": [0, 9], "span2": [162, 169]}, "bert_text": "<e1> Flurothyl </e1> seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl <e2> seizure </e2> testing.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1495": {"data": {"text": "Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing.\n", "entity1": "flurothyl", "entity2": "seizure", "span1": [152, 161], "span2": [10, 17]}, "bert_text": "Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in <e1> flurothyl </e1> <e2> seizure </e2> thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1496": {"data": {"text": "Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in flurothyl seizure testing.\n", "entity1": "flurothyl", "entity2": "seizure", "span1": [152, 161], "span2": [162, 169]}, "bert_text": "Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate (MSG): evaluation of experimental parameters in <e1> flurothyl </e1> <e2> seizure </e2> testing.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1497": {"data": {"text": "The effects on isoproterenol tachycardia were determined before and after atropine (0.04 mg/kg IV).", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [15, 28], "span2": [29, 40]}, "bert_text": "The effects on <e1> isoproterenol </e1> <e2> tachycardia </e2> were determined before and after atropine (0.04 mg/kg IV).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1498": {"data": {"text": "The effects on isoproterenol tachycardia were determined before and after atropine (0.04 mg/kg IV).", "entity1": "atropine", "entity2": "tachycardia", "span1": [74, 82], "span2": [29, 40]}, "bert_text": "The effects on isoproterenol tachycardia were determined before and after <e1> atropine </e1> <e2> tachycardia </e2> were determined before and after atropine (0.04 mg/kg IV).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1499": {"data": {"text": "We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with sumatriptan.", "entity1": "sumatriptan", "entity2": "ischemic colitis", "span1": [107, 118], "span2": [51, 67]}, "bert_text": "We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with <e1> sumatriptan </e1> <e2> ischemic colitis </e2> in patients with migraine treated with sumatriptan.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1500": {"data": {"text": "We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with sumatriptan.", "entity1": "sumatriptan", "entity2": "migraine", "span1": [107, 118], "span2": [85, 93]}, "bert_text": "We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with <e1> sumatriptan </e1> <e2> migraine </e2> treated with sumatriptan.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1501": {"data": {"text": "Tumor regression was observed with 0.5 mg doxorubicin/kg. Complete disappearance of the tumor was induced with 1.0 mg doxorubicin/kg.", "entity1": "doxorubicin", "entity2": "Tumor", "span1": [42, 53], "span2": [0, 5]}, "bert_text": "Tumor regression was observed with 0.5 mg <e1> doxorubicin </e1> <e2> Tumor </e2> regression was observed with 0.5 mg doxorubicin/kg. Complete disappearance of the tumor was induced with 1.0 mg doxorubicin/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1502": {"data": {"text": "Tumor regression was observed with 0.5 mg doxorubicin/kg. Complete disappearance of the tumor was induced with 1.0 mg doxorubicin/kg.", "entity1": "doxorubicin", "entity2": "tumor", "span1": [42, 53], "span2": [88, 93]}, "bert_text": "Tumor regression was observed with 0.5 mg <e1> doxorubicin </e1>/kg. Complete disappearance of the <e2> tumor </e2> was induced with 1.0 mg doxorubicin/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1503": {"data": {"text": "Tumor regression was observed with 0.5 mg doxorubicin/kg. Complete disappearance of the tumor was induced with 1.0 mg doxorubicin/kg.", "entity1": "doxorubicin", "entity2": "Tumor", "span1": [118, 129], "span2": [0, 5]}, "bert_text": "Tumor regression was observed with 0.5 mg doxorubicin/kg. Complete disappearance of the tumor was induced with 1.0 mg <e1> doxorubicin </e1> <e2> Tumor </e2> regression was observed with 0.5 mg doxorubicin/kg. Complete disappearance of the tumor was induced with 1.0 mg doxorubicin/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1504": {"data": {"text": "Tumor regression was observed with 0.5 mg doxorubicin/kg. Complete disappearance of the tumor was induced with 1.0 mg doxorubicin/kg.", "entity1": "doxorubicin", "entity2": "tumor", "span1": [118, 129], "span2": [88, 93]}, "bert_text": "Tumor regression was observed with 0.5 mg doxorubicin/kg. Complete disappearance of the tumor was induced with 1.0 mg <e1> doxorubicin </e1> <e2> tumor </e2> was induced with 1.0 mg doxorubicin/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1505": {"data": {"text": "Eight patients stopped using GTN because headache--attributed to its use--became intolerable.", "entity1": "GTN", "entity2": "headache--", "span1": [29, 32], "span2": [41, 51]}, "bert_text": "Eight patients stopped using <e1> GTN </e1> because <e2> headache-- </e2>attributed to its use--became intolerable.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1506": {"data": {"text": "Major azotemia (serum creatinine greater than 2.5 mg/dl or BUN greater than 50 mg/dl) occurred in only 2%.", "entity1": "creatinine", "entity2": "azotemia", "span1": [22, 32], "span2": [6, 14]}, "bert_text": "Major azotemia (serum <e1> creatinine </e1> <e2> azotemia </e2> (serum creatinine greater than 2.5 mg/dl or BUN greater than 50 mg/dl) occurred in only 2%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1507": {"data": {"text": "We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer.", "entity1": "paclitaxel", "entity2": "breast cancer", "span1": [33, 43], "span2": [212, 225]}, "bert_text": "We performed a phase II trial of <e1> paclitaxel </e1> 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1508": {"data": {"text": "We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer.", "entity1": "folinic acid", "entity2": "breast cancer", "span1": [88, 100], "span2": [212, 225]}, "bert_text": "We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by <e1> folinic acid </e1> 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1509": {"data": {"text": "We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic breast cancer.", "entity1": "5-fluorouracil", "entity2": "breast cancer", "span1": [127, 141], "span2": [212, 225]}, "bert_text": "We performed a phase II trial of paclitaxel 175 mg/m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before <e1> 5-fluorouracil </e1> 350 mg/m2 on days 1 to 3 every 28 days (TFL) in women with metastatic <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1510": {"data": {"text": "We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced tachycardia in two experiments involving nine normal subjects.", "entity1": "atenolol", "entity2": "tachycardia", "span1": [49, 57], "span2": [167, 178]}, "bert_text": "We compared the effects of single doses of 50 mg <e1> atenolol </e1> (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced <e2> tachycardia </e2> in two experiments involving nine normal subjects.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1511": {"data": {"text": "We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced tachycardia in two experiments involving nine normal subjects.", "entity1": "propranolol", "entity2": "tachycardia", "span1": [83, 94], "span2": [167, 178]}, "bert_text": "We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg <e1> propranolol </e1> (nonselective), and placebo on both exercise- and isoproterenol-induced <e2> tachycardia </e2> in two experiments involving nine normal subjects.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1512": {"data": {"text": "We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and isoproterenol-induced tachycardia in two experiments involving nine normal subjects.", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [145, 158], "span2": [167, 178]}, "bert_text": "We compared the effects of single doses of 50 mg atenolol (cardioselective), 40 mg propranolol (nonselective), and placebo on both exercise- and <e1> isoproterenol </e1>-induced <e2> tachycardia </e2> in two experiments involving nine normal subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1513": {"data": {"text": "The objective of this review is to summarize practical considerations of argatroban therapy in HIT.", "entity1": "argatroban", "entity2": "HIT", "span1": [73, 83], "span2": [95, 98]}, "bert_text": "The objective of this review is to summarize practical considerations of <e1> argatroban </e1> therapy in <e2> HIT </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1514": {"data": {"text": "Here we sought to generate information with regard to the interictal period in animals with pilocarpine-induced epilepsy.", "entity1": "pilocarpine", "entity2": "epilepsy", "span1": [92, 103], "span2": [112, 120]}, "bert_text": "Here we sought to generate information with regard to the interictal period in animals with <e1> pilocarpine </e1>-induced <e2> epilepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1515": {"data": {"text": "The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.", "entity1": "isradipine", "entity2": "headache", "span1": [142, 152], "span2": [27, 35]}, "bert_text": "The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with <e1> isradipine </e1> <e2> headache </e2>, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1516": {"data": {"text": "The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.", "entity1": "isradipine", "entity2": "dizziness", "span1": [142, 152], "span2": [37, 46]}, "bert_text": "The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with <e1> isradipine </e1> <e2> dizziness </e2>, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1517": {"data": {"text": "The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo.", "entity1": "isradipine", "entity2": "flushing", "span1": [142, 152], "span2": [64, 72]}, "bert_text": "The main side-effects were headache, dizziness, palpitation and flushing and these were not more frequent than reported in other studies with <e1> isradipine </e1> <e2> flushing </e2> and these were not more frequent than reported in other studies with isradipine or with placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1518": {"data": {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity1": "Chloroacetaldehyde", "entity2": "renal damage", "span1": [0, 18], "span2": [113, 125]}, "bert_text": "<e1> Chloroacetaldehyde </e1> (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for <e2> renal damage </e2> following anti-tumor therapy with IFO.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1519": {"data": {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity1": "Chloroacetaldehyde", "entity2": "tumor", "span1": [0, 18], "span2": [141, 146]}, "bert_text": "<e1> Chloroacetaldehyde </e1> (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-<e2> tumor </e2> therapy with IFO.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1520": {"data": {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity1": "CAA", "entity2": "renal damage", "span1": [20, 23], "span2": [113, 125]}, "bert_text": "Chloroacetaldehyde (<e1> CAA </e1>) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for <e2> renal damage </e2> following anti-tumor therapy with IFO.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1521": {"data": {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity1": "CAA", "entity2": "tumor", "span1": [20, 23], "span2": [141, 146]}, "bert_text": "Chloroacetaldehyde (<e1> CAA </e1>) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-<e2> tumor </e2> therapy with IFO.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1522": {"data": {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity1": "ifosfamide", "entity2": "renal damage", "span1": [65, 75], "span2": [113, 125]}, "bert_text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent <e1> ifosfamide </e1> (IFO) and putatively responsible for <e2> renal damage </e2> following anti-tumor therapy with IFO.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1523": {"data": {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity1": "ifosfamide", "entity2": "tumor", "span1": [65, 75], "span2": [141, 146]}, "bert_text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent <e1> ifosfamide </e1> (IFO) and putatively responsible for renal damage following anti-<e2> tumor </e2> therapy with IFO.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1524": {"data": {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity1": "IFO", "entity2": "renal damage", "span1": [77, 80], "span2": [113, 125]}, "bert_text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (<e1> IFO </e1>) and putatively responsible for <e2> renal damage </e2> following anti-tumor therapy with IFO.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1525": {"data": {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity1": "IFO", "entity2": "tumor", "span1": [77, 80], "span2": [141, 146]}, "bert_text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (<e1> IFO </e1>) and putatively responsible for renal damage following anti-<e2> tumor </e2> therapy with IFO.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1526": {"data": {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity1": "IFO", "entity2": "renal damage", "span1": [160, 163], "span2": [113, 125]}, "bert_text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with <e1> IFO </e1> <e2> renal damage </e2> following anti-tumor therapy with IFO.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1527": {"data": {"text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with IFO.", "entity1": "IFO", "entity2": "tumor", "span1": [160, 163], "span2": [141, 146]}, "bert_text": "Chloroacetaldehyde (CAA) is a metabolite of the alkylating agent ifosfamide (IFO) and putatively responsible for renal damage following anti-tumor therapy with <e1> IFO </e1> <e2> tumor </e2> therapy with IFO.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1528": {"data": {"text": "Early CY toxicity caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7-10 days.", "entity1": "CY", "entity2": "toxicity", "span1": [6, 8], "span2": [9, 17]}, "bert_text": "Early <e1> CY </e1> <e2> toxicity </e2> caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7-10 days.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1529": {"data": {"text": "Early CY toxicity caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7-10 days.", "entity1": "CY", "entity2": "haemorrhagic cystitis", "span1": [6, 8], "span2": [35, 56]}, "bert_text": "Early <e1> CY </e1> toxicity caused a typical <e2> haemorrhagic cystitis </e2> in both strains that was completely repaired in about 7-10 days.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1530": {"data": {"text": "The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.", "entity1": "examine vancomycin", "entity2": "renal impairment", "span1": [31, 49], "span2": [293, 309]}, "bert_text": "The aims of this study were to <e1> examine vancomycin </e1> (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2> renal impairment </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1531": {"data": {"text": "The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.", "entity1": "VCM", "entity2": "renal impairment", "span1": [281, 284], "span2": [293, 309]}, "bert_text": "The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible <e1> VCM </e1>-induced <e2> renal impairment </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, 0], "label": 1},
+	"1532": {"data": {"text": "The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.", "entity1": "oxygen", "entity2": "renal impairment", "span1": [118, 124], "span2": [293, 309]}, "bert_text": "The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive <e1> oxygen </e1> species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2> renal impairment </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1533": {"data": {"text": "The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of erdosteine, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced renal impairment in rats.", "entity1": "erdosteine", "entity2": "renal impairment", "span1": [170, 180], "span2": [293, 309]}, "bert_text": "The aims of this study were to examine vancomycin (VCM)-induced oxidative stress that promotes production of reactive oxygen species (ROS) and to investigate the role of <e1> erdosteine </e1>, an expectorant agent, which has also antioxidant properties, on kidney tissue against the possible VCM-induced <e2> renal impairment </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1534": {"data": {"text": "We recorded the eye movements of two patients with reversible downbeat nystagmus related to carbamazepine therapy.", "entity1": "carbamazepine", "entity2": "nystagmus", "span1": [92, 105], "span2": [71, 80]}, "bert_text": "We recorded the eye movements of two patients with reversible downbeat nystagmus related to <e1> carbamazepine </e1> <e2> nystagmus </e2> related to carbamazepine therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1535": {"data": {"text": "It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.", "entity1": "quinine", "entity2": "malaria", "span1": [158, 165], "span2": [48, 55]}, "bert_text": "It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <e1> quinine </e1> <e2> malaria </e2> patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1536": {"data": {"text": "It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.", "entity1": "quinine", "entity2": "jaundice", "span1": [158, 165], "span2": [69, 77]}, "bert_text": "It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <e1> quinine </e1> <e2> jaundice </e2> who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1537": {"data": {"text": "It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.", "entity1": "quinine", "entity2": "arrhythmia", "span1": [158, 165], "span2": [97, 107]}, "bert_text": "It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <e1> quinine </e1> <e2> arrhythmia </e2> (premature ventricular contraction) while getting quinine infusion was reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1538": {"data": {"text": "It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting quinine infusion was reported.", "entity1": "quinine", "entity2": "premature ventricular contraction", "span1": [158, 165], "span2": [109, 142]}, "bert_text": "It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia (premature ventricular contraction) while getting <e1> quinine </e1> <e2> premature ventricular contraction </e2>) while getting quinine infusion was reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1539": {"data": {"text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.\n", "entity1": "PEG", "entity2": "encephalopathy", "span1": [84, 87], "span2": [6, 20]}, "bert_text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including <e1> PEG </e1> <e2> encephalopathy </e2> and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1540": {"data": {"text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.\n", "entity1": "PEG", "entity2": "cerebral vasospasm", "span1": [84, 87], "span2": [25, 43]}, "bert_text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including <e1> PEG </e1> <e2> cerebral vasospasm </e2> after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1541": {"data": {"text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.\n", "entity1": "PEG", "entity2": "acute lymphoblastic leukemia", "span1": [84, 87], "span2": [149, 177]}, "bert_text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including <e1> PEG </e1>-asparaginase and intrathecal cytarabine for the treatment of <e2> acute lymphoblastic leukemia </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1542": {"data": {"text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.\n", "entity1": "cytarabine", "entity2": "encephalopathy", "span1": [117, 127], "span2": [6, 20]}, "bert_text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal <e1> cytarabine </e1> <e2> encephalopathy </e2> and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1543": {"data": {"text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.\n", "entity1": "cytarabine", "entity2": "cerebral vasospasm", "span1": [117, 127], "span2": [25, 43]}, "bert_text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal <e1> cytarabine </e1> <e2> cerebral vasospasm </e2> after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1544": {"data": {"text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia.\n", "entity1": "cytarabine", "entity2": "acute lymphoblastic leukemia", "span1": [117, 127], "span2": [149, 177]}, "bert_text": "Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG-asparaginase and intrathecal <e1> cytarabine </e1> for the treatment of <e2> acute lymphoblastic leukemia </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1545": {"data": {"text": "These findings demonstrate for the first time that a single high dose of METH induces long-lasting depressive-like behaviour in mice associated with a persistent disruption of frontostriatal dopaminergic and serotonergic homoeostasis.", "entity1": "METH", "entity2": "depressive", "span1": [73, 77], "span2": [99, 109]}, "bert_text": "These findings demonstrate for the first time that a single high dose of <e1> METH </e1> induces long-lasting <e2> depressive </e2>-like behaviour in mice associated with a persistent disruption of frontostriatal dopaminergic and serotonergic homoeostasis.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1546": {"data": {"text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.", "entity1": "puromycin aminonucleoside", "entity2": "structural injury", "span1": [108, 133], "span2": [79, 96]}, "bert_text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic <e1> puromycin aminonucleoside </e1> <e2> structural injury </e2> in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1547": {"data": {"text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.", "entity1": "puromycin aminonucleoside", "entity2": "nephropathy", "span1": [108, 133], "span2": [140, 151]}, "bert_text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic <e1> puromycin aminonucleoside </e1> (PAN) <e2> nephropathy </e2>, an experimental model of glomerular disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"1548": {"data": {"text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.", "entity1": "puromycin aminonucleoside", "entity2": "glomerular disease", "span1": [108, 133], "span2": [178, 196]}, "bert_text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic <e1> puromycin aminonucleoside </e1> (PAN) nephropathy, an experimental model of <e2> glomerular disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"1549": {"data": {"text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.", "entity1": "PAN", "entity2": "structural injury", "span1": [135, 138], "span2": [79, 96]}, "bert_text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (<e1> PAN </e1> <e2> structural injury </e2> in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1550": {"data": {"text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.", "entity1": "PAN", "entity2": "nephropathy", "span1": [135, 138], "span2": [140, 151]}, "bert_text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (<e1> PAN </e1>) <e2> nephropathy </e2>, an experimental model of glomerular disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"1551": {"data": {"text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease.", "entity1": "PAN", "entity2": "glomerular disease", "span1": [135, 138], "span2": [178, 196]}, "bert_text": "We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (<e1> PAN </e1>) nephropathy, an experimental model of <e2> glomerular disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"1552": {"data": {"text": "Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.\n", "entity1": "timolol", "entity2": "Intraoperative bradycardia", "span1": [59, 66], "span2": [0, 26]}, "bert_text": "Intraoperative bradycardia and hypotension associated with <e1> timolol </e1> <e2> Intraoperative bradycardia </e2> and hypotension associated with timolol and pilocarpine eye drops.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1553": {"data": {"text": "Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.\n", "entity1": "timolol", "entity2": "hypotension", "span1": [59, 66], "span2": [31, 42]}, "bert_text": "Intraoperative bradycardia and hypotension associated with <e1> timolol </e1> <e2> hypotension </e2> associated with timolol and pilocarpine eye drops.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1554": {"data": {"text": "Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.\n", "entity1": "pilocarpine", "entity2": "Intraoperative bradycardia", "span1": [71, 82], "span2": [0, 26]}, "bert_text": "Intraoperative bradycardia and hypotension associated with timolol and <e1> pilocarpine </e1> <e2> Intraoperative bradycardia </e2> and hypotension associated with timolol and pilocarpine eye drops.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1555": {"data": {"text": "Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops.\n", "entity1": "pilocarpine", "entity2": "hypotension", "span1": [71, 82], "span2": [31, 42]}, "bert_text": "Intraoperative bradycardia and hypotension associated with timolol and <e1> pilocarpine </e1> <e2> hypotension </e2> associated with timolol and pilocarpine eye drops.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1556": {"data": {"text": "Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.", "entity1": "phosphatidylserine", "entity2": "anemia", "span1": [131, 149], "span2": [15, 21]}, "bert_text": "Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of <e1> phosphatidylserine </e1> <e2> anemia </e2> could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1557": {"data": {"text": "Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.", "entity1": "phosphatidylserine", "entity2": "death", "span1": [131, 149], "span2": [73, 78]}, "bert_text": "Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of <e1> phosphatidylserine </e1> <e2> death </e2> or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1558": {"data": {"text": "Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.", "entity1": "PS", "entity2": "anemia", "span1": [151, 153], "span2": [15, 21]}, "bert_text": "Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (<e1> PS </e1> <e2> anemia </e2> could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1559": {"data": {"text": "Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.", "entity1": "PS", "entity2": "death", "span1": [151, 153], "span2": [73, 78]}, "bert_text": "Alternatively, anemia could result from accelerated suicidal erythrocyte death or eryptosis, which is characterized by exposure of phosphatidylserine (<e1> PS </e1> <e2> death </e2> or eryptosis, which is characterized by exposure of phosphatidylserine (PS) at the erythrocyte surface and by cell shrinkage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1560": {"data": {"text": "Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.", "entity1": "temsirolimus", "entity2": "tumor", "span1": [43, 55], "span2": [66, 71]}, "bert_text": "Comparison of the two biopsies showed that <e1> temsirolimus </e1> inhibited <e2> tumor </e2> cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1561": {"data": {"text": "Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic tumor cells.", "entity1": "temsirolimus", "entity2": "tumor", "span1": [43, 55], "span2": [175, 180]}, "bert_text": "Comparison of the two biopsies showed that <e1> temsirolimus </e1> inhibited tumor cell proliferation through cell cycle arrest, but did not induce any change in the number of apoptotic <e2> tumor </e2> cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1562": {"data": {"text": "At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms).", "entity1": "K", "entity2": "tremor", "span1": [150, 151], "span2": [127, 133]}, "bert_text": "At the end of each 14-day treatment, a dose-response curve (DRC) was performed, and airway (FEV1, FEF25-75) chronotropic (HR), tremor, and metabolic (<e1> K </e1> <e2> tremor </e2>, and metabolic (K, Glu) responses were measured at each step (from 100 to 4,000 micrograms).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1563": {"data": {"text": "A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve >19 mg/L x h or a peak serum level of indinavir >12 mg/L. In 4 children, indinavir was discontinued because of nephrotoxicity.", "entity1": "indinavir", "entity2": "nephrotoxicity", "span1": [146, 155], "span2": [219, 233]}, "bert_text": "A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve >19 mg/L x h or a peak serum level of <e1> indinavir </e1> >12 mg/L. In 4 children, indinavir was discontinued because of <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1564": {"data": {"text": "A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve >19 mg/L x h or a peak serum level of indinavir >12 mg/L. In 4 children, indinavir was discontinued because of nephrotoxicity.", "entity1": "indinavir", "entity2": "nephrotoxicity", "span1": [181, 190], "span2": [219, 233]}, "bert_text": "A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve >19 mg/L x h or a peak serum level of indinavir >12 mg/L. In 4 children, <e1> indinavir </e1> was discontinued because of <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1565": {"data": {"text": "On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).", "entity1": "lindane", "entity2": "convulsion", "span1": [204, 211], "span2": [83, 93]}, "bert_text": "On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of <e1> lindane </e1> <e2> convulsion </e2> incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1566": {"data": {"text": "On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).", "entity1": "lindane", "entity2": "convulsion", "span1": [204, 211], "span2": [147, 157]}, "bert_text": "On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of <e1> lindane </e1> <e2> convulsion </e2> following injection with a convulsive dose of lindane (8 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1567": {"data": {"text": "On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane (8 mg/kg, i.p.).", "entity1": "lindane", "entity2": "convulsive", "span1": [204, 211], "span2": [185, 195]}, "bert_text": "On the contrary, pretreatment with L-NAME (500, 700 and 900 mg/kg, i.p.) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of <e1> lindane </e1> <e2> convulsive </e2> dose of lindane (8 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1568": {"data": {"text": "Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke.", "entity1": "nimodipine", "entity2": "subarachnoid hemorrhage", "span1": [46, 56], "span2": [96, 119]}, "bert_text": "Selectivity for the cerebrovascular bed makes <e1> nimodipine </e1> potentially useful in the treatment of <e2> subarachnoid hemorrhage </e2>, migraine headache, dementia, and stroke.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1569": {"data": {"text": "Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke.", "entity1": "nimodipine", "entity2": "migraine headache", "span1": [46, 56], "span2": [121, 138]}, "bert_text": "Selectivity for the cerebrovascular bed makes <e1> nimodipine </e1> potentially useful in the treatment of subarachnoid hemorrhage, <e2> migraine headache </e2>, dementia, and stroke.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1570": {"data": {"text": "Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke.", "entity1": "nimodipine", "entity2": "dementia", "span1": [46, 56], "span2": [140, 148]}, "bert_text": "Selectivity for the cerebrovascular bed makes <e1> nimodipine </e1> potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, <e2> dementia </e2>, and stroke.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1571": {"data": {"text": "Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and stroke.", "entity1": "nimodipine", "entity2": "stroke", "span1": [46, 56], "span2": [154, 160]}, "bert_text": "Selectivity for the cerebrovascular bed makes <e1> nimodipine </e1> potentially useful in the treatment of subarachnoid hemorrhage, migraine headache, dementia, and <e2> stroke </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1572": {"data": {"text": "Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.", "entity1": "ATP", "entity2": "Hypotension", "span1": [23, 26], "span2": [0, 11]}, "bert_text": "Hypotension induced by <e1> ATP </e1> <e2> Hypotension </e2> induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1573": {"data": {"text": "Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.", "entity1": "ATP", "entity2": "Hypotension", "span1": [465, 468], "span2": [0, 11]}, "bert_text": "Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after <e1> ATP </e1> <e2> Hypotension </e2> induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1574": {"data": {"text": "Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.", "entity1": "oxygen", "entity2": "Hypotension", "span1": [334, 340], "span2": [0, 11]}, "bert_text": "Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body <e1> oxygen </e1> <e2> Hypotension </e2> induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure (p less than 0.001), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.001), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), total body oxygen consumption (p less than 0.05), and heart rate (p less than 0.001); all these variables returned normal within 30 min after ATP was stopped.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1575": {"data": {"text": "The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.\n", "entity1": "misoprostol", "entity2": "renal dysfunction", "span1": [29, 40], "span2": [65, 82]}, "bert_text": "The dose-dependent effect of <e1> misoprostol </e1> on indomethacin-induced <e2> renal dysfunction </e2> in well compensated cirrhosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1576": {"data": {"text": "The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.\n", "entity1": "misoprostol", "entity2": "cirrhosis", "span1": [29, 40], "span2": [103, 112]}, "bert_text": "The dose-dependent effect of <e1> misoprostol </e1> on indomethacin-induced renal dysfunction in well compensated <e2> cirrhosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1577": {"data": {"text": "The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.\n", "entity1": "indomethacin", "entity2": "renal dysfunction", "span1": [44, 56], "span2": [65, 82]}, "bert_text": "The dose-dependent effect of misoprostol on <e1> indomethacin </e1>-induced <e2> renal dysfunction </e2> in well compensated cirrhosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1578": {"data": {"text": "The dose-dependent effect of misoprostol on indomethacin-induced renal dysfunction in well compensated cirrhosis.\n", "entity1": "indomethacin", "entity2": "cirrhosis", "span1": [44, 56], "span2": [103, 112]}, "bert_text": "The dose-dependent effect of misoprostol on <e1> indomethacin </e1>-induced renal dysfunction in well compensated <e2> cirrhosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1579": {"data": {"text": "These findings indicate that GTN has a reduced efficacy and tolerability by comparison with DCF in the treatment of primary dysmenorrhea.", "entity1": "GTN", "entity2": "primary dysmenorrhea", "span1": [29, 32], "span2": [116, 136]}, "bert_text": "These findings indicate that <e1> GTN </e1> has a reduced efficacy and tolerability by comparison with DCF in the treatment of <e2> primary dysmenorrhea </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1580": {"data": {"text": "These findings indicate that GTN has a reduced efficacy and tolerability by comparison with DCF in the treatment of primary dysmenorrhea.", "entity1": "DCF", "entity2": "primary dysmenorrhea", "span1": [92, 95], "span2": [116, 136]}, "bert_text": "These findings indicate that GTN has a reduced efficacy and tolerability by comparison with <e1> DCF </e1> in the treatment of <e2> primary dysmenorrhea </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1581": {"data": {"text": "The side effects of azathioprine include anemia, which has been attributed to bone marrow suppression.", "entity1": "azathioprine", "entity2": "anemia", "span1": [20, 32], "span2": [41, 47]}, "bert_text": "The side effects of <e1> azathioprine </e1> include <e2> anemia </e2>, which has been attributed to bone marrow suppression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1582": {"data": {"text": "Dexamethasone- (Dex-) induced hypertension is associated with enhanced oxidative stress.", "entity1": "Dexamethasone-", "entity2": "hypertension", "span1": [0, 14], "span2": [30, 42]}, "bert_text": "<e1> Dexamethasone- </e1> (Dex-) induced <e2> hypertension </e2> is associated with enhanced oxidative stress.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1583": {"data": {"text": "Dexamethasone- (Dex-) induced hypertension is associated with enhanced oxidative stress.", "entity1": "Dex-", "entity2": "hypertension", "span1": [16, 20], "span2": [30, 42]}, "bert_text": "Dexamethasone- (<e1> Dex- </e1>) induced <e2> hypertension </e2> is associated with enhanced oxidative stress.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1584": {"data": {"text": "HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after heparin exposure.", "entity1": "heparin", "entity2": "HIT", "span1": [116, 123], "span2": [0, 3]}, "bert_text": "HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after <e1> heparin </e1> <e2> HIT </e2> must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after heparin exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1585": {"data": {"text": "HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after heparin exposure.", "entity1": "heparin", "entity2": "thrombosis", "span1": [116, 123], "span2": [58, 68]}, "bert_text": "HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after <e1> heparin </e1> <e2> thrombosis </e2> and suspected whenever thrombosis occurs after heparin exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1586": {"data": {"text": "HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after heparin exposure.", "entity1": "heparin", "entity2": "thrombosis", "span1": [116, 123], "span2": [92, 102]}, "bert_text": "HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after <e1> heparin </e1> <e2> thrombosis </e2> occurs after heparin exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1587": {"data": {"text": "The hyperactivity induced by D-amphetamine (10 mumol/kg) was significantly reduced by DSP4 pretreatment.", "entity1": "D-amphetamine", "entity2": "hyperactivity", "span1": [29, 42], "span2": [4, 17]}, "bert_text": "The hyperactivity induced by <e1> D-amphetamine </e1> <e2> hyperactivity </e2> induced by D-amphetamine (10 mumol/kg) was significantly reduced by DSP4 pretreatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1588": {"data": {"text": "S-1 may be administered safely to patients with 5-FU-induced cardiotoxicity.", "entity1": "5-FU", "entity2": "cardiotoxicity", "span1": [48, 52], "span2": [61, 75]}, "bert_text": "S-1 may be administered safely to patients with <e1> 5-FU </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1589": {"data": {"text": "The level of GFAP, CD11b, TNF-a, ROS and nitrite levels were increased.", "entity1": "nitrite", "entity2": "TNF", "span1": [41, 48], "span2": [26, 29]}, "bert_text": "The level of GFAP, CD11b, TNF-a, ROS and <e1> nitrite </e1> <e2> TNF </e2>-a, ROS and nitrite levels were increased.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1590": {"data": {"text": "Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion.", "entity1": "desvenlafaxine", "entity2": "nausea", "span1": [25, 39], "span2": [63, 69]}, "bert_text": "Her medications included <e1> desvenlafaxine </e1>, and symptoms included <e2> nausea </e2>, anxiety and confusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1591": {"data": {"text": "Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion.", "entity1": "desvenlafaxine", "entity2": "anxiety", "span1": [25, 39], "span2": [71, 78]}, "bert_text": "Her medications included <e1> desvenlafaxine </e1>, and symptoms included nausea, <e2> anxiety </e2> and confusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1592": {"data": {"text": "Her medications included desvenlafaxine, and symptoms included nausea, anxiety and confusion.", "entity1": "desvenlafaxine", "entity2": "confusion", "span1": [25, 39], "span2": [83, 92]}, "bert_text": "Her medications included <e1> desvenlafaxine </e1>, and symptoms included nausea, anxiety and <e2> confusion </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1593": {"data": {"text": "Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy.", "entity1": "cyclosporin A", "entity2": "hypertensive", "span1": [79, 92], "span2": [53, 65]}, "bert_text": "Seven of the 13 patients had exhibited a subclinical hypertensive state before <e1> cyclosporin A </e1> <e2> hypertensive </e2> state before cyclosporin A therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1594": {"data": {"text": "LIMITATIONS: New evidence on aspirin for the primary prevention of CVD is limited.", "entity1": "aspirin", "entity2": "CVD", "span1": [29, 36], "span2": [67, 70]}, "bert_text": "LIMITATIONS: New evidence on <e1> aspirin </e1> for the primary prevention of <e2> CVD </e2> is limited.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1595": {"data": {"text": "Growth-associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with cycloheximide.\n", "entity1": "cycloheximide", "entity2": "epileptic", "span1": [110, 123], "span2": [82, 91]}, "bert_text": "Growth-associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with <e1> cycloheximide </e1> <e2> epileptic </e2> rats treated with cycloheximide.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1596": {"data": {"text": "To our knowledge, this is the second case of minocycline-induced vasculitis satisfying the criteria.", "entity1": "minocycline", "entity2": "vasculitis", "span1": [45, 56], "span2": [65, 75]}, "bert_text": "To our knowledge, this is the second case of <e1> minocycline </e1>-induced <e2> vasculitis </e2> satisfying the criteria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1597": {"data": {"text": "Anti-thyroid drugs, like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of hyperthyroidism.", "entity1": "carbimazole", "entity2": "hyperthyroidism", "span1": [25, 36], "span2": [109, 124]}, "bert_text": "Anti-thyroid drugs, like <e1> carbimazole </e1> and propylthiouracil (PTU) are commonly prescribed for the treatment of <e2> hyperthyroidism </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1598": {"data": {"text": "Anti-thyroid drugs, like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of hyperthyroidism.", "entity1": "propylthiouracil", "entity2": "hyperthyroidism", "span1": [41, 57], "span2": [109, 124]}, "bert_text": "Anti-thyroid drugs, like carbimazole and <e1> propylthiouracil </e1> (PTU) are commonly prescribed for the treatment of <e2> hyperthyroidism </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1599": {"data": {"text": "Anti-thyroid drugs, like carbimazole and propylthiouracil (PTU) are commonly prescribed for the treatment of hyperthyroidism.", "entity1": "PTU", "entity2": "hyperthyroidism", "span1": [59, 62], "span2": [109, 124]}, "bert_text": "Anti-thyroid drugs, like carbimazole and propylthiouracil (<e1> PTU </e1>) are commonly prescribed for the treatment of <e2> hyperthyroidism </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1600": {"data": {"text": "Major bleeding is of primary concern in patients receiving heparin therapy.", "entity1": "heparin", "entity2": "bleeding", "span1": [59, 66], "span2": [6, 14]}, "bert_text": "Major bleeding is of primary concern in patients receiving <e1> heparin </e1> <e2> bleeding </e2> is of primary concern in patients receiving heparin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1601": {"data": {"text": "RESULTS: Anxiety was documented in both groups of PDN treated rats compared with controls.", "entity1": "PDN", "entity2": "Anxiety", "span1": [50, 53], "span2": [9, 16]}, "bert_text": "RESULTS: Anxiety was documented in both groups of <e1> PDN </e1> <e2> Anxiety </e2> was documented in both groups of PDN treated rats compared with controls.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1602": {"data": {"text": "In laboratory animals, histology is most commonly used to study doxorubicin-induced cardiotoxicity.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [64, 75], "span2": [84, 98]}, "bert_text": "In laboratory animals, histology is most commonly used to study <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1603": {"data": {"text": "Detailed history obtained retrospectively revealed that the patient took zolmitriptan sparingly only when she had migraines.", "entity1": "zolmitriptan", "entity2": "migraines", "span1": [73, 85], "span2": [114, 123]}, "bert_text": "Detailed history obtained retrospectively revealed that the patient took <e1> zolmitriptan </e1> sparingly only when she had <e2> migraines </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1604": {"data": {"text": "However, no reports are available on the role of Ca(2+) in aconitine poisoning.", "entity1": "Ca(2", "entity2": "poisoning", "span1": [49, 53], "span2": [69, 78]}, "bert_text": "However, no reports are available on the role of <e1> Ca(2 </e1>+) in aconitine <e2> poisoning </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1605": {"data": {"text": "However, no reports are available on the role of Ca(2+) in aconitine poisoning.", "entity1": "aconitine", "entity2": "poisoning", "span1": [59, 68], "span2": [69, 78]}, "bert_text": "However, no reports are available on the role of Ca(2+) in <e1> aconitine </e1> <e2> poisoning </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1606": {"data": {"text": "Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.\n", "entity1": "glucose", "entity2": "schizophrenia", "span1": [127, 134], "span2": [36, 49]}, "bert_text": "Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous <e1> glucose </e1> <e2> schizophrenia </e2> treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1607": {"data": {"text": "Four out of 23 consecutive patients treated with high-dose Ara-C for lymphomas in our institution developed a strikingly similar syndrome during the perfusion.", "entity1": "Ara", "entity2": "lymphomas", "span1": [59, 62], "span2": [69, 78]}, "bert_text": "Four out of 23 consecutive patients treated with high-dose <e1> Ara </e1>-C for <e2> lymphomas </e2> in our institution developed a strikingly similar syndrome during the perfusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1608": {"data": {"text": "We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during VPA treatment.", "entity1": "VPA", "entity2": "nonalcoholic fatty liver disease", "span1": [109, 112], "span2": [20, 52]}, "bert_text": "We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during <e1> VPA </e1> <e2> nonalcoholic fatty liver disease </e2> (NAFLD) arising in a child who developed obesity during VPA treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1609": {"data": {"text": "We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during VPA treatment.", "entity1": "VPA", "entity2": "NAFLD", "span1": [109, 112], "span2": [54, 59]}, "bert_text": "We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during <e1> VPA </e1> <e2> NAFLD </e2>) arising in a child who developed obesity during VPA treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1610": {"data": {"text": "We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during VPA treatment.", "entity1": "VPA", "entity2": "obesity", "span1": [109, 112], "span2": [94, 101]}, "bert_text": "We report a case of nonalcoholic fatty liver disease (NAFLD) arising in a child who developed obesity during <e1> VPA </e1> <e2> obesity </e2> during VPA treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1611": {"data": {"text": "Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication.\n", "entity1": "cocaine", "entity2": "Bilateral haemorrhagic infarction", "span1": [63, 70], "span2": [0, 33]}, "bert_text": "Bilateral haemorrhagic infarction of the globus pallidus after <e1> cocaine </e1> <e2> Bilateral haemorrhagic infarction </e2> of the globus pallidus after cocaine and alcohol intoxication.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1612": {"data": {"text": "Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication.\n", "entity1": "cocaine", "entity2": "intoxication", "span1": [63, 70], "span2": [83, 95]}, "bert_text": "Bilateral haemorrhagic infarction of the globus pallidus after <e1> cocaine </e1> and alcohol <e2> intoxication </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1613": {"data": {"text": "Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication.\n", "entity1": "alcohol", "entity2": "Bilateral haemorrhagic infarction", "span1": [75, 82], "span2": [0, 33]}, "bert_text": "Bilateral haemorrhagic infarction of the globus pallidus after cocaine and <e1> alcohol </e1> <e2> Bilateral haemorrhagic infarction </e2> of the globus pallidus after cocaine and alcohol intoxication.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1614": {"data": {"text": "Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication.\n", "entity1": "alcohol", "entity2": "intoxication", "span1": [75, 82], "span2": [83, 95]}, "bert_text": "Bilateral haemorrhagic infarction of the globus pallidus after cocaine and <e1> alcohol </e1> <e2> intoxication </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1615": {"data": {"text": "Neither progesterone nor estradiol effects on bupivacaine arrhythmogenicity were potentiated by epinephrine.", "entity1": "progesterone", "entity2": "arrhythmogenicity", "span1": [8, 20], "span2": [58, 75]}, "bert_text": "Neither <e1> progesterone </e1> nor estradiol effects on bupivacaine <e2> arrhythmogenicity </e2> were potentiated by epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1616": {"data": {"text": "Neither progesterone nor estradiol effects on bupivacaine arrhythmogenicity were potentiated by epinephrine.", "entity1": "estradiol", "entity2": "arrhythmogenicity", "span1": [25, 34], "span2": [58, 75]}, "bert_text": "Neither progesterone nor <e1> estradiol </e1> effects on bupivacaine <e2> arrhythmogenicity </e2> were potentiated by epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1617": {"data": {"text": "Neither progesterone nor estradiol effects on bupivacaine arrhythmogenicity were potentiated by epinephrine.", "entity1": "bupivacaine", "entity2": "arrhythmogenicity", "span1": [46, 57], "span2": [58, 75]}, "bert_text": "Neither progesterone nor estradiol effects on <e1> bupivacaine </e1> <e2> arrhythmogenicity </e2> were potentiated by epinephrine.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1618": {"data": {"text": "Neither progesterone nor estradiol effects on bupivacaine arrhythmogenicity were potentiated by epinephrine.", "entity1": "epinephrine", "entity2": "arrhythmogenicity", "span1": [96, 107], "span2": [58, 75]}, "bert_text": "Neither progesterone nor estradiol effects on bupivacaine arrhythmogenicity were potentiated by <e1> epinephrine </e1> <e2> arrhythmogenicity </e2> were potentiated by epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1619": {"data": {"text": "UNASSIGNED: Epidemiological studies of 1,3-butadiene have suggest that exposures to humans are associated with chronic myeloid leukemia (CML).", "entity1": "1,3-butadiene", "entity2": "chronic myeloid leukemia", "span1": [39, 52], "span2": [111, 135]}, "bert_text": "UNASSIGNED: Epidemiological studies of <e1> 1,3-butadiene </e1> have suggest that exposures to humans are associated with <e2> chronic myeloid leukemia </e2> (CML).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1620": {"data": {"text": "UNASSIGNED: Epidemiological studies of 1,3-butadiene have suggest that exposures to humans are associated with chronic myeloid leukemia (CML).", "entity1": "1,3-butadiene", "entity2": "CML", "span1": [39, 52], "span2": [137, 140]}, "bert_text": "UNASSIGNED: Epidemiological studies of <e1> 1,3-butadiene </e1> have suggest that exposures to humans are associated with chronic myeloid leukemia (<e2> CML </e2>).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1621": {"data": {"text": "We conclude that an H1 antagonist may be useful in preventing hypotension caused by iv cimetidine, since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor.", "entity1": "cimetidine", "entity2": "hypotension", "span1": [87, 97], "span2": [62, 73]}, "bert_text": "We conclude that an H1 antagonist may be useful in preventing hypotension caused by iv <e1> cimetidine </e1> <e2> hypotension </e2> caused by iv cimetidine, since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"1622": {"data": {"text": "We conclude that an H1 antagonist may be useful in preventing hypotension caused by iv cimetidine, since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor.", "entity1": "cimetidine", "entity2": "hypotension", "span1": [134, 144], "span2": [62, 73]}, "bert_text": "We conclude that an H1 antagonist may be useful in preventing hypotension caused by iv cimetidine, since the vasodilating activity of <e1> cimetidine </e1> <e2> hypotension </e2> caused by iv cimetidine, since the vasodilating activity of cimetidine is mediated, in part, through the H1 receptor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"1623": {"data": {"text": "Hence, our results suggest that aconitine significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.", "entity1": "aconitine", "entity2": "arrhythmia", "span1": [32, 41], "span2": [94, 104]}, "bert_text": "Hence, our results suggest that <e1> aconitine </e1> significantly aggravates Ca(2+) overload and causes <e2> arrhythmia </e2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1624": {"data": {"text": "Hence, our results suggest that aconitine significantly aggravates Ca(2+) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.", "entity1": "Ca(2", "entity2": "arrhythmia", "span1": [67, 71], "span2": [94, 104]}, "bert_text": "Hence, our results suggest that aconitine significantly aggravates <e1> Ca(2 </e1>+) overload and causes <e2> arrhythmia </e2> and finally promotes apoptotic development via phosphorylation of P38 mitogen-activated protein kinase.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1625": {"data": {"text": "Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.", "entity1": "cocaine", "entity2": "myocardial necrosis", "span1": [184, 191], "span2": [83, 102]}, "bert_text": "Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with <e1> cocaine </e1> <e2> myocardial necrosis </e2> make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"1626": {"data": {"text": "Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.", "entity1": "cocaine", "entity2": "myocardial infarction", "span1": [184, 191], "span2": [130, 151]}, "bert_text": "Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with <e1> cocaine </e1> <e2> myocardial infarction </e2> (MI) difficult in patients with cocaine-associated chest pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1627": {"data": {"text": "Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.", "entity1": "cocaine", "entity2": "MI", "span1": [184, 191], "span2": [153, 155]}, "bert_text": "Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with <e1> cocaine </e1> <e2> MI </e2>) difficult in patients with cocaine-associated chest pain.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1628": {"data": {"text": "Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with cocaine-associated chest pain.", "entity1": "cocaine", "entity2": "chest pain", "span1": [184, 191], "span2": [203, 213]}, "bert_text": "Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction (MI) difficult in patients with <e1> cocaine </e1>-associated <e2> chest pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1629": {"data": {"text": "Levodopa-induced dyskinesias are improved by fluoxetine.\n", "entity1": "Levodopa", "entity2": "dyskinesias", "span1": [0, 8], "span2": [17, 28]}, "bert_text": "<e1> Levodopa </e1>-induced <e2> dyskinesias </e2> are improved by fluoxetine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1630": {"data": {"text": "Levodopa-induced dyskinesias are improved by fluoxetine.\n", "entity1": "fluoxetine", "entity2": "dyskinesias", "span1": [45, 55], "span2": [17, 28]}, "bert_text": "Levodopa-induced dyskinesias are improved by <e1> fluoxetine </e1> <e2> dyskinesias </e2> are improved by fluoxetine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1631": {"data": {"text": "Misoprostol (200 micrograms) has been shown to acutely counteract the indomethacin-induced renal dysfunction in well compensated cirrhotic patients.", "entity1": "Misoprostol", "entity2": "renal dysfunction", "span1": [0, 11], "span2": [91, 108]}, "bert_text": "<e1> Misoprostol </e1> (200 micrograms) has been shown to acutely counteract the indomethacin-induced <e2> renal dysfunction </e2> in well compensated cirrhotic patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1632": {"data": {"text": "Misoprostol (200 micrograms) has been shown to acutely counteract the indomethacin-induced renal dysfunction in well compensated cirrhotic patients.", "entity1": "indomethacin", "entity2": "renal dysfunction", "span1": [70, 82], "span2": [91, 108]}, "bert_text": "Misoprostol (200 micrograms) has been shown to acutely counteract the <e1> indomethacin </e1>-induced <e2> renal dysfunction </e2> in well compensated cirrhotic patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1633": {"data": {"text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [71, 79], "span2": [50, 61]}, "bert_text": "We evaluated the severity of motor disability and dyskinesias in seven <e1> levodopa </e1> <e2> dyskinesias </e2> in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1634": {"data": {"text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [71, 79], "span2": [105, 124]}, "bert_text": "We evaluated the severity of motor disability and dyskinesias in seven <e1> levodopa </e1>-responsive patients with <e2> Parkinson's disease </e2> after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1635": {"data": {"text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "entity1": "dopamine", "entity2": "dyskinesias", "span1": [165, 173], "span2": [50, 61]}, "bert_text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed <e1> dopamine </e1> <e2> dyskinesias </e2> in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1636": {"data": {"text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "entity1": "dopamine", "entity2": "Parkinson's disease", "span1": [165, 173], "span2": [105, 124]}, "bert_text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed <e1> dopamine </e1> <e2> Parkinson's disease </e2> after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1637": {"data": {"text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "entity1": "apomorphine", "entity2": "dyskinesias", "span1": [183, 194], "span2": [50, 61]}, "bert_text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, <e1> apomorphine </e1> <e2> dyskinesias </e2> in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1638": {"data": {"text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "entity1": "apomorphine", "entity2": "Parkinson's disease", "span1": [183, 194], "span2": [105, 124]}, "bert_text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, <e1> apomorphine </e1> <e2> Parkinson's disease </e2> after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1639": {"data": {"text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "entity1": "fluoxetine", "entity2": "dyskinesias", "span1": [235, 245], "span2": [50, 61]}, "bert_text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of <e1> fluoxetine </e1> <e2> dyskinesias </e2> in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1640": {"data": {"text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "entity1": "fluoxetine", "entity2": "Parkinson's disease", "span1": [235, 245], "span2": [105, 124]}, "bert_text": "We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of <e1> fluoxetine </e1> <e2> Parkinson's disease </e2> after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/-", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1641": {"data": {"text": "Induction of the ventricular tachyarrhythmia was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.", "entity1": "l-sotalol", "entity2": "ventricular tachyarrhythmia", "span1": [69, 78], "span2": [17, 44]}, "bert_text": "Induction of the ventricular tachyarrhythmia was prevented by oral d,<e1> l-sotalol </e1> <e2> ventricular tachyarrhythmia </e2> was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1642": {"data": {"text": "Induction of the ventricular tachyarrhythmia was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.", "entity1": "l-sotalol", "entity2": "ventricular tachyarrhythmia", "span1": [69, 78], "span2": [105, 132]}, "bert_text": "Induction of the ventricular tachyarrhythmia was prevented by oral d,<e1> l-sotalol </e1> in 35 (43%) patients; the <e2> ventricular tachyarrhythmia </e2> remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1643": {"data": {"text": "Induction of the ventricular tachyarrhythmia was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.", "entity1": "l-sotalol", "entity2": "ventricular tachyarrhythmia", "span1": [231, 240], "span2": [17, 44]}, "bert_text": "Induction of the ventricular tachyarrhythmia was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,<e1> l-sotalol </e1> <e2> ventricular tachyarrhythmia </e2> was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1644": {"data": {"text": "Induction of the ventricular tachyarrhythmia was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.", "entity1": "l-sotalol", "entity2": "ventricular tachyarrhythmia", "span1": [231, 240], "span2": [105, 132]}, "bert_text": "Induction of the ventricular tachyarrhythmia was prevented by oral d,l-sotalol in 35 (43%) patients; the ventricular tachyarrhythmia remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,<e1> l-sotalol </e1> <e2> ventricular tachyarrhythmia </e2> remained inducible in 40 (49%) patients; and two (2.5%) patients did not tolerate even 40 mg of d,l-sotalol once daily.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1645": {"data": {"text": "Amiodarone is an anti-arrhythmic drug for life-threatening tachycardia, but various adverse effects have been reported.", "entity1": "Amiodarone", "entity2": "tachycardia", "span1": [0, 10], "span2": [59, 70]}, "bert_text": "<e1> Amiodarone </e1> is an anti-arrhythmic drug for life-threatening <e2> tachycardia </e2>, but various adverse effects have been reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1646": {"data": {"text": "Pilocarpine produced neuronal death in the hippocampus, which showed pyknotic changes.", "entity1": "Pilocarpine", "entity2": "neuronal death", "span1": [0, 11], "span2": [21, 35]}, "bert_text": "<e1> Pilocarpine </e1> produced <e2> neuronal death </e2> in the hippocampus, which showed pyknotic changes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1647": {"data": {"text": "Verapamil stimulation test in hyperprolactinemia: loss of prolactin response in anatomic or functional stalk effect.\n", "entity1": "Verapamil", "entity2": "hyperprolactinemia", "span1": [0, 9], "span2": [30, 48]}, "bert_text": "<e1> Verapamil </e1> stimulation test in <e2> hyperprolactinemia </e2>: loss of prolactin response in anatomic or functional stalk effect.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1648": {"data": {"text": "The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).", "entity1": "morphine", "entity2": "hyperalgesia", "span1": [26, 34], "span2": [146, 158]}, "bert_text": "The antinociception after <e1> morphine </e1> (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of <e2> hyperalgesia </e2> in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1649": {"data": {"text": "The antinociception after morphine (3.2 mg/kg) was increased by co-administration with CNSB002 from 28.0 and 31.7% to 114.6 and 56.9% reversal of hyperalgesia in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).", "entity1": "CNSB002", "entity2": "hyperalgesia", "span1": [87, 94], "span2": [146, 158]}, "bert_text": "The antinociception after morphine (3.2 mg/kg) was increased by co-administration with <e1> CNSB002 </e1> from 28.0 and 31.7% to 114.6 and 56.9% reversal of <e2> hyperalgesia </e2> in the inflammatory and neuropathic models, respectively (P < 0.01; one-way analysis of variance-significantly greater than either drug given alone).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1650": {"data": {"text": "Resuscitation with lipid, epinephrine, or both in levobupivacaine-induced cardiac toxicity in newborn piglets.\n", "entity1": "epinephrine", "entity2": "cardiac toxicity", "span1": [26, 37], "span2": [74, 90]}, "bert_text": "Resuscitation with lipid, <e1> epinephrine </e1>, or both in levobupivacaine-induced <e2> cardiac toxicity </e2> in newborn piglets.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1651": {"data": {"text": "Resuscitation with lipid, epinephrine, or both in levobupivacaine-induced cardiac toxicity in newborn piglets.\n", "entity1": "levobupivacaine", "entity2": "cardiac toxicity", "span1": [50, 65], "span2": [74, 90]}, "bert_text": "Resuscitation with lipid, epinephrine, or both in <e1> levobupivacaine </e1>-induced <e2> cardiac toxicity </e2> in newborn piglets.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1652": {"data": {"text": "Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "entity1": "progestagens", "entity2": "VTE", "span1": [32, 44], "span2": [58, 61]}, "bert_text": "Among users of third-generation <e1> progestagens </e1>, the risk of <e2> VTE </e2> was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1653": {"data": {"text": "Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "entity1": "desogestrel", "entity2": "VTE", "span1": [85, 96], "span2": [58, 61]}, "bert_text": "Among users of third-generation progestagens, the risk of VTE was higher in users of <e1> desogestrel </e1> <e2> VTE </e2> was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1654": {"data": {"text": "Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "entity1": "desogestrel", "entity2": "VTE", "span1": [155, 166], "span2": [58, 61]}, "bert_text": "Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or <e1> desogestrel </e1> <e2> VTE </e2> was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1655": {"data": {"text": "Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "entity1": "ethinyloestradiol", "entity2": "VTE", "span1": [107, 124], "span2": [58, 61]}, "bert_text": "Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g <e1> ethinyloestradiol </e1> <e2> VTE </e2> was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1656": {"data": {"text": "Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "entity1": "ethinyloestradiol", "entity2": "VTE", "span1": [177, 194], "span2": [58, 61]}, "bert_text": "Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g <e1> ethinyloestradiol </e1> <e2> VTE </e2> was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1657": {"data": {"text": "Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "entity1": "gestodene", "entity2": "VTE", "span1": [142, 151], "span2": [58, 61]}, "bert_text": "Among users of third-generation progestagens, the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of <e1> gestodene </e1> <e2> VTE </e2> was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"1658": {"data": {"text": "CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.", "entity1": "nicotine", "entity2": "anxiety", "span1": [65, 73], "span2": [94, 101]}, "bert_text": "CONCLUSIONS: Our results suggest that the antagonistic effect of <e1> nicotine </e1> on caffeine-induced <e2> anxiety </e2> is specific to caffeine, instead of a non-specific anxiolytic effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1659": {"data": {"text": "CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.", "entity1": "caffeine", "entity2": "anxiety", "span1": [77, 85], "span2": [94, 101]}, "bert_text": "CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on <e1> caffeine </e1>-induced <e2> anxiety </e2> is specific to caffeine, instead of a non-specific anxiolytic effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1660": {"data": {"text": "CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to caffeine, instead of a non-specific anxiolytic effect.", "entity1": "caffeine", "entity2": "anxiety", "span1": [117, 125], "span2": [94, 101]}, "bert_text": "CONCLUSIONS: Our results suggest that the antagonistic effect of nicotine on caffeine-induced anxiety is specific to <e1> caffeine </e1> <e2> anxiety </e2> is specific to caffeine, instead of a non-specific anxiolytic effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1661": {"data": {"text": "Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.", "entity1": "mirtazapine", "entity2": "RLS", "span1": [80, 91], "span2": [40, 43]}, "bert_text": "Our patient started to have symptoms of RLS only after he had been treated with <e1> mirtazapine </e1> <e2> RLS </e2> only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1662": {"data": {"text": "Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.", "entity1": "mirtazapine", "entity2": "RLS", "span1": [80, 91], "span2": [101, 104]}, "bert_text": "Our patient started to have symptoms of RLS only after he had been treated with <e1> mirtazapine </e1>, and his <e2> RLS </e2> symptoms resolved completely upon discontinuation of his mirtazapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1663": {"data": {"text": "Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.", "entity1": "mirtazapine", "entity2": "RLS", "span1": [162, 173], "span2": [40, 43]}, "bert_text": "Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his <e1> mirtazapine </e1> <e2> RLS </e2> only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1664": {"data": {"text": "Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his mirtazapine.", "entity1": "mirtazapine", "entity2": "RLS", "span1": [162, 173], "span2": [101, 104]}, "bert_text": "Our patient started to have symptoms of RLS only after he had been treated with mirtazapine, and his RLS symptoms resolved completely upon discontinuation of his <e1> mirtazapine </e1> <e2> RLS </e2> symptoms resolved completely upon discontinuation of his mirtazapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"1665": {"data": {"text": "A naloxone (5 mg/kg) challenge was also ineffective in altering the seizure thresholds of either control of MSG-treated mice.", "entity1": "naloxone", "entity2": "seizure", "span1": [2, 10], "span2": [68, 75]}, "bert_text": "A <e1> naloxone </e1> (5 mg/kg) challenge was also ineffective in altering the <e2> seizure </e2> thresholds of either control of MSG-treated mice.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1666": {"data": {"text": "Glomeruli with sclerosis contained significantly more CC than non-sclerotic glomeruli in the same kidneys.", "entity1": "CC", "entity2": "sclerosis", "span1": [54, 56], "span2": [15, 24]}, "bert_text": "Glomeruli with sclerosis contained significantly more <e1> CC </e1> <e2> sclerosis </e2> contained significantly more CC than non-sclerotic glomeruli in the same kidneys.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1667": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [50, 57], "span2": [90, 106]}, "bert_text": "However, additional important untoward effects of <e1> heparin </e1> therapy include heparin-induced <e2> thrombocytopenia </e2>, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1668": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [50, 57], "span2": [201, 217]}, "bert_text": "However, additional important untoward effects of <e1> heparin </e1> therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than <e2> thrombocytopenia </e2>, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1669": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "osteoporosis", "span1": [50, 57], "span2": [127, 139]}, "bert_text": "However, additional important untoward effects of <e1> heparin </e1> therapy include heparin-induced thrombocytopenia, heparin-associated <e2> osteoporosis </e2>, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1670": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "eosinophilia", "span1": [50, 57], "span2": [141, 153]}, "bert_text": "However, additional important untoward effects of <e1> heparin </e1> therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, <e2> eosinophilia </e2>, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1671": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "allergic", "span1": [50, 57], "span2": [171, 179]}, "bert_text": "However, additional important untoward effects of <e1> heparin </e1> therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, <e2> allergic </e2> reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1672": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "alopecia", "span1": [50, 57], "span2": [219, 227]}, "bert_text": "However, additional important untoward effects of <e1> heparin </e1> therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, <e2> alopecia </e2>, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1673": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "hyperkalemia", "span1": [50, 57], "span2": [246, 258]}, "bert_text": "However, additional important untoward effects of <e1> heparin </e1> therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, <e2> hyperkalemia </e2>, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1674": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "hypoaldosteronism", "span1": [50, 57], "span2": [260, 277]}, "bert_text": "However, additional important untoward effects of <e1> heparin </e1> therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, <e2> hypoaldosteronism </e2>, and priapism.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1675": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "priapism", "span1": [50, 57], "span2": [283, 291]}, "bert_text": "However, additional important untoward effects of <e1> heparin </e1> therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and <e2> priapism </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1676": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [74, 81], "span2": [90, 106]}, "bert_text": "However, additional important untoward effects of heparin therapy include <e1> heparin </e1>-induced <e2> thrombocytopenia </e2>, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1677": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [74, 81], "span2": [201, 217]}, "bert_text": "However, additional important untoward effects of heparin therapy include <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than <e2> thrombocytopenia </e2>, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1678": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "osteoporosis", "span1": [74, 81], "span2": [127, 139]}, "bert_text": "However, additional important untoward effects of heparin therapy include <e1> heparin </e1>-induced thrombocytopenia, heparin-associated <e2> osteoporosis </e2>, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1679": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "eosinophilia", "span1": [74, 81], "span2": [141, 153]}, "bert_text": "However, additional important untoward effects of heparin therapy include <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, <e2> eosinophilia </e2>, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1680": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "allergic", "span1": [74, 81], "span2": [171, 179]}, "bert_text": "However, additional important untoward effects of heparin therapy include <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, <e2> allergic </e2> reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1681": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "alopecia", "span1": [74, 81], "span2": [219, 227]}, "bert_text": "However, additional important untoward effects of heparin therapy include <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, <e2> alopecia </e2>, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1682": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "hyperkalemia", "span1": [74, 81], "span2": [246, 258]}, "bert_text": "However, additional important untoward effects of heparin therapy include <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, <e2> hyperkalemia </e2>, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1683": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "hypoaldosteronism", "span1": [74, 81], "span2": [260, 277]}, "bert_text": "However, additional important untoward effects of heparin therapy include <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, <e2> hypoaldosteronism </e2>, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1684": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "priapism", "span1": [74, 81], "span2": [283, 291]}, "bert_text": "However, additional important untoward effects of heparin therapy include <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and <e2> priapism </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1685": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [108, 115], "span2": [90, 106]}, "bert_text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, <e1> heparin </e1> <e2> thrombocytopenia </e2>, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"1686": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [108, 115], "span2": [201, 217]}, "bert_text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than <e2> thrombocytopenia </e2>, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1687": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "osteoporosis", "span1": [108, 115], "span2": [127, 139]}, "bert_text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, <e1> heparin </e1>-associated <e2> osteoporosis </e2>, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1688": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "eosinophilia", "span1": [108, 115], "span2": [141, 153]}, "bert_text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, <e2> eosinophilia </e2>, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1689": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "allergic", "span1": [108, 115], "span2": [171, 179]}, "bert_text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, eosinophilia, skin reactions, <e2> allergic </e2> reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1690": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "alopecia", "span1": [108, 115], "span2": [219, 227]}, "bert_text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, <e2> alopecia </e2>, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1691": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "hyperkalemia", "span1": [108, 115], "span2": [246, 258]}, "bert_text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, <e2> hyperkalemia </e2>, hypoaldosteronism, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1692": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "hypoaldosteronism", "span1": [108, 115], "span2": [260, 277]}, "bert_text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, <e2> hypoaldosteronism </e2>, and priapism.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1693": {"data": {"text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and priapism.", "entity1": "heparin", "entity2": "priapism", "span1": [108, 115], "span2": [283, 291]}, "bert_text": "However, additional important untoward effects of heparin therapy include heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia, alopecia, transaminasemia, hyperkalemia, hypoaldosteronism, and <e2> priapism </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1694": {"data": {"text": "Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.\n", "entity1": "eslicarbazepine acetate", "entity2": "seizures", "span1": [25, 48], "span2": [64, 72]}, "bert_text": "Anticonvulsant effect of <e1> eslicarbazepine acetate </e1> (BIA 2-093) on <e2> seizures </e2> induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1695": {"data": {"text": "Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.\n", "entity1": "BIA 2-093", "entity2": "seizures", "span1": [50, 59], "span2": [64, 72]}, "bert_text": "Anticonvulsant effect of eslicarbazepine acetate (<e1> BIA 2-093 </e1>) on <e2> seizures </e2> induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1696": {"data": {"text": "Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.\n", "entity1": "picrotoxin", "entity2": "seizures", "span1": [102, 112], "span2": [64, 72]}, "bert_text": "Anticonvulsant effect of eslicarbazepine acetate (BIA 2-093) on seizures induced by microperfusion of <e1> picrotoxin </e1> <e2> seizures </e2> induced by microperfusion of picrotoxin in the hippocampus of freely moving rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1697": {"data": {"text": "Coronary computerized tomography angiography for rapid discharge of low-risk patients with cocaine-associated chest pain.\n", "entity1": "cocaine", "entity2": "chest pain", "span1": [91, 98], "span2": [110, 120]}, "bert_text": "Coronary computerized tomography angiography for rapid discharge of low-risk patients with <e1> cocaine </e1>-associated <e2> chest pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1698": {"data": {"text": "BACKGROUND: Most patients presenting to emergency departments (EDs) with cocaine-associated chest pain are admitted for at least 12 hours and receive a \"rule out acute coronary syndrome\" protocol, often with noninvasive testing prior to discharge.", "entity1": "cocaine", "entity2": "chest pain", "span1": [73, 80], "span2": [92, 102]}, "bert_text": "BACKGROUND: Most patients presenting to emergency departments (EDs) with <e1> cocaine </e1>-associated <e2> chest pain </e2> are admitted for at least 12 hours and receive a \"rule out acute coronary syndrome\" protocol, often with noninvasive testing prior to discharge.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1699": {"data": {"text": "BACKGROUND: Most patients presenting to emergency departments (EDs) with cocaine-associated chest pain are admitted for at least 12 hours and receive a \"rule out acute coronary syndrome\" protocol, often with noninvasive testing prior to discharge.", "entity1": "cocaine", "entity2": "acute coronary syndrome", "span1": [73, 80], "span2": [162, 185]}, "bert_text": "BACKGROUND: Most patients presenting to emergency departments (EDs) with <e1> cocaine </e1>-associated chest pain are admitted for at least 12 hours and receive a \"rule out <e2> acute coronary syndrome </e2>\" protocol, often with noninvasive testing prior to discharge.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1700": {"data": {"text": "Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome.", "entity1": "CYA", "entity2": "aplastic anemia", "span1": [36, 39], "span2": [140, 155]}, "bert_text": "Eighty patients who were to receive <e1> CYA </e1> 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for <e2> aplastic anemia </e2>, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1701": {"data": {"text": "Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome.", "entity1": "CYA", "entity2": "Wiskott-Aldrich syndrome", "span1": [36, 39], "span2": [157, 181]}, "bert_text": "Eighty patients who were to receive <e1> CYA </e1> 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, <e2> Wiskott-Aldrich syndrome </e2>, or severe combined immunodeficiency syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1702": {"data": {"text": "Eighty patients who were to receive CYA 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined immunodeficiency syndrome.", "entity1": "CYA", "entity2": "immunodeficiency syndrome", "span1": [36, 39], "span2": [202, 227]}, "bert_text": "Eighty patients who were to receive <e1> CYA </e1> 50 mg/kg/d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia, Wiskott-Aldrich syndrome, or severe combined <e2> immunodeficiency syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1703": {"data": {"text": "Atrial thrombosis involving the heart of F-344 rats ingesting quinacrine hydrochloride.\n", "entity1": "quinacrine hydrochloride", "entity2": "Atrial thrombosis", "span1": [62, 86], "span2": [0, 17]}, "bert_text": "Atrial thrombosis involving the heart of F-344 rats ingesting <e1> quinacrine hydrochloride </e1> <e2> Atrial thrombosis </e2> involving the heart of F-344 rats ingesting quinacrine hydrochloride.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1704": {"data": {"text": "Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol.\nAlternating sinus rhythm and intermittent sinoatrial (S-A) block", "entity1": "propranolol", "entity2": "sinoatrial block", "span1": [70, 81], "span2": [42, 58]}, "bert_text": "Alternating sinus rhythm and intermittent sinoatrial block induced by <e1> propranolol </e1> <e2> sinoatrial block </e2> induced by propranolol.\nAlternating sinus rhythm and intermittent sinoatrial (S-A) block", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1705": {"data": {"text": "Acute interstitial nephritis due to nicergoline (Sermion).\n", "entity1": "nicergoline", "entity2": "interstitial nephritis", "span1": [36, 47], "span2": [6, 28]}, "bert_text": "Acute interstitial nephritis due to <e1> nicergoline </e1> <e2> interstitial nephritis </e2> due to nicergoline (Sermion).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1706": {"data": {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity1": "acetaminophen", "entity2": "psychiatric", "span1": [223, 236], "span2": [69, 80]}, "bert_text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for <e1> acetaminophen </e1> <e2> psychiatric </e2> co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1707": {"data": {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity1": "acetaminophen", "entity2": "ALF", "span1": [223, 236], "span2": [245, 248]}, "bert_text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for <e1> acetaminophen </e1>-induced <e2> ALF </e2> (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1708": {"data": {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity1": "acetaminophen", "entity2": "ALF", "span1": [223, 236], "span2": [344, 347]}, "bert_text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for <e1> acetaminophen </e1>-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced <e2> ALF </e2> (n=35) and elective LT for chronic liver disease (CLD, n=34).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1709": {"data": {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity1": "acetaminophen", "entity2": "chronic liver disease", "span1": [223, 236], "span2": [375, 396]}, "bert_text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for <e1> acetaminophen </e1>-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for <e2> chronic liver disease </e2> (CLD, n=34).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1710": {"data": {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity1": "acetaminophen", "entity2": "CLD", "span1": [223, 236], "span2": [398, 401]}, "bert_text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for <e1> acetaminophen </e1>-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (<e2> CLD </e2>, n=34).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1711": {"data": {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity1": "acetaminophen", "entity2": "psychiatric", "span1": [322, 335], "span2": [69, 80]}, "bert_text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-<e1> acetaminophen </e1> <e2> psychiatric </e2> co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1712": {"data": {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity1": "acetaminophen", "entity2": "ALF", "span1": [322, 335], "span2": [245, 248]}, "bert_text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-<e1> acetaminophen </e1> <e2> ALF </e2> (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1713": {"data": {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity1": "acetaminophen", "entity2": "ALF", "span1": [322, 335], "span2": [344, 347]}, "bert_text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-<e1> acetaminophen </e1>-induced <e2> ALF </e2> (n=35) and elective LT for chronic liver disease (CLD, n=34).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1714": {"data": {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity1": "acetaminophen", "entity2": "chronic liver disease", "span1": [322, 335], "span2": [375, 396]}, "bert_text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-<e1> acetaminophen </e1>-induced ALF (n=35) and elective LT for <e2> chronic liver disease </e2> (CLD, n=34).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1715": {"data": {"text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-acetaminophen-induced ALF (n=35) and elective LT for chronic liver disease (CLD, n=34).", "entity1": "acetaminophen", "entity2": "CLD", "span1": [322, 335], "span2": [398, 401]}, "bert_text": "AIMS AND METHODS: We compared the severity of pretransplant illness, psychiatric co-morbidity, medical and psychosocial outcomes of all patients who had undergone liver transplantation (LT) emergently between 1999-2004 for acetaminophen-induced ALF (n=36) with age- and sex-matched patients undergoing emergent LT for non-<e1> acetaminophen </e1>-induced ALF (n=35) and elective LT for chronic liver disease (<e2> CLD </e2>, n=34).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1716": {"data": {"text": "AIM: Verapamil stimulation test was previously investigated as a tool for differential diagnosis of hyperprolactinemia, but with conflicting results.", "entity1": "Verapamil", "entity2": "hyperprolactinemia", "span1": [5, 14], "span2": [100, 118]}, "bert_text": "AIM: <e1> Verapamil </e1> stimulation test was previously investigated as a tool for differential diagnosis of <e2> hyperprolactinemia </e2>, but with conflicting results.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1717": {"data": {"text": "This illustrates intravenous pamidronate as a valuable therapeutic tool when milk-alkali syndrome presents as hypercalcemic emergency.", "entity1": "pamidronate", "entity2": "milk-alkali syndrome", "span1": [29, 40], "span2": [77, 97]}, "bert_text": "This illustrates intravenous <e1> pamidronate </e1> as a valuable therapeutic tool when <e2> milk-alkali syndrome </e2> presents as hypercalcemic emergency.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1718": {"data": {"text": "This illustrates intravenous pamidronate as a valuable therapeutic tool when milk-alkali syndrome presents as hypercalcemic emergency.", "entity1": "pamidronate", "entity2": "hypercalcemic emergency", "span1": [29, 40], "span2": [110, 133]}, "bert_text": "This illustrates intravenous <e1> pamidronate </e1> as a valuable therapeutic tool when milk-alkali syndrome presents as <e2> hypercalcemic emergency </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1719": {"data": {"text": "Thalidomide neuropathy in patients treated for metastatic prostate cancer.\n", "entity1": "Thalidomide", "entity2": "neuropathy", "span1": [0, 11], "span2": [12, 22]}, "bert_text": "<e1> Thalidomide </e1> <e2> neuropathy </e2> in patients treated for metastatic prostate cancer.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1720": {"data": {"text": "Thalidomide neuropathy in patients treated for metastatic prostate cancer.\n", "entity1": "Thalidomide", "entity2": "prostate cancer", "span1": [0, 11], "span2": [58, 73]}, "bert_text": "<e1> Thalidomide </e1> neuropathy in patients treated for metastatic <e2> prostate cancer </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1721": {"data": {"text": "Cocaine is a risk factor for both ischemic and haemorrhagic stroke.", "entity1": "Cocaine", "entity2": "ischemic", "span1": [0, 7], "span2": [34, 42]}, "bert_text": "<e1> Cocaine </e1> is a risk factor for both <e2> ischemic </e2> and haemorrhagic stroke.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1722": {"data": {"text": "Cocaine is a risk factor for both ischemic and haemorrhagic stroke.", "entity1": "Cocaine", "entity2": "haemorrhagic stroke", "span1": [0, 7], "span2": [47, 66]}, "bert_text": "<e1> Cocaine </e1> is a risk factor for both ischemic and <e2> haemorrhagic stroke </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1723": {"data": {"text": "Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.", "entity1": "lithium", "entity2": "NDI", "span1": [100, 107], "span2": [116, 119]}, "bert_text": "Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1> lithium </e1>-induced <e2> NDI </e2>, and prevents the development of the severe polyuria associated with lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1724": {"data": {"text": "Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.", "entity1": "lithium", "entity2": "polyuria", "span1": [100, 107], "span2": [164, 172]}, "bert_text": "Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in <e1> lithium </e1>-induced NDI, and prevents the development of the severe <e2> polyuria </e2> associated with lithium therapy.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1725": {"data": {"text": "Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.", "entity1": "lithium", "entity2": "NDI", "span1": [189, 196], "span2": [116, 119]}, "bert_text": "Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with <e1> lithium </e1> <e2> NDI </e2>, and prevents the development of the severe polyuria associated with lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1726": {"data": {"text": "Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with lithium therapy.", "entity1": "lithium", "entity2": "polyuria", "span1": [189, 196], "span2": [164, 172]}, "bert_text": "Our data show that ablation of PKCa preserves AQP2 and UT-A1 protein expression and localization in lithium-induced NDI, and prevents the development of the severe polyuria associated with <e1> lithium </e1> <e2> polyuria </e2> associated with lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"1727": {"data": {"text": "Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.\n", "entity1": "Cocaine", "entity2": "hyperactivity", "span1": [0, 7], "span2": [16, 29]}, "bert_text": "<e1> Cocaine </e1>-induced <e2> hyperactivity </e2> is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1728": {"data": {"text": "Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.\n", "entity1": "Cocaine", "entity2": "hyperactivity", "span1": [0, 7], "span2": [105, 118]}, "bert_text": "<e1> Cocaine </e1>-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced <e2> hyperactivity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1729": {"data": {"text": "Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.\n", "entity1": "adenosine", "entity2": "hyperactivity", "span1": [52, 61], "span2": [16, 29]}, "bert_text": "Cocaine-induced hyperactivity is more influenced by <e1> adenosine </e1> <e2> hyperactivity </e2> is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1730": {"data": {"text": "Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.\n", "entity1": "adenosine", "entity2": "hyperactivity", "span1": [52, 61], "span2": [105, 118]}, "bert_text": "Cocaine-induced hyperactivity is more influenced by <e1> adenosine </e1> receptor agonists than amphetamine-induced <e2> hyperactivity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1731": {"data": {"text": "Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.\n", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [85, 96], "span2": [16, 29]}, "bert_text": "Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than <e1> amphetamine </e1> <e2> hyperactivity </e2> is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1732": {"data": {"text": "Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity.\n", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [85, 96], "span2": [105, 118]}, "bert_text": "Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than <e1> amphetamine </e1>-induced <e2> hyperactivity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1733": {"data": {"text": ".\nBACKGROUND: Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials, primarily because of concerns about the safety and tolerability of these agents, especially at the recommended doses.", "entity1": "angiotensin", "entity2": "chronic heart failure", "span1": [29, 40], "span2": [125, 146]}, "bert_text": ".\nBACKGROUND: Treatment with <e1> angiotensin </e1>-converting enzyme (ACE) inhibitors reduces mortality and morbidity in patients with <e2> chronic heart failure </e2> (CHF), but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials, primarily because of concerns about the safety and tolerability of these agents, especially at the recommended doses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1734": {"data": {"text": ".\nBACKGROUND: Treatment with angiotensin-converting enzyme (ACE) inhibitors reduces mortality and morbidity in patients with chronic heart failure (CHF), but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials, primarily because of concerns about the safety and tolerability of these agents, especially at the recommended doses.", "entity1": "angiotensin", "entity2": "CHF", "span1": [29, 40], "span2": [148, 151]}, "bert_text": ".\nBACKGROUND: Treatment with <e1> angiotensin </e1>-converting enzyme (ACE) inhibitors reduces mortality and morbidity in patients with chronic heart failure (<e2> CHF </e2>), but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials, primarily because of concerns about the safety and tolerability of these agents, especially at the recommended doses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1735": {"data": {"text": "FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of progestagen-only OCs.", "entity1": "progestagen", "entity2": "VTE", "span1": [81, 92], "span2": [50, 53]}, "bert_text": "FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of <e1> progestagen </e1> <e2> VTE </e2>, two of whom were users of progestagen-only OCs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1736": {"data": {"text": "FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of progestagen-only OCs.", "entity1": "OCs", "entity2": "VTE", "span1": [98, 101], "span2": [50, 53]}, "bert_text": "FINDINGS: 85 women met the inclusion criteria for VTE, two of whom were users of progestagen-only <e1> OCs </e1> <e2> VTE </e2>, two of whom were users of progestagen-only OCs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1737": {"data": {"text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.", "entity1": "clozapine-", "entity2": "impairment of", "span1": [27, 37], "span2": [113, 126]}, "bert_text": "CONCLUSIONS: Both nonobese <e1> clozapine- </e1> and olanzapine-treated groups displayed significant insulin resistance and <e2> impairment of </e2> glucose effectiveness compared with risperidone-treated subjects.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1738": {"data": {"text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.", "entity1": "clozapine-", "entity2": "effectiveness", "span1": [27, 37], "span2": [135, 148]}, "bert_text": "CONCLUSIONS: Both nonobese <e1> clozapine- </e1> and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose <e2> effectiveness </e2> compared with risperidone-treated subjects.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1739": {"data": {"text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.", "entity1": "olanzapine", "entity2": "impairment of", "span1": [42, 52], "span2": [113, 126]}, "bert_text": "CONCLUSIONS: Both nonobese clozapine- and <e1> olanzapine </e1>-treated groups displayed significant insulin resistance and <e2> impairment of </e2> glucose effectiveness compared with risperidone-treated subjects.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1740": {"data": {"text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.", "entity1": "olanzapine", "entity2": "effectiveness", "span1": [42, 52], "span2": [135, 148]}, "bert_text": "CONCLUSIONS: Both nonobese clozapine- and <e1> olanzapine </e1>-treated groups displayed significant insulin resistance and impairment of glucose <e2> effectiveness </e2> compared with risperidone-treated subjects.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1741": {"data": {"text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.", "entity1": "glucose", "entity2": "impairment of", "span1": [127, 134], "span2": [113, 126]}, "bert_text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of <e1> glucose </e1> <e2> impairment of </e2> glucose effectiveness compared with risperidone-treated subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1742": {"data": {"text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.", "entity1": "glucose", "entity2": "effectiveness", "span1": [127, 134], "span2": [135, 148]}, "bert_text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of <e1> glucose </e1> <e2> effectiveness </e2> compared with risperidone-treated subjects.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1743": {"data": {"text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.", "entity1": "risperidone", "entity2": "impairment of", "span1": [163, 174], "span2": [113, 126]}, "bert_text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with <e1> risperidone </e1> <e2> impairment of </e2> glucose effectiveness compared with risperidone-treated subjects.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1744": {"data": {"text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects.", "entity1": "risperidone", "entity2": "effectiveness", "span1": [163, 174], "span2": [135, 148]}, "bert_text": "CONCLUSIONS: Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with <e1> risperidone </e1> <e2> effectiveness </e2> compared with risperidone-treated subjects.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1745": {"data": {"text": "Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.\n", "entity1": "flecainide", "entity2": "Delirium", "span1": [33, 43], "span2": [0, 8]}, "bert_text": "Delirium in a patient with toxic <e1> flecainide </e1> <e2> Delirium </e2> in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1746": {"data": {"text": "Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.\n", "entity1": "paroxetine", "entity2": "Delirium", "span1": [119, 129], "span2": [0, 8]}, "bert_text": "Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with <e1> paroxetine </e1> <e2> Delirium </e2> in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1747": {"data": {"text": "In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo.", "entity1": "Ca(2", "entity2": "poisoning", "span1": [58, 62], "span2": [88, 97]}, "bert_text": "In this study, we explored the importance of pathological <e1> Ca(2 </e1>+) signaling in aconitine <e2> poisoning </e2> in vitro and in vivo.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1748": {"data": {"text": "In this study, we explored the importance of pathological Ca(2+) signaling in aconitine poisoning in vitro and in vivo.", "entity1": "aconitine", "entity2": "poisoning", "span1": [78, 87], "span2": [88, 97]}, "bert_text": "In this study, we explored the importance of pathological Ca(2+) signaling in <e1> aconitine </e1> <e2> poisoning </e2> in vitro and in vivo.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1749": {"data": {"text": "Lithium is implicated in drug-induced nephrogenic DI, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic DI.", "entity1": "Lithium", "entity2": "nephrogenic DI", "span1": [0, 7], "span2": [38, 52]}, "bert_text": "<e1> Lithium </e1> is implicated in drug-induced <e2> nephrogenic DI </e2>, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic DI.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1750": {"data": {"text": "Lithium is implicated in drug-induced nephrogenic DI, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic DI.", "entity1": "Lithium", "entity2": "DI", "span1": [0, 7], "span2": [187, 189]}, "bert_text": "<e1> Lithium </e1> is implicated in drug-induced nephrogenic DI, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic <e2> DI </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1751": {"data": {"text": "Lithium is implicated in drug-induced nephrogenic DI, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic DI.", "entity1": "lithium", "entity2": "nephrogenic DI", "span1": [95, 102], "span2": [38, 52]}, "bert_text": "Lithium is implicated in drug-induced nephrogenic DI, and because the patient had not received <e1> lithium </e1> <e2> nephrogenic DI </e2>, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic DI.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1752": {"data": {"text": "Lithium is implicated in drug-induced nephrogenic DI, and because the patient had not received lithium since being admitted to the hospital, his treatment changed to focus on nephrogenic DI.", "entity1": "lithium", "entity2": "DI", "span1": [95, 102], "span2": [187, 189]}, "bert_text": "Lithium is implicated in drug-induced nephrogenic DI, and because the patient had not received <e1> lithium </e1> since being admitted to the hospital, his treatment changed to focus on nephrogenic <e2> DI </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1753": {"data": {"text": "Carvedilol by itself did not affect any of the parameters measured for heart or liver mitochondria.", "entity1": "Carvedilol", "entity2": "liver mitochondria", "span1": [0, 10], "span2": [80, 98]}, "bert_text": "<e1> Carvedilol </e1> by itself did not affect any of the parameters measured for heart or <e2> liver mitochondria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1754": {"data": {"text": "However, until this apparent ability of 200 micrograms of misoprostol to prevent the adverse effects of indomethacin on renal function is confirmed with chronic frequent dosing, it would be prudent to avoid nonsteroidal anti-inflammatory therapy in patients with cirrhosis.", "entity1": "misoprostol", "entity2": "cirrhosis", "span1": [58, 69], "span2": [263, 272]}, "bert_text": "However, until this apparent ability of 200 micrograms of <e1> misoprostol </e1> to prevent the adverse effects of indomethacin on renal function is confirmed with chronic frequent dosing, it would be prudent to avoid nonsteroidal anti-inflammatory therapy in patients with <e2> cirrhosis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1755": {"data": {"text": "However, until this apparent ability of 200 micrograms of misoprostol to prevent the adverse effects of indomethacin on renal function is confirmed with chronic frequent dosing, it would be prudent to avoid nonsteroidal anti-inflammatory therapy in patients with cirrhosis.", "entity1": "indomethacin", "entity2": "cirrhosis", "span1": [104, 116], "span2": [263, 272]}, "bert_text": "However, until this apparent ability of 200 micrograms of misoprostol to prevent the adverse effects of <e1> indomethacin </e1> on renal function is confirmed with chronic frequent dosing, it would be prudent to avoid nonsteroidal anti-inflammatory therapy in patients with <e2> cirrhosis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1756": {"data": {"text": "Our findings suggest that alcohol consumption has a direct association with depression.", "entity1": "alcohol", "entity2": "depression", "span1": [26, 33], "span2": [76, 86]}, "bert_text": "Our findings suggest that <e1> alcohol </e1> consumption has a direct association with <e2> depression </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1757": {"data": {"text": "Kaliuretic effect of L-dopa treatment in parkinsonian patients.\n", "entity1": "L-dopa", "entity2": "parkinsonian", "span1": [21, 27], "span2": [41, 53]}, "bert_text": "Kaliuretic effect of <e1> L-dopa </e1> treatment in <e2> parkinsonian </e2> patients.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1758": {"data": {"text": "This suggestion of an association between metolachlor and liver cancer among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies.", "entity1": "metolachlor", "entity2": "liver cancer", "span1": [42, 53], "span2": [58, 70]}, "bert_text": "This suggestion of an association between <e1> metolachlor </e1> and <e2> liver cancer </e2> among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1759": {"data": {"text": "This suggestion of an association between metolachlor and liver cancer among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies.", "entity1": "metolachlor", "entity2": "liver neoplasms", "span1": [42, 53], "span2": [154, 169]}, "bert_text": "This suggestion of an association between <e1> metolachlor </e1> and liver cancer among pesticide applicators is a novel finding and echoes observation of increased <e2> liver neoplasms </e2> in some animal studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1760": {"data": {"text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.", "entity1": "cocaine", "entity2": "cardiac arrhythmia", "span1": [83, 90], "span2": [26, 44]}, "bert_text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to <e1> cocaine </e1> <e2> cardiac arrhythmia </e2> or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1761": {"data": {"text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.", "entity1": "cocaine", "entity2": "respiratory dysfunction", "span1": [83, 90], "span2": [48, 71]}, "bert_text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to <e1> cocaine </e1> <e2> respiratory dysfunction </e2> related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1762": {"data": {"text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.", "entity1": "cocaine", "entity2": "cerebral hypoperfusion", "span1": [83, 90], "span2": [141, 163]}, "bert_text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to <e1> cocaine </e1> and/or ethanol use were the most likely causes of <e2> cerebral hypoperfusion </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1763": {"data": {"text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.", "entity1": "ethanol", "entity2": "cardiac arrhythmia", "span1": [98, 105], "span2": [26, 44]}, "bert_text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or <e1> ethanol </e1> <e2> cardiac arrhythmia </e2> or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1764": {"data": {"text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.", "entity1": "ethanol", "entity2": "respiratory dysfunction", "span1": [98, 105], "span2": [48, 71]}, "bert_text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or <e1> ethanol </e1> <e2> respiratory dysfunction </e2> related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1765": {"data": {"text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or ethanol use were the most likely causes of cerebral hypoperfusion.", "entity1": "ethanol", "entity2": "cerebral hypoperfusion", "span1": [98, 105], "span2": [141, 163]}, "bert_text": "In our patient, transient cardiac arrhythmia or respiratory dysfunction related to cocaine and/or <e1> ethanol </e1> use were the most likely causes of <e2> cerebral hypoperfusion </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1766": {"data": {"text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "entity1": "tacrolimus", "entity2": "amyloidosis", "span1": [212, 222], "span2": [51, 62]}, "bert_text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from <e1> tacrolimus </e1> <e2> amyloidosis </e2> in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1767": {"data": {"text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "entity1": "tacrolimus", "entity2": "monoclonal gammapathy", "span1": [212, 222], "span2": [113, 134]}, "bert_text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from <e1> tacrolimus </e1> <e2> monoclonal gammapathy </e2> of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1768": {"data": {"text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "entity1": "tacrolimus", "entity2": "proteinuria", "span1": [212, 222], "span2": [178, 189]}, "bert_text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from <e1> tacrolimus </e1> <e2> proteinuria </e2> after conversion from tacrolimus to everolimus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1769": {"data": {"text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "entity1": "everolimus", "entity2": "amyloidosis", "span1": [226, 236], "span2": [51, 62]}, "bert_text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to <e1> everolimus </e1> <e2> amyloidosis </e2> in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1770": {"data": {"text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "entity1": "everolimus", "entity2": "monoclonal gammapathy", "span1": [226, 236], "span2": [113, 134]}, "bert_text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to <e1> everolimus </e1> <e2> monoclonal gammapathy </e2> of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1771": {"data": {"text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus.", "entity1": "everolimus", "entity2": "proteinuria", "span1": [226, 236], "span2": [178, 189]}, "bert_text": "In this case we report the unexpected diagnosis of amyloidosis in a renal-transplant patient with pre-transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to <e1> everolimus </e1> <e2> proteinuria </e2> after conversion from tacrolimus to everolimus.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1772": {"data": {"text": "Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.\nGarcinielliptone FC (GFC)", "entity1": "garcinielliptone FC", "entity2": "seizures", "span1": [61, 80], "span2": [104, 112]}, "bert_text": "Behavioral and neurochemical studies in mice pretreated with <e1> garcinielliptone FC </e1> in pilocarpine-induced <e2> seizures </e2>.\nGarcinielliptone FC (GFC)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1773": {"data": {"text": "Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.\nGarcinielliptone FC (GFC)", "entity1": "Garcinielliptone FC", "entity2": "seizures", "span1": [114, 133], "span2": [104, 112]}, "bert_text": "Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.\n<e1> Garcinielliptone FC </e1> <e2> seizures </e2>.\nGarcinielliptone FC (GFC)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1774": {"data": {"text": "Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.\nGarcinielliptone FC (GFC)", "entity1": "GFC", "entity2": "seizures", "span1": [135, 138], "span2": [104, 112]}, "bert_text": "Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.\nGarcinielliptone FC (<e1> GFC </e1> <e2> seizures </e2>.\nGarcinielliptone FC (GFC)", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1775": {"data": {"text": "Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine-induced seizures.\nGarcinielliptone FC (GFC)", "entity1": "pilocarpine", "entity2": "seizures", "span1": [84, 95], "span2": [104, 112]}, "bert_text": "Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in <e1> pilocarpine </e1>-induced <e2> seizures </e2>.\nGarcinielliptone FC (GFC)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1776": {"data": {"text": "In 2002, the U.S. Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss aspirin with adults who are at increased risk for coronary heart disease.", "entity1": "aspirin", "entity2": "coronary heart disease", "span1": [103, 110], "span2": [153, 175]}, "bert_text": "In 2002, the U.S. Preventive Services Task Force (USPSTF) strongly recommended that clinicians discuss <e1> aspirin </e1> with adults who are at increased risk for <e2> coronary heart disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1777": {"data": {"text": "Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "entity1": "fluoxetine", "entity2": "mania or hypomania", "span1": [71, 81], "span2": [45, 63]}, "bert_text": "Apparent risk factors for the development of mania or hypomania during <e1> fluoxetine </e1> <e2> mania or hypomania </e2> during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1778": {"data": {"text": "Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "entity1": "fluoxetine", "entity2": "bipolar disorder", "span1": [71, 81], "span2": [302, 318]}, "bert_text": "Apparent risk factors for the development of mania or hypomania during <e1> fluoxetine </e1> pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially <e2> bipolar disorder </e2>; and a diagnosis of bipolar disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1779": {"data": {"text": "Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "entity1": "fluoxetine", "entity2": "bipolar disorder", "span1": [71, 81], "span2": [339, 355]}, "bert_text": "Apparent risk factors for the development of mania or hypomania during <e1> fluoxetine </e1> pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of <e2> bipolar disorder </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1780": {"data": {"text": "Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "entity1": "fluoxetine", "entity2": "attention-deficit hyperactivity disorder", "span1": [71, 81], "span2": [141, 181]}, "bert_text": "Apparent risk factors for the development of mania or hypomania during <e1> fluoxetine </e1> pharmacotherapy in this population were the combination of <e2> attention-deficit hyperactivity disorder </e2> and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1781": {"data": {"text": "Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "entity1": "fluoxetine", "entity2": "depression", "span1": [71, 81], "span2": [215, 225]}, "bert_text": "Apparent risk factors for the development of mania or hypomania during <e1> fluoxetine </e1> pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major <e2> depression </e2> with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1782": {"data": {"text": "Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "entity1": "fluoxetine", "entity2": "psychotic", "span1": [71, 81], "span2": [231, 240]}, "bert_text": "Apparent risk factors for the development of mania or hypomania during <e1> fluoxetine </e1> pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with <e2> psychotic </e2> features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1783": {"data": {"text": "Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of affective disorder, especially bipolar disorder; and a diagnosis of bipolar disorder.", "entity1": "fluoxetine", "entity2": "affective disorder", "span1": [71, 81], "span2": [271, 289]}, "bert_text": "Apparent risk factors for the development of mania or hypomania during <e1> fluoxetine </e1> pharmacotherapy in this population were the combination of attention-deficit hyperactivity disorder and affective instability; major depression with psychotic features; a family history of <e2> affective disorder </e2>, especially bipolar disorder; and a diagnosis of bipolar disorder.", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1784": {"data": {"text": "After recovery of his renal function, we could safely treat the patient with HD-MTX therapy by controlling drainage from ileostoma with total parenteral nutrition.", "entity1": "MTX", "entity2": "HD", "span1": [80, 83], "span2": [77, 79]}, "bert_text": "After recovery of his renal function, we could safely treat the patient with HD-<e1> MTX </e1> <e2> HD </e2>-MTX therapy by controlling drainage from ileostoma with total parenteral nutrition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1785": {"data": {"text": "Mechanisms of hypertension induced by nitric oxide (NO) deficiency: focus on venous function.\n", "entity1": "nitric oxide", "entity2": "hypertension", "span1": [38, 50], "span2": [14, 26]}, "bert_text": "Mechanisms of hypertension induced by <e1> nitric oxide </e1> <e2> hypertension </e2> induced by nitric oxide (NO) deficiency: focus on venous function.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1786": {"data": {"text": "Mechanisms of hypertension induced by nitric oxide (NO) deficiency: focus on venous function.\n", "entity1": "NO", "entity2": "hypertension", "span1": [52, 54], "span2": [14, 26]}, "bert_text": "Mechanisms of hypertension induced by nitric oxide (<e1> NO </e1> <e2> hypertension </e2> induced by nitric oxide (NO) deficiency: focus on venous function.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1787": {"data": {"text": "Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.\n", "entity1": "thiotepa", "entity2": "polyneuropathy", "span1": [55, 63], "span2": [7, 21]}, "bert_text": "Severe polyneuropathy and motor loss after intrathecal <e1> thiotepa </e1> <e2> polyneuropathy </e2> and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1788": {"data": {"text": "n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).", "entity1": "caffeine", "entity2": "MDP", "span1": [137, 145], "span2": [25, 28]}, "bert_text": "n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg <e1> caffeine </e1> <e2> MDP </e2>, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1789": {"data": {"text": "n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).", "entity1": "caffeine", "entity2": "MD", "span1": [137, 145], "span2": [61, 63]}, "bert_text": "n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg <e1> caffeine </e1> <e2> MD </e2>, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1790": {"data": {"text": "n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).", "entity1": "caffeine", "entity2": "panic", "span1": [137, 145], "span2": [107, 112]}, "bert_text": "n = 12) of patients with MDP, 12.0% (n = 3) of patients with MD, and 7.1% (n= 2) of control subjects had a panic attack after the 480-mg <e1> caffeine </e1> <e2> panic </e2> attack after the 480-mg caffeine challenge test (chi(2)(3) = 16.22, P = .001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1791": {"data": {"text": "Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.", "entity1": "galactose", "entity2": "cognitive deficits", "span1": [5, 14], "span2": [137, 155]}, "bert_text": "Oral <e1> galactose </e1> exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of <e2> cognitive deficits </e2> associated with glucose hypometabolism in AD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1792": {"data": {"text": "Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.", "entity1": "galactose", "entity2": "glucose hypometabolism", "span1": [5, 14], "span2": [172, 194]}, "bert_text": "Oral <e1> galactose </e1> exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with <e2> glucose hypometabolism </e2> in AD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1793": {"data": {"text": "Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD.", "entity1": "galactose", "entity2": "AD", "span1": [5, 14], "span2": [198, 200]}, "bert_text": "Oral <e1> galactose </e1> exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in <e2> AD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1794": {"data": {"text": "DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.", "entity1": "Daptomycin", "entity2": "interstitial nephritis", "span1": [12, 22], "span2": [98, 120]}, "bert_text": "DISCUSSION: <e1> Daptomycin </e1> was initiated in our patient secondary to possible nafcillin-induced acute <e2> interstitial nephritis </e2> and relapsing bacteremia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1795": {"data": {"text": "DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.", "entity1": "Daptomycin", "entity2": "bacteremia", "span1": [12, 22], "span2": [135, 145]}, "bert_text": "DISCUSSION: <e1> Daptomycin </e1> was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing <e2> bacteremia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1796": {"data": {"text": "DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.", "entity1": "nafcillin", "entity2": "interstitial nephritis", "span1": [74, 83], "span2": [98, 120]}, "bert_text": "DISCUSSION: Daptomycin was initiated in our patient secondary to possible <e1> nafcillin </e1>-induced acute <e2> interstitial nephritis </e2> and relapsing bacteremia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"1797": {"data": {"text": "DISCUSSION: Daptomycin was initiated in our patient secondary to possible nafcillin-induced acute interstitial nephritis and relapsing bacteremia.", "entity1": "nafcillin", "entity2": "bacteremia", "span1": [74, 83], "span2": [135, 145]}, "bert_text": "DISCUSSION: Daptomycin was initiated in our patient secondary to possible <e1> nafcillin </e1>-induced acute interstitial nephritis and relapsing <e2> bacteremia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1798": {"data": {"text": "Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder.", "entity1": "propofol", "entity2": "nausea", "span1": [19, 27], "span2": [87, 93]}, "bert_text": "Anaesthesia with a <e1> propofol </e1> infusion and avoidance of serotonin antagonists provided a <e2> nausea </e2>-free postoperative course without exacerbation of the depression disorder.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1799": {"data": {"text": "Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder.", "entity1": "propofol", "entity2": "depression disorder", "span1": [19, 27], "span2": [148, 167]}, "bert_text": "Anaesthesia with a <e1> propofol </e1> infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the <e2> depression disorder </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1800": {"data": {"text": "Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder.", "entity1": "serotonin", "entity2": "nausea", "span1": [54, 63], "span2": [87, 93]}, "bert_text": "Anaesthesia with a propofol infusion and avoidance of <e1> serotonin </e1> antagonists provided a <e2> nausea </e2>-free postoperative course without exacerbation of the depression disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1801": {"data": {"text": "Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea-free postoperative course without exacerbation of the depression disorder.", "entity1": "serotonin", "entity2": "depression disorder", "span1": [54, 63], "span2": [148, 167]}, "bert_text": "Anaesthesia with a propofol infusion and avoidance of <e1> serotonin </e1> antagonists provided a nausea-free postoperative course without exacerbation of the <e2> depression disorder </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1802": {"data": {"text": "We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors.", "entity1": "OC", "entity2": "VTE", "span1": [87, 89], "span2": [62, 65]}, "bert_text": "We did a cohort analysis to estimate and compare incidence of VTE in users of the main <e1> OC </e1> <e2> VTE </e2> in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1803": {"data": {"text": "We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors.", "entity1": "OC", "entity2": "VTE", "span1": [87, 89], "span2": [168, 171]}, "bert_text": "We did a cohort analysis to estimate and compare incidence of VTE in users of the main <e1> OC </e1> preparations, and a nested case-control study to calculate the odds ratios of <e2> VTE </e2> associated with use of different types of OC, after adjustment for potential confounding factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1804": {"data": {"text": "We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors.", "entity1": "OC", "entity2": "VTE", "span1": [214, 216], "span2": [62, 65]}, "bert_text": "We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of <e1> OC </e1> <e2> VTE </e2> in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1805": {"data": {"text": "We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of OC, after adjustment for potential confounding factors.", "entity1": "OC", "entity2": "VTE", "span1": [214, 216], "span2": [168, 171]}, "bert_text": "We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations, and a nested case-control study to calculate the odds ratios of VTE associated with use of different types of <e1> OC </e1> <e2> VTE </e2> associated with use of different types of OC, after adjustment for potential confounding factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1806": {"data": {"text": "The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.", "entity1": "sodium chloride", "entity2": "CIN", "span1": [87, 102], "span2": [231, 234]}, "bert_text": "The aim of this study is to investigate and compare the protective effects of isotonic <e1> sodium chloride </e1> with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing <e2> CIN </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1807": {"data": {"text": "The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.", "entity1": "sodium chloride", "entity2": "CIN", "span1": [149, 164], "span2": [231, 234]}, "bert_text": "The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic <e1> sodium chloride </e1> infusion with diltiazem, a calcium channel blocker, in preventing <e2> CIN </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1808": {"data": {"text": "The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.", "entity1": "sodium bicarbonate", "entity2": "CIN", "span1": [108, 126], "span2": [231, 234]}, "bert_text": "The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with <e1> sodium bicarbonate </e1> infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing <e2> CIN </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1809": {"data": {"text": "The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.", "entity1": "diltiazem", "entity2": "CIN", "span1": [179, 188], "span2": [231, 234]}, "bert_text": "The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with <e1> diltiazem </e1>, a calcium channel blocker, in preventing <e2> CIN </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1810": {"data": {"text": "The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a calcium channel blocker, in preventing CIN.", "entity1": "calcium", "entity2": "CIN", "span1": [192, 199], "span2": [231, 234]}, "bert_text": "The aim of this study is to investigate and compare the protective effects of isotonic sodium chloride with sodium bicarbonate infusion and isotonic sodium chloride infusion with diltiazem, a <e1> calcium </e1> channel blocker, in preventing <e2> CIN </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1811": {"data": {"text": "On the 49th day of terbinafine therapy, he was brought to the emergency room for a decrease of his global health status, confusion and falls.", "entity1": "terbinafine", "entity2": "confusion", "span1": [19, 30], "span2": [121, 130]}, "bert_text": "On the 49th day of <e1> terbinafine </e1> therapy, he was brought to the emergency room for a decrease of his global health status, <e2> confusion </e2> and falls.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1812": {"data": {"text": "PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting PTU therapy.", "entity1": "PTU", "entity2": "hyperthyroidism", "span1": [173, 176], "span2": [54, 69]}, "bert_text": "PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting <e1> PTU </e1> <e2> hyperthyroidism </e2> due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting PTU therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1813": {"data": {"text": "PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting PTU therapy.", "entity1": "PTU", "entity2": "Graves' disease", "span1": [173, 176], "span2": [77, 92]}, "bert_text": "PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting <e1> PTU </e1> <e2> Graves' disease </e2> for the presence of MPO-ANCA, and for the development vasculitis after starting PTU therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1814": {"data": {"text": "PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting PTU therapy.", "entity1": "PTU", "entity2": "vasculitis", "span1": [173, 176], "span2": [147, 157]}, "bert_text": "PATIENTS: We investigated 102 untreated patients with hyperthyroidism due to Graves' disease for the presence of MPO-ANCA, and for the development vasculitis after starting <e1> PTU </e1> <e2> vasculitis </e2> after starting PTU therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1815": {"data": {"text": "Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported manic episodes.", "entity1": "Cotrimoxazole", "entity2": "manic", "span1": [0, 13], "span2": [76, 81]}, "bert_text": "<e1> Cotrimoxazole </e1>, metronidazole, and erythromycin were involved in 15 reported <e2> manic </e2> episodes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1816": {"data": {"text": "Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported manic episodes.", "entity1": "metronidazole", "entity2": "manic", "span1": [15, 28], "span2": [76, 81]}, "bert_text": "Cotrimoxazole, <e1> metronidazole </e1>, and erythromycin were involved in 15 reported <e2> manic </e2> episodes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1817": {"data": {"text": "Cotrimoxazole, metronidazole, and erythromycin were involved in 15 reported manic episodes.", "entity1": "erythromycin", "entity2": "manic", "span1": [34, 46], "span2": [76, 81]}, "bert_text": "Cotrimoxazole, metronidazole, and <e1> erythromycin </e1> were involved in 15 reported <e2> manic </e2> episodes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1818": {"data": {"text": "Consequently, dronedarone might be particularly suitable for the treatment and prevention of various clinical arrhythmias, without compromising the left ventricular function.", "entity1": "dronedarone", "entity2": "arrhythmias", "span1": [14, 25], "span2": [110, 121]}, "bert_text": "Consequently, <e1> dronedarone </e1> might be particularly suitable for the treatment and prevention of various clinical <e2> arrhythmias </e2>, without compromising the left ventricular function.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1819": {"data": {"text": "With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of triglyceride by livers from male and female rats.", "entity1": "tetracycline", "entity2": "depression", "span1": [137, 149], "span2": [205, 215]}, "bert_text": "With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of <e1> tetracycline </e1> and both accumulation of triglyceride in the liver and <e2> depression </e2> of output of triglyceride by livers from male and female rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1820": {"data": {"text": "With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of triglyceride by livers from male and female rats.", "entity1": "triglyceride", "entity2": "depression", "span1": [175, 187], "span2": [205, 215]}, "bert_text": "With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of <e1> triglyceride </e1> in the liver and <e2> depression </e2> of output of triglyceride by livers from male and female rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1821": {"data": {"text": "With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of triglyceride by livers from male and female rats.", "entity1": "triglyceride", "entity2": "depression", "span1": [229, 241], "span2": [205, 215]}, "bert_text": "With provision of adequate oleic acid as a substrate for the isolated perfused liver, a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of <e1> triglyceride </e1> <e2> depression </e2> of output of triglyceride by livers from male and female rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1822": {"data": {"text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "entity1": "cytarabine", "entity2": "acute encephalopathy", "span1": [253, 263], "span2": [22, 42]}, "bert_text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal <e1> cytarabine </e1> <e2> acute encephalopathy </e2> evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1823": {"data": {"text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "entity1": "cytarabine", "entity2": "aphasia", "span1": [253, 263], "span2": [76, 83]}, "bert_text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal <e1> cytarabine </e1> <e2> aphasia </e2>, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1824": {"data": {"text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "entity1": "cytarabine", "entity2": "incontinence", "span1": [253, 263], "span2": [85, 97]}, "bert_text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal <e1> cytarabine </e1> <e2> incontinence </e2>, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1825": {"data": {"text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "entity1": "cytarabine", "entity2": "visual hallucinations", "span1": [253, 263], "span2": [99, 120]}, "bert_text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal <e1> cytarabine </e1> <e2> visual hallucinations </e2>, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1826": {"data": {"text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "entity1": "cytarabine", "entity2": "weakness", "span1": [253, 263], "span2": [138, 146]}, "bert_text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal <e1> cytarabine </e1> <e2> weakness </e2> with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1827": {"data": {"text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine.", "entity1": "cytarabine", "entity2": "cerebral vasospasm", "span1": [253, 263], "span2": [160, 178]}, "bert_text": "The patient developed acute encephalopathy evidenced by behavioral changes, aphasia, incontinence, visual hallucinations, and right-sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal <e1> cytarabine </e1> <e2> cerebral vasospasm </e2> on magnetic resonance angiography after the administration of intrathecal cytarabine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1828": {"data": {"text": "The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.", "entity1": "caffeine", "entity2": "PD", "span1": [52, 60], "span2": [18, 20]}, "bert_text": "The patients with PD and MDP were more sensitive to <e1> caffeine </e1> <e2> PD </e2> and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1829": {"data": {"text": "The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.", "entity1": "caffeine", "entity2": "MDP", "span1": [52, 60], "span2": [25, 28]}, "bert_text": "The patients with PD and MDP were more sensitive to <e1> caffeine </e1> <e2> MDP </e2> were more sensitive to caffeine than were patients with MD and healthy volunteers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1830": {"data": {"text": "The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers.", "entity1": "caffeine", "entity2": "MD", "span1": [52, 60], "span2": [85, 87]}, "bert_text": "The patients with PD and MDP were more sensitive to <e1> caffeine </e1> than were patients with <e2> MD </e2> and healthy volunteers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1831": {"data": {"text": "Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.", "entity1": "prednisone", "entity2": "hoarseness", "span1": [24, 34], "span2": [98, 108]}, "bert_text": "Concomitant use of oral <e1> prednisone </e1> and topical beclomethasone may increase the risk of developing <e2> hoarseness </e2> or candidiasis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1832": {"data": {"text": "Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.", "entity1": "prednisone", "entity2": "candidiasis", "span1": [24, 34], "span2": [112, 123]}, "bert_text": "Concomitant use of oral <e1> prednisone </e1> and topical beclomethasone may increase the risk of developing hoarseness or <e2> candidiasis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1833": {"data": {"text": "Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.", "entity1": "beclomethasone", "entity2": "hoarseness", "span1": [47, 61], "span2": [98, 108]}, "bert_text": "Concomitant use of oral prednisone and topical <e1> beclomethasone </e1> may increase the risk of developing <e2> hoarseness </e2> or candidiasis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1834": {"data": {"text": "Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis.", "entity1": "beclomethasone", "entity2": "candidiasis", "span1": [47, 61], "span2": [112, 123]}, "bert_text": "Concomitant use of oral prednisone and topical <e1> beclomethasone </e1> may increase the risk of developing hoarseness or <e2> candidiasis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1835": {"data": {"text": "CONCLUSION: Ureteric obstruction caused by precipitated indinavir crystals may be difficult to diagnose with unenhanced CT.", "entity1": "indinavir", "entity2": "Ureteric obstruction", "span1": [56, 65], "span2": [12, 32]}, "bert_text": "CONCLUSION: Ureteric obstruction caused by precipitated <e1> indinavir </e1> <e2> Ureteric obstruction </e2> caused by precipitated indinavir crystals may be difficult to diagnose with unenhanced CT.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1836": {"data": {"text": "Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline infusion.\n", "entity1": "adrenaline", "entity2": "adrenaline-hypertension hypothesis", "span1": [85, 95], "span2": [12, 46]}, "bert_text": "Support for adrenaline-hypertension hypothesis: 18 hour pressor effect after 6 hours <e1> adrenaline </e1> <e2> adrenaline-hypertension hypothesis </e2>: 18 hour pressor effect after 6 hours adrenaline infusion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1837": {"data": {"text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.\n", "entity1": "tetrabenazine", "entity2": "Neuroleptic malignant syndrome", "span1": [67, 80], "span2": [0, 30]}, "bert_text": "Neuroleptic malignant syndrome induced by combination therapy with <e1> tetrabenazine </e1> <e2> Neuroleptic malignant syndrome </e2> induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1838": {"data": {"text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.\n", "entity1": "tetrabenazine", "entity2": "Huntington's disease", "span1": [67, 80], "span2": [121, 141]}, "bert_text": "Neuroleptic malignant syndrome induced by combination therapy with <e1> tetrabenazine </e1> and tiapride in a Japanese patient with <e2> Huntington's disease </e2> at the terminal stage of recurrent breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1839": {"data": {"text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.\n", "entity1": "tetrabenazine", "entity2": "breast cancer", "span1": [67, 80], "span2": [177, 190]}, "bert_text": "Neuroleptic malignant syndrome induced by combination therapy with <e1> tetrabenazine </e1> and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent <e2> breast cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1840": {"data": {"text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.\n", "entity1": "tiapride", "entity2": "Neuroleptic malignant syndrome", "span1": [85, 93], "span2": [0, 30]}, "bert_text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and <e1> tiapride </e1> <e2> Neuroleptic malignant syndrome </e2> induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1841": {"data": {"text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.\n", "entity1": "tiapride", "entity2": "Huntington's disease", "span1": [85, 93], "span2": [121, 141]}, "bert_text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and <e1> tiapride </e1> in a Japanese patient with <e2> Huntington's disease </e2> at the terminal stage of recurrent breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1842": {"data": {"text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington's disease at the terminal stage of recurrent breast cancer.\n", "entity1": "tiapride", "entity2": "breast cancer", "span1": [85, 93], "span2": [177, 190]}, "bert_text": "Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and <e1> tiapride </e1> in a Japanese patient with Huntington's disease at the terminal stage of recurrent <e2> breast cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"1843": {"data": {"text": "Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis.\n", "entity1": "aminonucleoside", "entity2": "glomerular sclerosis", "span1": [57, 72], "span2": [23, 43]}, "bert_text": "Mesangial function and glomerular sclerosis in rats with <e1> aminonucleoside </e1> <e2> glomerular sclerosis </e2> in rats with aminonucleoside nephrosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1844": {"data": {"text": "Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis.\n", "entity1": "aminonucleoside", "entity2": "nephrosis", "span1": [57, 72], "span2": [73, 82]}, "bert_text": "Mesangial function and glomerular sclerosis in rats with <e1> aminonucleoside </e1> <e2> nephrosis </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1845": {"data": {"text": "Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.\n", "entity1": "cisplatin", "entity2": "Hypotension", "span1": [77, 86], "span2": [0, 11]}, "bert_text": "Hypotension as a manifestation of cardiotoxicity in three patients receiving <e1> cisplatin </e1> <e2> Hypotension </e2> as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1846": {"data": {"text": "Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.\n", "entity1": "cisplatin", "entity2": "cardiotoxicity", "span1": [77, 86], "span2": [34, 48]}, "bert_text": "Hypotension as a manifestation of cardiotoxicity in three patients receiving <e1> cisplatin </e1> <e2> cardiotoxicity </e2> in three patients receiving cisplatin and 5-fluorouracil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1847": {"data": {"text": "Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.\n", "entity1": "5-fluorouracil", "entity2": "Hypotension", "span1": [91, 105], "span2": [0, 11]}, "bert_text": "Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and <e1> 5-fluorouracil </e1> <e2> Hypotension </e2> as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1848": {"data": {"text": "Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.\n", "entity1": "5-fluorouracil", "entity2": "cardiotoxicity", "span1": [91, 105], "span2": [34, 48]}, "bert_text": "Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and <e1> 5-fluorouracil </e1> <e2> cardiotoxicity </e2> in three patients receiving cisplatin and 5-fluorouracil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1849": {"data": {"text": "Thirty-six rats bearing breast tumors induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus hydroxytyrosol.", "entity1": "hydroxytyrosol", "entity2": "breast tumors", "span1": [94, 108], "span2": [24, 37]}, "bert_text": "Thirty-six rats bearing breast tumors induced chemically were divided into 4 groups: control, <e1> hydroxytyrosol </e1> <e2> breast tumors </e2> induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus hydroxytyrosol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1850": {"data": {"text": "Thirty-six rats bearing breast tumors induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus hydroxytyrosol.", "entity1": "hydroxytyrosol", "entity2": "breast tumors", "span1": [181, 195], "span2": [24, 37]}, "bert_text": "Thirty-six rats bearing breast tumors induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus <e1> hydroxytyrosol </e1> <e2> breast tumors </e2> induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus hydroxytyrosol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1851": {"data": {"text": "Thirty-six rats bearing breast tumors induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus hydroxytyrosol.", "entity1": "doxorubicin", "entity2": "breast tumors", "span1": [133, 144], "span2": [24, 37]}, "bert_text": "Thirty-six rats bearing breast tumors induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), <e1> doxorubicin </e1> <e2> breast tumors </e2> induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus hydroxytyrosol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1852": {"data": {"text": "Thirty-six rats bearing breast tumors induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus hydroxytyrosol.", "entity1": "doxorubicin", "entity2": "breast tumors", "span1": [164, 175], "span2": [24, 37]}, "bert_text": "Thirty-six rats bearing breast tumors induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and <e1> doxorubicin </e1> <e2> breast tumors </e2> induced chemically were divided into 4 groups: control, hydroxytyrosol (0.5mg/kg, 5days/week), doxorubicin (1mg/kg/week), and doxorubicin plus hydroxytyrosol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1853": {"data": {"text": "Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of citrate toxicity.", "entity1": "citrate", "entity2": "toxicity", "span1": [48, 55], "span2": [137, 145]}, "bert_text": "Systemic anticoagulation is unsafe and regional <e1> citrate </e1> anticoagulation in the absence of a functional liver carries the risk of citrate <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1854": {"data": {"text": "Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of citrate toxicity.", "entity1": "citrate", "entity2": "toxicity", "span1": [129, 136], "span2": [137, 145]}, "bert_text": "Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of <e1> citrate </e1> <e2> toxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1855": {"data": {"text": "Busulfan is known to be neurotoxic in animals and humans, but its acute neurotoxicity remains poorly characterized in children.", "entity1": "Busulfan", "entity2": "neurotoxic", "span1": [0, 8], "span2": [24, 34]}, "bert_text": "<e1> Busulfan </e1> is known to be <e2> neurotoxic </e2> in animals and humans, but its acute neurotoxicity remains poorly characterized in children.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1856": {"data": {"text": "Busulfan is known to be neurotoxic in animals and humans, but its acute neurotoxicity remains poorly characterized in children.", "entity1": "Busulfan", "entity2": "neurotoxicity", "span1": [0, 8], "span2": [72, 85]}, "bert_text": "<e1> Busulfan </e1> is known to be neurotoxic in animals and humans, but its acute <e2> neurotoxicity </e2> remains poorly characterized in children.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1857": {"data": {"text": "LF prevented body weight loss and significantly reduced the elevated plasma H2O2 and increased FRAP values.", "entity1": "LF", "entity2": "weight loss", "span1": [0, 2], "span2": [18, 29]}, "bert_text": "<e1> LF </e1> prevented body <e2> weight loss </e2> and significantly reduced the elevated plasma H2O2 and increased FRAP values.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1858": {"data": {"text": "LF prevented body weight loss and significantly reduced the elevated plasma H2O2 and increased FRAP values.", "entity1": "H2O2", "entity2": "weight loss", "span1": [76, 80], "span2": [18, 29]}, "bert_text": "LF prevented body weight loss and significantly reduced the elevated plasma <e1> H2O2 </e1> <e2> weight loss </e2> and significantly reduced the elevated plasma H2O2 and increased FRAP values.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"1859": {"data": {"text": "Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.", "entity1": "nitric oxide", "entity2": "hypertension", "span1": [33, 45], "span2": [54, 66]}, "bert_text": "Loss of endothelial cell-derived <e1> nitric oxide </e1> (NO) in <e2> hypertension </e2> is a hallmark of arterial dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1860": {"data": {"text": "Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.", "entity1": "nitric oxide", "entity2": "arterial dysfunction", "span1": [33, 45], "span2": [84, 104]}, "bert_text": "Loss of endothelial cell-derived <e1> nitric oxide </e1> (NO) in hypertension is a hallmark of <e2> arterial dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1861": {"data": {"text": "Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.", "entity1": "NO", "entity2": "hypertension", "span1": [47, 49], "span2": [54, 66]}, "bert_text": "Loss of endothelial cell-derived nitric oxide (<e1> NO </e1>) in <e2> hypertension </e2> is a hallmark of arterial dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1862": {"data": {"text": "Loss of endothelial cell-derived nitric oxide (NO) in hypertension is a hallmark of arterial dysfunction.", "entity1": "NO", "entity2": "arterial dysfunction", "span1": [47, 49], "span2": [84, 104]}, "bert_text": "Loss of endothelial cell-derived nitric oxide (<e1> NO </e1>) in hypertension is a hallmark of <e2> arterial dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1863": {"data": {"text": "However, DA response was lost if a 9-month long haloperidol-induced hyperprolactinemia was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule.", "entity1": "DA", "entity2": "hyperprolactinemia", "span1": [9, 11], "span2": [68, 86]}, "bert_text": "However, <e1> DA </e1> response was lost if a 9-month long haloperidol-induced <e2> hyperprolactinemia </e2> was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1864": {"data": {"text": "However, DA response was lost if a 9-month long haloperidol-induced hyperprolactinemia was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule.", "entity1": "haloperidol", "entity2": "hyperprolactinemia", "span1": [48, 59], "span2": [68, 86]}, "bert_text": "However, DA response was lost if a 9-month long <e1> haloperidol </e1>-induced <e2> hyperprolactinemia </e2> was followed by a 1 1/2 month-long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1865": {"data": {"text": "The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).", "entity1": "chloroform-adrenaline", "entity2": "arrhythmia", "span1": [151, 172], "span2": [77, 87]}, "bert_text": "The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by <e1> chloroform-adrenaline </e1> <e2> arrhythmia </e2> used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1866": {"data": {"text": "The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).", "entity1": "chloroform-adrenaline", "entity2": "arrhythmia", "span1": [151, 172], "span2": [129, 139]}, "bert_text": "The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by <e1> chloroform-adrenaline </e1> <e2> arrhythmia </e2> induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1867": {"data": {"text": "The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).", "entity1": "BaCl2", "entity2": "arrhythmia", "span1": [199, 204], "span2": [77, 87]}, "bert_text": "The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with <e1> BaCl2 </e1> <e2> arrhythmia </e2> used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1868": {"data": {"text": "The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).", "entity1": "BaCl2", "entity2": "arrhythmia", "span1": [199, 204], "span2": [129, 139]}, "bert_text": "The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used, causing greatest inhibition on the arrhythmia induced by chloroform-adrenaline (in 90 per cent) and with <e1> BaCl2 </e1> <e2> arrhythmia </e2> induced by chloroform-adrenaline (in 90 per cent) and with BaCl2 (in 84 per cent).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1869": {"data": {"text": "The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders.", "entity1": "levodopa", "entity2": "hypotensive", "span1": [43, 51], "span2": [21, 32]}, "bert_text": "The magnitude of the hypotensive effect of <e1> levodopa </e1> <e2> hypotensive </e2> effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1870": {"data": {"text": "To the best of our knowledge this is the first ANCA positive carbimazole induced vasculitis case reported from India.", "entity1": "carbimazole", "entity2": "vasculitis", "span1": [61, 72], "span2": [81, 91]}, "bert_text": "To the best of our knowledge this is the first ANCA positive <e1> carbimazole </e1> induced <e2> vasculitis </e2> case reported from India.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1871": {"data": {"text": "UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring.", "entity1": "caffeine", "entity2": "intrauterine growth retardation", "span1": [59, 67], "span2": [96, 127]}, "bert_text": "UNASSIGNED: Our previous study has indicated that prenatal <e1> caffeine </e1> exposure (PCE) could induce <e2> intrauterine growth retardation </e2> (IUGR) of offspring.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1872": {"data": {"text": "UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring.", "entity1": "caffeine", "entity2": "IUGR", "span1": [59, 67], "span2": [129, 133]}, "bert_text": "UNASSIGNED: Our previous study has indicated that prenatal <e1> caffeine </e1> exposure (PCE) could induce intrauterine growth retardation (<e2> IUGR </e2>) of offspring.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1873": {"data": {"text": "Oxitropium proves to be a valuable alternative to theophylline in nocturnal asthma, since it is equally potent, safer and does not require the titration of dosage.", "entity1": "Oxitropium", "entity2": "nocturnal asthma", "span1": [0, 10], "span2": [66, 82]}, "bert_text": "<e1> Oxitropium </e1> proves to be a valuable alternative to theophylline in <e2> nocturnal asthma </e2>, since it is equally potent, safer and does not require the titration of dosage.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1874": {"data": {"text": "Oxitropium proves to be a valuable alternative to theophylline in nocturnal asthma, since it is equally potent, safer and does not require the titration of dosage.", "entity1": "theophylline", "entity2": "nocturnal asthma", "span1": [50, 62], "span2": [66, 82]}, "bert_text": "Oxitropium proves to be a valuable alternative to <e1> theophylline </e1> in <e2> nocturnal asthma </e2>, since it is equally potent, safer and does not require the titration of dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1875": {"data": {"text": "Capsaicin injection was reproducible for secondary hyperalgesia (ICC > 0.70) and allodynia (ICC > 0.71).", "entity1": "Capsaicin", "entity2": "hyperalgesia", "span1": [0, 9], "span2": [51, 63]}, "bert_text": "<e1> Capsaicin </e1> injection was reproducible for secondary <e2> hyperalgesia </e2> (ICC > 0.70) and allodynia (ICC > 0.71).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1876": {"data": {"text": "Capsaicin injection was reproducible for secondary hyperalgesia (ICC > 0.70) and allodynia (ICC > 0.71).", "entity1": "Capsaicin", "entity2": "allodynia", "span1": [0, 9], "span2": [81, 90]}, "bert_text": "<e1> Capsaicin </e1> injection was reproducible for secondary hyperalgesia (ICC > 0.70) and <e2> allodynia </e2> (ICC > 0.71).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1877": {"data": {"text": "Studies on the bradycardia induced by bepridil.\n", "entity1": "bepridil", "entity2": "bradycardia", "span1": [38, 46], "span2": [15, 26]}, "bert_text": "Studies on the bradycardia induced by <e1> bepridil </e1> <e2> bradycardia </e2> induced by bepridil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1878": {"data": {"text": "Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo.", "entity1": "Bepridil", "entity2": "anginal attacks", "span1": [0, 8], "span2": [64, 79]}, "bert_text": "<e1> Bepridil </e1>, a novel active compound for prophylactic treatment of <e2> anginal attacks </e2>, induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1879": {"data": {"text": "Bepridil, a novel active compound for prophylactic treatment of anginal attacks, induced persistent bradycardia and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo.", "entity1": "Bepridil", "entity2": "bradycardia", "span1": [0, 8], "span2": [100, 111]}, "bert_text": "<e1> Bepridil </e1>, a novel active compound for prophylactic treatment of anginal attacks, induced persistent <e2> bradycardia </e2> and a non-specific anti-tachycardial effect, the mechanisms of which were investigated in vitro and in vivo.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1880": {"data": {"text": "The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of amiodarone on the function of this receptor were indirect.", "entity1": "amiodarone", "entity2": "hepatoma", "span1": [17, 27], "span2": [118, 126]}, "bert_text": "The inability of <e1> amiodarone </e1> to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 <e2> hepatoma </e2> cells indicates that the effects of amiodarone on the function of this receptor were indirect.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1881": {"data": {"text": "The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of amiodarone on the function of this receptor were indirect.", "entity1": "amiodarone", "entity2": "hepatoma", "span1": [163, 173], "span2": [118, 126]}, "bert_text": "The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of <e1> amiodarone </e1> <e2> hepatoma </e2> cells indicates that the effects of amiodarone on the function of this receptor were indirect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1882": {"data": {"text": "The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of amiodarone on the function of this receptor were indirect.", "entity1": "PPARalpha", "entity2": "hepatoma", "span1": [71, 80], "span2": [118, 126]}, "bert_text": "The inability of amiodarone to directly activate either human or mouse <e1> PPARalpha </e1> transiently expressed in human HepG2 <e2> hepatoma </e2> cells indicates that the effects of amiodarone on the function of this receptor were indirect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1883": {"data": {"text": "Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.\n", "entity1": "Na", "entity2": "OAT", "span1": [24, 26], "span2": [58, 61]}, "bert_text": "Decreased Expression of <e1> Na </e1>/K-ATPase, NHE3, NBC1, AQP1 and <e2> OAT </e2> in Gentamicin-induced Nephropathy.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1884": {"data": {"text": "Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.\n", "entity1": "Na", "entity2": "Nephropathy", "span1": [24, 26], "span2": [84, 95]}, "bert_text": "Decreased Expression of <e1> Na </e1>/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced <e2> Nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1885": {"data": {"text": "Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.\n", "entity1": "K", "entity2": "OAT", "span1": [27, 28], "span2": [58, 61]}, "bert_text": "Decreased Expression of Na/<e1> K </e1>-ATPase, NHE3, NBC1, AQP1 and <e2> OAT </e2> in Gentamicin-induced Nephropathy.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1886": {"data": {"text": "Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.\n", "entity1": "K", "entity2": "Nephropathy", "span1": [27, 28], "span2": [84, 95]}, "bert_text": "Decreased Expression of Na/<e1> K </e1>-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced <e2> Nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1887": {"data": {"text": "Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.\n", "entity1": "Gentamicin", "entity2": "OAT", "span1": [65, 75], "span2": [58, 61]}, "bert_text": "Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in <e1> Gentamicin </e1> <e2> OAT </e2> in Gentamicin-induced Nephropathy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1888": {"data": {"text": "Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in Gentamicin-induced Nephropathy.\n", "entity1": "Gentamicin", "entity2": "Nephropathy", "span1": [65, 75], "span2": [84, 95]}, "bert_text": "Decreased Expression of Na/K-ATPase, NHE3, NBC1, AQP1 and OAT in <e1> Gentamicin </e1>-induced <e2> Nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1889": {"data": {"text": "Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC.", "entity1": "CAA", "entity2": "toxicity", "span1": [6, 9], "span2": [86, 94]}, "bert_text": "Thus, <e1> CAA </e1> directly reacts with cellular protein and non-protein thiols, mediating its <e2> toxicity </e2> on hRPTEC.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1890": {"data": {"text": "Thus, CAA directly reacts with cellular protein and non-protein thiols, mediating its toxicity on hRPTEC.", "entity1": "thiols", "entity2": "toxicity", "span1": [64, 70], "span2": [86, 94]}, "bert_text": "Thus, CAA directly reacts with cellular protein and non-protein <e1> thiols </e1>, mediating its <e2> toxicity </e2> on hRPTEC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1891": {"data": {"text": "Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.", "entity1": "cyclosporine", "entity2": "thrombotic microangiopathy", "span1": [83, 95], "span2": [40, 66]}, "bert_text": "Furthermore, there have been reports of thrombotic microangiopathy precipitated by <e1> cyclosporine </e1> <e2> thrombotic microangiopathy </e2> precipitated by cyclosporine in patients with SSc.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1892": {"data": {"text": "Furthermore, there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc.", "entity1": "cyclosporine", "entity2": "SSc", "span1": [83, 95], "span2": [113, 116]}, "bert_text": "Furthermore, there have been reports of thrombotic microangiopathy precipitated by <e1> cyclosporine </e1> in patients with <e2> SSc </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1893": {"data": {"text": "Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment, we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where sclerosis will develop subsequently.", "entity1": "CC", "entity2": "sclerosis", "span1": [16, 18], "span2": [258, 267]}, "bert_text": "Since mesangial <e1> CC </e1> clearance from the mesangium did not change during chronic PAN treatment, we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where <e2> sclerosis </e2> will develop subsequently.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1894": {"data": {"text": "Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment, we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where sclerosis will develop subsequently.", "entity1": "CC", "entity2": "sclerosis", "span1": [128, 130], "span2": [258, 267]}, "bert_text": "Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment, we conclude that this preferential <e1> CC </e1> localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where <e2> sclerosis </e2> will develop subsequently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1895": {"data": {"text": "Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment, we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where sclerosis will develop subsequently.", "entity1": "CC", "entity2": "sclerosis", "span1": [189, 191], "span2": [258, 267]}, "bert_text": "Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment, we conclude that this preferential CC localization within the lesions is caused by an increased <e1> CC </e1> uptake shortly after injection in apparent vulnerable areas where <e2> sclerosis </e2> will develop subsequently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1896": {"data": {"text": "Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment, we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where sclerosis will develop subsequently.", "entity1": "PAN", "entity2": "sclerosis", "span1": [78, 81], "span2": [258, 267]}, "bert_text": "Since mesangial CC clearance from the mesangium did not change during chronic <e1> PAN </e1> treatment, we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where <e2> sclerosis </e2> will develop subsequently.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1897": {"data": {"text": "Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease.\n", "entity1": "cyclophosphamide", "entity2": "carcinoma of the renal pelvis", "span1": [49, 65], "span2": [9, 38]}, "bert_text": "Invasive carcinoma of the renal pelvis following <e1> cyclophosphamide </e1> <e2> carcinoma of the renal pelvis </e2> following cyclophosphamide therapy for nonmalignant disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1898": {"data": {"text": "The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.", "entity1": "flavonoid monohydroxyethylrutoside", "entity2": "cardiotoxicity", "span1": [18, 52], "span2": [107, 121]}, "bert_text": "The semisynthetic <e1> flavonoid monohydroxyethylrutoside </e1> (monoHER) showed cardioprotection against DOX-induced <e2> cardiotoxicity </e2> through its radical scavenging and iron chelating properties.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1899": {"data": {"text": "The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [95, 98], "span2": [107, 121]}, "bert_text": "The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against <e1> DOX </e1>-induced <e2> cardiotoxicity </e2> through its radical scavenging and iron chelating properties.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1900": {"data": {"text": "The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and iron chelating properties.", "entity1": "iron", "entity2": "cardiotoxicity", "span1": [157, 161], "span2": [107, 121]}, "bert_text": "The semisynthetic flavonoid monohydroxyethylrutoside (monoHER) showed cardioprotection against DOX-induced cardiotoxicity through its radical scavenging and <e1> iron </e1> <e2> cardiotoxicity </e2> through its radical scavenging and iron chelating properties.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1901": {"data": {"text": "Histamine antagonists and d-tubocurarine-induced hypotension in cardiac surgical patients.\n", "entity1": "Histamine", "entity2": "hypotension", "span1": [0, 9], "span2": [49, 60]}, "bert_text": "<e1> Histamine </e1> antagonists and d-tubocurarine-induced <e2> hypotension </e2> in cardiac surgical patients.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1902": {"data": {"text": "Histamine antagonists and d-tubocurarine-induced hypotension in cardiac surgical patients.\n", "entity1": "d-tubocurarine", "entity2": "hypotension", "span1": [26, 40], "span2": [49, 60]}, "bert_text": "Histamine antagonists and <e1> d-tubocurarine </e1>-induced <e2> hypotension </e2> in cardiac surgical patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1903": {"data": {"text": "Two hours after the sixth dose of TNA, she had an episode of generalized tonic clonic convulsions.", "entity1": "TNA", "entity2": "tonic clonic convulsions", "span1": [34, 37], "span2": [73, 97]}, "bert_text": "Two hours after the sixth dose of <e1> TNA </e1>, she had an episode of generalized <e2> tonic clonic convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1904": {"data": {"text": "During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.", "entity1": "haloperidol", "entity2": "hyperprolactinemia", "span1": [21, 32], "span2": [56, 74]}, "bert_text": "During the course of <e1> haloperidol </e1> infusions, significant <e2> hyperprolactinemia </e2> was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1905": {"data": {"text": "CONCLUSIONS: Our updated evaluation of diazinon provides additional evidence of an association with lung cancer risk.", "entity1": "diazinon", "entity2": "lung cancer", "span1": [39, 47], "span2": [100, 111]}, "bert_text": "CONCLUSIONS: Our updated evaluation of <e1> diazinon </e1> provides additional evidence of an association with <e2> lung cancer </e2> risk.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1906": {"data": {"text": "A reversible toxic liver damage was observed in a non-alcoholic woman treated with disulfiram.", "entity1": "disulfiram", "entity2": "toxic liver damage", "span1": [83, 93], "span2": [13, 31]}, "bert_text": "A reversible toxic liver damage was observed in a non-alcoholic woman treated with <e1> disulfiram </e1> <e2> toxic liver damage </e2> was observed in a non-alcoholic woman treated with disulfiram.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1907": {"data": {"text": "However, verapamil unresponsiveness discriminates stalk effect (i.e., anatomically or functionally inhibited dopaminergic tonus) from other causes of hyperprolactinemia with varying degrees of responsiveness.", "entity1": "verapamil", "entity2": "hyperprolactinemia", "span1": [9, 18], "span2": [150, 168]}, "bert_text": "However, <e1> verapamil </e1> unresponsiveness discriminates stalk effect (i.e., anatomically or functionally inhibited dopaminergic tonus) from other causes of <e2> hyperprolactinemia </e2> with varying degrees of responsiveness.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1908": {"data": {"text": "The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg/kg of metformin.", "entity1": "metformin", "entity2": "ventricular dysfunction", "span1": [102, 111], "span2": [9, 32]}, "bert_text": "The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg/kg of <e1> metformin </e1> <e2> ventricular dysfunction </e2> was significantly lower in the groups treated with 25 and 50mg/kg of metformin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1909": {"data": {"text": "Nissl-staining and antibodies against the neuron-specific calcium-binding protein, parvalbumin, served to detect neuronal damage in SNR.", "entity1": "calcium", "entity2": "neuronal damage", "span1": [58, 65], "span2": [113, 128]}, "bert_text": "Nissl-staining and antibodies against the neuron-specific <e1> calcium </e1>-binding protein, parvalbumin, served to detect <e2> neuronal damage </e2> in SNR.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1910": {"data": {"text": "Spontaneous pain behaviors following the administration of CYP were observed.", "entity1": "CYP", "entity2": "pain", "span1": [59, 62], "span2": [12, 16]}, "bert_text": "Spontaneous pain behaviors following the administration of <e1> CYP </e1> <e2> pain </e2> behaviors following the administration of CYP were observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1911": {"data": {"text": "The glomerulosclerosis index (GSI) was 6.21 % at 4 weeks and respectively 25.35 % and 30.49 % at 14 and 20 weeks in the PAN group.", "entity1": "PAN", "entity2": "glomerulosclerosis", "span1": [120, 123], "span2": [4, 22]}, "bert_text": "The glomerulosclerosis index (GSI) was 6.21 % at 4 weeks and respectively 25.35 % and 30.49 % at 14 and 20 weeks in the <e1> PAN </e1> <e2> glomerulosclerosis </e2> index (GSI) was 6.21 % at 4 weeks and respectively 25.35 % and 30.49 % at 14 and 20 weeks in the PAN group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1912": {"data": {"text": "The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "entity1": "oxygen", "entity2": "RNS", "span1": [71, 77], "span2": [102, 105]}, "bert_text": "The purpose of the present study was to determine if elevated reactive <e1> oxygen </e1> (ROS)/nitrogen species (<e2> RNS </e2>) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1913": {"data": {"text": "The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "entity1": "oxygen", "entity2": "cardiotoxicity", "span1": [71, 77], "span2": [158, 172]}, "bert_text": "The purpose of the present study was to determine if elevated reactive <e1> oxygen </e1> (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced <e2> cardiotoxicity </e2> actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1914": {"data": {"text": "The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "entity1": "adriamycin", "entity2": "RNS", "span1": [133, 143], "span2": [102, 105]}, "bert_text": "The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in <e1> adriamycin </e1> <e2> RNS </e2>) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1915": {"data": {"text": "The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "entity1": "adriamycin", "entity2": "cardiotoxicity", "span1": [133, 143], "span2": [158, 172]}, "bert_text": "The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in <e1> adriamycin </e1> (ADR)-induced <e2> cardiotoxicity </e2> actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1916": {"data": {"text": "The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "entity1": "ADR)-induced", "entity2": "RNS", "span1": [145, 157], "span2": [102, 105]}, "bert_text": "The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (<e1> ADR)-induced </e1> <e2> RNS </e2>) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1917": {"data": {"text": "The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (ADR)-induced cardiotoxicity actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "entity1": "ADR)-induced", "entity2": "cardiotoxicity", "span1": [145, 157], "span2": [158, 172]}, "bert_text": "The purpose of the present study was to determine if elevated reactive oxygen (ROS)/nitrogen species (RNS) reported to be present in adriamycin (<e1> ADR)-induced </e1> <e2> cardiotoxicity </e2> actually resulted in cardiomyocyte oxidative/nitrative damage, and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1918": {"data": {"text": "A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.\n", "entity1": "methamphetamine", "entity2": "neurotoxic", "span1": [28, 43], "span2": [9, 19]}, "bert_text": "A single neurotoxic dose of <e1> methamphetamine </e1> <e2> neurotoxic </e2> dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1919": {"data": {"text": "A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice.\n", "entity1": "methamphetamine", "entity2": "depressive", "span1": [28, 43], "span2": [67, 77]}, "bert_text": "A single neurotoxic dose of <e1> methamphetamine </e1> induces a long-lasting <e2> depressive </e2>-like behaviour in mice.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1920": {"data": {"text": "Thus the present study concluded that metformin may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by seizures.", "entity1": "metformin", "entity2": "epilepsy", "span1": [38, 47], "span2": [94, 102]}, "bert_text": "Thus the present study concluded that <e1> metformin </e1> may be a potential agent for the treatment of <e2> epilepsy </e2> as well as a protective medicine against cognitive impairment induced by seizures.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1921": {"data": {"text": "Thus the present study concluded that metformin may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by seizures.", "entity1": "metformin", "entity2": "cognitive impairment", "span1": [38, 47], "span2": [144, 164]}, "bert_text": "Thus the present study concluded that <e1> metformin </e1> may be a potential agent for the treatment of epilepsy as well as a protective medicine against <e2> cognitive impairment </e2> induced by seizures.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1922": {"data": {"text": "Thus the present study concluded that metformin may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by seizures.", "entity1": "metformin", "entity2": "seizures", "span1": [38, 47], "span2": [176, 184]}, "bert_text": "Thus the present study concluded that <e1> metformin </e1> may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1923": {"data": {"text": "The results indicate that centrally applied AVP and ANP exert differential effects on blood pressure and baroreflex control of heart rate in WKY and SHR and suggest interaction of these two peptides in blood pressure regulation at the level of central nervous system.", "entity1": "AVP", "entity2": "SHR", "span1": [44, 47], "span2": [149, 152]}, "bert_text": "The results indicate that centrally applied <e1> AVP </e1> and ANP exert differential effects on blood pressure and baroreflex control of heart rate in WKY and <e2> SHR </e2> and suggest interaction of these two peptides in blood pressure regulation at the level of central nervous system.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1924": {"data": {"text": "Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?\n", "entity1": "amitriptyline", "entity2": "Encephalopathy", "span1": [22, 35], "span2": [0, 14]}, "bert_text": "Encephalopathy during <e1> amitriptyline </e1> <e2> Encephalopathy </e2> during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1925": {"data": {"text": "Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?\n", "entity1": "amitriptyline", "entity2": "neuroleptic malignant syndrome", "span1": [22, 35], "span2": [49, 79]}, "bert_text": "Encephalopathy during <e1> amitriptyline </e1> therapy: are <e2> neuroleptic malignant syndrome </e2> and serotonin syndrome spectrum disorders?\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1926": {"data": {"text": "Encephalopathy during amitriptyline therapy: are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders?\n", "entity1": "amitriptyline", "entity2": "serotonin syndrome spectrum disorders", "span1": [22, 35], "span2": [84, 121]}, "bert_text": "Encephalopathy during <e1> amitriptyline </e1> therapy: are neuroleptic malignant syndrome and <e2> serotonin syndrome spectrum disorders </e2>?\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1927": {"data": {"text": "Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.", "entity1": "CAA", "entity2": "necrosis", "span1": [44, 47], "span2": [106, 114]}, "bert_text": "Acidification, which slowed the reaction of <e1> CAA </e1> with thiol donors, could also attenuate effects of CAA on <e2> necrosis </e2> markers, thiol depletion and cysteine protease inhibition in living cells.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1928": {"data": {"text": "Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.", "entity1": "CAA", "entity2": "necrosis", "span1": [99, 102], "span2": [106, 114]}, "bert_text": "Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of <e1> CAA </e1> on <e2> necrosis </e2> markers, thiol depletion and cysteine protease inhibition in living cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1929": {"data": {"text": "Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.", "entity1": "thiol", "entity2": "necrosis", "span1": [53, 58], "span2": [106, 114]}, "bert_text": "Acidification, which slowed the reaction of CAA with <e1> thiol </e1> donors, could also attenuate effects of CAA on <e2> necrosis </e2> markers, thiol depletion and cysteine protease inhibition in living cells.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1930": {"data": {"text": "Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, thiol depletion and cysteine protease inhibition in living cells.", "entity1": "thiol", "entity2": "necrosis", "span1": [124, 129], "span2": [106, 114]}, "bert_text": "Acidification, which slowed the reaction of CAA with thiol donors, could also attenuate effects of CAA on necrosis markers, <e1> thiol </e1> <e2> necrosis </e2> markers, thiol depletion and cysteine protease inhibition in living cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1931": {"data": {"text": "In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity.", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [59, 70], "span2": [85, 99]}, "bert_text": "In this study, we have utilized a rat model of progressive <e1> doxorubicin </e1> (DOX)-induced <e2> cardiomyopathy </e2>, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1932": {"data": {"text": "In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity.", "entity1": "doxorubicin", "entity2": "toxicity", "span1": [59, 70], "span2": [328, 336]}, "bert_text": "In this study, we have utilized a rat model of progressive <e1> doxorubicin </e1> (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1933": {"data": {"text": "In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity.", "entity1": "DOX)-induced", "entity2": "cardiomyopathy", "span1": [72, 84], "span2": [85, 99]}, "bert_text": "In this study, we have utilized a rat model of progressive doxorubicin (<e1> DOX)-induced </e1> <e2> cardiomyopathy </e2>, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1934": {"data": {"text": "In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity.", "entity1": "DOX)-induced", "entity2": "toxicity", "span1": [72, 84], "span2": [328, 336]}, "bert_text": "In this study, we have utilized a rat model of progressive doxorubicin (<e1> DOX)-induced </e1> cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1935": {"data": {"text": "With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.", "entity1": "OCs", "entity2": "VTE", "span1": [27, 30], "span2": [69, 72]}, "bert_text": "With all second-generation <e1> OCs </e1> as the reference, the odds ratios for <e2> VTE </e2> were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1936": {"data": {"text": "With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.", "entity1": "desogestrel", "entity2": "VTE", "span1": [100, 111], "span2": [69, 72]}, "bert_text": "With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for <e1> desogestrel </e1> <e2> VTE </e2> were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1937": {"data": {"text": "With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.", "entity1": "ethinyloestradiol", "entity2": "VTE", "span1": [122, 139], "span2": [69, 72]}, "bert_text": "With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g <e1> ethinyloestradiol </e1> <e2> VTE </e2> were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1938": {"data": {"text": "With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.", "entity1": "progestagens", "entity2": "VTE", "span1": [192, 204], "span2": [69, 72]}, "bert_text": "With all second-generation OCs as the reference, the odds ratios for VTE were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation <e1> progestagens </e1> <e2> VTE </e2> were 3.49 (1.21-10.12) for desogestrel plus 20 g ethinyloestradiol and 1.18 (0.66-2.17) for the other third-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1939": {"data": {"text": "AIMS: To investigate whether alterations of myocardial strain and high-sensitive cardiac troponin T (cTnT) could predict future cardiac dysfunction in patients after epirubicin exposure.", "entity1": "epirubicin", "entity2": "cardiac dysfunction", "span1": [166, 176], "span2": [128, 147]}, "bert_text": "AIMS: To investigate whether alterations of myocardial strain and high-sensitive cardiac troponin T (cTnT) could predict future cardiac dysfunction in patients after <e1> epirubicin </e1> <e2> cardiac dysfunction </e2> in patients after epirubicin exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1940": {"data": {"text": "She developed leucopenia after being treated with quetiapine.", "entity1": "quetiapine", "entity2": "leucopenia", "span1": [50, 60], "span2": [14, 24]}, "bert_text": "She developed leucopenia after being treated with <e1> quetiapine </e1> <e2> leucopenia </e2> after being treated with quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1941": {"data": {"text": "Fluconazole associated agranulocytosis and thrombocytopenia.\n", "entity1": "Fluconazole", "entity2": "agranulocytosis", "span1": [0, 11], "span2": [23, 38]}, "bert_text": "<e1> Fluconazole </e1> associated <e2> agranulocytosis </e2> and thrombocytopenia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1942": {"data": {"text": "Fluconazole associated agranulocytosis and thrombocytopenia.\n", "entity1": "Fluconazole", "entity2": "thrombocytopenia", "span1": [0, 11], "span2": [43, 59]}, "bert_text": "<e1> Fluconazole </e1> associated agranulocytosis and <e2> thrombocytopenia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1943": {"data": {"text": "Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.\n", "entity1": "carbamazepine", "entity2": "hypersensitivity", "span1": [6, 19], "span2": [52, 68]}, "bert_text": "Fatal <e1> carbamazepine </e1> induced fulminant eosinophilic (<e2> hypersensitivity </e2>) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1944": {"data": {"text": "Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.\n", "entity1": "carbamazepine", "entity2": "drug hypersensitivity", "span1": [6, 19], "span2": [167, 188]}, "bert_text": "Fatal <e1> carbamazepine </e1> induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of <e2> drug hypersensitivity </e2> and differential diagnosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1945": {"data": {"text": "Fatal carbamazepine induced fulminant eosinophilic (hypersensitivity) myocarditis: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.\n", "entity1": "carbamazepine", "entity2": "myocarditis", "span1": [6, 19], "span2": [70, 81]}, "bert_text": "Fatal <e1> carbamazepine </e1> induced fulminant eosinophilic (hypersensitivity) <e2> myocarditis </e2>: emphasis on anatomical and histological characteristics, mechanisms and genetics of drug hypersensitivity and differential diagnosis.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1946": {"data": {"text": "CASE: We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy.", "entity1": "fluconazole", "entity2": "agranulocytosis", "span1": [35, 46], "span2": [58, 73]}, "bert_text": "CASE: We describe a second case of <e1> fluconazole </e1> associated <e2> agranulocytosis </e2> with thrombocytopenia and recovery upon discontinuation of therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1947": {"data": {"text": "CASE: We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy.", "entity1": "fluconazole", "entity2": "thrombocytopenia", "span1": [35, 46], "span2": [79, 95]}, "bert_text": "CASE: We describe a second case of <e1> fluconazole </e1> associated agranulocytosis with <e2> thrombocytopenia </e2> and recovery upon discontinuation of therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1948": {"data": {"text": "A 61 year old female developed fatal hepatic failure after phenytoin administration.", "entity1": "phenytoin", "entity2": "hepatic failure", "span1": [59, 68], "span2": [37, 52]}, "bert_text": "A 61 year old female developed fatal hepatic failure after <e1> phenytoin </e1> <e2> hepatic failure </e2> after phenytoin administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1949": {"data": {"text": "Meloxicam-induced liver toxicity.\n", "entity1": "Meloxicam", "entity2": "liver toxicity", "span1": [0, 9], "span2": [18, 32]}, "bert_text": "<e1> Meloxicam </e1>-induced <e2> liver toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1950": {"data": {"text": "On average, MA abusers had 7.8% smaller hippocampal volumes than control subjects (p < 0.01; left, p = 0.01; right, p < 0.05) and significant white-matter hypertrophy (7.0%; p < 0.01).", "entity1": "MA", "entity2": "white-matter hypertrophy", "span1": [12, 14], "span2": [142, 166]}, "bert_text": "On average, <e1> MA </e1> abusers had 7.8% smaller hippocampal volumes than control subjects (p < 0.01; left, p = 0.01; right, p < 0.05) and significant <e2> white-matter hypertrophy </e2> (7.0%; p < 0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1951": {"data": {"text": "We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.", "entity1": "levodopa", "entity2": "ocular dyskinesias", "span1": [93, 101], "span2": [235, 253]}, "bert_text": "We report on a patient with leftward and upward deviations of gaze during the peak effect of <e1> levodopa </e1>, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce <e2> ocular dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1952": {"data": {"text": "We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa-induce ocular dyskinesias.", "entity1": "levodopa", "entity2": "ocular dyskinesias", "span1": [219, 227], "span2": [235, 253]}, "bert_text": "We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa, and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these <e1> levodopa </e1>-induce <e2> ocular dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1953": {"data": {"text": "Furthermore, reduction of ER stress in the TM with sodium 4-phenylbutyrate prevented dexamethasone-induced ocular hypertension in WT mice.", "entity1": "sodium 4-phenylbutyrate", "entity2": "ocular hypertension", "span1": [51, 74], "span2": [107, 126]}, "bert_text": "Furthermore, reduction of ER stress in the TM with <e1> sodium 4-phenylbutyrate </e1> prevented dexamethasone-induced <e2> ocular hypertension </e2> in WT mice.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1954": {"data": {"text": "Furthermore, reduction of ER stress in the TM with sodium 4-phenylbutyrate prevented dexamethasone-induced ocular hypertension in WT mice.", "entity1": "dexamethasone", "entity2": "ocular hypertension", "span1": [85, 98], "span2": [107, 126]}, "bert_text": "Furthermore, reduction of ER stress in the TM with sodium 4-phenylbutyrate prevented <e1> dexamethasone </e1>-induced <e2> ocular hypertension </e2> in WT mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1955": {"data": {"text": "Infants were assigned to the cocaine-exposed group if there was a maternal history of cocaine abuse during pregnancy or if maternal or neonatal urine toxicology results were positive at the time of delivery.", "entity1": "cocaine", "entity2": "cocaine abuse", "span1": [29, 36], "span2": [86, 99]}, "bert_text": "Infants were assigned to the <e1> cocaine </e1>-exposed group if there was a maternal history of <e2> cocaine abuse </e2> during pregnancy or if maternal or neonatal urine toxicology results were positive at the time of delivery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1956": {"data": {"text": "RATIONALE: NG-nitro-L-arginine (L-NOARG), an inhibitor of nitric-oxide synthase (NOS), induces catalepsy in mice.", "entity1": "nitric-oxide", "entity2": "catalepsy", "span1": [58, 70], "span2": [95, 104]}, "bert_text": "RATIONALE: NG-nitro-L-arginine (L-NOARG), an inhibitor of <e1> nitric-oxide </e1> synthase (NOS), induces <e2> catalepsy </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1957": {"data": {"text": "RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "entity1": "ibuprofen", "entity2": "tonic pain", "span1": [49, 58], "span2": [89, 99]}, "bert_text": "RESULTS: As described earlier, administration of <e1> ibuprofen </e1> was followed by a decrease in <e2> tonic pain </e2> but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1958": {"data": {"text": "RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "entity1": "ibuprofen", "entity2": "pain", "span1": [49, 58], "span2": [160, 164]}, "bert_text": "RESULTS: As described earlier, administration of <e1> ibuprofen </e1> was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic <e2> pain </e2>, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1959": {"data": {"text": "RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "entity1": "ibuprofen", "entity2": "pain", "span1": [49, 58], "span2": [239, 243]}, "bert_text": "RESULTS: As described earlier, administration of <e1> ibuprofen </e1> was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the <e2> pain </e2> stimuli under these special experimental conditions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1960": {"data": {"text": "RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "entity1": "ibuprofen", "entity2": "tonic pain", "span1": [198, 207], "span2": [89, 99]}, "bert_text": "RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of <e1> ibuprofen </e1> <e2> tonic pain </e2> but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1961": {"data": {"text": "RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "entity1": "ibuprofen", "entity2": "pain", "span1": [198, 207], "span2": [160, 164]}, "bert_text": "RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of <e1> ibuprofen </e1> <e2> pain </e2>, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1962": {"data": {"text": "RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions.", "entity1": "ibuprofen", "entity2": "pain", "span1": [198, 207], "span2": [239, 243]}, "bert_text": "RESULTS: As described earlier, administration of ibuprofen was followed by a decrease in tonic pain but-relative to placebo-an increase in correlates of phasic pain, indicating a specific effect of <e1> ibuprofen </e1> on the interaction between the <e2> pain </e2> stimuli under these special experimental conditions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1963": {"data": {"text": "Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage.", "entity1": "Hydroxytyrosol", "entity2": "cardiac disturbances", "span1": [0, 14], "span2": [28, 48]}, "bert_text": "<e1> Hydroxytyrosol </e1> improved the <e2> cardiac disturbances </e2> enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1964": {"data": {"text": "Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage.", "entity1": "doxorubicin", "entity2": "cardiac disturbances", "span1": [61, 72], "span2": [28, 48]}, "bert_text": "Hydroxytyrosol improved the cardiac disturbances enhanced by <e1> doxorubicin </e1> <e2> cardiac disturbances </e2> enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1965": {"data": {"text": "Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis.", "entity1": "aminocaproic acid", "entity2": "subarachnoid hemorrhage", "span1": [50, 67], "span2": [10, 33]}, "bert_text": "Recurrent subarachnoid hemorrhage associated with <e1> aminocaproic acid </e1> <e2> subarachnoid hemorrhage </e2> associated with aminocaproic acid therapy and acute renal artery thrombosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1966": {"data": {"text": "Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis.", "entity1": "aminocaproic acid", "entity2": "acute renal artery thrombosis", "span1": [50, 67], "span2": [80, 109]}, "bert_text": "Recurrent subarachnoid hemorrhage associated with <e1> aminocaproic acid </e1> therapy and <e2> acute renal artery thrombosis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1967": {"data": {"text": "Blockade of histamine H1 receptors may reduce mortality in pertussis immunization-induced encephalopathy in mice.", "entity1": "histamine", "entity2": "encephalopathy", "span1": [12, 21], "span2": [90, 104]}, "bert_text": "Blockade of <e1> histamine </e1> H1 receptors may reduce mortality in pertussis immunization-induced <e2> encephalopathy </e2> in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1968": {"data": {"text": "The patients, a 43-year-old man, presented all the signs and symptoms of APL and was included in a treatment protocol with ATRA.", "entity1": "ATRA", "entity2": "APL", "span1": [123, 127], "span2": [73, 76]}, "bert_text": "The patients, a 43-year-old man, presented all the signs and symptoms of APL and was included in a treatment protocol with <e1> ATRA </e1> <e2> APL </e2> and was included in a treatment protocol with ATRA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1969": {"data": {"text": "OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia.", "entity1": "dehydroepiandrosterone", "entity2": "schizophrenia", "span1": [37, 59], "span2": [87, 100]}, "bert_text": "OBJECTIVE: To examine the effects of <e1> dehydroepiandrosterone </e1> (DHEA) on animal models of <e2> schizophrenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1970": {"data": {"text": "OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia.", "entity1": "DHEA", "entity2": "schizophrenia", "span1": [61, 65], "span2": [87, 100]}, "bert_text": "OBJECTIVE: To examine the effects of dehydroepiandrosterone (<e1> DHEA </e1>) on animal models of <e2> schizophrenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1971": {"data": {"text": "She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a serotonin antagonist.", "entity1": "serotonin", "entity2": "major depression disorder", "span1": [123, 132], "span2": [33, 58]}, "bert_text": "She had developed a severe acute major depression disorder almost immediately thereafter, possibly related to the use of a <e1> serotonin </e1> <e2> major depression disorder </e2> almost immediately thereafter, possibly related to the use of a serotonin antagonist.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1972": {"data": {"text": "Misoprostol has been associated with adverse reactions, including gastrointestinal symptoms, gynecologic problems, and headache.", "entity1": "Misoprostol", "entity2": "gastrointestinal symptoms", "span1": [0, 11], "span2": [66, 91]}, "bert_text": "<e1> Misoprostol </e1> has been associated with adverse reactions, including <e2> gastrointestinal symptoms </e2>, gynecologic problems, and headache.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1973": {"data": {"text": "Misoprostol has been associated with adverse reactions, including gastrointestinal symptoms, gynecologic problems, and headache.", "entity1": "Misoprostol", "entity2": "headache", "span1": [0, 11], "span2": [119, 127]}, "bert_text": "<e1> Misoprostol </e1> has been associated with adverse reactions, including gastrointestinal symptoms, gynecologic problems, and <e2> headache </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1974": {"data": {"text": "OBJECTIVES: The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "entity1": "amiodarone", "entity2": "atrial fibrillation", "span1": [70, 80], "span2": [98, 117]}, "bert_text": "OBJECTIVES: The aim of this study was to determine whether the use of <e1> amiodarone </e1> in patients with <e2> atrial fibrillation </e2> (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1975": {"data": {"text": "OBJECTIVES: The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "entity1": "amiodarone", "entity2": "AF", "span1": [70, 80], "span2": [119, 121]}, "bert_text": "OBJECTIVES: The aim of this study was to determine whether the use of <e1> amiodarone </e1> in patients with atrial fibrillation (<e2> AF </e2>) increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"1976": {"data": {"text": "OBJECTIVES: The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation (AF) increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "entity1": "amiodarone", "entity2": "bradyarrhythmia", "span1": [70, 80], "span2": [145, 160]}, "bert_text": "OBJECTIVES: The aim of this study was to determine whether the use of <e1> amiodarone </e1> in patients with atrial fibrillation (AF) increases the risk of <e2> bradyarrhythmia </e2> requiring a permanent pacemaker.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"1977": {"data": {"text": "Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the convulsions induced by isoniazid (200 mg/kg s.c.).(ABSTRACT TRUNCATED AT 250 WORDS)", "entity1": "carboline", "entity2": "convulsions", "span1": [34, 43], "span2": [103, 114]}, "bert_text": "Moreover, 0.05 mg/kg of this beta-<e1> carboline </e1> reduced markedly the increase of [35S]TBPS binding and the <e2> convulsions </e2> induced by isoniazid (200 mg/kg s.c.).(ABSTRACT TRUNCATED AT 250 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1978": {"data": {"text": "Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the convulsions induced by isoniazid (200 mg/kg s.c.).(ABSTRACT TRUNCATED AT 250 WORDS)", "entity1": "isoniazid", "entity2": "convulsions", "span1": [126, 135], "span2": [103, 114]}, "bert_text": "Moreover, 0.05 mg/kg of this beta-carboline reduced markedly the increase of [35S]TBPS binding and the convulsions induced by <e1> isoniazid </e1> <e2> convulsions </e2> induced by isoniazid (200 mg/kg s.c.).(ABSTRACT TRUNCATED AT 250 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1979": {"data": {"text": "Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy.\n", "entity1": "fluocinolone acetonide", "entity2": "birdshot retinochoroidopathy", "span1": [23, 45], "span2": [80, 108]}, "bert_text": "Safety and efficacy of <e1> fluocinolone acetonide </e1> intravitreal implant (0.59 mg) in <e2> birdshot retinochoroidopathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1980": {"data": {"text": "S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8", "entity1": "S-312-d", "entity2": "tonic convulsions", "span1": [7, 14], "span2": [117, 134]}, "bert_text": "S-312, <e1> S-312-d </e1>, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic <e2> tonic convulsions </e2> in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1981": {"data": {"text": "S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8", "entity1": "calcium", "entity2": "tonic convulsions", "span1": [40, 47], "span2": [117, 134]}, "bert_text": "S-312, S-312-d, but not S-312-l, L-type <e1> calcium </e1> channel antagonists, showed anticonvulsant effects on the audiogenic <e2> tonic convulsions </e2> in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1982": {"data": {"text": "S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8", "entity1": "flunarizine", "entity2": "tonic convulsions", "span1": [268, 279], "span2": [117, 134]}, "bert_text": "S-312, S-312-d, but not S-312-l, L-type calcium channel antagonists, showed anticonvulsant effects on the audiogenic tonic convulsions in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of <e1> flunarizine </e1> <e2> tonic convulsions </e2> in DBA/2 mice; and their ED50 values were 18.4 (12.8-27.1) mg/kg, p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, while that of flunarizine was 34.0 (26.0-44.8", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1983": {"data": {"text": "Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen-induced tumor.\n", "entity1": "estrogen", "entity2": "tumor", "span1": [68, 76], "span2": [22, 27]}, "bert_text": "Genetic separation of tumor growth and hemorrhagic phenotypes in an <e1> estrogen </e1> <e2> tumor </e2> growth and hemorrhagic phenotypes in an estrogen-induced tumor.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1984": {"data": {"text": "Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen-induced tumor.\n", "entity1": "estrogen", "entity2": "tumor", "span1": [68, 76], "span2": [85, 90]}, "bert_text": "Genetic separation of tumor growth and hemorrhagic phenotypes in an <e1> estrogen </e1>-induced <e2> tumor </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1985": {"data": {"text": "Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen-induced tumor.\n", "entity1": "estrogen", "entity2": "hemorrhagic", "span1": [68, 76], "span2": [39, 50]}, "bert_text": "Genetic separation of tumor growth and hemorrhagic phenotypes in an <e1> estrogen </e1> <e2> hemorrhagic </e2> phenotypes in an estrogen-induced tumor.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1986": {"data": {"text": "CONCLUSION: The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH.", "entity1": "PPH", "entity2": "PPH", "span1": [50, 53], "span2": [245, 248]}, "bert_text": "CONCLUSION: The magnitude of the association with <e1> PPH </e1>, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to <e2> PPH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1987": {"data": {"text": "CONCLUSION: The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH.", "entity1": "fenfluramines", "entity2": "PPH", "span1": [140, 153], "span2": [245, 248]}, "bert_text": "CONCLUSION: The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for <e1> fenfluramines </e1> are consistent with previous studies indicating that fenfluramines are causally related to <e2> PPH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1988": {"data": {"text": "CONCLUSION: The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH.", "entity1": "fenfluramines", "entity2": "PPH", "span1": [207, 220], "span2": [245, 248]}, "bert_text": "CONCLUSION: The magnitude of the association with PPH, the increase of association with increasing duration of use, and the specificity for fenfluramines are consistent with previous studies indicating that <e1> fenfluramines </e1> are causally related to <e2> PPH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1989": {"data": {"text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.", "entity1": "dl-sotalol", "entity2": "torsade de pointes", "span1": [176, 186], "span2": [119, 137]}, "bert_text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by <e1> dl-sotalol </e1> <e2> torsade de pointes </e2> (TdP) with QT prolongation induced by dl-sotalol and azimilide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1990": {"data": {"text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.", "entity1": "dl-sotalol", "entity2": "TdP", "span1": [176, 186], "span2": [139, 142]}, "bert_text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by <e1> dl-sotalol </e1> <e2> TdP </e2>) with QT prolongation induced by dl-sotalol and azimilide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1991": {"data": {"text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.", "entity1": "dl-sotalol", "entity2": "QT prolongation", "span1": [176, 186], "span2": [149, 164]}, "bert_text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by <e1> dl-sotalol </e1> <e2> QT prolongation </e2> induced by dl-sotalol and azimilide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1992": {"data": {"text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.", "entity1": "azimilide", "entity2": "torsade de pointes", "span1": [191, 200], "span2": [119, 137]}, "bert_text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and <e1> azimilide </e1> <e2> torsade de pointes </e2> (TdP) with QT prolongation induced by dl-sotalol and azimilide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1993": {"data": {"text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.", "entity1": "azimilide", "entity2": "TdP", "span1": [191, 200], "span2": [139, 142]}, "bert_text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and <e1> azimilide </e1> <e2> TdP </e2>) with QT prolongation induced by dl-sotalol and azimilide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1994": {"data": {"text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide.", "entity1": "azimilide", "entity2": "QT prolongation", "span1": [191, 200], "span2": [149, 164]}, "bert_text": "BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and <e1> azimilide </e1> <e2> QT prolongation </e2> induced by dl-sotalol and azimilide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1995": {"data": {"text": "We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb).", "entity1": "anthraquinone", "entity2": "acute renal failure", "span1": [149, 162], "span2": [44, 63]}, "bert_text": "We report a 23-year-old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained <e1> anthraquinone </e1> <e2> acute renal failure </e2> following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives, extracted from Rhizoma Rhei (rhubarb).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1996": {"data": {"text": "This electrophysiological parameter provides information about subclinical neurotoxic potential of thalidomide but is not helpful in predicting the appearance of sensory symptoms.", "entity1": "thalidomide", "entity2": "neurotoxic", "span1": [99, 110], "span2": [75, 85]}, "bert_text": "This electrophysiological parameter provides information about subclinical neurotoxic potential of <e1> thalidomide </e1> <e2> neurotoxic </e2> potential of thalidomide but is not helpful in predicting the appearance of sensory symptoms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1997": {"data": {"text": "Zidovudine-induced hepatitis.\n", "entity1": "Zidovudine", "entity2": "hepatitis", "span1": [0, 10], "span2": [19, 28]}, "bert_text": "<e1> Zidovudine </e1>-induced <e2> hepatitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"1998": {"data": {"text": "Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day.", "entity1": "levodopa", "entity2": "parkinsonian disability", "span1": [151, 159], "span2": [27, 50]}, "bert_text": "Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to <e1> levodopa </e1> <e2> parkinsonian disability </e2>, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"1999": {"data": {"text": "Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [151, 159], "span2": [52, 62]}, "bert_text": "Animals were evaluated for parkinsonian disability, dyskinesia and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to <e1> levodopa </e1> <e2> dyskinesia </e2> and on-time (motor fluctuations) and neuropsychiatric-like behaviors on Day 0 (prior to levodopa) and on Days 1, 7, 13, 27 and 30 of treatment using post hoc DVD analysis by a trained rater, blind to the treatment day.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2000": {"data": {"text": "Pulmonary infections were less common in cyclosporine-treated renal patients than in Aza-treated patients (P less than 0.05).", "entity1": "cyclosporine", "entity2": "Pulmonary infections", "span1": [41, 53], "span2": [0, 20]}, "bert_text": "Pulmonary infections were less common in <e1> cyclosporine </e1> <e2> Pulmonary infections </e2> were less common in cyclosporine-treated renal patients than in Aza-treated patients (P less than 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2001": {"data": {"text": "Pulmonary infections were less common in cyclosporine-treated renal patients than in Aza-treated patients (P less than 0.05).", "entity1": "Aza", "entity2": "Pulmonary infections", "span1": [85, 88], "span2": [0, 20]}, "bert_text": "Pulmonary infections were less common in cyclosporine-treated renal patients than in <e1> Aza </e1> <e2> Pulmonary infections </e2> were less common in cyclosporine-treated renal patients than in Aza-treated patients (P less than 0.05).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2002": {"data": {"text": "Aspirin does not seem to affect CVD mortality or all-cause mortality in either men or women.", "entity1": "Aspirin", "entity2": "CVD", "span1": [0, 7], "span2": [32, 35]}, "bert_text": "<e1> Aspirin </e1> does not seem to affect <e2> CVD </e2> mortality or all-cause mortality in either men or women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2003": {"data": {"text": "Morphological analysis of frontal forebrain sections with light microscopy revealed seizure-related damage to the hippocampal formation, thalamus, amygdala, olfactory cortex, substantia nigra and neocortex, which is typically observed with pilocarpine in doses exceeding 350 mg/kg.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [240, 251], "span2": [84, 91]}, "bert_text": "Morphological analysis of frontal forebrain sections with light microscopy revealed seizure-related damage to the hippocampal formation, thalamus, amygdala, olfactory cortex, substantia nigra and neocortex, which is typically observed with <e1> pilocarpine </e1> <e2> seizure </e2>-related damage to the hippocampal formation, thalamus, amygdala, olfactory cortex, substantia nigra and neocortex, which is typically observed with pilocarpine in doses exceeding 350 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2004": {"data": {"text": "Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and digoxin excess.", "entity1": "digoxin", "entity2": "TdP", "span1": [130, 137], "span2": [43, 46]}, "bert_text": "Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and <e1> digoxin </e1> <e2> TdP </e2> occurred in the context of multiple exacerbating factors including hypokalemia and digoxin excess.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2005": {"data": {"text": "Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and digoxin excess.", "entity1": "digoxin", "entity2": "hypokalemia", "span1": [130, 137], "span2": [114, 125]}, "bert_text": "Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and <e1> digoxin </e1> <e2> hypokalemia </e2> and digoxin excess.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2006": {"data": {"text": "Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs.", "entity1": "SSRIs", "entity2": "cognitive disorders", "span1": [108, 113], "span2": [11, 30]}, "bert_text": "Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of <e1> SSRIs </e1> <e2> cognitive disorders </e2>, such as delirium, have not been previously linked with high blood levels of SSRIs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2007": {"data": {"text": "Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of SSRIs.", "entity1": "SSRIs", "entity2": "delirium", "span1": [108, 113], "span2": [40, 48]}, "bert_text": "Widespread cognitive disorders, such as delirium, have not been previously linked with high blood levels of <e1> SSRIs </e1> <e2> delirium </e2>, have not been previously linked with high blood levels of SSRIs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2008": {"data": {"text": "The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute infarction.", "entity1": "lidocaine", "entity2": "myocardial infarction", "span1": [19, 28], "span2": [90, 111]}, "bert_text": "The average plasma <e1> lidocaine </e1> level 10 minutes after administration for patients without a <e2> myocardial infarction </e2> was significantly higher than that for patients with an acute infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2009": {"data": {"text": "The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute infarction.", "entity1": "lidocaine", "entity2": "infarction", "span1": [19, 28], "span2": [174, 184]}, "bert_text": "The average plasma <e1> lidocaine </e1> level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute <e2> infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2010": {"data": {"text": "desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c.", "entity1": "desmethylimipramine", "entity2": "tachycardia", "span1": [0, 19], "span2": [126, 137]}, "bert_text": "<e1> desmethylimipramine </e1> (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the <e2> tachycardia </e2> following i.c.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2011": {"data": {"text": "desmethylimipramine (0.3 mg), while propranolol (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the tachycardia following i.c.", "entity1": "propranolol", "entity2": "tachycardia", "span1": [36, 47], "span2": [126, 137]}, "bert_text": "desmethylimipramine (0.3 mg), while <e1> propranolol </e1> (0.5 mg) i.v. selectively inhibited the enlargement of pulse pressure and the <e2> tachycardia </e2> following i.c.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2012": {"data": {"text": "CONCLUSIONS: PTU therapy may be related to the appearance of MPO-ANCA, but MPO-ANCA does not appear to be closely related to vasculitis.", "entity1": "PTU", "entity2": "vasculitis", "span1": [13, 16], "span2": [125, 135]}, "bert_text": "CONCLUSIONS: <e1> PTU </e1> therapy may be related to the appearance of MPO-ANCA, but MPO-ANCA does not appear to be closely related to <e2> vasculitis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2013": {"data": {"text": "Biochemical effects of Solidago virgaurea extract on experimental cardiotoxicity.\n", "entity1": "Solidago virgaurea extract", "entity2": "cardiotoxicity", "span1": [23, 49], "span2": [66, 80]}, "bert_text": "Biochemical effects of <e1> Solidago virgaurea extract </e1> on experimental <e2> cardiotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2014": {"data": {"text": "CAPD is inefficient in removing piperacillin, whereas hemodialysis can rapidly terminate the piperacillin-induced encephalopathy.", "entity1": "piperacillin", "entity2": "encephalopathy", "span1": [32, 44], "span2": [114, 128]}, "bert_text": "CAPD is inefficient in removing <e1> piperacillin </e1>, whereas hemodialysis can rapidly terminate the piperacillin-induced <e2> encephalopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2015": {"data": {"text": "CAPD is inefficient in removing piperacillin, whereas hemodialysis can rapidly terminate the piperacillin-induced encephalopathy.", "entity1": "piperacillin", "entity2": "encephalopathy", "span1": [93, 105], "span2": [114, 128]}, "bert_text": "CAPD is inefficient in removing piperacillin, whereas hemodialysis can rapidly terminate the <e1> piperacillin </e1>-induced <e2> encephalopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2016": {"data": {"text": "During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.", "entity1": "cisplatinum", "entity2": "ovarian cancer", "span1": [96, 107], "span2": [46, 60]}, "bert_text": "During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of <e1> cisplatinum </e1> <e2> ovarian cancer </e2> were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2017": {"data": {"text": "During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.", "entity1": "adriamycin", "entity2": "ovarian cancer", "span1": [126, 136], "span2": [46, 60]}, "bert_text": "During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, <e1> adriamycin </e1> <e2> ovarian cancer </e2> were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2018": {"data": {"text": "During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.", "entity1": "cyclophosphamide", "entity2": "ovarian cancer", "span1": [148, 164], "span2": [46, 60]}, "bert_text": "During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, <e1> cyclophosphamide </e1> <e2> ovarian cancer </e2> were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2019": {"data": {"text": "During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.", "entity1": "hexamethylmelamine", "entity2": "ovarian cancer", "span1": [191, 209], "span2": [46, 60]}, "bert_text": "During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and <e1> hexamethylmelamine </e1> <e2> ovarian cancer </e2> were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2020": {"data": {"text": "During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.", "entity1": "HMM", "entity2": "ovarian cancer", "span1": [211, 214], "span2": [46, 60]}, "bert_text": "During the last 2 1/2 years, 38 patients with ovarian cancer were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (<e1> HMM </e1> <e2> ovarian cancer </e2> were treated with a combination of cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, cyclophosphamide, 300 mg/m2, on day 1; and hexamethylmelamine (HMM), 6 mg/kg daily, for 14 days.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2021": {"data": {"text": "Multivariate regression analysis allowed attribution of 31.8% of QTc variability to methadone dose, cytochrome P-450 3A4 drug-drug interactions, hypokalemia, and altered liver function.", "entity1": "methadone", "entity2": "hypokalemia", "span1": [84, 93], "span2": [145, 156]}, "bert_text": "Multivariate regression analysis allowed attribution of 31.8% of QTc variability to <e1> methadone </e1> dose, cytochrome P-450 3A4 drug-drug interactions, <e2> hypokalemia </e2>, and altered liver function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2022": {"data": {"text": "Clinical trials of aminoglycosides in seriously ill patients indicate that the relative risk for developing acute renal failure during therapy ranges from 8 to 10 and that the attributable risk is 70% to 80%.", "entity1": "aminoglycosides", "entity2": "acute renal failure", "span1": [19, 34], "span2": [108, 127]}, "bert_text": "Clinical trials of <e1> aminoglycosides </e1> in seriously ill patients indicate that the relative risk for developing <e2> acute renal failure </e2> during therapy ranges from 8 to 10 and that the attributable risk is 70% to 80%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2023": {"data": {"text": "Increased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients.\n", "entity1": "angiotensin", "entity2": "angio-oedema", "span1": [83, 94], "span2": [36, 48]}, "bert_text": "Increased frequency and severity of angio-oedema related to long-term therapy with <e1> angiotensin </e1> <e2> angio-oedema </e2> related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2024": {"data": {"text": "CONCLUSIONS: Severity of ifosfamide related encephalopathy correlates with EEG changes.", "entity1": "ifosfamide", "entity2": "encephalopathy", "span1": [25, 35], "span2": [44, 58]}, "bert_text": "CONCLUSIONS: Severity of <e1> ifosfamide </e1> related <e2> encephalopathy </e2> correlates with EEG changes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2025": {"data": {"text": "All patients received succinylcholine 1.5 mg/kg at 2 minutes after the precurarization, and were assessed the incidence and severity of fasciculations, while myalgia was assessed at 24 hours after surgery.", "entity1": "succinylcholine", "entity2": "fasciculations", "span1": [22, 37], "span2": [136, 150]}, "bert_text": "All patients received <e1> succinylcholine </e1> 1.5 mg/kg at 2 minutes after the precurarization, and were assessed the incidence and severity of <e2> fasciculations </e2>, while myalgia was assessed at 24 hours after surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2026": {"data": {"text": "All patients received succinylcholine 1.5 mg/kg at 2 minutes after the precurarization, and were assessed the incidence and severity of fasciculations, while myalgia was assessed at 24 hours after surgery.", "entity1": "succinylcholine", "entity2": "myalgia", "span1": [22, 37], "span2": [158, 165]}, "bert_text": "All patients received <e1> succinylcholine </e1> 1.5 mg/kg at 2 minutes after the precurarization, and were assessed the incidence and severity of fasciculations, while <e2> myalgia </e2> was assessed at 24 hours after surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2027": {"data": {"text": "We studied the efficacy and safety of propranolol in the treatment of PPA-induced hypertension.", "entity1": "propranolol", "entity2": "hypertension", "span1": [38, 49], "span2": [82, 94]}, "bert_text": "We studied the efficacy and safety of <e1> propranolol </e1> in the treatment of PPA-induced <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2028": {"data": {"text": "We studied the efficacy and safety of propranolol in the treatment of PPA-induced hypertension.", "entity1": "PPA", "entity2": "hypertension", "span1": [70, 73], "span2": [82, 94]}, "bert_text": "We studied the efficacy and safety of propranolol in the treatment of <e1> PPA </e1>-induced <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2029": {"data": {"text": "Effect of vincristine sulfate on Pseudomonas infections in monkeys.\n", "entity1": "vincristine sulfate", "entity2": "infections", "span1": [10, 29], "span2": [45, 55]}, "bert_text": "Effect of <e1> vincristine sulfate </e1> on Pseudomonas <e2> infections </e2> in monkeys.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2030": {"data": {"text": "High doses of inhaled salbutamol produce substantial improvements in airway response in patients with asthma, and are associated with dose-dependent systemic beta-adrenoceptor responses.", "entity1": "salbutamol", "entity2": "asthma", "span1": [22, 32], "span2": [102, 108]}, "bert_text": "High doses of inhaled <e1> salbutamol </e1> produce substantial improvements in airway response in patients with <e2> asthma </e2>, and are associated with dose-dependent systemic beta-adrenoceptor responses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2031": {"data": {"text": "After 30 days of CY injection ulcerous and non-ulcerous forms of chronic cystitis appeared in 86% of DBA/2 mice but only in 4% of C57BL/6 mice.", "entity1": "CY", "entity2": "ulcerous", "span1": [17, 19], "span2": [30, 38]}, "bert_text": "After 30 days of <e1> CY </e1> injection <e2> ulcerous </e2> and non-ulcerous forms of chronic cystitis appeared in 86% of DBA/2 mice but only in 4% of C57BL/6 mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2032": {"data": {"text": "After 30 days of CY injection ulcerous and non-ulcerous forms of chronic cystitis appeared in 86% of DBA/2 mice but only in 4% of C57BL/6 mice.", "entity1": "CY", "entity2": "ulcerous", "span1": [17, 19], "span2": [47, 55]}, "bert_text": "After 30 days of <e1> CY </e1> injection ulcerous and non-<e2> ulcerous </e2> forms of chronic cystitis appeared in 86% of DBA/2 mice but only in 4% of C57BL/6 mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2033": {"data": {"text": "After 30 days of CY injection ulcerous and non-ulcerous forms of chronic cystitis appeared in 86% of DBA/2 mice but only in 4% of C57BL/6 mice.", "entity1": "CY", "entity2": "cystitis", "span1": [17, 19], "span2": [73, 81]}, "bert_text": "After 30 days of <e1> CY </e1> injection ulcerous and non-ulcerous forms of chronic <e2> cystitis </e2> appeared in 86% of DBA/2 mice but only in 4% of C57BL/6 mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2034": {"data": {"text": "L-Dopa intake was found to cause an increased excretion of potassium, and sometimes also of sodium, in the hypokalemic but not in the normokalemic patients.", "entity1": "L-Dopa", "entity2": "hypokalemic", "span1": [0, 6], "span2": [107, 118]}, "bert_text": "<e1> L-Dopa </e1> intake was found to cause an increased excretion of potassium, and sometimes also of sodium, in the <e2> hypokalemic </e2> but not in the normokalemic patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2035": {"data": {"text": "L-Dopa intake was found to cause an increased excretion of potassium, and sometimes also of sodium, in the hypokalemic but not in the normokalemic patients.", "entity1": "potassium", "entity2": "hypokalemic", "span1": [59, 68], "span2": [107, 118]}, "bert_text": "L-Dopa intake was found to cause an increased excretion of <e1> potassium </e1>, and sometimes also of sodium, in the <e2> hypokalemic </e2> but not in the normokalemic patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2036": {"data": {"text": "L-Dopa intake was found to cause an increased excretion of potassium, and sometimes also of sodium, in the hypokalemic but not in the normokalemic patients.", "entity1": "sodium", "entity2": "hypokalemic", "span1": [92, 98], "span2": [107, 118]}, "bert_text": "L-Dopa intake was found to cause an increased excretion of potassium, and sometimes also of <e1> sodium </e1>, in the <e2> hypokalemic </e2> but not in the normokalemic patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2037": {"data": {"text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "entity1": "methotrexate", "entity2": "neurotoxicity", "span1": [25, 37], "span2": [44, 57]}, "bert_text": "Concerns about long-term <e1> methotrexate </e1> (MTX) <e2> neurotoxicity </e2> in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2038": {"data": {"text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "entity1": "methotrexate", "entity2": "acute lymphoblastic leukemia", "span1": [25, 37], "span2": [202, 230]}, "bert_text": "Concerns about long-term <e1> methotrexate </e1> (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with <e2> acute lymphoblastic leukemia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2039": {"data": {"text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "entity1": "MTX", "entity2": "neurotoxicity", "span1": [39, 42], "span2": [44, 57]}, "bert_text": "Concerns about long-term methotrexate (<e1> MTX </e1>) <e2> neurotoxicity </e2> in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2040": {"data": {"text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "entity1": "MTX", "entity2": "acute lymphoblastic leukemia", "span1": [39, 42], "span2": [202, 230]}, "bert_text": "Concerns about long-term methotrexate (<e1> MTX </e1>) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with <e2> acute lymphoblastic leukemia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2041": {"data": {"text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "entity1": "MTX", "entity2": "neurotoxicity", "span1": [166, 169], "span2": [44, 57]}, "bert_text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic <e1> MTX </e1> <e2> neurotoxicity </e2> in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2042": {"data": {"text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "entity1": "MTX", "entity2": "acute lymphoblastic leukemia", "span1": [166, 169], "span2": [202, 230]}, "bert_text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic <e1> MTX </e1> administration in children with <e2> acute lymphoblastic leukemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2043": {"data": {"text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "entity1": "leucovorin", "entity2": "neurotoxicity", "span1": [121, 131], "span2": [44, 57]}, "bert_text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, <e1> leucovorin </e1> <e2> neurotoxicity </e2> in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2044": {"data": {"text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, leucovorin rescue, and frequency of systemic MTX administration in children with acute lymphoblastic leukemia.", "entity1": "leucovorin", "entity2": "acute lymphoblastic leukemia", "span1": [121, 131], "span2": [202, 230]}, "bert_text": "Concerns about long-term methotrexate (MTX) neurotoxicity in the 1990s led to modifications in intrathecal (IT) therapy, <e1> leucovorin </e1> rescue, and frequency of systemic MTX administration in children with <e2> acute lymphoblastic leukemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2045": {"data": {"text": "Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.\n", "entity1": "bovine lactoferrin", "entity2": "hypertension", "span1": [23, 41], "span2": [67, 79]}, "bert_text": "Antioxidant effects of <e1> bovine lactoferrin </e1> on dexamethasone-induced <e2> hypertension </e2> in rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2046": {"data": {"text": "Antioxidant effects of bovine lactoferrin on dexamethasone-induced hypertension in rat.\n", "entity1": "dexamethasone", "entity2": "hypertension", "span1": [45, 58], "span2": [67, 79]}, "bert_text": "Antioxidant effects of bovine lactoferrin on <e1> dexamethasone </e1>-induced <e2> hypertension </e2> in rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2047": {"data": {"text": "AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.", "entity1": "testosterone", "entity2": "memory impairment", "span1": [29, 41], "span2": [74, 91]}, "bert_text": "AIM: To study the effects of <e1> testosterone </e1> on streptozotocin (STZ)-induced <e2> memory impairment </e2> in male rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2048": {"data": {"text": "AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.", "entity1": "streptozotocin", "entity2": "memory impairment", "span1": [45, 59], "span2": [74, 91]}, "bert_text": "AIM: To study the effects of testosterone on <e1> streptozotocin </e1> (STZ)-induced <e2> memory impairment </e2> in male rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2049": {"data": {"text": "AIM: To study the effects of testosterone on streptozotocin (STZ)-induced memory impairment in male rats.", "entity1": "STZ)-induced", "entity2": "memory impairment", "span1": [61, 73], "span2": [74, 91]}, "bert_text": "AIM: To study the effects of testosterone on streptozotocin (<e1> STZ)-induced </e1> <e2> memory impairment </e2> in male rats.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2050": {"data": {"text": "Effects of exercise on the severity of isoproterenol-induced myocardial infarction.\n", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [39, 52], "span2": [61, 82]}, "bert_text": "Effects of exercise on the severity of <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2051": {"data": {"text": "In the first, cobalt cardiomyopathy was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/-", "entity1": "cobalt", "entity2": "cardiomyopathy", "span1": [14, 20], "span2": [21, 35]}, "bert_text": "In the first, <e1> cobalt </e1> <e2> cardiomyopathy </e2> was induced in eight dogs; VIP (by radioimmunoassay) decreased from 35 +/-", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2052": {"data": {"text": "Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.", "entity1": "mirtazapine", "entity2": "RLS", "span1": [48, 59], "span2": [80, 83]}, "bert_text": "Such a temporal relationship between the use of <e1> mirtazapine </e1> and the symptoms of <e2> RLS </e2> in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2053": {"data": {"text": "Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.", "entity1": "mirtazapine", "entity2": "RLS", "span1": [48, 59], "span2": [177, 180]}, "bert_text": "Such a temporal relationship between the use of <e1> mirtazapine </e1> and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated <e2> RLS </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2054": {"data": {"text": "Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.", "entity1": "mirtazapine", "entity2": "RLS", "span1": [154, 165], "span2": [80, 83]}, "bert_text": "Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on <e1> mirtazapine </e1> <e2> RLS </e2> in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2055": {"data": {"text": "Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine-associated RLS.", "entity1": "mirtazapine", "entity2": "RLS", "span1": [154, 165], "span2": [177, 180]}, "bert_text": "Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on <e1> mirtazapine </e1>-associated <e2> RLS </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2056": {"data": {"text": "Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of lidocaine vs placebo.", "entity1": "lidocaine", "entity2": "myocardial infarction", "span1": [151, 160], "span2": [41, 62]}, "bert_text": "Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of <e1> lidocaine </e1> <e2> myocardial infarction </e2> seen within 6 hours of the onset of symptoms entered a double-blind randomized trial of lidocaine vs placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2057": {"data": {"text": "This study investigated the visual defects associated with the antiepileptic drug vigabatrin (VGB).", "entity1": "vigabatrin", "entity2": "visual defects", "span1": [82, 92], "span2": [28, 42]}, "bert_text": "This study investigated the visual defects associated with the antiepileptic drug <e1> vigabatrin </e1> <e2> visual defects </e2> associated with the antiepileptic drug vigabatrin (VGB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2058": {"data": {"text": "This study investigated the visual defects associated with the antiepileptic drug vigabatrin (VGB).", "entity1": "VGB", "entity2": "visual defects", "span1": [94, 97], "span2": [28, 42]}, "bert_text": "This study investigated the visual defects associated with the antiepileptic drug vigabatrin (<e1> VGB </e1> <e2> visual defects </e2> associated with the antiepileptic drug vigabatrin (VGB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2059": {"data": {"text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).", "entity1": "doxorubicin", "entity2": "idiopathic cardiomyopathy", "span1": [227, 238], "span2": [37, 62]}, "bert_text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and <e1> doxorubicin </e1> <e2> idiopathic cardiomyopathy </e2> (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2060": {"data": {"text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).", "entity1": "doxorubicin", "entity2": "congenital heart disease", "span1": [227, 238], "span2": [70, 94]}, "bert_text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and <e1> doxorubicin </e1> <e2> congenital heart disease </e2> (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2061": {"data": {"text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).", "entity1": "doxorubicin", "entity2": "hypertrophic cardiomyopathy", "span1": [227, 238], "span2": [160, 187]}, "bert_text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and <e1> doxorubicin </e1> <e2> hypertrophic cardiomyopathy </e2> (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2062": {"data": {"text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).", "entity1": "doxorubicin", "entity2": "valvular heart disease", "span1": [227, 238], "span2": [194, 216]}, "bert_text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and <e1> doxorubicin </e1> <e2> valvular heart disease </e2> (3%), and doxorubicin cardiomyopathy (5%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2063": {"data": {"text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and doxorubicin cardiomyopathy (5%).", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [227, 238], "span2": [239, 253]}, "bert_text": "Indications for transplantation were idiopathic cardiomyopathy (52%), congenital heart disease (35%) with and without prior repair (71% and 29%, respectively), hypertrophic cardiomyopathy (5%), valvular heart disease (3%), and <e1> doxorubicin </e1> <e2> cardiomyopathy </e2> (5%).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2064": {"data": {"text": "We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use.", "entity1": "alcohol", "entity2": "ischemia", "span1": [104, 111], "span2": [56, 64]}, "bert_text": "We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive <e1> alcohol </e1> <e2> ischemia </e2> of the globus pallidus after excessive alcohol and intranasal cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2065": {"data": {"text": "We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use.", "entity1": "cocaine", "entity2": "ischemia", "span1": [127, 134], "span2": [56, 64]}, "bert_text": "We present the case of a 31-year-old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal <e1> cocaine </e1> <e2> ischemia </e2> of the globus pallidus after excessive alcohol and intranasal cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2066": {"data": {"text": "BACKGROUND: Renal dysfunction induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (PTRA).", "entity1": "CM", "entity2": "Renal dysfunction", "span1": [68, 70], "span2": [12, 29]}, "bert_text": "BACKGROUND: Renal dysfunction induced by iodinated contrast medium (<e1> CM </e1> <e2> Renal dysfunction </e2> induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (PTRA).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2067": {"data": {"text": "BACKGROUND: Renal dysfunction induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (PTRA).", "entity1": "PTRA", "entity2": "Renal dysfunction", "span1": [186, 190], "span2": [12, 29]}, "bert_text": "BACKGROUND: Renal dysfunction induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (<e1> PTRA </e1> <e2> Renal dysfunction </e2> induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (PTRA).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2068": {"data": {"text": "The results indicated that exercise reduced the mortality associated with the effects of large dosages of isoproterenol but had little on the severity of the infarction.", "entity1": "isoproterenol", "entity2": "infarction", "span1": [106, 119], "span2": [158, 168]}, "bert_text": "The results indicated that exercise reduced the mortality associated with the effects of large dosages of <e1> isoproterenol </e1> but had little on the severity of the <e2> infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2069": {"data": {"text": "Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder.", "entity1": "quetiapine", "entity2": "agitation", "span1": [54, 64], "span2": [114, 123]}, "bert_text": "Within the 48 h following the gradual introduction of <e1> quetiapine </e1> (up to 600 mg/day), the patient presented severe <e2> agitation </e2> without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2070": {"data": {"text": "Within the 48 h following the gradual introduction of quetiapine (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of aggressiveness or personality disorder.", "entity1": "quetiapine", "entity2": "aggressiveness or personality disorder", "span1": [54, 64], "span2": [207, 245]}, "bert_text": "Within the 48 h following the gradual introduction of <e1> quetiapine </e1> (up to 600 mg/day), the patient presented severe agitation without an environmental explanation, contrasting with the absence of a history of <e2> aggressiveness or personality disorder </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2071": {"data": {"text": "To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported.", "entity1": "tetrabenazine", "entity2": "neuroleptic malignant syndrome", "span1": [111, 124], "span2": [48, 78]}, "bert_text": "To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with <e1> tetrabenazine </e1> <e2> neuroleptic malignant syndrome </e2> due to combination therapy with tetrabenazine and tiapride has not been previously reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2072": {"data": {"text": "To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported.", "entity1": "tiapride", "entity2": "neuroleptic malignant syndrome", "span1": [129, 137], "span2": [48, 78]}, "bert_text": "To the best of our knowledge, the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and <e1> tiapride </e1> <e2> neuroleptic malignant syndrome </e2> due to combination therapy with tetrabenazine and tiapride has not been previously reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2073": {"data": {"text": "Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.", "entity1": "Phenylpropanolamine", "entity2": "overdose", "span1": [0, 19], "span2": [26, 34]}, "bert_text": "<e1> Phenylpropanolamine </e1> (PPA) <e2> overdose </e2> can cause severe hypertension, intracerebral hemorrhage, and death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2074": {"data": {"text": "Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.", "entity1": "Phenylpropanolamine", "entity2": "hypertension", "span1": [0, 19], "span2": [52, 64]}, "bert_text": "<e1> Phenylpropanolamine </e1> (PPA) overdose can cause severe <e2> hypertension </e2>, intracerebral hemorrhage, and death.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2075": {"data": {"text": "Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.", "entity1": "Phenylpropanolamine", "entity2": "intracerebral hemorrhage", "span1": [0, 19], "span2": [66, 90]}, "bert_text": "<e1> Phenylpropanolamine </e1> (PPA) overdose can cause severe hypertension, <e2> intracerebral hemorrhage </e2>, and death.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2076": {"data": {"text": "Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.", "entity1": "Phenylpropanolamine", "entity2": "death", "span1": [0, 19], "span2": [96, 101]}, "bert_text": "<e1> Phenylpropanolamine </e1> (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and <e2> death </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2077": {"data": {"text": "Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.", "entity1": "PPA", "entity2": "overdose", "span1": [21, 24], "span2": [26, 34]}, "bert_text": "Phenylpropanolamine (<e1> PPA </e1>) <e2> overdose </e2> can cause severe hypertension, intracerebral hemorrhage, and death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2078": {"data": {"text": "Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.", "entity1": "PPA", "entity2": "hypertension", "span1": [21, 24], "span2": [52, 64]}, "bert_text": "Phenylpropanolamine (<e1> PPA </e1>) overdose can cause severe <e2> hypertension </e2>, intracerebral hemorrhage, and death.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2079": {"data": {"text": "Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.", "entity1": "PPA", "entity2": "intracerebral hemorrhage", "span1": [21, 24], "span2": [66, 90]}, "bert_text": "Phenylpropanolamine (<e1> PPA </e1>) overdose can cause severe hypertension, <e2> intracerebral hemorrhage </e2>, and death.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2080": {"data": {"text": "Phenylpropanolamine (PPA) overdose can cause severe hypertension, intracerebral hemorrhage, and death.", "entity1": "PPA", "entity2": "death", "span1": [21, 24], "span2": [96, 101]}, "bert_text": "Phenylpropanolamine (<e1> PPA </e1>) overdose can cause severe hypertension, intracerebral hemorrhage, and <e2> death </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2081": {"data": {"text": "Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma.", "entity1": "oestrogen", "entity2": "endometrial hyperplasia", "span1": [18, 27], "span2": [105, 128]}, "bert_text": "Cyclical low-dose <e1> oestrogen </e1> therapy with 7--13 days of progestagen does not seem to increase the risk of <e2> endometrial hyperplasia </e2> or carcinoma.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2082": {"data": {"text": "Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma.", "entity1": "oestrogen", "entity2": "carcinoma", "span1": [18, 27], "span2": [132, 141]}, "bert_text": "Cyclical low-dose <e1> oestrogen </e1> therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or <e2> carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2083": {"data": {"text": "Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma.", "entity1": "progestagen", "entity2": "endometrial hyperplasia", "span1": [55, 66], "span2": [105, 128]}, "bert_text": "Cyclical low-dose oestrogen therapy with 7--13 days of <e1> progestagen </e1> does not seem to increase the risk of <e2> endometrial hyperplasia </e2> or carcinoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2084": {"data": {"text": "Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma.", "entity1": "progestagen", "entity2": "carcinoma", "span1": [55, 66], "span2": [132, 141]}, "bert_text": "Cyclical low-dose oestrogen therapy with 7--13 days of <e1> progestagen </e1> does not seem to increase the risk of endometrial hyperplasia or <e2> carcinoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2085": {"data": {"text": "As tranexamic acid is the only modifiable factor, its administration, particularly in doses exceeding 80 mg.kg(-1), should be weighed against the risk of postoperative seizures.", "entity1": "tranexamic acid", "entity2": "postoperative seizures", "span1": [3, 18], "span2": [154, 176]}, "bert_text": "As <e1> tranexamic acid </e1> is the only modifiable factor, its administration, particularly in doses exceeding 80 mg.kg(-1), should be weighed against the risk of <e2> postoperative seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2086": {"data": {"text": "Cocaine induced no significant change in heart rate, LV dP/dt (positive or negative), or LV end-diastolic volume, but it caused an increase in systolic and mean arterial pressures, LV end-diastolic pressure, and LV end-systolic volume, as well as a decrease in LV ejection fraction.", "entity1": "Cocaine", "entity2": "LV", "span1": [0, 7], "span2": [53, 55]}, "bert_text": "<e1> Cocaine </e1> induced no significant change in heart rate, <e2> LV </e2> dP/dt (positive or negative), or LV end-diastolic volume, but it caused an increase in systolic and mean arterial pressures, LV end-diastolic pressure, and LV end-systolic volume, as well as a decrease in LV ejection fraction.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2087": {"data": {"text": "Cocaine induced no significant change in heart rate, LV dP/dt (positive or negative), or LV end-diastolic volume, but it caused an increase in systolic and mean arterial pressures, LV end-diastolic pressure, and LV end-systolic volume, as well as a decrease in LV ejection fraction.", "entity1": "Cocaine", "entity2": "LV", "span1": [0, 7], "span2": [89, 91]}, "bert_text": "<e1> Cocaine </e1> induced no significant change in heart rate, LV dP/dt (positive or negative), or <e2> LV </e2> end-diastolic volume, but it caused an increase in systolic and mean arterial pressures, LV end-diastolic pressure, and LV end-systolic volume, as well as a decrease in LV ejection fraction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2088": {"data": {"text": "Cocaine induced no significant change in heart rate, LV dP/dt (positive or negative), or LV end-diastolic volume, but it caused an increase in systolic and mean arterial pressures, LV end-diastolic pressure, and LV end-systolic volume, as well as a decrease in LV ejection fraction.", "entity1": "Cocaine", "entity2": "LV", "span1": [0, 7], "span2": [181, 183]}, "bert_text": "<e1> Cocaine </e1> induced no significant change in heart rate, LV dP/dt (positive or negative), or LV end-diastolic volume, but it caused an increase in systolic and mean arterial pressures, <e2> LV </e2> end-diastolic pressure, and LV end-systolic volume, as well as a decrease in LV ejection fraction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2089": {"data": {"text": "Cocaine induced no significant change in heart rate, LV dP/dt (positive or negative), or LV end-diastolic volume, but it caused an increase in systolic and mean arterial pressures, LV end-diastolic pressure, and LV end-systolic volume, as well as a decrease in LV ejection fraction.", "entity1": "Cocaine", "entity2": "LV", "span1": [0, 7], "span2": [212, 214]}, "bert_text": "<e1> Cocaine </e1> induced no significant change in heart rate, LV dP/dt (positive or negative), or LV end-diastolic volume, but it caused an increase in systolic and mean arterial pressures, LV end-diastolic pressure, and <e2> LV </e2> end-systolic volume, as well as a decrease in LV ejection fraction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2090": {"data": {"text": "Cocaine induced no significant change in heart rate, LV dP/dt (positive or negative), or LV end-diastolic volume, but it caused an increase in systolic and mean arterial pressures, LV end-diastolic pressure, and LV end-systolic volume, as well as a decrease in LV ejection fraction.", "entity1": "Cocaine", "entity2": "LV", "span1": [0, 7], "span2": [261, 263]}, "bert_text": "<e1> Cocaine </e1> induced no significant change in heart rate, LV dP/dt (positive or negative), or LV end-diastolic volume, but it caused an increase in systolic and mean arterial pressures, LV end-diastolic pressure, and LV end-systolic volume, as well as a decrease in <e2> LV </e2> ejection fraction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2091": {"data": {"text": "PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [55, 62], "span2": [71, 87]}, "bert_text": "PURPOSE: The case of an oncology patient who developed <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2092": {"data": {"text": "PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "entity1": "heparin", "entity2": "thrombosis", "span1": [55, 62], "span2": [93, 103]}, "bert_text": "PURPOSE: The case of an oncology patient who developed <e1> heparin </e1>-induced thrombocytopenia with <e2> thrombosis </e2> (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2093": {"data": {"text": "PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "entity1": "heparin", "entity2": "HITT", "span1": [55, 62], "span2": [105, 109]}, "bert_text": "PURPOSE: The case of an oncology patient who developed <e1> heparin </e1>-induced thrombocytopenia with thrombosis (<e2> HITT </e2>) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2094": {"data": {"text": "PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "entity1": "argatroban", "entity2": "thrombocytopenia", "span1": [132, 142], "span2": [71, 87]}, "bert_text": "PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with <e1> argatroban </e1> <e2> thrombocytopenia </e2> with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2095": {"data": {"text": "PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "entity1": "argatroban", "entity2": "thrombosis", "span1": [132, 142], "span2": [93, 103]}, "bert_text": "PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with <e1> argatroban </e1> <e2> thrombosis </e2> (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2096": {"data": {"text": "PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "entity1": "argatroban", "entity2": "HITT", "span1": [132, 142], "span2": [105, 109]}, "bert_text": "PURPOSE: The case of an oncology patient who developed heparin-induced thrombocytopenia with thrombosis (HITT) and was treated with <e1> argatroban </e1> <e2> HITT </e2>) and was treated with argatroban plus catheter-directed thrombolysis (CDT) with alteplase is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2097": {"data": {"text": "Erdosteine showed histopathological protection against VCM-induced nephrotoxicity.", "entity1": "Erdosteine", "entity2": "nephrotoxicity", "span1": [0, 10], "span2": [67, 81]}, "bert_text": "<e1> Erdosteine </e1> showed histopathological protection against VCM-induced <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2098": {"data": {"text": "Erdosteine showed histopathological protection against VCM-induced nephrotoxicity.", "entity1": "VCM", "entity2": "nephrotoxicity", "span1": [55, 58], "span2": [67, 81]}, "bert_text": "Erdosteine showed histopathological protection against <e1> VCM </e1>-induced <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2099": {"data": {"text": "In patients with various chest pain syndromes, verapamil neither increased the frequency of junctional rhythms nor suppressed their role as escape rhythms under physiologically appropriate circumstances.", "entity1": "verapamil", "entity2": "chest pain", "span1": [47, 56], "span2": [25, 35]}, "bert_text": "In patients with various chest pain syndromes, <e1> verapamil </e1> <e2> chest pain </e2> syndromes, verapamil neither increased the frequency of junctional rhythms nor suppressed their role as escape rhythms under physiologically appropriate circumstances.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2100": {"data": {"text": "In a series of five experiments, the modulating role of naloxone on a scopolamine-induced retention deficit in a passive avoidance paradigm was investigated in mice.", "entity1": "naloxone", "entity2": "retention deficit", "span1": [56, 64], "span2": [90, 107]}, "bert_text": "In a series of five experiments, the modulating role of <e1> naloxone </e1> on a scopolamine-induced <e2> retention deficit </e2> in a passive avoidance paradigm was investigated in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2101": {"data": {"text": "In a series of five experiments, the modulating role of naloxone on a scopolamine-induced retention deficit in a passive avoidance paradigm was investigated in mice.", "entity1": "scopolamine", "entity2": "retention deficit", "span1": [70, 81], "span2": [90, 107]}, "bert_text": "In a series of five experiments, the modulating role of naloxone on a <e1> scopolamine </e1>-induced <e2> retention deficit </e2> in a passive avoidance paradigm was investigated in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2102": {"data": {"text": "CONCLUSIONS: Children treated with indinavir have a high cumulative incidence of persistent sterile leukocyturia.", "entity1": "indinavir", "entity2": "sterile leukocyturia", "span1": [35, 44], "span2": [92, 112]}, "bert_text": "CONCLUSIONS: Children treated with <e1> indinavir </e1> have a high cumulative incidence of persistent <e2> sterile leukocyturia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2103": {"data": {"text": "Co-administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti-amnesic effect.", "entity1": "nefiracetam", "entity2": "amnesic", "span1": [21, 32], "span2": [112, 119]}, "bert_text": "Co-administration of <e1> nefiracetam </e1> and apomorphine during training or 10h thereafter produced no significant anti-<e2> amnesic </e2> effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2104": {"data": {"text": "Co-administration of nefiracetam and apomorphine during training or 10h thereafter produced no significant anti-amnesic effect.", "entity1": "apomorphine", "entity2": "amnesic", "span1": [37, 48], "span2": [112, 119]}, "bert_text": "Co-administration of nefiracetam and <e1> apomorphine </e1> during training or 10h thereafter produced no significant anti-<e2> amnesic </e2> effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2105": {"data": {"text": "Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.", "entity1": "dronedarone", "entity2": "tachycardia", "span1": [5, 16], "span2": [75, 86]}, "bert_text": "Both <e1> dronedarone </e1> and amiodarone significantly reduced the exercise-induced <e2> tachycardia </e2> and, at the highest dose, decreased the isoproterenol-induced tachycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2106": {"data": {"text": "Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.", "entity1": "dronedarone", "entity2": "tachycardia", "span1": [5, 16], "span2": [149, 160]}, "bert_text": "Both <e1> dronedarone </e1> and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced <e2> tachycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2107": {"data": {"text": "Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.", "entity1": "amiodarone", "entity2": "tachycardia", "span1": [21, 31], "span2": [75, 86]}, "bert_text": "Both dronedarone and <e1> amiodarone </e1> significantly reduced the exercise-induced <e2> tachycardia </e2> and, at the highest dose, decreased the isoproterenol-induced tachycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2108": {"data": {"text": "Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.", "entity1": "amiodarone", "entity2": "tachycardia", "span1": [21, 31], "span2": [149, 160]}, "bert_text": "Both dronedarone and <e1> amiodarone </e1> significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced <e2> tachycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2109": {"data": {"text": "Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [127, 140], "span2": [75, 86]}, "bert_text": "Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the <e1> isoproterenol </e1> <e2> tachycardia </e2> and, at the highest dose, decreased the isoproterenol-induced tachycardia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2110": {"data": {"text": "Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the isoproterenol-induced tachycardia.", "entity1": "isoproterenol", "entity2": "tachycardia", "span1": [127, 140], "span2": [149, 160]}, "bert_text": "Both dronedarone and amiodarone significantly reduced the exercise-induced tachycardia and, at the highest dose, decreased the <e1> isoproterenol </e1>-induced <e2> tachycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2111": {"data": {"text": "We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with danazol for a continuous period of 6 months or longer.", "entity1": "danazol", "entity2": "hereditary angioedema", "span1": [50, 57], "span2": [128, 149]}, "bert_text": "We therefore investigated the long-term safety of <e1> danazol </e1> by performing a retrospective chart review of 60 female patients with <e2> hereditary angioedema </e2> treated with danazol for a continuous period of 6 months or longer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2112": {"data": {"text": "We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with danazol for a continuous period of 6 months or longer.", "entity1": "danazol", "entity2": "hereditary angioedema", "span1": [163, 170], "span2": [128, 149]}, "bert_text": "We therefore investigated the long-term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with <e1> danazol </e1> <e2> hereditary angioedema </e2> treated with danazol for a continuous period of 6 months or longer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2113": {"data": {"text": "This study shows that busulfan neurotoxicity is dose-dependent in children and efficiently prevented by clonazepam.", "entity1": "busulfan", "entity2": "neurotoxicity", "span1": [22, 30], "span2": [31, 44]}, "bert_text": "This study shows that <e1> busulfan </e1> <e2> neurotoxicity </e2> is dose-dependent in children and efficiently prevented by clonazepam.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2114": {"data": {"text": "This study shows that busulfan neurotoxicity is dose-dependent in children and efficiently prevented by clonazepam.", "entity1": "clonazepam", "entity2": "neurotoxicity", "span1": [104, 114], "span2": [31, 44]}, "bert_text": "This study shows that busulfan neurotoxicity is dose-dependent in children and efficiently prevented by <e1> clonazepam </e1> <e2> neurotoxicity </e2> is dose-dependent in children and efficiently prevented by clonazepam.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2115": {"data": {"text": "Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction.\n", "entity1": "metformin", "entity2": "left ventricular dysfunction", "span1": [23, 32], "span2": [90, 118]}, "bert_text": "Chronic treatment with <e1> metformin </e1> suppresses toll-like receptor 4 signaling and attenuates <e2> left ventricular dysfunction </e2> following myocardial infarction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2116": {"data": {"text": "Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction.\n", "entity1": "metformin", "entity2": "myocardial infarction", "span1": [23, 32], "span2": [129, 150]}, "bert_text": "Chronic treatment with <e1> metformin </e1> suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2117": {"data": {"text": "In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.", "entity1": "biperiden lactate", "entity2": "trigeminal neuralgia", "span1": [122, 139], "span2": [67, 87]}, "bert_text": "In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg <e1> biperiden lactate </e1> <e2> trigeminal neuralgia </e2>, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2118": {"data": {"text": "In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.", "entity1": "biperiden lactate", "entity2": "bradycardia", "span1": [122, 139], "span2": [213, 224]}, "bert_text": "In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg <e1> biperiden lactate </e1> led to a long-lasting paradoxical reaction characterized by considerable <e2> bradycardia </e2>, dysarthria, and dysphagia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2119": {"data": {"text": "In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.", "entity1": "biperiden lactate", "entity2": "dysarthria", "span1": [122, 139], "span2": [226, 236]}, "bert_text": "In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg <e1> biperiden lactate </e1> led to a long-lasting paradoxical reaction characterized by considerable bradycardia, <e2> dysarthria </e2>, and dysphagia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2120": {"data": {"text": "In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg biperiden lactate led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and dysphagia.", "entity1": "biperiden lactate", "entity2": "dysphagia", "span1": [122, 139], "span2": [242, 251]}, "bert_text": "In a 38-year-old male patient suffering from a severe postzosteric trigeminal neuralgia, intravenous application of 10 mg <e1> biperiden lactate </e1> led to a long-lasting paradoxical reaction characterized by considerable bradycardia, dysarthria, and <e2> dysphagia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2121": {"data": {"text": "For PCI, argatroban has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or obesity, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition.", "entity1": "argatroban", "entity2": "obesity", "span1": [9, 19], "span2": [149, 156]}, "bert_text": "For PCI, <e1> argatroban </e1> has not been investigated in hepatically impaired patients; dose adjustment is unnecessary for adult age, sex, race/ethnicity or <e2> obesity </e2>, and lesser doses may be adequate with concurrent glycoprotein IIb/IIIa inhibition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2122": {"data": {"text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "entity1": "dobutamine", "entity2": "heart failure", "span1": [315, 325], "span2": [74, 87]}, "bert_text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) <e1> dobutamine </e1> <e2> heart failure </e2> secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2123": {"data": {"text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "entity1": "dobutamine", "entity2": "dilated cardiomyopathy", "span1": [315, 325], "span2": [101, 123]}, "bert_text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) <e1> dobutamine </e1> <e2> dilated cardiomyopathy </e2> and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2124": {"data": {"text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "entity1": "dobutamine", "entity2": "ventricular arrhythmias", "span1": [315, 325], "span2": [151, 174]}, "bert_text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) <e1> dobutamine </e1> <e2> ventricular arrhythmias </e2> who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2125": {"data": {"text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "entity1": "dobutamine", "entity2": "QT prolongation", "span1": [315, 325], "span2": [189, 204]}, "bert_text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) <e1> dobutamine </e1> <e2> QT prolongation </e2> and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2126": {"data": {"text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "entity1": "dobutamine", "entity2": "torsade de pointes", "span1": [315, 325], "span2": [209, 227]}, "bert_text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) <e1> dobutamine </e1> <e2> torsade de pointes </e2> ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2127": {"data": {"text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "entity1": "dobutamine", "entity2": "ventricular tachycardia", "span1": [315, 325], "span2": [228, 251]}, "bert_text": "The authors describe the case of a 56-year-old woman with chronic, severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose (2.5 mcg/kg per min) <e1> dobutamine </e1> <e2> ventricular tachycardia </e2> during one cycle of intermittent low dose (2.5 mcg/kg per min) dobutamine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2128": {"data": {"text": "Bradycardia due to biperiden.\n", "entity1": "biperiden", "entity2": "Bradycardia", "span1": [19, 28], "span2": [0, 11]}, "bert_text": "Bradycardia due to <e1> biperiden </e1> <e2> Bradycardia </e2> due to biperiden.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2129": {"data": {"text": "Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg.", "entity1": "isoniazid", "entity2": "seizures", "span1": [38, 47], "span2": [64, 72]}, "bert_text": "Bilateral intrastriatal injections of <e1> isoniazid </e1> did not augment <e2> seizures </e2> produced by pilocarpine, 200 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2130": {"data": {"text": "Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine, 200 mg/kg.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [85, 96], "span2": [64, 72]}, "bert_text": "Bilateral intrastriatal injections of isoniazid did not augment seizures produced by <e1> pilocarpine </e1> <e2> seizures </e2> produced by pilocarpine, 200 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2131": {"data": {"text": "The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of 5-FU cardiotoxicity that may be influenced by CDDP.", "entity1": "5-FU", "entity2": "cardiotoxicity", "span1": [140, 144], "span2": [145, 159]}, "bert_text": "The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of <e1> 5-FU </e1> <e2> cardiotoxicity </e2> that may be influenced by CDDP.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2132": {"data": {"text": "The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of 5-FU cardiotoxicity that may be influenced by CDDP.", "entity1": "CDDP", "entity2": "cardiotoxicity", "span1": [186, 190], "span2": [145, 159]}, "bert_text": "The presentation and cardiac evaluation (hemodynamic, echocardiographic, and scintigraphic) of these patients suggest new manifestations of 5-FU cardiotoxicity that may be influenced by <e1> CDDP </e1> <e2> cardiotoxicity </e2> that may be influenced by CDDP.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2133": {"data": {"text": "We conclude that ATRA is a valid therapeutic choice for patients with APL, although the procoagulant tendency is not completely corrected.", "entity1": "ATRA", "entity2": "APL", "span1": [17, 21], "span2": [70, 73]}, "bert_text": "We conclude that <e1> ATRA </e1> is a valid therapeutic choice for patients with <e2> APL </e2>, although the procoagulant tendency is not completely corrected.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2134": {"data": {"text": "Electrocardiographic changes after dipyridamole infusion (0.568 mg/kg/4 min) were studied in 41 patients with coronary artery disease and compared with those after submaximal treadmill exercise by use of the body surface mapping technique.", "entity1": "dipyridamole", "entity2": "coronary artery disease", "span1": [35, 47], "span2": [110, 133]}, "bert_text": "Electrocardiographic changes after <e1> dipyridamole </e1> infusion (0.568 mg/kg/4 min) were studied in 41 patients with <e2> coronary artery disease </e2> and compared with those after submaximal treadmill exercise by use of the body surface mapping technique.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2135": {"data": {"text": "The use of aspirin for primary prevention increases the risk for major bleeding events, primarily gastrointestinal bleeding events, in both men and women.", "entity1": "aspirin", "entity2": "bleeding", "span1": [11, 18], "span2": [71, 79]}, "bert_text": "The use of <e1> aspirin </e1> for primary prevention increases the risk for major <e2> bleeding </e2> events, primarily gastrointestinal bleeding events, in both men and women.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2136": {"data": {"text": "The use of aspirin for primary prevention increases the risk for major bleeding events, primarily gastrointestinal bleeding events, in both men and women.", "entity1": "aspirin", "entity2": "gastrointestinal bleeding", "span1": [11, 18], "span2": [98, 123]}, "bert_text": "The use of <e1> aspirin </e1> for primary prevention increases the risk for major bleeding events, primarily <e2> gastrointestinal bleeding </e2> events, in both men and women.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2137": {"data": {"text": "Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications.", "entity1": "Mirtazapine", "entity2": "RLS", "span1": [0, 11], "span2": [112, 115]}, "bert_text": "<e1> Mirtazapine </e1>, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with <e2> RLS </e2> in several recent publications.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2138": {"data": {"text": "Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications.", "entity1": "antidepressant", "entity2": "RLS", "span1": [63, 77], "span2": [112, 115]}, "bert_text": "Mirtazapine, the first noradrenergic and specific serotonergic <e1> antidepressant </e1> (NaSSA), has been associated with <e2> RLS </e2> in several recent publications.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2139": {"data": {"text": "Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (NaSSA), has been associated with RLS in several recent publications.", "entity1": "NaSSA", "entity2": "RLS", "span1": [79, 84], "span2": [112, 115]}, "bert_text": "Mirtazapine, the first noradrenergic and specific serotonergic antidepressant (<e1> NaSSA </e1>), has been associated with <e2> RLS </e2> in several recent publications.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2140": {"data": {"text": "Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy.\n", "entity1": "oestrogen", "entity2": "endometrial disease", "span1": [79, 88], "span2": [28, 47]}, "bert_text": "Prevention and treatment of endometrial disease in climacteric women receiving <e1> oestrogen </e1> <e2> endometrial disease </e2> in climacteric women receiving oestrogen therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2141": {"data": {"text": "In patients with atrial fibrillation digoxin is beneficial for ventricular rate control.", "entity1": "digoxin", "entity2": "atrial fibrillation", "span1": [37, 44], "span2": [17, 36]}, "bert_text": "In patients with atrial fibrillation <e1> digoxin </e1> <e2> atrial fibrillation </e2> digoxin is beneficial for ventricular rate control.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2142": {"data": {"text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.", "entity1": "streptozotocin", "entity2": "diabetes", "span1": [83, 97], "span2": [98, 106]}, "bert_text": "The acute effect of insulin treatment on the earlier reported protective effect of <e1> streptozotocin </e1> <e2> diabetes </e2> against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2143": {"data": {"text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.", "entity1": "streptozotocin", "entity2": "cardiotoxic", "span1": [83, 97], "span2": [119, 130]}, "bert_text": "The acute effect of insulin treatment on the earlier reported protective effect of <e1> streptozotocin </e1> diabetes against the <e2> cardiotoxic </e2> effect of high doses of isoproterenol (ISO) was investigated in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2144": {"data": {"text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.", "entity1": "isoproterenol", "entity2": "diabetes", "span1": [155, 168], "span2": [98, 106]}, "bert_text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of <e1> isoproterenol </e1> <e2> diabetes </e2> against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2145": {"data": {"text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.", "entity1": "isoproterenol", "entity2": "cardiotoxic", "span1": [155, 168], "span2": [119, 130]}, "bert_text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of <e1> isoproterenol </e1> <e2> cardiotoxic </e2> effect of high doses of isoproterenol (ISO) was investigated in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2146": {"data": {"text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.", "entity1": "ISO", "entity2": "diabetes", "span1": [170, 173], "span2": [98, 106]}, "bert_text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (<e1> ISO </e1> <e2> diabetes </e2> against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2147": {"data": {"text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (ISO) was investigated in rats.", "entity1": "ISO", "entity2": "cardiotoxic", "span1": [170, 173], "span2": [119, 130]}, "bert_text": "The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol (<e1> ISO </e1> <e2> cardiotoxic </e2> effect of high doses of isoproterenol (ISO) was investigated in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2148": {"data": {"text": "Azotemia was not related to duration of therapy or serum tobramycin concentration.", "entity1": "tobramycin", "entity2": "Azotemia", "span1": [57, 67], "span2": [0, 8]}, "bert_text": "Azotemia was not related to duration of therapy or serum <e1> tobramycin </e1> <e2> Azotemia </e2> was not related to duration of therapy or serum tobramycin concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2149": {"data": {"text": "Two acetaminophen-induced ALF patients reattempted suicide post-LT (one died 8 years post-LT).", "entity1": "acetaminophen", "entity2": "ALF", "span1": [4, 17], "span2": [26, 29]}, "bert_text": "Two <e1> acetaminophen </e1>-induced <e2> ALF </e2> patients reattempted suicide post-LT (one died 8 years post-LT).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2150": {"data": {"text": "Sulfadiazine acute nephrotoxicity is reviving specially because of its use in toxoplasmosis in HIV-positive patients.", "entity1": "Sulfadiazine", "entity2": "nephrotoxicity", "span1": [0, 12], "span2": [19, 33]}, "bert_text": "<e1> Sulfadiazine </e1> acute <e2> nephrotoxicity </e2> is reviving specially because of its use in toxoplasmosis in HIV-positive patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2151": {"data": {"text": "We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes.", "entity1": "streptozotocin", "entity2": "renal interstitial fibrosis independently of microalbuminuria", "span1": [196, 210], "span2": [121, 182]}, "bert_text": "We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with <e1> streptozotocin </e1> <e2> renal interstitial fibrosis independently of microalbuminuria </e2> in mice with streptozotocin (STZ)-induced diabetes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2152": {"data": {"text": "We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes.", "entity1": "streptozotocin", "entity2": "diabetes", "span1": [196, 210], "span2": [225, 233]}, "bert_text": "We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with <e1> streptozotocin </e1> (STZ)-induced <e2> diabetes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2153": {"data": {"text": "We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes.", "entity1": "STZ)-induced", "entity2": "renal interstitial fibrosis independently of microalbuminuria", "span1": [212, 224], "span2": [121, 182]}, "bert_text": "We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (<e1> STZ)-induced </e1> <e2> renal interstitial fibrosis independently of microalbuminuria </e2> in mice with streptozotocin (STZ)-induced diabetes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2154": {"data": {"text": "We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (STZ)-induced diabetes.", "entity1": "STZ)-induced", "entity2": "diabetes", "span1": [212, 224], "span2": [225, 233]}, "bert_text": "We have previously demonstrated that endothelial-mesenchymal-transition (EndoMT) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin (<e1> STZ)-induced </e1> <e2> diabetes </e2>.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2155": {"data": {"text": "The association between psychiatric co-morbidity and methamphetamine-induced psychosis was also studied.", "entity1": "methamphetamine", "entity2": "psychiatric", "span1": [53, 68], "span2": [24, 35]}, "bert_text": "The association between psychiatric co-morbidity and <e1> methamphetamine </e1> <e2> psychiatric </e2> co-morbidity and methamphetamine-induced psychosis was also studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2156": {"data": {"text": "The association between psychiatric co-morbidity and methamphetamine-induced psychosis was also studied.", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [53, 68], "span2": [77, 86]}, "bert_text": "The association between psychiatric co-morbidity and <e1> methamphetamine </e1>-induced <e2> psychosis </e2> was also studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2157": {"data": {"text": "A case of branch retinal vein occlusion associated with fluoxetine-induced secondary hypertension is described.", "entity1": "fluoxetine", "entity2": "branch retinal vein occlusion", "span1": [56, 66], "span2": [10, 39]}, "bert_text": "A case of branch retinal vein occlusion associated with <e1> fluoxetine </e1> <e2> branch retinal vein occlusion </e2> associated with fluoxetine-induced secondary hypertension is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2158": {"data": {"text": "A case of branch retinal vein occlusion associated with fluoxetine-induced secondary hypertension is described.", "entity1": "fluoxetine", "entity2": "hypertension", "span1": [56, 66], "span2": [85, 97]}, "bert_text": "A case of branch retinal vein occlusion associated with <e1> fluoxetine </e1>-induced secondary <e2> hypertension </e2> is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2159": {"data": {"text": "Thirty-five patients (13.4%) had visual field abnormalities, which were attributed to hydroxychloroquine treatment in 4 patients (1.5%).", "entity1": "hydroxychloroquine", "entity2": "visual field abnormalities", "span1": [86, 104], "span2": [33, 59]}, "bert_text": "Thirty-five patients (13.4%) had visual field abnormalities, which were attributed to <e1> hydroxychloroquine </e1> <e2> visual field abnormalities </e2>, which were attributed to hydroxychloroquine treatment in 4 patients (1.5%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2160": {"data": {"text": "Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.\n", "entity1": "adenosine triphosphate", "entity2": "hypotension", "span1": [49, 71], "span2": [26, 37]}, "bert_text": "Cardiovascular effects of hypotension induced by <e1> adenosine triphosphate </e1> <e2> hypotension </e2> induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2161": {"data": {"text": "Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.\n", "entity1": "sodium", "entity2": "hypotension", "span1": [76, 82], "span2": [26, 37]}, "bert_text": "Cardiovascular effects of hypotension induced by adenosine triphosphate and <e1> sodium </e1> <e2> hypotension </e2> induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2162": {"data": {"text": "Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.\n", "entity1": "nitroprusside", "entity2": "hypotension", "span1": [83, 96], "span2": [26, 37]}, "bert_text": "Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium <e1> nitroprusside </e1> <e2> hypotension </e2> induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2163": {"data": {"text": "This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism.", "entity1": "prostaglandin", "entity2": "hyporeninemic hypoaidosteronism", "span1": [51, 64], "span2": [90, 121]}, "bert_text": "This complication may result from an inhibition of <e1> prostaglandin </e1> synthesis and consequent <e2> hyporeninemic hypoaidosteronism </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2164": {"data": {"text": "Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.\n", "entity1": "Fluoxetine", "entity2": "memory deficits", "span1": [0, 10], "span2": [24, 39]}, "bert_text": "<e1> Fluoxetine </e1> improves the <e2> memory deficits </e2> caused by the chemotherapy agent 5-fluorouracil.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2165": {"data": {"text": "Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil.\n", "entity1": "5-fluorouracil", "entity2": "memory deficits", "span1": [73, 87], "span2": [24, 39]}, "bert_text": "Fluoxetine improves the memory deficits caused by the chemotherapy agent <e1> 5-fluorouracil </e1> <e2> memory deficits </e2> caused by the chemotherapy agent 5-fluorouracil.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, 0, -1, -1, -1, 0, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2166": {"data": {"text": "Convulsion following intravenous fluorescein angiography.\n", "entity1": "fluorescein", "entity2": "Convulsion", "span1": [33, 44], "span2": [0, 10]}, "bert_text": "Convulsion following intravenous <e1> fluorescein </e1> <e2> Convulsion </e2> following intravenous fluorescein angiography.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2167": {"data": {"text": "RESULTS: Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil.", "entity1": "remifentanil", "entity2": "hypotension", "span1": [111, 123], "span2": [20, 31]}, "bert_text": "RESULTS: Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of <e1> remifentanil </e1> <e2> hypotension </e2> was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2168": {"data": {"text": "RESULTS: Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil.", "entity1": "remifentanil", "entity2": "hypotension", "span1": [157, 169], "span2": [20, 31]}, "bert_text": "RESULTS: Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of <e1> remifentanil </e1> <e2> hypotension </e2> was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2169": {"data": {"text": "Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).", "entity1": "argatroban", "entity2": "HIT", "span1": [54, 64], "span2": [76, 79]}, "bert_text": "Improved familiarity of healthcare professionals with <e1> argatroban </e1> therapy in <e2> HIT </e2>, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2170": {"data": {"text": "Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).", "entity1": "argatroban", "entity2": "HIT", "span1": [54, 64], "span2": [179, 182]}, "bert_text": "Improved familiarity of healthcare professionals with <e1> argatroban </e1> therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with <e2> HIT </e2> (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2171": {"data": {"text": "Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).", "entity1": "argatroban", "entity2": "thromboses", "span1": [54, 64], "span2": [195, 205]}, "bert_text": "Improved familiarity of healthcare professionals with <e1> argatroban </e1> therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer <e2> thromboses </e2>) or its treatment (e.g. fewer argatroban medication errors).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2172": {"data": {"text": "Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).", "entity1": "argatroban", "entity2": "HIT", "span1": [236, 246], "span2": [76, 79]}, "bert_text": "Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer <e1> argatroban </e1> <e2> HIT </e2>, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2173": {"data": {"text": "Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).", "entity1": "argatroban", "entity2": "HIT", "span1": [236, 246], "span2": [179, 182]}, "bert_text": "Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer <e1> argatroban </e1> <e2> HIT </e2> (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2174": {"data": {"text": "Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer argatroban medication errors).", "entity1": "argatroban", "entity2": "thromboses", "span1": [236, 246], "span2": [195, 205]}, "bert_text": "Improved familiarity of healthcare professionals with argatroban therapy in HIT, including in special populations and during PCI, may facilitate reduction of harm associated with HIT (e.g. fewer thromboses) or its treatment (e.g. fewer <e1> argatroban </e1> <e2> thromboses </e2>) or its treatment (e.g. fewer argatroban medication errors).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2175": {"data": {"text": "These results highlight the kinin B2 receptor antagonist treatment in amelioration of nephrotoxicity induced by cisplatin therapy.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [112, 121], "span2": [86, 100]}, "bert_text": "These results highlight the kinin B2 receptor antagonist treatment in amelioration of nephrotoxicity induced by <e1> cisplatin </e1> <e2> nephrotoxicity </e2> induced by cisplatin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2176": {"data": {"text": "Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias.", "entity1": "Bupivacaine", "entity2": "VT", "span1": [0, 11], "span2": [88, 90]}, "bert_text": "<e1> Bupivacaine </e1> antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to <e2> VT </e2> and in anesthetized dogs with spontaneous postinfarct dysrhythmias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2177": {"data": {"text": "Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias.", "entity1": "Bupivacaine", "entity2": "dysrhythmias", "span1": [0, 11], "span2": [145, 157]}, "bert_text": "<e1> Bupivacaine </e1> antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct <e2> dysrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2178": {"data": {"text": "Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias.", "entity1": "epinephrine", "entity2": "VT", "span1": [24, 35], "span2": [88, 90]}, "bert_text": "Bupivacaine antagonizes <e1> epinephrine </e1> dysrhythmogenicity in conscious dogs susceptible to <e2> VT </e2> and in anesthetized dogs with spontaneous postinfarct dysrhythmias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2179": {"data": {"text": "Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias.", "entity1": "epinephrine", "entity2": "dysrhythmias", "span1": [24, 35], "span2": [145, 157]}, "bert_text": "Bupivacaine antagonizes <e1> epinephrine </e1> dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct <e2> dysrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2180": {"data": {"text": "Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy.\n", "entity1": "calcium carbonate", "entity2": "hypercalcemia", "span1": [54, 71], "span2": [12, 25]}, "bert_text": "Etiology of hypercalcemia in hemodialysis patients on <e1> calcium carbonate </e1> <e2> hypercalcemia </e2> in hemodialysis patients on calcium carbonate therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2181": {"data": {"text": "Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.", "entity1": "potassium", "entity2": "hyperkalemia", "span1": [128, 137], "span2": [49, 61]}, "bert_text": "Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with <e1> potassium </e1> <e2> hyperkalemia </e2>, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2182": {"data": {"text": "Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with potassium sparing agents and who have mild renal disturbance.", "entity1": "potassium", "entity2": "renal disturbance", "span1": [128, 137], "span2": [171, 188]}, "bert_text": "Clinicians should be alert to the possibility of hyperkalemia, especially in elderly patients using ACE/ARB in combination with <e1> potassium </e1> sparing agents and who have mild <e2> renal disturbance </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2183": {"data": {"text": "In this article, we report a patient with SRC induced by tacrolimus and corticosteroids.", "entity1": "tacrolimus", "entity2": "SRC", "span1": [57, 67], "span2": [42, 45]}, "bert_text": "In this article, we report a patient with SRC induced by <e1> tacrolimus </e1> <e2> SRC </e2> induced by tacrolimus and corticosteroids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2184": {"data": {"text": "In this article, we report a patient with SRC induced by tacrolimus and corticosteroids.", "entity1": "corticosteroids", "entity2": "SRC", "span1": [72, 87], "span2": [42, 45]}, "bert_text": "In this article, we report a patient with SRC induced by tacrolimus and <e1> corticosteroids </e1> <e2> SRC </e2> induced by tacrolimus and corticosteroids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2185": {"data": {"text": "We prospectively evaluated thalidomide-induced neuropathy using electrodiagnostic studies.", "entity1": "thalidomide", "entity2": "neuropathy", "span1": [27, 38], "span2": [47, 57]}, "bert_text": "We prospectively evaluated <e1> thalidomide </e1>-induced <e2> neuropathy </e2> using electrodiagnostic studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2186": {"data": {"text": "The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model.", "entity1": "puromycin aminonucleoside", "entity2": "mesangial dysfunction", "span1": [115, 140], "span2": [34, 55]}, "bert_text": "The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the <e1> puromycin aminonucleoside </e1> <e2> mesangial dysfunction </e2> and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2187": {"data": {"text": "The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model.", "entity1": "puromycin aminonucleoside", "entity2": "glomerular sclerosis", "span1": [115, 140], "span2": [75, 95]}, "bert_text": "The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the <e1> puromycin aminonucleoside </e1> <e2> glomerular sclerosis </e2> was studied in the puromycin aminonucleoside (PAN) model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2188": {"data": {"text": "The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model.", "entity1": "PAN", "entity2": "mesangial dysfunction", "span1": [142, 145], "span2": [34, 55]}, "bert_text": "The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (<e1> PAN </e1> <e2> mesangial dysfunction </e2> and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2189": {"data": {"text": "The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (PAN) model.", "entity1": "PAN", "entity2": "glomerular sclerosis", "span1": [142, 145], "span2": [75, 95]}, "bert_text": "The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside (<e1> PAN </e1> <e2> glomerular sclerosis </e2> was studied in the puromycin aminonucleoside (PAN) model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2190": {"data": {"text": "Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.\n", "entity1": "labetalol", "entity2": "hypotension", "span1": [34, 43], "span2": [11, 22]}, "bert_text": "Deliberate hypotension induced by <e1> labetalol </e1> <e2> hypotension </e2> induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2191": {"data": {"text": "Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.\n", "entity1": "halothane", "entity2": "hypotension", "span1": [49, 58], "span2": [11, 22]}, "bert_text": "Deliberate hypotension induced by labetalol with <e1> halothane </e1> <e2> hypotension </e2> induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2192": {"data": {"text": "Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.\n", "entity1": "enflurane", "entity2": "hypotension", "span1": [60, 69], "span2": [11, 22]}, "bert_text": "Deliberate hypotension induced by labetalol with halothane, <e1> enflurane </e1> <e2> hypotension </e2> induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2193": {"data": {"text": "Deliberate hypotension induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.\n", "entity1": "isoflurane", "entity2": "hypotension", "span1": [73, 83], "span2": [11, 22]}, "bert_text": "Deliberate hypotension induced by labetalol with halothane, enflurane or <e1> isoflurane </e1> <e2> hypotension </e2> induced by labetalol with halothane, enflurane or isoflurane for middle-ear surgery.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2194": {"data": {"text": "Although an infrequent complication of selective serotonin reuptake inhibitor therapy, it is important that ophthalmologists are aware that these agents can cause hypertension because this class of drugs is widely prescribed.", "entity1": "serotonin", "entity2": "hypertension", "span1": [49, 58], "span2": [163, 175]}, "bert_text": "Although an infrequent complication of selective <e1> serotonin </e1> reuptake inhibitor therapy, it is important that ophthalmologists are aware that these agents can cause <e2> hypertension </e2> because this class of drugs is widely prescribed.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2195": {"data": {"text": "The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.", "entity1": "labetalol", "entity2": "hypotensive", "span1": [25, 34], "span2": [87, 98]}, "bert_text": "The feasibility of using <e1> labetalol </e1>, an alpha- and beta-adrenergic blocking agent, as a <e2> hypotensive </e2> agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2196": {"data": {"text": "The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.", "entity1": "halothane", "entity2": "hypotensive", "span1": [150, 159], "span2": [87, 98]}, "bert_text": "The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (<e1> halothane </e1> <e2> hypotensive </e2> agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2197": {"data": {"text": "The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.", "entity1": "enflurane", "entity2": "hypotensive", "span1": [161, 170], "span2": [87, 98]}, "bert_text": "The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, <e1> enflurane </e1> <e2> hypotensive </e2> agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2198": {"data": {"text": "The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.", "entity1": "isoflurane", "entity2": "hypotensive", "span1": [174, 184], "span2": [87, 98]}, "bert_text": "The feasibility of using labetalol, an alpha- and beta-adrenergic blocking agent, as a hypotensive agent in combination with inhalation anaesthetics (halothane, enflurane or <e1> isoflurane </e1> <e2> hypotensive </e2> agent in combination with inhalation anaesthetics (halothane, enflurane or isoflurane) was studied in 23 adult patients undergoing middle-ear surgery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2199": {"data": {"text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "entity1": "rifampicin", "entity2": "renal failure", "span1": [35, 45], "span2": [57, 70]}, "bert_text": "Antirifampicin antibodies in acute <e1> rifampicin </e1>-associated <e2> renal failure </e2>.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2200": {"data": {"text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "entity1": "rifampicin", "entity2": "acute renal failure", "span1": [35, 45], "span2": [88, 107]}, "bert_text": "Antirifampicin antibodies in acute <e1> rifampicin </e1>-associated renal failure.\n5 patients with <e2> acute renal failure </e2> (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2201": {"data": {"text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "entity1": "rifampicin", "entity2": "thrombopenia", "span1": [35, 45], "span2": [116, 128]}, "bert_text": "Antirifampicin antibodies in acute <e1> rifampicin </e1>-associated renal failure.\n5 patients with acute renal failure (3 with <e2> thrombopenia </e2> and hemolysis) induced by the reintroduction of rifampicin are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2202": {"data": {"text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "entity1": "rifampicin", "entity2": "hemolysis", "span1": [35, 45], "span2": [133, 142]}, "bert_text": "Antirifampicin antibodies in acute <e1> rifampicin </e1>-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and <e2> hemolysis </e2>) induced by the reintroduction of rifampicin are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2203": {"data": {"text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "entity1": "rifampicin", "entity2": "renal failure", "span1": [177, 187], "span2": [57, 70]}, "bert_text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of <e1> rifampicin </e1> <e2> renal failure </e2>.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2204": {"data": {"text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "entity1": "rifampicin", "entity2": "acute renal failure", "span1": [177, 187], "span2": [88, 107]}, "bert_text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of <e1> rifampicin </e1> <e2> acute renal failure </e2> (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2205": {"data": {"text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "entity1": "rifampicin", "entity2": "thrombopenia", "span1": [177, 187], "span2": [116, 128]}, "bert_text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of <e1> rifampicin </e1> <e2> thrombopenia </e2> and hemolysis) induced by the reintroduction of rifampicin are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2206": {"data": {"text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of rifampicin are described.", "entity1": "rifampicin", "entity2": "hemolysis", "span1": [177, 187], "span2": [133, 142]}, "bert_text": "Antirifampicin antibodies in acute rifampicin-associated renal failure.\n5 patients with acute renal failure (3 with thrombopenia and hemolysis) induced by the reintroduction of <e1> rifampicin </e1> <e2> hemolysis </e2>) induced by the reintroduction of rifampicin are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2207": {"data": {"text": "Coronary vasospasm may be induced by the non-selective beta-blocking properties of sotalol.", "entity1": "sotalol", "entity2": "Coronary vasospasm", "span1": [83, 90], "span2": [0, 18]}, "bert_text": "Coronary vasospasm may be induced by the non-selective beta-blocking properties of <e1> sotalol </e1> <e2> Coronary vasospasm </e2> may be induced by the non-selective beta-blocking properties of sotalol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2208": {"data": {"text": "Vincristine was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by encephalopathy and death.", "entity1": "Vincristine", "entity2": "leukaemia", "span1": [0, 11], "span2": [65, 74]}, "bert_text": "<e1> Vincristine </e1> was accidentally given intrathecally to a child with <e2> leukaemia </e2>, producing sensory and motor dysfunction followed by encephalopathy and death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2209": {"data": {"text": "Vincristine was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by encephalopathy and death.", "entity1": "Vincristine", "entity2": "encephalopathy", "span1": [0, 11], "span2": [128, 142]}, "bert_text": "<e1> Vincristine </e1> was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by <e2> encephalopathy </e2> and death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2210": {"data": {"text": "Vincristine was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by encephalopathy and death.", "entity1": "Vincristine", "entity2": "death", "span1": [0, 11], "span2": [147, 152]}, "bert_text": "<e1> Vincristine </e1> was accidentally given intrathecally to a child with leukaemia, producing sensory and motor dysfunction followed by encephalopathy and <e2> death </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2211": {"data": {"text": "Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.", "entity1": "ISO", "entity2": "fibrosis", "span1": [62, 65], "span2": [112, 120]}, "bert_text": "Thirty to 135 min after the injection of crystalline insulin, <e1> ISO </e1> was given subcutaneously and when ISO induced <e2> fibrosis </e2> in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2212": {"data": {"text": "Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.", "entity1": "ISO", "entity2": "fibrosis", "span1": [100, 103], "span2": [112, 120]}, "bert_text": "Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when <e1> ISO </e1> induced <e2> fibrosis </e2> in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2213": {"data": {"text": "Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.", "entity1": "glucose", "entity2": "fibrosis", "span1": [274, 281], "span2": [112, 120]}, "bert_text": "Thirty to 135 min after the injection of crystalline insulin, ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood <e1> glucose </e1> <e2> fibrosis </e2> in the myocardium was morphometrically analyzed 7 days later, a highly significant correlation (r = 0.83, 2 p = 0.006) to the slope of the fall in blood glucose after insulin treatment appeared.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2214": {"data": {"text": "Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on gentamicin (GM)-mediated nephropathy.", "entity1": "gentamicin", "entity2": "nephropathy", "span1": [106, 116], "span2": [131, 142]}, "bert_text": "Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on <e1> gentamicin </e1> (GM)-mediated <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2215": {"data": {"text": "Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on gentamicin (GM)-mediated nephropathy.", "entity1": "GM)-mediated", "entity2": "nephropathy", "span1": [118, 130], "span2": [131, 142]}, "bert_text": "Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on gentamicin (<e1> GM)-mediated </e1> <e2> nephropathy </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2216": {"data": {"text": "Re (300 mg/kg) inhibited OIH in both the thermal sensitivity test and the acetic acid-induced writhing test.", "entity1": "acetic acid", "entity2": "OIH", "span1": [74, 85], "span2": [25, 28]}, "bert_text": "Re (300 mg/kg) inhibited OIH in both the thermal sensitivity test and the <e1> acetic acid </e1> <e2> OIH </e2> in both the thermal sensitivity test and the acetic acid-induced writhing test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2217": {"data": {"text": "Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced hyperactivity.", "entity1": "adenosine", "entity2": "hyperactivity", "span1": [15, 24], "span2": [73, 86]}, "bert_text": "Similarly, all <e1> adenosine </e1> receptor agonists decreased amphetamine-induced <e2> hyperactivity </e2>, but at the higher doses than those which were active in cocaine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2218": {"data": {"text": "Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced hyperactivity.", "entity1": "adenosine", "entity2": "hyperactivity", "span1": [15, 24], "span2": [160, 173]}, "bert_text": "Similarly, all <e1> adenosine </e1> receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2219": {"data": {"text": "Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced hyperactivity.", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [53, 64], "span2": [73, 86]}, "bert_text": "Similarly, all adenosine receptor agonists decreased <e1> amphetamine </e1>-induced <e2> hyperactivity </e2>, but at the higher doses than those which were active in cocaine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2220": {"data": {"text": "Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced hyperactivity.", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [53, 64], "span2": [160, 173]}, "bert_text": "Similarly, all adenosine receptor agonists decreased <e1> amphetamine </e1>-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2221": {"data": {"text": "Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced hyperactivity.", "entity1": "cocaine", "entity2": "hyperactivity", "span1": [144, 151], "span2": [73, 86]}, "bert_text": "Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in <e1> cocaine </e1> <e2> hyperactivity </e2>, but at the higher doses than those which were active in cocaine-induced hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2222": {"data": {"text": "Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in cocaine-induced hyperactivity.", "entity1": "cocaine", "entity2": "hyperactivity", "span1": [144, 151], "span2": [160, 173]}, "bert_text": "Similarly, all adenosine receptor agonists decreased amphetamine-induced hyperactivity, but at the higher doses than those which were active in <e1> cocaine </e1>-induced <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2223": {"data": {"text": "According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and thrombocytopenia occurred as a result of therapy with fluconazole is probable, with a total of six points.", "entity1": "fluconazole", "entity2": "agranulocytosis", "span1": [141, 152], "span2": [67, 82]}, "bert_text": "According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and thrombocytopenia occurred as a result of therapy with <e1> fluconazole </e1> <e2> agranulocytosis </e2> and thrombocytopenia occurred as a result of therapy with fluconazole is probable, with a total of six points.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2224": {"data": {"text": "According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and thrombocytopenia occurred as a result of therapy with fluconazole is probable, with a total of six points.", "entity1": "fluconazole", "entity2": "thrombocytopenia", "span1": [141, 152], "span2": [87, 103]}, "bert_text": "According to Naranjo's algorithm the likelihood that our patient's agranulocytosis and thrombocytopenia occurred as a result of therapy with <e1> fluconazole </e1> <e2> thrombocytopenia </e2> occurred as a result of therapy with fluconazole is probable, with a total of six points.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2225": {"data": {"text": "OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).", "entity1": "angiotensin", "entity2": "diabetes", "span1": [83, 94], "span2": [126, 134]}, "bert_text": "OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-<e1> angiotensin </e1> system in patients with type 1 <e2> diabetes </e2> and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2226": {"data": {"text": "OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).", "entity1": "angiotensin", "entity2": "nephropathy", "span1": [83, 94], "span2": [190, 201]}, "bert_text": "OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-<e1> angiotensin </e1> system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of <e2> nephropathy </e2>, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2227": {"data": {"text": "OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).", "entity1": "angiotensin", "entity2": "diabetic nephropathy", "span1": [83, 94], "span2": [280, 300]}, "bert_text": "OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-<e1> angiotensin </e1> system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early <e2> diabetic nephropathy </e2> (diabetic nephropathy).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2228": {"data": {"text": "OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (diabetic nephropathy).", "entity1": "angiotensin", "entity2": "diabetic nephropathy", "span1": [83, 94], "span2": [302, 322]}, "bert_text": "OBJECTIVE: A multicenter, controlled trial showed that early blockade of the renin-<e1> angiotensin </e1> system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy, suggesting that other mechanism(s) are involved in the pathogenesis of early diabetic nephropathy (<e2> diabetic nephropathy </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2229": {"data": {"text": "However, while DES-induced pituitary growth exhibited quantitative, additive inheritance, the hemorrhagic phenotype exhibited recessive, epistatic inheritance.", "entity1": "DES", "entity2": "hemorrhagic", "span1": [15, 18], "span2": [94, 105]}, "bert_text": "However, while <e1> DES </e1>-induced pituitary growth exhibited quantitative, additive inheritance, the <e2> hemorrhagic </e2> phenotype exhibited recessive, epistatic inheritance.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2230": {"data": {"text": "Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a methotrexate consequence?", "entity1": "methotrexate", "entity2": "acute lymphoblastic leukemia", "span1": [224, 236], "span2": [171, 199]}, "bert_text": "Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group (POG) P9605 (standard risk) and P9201 (lesser risk) acute lymphoblastic leukemia protocols (ACCL0131): a <e1> methotrexate </e1> <e2> acute lymphoblastic leukemia </e2> protocols (ACCL0131): a methotrexate consequence?", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2231": {"data": {"text": "Succinylcholine apnoea: attempted reversal with anticholinesterases.\n", "entity1": "Succinylcholine", "entity2": "apnoea", "span1": [0, 15], "span2": [16, 22]}, "bert_text": "<e1> Succinylcholine </e1> <e2> apnoea </e2>: attempted reversal with anticholinesterases.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2232": {"data": {"text": "Four (5%) patients had from torsades de pointes during the initial oral treatment with d,l-sotalol.", "entity1": "l-sotalol", "entity2": "torsades de pointes", "span1": [89, 98], "span2": [28, 47]}, "bert_text": "Four (5%) patients had from torsades de pointes during the initial oral treatment with d,<e1> l-sotalol </e1> <e2> torsades de pointes </e2> during the initial oral treatment with d,l-sotalol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2233": {"data": {"text": "One of the major complications of cisplatin use is dose-limiting nephrotoxicity.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [34, 43], "span2": [65, 79]}, "bert_text": "One of the major complications of <e1> cisplatin </e1> use is dose-limiting <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2234": {"data": {"text": "We used Poisson regression to evaluate relations between two metrics of metolachlor use (lifetime days, intensity-weighted lifetime days) and cancer incidence.", "entity1": "metolachlor", "entity2": "cancer", "span1": [72, 83], "span2": [142, 148]}, "bert_text": "We used Poisson regression to evaluate relations between two metrics of <e1> metolachlor </e1> use (lifetime days, intensity-weighted lifetime days) and <e2> cancer </e2> incidence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2235": {"data": {"text": "Adenosine triphosphate (ATP) and sodium nitroprusside (SNP) are administered to patients to induce and control hypotension during anesthesia.", "entity1": "Adenosine triphosphate", "entity2": "hypotension", "span1": [0, 22], "span2": [111, 122]}, "bert_text": "<e1> Adenosine triphosphate </e1> (ATP) and sodium nitroprusside (SNP) are administered to patients to induce and control <e2> hypotension </e2> during anesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2236": {"data": {"text": "Adenosine triphosphate (ATP) and sodium nitroprusside (SNP) are administered to patients to induce and control hypotension during anesthesia.", "entity1": "ATP", "entity2": "hypotension", "span1": [24, 27], "span2": [111, 122]}, "bert_text": "Adenosine triphosphate (<e1> ATP </e1>) and sodium nitroprusside (SNP) are administered to patients to induce and control <e2> hypotension </e2> during anesthesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2237": {"data": {"text": "Adenosine triphosphate (ATP) and sodium nitroprusside (SNP) are administered to patients to induce and control hypotension during anesthesia.", "entity1": "sodium nitroprusside", "entity2": "hypotension", "span1": [33, 53], "span2": [111, 122]}, "bert_text": "Adenosine triphosphate (ATP) and <e1> sodium nitroprusside </e1> (SNP) are administered to patients to induce and control <e2> hypotension </e2> during anesthesia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2238": {"data": {"text": "Adenosine triphosphate (ATP) and sodium nitroprusside (SNP) are administered to patients to induce and control hypotension during anesthesia.", "entity1": "SNP", "entity2": "hypotension", "span1": [55, 58], "span2": [111, 122]}, "bert_text": "Adenosine triphosphate (ATP) and sodium nitroprusside (<e1> SNP </e1>) are administered to patients to induce and control <e2> hypotension </e2> during anesthesia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2239": {"data": {"text": "Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation.\n", "entity1": "amiodarone", "entity2": "hepatic lipid homeostasis", "span1": [54, 64], "span2": [14, 39]}, "bert_text": "Disruption of hepatic lipid homeostasis in mice after <e1> amiodarone </e1> <e2> hepatic lipid homeostasis </e2> in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2240": {"data": {"text": "Administration of the dopamine precursor levodopa enhances learning in healthy subjects and stroke patients.", "entity1": "dopamine", "entity2": "stroke", "span1": [22, 30], "span2": [92, 98]}, "bert_text": "Administration of the <e1> dopamine </e1> precursor levodopa enhances learning in healthy subjects and <e2> stroke </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2241": {"data": {"text": "Administration of the dopamine precursor levodopa enhances learning in healthy subjects and stroke patients.", "entity1": "levodopa", "entity2": "stroke", "span1": [41, 49], "span2": [92, 98]}, "bert_text": "Administration of the dopamine precursor <e1> levodopa </e1> enhances learning in healthy subjects and <e2> stroke </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2242": {"data": {"text": "Tonic-clonic seizures followed intravenous fluorescein injection for fundus angiography in a 47-year-old male.", "entity1": "fluorescein", "entity2": "Tonic-clonic seizures", "span1": [43, 54], "span2": [0, 21]}, "bert_text": "Tonic-clonic seizures followed intravenous <e1> fluorescein </e1> <e2> Tonic-clonic seizures </e2> followed intravenous fluorescein injection for fundus angiography in a 47-year-old male.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2243": {"data": {"text": "We also investigated whether trazodone induces catalepsy in rats.", "entity1": "trazodone", "entity2": "catalepsy", "span1": [29, 38], "span2": [47, 56]}, "bert_text": "We also investigated whether <e1> trazodone </e1> induces <e2> catalepsy </e2> in rats.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2244": {"data": {"text": "BACKGROUND: Recent studies confirmed a high incidence of sensory axonal neuropathy in patients treated with different doses of thalidomide.", "entity1": "thalidomide", "entity2": "sensory axonal neuropathy", "span1": [127, 138], "span2": [57, 82]}, "bert_text": "BACKGROUND: Recent studies confirmed a high incidence of sensory axonal neuropathy in patients treated with different doses of <e1> thalidomide </e1> <e2> sensory axonal neuropathy </e2> in patients treated with different doses of thalidomide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2245": {"data": {"text": "Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and PAP nephrotoxicity and metabolism was determined.", "entity1": "bis(p-nitrophenyl", "entity2": "nephrotoxicity", "span1": [25, 42], "span2": [104, 118]}, "bert_text": "Therefore, the effect of <e1> bis(p-nitrophenyl </e1>) phosphate (BNPP), an acylamidase inhibitor, on APAP and PAP <e2> nephrotoxicity </e2> and metabolism was determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2246": {"data": {"text": "Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and PAP nephrotoxicity and metabolism was determined.", "entity1": "phosphate", "entity2": "nephrotoxicity", "span1": [44, 53], "span2": [104, 118]}, "bert_text": "Therefore, the effect of bis(p-nitrophenyl) <e1> phosphate </e1> (BNPP), an acylamidase inhibitor, on APAP and PAP <e2> nephrotoxicity </e2> and metabolism was determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2247": {"data": {"text": "Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and PAP nephrotoxicity and metabolism was determined.", "entity1": "APAP", "entity2": "nephrotoxicity", "span1": [91, 95], "span2": [104, 118]}, "bert_text": "Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on <e1> APAP </e1> and PAP <e2> nephrotoxicity </e2> and metabolism was determined.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2248": {"data": {"text": "Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and PAP nephrotoxicity and metabolism was determined.", "entity1": "PAP", "entity2": "nephrotoxicity", "span1": [100, 103], "span2": [104, 118]}, "bert_text": "Therefore, the effect of bis(p-nitrophenyl) phosphate (BNPP), an acylamidase inhibitor, on APAP and <e1> PAP </e1> <e2> nephrotoxicity </e2> and metabolism was determined.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2249": {"data": {"text": "Sixty-seven men with metastatic androgen-independent prostate cancer in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment.", "entity1": "thalidomide", "entity2": "prostate cancer", "span1": [100, 111], "span2": [53, 68]}, "bert_text": "Sixty-seven men with metastatic androgen-independent prostate cancer in an open-label trial of oral <e1> thalidomide </e1> <e2> prostate cancer </e2> in an open-label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies (NCS) prior to and at 3-month intervals during treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2250": {"data": {"text": "In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.", "entity1": "MT", "entity2": "toxicity", "span1": [15, 17], "span2": [59, 67]}, "bert_text": "In conclusion, <e1> MT </e1> induction halts BCNU-induced hippocampal <e2> toxicity </e2> as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2251": {"data": {"text": "In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.", "entity1": "BCNU", "entity2": "toxicity", "span1": [34, 38], "span2": [59, 67]}, "bert_text": "In conclusion, MT induction halts <e1> BCNU </e1>-induced hippocampal <e2> toxicity </e2> as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2252": {"data": {"text": "In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.", "entity1": "GSH", "entity2": "toxicity", "span1": [102, 105], "span2": [59, 67]}, "bert_text": "In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and <e1> GSH </e1> <e2> toxicity </e2> as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2253": {"data": {"text": "In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.", "entity1": "TNFalpha", "entity2": "toxicity", "span1": [157, 165], "span2": [59, 67]}, "bert_text": "In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of <e1> TNFalpha </e1> <e2> toxicity </e2> as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2254": {"data": {"text": "In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.", "entity1": "MDA", "entity2": "toxicity", "span1": [167, 170], "span2": [59, 67]}, "bert_text": "In conclusion, MT induction halts BCNU-induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, <e1> MDA </e1> <e2> toxicity </e2> as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha, MDA and caspase-3 activity with subsequent preservation of cognition.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2255": {"data": {"text": "Methyldopa causes an autoimmune hemolytic anemia in a small percentage of patients who take the drug.", "entity1": "Methyldopa", "entity2": "autoimmune hemolytic anemia", "span1": [0, 10], "span2": [21, 48]}, "bert_text": "<e1> Methyldopa </e1> causes an <e2> autoimmune hemolytic anemia </e2> in a small percentage of patients who take the drug.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2256": {"data": {"text": "RESULTS: All five patients experienced symptoms of encephalopathy soon after (within 12 h-2 days) receiving ifosfamide.", "entity1": "ifosfamide", "entity2": "encephalopathy", "span1": [108, 118], "span2": [51, 65]}, "bert_text": "RESULTS: All five patients experienced symptoms of encephalopathy soon after (within 12 h-2 days) receiving <e1> ifosfamide </e1> <e2> encephalopathy </e2> soon after (within 12 h-2 days) receiving ifosfamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2257": {"data": {"text": "The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving oestrogen therapy.", "entity1": "oestrogen", "entity2": "endometrial disease", "span1": [115, 124], "span2": [57, 76]}, "bert_text": "The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving <e1> oestrogen </e1> <e2> endometrial disease </e2> among 850 climacteric women receiving oestrogen therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2258": {"data": {"text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.", "entity1": "steroids", "entity2": "myopathic", "span1": [113, 121], "span2": [73, 82]}, "bert_text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing <e1> steroids </e1> <e2> myopathic </e2> patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2259": {"data": {"text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.", "entity1": "steroids", "entity2": "myopathic", "span1": [113, 121], "span2": [261, 270]}, "bert_text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing <e1> steroids </e1> have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered <e2> myopathic </e2> by a diet deficient in vitamin E.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2260": {"data": {"text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.", "entity1": "Dianabol", "entity2": "myopathic", "span1": [214, 222], "span2": [73, 82]}, "bert_text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (<e1> Dianabol </e1> <e2> myopathic </e2> patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2261": {"data": {"text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.", "entity1": "Dianabol", "entity2": "myopathic", "span1": [214, 222], "span2": [261, 270]}, "bert_text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (<e1> Dianabol </e1>, CIBA) at high doses in rats rendered <e2> myopathic </e2> by a diet deficient in vitamin E.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2262": {"data": {"text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.", "entity1": "vitamin", "entity2": "myopathic", "span1": [294, 301], "span2": [73, 82]}, "bert_text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in <e1> vitamin </e1> <e2> myopathic </e2> patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2263": {"data": {"text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in vitamin E.", "entity1": "vitamin", "entity2": "myopathic", "span1": [294, 301], "span2": [261, 270]}, "bert_text": "The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent (Dianabol, CIBA) at high doses in rats rendered myopathic by a diet deficient in <e1> vitamin </e1> <e2> myopathic </e2> by a diet deficient in vitamin E.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2264": {"data": {"text": "Thus, phasic signaling seems to be the critical mechanism by which dopamine enhances associative learning in healthy subjects and stroke patients.", "entity1": "dopamine", "entity2": "stroke", "span1": [67, 75], "span2": [130, 136]}, "bert_text": "Thus, phasic signaling seems to be the critical mechanism by which <e1> dopamine </e1> enhances associative learning in healthy subjects and <e2> stroke </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2265": {"data": {"text": "As a function of dose, FZP first protected against convulsions and death.", "entity1": "FZP", "entity2": "convulsions", "span1": [23, 26], "span2": [51, 62]}, "bert_text": "As a function of dose, <e1> FZP </e1> first protected against <e2> convulsions </e2> and death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2266": {"data": {"text": "As a function of dose, FZP first protected against convulsions and death.", "entity1": "FZP", "entity2": "death", "span1": [23, 26], "span2": [67, 72]}, "bert_text": "As a function of dose, <e1> FZP </e1> first protected against convulsions and <e2> death </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2267": {"data": {"text": "The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose-dependently.", "entity1": "aconitine", "entity2": "myocardial injury", "span1": [24, 33], "span2": [46, 63]}, "bert_text": "The results showed that <e1> aconitine </e1> resulted in <e2> myocardial injury </e2> and reduced NRVMs viability dose-dependently.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2268": {"data": {"text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "entity1": "oxygen", "entity2": "ototoxicity", "span1": [30, 36], "span2": [71, 82]}, "bert_text": "The participation of reactive <e1> oxygen </e1> species in aminoglycoside-induced <e2> ototoxicity </e2> has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2269": {"data": {"text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "entity1": "oxygen", "entity2": "ototoxicity", "span1": [30, 36], "span2": [240, 251]}, "bert_text": "The participation of reactive <e1> oxygen </e1> species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate <e2> ototoxicity </e2> in vivo.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2270": {"data": {"text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "entity1": "aminoglycoside", "entity2": "ototoxicity", "span1": [48, 62], "span2": [71, 82]}, "bert_text": "The participation of reactive oxygen species in <e1> aminoglycoside </e1>-induced <e2> ototoxicity </e2> has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2271": {"data": {"text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "entity1": "aminoglycoside", "entity2": "ototoxicity", "span1": [48, 62], "span2": [240, 251]}, "bert_text": "The participation of reactive oxygen species in <e1> aminoglycoside </e1>-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate <e2> ototoxicity </e2> in vivo.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2272": {"data": {"text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "entity1": "aminoglycoside", "entity2": "ototoxicity", "span1": [123, 137], "span2": [71, 82]}, "bert_text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that <e1> aminoglycoside </e1> <e2> ototoxicity </e2> has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2273": {"data": {"text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "entity1": "aminoglycoside", "entity2": "ototoxicity", "span1": [123, 137], "span2": [240, 251]}, "bert_text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that <e1> aminoglycoside </e1>-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate <e2> ototoxicity </e2> in vivo.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2274": {"data": {"text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "entity1": "iron", "entity2": "ototoxicity", "span1": [138, 142], "span2": [71, 82]}, "bert_text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-<e1> iron </e1> <e2> ototoxicity </e2> has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2275": {"data": {"text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "entity1": "iron", "entity2": "ototoxicity", "span1": [138, 142], "span2": [240, 251]}, "bert_text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-<e1> iron </e1> complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate <e2> ototoxicity </e2> in vivo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2276": {"data": {"text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "entity1": "superoxide", "entity2": "ototoxicity", "span1": [179, 189], "span2": [71, 82]}, "bert_text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of <e1> superoxide </e1> <e2> ototoxicity </e2> has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2277": {"data": {"text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo.", "entity1": "superoxide", "entity2": "ototoxicity", "span1": [179, 189], "span2": [240, 251]}, "bert_text": "The participation of reactive oxygen species in aminoglycoside-induced ototoxicity has been deduced from observations that aminoglycoside-iron complexes catalyze the formation of <e1> superoxide </e1> radicals in vitro and that antioxidants attenuate <e2> ototoxicity </e2> in vivo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2278": {"data": {"text": "He was found to have atrial flutter at a ventricular rate of 70/min which slowed down to 30-40/min when nifedipine (60 mg) in 3 divided doses, during which he was paced at a rate of 70/min.", "entity1": "nifedipine", "entity2": "atrial flutter", "span1": [104, 114], "span2": [21, 35]}, "bert_text": "He was found to have atrial flutter at a ventricular rate of 70/min which slowed down to 30-40/min when <e1> nifedipine </e1> <e2> atrial flutter </e2> at a ventricular rate of 70/min which slowed down to 30-40/min when nifedipine (60 mg) in 3 divided doses, during which he was paced at a rate of 70/min.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2279": {"data": {"text": "Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.\n", "entity1": "Nelarabine", "entity2": "neurotoxicity", "span1": [0, 10], "span2": [11, 24]}, "bert_text": "<e1> Nelarabine </e1> <e2> neurotoxicity </e2> with concurrent intrathecal chemotherapy: Case report and review of literature.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2280": {"data": {"text": "These side effects are relatively rare in a given individual, but given the extremely widespread use of heparin, some are quite common, particularly HITT and osteoporosis.", "entity1": "heparin", "entity2": "osteoporosis", "span1": [104, 111], "span2": [158, 170]}, "bert_text": "These side effects are relatively rare in a given individual, but given the extremely widespread use of <e1> heparin </e1>, some are quite common, particularly HITT and <e2> osteoporosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2281": {"data": {"text": "The studies suggest that propranolol is a useful drug in selected patients with severe idiopathic orthostatic hypotension.", "entity1": "propranolol", "entity2": "idiopathic orthostatic hypotension", "span1": [25, 36], "span2": [87, 121]}, "bert_text": "The studies suggest that <e1> propranolol </e1> is a useful drug in selected patients with severe <e2> idiopathic orthostatic hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2282": {"data": {"text": "In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100", "entity1": "gemcitabine", "entity2": "HL", "span1": [99, 110], "span2": [83, 85]}, "bert_text": "In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with <e1> gemcitabine </e1> <e2> HL </e2> treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2283": {"data": {"text": "In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100", "entity1": "methylprednisolone", "entity2": "HL", "span1": [147, 165], "span2": [83, 85]}, "bert_text": "In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; <e1> methylprednisolone </e1> <e2> HL </e2> treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2284": {"data": {"text": "In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100", "entity1": "cisplatin", "entity2": "HL", "span1": [185, 194], "span2": [83, 85]}, "bert_text": "In this retrospective single-centre analysis, patients with relapsed or refractory HL treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and <e1> cisplatin </e1> <e2> HL </e2> treated with gemcitabine 1,000 mg/m(2) day (D)1, D8 and D15; methylprednisolone 1,000 mg D1-5; and cisplatin 100", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2285": {"data": {"text": "Amphotericin B concentrations in the kidney in NS-718-treated rats were higher than those in D-AmB-treated rats.", "entity1": "Amphotericin B", "entity2": "NS-718-treated", "span1": [0, 14], "span2": [47, 61]}, "bert_text": "<e1> Amphotericin B </e1> concentrations in the kidney in <e2> NS-718-treated </e2> rats were higher than those in D-AmB-treated rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2286": {"data": {"text": "Amphotericin B concentrations in the kidney in NS-718-treated rats were higher than those in D-AmB-treated rats.", "entity1": "D-AmB", "entity2": "NS-718-treated", "span1": [93, 98], "span2": [47, 61]}, "bert_text": "Amphotericin B concentrations in the kidney in NS-718-treated rats were higher than those in <e1> D-AmB </e1> <e2> NS-718-treated </e2> rats were higher than those in D-AmB-treated rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2287": {"data": {"text": "This case report suggests that desvenlafaxine might cause clinically significant hyponatremia.", "entity1": "desvenlafaxine", "entity2": "hyponatremia", "span1": [31, 45], "span2": [81, 93]}, "bert_text": "This case report suggests that <e1> desvenlafaxine </e1> might cause clinically significant <e2> hyponatremia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2288": {"data": {"text": "Treatment of WT mice with topical ocular 0.1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients.", "entity1": "dexamethasone", "entity2": "retinal", "span1": [46, 59], "span2": [142, 149]}, "bert_text": "Treatment of WT mice with topical ocular 0.1% <e1> dexamethasone </e1> led to elevation of intraocular pressure (IOP), functional and structural loss of <e2> retinal </e2> ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2289": {"data": {"text": "Treatment of WT mice with topical ocular 0.1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients.", "entity1": "dexamethasone", "entity2": "axonal degeneration", "span1": [46, 59], "span2": [170, 189]}, "bert_text": "Treatment of WT mice with topical ocular 0.1% <e1> dexamethasone </e1> led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and <e2> axonal degeneration </e2>, resembling glucocorticoid-induced glaucoma in human patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2290": {"data": {"text": "Treatment of WT mice with topical ocular 0.1% dexamethasone led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced glaucoma in human patients.", "entity1": "dexamethasone", "entity2": "glaucoma", "span1": [46, 59], "span2": [225, 233]}, "bert_text": "Treatment of WT mice with topical ocular 0.1% <e1> dexamethasone </e1> led to elevation of intraocular pressure (IOP), functional and structural loss of retinal ganglion cells, and axonal degeneration, resembling glucocorticoid-induced <e2> glaucoma </e2> in human patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2291": {"data": {"text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "entity1": "isoproterenol", "entity2": "myocardial ischemia", "span1": [21, 34], "span2": [49, 68]}, "bert_text": "Effects of CD-832 on <e1> isoproterenol </e1> (ISO)-induced <e2> myocardial ischemia </e2> were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2292": {"data": {"text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "entity1": "isoproterenol", "entity2": "coronary stenosis", "span1": [21, 34], "span2": [103, 120]}, "bert_text": "Effects of CD-832 on <e1> isoproterenol </e1> (ISO)-induced myocardial ischemia were studied in dogs with partial <e2> coronary stenosis </e2> of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2293": {"data": {"text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "entity1": "ISO)-induced", "entity2": "myocardial ischemia", "span1": [36, 48], "span2": [49, 68]}, "bert_text": "Effects of CD-832 on isoproterenol (<e1> ISO)-induced </e1> <e2> myocardial ischemia </e2> were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2294": {"data": {"text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "entity1": "ISO)-induced", "entity2": "coronary stenosis", "span1": [36, 48], "span2": [103, 120]}, "bert_text": "Effects of CD-832 on isoproterenol (<e1> ISO)-induced </e1> myocardial ischemia were studied in dogs with partial <e2> coronary stenosis </e2> of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2295": {"data": {"text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "entity1": "nifedipine", "entity2": "myocardial ischemia", "span1": [202, 212], "span2": [49, 68]}, "bert_text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for <e1> nifedipine </e1> <e2> myocardial ischemia </e2> were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2296": {"data": {"text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "entity1": "nifedipine", "entity2": "coronary stenosis", "span1": [202, 212], "span2": [103, 120]}, "bert_text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for <e1> nifedipine </e1> <e2> coronary stenosis </e2> of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2297": {"data": {"text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "entity1": "diltiazem", "entity2": "myocardial ischemia", "span1": [216, 225], "span2": [49, 68]}, "bert_text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or <e1> diltiazem </e1> <e2> myocardial ischemia </e2> were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2298": {"data": {"text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "entity1": "diltiazem", "entity2": "coronary stenosis", "span1": [216, 225], "span2": [103, 120]}, "bert_text": "Effects of CD-832 on isoproterenol (ISO)-induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or <e1> diltiazem </e1> <e2> coronary stenosis </e2> of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2299": {"data": {"text": "The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease).", "entity1": "gemfibrozil-lovastatin", "entity2": "hyperlipidemia", "span1": [140, 162], "span2": [207, 221]}, "bert_text": "The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, <e1> gemfibrozil-lovastatin </e1> treatment in 80 patients with primary mixed <e2> hyperlipidemia </e2> (68% of whom had atherosclerotic vascular disease).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2300": {"data": {"text": "The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, gemfibrozil-lovastatin treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had atherosclerotic vascular disease).", "entity1": "gemfibrozil-lovastatin", "entity2": "atherosclerotic vascular disease", "span1": [140, 162], "span2": [239, 271]}, "bert_text": "The specific aim of this retrospective, observational study was to assess safety and efficacy of long-term (21 months/patient), open-label, <e1> gemfibrozil-lovastatin </e1> treatment in 80 patients with primary mixed hyperlipidemia (68% of whom had <e2> atherosclerotic vascular disease </e2>).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2301": {"data": {"text": "The treatment of HIT mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy, most commonly using a direct thrombin inhibitor.", "entity1": "heparin", "entity2": "HIT", "span1": [60, 67], "span2": [17, 20]}, "bert_text": "The treatment of HIT mandates an immediate cessation of all <e1> heparin </e1> <e2> HIT </e2> mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy, most commonly using a direct thrombin inhibitor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2302": {"data": {"text": "The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice.", "entity1": "nociceptin", "entity2": "impairment of learning and memory", "span1": [54, 64], "span2": [107, 140]}, "bert_text": "The present study was designed to investigate whether <e1> nociceptin </e1>/orphanin FQ and nocistatin could modulate <e2> impairment of learning and memory </e2> induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2303": {"data": {"text": "The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice.", "entity1": "orphanin FQ", "entity2": "impairment of learning and memory", "span1": [65, 76], "span2": [107, 140]}, "bert_text": "The present study was designed to investigate whether nociceptin/<e1> orphanin FQ </e1> and nocistatin could modulate <e2> impairment of learning and memory </e2> induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2304": {"data": {"text": "The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice.", "entity1": "nocistatin", "entity2": "impairment of learning and memory", "span1": [81, 91], "span2": [107, 140]}, "bert_text": "The present study was designed to investigate whether nociceptin/orphanin FQ and <e1> nocistatin </e1> could modulate <e2> impairment of learning and memory </e2> induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2305": {"data": {"text": "The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice.", "entity1": "scopolamine", "entity2": "impairment of learning and memory", "span1": [152, 163], "span2": [107, 140]}, "bert_text": "The present study was designed to investigate whether nociceptin/orphanin FQ and nocistatin could modulate impairment of learning and memory induced by <e1> scopolamine </e1> <e2> impairment of learning and memory </e2> induced by scopolamine, a muscarinic cholinergic receptor antagonist, using spontaneous alternation of Y-maze and step-down type passive avoidance tasks in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2306": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "morphine", "entity2": "pain", "span1": [54, 62], "span2": [229, 233]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of <e1> morphine </e1> and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat <e2> pain </e2> models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2307": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "morphine", "entity2": "inflammation", "span1": [54, 62], "span2": [266, 278]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of <e1> morphine </e1> and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw <e2> inflammation </e2> and streptozotocin (STZ)-induced diabetic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2308": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "morphine", "entity2": "diabetic neuropathy", "span1": [54, 62], "span2": [312, 331]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of <e1> morphine </e1> and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced <e2> diabetic neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2309": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "CNSB002", "entity2": "pain", "span1": [67, 74], "span2": [229, 233]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and <e1> CNSB002 </e1> given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat <e2> pain </e2> models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2310": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "CNSB002", "entity2": "inflammation", "span1": [67, 74], "span2": [266, 278]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and <e1> CNSB002 </e1> given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw <e2> inflammation </e2> and streptozotocin (STZ)-induced diabetic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2311": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "CNSB002", "entity2": "diabetic neuropathy", "span1": [67, 74], "span2": [312, 331]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and <e1> CNSB002 </e1> given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced <e2> diabetic neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2312": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "carrageenan", "entity2": "pain", "span1": [242, 253], "span2": [229, 233]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: <e1> carrageenan </e1> <e2> pain </e2> models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2313": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "carrageenan", "entity2": "inflammation", "span1": [242, 253], "span2": [266, 278]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: <e1> carrageenan </e1>-induced paw <e2> inflammation </e2> and streptozotocin (STZ)-induced diabetic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2314": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "carrageenan", "entity2": "diabetic neuropathy", "span1": [242, 253], "span2": [312, 331]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: <e1> carrageenan </e1>-induced paw inflammation and streptozotocin (STZ)-induced <e2> diabetic neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2315": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "streptozotocin", "entity2": "pain", "span1": [283, 297], "span2": [229, 233]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and <e1> streptozotocin </e1> <e2> pain </e2> models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2316": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "streptozotocin", "entity2": "inflammation", "span1": [283, 297], "span2": [266, 278]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and <e1> streptozotocin </e1> <e2> inflammation </e2> and streptozotocin (STZ)-induced diabetic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2317": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "streptozotocin", "entity2": "diabetic neuropathy", "span1": [283, 297], "span2": [312, 331]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and <e1> streptozotocin </e1> (STZ)-induced <e2> diabetic neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2318": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "STZ)-induced", "entity2": "pain", "span1": [299, 311], "span2": [229, 233]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (<e1> STZ)-induced </e1> <e2> pain </e2> models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2319": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "STZ)-induced", "entity2": "inflammation", "span1": [299, 311], "span2": [266, 278]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (<e1> STZ)-induced </e1> <e2> inflammation </e2> and streptozotocin (STZ)-induced diabetic neuropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2320": {"data": {"text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (STZ)-induced diabetic neuropathy.", "entity1": "STZ)-induced", "entity2": "diabetic neuropathy", "span1": [299, 311], "span2": [312, 331]}, "bert_text": "DESIGN: Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models: carrageenan-induced paw inflammation and streptozotocin (<e1> STZ)-induced </e1> <e2> diabetic neuropathy </e2>.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2321": {"data": {"text": "Pre-treatment with a dose of 30 mg/kg 2h before picrotoxin microperfusion prevented seizures in the 75% of the rats.", "entity1": "picrotoxin", "entity2": "seizures", "span1": [48, 58], "span2": [84, 92]}, "bert_text": "Pre-treatment with a dose of 30 mg/kg 2h before <e1> picrotoxin </e1> microperfusion prevented <e2> seizures </e2> in the 75% of the rats.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2322": {"data": {"text": "Children are particularly sensitive to DOX-induced heart failure.", "entity1": "DOX", "entity2": "heart failure", "span1": [39, 42], "span2": [51, 64]}, "bert_text": "Children are particularly sensitive to <e1> DOX </e1>-induced <e2> heart failure </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2323": {"data": {"text": "These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "entity1": "DMTU", "entity2": "nephropathy", "span1": [43, 47], "span2": [87, 98]}, "bert_text": "These results suggest that 1) both SOD and <e1> DMTU </e1> have protective effects on GM-mediated <e2> nephropathy </e2>, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2324": {"data": {"text": "These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "entity1": "DMTU", "entity2": "nephropathy", "span1": [164, 168], "span2": [87, 98]}, "bert_text": "These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and <e1> DMTU </e1> <e2> nephropathy </e2>, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2325": {"data": {"text": "These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "entity1": "GM", "entity2": "nephropathy", "span1": [75, 77], "span2": [87, 98]}, "bert_text": "These results suggest that 1) both SOD and DMTU have protective effects on <e1> GM </e1>-mediated <e2> nephropathy </e2>, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2326": {"data": {"text": "These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "entity1": "GM", "entity2": "nephropathy", "span1": [219, 221], "span2": [87, 98]}, "bert_text": "These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in <e1> GM </e1> <e2> nephropathy </e2>, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2327": {"data": {"text": "These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "entity1": "superoxide", "entity2": "nephropathy", "span1": [177, 187], "span2": [87, 98]}, "bert_text": "These results suggest that 1) both SOD and DMTU have protective effects on GM-mediated nephropathy, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) <e1> superoxide </e1> <e2> nephropathy </e2>, 2) the mechanisms for the protective effects differ for SOD and DMTU, and 3) superoxide anions play a critical role in GM-induced renal vasoconstriction.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2328": {"data": {"text": "Similarly, ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats (76 +/-", "entity1": "hexamethonium", "entity2": "hypertensive", "span1": [36, 49], "span2": [94, 106]}, "bert_text": "Similarly, ganglionic blockade with <e1> hexamethonium </e1> caused a significantly greater fall in LNNA <e2> hypertensive </e2> rats (76 +/-", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2329": {"data": {"text": "The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological malignancies.", "entity1": "thalidomide", "entity2": "haematological malignancies", "span1": [30, 41], "span2": [115, 142]}, "bert_text": "The antiangiogenic effects of <e1> thalidomide </e1> have been assessed in clinical trials in patients with various solid and <e2> haematological malignancies </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2330": {"data": {"text": "Apart from this cytostatic effect, temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression.", "entity1": "temsirolimus", "entity2": "tumor", "span1": [35, 47], "span2": [94, 99]}, "bert_text": "Apart from this cytostatic effect, <e1> temsirolimus </e1> had an antiangiogenic effect with decrease of <e2> tumor </e2> microvessel density and of VEGF expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2331": {"data": {"text": "STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.", "entity1": "STZ", "entity2": "synaptic neurotoxicity", "span1": [0, 3], "span2": [200, 222]}, "bert_text": "<e1> STZ </e1> treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post <e2> synaptic neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2332": {"data": {"text": "STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.", "entity1": "CaMKIIa", "entity2": "synaptic neurotoxicity", "span1": [66, 73], "span2": [200, 222]}, "bert_text": "STZ treatment showed decrease expression of post synaptic markers <e1> CaMKIIa </e1> and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post <e2> synaptic neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2333": {"data": {"text": "STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (synaptophysin and SNAP-25) remains unaltered indicating selective post synaptic neurotoxicity.", "entity1": "synaptophysin", "entity2": "synaptic neurotoxicity", "span1": [129, 142], "span2": [200, 222]}, "bert_text": "STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD-95, while, expression of pre synaptic markers (<e1> synaptophysin </e1> and SNAP-25) remains unaltered indicating selective post <e2> synaptic neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2334": {"data": {"text": "In this patient the time relation between the ingestion of diphenylhydantoin and the occurrence of the skin rash, lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection.", "entity1": "diphenylhydantoin", "entity2": "skin rash", "span1": [59, 76], "span2": [103, 112]}, "bert_text": "In this patient the time relation between the ingestion of <e1> diphenylhydantoin </e1> and the occurrence of the <e2> skin rash </e2>, lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2335": {"data": {"text": "In this patient the time relation between the ingestion of diphenylhydantoin and the occurrence of the skin rash, lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection.", "entity1": "diphenylhydantoin", "entity2": "lymphadenopathy", "span1": [59, 76], "span2": [114, 129]}, "bert_text": "In this patient the time relation between the ingestion of <e1> diphenylhydantoin </e1> and the occurrence of the skin rash, <e2> lymphadenopathy </e2> and pure red cell aplasia is very suggestive of a direct connection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2336": {"data": {"text": "In this patient the time relation between the ingestion of diphenylhydantoin and the occurrence of the skin rash, lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection.", "entity1": "diphenylhydantoin", "entity2": "pure red cell aplasia", "span1": [59, 76], "span2": [134, 155]}, "bert_text": "In this patient the time relation between the ingestion of <e1> diphenylhydantoin </e1> and the occurrence of the skin rash, lymphadenopathy and <e2> pure red cell aplasia </e2> is very suggestive of a direct connection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2337": {"data": {"text": "Neuropathy may thus be a common complication of thalidomide in older patients.", "entity1": "thalidomide", "entity2": "Neuropathy", "span1": [48, 59], "span2": [0, 10]}, "bert_text": "Neuropathy may thus be a common complication of <e1> thalidomide </e1> <e2> Neuropathy </e2> may thus be a common complication of thalidomide in older patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2338": {"data": {"text": "The age-related decrease in hypothalamic dopamine function may be associated with increases in PRL secretion.", "entity1": "dopamine", "entity2": "hypothalamic", "span1": [41, 49], "span2": [28, 40]}, "bert_text": "The age-related decrease in hypothalamic <e1> dopamine </e1> <e2> hypothalamic </e2> dopamine function may be associated with increases in PRL secretion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2339": {"data": {"text": "As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.", "entity1": "5-FU", "entity2": "pain", "span1": [74, 78], "span2": [18, 22]}, "bert_text": "As the precordial pain in this patient was considered to have been due to <e1> 5-FU </e1> <e2> pain </e2> in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2340": {"data": {"text": "As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.", "entity1": "5-FU", "entity2": "cardiotoxicity", "span1": [74, 78], "span2": [87, 101]}, "bert_text": "As the precordial pain in this patient was considered to have been due to <e1> 5-FU </e1>-induced <e2> cardiotoxicity </e2>, the administration of 5-FU was abandoned.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2341": {"data": {"text": "As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.", "entity1": "5-FU", "entity2": "pain", "span1": [125, 129], "span2": [18, 22]}, "bert_text": "As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of <e1> 5-FU </e1> <e2> pain </e2> in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2342": {"data": {"text": "As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned.", "entity1": "5-FU", "entity2": "cardiotoxicity", "span1": [125, 129], "span2": [87, 101]}, "bert_text": "As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of <e1> 5-FU </e1> <e2> cardiotoxicity </e2>, the administration of 5-FU was abandoned.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2343": {"data": {"text": "An investigation of the pattern of kidney injury in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).\n", "entity1": "tenofovir disoproxil fumarate", "entity2": "kidney injury", "span1": [84, 113], "span2": [35, 48]}, "bert_text": "An investigation of the pattern of kidney injury in HIV-positive persons exposed to <e1> tenofovir disoproxil fumarate </e1> <e2> kidney injury </e2> in HIV-positive persons exposed to tenofovir disoproxil fumarate: an examination of a large population database (MHRA database).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2344": {"data": {"text": "Mechanisms for protective effects of free radical scavengers on gentamicin-mediated nephropathy in rats.\n", "entity1": "gentamicin", "entity2": "nephropathy", "span1": [64, 74], "span2": [84, 95]}, "bert_text": "Mechanisms for protective effects of free radical scavengers on <e1> gentamicin </e1>-mediated <e2> nephropathy </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2345": {"data": {"text": "Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of lorazepam.", "entity1": "lorazepam", "entity2": "myoclonus", "span1": [118, 127], "span2": [64, 73]}, "bert_text": "Three young infants, all of birth weight < 1,500 g, experienced myoclonus following the intravenous administration of <e1> lorazepam </e1> <e2> myoclonus </e2> following the intravenous administration of lorazepam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2346": {"data": {"text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "entity1": "naloxone", "entity2": "pain", "span1": [89, 97], "span2": [58, 62]}, "bert_text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training <e1> naloxone </e1> <e2> pain </e2> sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2347": {"data": {"text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "entity1": "naloxone", "entity2": "retention deficit", "span1": [89, 97], "span2": [236, 253]}, "bert_text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training <e1> naloxone </e1>) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced <e2> retention deficit </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2348": {"data": {"text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "entity1": "naloxone", "entity2": "pain", "span1": [144, 152], "span2": [58, 62]}, "bert_text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training <e1> naloxone </e1> <e2> pain </e2> sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2349": {"data": {"text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "entity1": "naloxone", "entity2": "retention deficit", "span1": [144, 152], "span2": [236, 253]}, "bert_text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training <e1> naloxone </e1>) appear to be responsible for the influence of naloxone on the scopolamine-induced <e2> retention deficit </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2350": {"data": {"text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "entity1": "naloxone", "entity2": "pain", "span1": [200, 208], "span2": [58, 62]}, "bert_text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of <e1> naloxone </e1> <e2> pain </e2> sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2351": {"data": {"text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "entity1": "naloxone", "entity2": "retention deficit", "span1": [200, 208], "span2": [236, 253]}, "bert_text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of <e1> naloxone </e1> on the scopolamine-induced <e2> retention deficit </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2352": {"data": {"text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "entity1": "scopolamine", "entity2": "pain", "span1": [216, 227], "span2": [58, 62]}, "bert_text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the <e1> scopolamine </e1> <e2> pain </e2> sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2353": {"data": {"text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the scopolamine-induced retention deficit.", "entity1": "scopolamine", "entity2": "retention deficit", "span1": [216, 227], "span2": [236, 253]}, "bert_text": "Control experiments indicated that neither an increase in pain sensitivity (pre-training naloxone) nor an induced aversive state (post-training naloxone) appear to be responsible for the influence of naloxone on the <e1> scopolamine </e1>-induced <e2> retention deficit </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2354": {"data": {"text": "Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses.", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [16, 32], "span2": [41, 49]}, "bert_text": "Fully developed <e1> cyclophosphamide </e1>-induced <e2> cystitis </e2> is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2355": {"data": {"text": "Fully developed cyclophosphamide-induced cystitis is characterized by nearly complete detachment of the urothelium, severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses.", "entity1": "cyclophosphamide", "entity2": "submucosal edema", "span1": [16, 32], "span2": [123, 139]}, "bert_text": "Fully developed <e1> cyclophosphamide </e1>-induced cystitis is characterized by nearly complete detachment of the urothelium, severe <e2> submucosal edema </e2> owing to damage to the microvascular bed and focal muscle necroses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2356": {"data": {"text": "PARTICIPANTS: Patients with cocaine-associated MI who received lidocaine in the emergency department", "entity1": "cocaine", "entity2": "MI", "span1": [28, 35], "span2": [47, 49]}, "bert_text": "PARTICIPANTS: Patients with <e1> cocaine </e1>-associated <e2> MI </e2> who received lidocaine in the emergency department", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2357": {"data": {"text": "PARTICIPANTS: Patients with cocaine-associated MI who received lidocaine in the emergency department", "entity1": "lidocaine", "entity2": "MI", "span1": [63, 72], "span2": [47, 49]}, "bert_text": "PARTICIPANTS: Patients with cocaine-associated MI who received <e1> lidocaine </e1> <e2> MI </e2> who received lidocaine in the emergency department", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2358": {"data": {"text": "The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside-induced ototoxicity.", "entity1": "superoxide", "entity2": "ototoxicity", "span1": [36, 46], "span2": [152, 163]}, "bert_text": "The protection by overexpression of <e1> superoxide </e1> dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside-induced <e2> ototoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2359": {"data": {"text": "The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside-induced ototoxicity.", "entity1": "aminoglycoside", "entity2": "ototoxicity", "span1": [129, 143], "span2": [152, 163]}, "bert_text": "The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in <e1> aminoglycoside </e1>-induced <e2> ototoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2360": {"data": {"text": "OBJECTIVE: To assess whether prednisone (PDN) produces anxiety and/or cerebral glial changes in rats.", "entity1": "prednisone", "entity2": "anxiety", "span1": [29, 39], "span2": [55, 62]}, "bert_text": "OBJECTIVE: To assess whether <e1> prednisone </e1> (PDN) produces <e2> anxiety </e2> and/or cerebral glial changes in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2361": {"data": {"text": "OBJECTIVE: To assess whether prednisone (PDN) produces anxiety and/or cerebral glial changes in rats.", "entity1": "PDN", "entity2": "anxiety", "span1": [41, 44], "span2": [55, 62]}, "bert_text": "OBJECTIVE: To assess whether prednisone (<e1> PDN </e1>) produces <e2> anxiety </e2> and/or cerebral glial changes in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2362": {"data": {"text": "Mesna significantly reduces IFO's genotoxicity, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.", "entity1": "Mesna", "entity2": "genotoxicity", "span1": [0, 5], "span2": [34, 46]}, "bert_text": "<e1> Mesna </e1> significantly reduces IFO's <e2> genotoxicity </e2>, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2363": {"data": {"text": "Mesna significantly reduces IFO's genotoxicity, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.", "entity1": "IFO's", "entity2": "genotoxicity", "span1": [28, 33], "span2": [34, 46]}, "bert_text": "Mesna significantly reduces <e1> IFO's </e1> <e2> genotoxicity </e2>, while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2364": {"data": {"text": "Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.\n", "entity1": "Cocaine", "entity2": "cocaethylene cardiotoxity", "span1": [0, 7], "span2": [22, 47]}, "bert_text": "<e1> Cocaine </e1>, ethanol, and <e2> cocaethylene cardiotoxity </e2> in an animal model of cocaine and ethanol abuse.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2365": {"data": {"text": "Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.\n", "entity1": "cocaine", "entity2": "cocaethylene cardiotoxity", "span1": [70, 77], "span2": [22, 47]}, "bert_text": "Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of <e1> cocaine </e1> <e2> cocaethylene cardiotoxity </e2> in an animal model of cocaine and ethanol abuse.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2366": {"data": {"text": "Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.\n", "entity1": "ethanol", "entity2": "cocaethylene cardiotoxity", "span1": [9, 16], "span2": [22, 47]}, "bert_text": "Cocaine, <e1> ethanol </e1>, and <e2> cocaethylene cardiotoxity </e2> in an animal model of cocaine and ethanol abuse.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2367": {"data": {"text": "Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse.\n", "entity1": "ethanol", "entity2": "cocaethylene cardiotoxity", "span1": [82, 89], "span2": [22, 47]}, "bert_text": "Cocaine, ethanol, and cocaethylene cardiotoxity in an animal model of cocaine and <e1> ethanol </e1> <e2> cocaethylene cardiotoxity </e2> in an animal model of cocaine and ethanol abuse.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2368": {"data": {"text": "Cortical maps revealed severe gray-matter deficits in the cingulate, limbic, and paralimbic cortices of MA abusers (averaging 11.3% below control; p < 0.05).", "entity1": "MA", "entity2": "gray-matter deficits", "span1": [104, 106], "span2": [30, 50]}, "bert_text": "Cortical maps revealed severe gray-matter deficits in the cingulate, limbic, and paralimbic cortices of <e1> MA </e1> <e2> gray-matter deficits </e2> in the cingulate, limbic, and paralimbic cortices of MA abusers (averaging 11.3% below control; p < 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2369": {"data": {"text": "METHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs.", "entity1": "N", "entity2": "hypersensitivity", "span1": [62, 63], "span2": [36, 52]}, "bert_text": "METHODS: We studied 9 patients with hypersensitivity to P and <e1> N </e1> <e2> hypersensitivity </e2> to P and N with or without associated reactions to classic NSAIDs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2370": {"data": {"text": "Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to zolmitriptan, but none of the cases were associated with TS.", "entity1": "zolmitriptan", "entity2": "coronary artery vasospasm", "span1": [94, 106], "span2": [55, 80]}, "bert_text": "Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to <e1> zolmitriptan </e1> <e2> coronary artery vasospasm </e2> secondary to zolmitriptan, but none of the cases were associated with TS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2371": {"data": {"text": "Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to zolmitriptan, but none of the cases were associated with TS.", "entity1": "zolmitriptan", "entity2": "TS", "span1": [94, 106], "span2": [151, 153]}, "bert_text": "Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to <e1> zolmitriptan </e1>, but none of the cases were associated with <e2> TS </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2372": {"data": {"text": "Levodopa-induced ocular dyskinesias are very uncommon.", "entity1": "Levodopa", "entity2": "ocular dyskinesias", "span1": [0, 8], "span2": [17, 35]}, "bert_text": "<e1> Levodopa </e1>-induced <e2> ocular dyskinesias </e2> are very uncommon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2373": {"data": {"text": "Vasovagal syncope and severe bradycardia following intranasal dexmedetomidine for pediatric procedural sedation.\n", "entity1": "dexmedetomidine", "entity2": "Vasovagal syncope", "span1": [62, 77], "span2": [0, 17]}, "bert_text": "Vasovagal syncope and severe bradycardia following intranasal <e1> dexmedetomidine </e1> <e2> Vasovagal syncope </e2> and severe bradycardia following intranasal dexmedetomidine for pediatric procedural sedation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2374": {"data": {"text": "Vasovagal syncope and severe bradycardia following intranasal dexmedetomidine for pediatric procedural sedation.\n", "entity1": "dexmedetomidine", "entity2": "bradycardia", "span1": [62, 77], "span2": [29, 40]}, "bert_text": "Vasovagal syncope and severe bradycardia following intranasal <e1> dexmedetomidine </e1> <e2> bradycardia </e2> following intranasal dexmedetomidine for pediatric procedural sedation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2375": {"data": {"text": "We therefore hypothesized that overexpression of Cu/Zn-superoxide dismutase (h-SOD1) should protect transgenic mice from ototoxicity.", "entity1": "Zn-superoxide", "entity2": "ototoxicity", "span1": [52, 65], "span2": [121, 132]}, "bert_text": "We therefore hypothesized that overexpression of Cu/<e1> Zn-superoxide </e1> dismutase (h-SOD1) should protect transgenic mice from <e2> ototoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2376": {"data": {"text": "Large doses of the cholinomimetic, pilocarpine, could induce catalepsy when peripheral cholinergic receptors were blocked.", "entity1": "pilocarpine", "entity2": "catalepsy", "span1": [35, 46], "span2": [61, 70]}, "bert_text": "Large doses of the cholinomimetic, <e1> pilocarpine </e1>, could induce <e2> catalepsy </e2> when peripheral cholinergic receptors were blocked.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2377": {"data": {"text": "Soon after the introduction of ACE inhibitors, acute bouts of angio-oedema were reported in association with the use of these drugs.", "entity1": "ACE inhibitors", "entity2": "angio-oedema", "span1": [31, 45], "span2": [62, 74]}, "bert_text": "Soon after the introduction of <e1> ACE inhibitors </e1>, acute bouts of <e2> angio-oedema </e2> were reported in association with the use of these drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2378": {"data": {"text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "entity1": "warfarin", "entity2": "ICH", "span1": [288, 296], "span2": [38, 41]}, "bert_text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in <e1> warfarin </e1> <e2> ICH </e2> and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2379": {"data": {"text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "entity1": "warfarin", "entity2": "ICH", "span1": [288, 296], "span2": [84, 87]}, "bert_text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in <e1> warfarin </e1> <e2> ICH </e2> vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2380": {"data": {"text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "entity1": "warfarin", "entity2": "IS", "span1": [288, 296], "span2": [51, 53]}, "bert_text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in <e1> warfarin </e1> <e2> IS </e2>/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2381": {"data": {"text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "entity1": "warfarin", "entity2": "IS", "span1": [288, 296], "span2": [91, 93]}, "bert_text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in <e1> warfarin </e1> <e2> IS </e2>/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2382": {"data": {"text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "entity1": "warfarin", "entity2": "TIA", "span1": [288, 296], "span2": [54, 57]}, "bert_text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in <e1> warfarin </e1> <e2> TIA </e2>, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2383": {"data": {"text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "entity1": "warfarin", "entity2": "TIA", "span1": [288, 296], "span2": [94, 97]}, "bert_text": "RESULTS: In a pooled analysis of 1460 ICH and 3817 IS/TIA, MB were more frequent in ICH vs IS/TIA in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in <e1> warfarin </e1> <e2> TIA </e2> in all treatment groups, but the excess increased from 2.8 (odds ratio; range, 2.3-3.5) in nonantithrombotic users to 5.7 (range, 3.4-9.7) in antiplatelet users and 8.0 (range, 3.5-17.8) in warfarin users (P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2384": {"data": {"text": "Similar to the remnant kidney model in PAN nephrosis the development of glomerular sclerosis may be related to \"mesangial overloading.\"", "entity1": "PAN", "entity2": "nephrosis", "span1": [39, 42], "span2": [43, 52]}, "bert_text": "Similar to the remnant kidney model in <e1> PAN </e1> <e2> nephrosis </e2> the development of glomerular sclerosis may be related to \"mesangial overloading.\"", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2385": {"data": {"text": "Similar to the remnant kidney model in PAN nephrosis the development of glomerular sclerosis may be related to \"mesangial overloading.\"", "entity1": "PAN", "entity2": "glomerular sclerosis", "span1": [39, 42], "span2": [72, 92]}, "bert_text": "Similar to the remnant kidney model in <e1> PAN </e1> nephrosis the development of <e2> glomerular sclerosis </e2> may be related to \"mesangial overloading.\"", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2386": {"data": {"text": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in quinine toxicity, to our knowledge, have not been previously reported.", "entity1": "quinine", "entity2": "toxicity", "span1": [109, 116], "span2": [117, 125]}, "bert_text": "A transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials in <e1> quinine </e1> <e2> toxicity </e2>, to our knowledge, have not been previously reported.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2387": {"data": {"text": "Long-term lithium therapy leading to hyperparathyroidism: a case report.\n", "entity1": "lithium", "entity2": "hyperparathyroidism", "span1": [10, 17], "span2": [37, 56]}, "bert_text": "Long-term <e1> lithium </e1> therapy leading to <e2> hyperparathyroidism </e2>: a case report.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2388": {"data": {"text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "entity1": "aspirin", "entity2": "GI", "span1": [19, 26], "span2": [108, 110]}, "bert_text": "Among non-users of <e1> aspirin </e1>, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/<e2> GI </e2> vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2389": {"data": {"text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "entity1": "aspirin", "entity2": "GI", "span1": [141, 148], "span2": [108, 110]}, "bert_text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no <e1> aspirin </e1> <e2> GI </e2> vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2390": {"data": {"text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "entity1": "AMI", "entity2": "GI", "span1": [104, 107], "span2": [108, 110]}, "bert_text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for <e1> AMI </e1>/<e2> GI </e2> vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2391": {"data": {"text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "entity1": "acetaminophen", "entity2": "GI", "span1": [118, 131], "span2": [108, 110]}, "bert_text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the <e1> acetaminophen </e1> <e2> GI </e2> vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2392": {"data": {"text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "entity1": "rofecoxib", "entity2": "GI", "span1": [162, 171], "span2": [108, 110]}, "bert_text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: <e1> rofecoxib </e1> <e2> GI </e2> vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2393": {"data": {"text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "entity1": "celecoxib", "entity2": "GI", "span1": [191, 200], "span2": [108, 110]}, "bert_text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), <e1> celecoxib </e1> <e2> GI </e2> vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2394": {"data": {"text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "entity1": "naproxen", "entity2": "GI", "span1": [220, 228], "span2": [108, 110]}, "bert_text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), <e1> naproxen </e1> <e2> GI </e2> vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2395": {"data": {"text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "entity1": "diclofenac", "entity2": "GI", "span1": [248, 258], "span2": [108, 110]}, "bert_text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), <e1> diclofenac </e1> <e2> GI </e2> vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2396": {"data": {"text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "entity1": "ibuprofen", "entity2": "GI", "span1": [281, 290], "span2": [108, 110]}, "bert_text": "Among non-users of aspirin, the adjusted hazard ratios (95% confidence interval) of hospitalization for AMI/GI vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and <e1> ibuprofen </e1> <e2> GI </e2> vs the acetaminophen (with no aspirin) group were: rofecoxib 1.27 (1.13, 1.42), celecoxib 0.93 (0.83, 1.03), naproxen 1.59 (1.31, 1.93), diclofenac 1.17 (0.99, 1.38) and ibuprofen 1.05 (0.74, 1.51).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2397": {"data": {"text": "During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects.", "entity1": "penicillamine", "entity2": "lichenoid dermatitis", "span1": [37, 50], "span2": [93, 113]}, "bert_text": "During the follow-up of our patient, <e1> penicillamine </e1> was interrupted after the appearance of a <e2> lichenoid dermatitis </e2>, and zinc acetate permitted to continue the successful treatment of the patient without side-effects.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2398": {"data": {"text": "During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted to continue the successful treatment of the patient without side-effects.", "entity1": "zinc acetate", "entity2": "lichenoid dermatitis", "span1": [119, 131], "span2": [93, 113]}, "bert_text": "During the follow-up of our patient, penicillamine was interrupted after the appearance of a lichenoid dermatitis, and <e1> zinc acetate </e1> <e2> lichenoid dermatitis </e2>, and zinc acetate permitted to continue the successful treatment of the patient without side-effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2399": {"data": {"text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "entity1": "Fungizone", "entity2": "toxicity", "span1": [48, 57], "span2": [16, 24]}, "bert_text": "We compared the toxicity of NS-718 with that of <e1> Fungizone </e1> <e2> toxicity </e2> of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2400": {"data": {"text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "entity1": "Fungizone", "entity2": "NS-718", "span1": [48, 57], "span2": [28, 34]}, "bert_text": "We compared the toxicity of NS-718 with that of <e1> Fungizone </e1> <e2> NS-718 </e2> with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2401": {"data": {"text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "entity1": "D-AmB", "entity2": "toxicity", "span1": [95, 100], "span2": [16, 24]}, "bert_text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; <e1> D-AmB </e1> <e2> toxicity </e2> of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2402": {"data": {"text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "entity1": "D-AmB", "entity2": "NS-718", "span1": [95, 100], "span2": [28, 34]}, "bert_text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; <e1> D-AmB </e1> <e2> NS-718 </e2> with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2403": {"data": {"text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "entity1": "amphotericin B", "entity2": "toxicity", "span1": [241, 255], "span2": [16, 24]}, "bert_text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of <e1> amphotericin B </e1> <e2> toxicity </e2> of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2404": {"data": {"text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "entity1": "amphotericin B", "entity2": "NS-718", "span1": [241, 255], "span2": [28, 34]}, "bert_text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of <e1> amphotericin B </e1> <e2> NS-718 </e2> with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2405": {"data": {"text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "entity1": "amphotericin B-sodium deoxycholate", "entity2": "toxicity", "span1": [59, 93], "span2": [16, 24]}, "bert_text": "We compared the toxicity of NS-718 with that of Fungizone (<e1> amphotericin B-sodium deoxycholate </e1> <e2> toxicity </e2> of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2406": {"data": {"text": "We compared the toxicity of NS-718 with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "entity1": "amphotericin B-sodium deoxycholate", "entity2": "NS-718", "span1": [59, 93], "span2": [28, 34]}, "bert_text": "We compared the toxicity of NS-718 with that of Fungizone (<e1> amphotericin B-sodium deoxycholate </e1> <e2> NS-718 </e2> with that of Fungizone (amphotericin B-sodium deoxycholate; D-AmB) in vitro using renal cell cultures and in vivo by biochemical analysis, histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2407": {"data": {"text": "Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.\n", "entity1": "calcium", "entity2": "myocardial ischemia", "span1": [17, 24], "span2": [70, 89]}, "bert_text": "Effects of a new <e1> calcium </e1> antagonist, CD-832, on isoproterenol-induced <e2> myocardial ischemia </e2> in dogs with partial coronary stenosis.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2408": {"data": {"text": "Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.\n", "entity1": "calcium", "entity2": "coronary stenosis", "span1": [17, 24], "span2": [111, 128]}, "bert_text": "Effects of a new <e1> calcium </e1> antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial <e2> coronary stenosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2409": {"data": {"text": "Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.\n", "entity1": "isoproterenol", "entity2": "myocardial ischemia", "span1": [48, 61], "span2": [70, 89]}, "bert_text": "Effects of a new calcium antagonist, CD-832, on <e1> isoproterenol </e1>-induced <e2> myocardial ischemia </e2> in dogs with partial coronary stenosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2410": {"data": {"text": "Effects of a new calcium antagonist, CD-832, on isoproterenol-induced myocardial ischemia in dogs with partial coronary stenosis.\n", "entity1": "isoproterenol", "entity2": "coronary stenosis", "span1": [48, 61], "span2": [111, 128]}, "bert_text": "Effects of a new calcium antagonist, CD-832, on <e1> isoproterenol </e1>-induced myocardial ischemia in dogs with partial <e2> coronary stenosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2411": {"data": {"text": "Men have an increased risk for hemorrhagic strokes with aspirin use.", "entity1": "aspirin", "entity2": "hemorrhagic strokes", "span1": [56, 63], "span2": [31, 50]}, "bert_text": "Men have an increased risk for hemorrhagic strokes with <e1> aspirin </e1> <e2> hemorrhagic strokes </e2> with aspirin use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2412": {"data": {"text": "LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex-induced hypertension.", "entity1": "Dex", "entity2": "LF", "span1": [65, 68], "span2": [0, 2]}, "bert_text": "LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) <e1> Dex </e1> <e2> LF </e2> lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex-induced hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2413": {"data": {"text": "LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) Dex-induced hypertension.", "entity1": "Dex", "entity2": "hypertension", "span1": [65, 68], "span2": [77, 89]}, "bert_text": "LF lowered (P < 0.01) and dose dependently prevented (P < 0.001) <e1> Dex </e1>-induced <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2414": {"data": {"text": "Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters.", "entity1": "diethylstilbesterol", "entity2": "renal carcinomas", "span1": [99, 118], "span2": [127, 143]}, "bert_text": "Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary <e1> diethylstilbesterol </e1> induced <e2> renal carcinomas </e2> in three hamsters.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2415": {"data": {"text": "In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM.", "entity1": "bortezomib", "entity2": "MM", "span1": [93, 103], "span2": [212, 214]}, "bert_text": "In this study, we retrospectively analyzed the safety and efficacy of combination regimen of <e1> bortezomib </e1>, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed <e2> MM </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2416": {"data": {"text": "In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM.", "entity1": "thalidomide", "entity2": "MM", "span1": [105, 116], "span2": [212, 214]}, "bert_text": "In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, <e1> thalidomide </e1>, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed <e2> MM </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2417": {"data": {"text": "In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and dexamethasone (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed MM.", "entity1": "dexamethasone", "entity2": "MM", "span1": [122, 135], "span2": [212, 214]}, "bert_text": "In this study, we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib, thalidomide, and <e1> dexamethasone </e1> (VTD) as consolidation therapy in 24 Japanese patients with newly diagnosed <e2> MM </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2418": {"data": {"text": "We suggest that ecstasy-associated dysfunction in fronto-temporal circuitry may underlie overnight consolidation memory impairments in regular ecstasy users.", "entity1": "ecstasy", "entity2": "memory impairments", "span1": [16, 23], "span2": [113, 131]}, "bert_text": "We suggest that <e1> ecstasy </e1>-associated dysfunction in fronto-temporal circuitry may underlie overnight consolidation <e2> memory impairments </e2> in regular ecstasy users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2419": {"data": {"text": "We suggest that ecstasy-associated dysfunction in fronto-temporal circuitry may underlie overnight consolidation memory impairments in regular ecstasy users.", "entity1": "ecstasy", "entity2": "memory impairments", "span1": [143, 150], "span2": [113, 131]}, "bert_text": "We suggest that ecstasy-associated dysfunction in fronto-temporal circuitry may underlie overnight consolidation memory impairments in regular <e1> ecstasy </e1> <e2> memory impairments </e2> in regular ecstasy users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2420": {"data": {"text": "Patients with anxiety disorders may benefit by avoiding caffeine-containing foods and beverages.", "entity1": "caffeine", "entity2": "anxiety disorders", "span1": [56, 64], "span2": [14, 31]}, "bert_text": "Patients with anxiety disorders may benefit by avoiding <e1> caffeine </e1> <e2> anxiety disorders </e2> may benefit by avoiding caffeine-containing foods and beverages.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2421": {"data": {"text": "Salicylate nephropathy in the Gunn rat: potential role of prostaglandins.\n", "entity1": "Salicylate", "entity2": "nephropathy", "span1": [0, 10], "span2": [11, 22]}, "bert_text": "<e1> Salicylate </e1> <e2> nephropathy </e2> in the Gunn rat: potential role of prostaglandins.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2422": {"data": {"text": "Salicylate nephropathy in the Gunn rat: potential role of prostaglandins.\n", "entity1": "prostaglandins", "entity2": "nephropathy", "span1": [58, 72], "span2": [11, 22]}, "bert_text": "Salicylate nephropathy in the Gunn rat: potential role of <e1> prostaglandins </e1> <e2> nephropathy </e2> in the Gunn rat: potential role of prostaglandins.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2423": {"data": {"text": "Since bupivacaine and epinephrine may both precipitate dysrhythmias, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.", "entity1": "bupivacaine", "entity2": "dysrhythmias", "span1": [6, 17], "span2": [55, 67]}, "bert_text": "Since <e1> bupivacaine </e1> and epinephrine may both precipitate <e2> dysrhythmias </e2>, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2424": {"data": {"text": "Since bupivacaine and epinephrine may both precipitate dysrhythmias, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.", "entity1": "bupivacaine", "entity2": "dysrhythmias", "span1": [81, 92], "span2": [55, 67]}, "bert_text": "Since bupivacaine and epinephrine may both precipitate dysrhythmias, circulating <e1> bupivacaine </e1> <e2> dysrhythmias </e2>, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2425": {"data": {"text": "Since bupivacaine and epinephrine may both precipitate dysrhythmias, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.", "entity1": "epinephrine", "entity2": "dysrhythmias", "span1": [22, 33], "span2": [55, 67]}, "bert_text": "Since bupivacaine and <e1> epinephrine </e1> may both precipitate <e2> dysrhythmias </e2>, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2426": {"data": {"text": "Since bupivacaine and epinephrine may both precipitate dysrhythmias, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.", "entity1": "epinephrine", "entity2": "dysrhythmias", "span1": [164, 175], "span2": [55, 67]}, "bert_text": "Since bupivacaine and epinephrine may both precipitate dysrhythmias, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of <e1> epinephrine </e1> <e2> dysrhythmias </e2>, circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2427": {"data": {"text": "No panic attack was observed after the caffeine-free solution intake.", "entity1": "caffeine", "entity2": "panic", "span1": [39, 47], "span2": [3, 8]}, "bert_text": "No panic attack was observed after the <e1> caffeine </e1> <e2> panic </e2> attack was observed after the caffeine-free solution intake.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2428": {"data": {"text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "entity1": "acetaminophen", "entity2": "psychiatric disturbance", "span1": [117, 130], "span2": [42, 65]}, "bert_text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for <e1> acetaminophen </e1> <e2> psychiatric disturbance </e2>, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2429": {"data": {"text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "entity1": "acetaminophen", "entity2": "ALF", "span1": [117, 130], "span2": [139, 142]}, "bert_text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for <e1> acetaminophen </e1>-induced <e2> ALF </e2> were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2430": {"data": {"text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "entity1": "acetaminophen", "entity2": "ALF", "span1": [117, 130], "span2": [211, 214]}, "bert_text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for <e1> acetaminophen </e1>-induced ALF were comparable to those transplanted for non-acetaminophen-induced <e2> ALF </e2> and electively for CLD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2431": {"data": {"text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "entity1": "acetaminophen", "entity2": "CLD", "span1": [117, 130], "span2": [234, 237]}, "bert_text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for <e1> acetaminophen </e1>-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for <e2> CLD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2432": {"data": {"text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "entity1": "acetaminophen", "entity2": "psychiatric disturbance", "span1": [189, 202], "span2": [42, 65]}, "bert_text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-<e1> acetaminophen </e1> <e2> psychiatric disturbance </e2>, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2433": {"data": {"text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "entity1": "acetaminophen", "entity2": "ALF", "span1": [189, 202], "span2": [139, 142]}, "bert_text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-<e1> acetaminophen </e1> <e2> ALF </e2> were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2434": {"data": {"text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "entity1": "acetaminophen", "entity2": "ALF", "span1": [189, 202], "span2": [211, 214]}, "bert_text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-<e1> acetaminophen </e1>-induced <e2> ALF </e2> and electively for CLD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2435": {"data": {"text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-acetaminophen-induced ALF and electively for CLD.", "entity1": "acetaminophen", "entity2": "CLD", "span1": [189, 202], "span2": [234, 237]}, "bert_text": "CONCLUSIONS: Despite a high prevalence of psychiatric disturbance, outcomes for patients transplanted emergently for acetaminophen-induced ALF were comparable to those transplanted for non-<e1> acetaminophen </e1>-induced ALF and electively for <e2> CLD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2436": {"data": {"text": "Ethambutol and optic neuropathy.\n", "entity1": "Ethambutol", "entity2": "optic neuropathy", "span1": [0, 10], "span2": [15, 31]}, "bert_text": "<e1> Ethambutol </e1> and <e2> optic neuropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2437": {"data": {"text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "entity1": "methamphetamine", "entity2": "depressive disorder", "span1": [191, 206], "span2": [16, 35]}, "bert_text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy <e1> methamphetamine </e1> <e2> depressive disorder </e2> (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2438": {"data": {"text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "entity1": "methamphetamine", "entity2": "bipolar disorder", "span1": [191, 206], "span2": [67, 83]}, "bert_text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy <e1> methamphetamine </e1> <e2> bipolar disorder </e2> (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2439": {"data": {"text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "entity1": "methamphetamine", "entity2": "personality disorder", "span1": [191, 206], "span2": [128, 148]}, "bert_text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy <e1> methamphetamine </e1> <e2> personality disorder </e2> (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2440": {"data": {"text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [191, 206], "span2": [280, 289]}, "bert_text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy <e1> methamphetamine </e1> uses were significantly associated with lifetime methamphetamine-induced <e2> psychosis </e2> after adjusted for other factors.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2441": {"data": {"text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "entity1": "methamphetamine", "entity2": "depressive disorder", "span1": [256, 271], "span2": [16, 35]}, "bert_text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime <e1> methamphetamine </e1> <e2> depressive disorder </e2> (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2442": {"data": {"text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "entity1": "methamphetamine", "entity2": "bipolar disorder", "span1": [256, 271], "span2": [67, 83]}, "bert_text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime <e1> methamphetamine </e1> <e2> bipolar disorder </e2> (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2443": {"data": {"text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "entity1": "methamphetamine", "entity2": "personality disorder", "span1": [256, 271], "span2": [128, 148]}, "bert_text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime <e1> methamphetamine </e1> <e2> personality disorder </e2> (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2444": {"data": {"text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine-induced psychosis after adjusted for other factors.", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [256, 271], "span2": [280, 289]}, "bert_text": "Co-morbid major depressive disorder (OR=7.18, 95 CI=2.612-19.708), bipolar disorder (OR=13.807, 95 CI=5.194-36.706), antisocial personality disorder (OR=12.619, 95 CI=6.702-23.759) and heavy methamphetamine uses were significantly associated with lifetime <e1> methamphetamine </e1>-induced <e2> psychosis </e2> after adjusted for other factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2445": {"data": {"text": "Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension.", "entity1": "vasopressin", "entity2": "hypertension", "span1": [35, 46], "span2": [107, 119]}, "bert_text": "Furthermore, the pressor action of <e1> vasopressin </e1> appears to be important in the development of this model of <e2> hypertension </e2>, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2446": {"data": {"text": "Furthermore, the pressor action of vasopressin appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension.", "entity1": "vasopressin", "entity2": "hypertension", "span1": [35, 46], "span2": [215, 227]}, "bert_text": "Furthermore, the pressor action of <e1> vasopressin </e1> appears to be important in the development of this model of hypertension, since the enhanced pressor responsiveness to the hormone was observed in the initial stage of <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2447": {"data": {"text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "entity1": "nitroprusside", "entity2": "hypotension", "span1": [153, 166], "span2": [38, 49]}, "bert_text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that <e1> nitroprusside </e1> <e2> hypotension </e2> on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2448": {"data": {"text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "entity1": "nitroprusside", "entity2": "hypotension", "span1": [153, 166], "span2": [167, 178]}, "bert_text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that <e1> nitroprusside </e1> <e2> hypotension </e2> could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2449": {"data": {"text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "entity1": "nitroprusside", "entity2": "hypotension", "span1": [153, 166], "span2": [262, 273]}, "bert_text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that <e1> nitroprusside </e1> hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan <e2> hypotension </e2> to 20% mean blood pressure decrease.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2450": {"data": {"text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "entity1": "trimetaphan", "entity2": "hypotension", "span1": [250, 261], "span2": [38, 49]}, "bert_text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, <e1> trimetaphan </e1> <e2> hypotension </e2> on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2451": {"data": {"text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "entity1": "trimetaphan", "entity2": "hypotension", "span1": [250, 261], "span2": [167, 178]}, "bert_text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, <e1> trimetaphan </e1> <e2> hypotension </e2> could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2452": {"data": {"text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, trimetaphan hypotension to 20% mean blood pressure decrease.", "entity1": "trimetaphan", "entity2": "hypotension", "span1": [250, 261], "span2": [262, 273]}, "bert_text": "Regarding the effects of drug-induced hypotension on coronary blood flow, aortic and coronary sinus metabolic data (pH, pO2, pCO2) we could confirm that nitroprusside hypotension could be safely used to 30% mean blood pressure decrease from control, <e1> trimetaphan </e1> <e2> hypotension </e2> to 20% mean blood pressure decrease.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2453": {"data": {"text": "To best of our knowledge this is the second case of fatal carbamazepine induced myocarditis reported in English literature.", "entity1": "carbamazepine", "entity2": "myocarditis", "span1": [58, 71], "span2": [80, 91]}, "bert_text": "To best of our knowledge this is the second case of fatal <e1> carbamazepine </e1> induced <e2> myocarditis </e2> reported in English literature.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2454": {"data": {"text": "Carboplatin did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks.", "entity1": "Carboplatin", "entity2": "toxicities", "span1": [0, 11], "span2": [53, 63]}, "bert_text": "<e1> Carboplatin </e1> did not appear to add to the hematologic <e2> toxicities </e2> observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2455": {"data": {"text": "Carboplatin did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks.", "entity1": "carboplatin", "entity2": "toxicities", "span1": [93, 104], "span2": [53, 63]}, "bert_text": "Carboplatin did not appear to add to the hematologic toxicities observed, and the paclitaxel/<e1> carboplatin </e1> <e2> toxicities </e2> observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2456": {"data": {"text": "Carboplatin did not appear to add to the hematologic toxicities observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks.", "entity1": "paclitaxel", "entity2": "toxicities", "span1": [82, 92], "span2": [53, 63]}, "bert_text": "Carboplatin did not appear to add to the hematologic toxicities observed, and the <e1> paclitaxel </e1> <e2> toxicities </e2> observed, and the paclitaxel/carboplatin combination could be dosed every 3 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2457": {"data": {"text": "Absence of PKC-alpha attenuates lithium-induced nephrogenic diabetes insipidus.\n", "entity1": "lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [32, 39], "span2": [48, 78]}, "bert_text": "Absence of PKC-alpha attenuates <e1> lithium </e1>-induced <e2> nephrogenic diabetes insipidus </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2458": {"data": {"text": "PURPOSE: To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI).", "entity1": "CM", "entity2": "nephrotoxic", "span1": [64, 66], "span2": [42, 53]}, "bert_text": "PURPOSE: To compare the susceptibility to nephrotoxic effect of <e1> CM </e1> <e2> nephrotoxic </e2> effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2459": {"data": {"text": "PURPOSE: To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI).", "entity1": "PTRA", "entity2": "nephrotoxic", "span1": [90, 94], "span2": [42, 53]}, "bert_text": "PURPOSE: To compare the susceptibility to nephrotoxic effect of CM in patients undergoing <e1> PTRA </e1> <e2> nephrotoxic </e2> effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2460": {"data": {"text": "The 0.25 per cent CHP cream was closest to AgSD in pain tolerance; however, none of the treatments differed statistically from AgSD or from each other.", "entity1": "CHP cream", "entity2": "pain", "span1": [18, 27], "span2": [51, 55]}, "bert_text": "The 0.25 per cent <e1> CHP cream </e1> was closest to AgSD in <e2> pain </e2> tolerance; however, none of the treatments differed statistically from AgSD or from each other.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2461": {"data": {"text": "The 0.25 per cent CHP cream was closest to AgSD in pain tolerance; however, none of the treatments differed statistically from AgSD or from each other.", "entity1": "AgSD", "entity2": "pain", "span1": [43, 47], "span2": [51, 55]}, "bert_text": "The 0.25 per cent CHP cream was closest to <e1> AgSD </e1> in <e2> pain </e2> tolerance; however, none of the treatments differed statistically from AgSD or from each other.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2462": {"data": {"text": "The 0.25 per cent CHP cream was closest to AgSD in pain tolerance; however, none of the treatments differed statistically from AgSD or from each other.", "entity1": "AgSD", "entity2": "pain", "span1": [127, 131], "span2": [51, 55]}, "bert_text": "The 0.25 per cent CHP cream was closest to AgSD in pain tolerance; however, none of the treatments differed statistically from <e1> AgSD </e1> <e2> pain </e2> tolerance; however, none of the treatments differed statistically from AgSD or from each other.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2463": {"data": {"text": "CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.", "entity1": "CPA", "entity2": "Ischaemic coronary arteriosclerosis", "span1": [104, 107], "span2": [13, 48]}, "bert_text": "CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged <e1> CPA </e1> <e2> Ischaemic coronary arteriosclerosis </e2> with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2464": {"data": {"text": "CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.", "entity1": "cholesterol", "entity2": "Ischaemic coronary arteriosclerosis", "span1": [151, 162], "span2": [13, 48]}, "bert_text": "CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL <e1> cholesterol </e1> <e2> Ischaemic coronary arteriosclerosis </e2> with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2465": {"data": {"text": "CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.", "entity1": "estrogen", "entity2": "Ischaemic coronary arteriosclerosis", "span1": [258, 266], "span2": [13, 48]}, "bert_text": "CONCLUSIONS: Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by <e1> estrogen </e1> <e2> Ischaemic coronary arteriosclerosis </e2> with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2466": {"data": {"text": "A total of 261 adverse ocular reactions occurred in 237 patients who received isotretinoin, a commonly used drug in the treatment of severe cystic acne.", "entity1": "isotretinoin", "entity2": "cystic acne", "span1": [78, 90], "span2": [140, 151]}, "bert_text": "A total of 261 adverse ocular reactions occurred in 237 patients who received <e1> isotretinoin </e1>, a commonly used drug in the treatment of severe <e2> cystic acne </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2467": {"data": {"text": "Bleeding is the primary untoward effect of heparin.", "entity1": "heparin", "entity2": "Bleeding", "span1": [43, 50], "span2": [0, 8]}, "bert_text": "Bleeding is the primary untoward effect of <e1> heparin </e1> <e2> Bleeding </e2> is the primary untoward effect of heparin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2468": {"data": {"text": "An earlier suggestion of increased lung cancer risk at high levels of metolachlor use in this cohort was not confirmed in this update.", "entity1": "metolachlor", "entity2": "lung cancer", "span1": [70, 81], "span2": [35, 46]}, "bert_text": "An earlier suggestion of increased lung cancer risk at high levels of <e1> metolachlor </e1> <e2> lung cancer </e2> risk at high levels of metolachlor use in this cohort was not confirmed in this update.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2469": {"data": {"text": "Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation.\n", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [56, 66], "span2": [14, 25]}, "bert_text": "Intramuscular hepatitis B immune globulin combined with <e1> lamivudine </e1> <e2> hepatitis B </e2> immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2470": {"data": {"text": "Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation.\n", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [56, 66], "span2": [84, 95]}, "bert_text": "Intramuscular hepatitis B immune globulin combined with <e1> lamivudine </e1> in prevention of <e2> hepatitis B </e2> recurrence after liver transplantation.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2471": {"data": {"text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "entity1": "lithium", "entity2": "asterixis", "span1": [147, 154], "span2": [12, 21]}, "bert_text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as <e1> lithium </e1> <e2> asterixis </e2> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2472": {"data": {"text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "entity1": "lithium", "entity2": "neurotoxicity", "span1": [147, 154], "span2": [57, 70]}, "bert_text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as <e1> lithium </e1> <e2> neurotoxicity </e2>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2473": {"data": {"text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "entity1": "clozapine", "entity2": "asterixis", "span1": [158, 167], "span2": [12, 21]}, "bert_text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or <e1> clozapine </e1> <e2> asterixis </e2> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2474": {"data": {"text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "entity1": "clozapine", "entity2": "neurotoxicity", "span1": [158, 167], "span2": [57, 70]}, "bert_text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or <e1> clozapine </e1> <e2> neurotoxicity </e2>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2475": {"data": {"text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "entity1": "CBZ", "entity2": "asterixis", "span1": [197, 200], "span2": [12, 21]}, "bert_text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with <e1> CBZ </e1> <e2> asterixis </e2> to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2476": {"data": {"text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "entity1": "CBZ", "entity2": "neurotoxicity", "span1": [197, 200], "span2": [57, 70]}, "bert_text": "We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with <e1> CBZ </e1> <e2> neurotoxicity </e2>, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with CBZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2477": {"data": {"text": "Randomized clinical trials comparing VNR with other drugs in the treatment of cancer were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002.", "entity1": "VNR", "entity2": "cancer", "span1": [37, 40], "span2": [78, 84]}, "bert_text": "Randomized clinical trials comparing <e1> VNR </e1> with other drugs in the treatment of <e2> cancer </e2> were searched in Medline, Embase, Evidence-based Medicine Reviews databases and the Cochrane library from 1987 to 2002.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2478": {"data": {"text": "METHOD: Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed.", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [82, 92], "span2": [40, 56]}, "bert_text": "METHOD: Thirteen patients who developed optic neuropathy after being treated with <e1> ethambutol </e1> <e2> optic neuropathy </e2> after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2479": {"data": {"text": "METHOD: Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed.", "entity1": "ethambutol", "entity2": "tuberculosis", "span1": [82, 92], "span2": [97, 109]}, "bert_text": "METHOD: Thirteen patients who developed optic neuropathy after being treated with <e1> ethambutol </e1> for <e2> tuberculosis </e2> of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2480": {"data": {"text": "Cardioprotective effects of Picrorrhiza kurroa against isoproterenol-induced myocardial stress in rats.\n", "entity1": "isoproterenol", "entity2": "myocardial stress", "span1": [55, 68], "span2": [77, 94]}, "bert_text": "Cardioprotective effects of Picrorrhiza kurroa against <e1> isoproterenol </e1>-induced <e2> myocardial stress </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2481": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "Plasmodium falciparum", "entity2": "malaria", "span1": [44, 65], "span2": [223, 230]}, "bert_text": "On admission, laboratory examination showed <e1> Plasmodium falciparum </e1> (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe <e2> malaria </e2> with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2482": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "Plasmodium falciparum", "entity2": "jaundice", "span1": [44, 65], "span2": [236, 244]}, "bert_text": "On admission, laboratory examination showed <e1> Plasmodium falciparum </e1> (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with <e2> jaundice </e2> and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2483": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "bilirubin", "entity2": "malaria", "span1": [80, 89], "span2": [223, 230]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total <e1> bilirubin </e1> 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe <e2> malaria </e2> with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2484": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "bilirubin", "entity2": "jaundice", "span1": [80, 89], "span2": [236, 244]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total <e1> bilirubin </e1> 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with <e2> jaundice </e2> and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2485": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "bilirubin", "entity2": "malaria", "span1": [113, 122], "span2": [223, 230]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated <e1> bilirubin </e1> 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe <e2> malaria </e2> with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2486": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "bilirubin", "entity2": "jaundice", "span1": [113, 122], "span2": [236, 244]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated <e1> bilirubin </e1> 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with <e2> jaundice </e2> and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2487": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "bilirubin", "entity2": "malaria", "span1": [148, 157], "span2": [223, 230]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated <e1> bilirubin </e1> 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe <e2> malaria </e2> with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2488": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "bilirubin", "entity2": "jaundice", "span1": [148, 157], "span2": [236, 244]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated <e1> bilirubin </e1> 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with <e2> jaundice </e2> and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2489": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "potassium", "entity2": "malaria", "span1": [170, 179], "span2": [223, 230]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, <e1> potassium </e1> 3.52 meq/L Patient was diagnosed as severe <e2> malaria </e2> with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2490": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "potassium", "entity2": "jaundice", "span1": [170, 179], "span2": [236, 244]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, <e1> potassium </e1> 3.52 meq/L Patient was diagnosed as severe malaria with <e2> jaundice </e2> and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2491": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "quinine", "entity2": "malaria", "span1": [253, 260], "span2": [223, 230]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got <e1> quinine </e1> <e2> malaria </e2> with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2492": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "quinine", "entity2": "jaundice", "span1": [253, 260], "span2": [236, 244]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got <e1> quinine </e1> <e2> jaundice </e2> and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2493": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "dextrose", "entity2": "malaria", "span1": [273, 281], "span2": [223, 230]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in <e1> dextrose </e1> <e2> malaria </e2> with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2494": {"data": {"text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5% 500 mg/8 hour.", "entity1": "dextrose", "entity2": "jaundice", "span1": [273, 281], "span2": [236, 244]}, "bert_text": "On admission, laboratory examination showed Plasmodium falciparum (++++), total bilirubin 8.25 mg/dL, conjugated bilirubin 4.36 mg/dL, unconjugated bilirubin 3.89 mg/dL, potassium 3.52 meq/L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in <e1> dextrose </e1> <e2> jaundice </e2> and got quinine infusion in dextrose 5% 500 mg/8 hour.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2495": {"data": {"text": "BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [60, 70], "span2": [21, 32]}, "bert_text": "BACKGROUND: Combined hepatitis B immune globulin (HBIg) and <e1> lamivudine </e1> <e2> hepatitis B </e2> immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2496": {"data": {"text": "BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [60, 70], "span2": [107, 118]}, "bert_text": "BACKGROUND: Combined hepatitis B immune globulin (HBIg) and <e1> lamivudine </e1> in prophylaxis of the recurrence of <e2> hepatitis B </e2> after liver transplantation has significantly improved the survival of HBsAg positive patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2497": {"data": {"text": "BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.", "entity1": "HBsAg", "entity2": "hepatitis B", "span1": [190, 195], "span2": [21, 32]}, "bert_text": "BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of <e1> HBsAg </e1> <e2> hepatitis B </e2> immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2498": {"data": {"text": "BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients.", "entity1": "HBsAg", "entity2": "hepatitis B", "span1": [190, 195], "span2": [107, 118]}, "bert_text": "BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of <e1> HBsAg </e1> <e2> hepatitis B </e2> after liver transplantation has significantly improved the survival of HBsAg positive patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2499": {"data": {"text": "Myoclonus associated with lorazepam therapy in very-low-birth-weight infants.\n", "entity1": "lorazepam", "entity2": "Myoclonus", "span1": [26, 35], "span2": [0, 9]}, "bert_text": "Myoclonus associated with <e1> lorazepam </e1> <e2> Myoclonus </e2> associated with lorazepam therapy in very-low-birth-weight infants.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2500": {"data": {"text": "Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings.\n", "entity1": "Amiodarone", "entity2": "membranous glomerulonephritis", "span1": [0, 10], "span2": [45, 74]}, "bert_text": "<e1> Amiodarone </e1>-related pulmonary mass and unique <e2> membranous glomerulonephritis </e2> in a patient with valvular heart disease: Diagnostic pitfall and new findings.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2501": {"data": {"text": "Amiodarone-related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease: Diagnostic pitfall and new findings.\n", "entity1": "Amiodarone", "entity2": "valvular heart disease", "span1": [0, 10], "span2": [93, 115]}, "bert_text": "<e1> Amiodarone </e1>-related pulmonary mass and unique membranous glomerulonephritis in a patient with <e2> valvular heart disease </e2>: Diagnostic pitfall and new findings.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2502": {"data": {"text": "DISCUSSION: Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients.", "entity1": "Flecainide", "entity2": "delirium", "span1": [12, 22], "span2": [105, 113]}, "bert_text": "DISCUSSION: <e1> Flecainide </e1> and pharmacologically similar agents that interact with sodium channels may cause <e2> delirium </e2> in susceptible patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2503": {"data": {"text": "DISCUSSION: Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients.", "entity1": "sodium", "entity2": "delirium", "span1": [79, 85], "span2": [105, 113]}, "bert_text": "DISCUSSION: Flecainide and pharmacologically similar agents that interact with <e1> sodium </e1> channels may cause <e2> delirium </e2> in susceptible patients.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2504": {"data": {"text": "Our results suggest that oxidative damage is associated with acute cardiotoxicity induced by a single dose of DOX only.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [110, 113], "span2": [67, 81]}, "bert_text": "Our results suggest that oxidative damage is associated with acute cardiotoxicity induced by a single dose of <e1> DOX </e1> <e2> cardiotoxicity </e2> induced by a single dose of DOX only.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2505": {"data": {"text": "Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases.", "entity1": "calcium", "entity2": "cardiovascular disease", "span1": [44, 51], "span2": [75, 97]}, "bert_text": "Increasing recognition of the importance of <e1> calcium </e1> in the pathogenesis of <e2> cardiovascular disease </e2> has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2506": {"data": {"text": "Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases.", "entity1": "calcium", "entity2": "cardiovascular diseases", "span1": [44, 51], "span2": [200, 223]}, "bert_text": "Increasing recognition of the importance of <e1> calcium </e1> in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of <e2> cardiovascular diseases </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2507": {"data": {"text": "Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases.", "entity1": "calcium", "entity2": "cardiovascular disease", "span1": [138, 145], "span2": [75, 97]}, "bert_text": "Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of <e1> calcium </e1> <e2> cardiovascular disease </e2> has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2508": {"data": {"text": "Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases.", "entity1": "calcium", "entity2": "cardiovascular diseases", "span1": [138, 145], "span2": [200, 223]}, "bert_text": "Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of <e1> calcium </e1> channel blocking agents for treatment of a variety of <e2> cardiovascular diseases </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2509": {"data": {"text": "It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl.", "entity1": "NA", "entity2": "catalepsy", "span1": [50, 52], "span2": [147, 156]}, "bert_text": "It was found that three drugs stimulating central <e1> NA </e1> receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced <e2> catalepsy </e2> induced by morphine and fentanyl.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2510": {"data": {"text": "It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl.", "entity1": "morphine", "entity2": "catalepsy", "span1": [168, 176], "span2": [147, 156]}, "bert_text": "It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by <e1> morphine </e1> <e2> catalepsy </e2> induced by morphine and fentanyl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2511": {"data": {"text": "It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl.", "entity1": "fentanyl", "entity2": "catalepsy", "span1": [181, 189], "span2": [147, 156]}, "bert_text": "It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and <e1> fentanyl </e1> <e2> catalepsy </e2> induced by morphine and fentanyl.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2512": {"data": {"text": "In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from barium-exposed rats.", "entity1": "barium", "entity2": "depressed", "span1": [144, 150], "span2": [67, 76]}, "bert_text": "In addition, the excitability of the cardiac conduction system was depressed preferentially in the atrioventricular nodal region of hearts from <e1> barium </e1> <e2> depressed </e2> preferentially in the atrioventricular nodal region of hearts from barium-exposed rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2513": {"data": {"text": "We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of epinephrine in conscious, healthy dogs and in anesthetized dogs with myocardial infarction.", "entity1": "bupivacaine", "entity2": "myocardial infarction", "span1": [30, 41], "span2": [173, 194]}, "bert_text": "We therefore examined whether <e1> bupivacaine </e1> alters the dysrhythmogenicity of subsequent administration of epinephrine in conscious, healthy dogs and in anesthetized dogs with <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2514": {"data": {"text": "We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of epinephrine in conscious, healthy dogs and in anesthetized dogs with myocardial infarction.", "entity1": "epinephrine", "entity2": "myocardial infarction", "span1": [104, 115], "span2": [173, 194]}, "bert_text": "We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of <e1> epinephrine </e1> in conscious, healthy dogs and in anesthetized dogs with <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2515": {"data": {"text": "The risk of clinically important idiopathic liver disease was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed trimethoprim alone (3.8/100,000).", "entity1": "TMP-SMZ", "entity2": "idiopathic liver disease", "span1": [93, 100], "span2": [33, 57]}, "bert_text": "The risk of clinically important idiopathic liver disease was similar for persons prescribed <e1> TMP-SMZ </e1> <e2> idiopathic liver disease </e2> was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed trimethoprim alone (3.8/100,000).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2516": {"data": {"text": "The risk of clinically important idiopathic liver disease was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed trimethoprim alone (3.8/100,000).", "entity1": "trimethoprim", "entity2": "idiopathic liver disease", "span1": [136, 148], "span2": [33, 57]}, "bert_text": "The risk of clinically important idiopathic liver disease was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed <e1> trimethoprim </e1> <e2> idiopathic liver disease </e2> was similar for persons prescribed TMP-SMZ (5.2/100,000) and those prescribed trimethoprim alone (3.8/100,000).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2517": {"data": {"text": "CONCLUSION: This report describes the case of a woman with LACNP that developed after a steroid injection for the treatment of lateral epicondylitis.", "entity1": "steroid", "entity2": "lateral epicondylitis", "span1": [88, 95], "span2": [127, 148]}, "bert_text": "CONCLUSION: This report describes the case of a woman with LACNP that developed after a <e1> steroid </e1> injection for the treatment of <e2> lateral epicondylitis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2518": {"data": {"text": "Abnormalities of the pupil and visual-evoked potential in quinine amblyopia.\n", "entity1": "quinine", "entity2": "amblyopia", "span1": [58, 65], "span2": [66, 75]}, "bert_text": "Abnormalities of the pupil and visual-evoked potential in <e1> quinine </e1> <e2> amblyopia </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2519": {"data": {"text": "Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.", "entity1": "Gentamicin", "entity2": "nephropathy", "span1": [0, 10], "span2": [19, 30]}, "bert_text": "<e1> Gentamicin </e1>-induced <e2> nephropathy </e2> may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2520": {"data": {"text": "Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.", "entity1": "Gentamicin", "entity2": "OAT", "span1": [0, 10], "span2": [143, 146]}, "bert_text": "<e1> Gentamicin </e1>-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and <e2> OAT </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2521": {"data": {"text": "Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.", "entity1": "Na(+)/K(+)-ATPase", "entity2": "nephropathy", "span1": [103, 120], "span2": [19, 30]}, "bert_text": "Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of <e1> Na(+)/K(+)-ATPase </e1> <e2> nephropathy </e2> may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2522": {"data": {"text": "Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of Na(+)/K(+)-ATPase, NHE3, NBC1, AQP1 and OAT.", "entity1": "Na(+)/K(+)-ATPase", "entity2": "OAT", "span1": [103, 120], "span2": [143, 146]}, "bert_text": "Gentamicin-induced nephropathy may at least in part be causally related with a decreased expression of <e1> Na(+)/K(+)-ATPase </e1>, NHE3, NBC1, AQP1 and <e2> OAT </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2523": {"data": {"text": "We found that Ca(2+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats.", "entity1": "Ca(2", "entity2": "arrhythmia", "span1": [14, 18], "span2": [110, 120]}, "bert_text": "We found that <e1> Ca(2 </e1>+) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused <e2> arrhythmia </e2> in conscious freely moving rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2524": {"data": {"text": "Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial.", "entity1": "angiotensin", "entity2": "chronic heart failure", "span1": [28, 39], "span2": [86, 107]}, "bert_text": "Toleration of high doses of <e1> angiotensin </e1>-converting enzyme inhibitors in patients with <e2> chronic heart failure </e2>: results from the ATLAS trial.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2525": {"data": {"text": "Using mice derived from a classical F2 and backcross genetic design, a relationship between nicotine-induced seizures and alpha-bungarotoxin nicotinic receptor concentration was found.", "entity1": "nicotine", "entity2": "seizures", "span1": [92, 100], "span2": [109, 117]}, "bert_text": "Using mice derived from a classical F2 and backcross genetic design, a relationship between <e1> nicotine </e1>-induced <e2> seizures </e2> and alpha-bungarotoxin nicotinic receptor concentration was found.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2526": {"data": {"text": "Using mice derived from a classical F2 and backcross genetic design, a relationship between nicotine-induced seizures and alpha-bungarotoxin nicotinic receptor concentration was found.", "entity1": "alpha-bungarotoxin", "entity2": "seizures", "span1": [122, 140], "span2": [109, 117]}, "bert_text": "Using mice derived from a classical F2 and backcross genetic design, a relationship between nicotine-induced seizures and <e1> alpha-bungarotoxin </e1> <e2> seizures </e2> and alpha-bungarotoxin nicotinic receptor concentration was found.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2527": {"data": {"text": "To examine the role of the kinin B2 receptor in cisplatin-induced acute kidney injury, kinin B2 receptor knockout mice were challenged with cisplatin.", "entity1": "cisplatin", "entity2": "acute kidney injury", "span1": [48, 57], "span2": [66, 85]}, "bert_text": "To examine the role of the kinin B2 receptor in <e1> cisplatin </e1>-induced <e2> acute kidney injury </e2>, kinin B2 receptor knockout mice were challenged with cisplatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2528": {"data": {"text": "To examine the role of the kinin B2 receptor in cisplatin-induced acute kidney injury, kinin B2 receptor knockout mice were challenged with cisplatin.", "entity1": "cisplatin", "entity2": "acute kidney injury", "span1": [140, 149], "span2": [66, 85]}, "bert_text": "To examine the role of the kinin B2 receptor in cisplatin-induced acute kidney injury, kinin B2 receptor knockout mice were challenged with <e1> cisplatin </e1> <e2> acute kidney injury </e2>, kinin B2 receptor knockout mice were challenged with cisplatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2529": {"data": {"text": "These doses of FZP were lower than those that would alone cause convulsions.", "entity1": "FZP", "entity2": "convulsions", "span1": [15, 18], "span2": [64, 75]}, "bert_text": "These doses of <e1> FZP </e1> were lower than those that would alone cause <e2> convulsions </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2530": {"data": {"text": "The authors conclude that in a patient starting DPH treatment an unexpected increase in seizures, with EEG and mental changes occurring simultaneously, should alert the physician to the possible need for eliminating DPH from the therapeutic regimen, even if plasma concentrations are low.", "entity1": "DPH", "entity2": "seizures", "span1": [48, 51], "span2": [88, 96]}, "bert_text": "The authors conclude that in a patient starting <e1> DPH </e1> treatment an unexpected increase in <e2> seizures </e2>, with EEG and mental changes occurring simultaneously, should alert the physician to the possible need for eliminating DPH from the therapeutic regimen, even if plasma concentrations are low.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2531": {"data": {"text": "The authors conclude that in a patient starting DPH treatment an unexpected increase in seizures, with EEG and mental changes occurring simultaneously, should alert the physician to the possible need for eliminating DPH from the therapeutic regimen, even if plasma concentrations are low.", "entity1": "DPH", "entity2": "seizures", "span1": [216, 219], "span2": [88, 96]}, "bert_text": "The authors conclude that in a patient starting DPH treatment an unexpected increase in seizures, with EEG and mental changes occurring simultaneously, should alert the physician to the possible need for eliminating <e1> DPH </e1> <e2> seizures </e2>, with EEG and mental changes occurring simultaneously, should alert the physician to the possible need for eliminating DPH from the therapeutic regimen, even if plasma concentrations are low.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2532": {"data": {"text": "Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells.", "entity1": "3H-17 beta estradiol", "entity2": "tumor", "span1": [51, 71], "span2": [111, 116]}, "bert_text": "Radiolabelling, following the in vivo injection of <e1> 3H-17 beta estradiol </e1>, was increased only over the nuclei of <e2> tumor </e2> cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2533": {"data": {"text": "Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells.", "entity1": "silver", "entity2": "tumor", "span1": [206, 212], "span2": [111, 116]}, "bert_text": "Radiolabelling, following the in vivo injection of 3H-17 beta estradiol, was increased only over the nuclei of tumor cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced <e1> silver </e1> <e2> tumor </e2> cells; stereologic analysis revealed a 4.5- to 6.7-times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2534": {"data": {"text": "RESULTS: The hyperventilation maneuver caused a decrease in spontaneous ventilation in pilocarpine-treated and control rats.", "entity1": "pilocarpine", "entity2": "hyperventilation maneuver", "span1": [87, 98], "span2": [13, 38]}, "bert_text": "RESULTS: The hyperventilation maneuver caused a decrease in spontaneous ventilation in <e1> pilocarpine </e1> <e2> hyperventilation maneuver </e2> caused a decrease in spontaneous ventilation in pilocarpine-treated and control rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2535": {"data": {"text": "CONCLUSION: Aspirin reduces the risk for myocardial infarction in men and strokes in women.", "entity1": "Aspirin", "entity2": "myocardial infarction", "span1": [12, 19], "span2": [41, 62]}, "bert_text": "CONCLUSION: <e1> Aspirin </e1> reduces the risk for <e2> myocardial infarction </e2> in men and strokes in women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2536": {"data": {"text": "CONCLUSION: Aspirin reduces the risk for myocardial infarction in men and strokes in women.", "entity1": "Aspirin", "entity2": "strokes", "span1": [12, 19], "span2": [74, 81]}, "bert_text": "CONCLUSION: <e1> Aspirin </e1> reduces the risk for myocardial infarction in men and <e2> strokes </e2> in women.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2537": {"data": {"text": "Bilateral visual field constriction was observed in 59% of patients currently taking VGB, 43% of patients who previously took VGB, and 24% of patients with no exposure to VGB.", "entity1": "VGB", "entity2": "Bilateral visual field constriction", "span1": [85, 88], "span2": [0, 35]}, "bert_text": "Bilateral visual field constriction was observed in 59% of patients currently taking <e1> VGB </e1> <e2> Bilateral visual field constriction </e2> was observed in 59% of patients currently taking VGB, 43% of patients who previously took VGB, and 24% of patients with no exposure to VGB.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2538": {"data": {"text": "Bilateral visual field constriction was observed in 59% of patients currently taking VGB, 43% of patients who previously took VGB, and 24% of patients with no exposure to VGB.", "entity1": "VGB", "entity2": "Bilateral visual field constriction", "span1": [126, 129], "span2": [0, 35]}, "bert_text": "Bilateral visual field constriction was observed in 59% of patients currently taking VGB, 43% of patients who previously took <e1> VGB </e1> <e2> Bilateral visual field constriction </e2> was observed in 59% of patients currently taking VGB, 43% of patients who previously took VGB, and 24% of patients with no exposure to VGB.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2539": {"data": {"text": "Bilateral visual field constriction was observed in 59% of patients currently taking VGB, 43% of patients who previously took VGB, and 24% of patients with no exposure to VGB.", "entity1": "VGB", "entity2": "Bilateral visual field constriction", "span1": [171, 174], "span2": [0, 35]}, "bert_text": "Bilateral visual field constriction was observed in 59% of patients currently taking VGB, 43% of patients who previously took VGB, and 24% of patients with no exposure to <e1> VGB </e1> <e2> Bilateral visual field constriction </e2> was observed in 59% of patients currently taking VGB, 43% of patients who previously took VGB, and 24% of patients with no exposure to VGB.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2540": {"data": {"text": "Two cases of amisulpride overdose: a cause for prolonged QT syndrome.\n", "entity1": "amisulpride", "entity2": "overdose", "span1": [13, 24], "span2": [25, 33]}, "bert_text": "Two cases of <e1> amisulpride </e1> <e2> overdose </e2>: a cause for prolonged QT syndrome.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2541": {"data": {"text": "Two cases of amisulpride overdose: a cause for prolonged QT syndrome.\n", "entity1": "amisulpride", "entity2": "prolonged QT syndrome", "span1": [13, 24], "span2": [47, 68]}, "bert_text": "Two cases of <e1> amisulpride </e1> overdose: a cause for <e2> prolonged QT syndrome </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2542": {"data": {"text": "A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.", "entity1": "flecainide", "entity2": "delirium", "span1": [107, 117], "span2": [223, 231]}, "bert_text": "A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between <e1> flecainide </e1>, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced <e2> delirium </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2543": {"data": {"text": "A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.", "entity1": "flecainide", "entity2": "delirium", "span1": [204, 214], "span2": [223, 231]}, "bert_text": "A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of <e1> flecainide </e1>-induced <e2> delirium </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2544": {"data": {"text": "A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and paroxetine, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced delirium.", "entity1": "paroxetine", "entity2": "delirium", "span1": [143, 153], "span2": [223, 231]}, "bert_text": "A MEDLINE search (1966-January 2009) revealed one in vivo pharmacokinetic study on the interaction between flecainide, a CYP2D6 substrate, and <e1> paroxetine </e1>, a CYP2D6 inhibitor, as well as 3 case reports of flecainide-induced <e2> delirium </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2545": {"data": {"text": "Two cases of deliberate self-poisoning with 5 g and 3.6 g of amisulpride, respectively, are reported.", "entity1": "amisulpride", "entity2": "poisoning", "span1": [61, 72], "span2": [29, 38]}, "bert_text": "Two cases of deliberate self-poisoning with 5 g and 3.6 g of <e1> amisulpride </e1> <e2> poisoning </e2> with 5 g and 3.6 g of amisulpride, respectively, are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2546": {"data": {"text": "Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus (NDI) in  40% of patients.", "entity1": "Lithium", "entity2": "nephrogenic diabetes insipidus", "span1": [0, 7], "span2": [45, 75]}, "bert_text": "<e1> Lithium </e1>, an effective antipsychotic, induces <e2> nephrogenic diabetes insipidus </e2> (NDI) in  40% of patients.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2547": {"data": {"text": "Lithium, an effective antipsychotic, induces nephrogenic diabetes insipidus (NDI) in  40% of patients.", "entity1": "Lithium", "entity2": "NDI", "span1": [0, 7], "span2": [77, 80]}, "bert_text": "<e1> Lithium </e1>, an effective antipsychotic, induces nephrogenic diabetes insipidus (<e2> NDI </e2>) in  40% of patients.", "weak_labels": [1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2548": {"data": {"text": "Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.\n", "entity1": "aracytine", "entity2": "Pulmonary edema", "span1": [42, 51], "span2": [0, 15]}, "bert_text": "Pulmonary edema and shock after high-dose <e1> aracytine </e1> <e2> Pulmonary edema </e2> and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2549": {"data": {"text": "Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.\n", "entity1": "aracytine", "entity2": "shock", "span1": [42, 51], "span2": [20, 25]}, "bert_text": "Pulmonary edema and shock after high-dose <e1> aracytine </e1> <e2> shock </e2> after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2550": {"data": {"text": "Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF.\n", "entity1": "aracytine", "entity2": "lymphoma", "span1": [42, 51], "span2": [58, 66]}, "bert_text": "Pulmonary edema and shock after high-dose <e1> aracytine </e1>-C for <e2> lymphoma </e2>; possible role of TNF-alpha and PAF.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2551": {"data": {"text": "Continuously nebulized albuterol in severe exacerbations of asthma in adults: a case-controlled study.\n", "entity1": "albuterol", "entity2": "asthma", "span1": [23, 32], "span2": [60, 66]}, "bert_text": "Continuously nebulized <e1> albuterol </e1> in severe exacerbations of <e2> asthma </e2> in adults: a case-controlled study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2552": {"data": {"text": "Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia.\n", "entity1": "melatonin", "entity2": "cortical dysplasia", "span1": [27, 36], "span2": [107, 125]}, "bert_text": "Neuroprotective effects of <e1> melatonin </e1> upon the offspring cerebellar cortex in the rat model of BCNU-induced <e2> cortical dysplasia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2553": {"data": {"text": "Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia.\n", "entity1": "BCNU", "entity2": "cortical dysplasia", "span1": [94, 98], "span2": [107, 125]}, "bert_text": "Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of <e1> BCNU </e1>-induced <e2> cortical dysplasia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2554": {"data": {"text": "It was possible to suppress the increased ornithine decarboxylase activity with both beta-blockers in hypertrophied hearts, but there was no effect on the heart mass.", "entity1": "ornithine", "entity2": "hypertrophied", "span1": [42, 51], "span2": [102, 115]}, "bert_text": "It was possible to suppress the increased <e1> ornithine </e1> decarboxylase activity with both beta-blockers in <e2> hypertrophied </e2> hearts, but there was no effect on the heart mass.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2555": {"data": {"text": "Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.\n", "entity1": "rocuronium", "entity2": "fasciculation", "span1": [30, 40], "span2": [53, 66]}, "bert_text": "Optimal precurarizing dose of <e1> rocuronium </e1> to decrease <e2> fasciculation </e2> and myalgia following succinylcholine administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2556": {"data": {"text": "Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.\n", "entity1": "rocuronium", "entity2": "myalgia", "span1": [30, 40], "span2": [71, 78]}, "bert_text": "Optimal precurarizing dose of <e1> rocuronium </e1> to decrease fasciculation and <e2> myalgia </e2> following succinylcholine administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2557": {"data": {"text": "Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.\n", "entity1": "succinylcholine", "entity2": "fasciculation", "span1": [89, 104], "span2": [53, 66]}, "bert_text": "Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following <e1> succinylcholine </e1> <e2> fasciculation </e2> and myalgia following succinylcholine administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2558": {"data": {"text": "Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration.\n", "entity1": "succinylcholine", "entity2": "myalgia", "span1": [89, 104], "span2": [71, 78]}, "bert_text": "Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following <e1> succinylcholine </e1> <e2> myalgia </e2> following succinylcholine administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2559": {"data": {"text": "Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.", "entity1": "clentiazem", "entity2": "death", "span1": [15, 25], "span2": [56, 61]}, "bert_text": "Treatment with <e1> clentiazem </e1> prevented epinephrine-induced <e2> death </e2> (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2560": {"data": {"text": "Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.", "entity1": "clentiazem", "entity2": "ventricular ischemic lesions", "span1": [15, 25], "span2": [92, 120]}, "bert_text": "Treatment with <e1> clentiazem </e1> prevented epinephrine-induced death (P < .05), and attenuated the <e2> ventricular ischemic lesions </e2> and fibrosis, in a dose-dependent manner.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2561": {"data": {"text": "Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.", "entity1": "clentiazem", "entity2": "fibrosis", "span1": [15, 25], "span2": [125, 133]}, "bert_text": "Treatment with <e1> clentiazem </e1> prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and <e2> fibrosis </e2>, in a dose-dependent manner.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2562": {"data": {"text": "Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.", "entity1": "epinephrine", "entity2": "death", "span1": [36, 47], "span2": [56, 61]}, "bert_text": "Treatment with clentiazem prevented <e1> epinephrine </e1>-induced <e2> death </e2> (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2563": {"data": {"text": "Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.", "entity1": "epinephrine", "entity2": "ventricular ischemic lesions", "span1": [36, 47], "span2": [92, 120]}, "bert_text": "Treatment with clentiazem prevented <e1> epinephrine </e1>-induced death (P < .05), and attenuated the <e2> ventricular ischemic lesions </e2> and fibrosis, in a dose-dependent manner.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2564": {"data": {"text": "Treatment with clentiazem prevented epinephrine-induced death (P < .05), and attenuated the ventricular ischemic lesions and fibrosis, in a dose-dependent manner.", "entity1": "epinephrine", "entity2": "fibrosis", "span1": [36, 47], "span2": [125, 133]}, "bert_text": "Treatment with clentiazem prevented <e1> epinephrine </e1>-induced death (P < .05), and attenuated the ventricular ischemic lesions and <e2> fibrosis </e2>, in a dose-dependent manner.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2565": {"data": {"text": "Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.\n", "entity1": "l-sotalol", "entity2": "ventricular tachyarrhythmias", "span1": [45, 54], "span2": [69, 97]}, "bert_text": "Efficacy and proarrhythmia with the use of d,<e1> l-sotalol </e1> for sustained <e2> ventricular tachyarrhythmias </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2566": {"data": {"text": "A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported.", "entity1": "albuterol", "entity2": "asthma", "span1": [175, 184], "span2": [132, 138]}, "bert_text": "A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized <e1> albuterol </e1> <e2> asthma </e2> who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2567": {"data": {"text": "A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported.", "entity1": "albuterol", "entity2": "asthma", "span1": [211, 220], "span2": [132, 138]}, "bert_text": "A retrospective, case-controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol (CNA) versus intermittent <e1> albuterol </e1> <e2> asthma </e2> who received continuously nebulized albuterol (CNA) versus intermittent albuterol (INA) treatments is reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2568": {"data": {"text": "OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.", "entity1": "clonidine", "entity2": "atrioventricular (AV) block", "span1": [73, 82], "span2": [110, 137]}, "bert_text": "OBJECTIVE: To report two cases of a possible adverse interaction between <e1> clonidine </e1> and verapamil resulting in <e2> atrioventricular (AV) block </e2> in both patients and severe hypotension in one patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2569": {"data": {"text": "OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.", "entity1": "clonidine", "entity2": "hypotension", "span1": [73, 82], "span2": [166, 177]}, "bert_text": "OBJECTIVE: To report two cases of a possible adverse interaction between <e1> clonidine </e1> and verapamil resulting in atrioventricular (AV) block in both patients and severe <e2> hypotension </e2> in one patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2570": {"data": {"text": "OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.", "entity1": "verapamil", "entity2": "atrioventricular (AV) block", "span1": [87, 96], "span2": [110, 137]}, "bert_text": "OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and <e1> verapamil </e1> resulting in <e2> atrioventricular (AV) block </e2> in both patients and severe hypotension in one patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2571": {"data": {"text": "OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular (AV) block in both patients and severe hypotension in one patient.", "entity1": "verapamil", "entity2": "hypotension", "span1": [87, 96], "span2": [166, 177]}, "bert_text": "OBJECTIVE: To report two cases of a possible adverse interaction between clonidine and <e1> verapamil </e1> resulting in atrioventricular (AV) block in both patients and severe <e2> hypotension </e2> in one patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2572": {"data": {"text": "Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in doxorubicin cardiotoxicity.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [140, 151], "span2": [152, 166]}, "bert_text": "Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in <e1> doxorubicin </e1> <e2> cardiotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2573": {"data": {"text": "The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "entity1": "ecstasy", "entity2": "anxiety", "span1": [95, 102], "span2": [17, 24]}, "bert_text": "The increases in anxiety and depression are in line with previous observations in recreational <e1> ecstasy </e1> <e2> anxiety </e2> and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2574": {"data": {"text": "The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "entity1": "ecstasy", "entity2": "depression", "span1": [95, 102], "span2": [29, 39]}, "bert_text": "The increases in anxiety and depression are in line with previous observations in recreational <e1> ecstasy </e1> <e2> depression </e2> are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2575": {"data": {"text": "The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "entity1": "ecstasy", "entity2": "anxiety", "span1": [344, 351], "span2": [17, 24]}, "bert_text": "The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of <e1> ecstasy </e1> <e2> anxiety </e2> and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2576": {"data": {"text": "The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "entity1": "ecstasy", "entity2": "depression", "span1": [344, 351], "span2": [29, 39]}, "bert_text": "The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of <e1> ecstasy </e1> <e2> depression </e2> are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2577": {"data": {"text": "The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "entity1": "cortisol", "entity2": "anxiety", "span1": [140, 148], "span2": [17, 24]}, "bert_text": "The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal <e1> cortisol </e1> <e2> anxiety </e2> and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2578": {"data": {"text": "The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "entity1": "cortisol", "entity2": "depression", "span1": [140, 148], "span2": [29, 39]}, "bert_text": "The increases in anxiety and depression are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal <e1> cortisol </e1> <e2> depression </e2> are in line with previous observations in recreational ecstasy-polydrug users. Dysregulated diurnal cortisol may be indicative of inappropriate anticipation of forthcoming demands and hypersecretion may lead to the increased psychological and physical morbidity associated with heavy recreational use of ecstasy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2579": {"data": {"text": "The reduction in the levodopa dose is useful in controlling drug-induced dyskinesias.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [21, 29], "span2": [73, 84]}, "bert_text": "The reduction in the <e1> levodopa </e1> dose is useful in controlling drug-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2580": {"data": {"text": "Longitudinal association of alcohol use with HIV disease progression and psychological health of women with HIV.\n", "entity1": "alcohol", "entity2": "HIV disease", "span1": [28, 35], "span2": [45, 56]}, "bert_text": "Longitudinal association of <e1> alcohol </e1> use with <e2> HIV disease </e2> progression and psychological health of women with HIV.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2581": {"data": {"text": "Longitudinal association of alcohol use with HIV disease progression and psychological health of women with HIV.\n", "entity1": "alcohol", "entity2": "HIV", "span1": [28, 35], "span2": [108, 111]}, "bert_text": "Longitudinal association of <e1> alcohol </e1> use with HIV disease progression and psychological health of women with <e2> HIV </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2582": {"data": {"text": "Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "entity1": "cocaine", "entity2": "myocardial ischemia", "span1": [9, 16], "span2": [28, 47]}, "bert_text": "Although <e1> cocaine </e1>-associated <e2> myocardial ischemia </e2> can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2583": {"data": {"text": "Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "entity1": "cocaine", "entity2": "chest pain", "span1": [9, 16], "span2": [124, 134]}, "bert_text": "Although <e1> cocaine </e1>-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated <e2> chest pain </e2>, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2584": {"data": {"text": "Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "entity1": "cocaine", "entity2": "ischemic", "span1": [9, 16], "span2": [142, 150]}, "bert_text": "Although <e1> cocaine </e1>-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-<e2> ischemic </e2> ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2585": {"data": {"text": "Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "entity1": "cocaine", "entity2": "myocardial ischemia", "span1": [105, 112], "span2": [28, 47]}, "bert_text": "Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with <e1> cocaine </e1> <e2> myocardial ischemia </e2> can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2586": {"data": {"text": "Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "entity1": "cocaine", "entity2": "chest pain", "span1": [105, 112], "span2": [124, 134]}, "bert_text": "Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with <e1> cocaine </e1> associated <e2> chest pain </e2>, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2587": {"data": {"text": "Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with cocaine associated chest pain, a non-ischemic ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "entity1": "cocaine", "entity2": "ischemic", "span1": [105, 112], "span2": [142, 150]}, "bert_text": "Although cocaine-associated myocardial ischemia can result from coronary vasoconstriction, patients with <e1> cocaine </e1> associated chest pain, a non-<e2> ischemic </e2> ECG, and a TIMI risk score <2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30-day adverse events.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2588": {"data": {"text": "Linezolid-induced optic neuropathy.\n", "entity1": "Linezolid", "entity2": "optic neuropathy", "span1": [0, 9], "span2": [18, 34]}, "bert_text": "<e1> Linezolid </e1>-induced <e2> optic neuropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2589": {"data": {"text": "The muscarinic cholinergic agonist pilocarpine induces in rats seizures and status epilepticus followed by widespread damage to the forebrain.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [35, 46], "span2": [63, 71]}, "bert_text": "The muscarinic cholinergic agonist <e1> pilocarpine </e1> induces in rats <e2> seizures </e2> and status epilepticus followed by widespread damage to the forebrain.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2590": {"data": {"text": "The muscarinic cholinergic agonist pilocarpine induces in rats seizures and status epilepticus followed by widespread damage to the forebrain.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [35, 46], "span2": [76, 94]}, "bert_text": "The muscarinic cholinergic agonist <e1> pilocarpine </e1> induces in rats seizures and <e2> status epilepticus </e2> followed by widespread damage to the forebrain.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2591": {"data": {"text": "Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only.", "entity1": "aminoglycoside", "entity2": "acute renal failure", "span1": [84, 98], "span2": [34, 53]}, "bert_text": "Dehydrated rats regularly develop acute renal failure following single injection of <e1> aminoglycoside </e1> <e2> acute renal failure </e2> following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2592": {"data": {"text": "Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only.", "entity1": "dextran", "entity2": "acute renal failure", "span1": [125, 132], "span2": [34, 53]}, "bert_text": "Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with <e1> dextran </e1> <e2> acute renal failure </e2> following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2593": {"data": {"text": "The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol-induced myocardial infarction in rats with respect to lipid metabolism in serum and heart tissue has been investigated.", "entity1": "ethanol", "entity2": "myocardial infarction", "span1": [35, 42], "span2": [122, 143]}, "bert_text": "The cardioprotective effect of the <e1> ethanol </e1> extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol-induced <e2> myocardial infarction </e2> in rats with respect to lipid metabolism in serum and heart tissue has been investigated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2594": {"data": {"text": "The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK) on isoproterenol-induced myocardial infarction in rats with respect to lipid metabolism in serum and heart tissue has been investigated.", "entity1": "isoproterenol", "entity2": "myocardial infarction", "span1": [100, 113], "span2": [122, 143]}, "bert_text": "The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots (PK) on <e1> isoproterenol </e1>-induced <e2> myocardial infarction </e2> in rats with respect to lipid metabolism in serum and heart tissue has been investigated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2595": {"data": {"text": "This study investigates the role of ILK in liver enlargement induced by phenobarbital (PB).", "entity1": "phenobarbital", "entity2": "liver enlargement", "span1": [72, 85], "span2": [43, 60]}, "bert_text": "This study investigates the role of ILK in liver enlargement induced by <e1> phenobarbital </e1> <e2> liver enlargement </e2> induced by phenobarbital (PB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2596": {"data": {"text": "This study investigates the role of ILK in liver enlargement induced by phenobarbital (PB).", "entity1": "PB", "entity2": "liver enlargement", "span1": [87, 89], "span2": [43, 60]}, "bert_text": "This study investigates the role of ILK in liver enlargement induced by phenobarbital (<e1> PB </e1> <e2> liver enlargement </e2> induced by phenobarbital (PB).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2597": {"data": {"text": "During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group.", "entity1": "creatinine", "entity2": "hypotension", "span1": [30, 40], "span2": [7, 18]}, "bert_text": "During hypotension, the serum <e1> creatinine </e1> <e2> hypotension </e2>, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2598": {"data": {"text": "During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group.", "entity1": "creatinine", "entity2": "hypotension", "span1": [30, 40], "span2": [111, 122]}, "bert_text": "During hypotension, the serum <e1> creatinine </e1> concentration rose significantly in all groups from the values before <e2> hypotension </e2> and returned postoperatively to the initial level in the other groups, except the isoflurane group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2599": {"data": {"text": "During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group.", "entity1": "isoflurane", "entity2": "hypotension", "span1": [205, 215], "span2": [7, 18]}, "bert_text": "During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the <e1> isoflurane </e1> <e2> hypotension </e2>, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2600": {"data": {"text": "During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the isoflurane group.", "entity1": "isoflurane", "entity2": "hypotension", "span1": [205, 215], "span2": [111, 122]}, "bert_text": "During hypotension, the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups, except the <e1> isoflurane </e1> <e2> hypotension </e2> and returned postoperatively to the initial level in the other groups, except the isoflurane group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2601": {"data": {"text": "In rats with PAN nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA.", "entity1": "PAN", "entity2": "nephropathy", "span1": [13, 16], "span2": [17, 28]}, "bert_text": "In rats with <e1> PAN </e1> <e2> nephropathy </e2>, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2602": {"data": {"text": "We suggest a timely EEG evaluation for patients receiving ifosfamide who develop features of encephalopathy.", "entity1": "ifosfamide", "entity2": "encephalopathy", "span1": [58, 68], "span2": [93, 107]}, "bert_text": "We suggest a timely EEG evaluation for patients receiving <e1> ifosfamide </e1> who develop features of <e2> encephalopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2603": {"data": {"text": "The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in diabetic rats.", "entity1": "streptozotocin", "entity2": "diabetic", "span1": [74, 88], "span2": [211, 219]}, "bert_text": "The rapid reversion after insulin treatment excludes the possibility that <e1> streptozotocin </e1> in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in <e2> diabetic </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2604": {"data": {"text": "The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in diabetic rats.", "entity1": "ISO", "entity2": "diabetic", "span1": [110, 113], "span2": [211, 219]}, "bert_text": "The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the <e1> ISO </e1> resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in <e2> diabetic </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2605": {"data": {"text": "The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in diabetic rats.", "entity1": "catecholamine", "entity2": "diabetic", "span1": [182, 195], "span2": [211, 219]}, "bert_text": "The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial <e1> catecholamine </e1> sensitivity in <e2> diabetic </e2> rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2606": {"data": {"text": "Increases of MAP occurred after LV administration of 1, 10 and 50 ng of AVP in WKY and of 10 and 50 ng in SHR.", "entity1": "AVP", "entity2": "LV", "span1": [72, 75], "span2": [32, 34]}, "bert_text": "Increases of MAP occurred after LV administration of 1, 10 and 50 ng of <e1> AVP </e1> <e2> LV </e2> administration of 1, 10 and 50 ng of AVP in WKY and of 10 and 50 ng in SHR.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2607": {"data": {"text": "An electrical seizure measured with hippocampal EEG appeared in the pilocarpine-treated group.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [68, 79], "span2": [14, 21]}, "bert_text": "An electrical seizure measured with hippocampal EEG appeared in the <e1> pilocarpine </e1> <e2> seizure </e2> measured with hippocampal EEG appeared in the pilocarpine-treated group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 1},
+	"2608": {"data": {"text": "Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated dopamine release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon.", "entity1": "dopamine", "entity2": "paranoia", "span1": [124, 132], "span2": [46, 54]}, "bert_text": "Although the pharmacology and neurobiology of paranoia remain cryptic, several mechanisms, including 5HT3 receptor-mediated <e1> dopamine </e1> <e2> paranoia </e2> remain cryptic, several mechanisms, including 5HT3 receptor-mediated dopamine release, beta-noradrenergic receptor downregulation, or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia (possibly in lateral orbitofrontal or anterior cingulate circuits), might apply to this phenomenon.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2609": {"data": {"text": "The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and levodopa-induced dyskinesias (LIDs) is severely impaired.", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [90, 98], "span2": [61, 80]}, "bert_text": "The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and <e1> levodopa </e1> <e2> Parkinson's disease </e2> (PD) and levodopa-induced dyskinesias (LIDs) is severely impaired.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2610": {"data": {"text": "The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and levodopa-induced dyskinesias (LIDs) is severely impaired.", "entity1": "levodopa", "entity2": "PD", "span1": [90, 98], "span2": [82, 84]}, "bert_text": "The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and <e1> levodopa </e1> <e2> PD </e2>) and levodopa-induced dyskinesias (LIDs) is severely impaired.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2611": {"data": {"text": "The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and levodopa-induced dyskinesias (LIDs) is severely impaired.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [90, 98], "span2": [107, 118]}, "bert_text": "The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and <e1> levodopa </e1>-induced <e2> dyskinesias </e2> (LIDs) is severely impaired.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2612": {"data": {"text": "The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and levodopa-induced dyskinesias (LIDs) is severely impaired.", "entity1": "levodopa", "entity2": "LIDs", "span1": [90, 98], "span2": [120, 124]}, "bert_text": "The plasticity of primary motor cortex (M1) in patients with Parkinson's disease (PD) and <e1> levodopa </e1>-induced dyskinesias (<e2> LIDs </e2>) is severely impaired.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2613": {"data": {"text": "CONCLUSIONS: Aerosolized crack cocaine use can be associated with the development of corneal ulcers.", "entity1": "cocaine", "entity2": "corneal ulcers", "span1": [31, 38], "span2": [85, 99]}, "bert_text": "CONCLUSIONS: Aerosolized crack <e1> cocaine </e1> use can be associated with the development of <e2> corneal ulcers </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2614": {"data": {"text": "Second, the anticonvulsant effect of MK-801 in the lithium-pilocarpine model only occurred after initial periods of seizure activity.", "entity1": "MK-801", "entity2": "seizure", "span1": [37, 43], "span2": [116, 123]}, "bert_text": "Second, the anticonvulsant effect of <e1> MK-801 </e1> in the lithium-pilocarpine model only occurred after initial periods of <e2> seizure </e2> activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2615": {"data": {"text": "Second, the anticonvulsant effect of MK-801 in the lithium-pilocarpine model only occurred after initial periods of seizure activity.", "entity1": "lithium", "entity2": "seizure", "span1": [51, 58], "span2": [116, 123]}, "bert_text": "Second, the anticonvulsant effect of MK-801 in the <e1> lithium </e1>-pilocarpine model only occurred after initial periods of <e2> seizure </e2> activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2616": {"data": {"text": "Second, the anticonvulsant effect of MK-801 in the lithium-pilocarpine model only occurred after initial periods of seizure activity.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [59, 70], "span2": [116, 123]}, "bert_text": "Second, the anticonvulsant effect of MK-801 in the lithium-<e1> pilocarpine </e1> model only occurred after initial periods of <e2> seizure </e2> activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2617": {"data": {"text": "RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from acetaminophen which was ingested over a 2-day period.", "entity1": "acetaminophen", "entity2": "toxicity", "span1": [105, 118], "span2": [91, 99]}, "bert_text": "RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from <e1> acetaminophen </e1> <e2> toxicity </e2> from acetaminophen which was ingested over a 2-day period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2618": {"data": {"text": "We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope.", "entity1": "methyldopa", "entity2": "hemolytic anemia", "span1": [20, 30], "span2": [39, 55]}, "bert_text": "We report a case of <e1> methyldopa </e1>-induced <e2> hemolytic anemia </e2> in a 15-year-old boy who presented to the emergency department with near-syncope.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2619": {"data": {"text": "We report a case of methyldopa-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-syncope.", "entity1": "methyldopa", "entity2": "syncope", "span1": [20, 30], "span2": [129, 136]}, "bert_text": "We report a case of <e1> methyldopa </e1>-induced hemolytic anemia in a 15-year-old boy who presented to the emergency department with near-<e2> syncope </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2620": {"data": {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "entity1": "Scopolamine", "entity2": "seizure", "span1": [0, 11], "span2": [77, 84]}, "bert_text": "<e1> Scopolamine </e1> and pentobarbital blocked the pilocarpine-induced electrographic <e2> seizure </e2>, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2621": {"data": {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "entity1": "Scopolamine", "entity2": "seizure", "span1": [0, 11], "span2": [132, 139]}, "bert_text": "<e1> Scopolamine </e1> and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic <e2> seizure </e2> induced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2622": {"data": {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "entity1": "pentobarbital", "entity2": "seizure", "span1": [16, 29], "span2": [77, 84]}, "bert_text": "Scopolamine and <e1> pentobarbital </e1> blocked the pilocarpine-induced electrographic <e2> seizure </e2>, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2623": {"data": {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "entity1": "pentobarbital", "entity2": "seizure", "span1": [16, 29], "span2": [132, 139]}, "bert_text": "Scopolamine and <e1> pentobarbital </e1> blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic <e2> seizure </e2> induced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2624": {"data": {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [42, 53], "span2": [77, 84]}, "bert_text": "Scopolamine and pentobarbital blocked the <e1> pilocarpine </e1>-induced electrographic <e2> seizure </e2>, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2625": {"data": {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [42, 53], "span2": [132, 139]}, "bert_text": "Scopolamine and pentobarbital blocked the <e1> pilocarpine </e1>-induced electrographic seizure, MK-801 treatment augmented the electrographic <e2> seizure </e2> induced by pilocarpine.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2626": {"data": {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [151, 162], "span2": [77, 84]}, "bert_text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by <e1> pilocarpine </e1> <e2> seizure </e2>, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2627": {"data": {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [151, 162], "span2": [132, 139]}, "bert_text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by <e1> pilocarpine </e1> <e2> seizure </e2> induced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2628": {"data": {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "entity1": "MK-801", "entity2": "seizure", "span1": [86, 92], "span2": [77, 84]}, "bert_text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, <e1> MK-801 </e1> <e2> seizure </e2>, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2629": {"data": {"text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, MK-801 treatment augmented the electrographic seizure induced by pilocarpine.", "entity1": "MK-801", "entity2": "seizure", "span1": [86, 92], "span2": [132, 139]}, "bert_text": "Scopolamine and pentobarbital blocked the pilocarpine-induced electrographic seizure, <e1> MK-801 </e1> treatment augmented the electrographic <e2> seizure </e2> induced by pilocarpine.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2630": {"data": {"text": "Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment.\n", "entity1": "tacrolimus", "entity2": "dermatitis", "span1": [92, 102], "span2": [25, 35]}, "bert_text": "Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with <e1> tacrolimus </e1> <e2> dermatitis </e2> during treatment of facial inflammatory dermatoses with tacrolimus ointment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2631": {"data": {"text": "Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy.\n", "entity1": "Levetiracetam", "entity2": "idiopathic epilepsy", "span1": [0, 13], "span2": [78, 97]}, "bert_text": "<e1> Levetiracetam </e1> as an adjunct to phenobarbital treatment in cats with suspected <e2> idiopathic epilepsy </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2632": {"data": {"text": "Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy.\n", "entity1": "phenobarbital", "entity2": "idiopathic epilepsy", "span1": [31, 44], "span2": [78, 97]}, "bert_text": "Levetiracetam as an adjunct to <e1> phenobarbital </e1> treatment in cats with suspected <e2> idiopathic epilepsy </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2633": {"data": {"text": "RESULTS: Of 405 patients not previously receiving an ACE inhibitor, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or hyperkalemia (2.3%).", "entity1": "ACE inhibitor", "entity2": "hypotension", "span1": [53, 66], "span2": [196, 207]}, "bert_text": "RESULTS: Of 405 patients not previously receiving an <e1> ACE inhibitor </e1>, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to <e2> hypotension </e2> (2.0%) or because of renal dysfunction or hyperkalemia (2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2634": {"data": {"text": "RESULTS: Of 405 patients not previously receiving an ACE inhibitor, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or hyperkalemia (2.3%).", "entity1": "ACE inhibitor", "entity2": "renal dysfunction", "span1": [53, 66], "span2": [229, 246]}, "bert_text": "RESULTS: Of 405 patients not previously receiving an <e1> ACE inhibitor </e1>, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of <e2> renal dysfunction </e2> or hyperkalemia (2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2635": {"data": {"text": "RESULTS: Of 405 patients not previously receiving an ACE inhibitor, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or hyperkalemia (2.3%).", "entity1": "ACE inhibitor", "entity2": "hyperkalemia", "span1": [53, 66], "span2": [250, 262]}, "bert_text": "RESULTS: Of 405 patients not previously receiving an <e1> ACE inhibitor </e1>, doses in only 4.2% could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension (2.0%) or because of renal dysfunction or <e2> hyperkalemia </e2> (2.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2636": {"data": {"text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "entity1": "acetaminophen", "entity2": "ALF", "span1": [13, 26], "span2": [35, 38]}, "bert_text": "Twenty (56%) <e1> acetaminophen </e1>-induced <e2> ALF </e2> patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2637": {"data": {"text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "entity1": "acetaminophen", "entity2": "ALF=0/35", "span1": [13, 26], "span2": [120, 128]}, "bert_text": "Twenty (56%) <e1> acetaminophen </e1>-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced <e2> ALF=0/35 </e2>, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2638": {"data": {"text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "entity1": "acetaminophen", "entity2": "psychiatric diagnosis", "span1": [13, 26], "span2": [61, 82]}, "bert_text": "Twenty (56%) <e1> acetaminophen </e1>-induced ALF patients had a formal <e2> psychiatric diagnosis </e2> before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2639": {"data": {"text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "entity1": "acetaminophen", "entity2": "CLD=2/34", "span1": [13, 26], "span2": [130, 138]}, "bert_text": "Twenty (56%) <e1> acetaminophen </e1>-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, <e2> CLD=2/34 </e2>; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2640": {"data": {"text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "entity1": "acetaminophen", "entity2": "ALF", "span1": [98, 111], "span2": [35, 38]}, "bert_text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-<e1> acetaminophen </e1> <e2> ALF </e2> patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2641": {"data": {"text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "entity1": "acetaminophen", "entity2": "ALF=0/35", "span1": [98, 111], "span2": [120, 128]}, "bert_text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-<e1> acetaminophen </e1>-induced <e2> ALF=0/35 </e2>, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2642": {"data": {"text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "entity1": "acetaminophen", "entity2": "psychiatric diagnosis", "span1": [98, 111], "span2": [61, 82]}, "bert_text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-<e1> acetaminophen </e1> <e2> psychiatric diagnosis </e2> before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2643": {"data": {"text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-acetaminophen-induced ALF=0/35, CLD=2/34; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "entity1": "acetaminophen", "entity2": "CLD=2/34", "span1": [98, 111], "span2": [130, 138]}, "bert_text": "Twenty (56%) acetaminophen-induced ALF patients had a formal psychiatric diagnosis before LT (non-<e1> acetaminophen </e1>-induced ALF=0/35, <e2> CLD=2/34 </e2>; P<0.01 for all) and nine (25%) had a previous suicide attempt.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2644": {"data": {"text": "Indomethacin induced hypotension in sodium and volume depleted rats.\n", "entity1": "Indomethacin", "entity2": "hypotension", "span1": [0, 12], "span2": [21, 32]}, "bert_text": "<e1> Indomethacin </e1> induced <e2> hypotension </e2> in sodium and volume depleted rats.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2645": {"data": {"text": "Indomethacin induced hypotension in sodium and volume depleted rats.\n", "entity1": "sodium", "entity2": "hypotension", "span1": [36, 42], "span2": [21, 32]}, "bert_text": "Indomethacin induced hypotension in <e1> sodium </e1> <e2> hypotension </e2> in sodium and volume depleted rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2646": {"data": {"text": "The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients.", "entity1": "cyclosporin A", "entity2": "gingival hyperplasia", "span1": [48, 61], "span2": [171, 191]}, "bert_text": "The adverse events during combined therapy with <e1> cyclosporin A </e1> and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of <e2> gingival hyperplasia </e2> in 2 of the 13 patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2647": {"data": {"text": "The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients.", "entity1": "nifedipine", "entity2": "gingival hyperplasia", "span1": [66, 76], "span2": [171, 191]}, "bert_text": "The adverse events during combined therapy with cyclosporin A and <e1> nifedipine </e1> included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of <e2> gingival hyperplasia </e2> in 2 of the 13 patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2648": {"data": {"text": "RESULTS: The incidence and severity of visible muscle fasciculation was significantly less with increasing the amount of precurarizing dose of rocuronium (P < 0.001).", "entity1": "rocuronium", "entity2": "muscle fasciculation", "span1": [143, 153], "span2": [47, 67]}, "bert_text": "RESULTS: The incidence and severity of visible muscle fasciculation was significantly less with increasing the amount of precurarizing dose of <e1> rocuronium </e1> <e2> muscle fasciculation </e2> was significantly less with increasing the amount of precurarizing dose of rocuronium (P < 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2649": {"data": {"text": "Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.\n", "entity1": "Penicillamine", "entity2": "lichenoid dermatitis", "span1": [0, 13], "span2": [22, 42]}, "bert_text": "<e1> Penicillamine </e1>-related <e2> lichenoid dermatitis </e2> and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2650": {"data": {"text": "Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.\n", "entity1": "Penicillamine", "entity2": "Wilson disease", "span1": [0, 13], "span2": [76, 90]}, "bert_text": "<e1> Penicillamine </e1>-related lichenoid dermatitis and utility of zinc acetate in a <e2> Wilson disease </e2> patient with hepatic presentation, anxiety and SPECT abnormalities.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2651": {"data": {"text": "Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.\n", "entity1": "Penicillamine", "entity2": "anxiety", "span1": [0, 13], "span2": [126, 133]}, "bert_text": "<e1> Penicillamine </e1>-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, <e2> anxiety </e2> and SPECT abnormalities.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2652": {"data": {"text": "Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.\n", "entity1": "zinc acetate", "entity2": "lichenoid dermatitis", "span1": [58, 70], "span2": [22, 42]}, "bert_text": "Penicillamine-related lichenoid dermatitis and utility of <e1> zinc acetate </e1> <e2> lichenoid dermatitis </e2> and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2653": {"data": {"text": "Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.\n", "entity1": "zinc acetate", "entity2": "Wilson disease", "span1": [58, 70], "span2": [76, 90]}, "bert_text": "Penicillamine-related lichenoid dermatitis and utility of <e1> zinc acetate </e1> in a <e2> Wilson disease </e2> patient with hepatic presentation, anxiety and SPECT abnormalities.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2654": {"data": {"text": "Penicillamine-related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation, anxiety and SPECT abnormalities.\n", "entity1": "zinc acetate", "entity2": "anxiety", "span1": [58, 70], "span2": [126, 133]}, "bert_text": "Penicillamine-related lichenoid dermatitis and utility of <e1> zinc acetate </e1> in a Wilson disease patient with hepatic presentation, <e2> anxiety </e2> and SPECT abnormalities.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2655": {"data": {"text": "CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [69, 79], "span2": [112, 123]}, "bert_text": "CONCLUSION: Although the natural occurrence of YMDD motif mutants in <e1> lamivudine </e1>-untreated patients with chronic <e2> hepatitis B </e2> has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2656": {"data": {"text": "CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [69, 79], "span2": [215, 226]}, "bert_text": "CONCLUSION: Although the natural occurrence of YMDD motif mutants in <e1> lamivudine </e1>-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic <e2> hepatitis B </e2> patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2657": {"data": {"text": "CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [186, 196], "span2": [112, 123]}, "bert_text": "CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian <e1> lamivudine </e1> <e2> hepatitis B </e2> has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"2658": {"data": {"text": "CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients.", "entity1": "lamivudine", "entity2": "hepatitis B", "span1": [186, 196], "span2": [215, 226]}, "bert_text": "CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian <e1> lamivudine </e1>-untreated chronic <e2> hepatitis B </e2> patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2659": {"data": {"text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "entity1": "olanzapine", "entity2": "schizophrenia", "span1": [226, 236], "span2": [98, 111]}, "bert_text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with <e1> olanzapine </e1> <e2> schizophrenia </e2> (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2660": {"data": {"text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "entity1": "olanzapine", "entity2": "schizophreniform disorder", "span1": [226, 236], "span2": [119, 144]}, "bert_text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with <e1> olanzapine </e1> <e2> schizophreniform disorder </e2> (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2661": {"data": {"text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "entity1": "olanzapine", "entity2": "schizoaffective disorder", "span1": [226, 236], "span2": [155, 179]}, "bert_text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with <e1> olanzapine </e1> <e2> schizoaffective disorder </e2> (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2662": {"data": {"text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "entity1": "risperidone", "entity2": "schizophrenia", "span1": [256, 267], "span2": [98, 111]}, "bert_text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or <e1> risperidone </e1> <e2> schizophrenia </e2> (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2663": {"data": {"text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "entity1": "risperidone", "entity2": "schizophreniform disorder", "span1": [256, 267], "span2": [119, 144]}, "bert_text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or <e1> risperidone </e1> <e2> schizophreniform disorder </e2> (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2664": {"data": {"text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "entity1": "risperidone", "entity2": "schizoaffective disorder", "span1": [256, 267], "span2": [155, 179]}, "bert_text": "METHOD: One hundred twelve subjects (70% male; mean age=23.3 years [SD = 5.1]) with first-episode schizophrenia (75%), schizophreniform disorder (17%), or schizoaffective disorder (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or <e1> risperidone </e1> <e2> schizoaffective disorder </e2> (8%) were randomly assigned to treatment with olanzapine (2.5-20 mg/day) or risperidone (1-6 mg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2665": {"data": {"text": "CONCLUSIONS: Although neutropenia is not a common side effect of quetiapine, physicians should be cautious about its presentation and associated risk factors.", "entity1": "quetiapine", "entity2": "neutropenia", "span1": [65, 75], "span2": [22, 33]}, "bert_text": "CONCLUSIONS: Although neutropenia is not a common side effect of <e1> quetiapine </e1> <e2> neutropenia </e2> is not a common side effect of quetiapine, physicians should be cautious about its presentation and associated risk factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2666": {"data": {"text": "Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol-remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT.", "entity1": "propofol-remifentanil-TIVA", "entity2": "hypotension", "span1": [143, 169], "span2": [110, 121]}, "bert_text": "Sixty normotensive American Society of Anesthesiologists I-II adult patients undergoing FESS under controlled hypotension anesthesia caused by <e1> propofol-remifentanil-TIVA </e1> <e2> hypotension </e2> anesthesia caused by propofol-remifentanil-TIVA were randomly assigned into two groups: group I, FRLMA; group II, ETT.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2667": {"data": {"text": "To our knowledge, this is the first report of nicergoline-associated AIN.", "entity1": "nicergoline", "entity2": "AIN", "span1": [46, 57], "span2": [69, 72]}, "bert_text": "To our knowledge, this is the first report of <e1> nicergoline </e1>-associated <e2> AIN </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2668": {"data": {"text": "Oral administration of betaine (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling.", "entity1": "betaine", "entity2": "ventricular remodeling", "span1": [23, 30], "span2": [140, 162]}, "bert_text": "Oral administration of <e1> betaine </e1> (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left <e2> ventricular remodeling </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2669": {"data": {"text": "The intracerebroventricular (ICV) administration of ouabain (a Na(+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania.", "entity1": "ouabain", "entity2": "bipolar mania", "span1": [52, 59], "span2": [151, 164]}, "bert_text": "The intracerebroventricular (ICV) administration of <e1> ouabain </e1> (a Na(+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human <e2> bipolar mania </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2670": {"data": {"text": "The intracerebroventricular (ICV) administration of ouabain (a Na(+)/K(+)-ATPase inhibitor) in rats has been suggested to mimic some symptoms of human bipolar mania.", "entity1": "Na(+)/K(+)-ATPase", "entity2": "bipolar mania", "span1": [63, 80], "span2": [151, 164]}, "bert_text": "The intracerebroventricular (ICV) administration of ouabain (a <e1> Na(+)/K(+)-ATPase </e1> inhibitor) in rats has been suggested to mimic some symptoms of human <e2> bipolar mania </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2671": {"data": {"text": "This particular case is of interest as rhabdomyolysis only occurred after an increase in the dose of clarithromycin.", "entity1": "clarithromycin", "entity2": "rhabdomyolysis", "span1": [101, 115], "span2": [39, 53]}, "bert_text": "This particular case is of interest as rhabdomyolysis only occurred after an increase in the dose of <e1> clarithromycin </e1> <e2> rhabdomyolysis </e2> only occurred after an increase in the dose of clarithromycin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2672": {"data": {"text": "Early infections in kidney, heart, and liver transplant recipients on cyclosporine.\n", "entity1": "cyclosporine", "entity2": "infections", "span1": [70, 82], "span2": [6, 16]}, "bert_text": "Early infections in kidney, heart, and liver transplant recipients on <e1> cyclosporine </e1> <e2> infections </e2> in kidney, heart, and liver transplant recipients on cyclosporine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2673": {"data": {"text": "In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.", "entity1": "bupivacaine", "entity2": "postoperative pain", "span1": [65, 76], "span2": [177, 195]}, "bert_text": "In the present study, we describe the proinflammatory effects of <e1> bupivacaine </e1> on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases <e2> postoperative pain </e2> in human subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2674": {"data": {"text": "In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.", "entity1": "prostaglandin E2", "entity2": "postoperative pain", "span1": [86, 102], "span2": [177, 195]}, "bert_text": "In the present study, we describe the proinflammatory effects of bupivacaine on local <e1> prostaglandin E2 </e1> (PGE2) production and cyclooxygenase (COX) gene expression that increases <e2> postoperative pain </e2> in human subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2675": {"data": {"text": "In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (PGE2) production and cyclooxygenase (COX) gene expression that increases postoperative pain in human subjects.", "entity1": "PGE2", "entity2": "postoperative pain", "span1": [104, 108], "span2": [177, 195]}, "bert_text": "In the present study, we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 (<e1> PGE2 </e1>) production and cyclooxygenase (COX) gene expression that increases <e2> postoperative pain </e2> in human subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2676": {"data": {"text": "CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.", "entity1": "CE", "entity2": "hypersensitivity", "span1": [50, 52], "span2": [21, 37]}, "bert_text": "CONCLUSION: Only one hypersensitivity reaction to <e1> CE </e1> <e2> hypersensitivity </e2> reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2677": {"data": {"text": "CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.", "entity1": "N", "entity2": "hypersensitivity", "span1": [82, 83], "span2": [21, 37]}, "bert_text": "CONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and <e1> N </e1> <e2> hypersensitivity </e2> reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2678": {"data": {"text": "However, physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.", "entity1": "mirtazapine", "entity2": "RLS", "span1": [60, 71], "span2": [95, 98]}, "bert_text": "However, physicians should be aware of the possibility that <e1> mirtazapine </e1> can be associated with <e2> RLS </e2> in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2679": {"data": {"text": "However, physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.", "entity1": "dopamine", "entity2": "RLS", "span1": [159, 167], "span2": [95, 98]}, "bert_text": "However, physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals, especially those receiving concomitant <e1> dopamine </e1> <e2> RLS </e2> in some individuals, especially those receiving concomitant dopamine D2 receptor antagonists.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2680": {"data": {"text": "Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran.", "entity1": "2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone", "entity2": "renal failure", "span1": [23, 66], "span2": [90, 103]}, "bert_text": "Oral administration of <e1> 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone </e1> protected rats against <e2> renal failure </e2> induced by kanamycin-dextran.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2681": {"data": {"text": "Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran.", "entity1": "kanamycin", "entity2": "renal failure", "span1": [115, 124], "span2": [90, 103]}, "bert_text": "Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by <e1> kanamycin </e1> <e2> renal failure </e2> induced by kanamycin-dextran.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2682": {"data": {"text": "Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-dextran.", "entity1": "dextran", "entity2": "renal failure", "span1": [125, 132], "span2": [90, 103]}, "bert_text": "Oral administration of 2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected rats against renal failure induced by kanamycin-<e1> dextran </e1> <e2> renal failure </e2> induced by kanamycin-dextran.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2683": {"data": {"text": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "entity1": "valproic acid", "entity2": "dementia", "span1": [11, 24], "span2": [33, 41]}, "bert_text": "Reversible <e1> valproic acid </e1>-induced <e2> dementia </e2> was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2684": {"data": {"text": "Reversible valproic acid-induced dementia was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "entity1": "valproic acid", "entity2": "epilepsy", "span1": [11, 24], "span2": [83, 91]}, "bert_text": "Reversible <e1> valproic acid </e1>-induced dementia was documented in a 21-year-old man with <e2> epilepsy </e2> who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2685": {"data": {"text": "Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.\n", "entity1": "lead", "entity2": "cognitive impairment", "span1": [75, 79], "span2": [114, 134]}, "bert_text": "Succimer chelation improves learning, attention, and arousal regulation in <e1> lead </e1>-exposed rats but produces lasting <e2> cognitive impairment </e2> in the absence of lead exposure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2686": {"data": {"text": "Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure.\n", "entity1": "lead", "entity2": "cognitive impairment", "span1": [153, 157], "span2": [114, 134]}, "bert_text": "Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of <e1> lead </e1> <e2> cognitive impairment </e2> in the absence of lead exposure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2687": {"data": {"text": "Myopathy due to lack of vitamin E and myopathy induced by certain viruses have much in common anatomically and pathologically with the human form.", "entity1": "vitamin E", "entity2": "Myopathy", "span1": [24, 33], "span2": [0, 8]}, "bert_text": "Myopathy due to lack of <e1> vitamin E </e1> <e2> Myopathy </e2> due to lack of vitamin E and myopathy induced by certain viruses have much in common anatomically and pathologically with the human form.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2688": {"data": {"text": "Myopathy due to lack of vitamin E and myopathy induced by certain viruses have much in common anatomically and pathologically with the human form.", "entity1": "vitamin E", "entity2": "myopathy", "span1": [24, 33], "span2": [38, 46]}, "bert_text": "Myopathy due to lack of <e1> vitamin E </e1> and <e2> myopathy </e2> induced by certain viruses have much in common anatomically and pathologically with the human form.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2689": {"data": {"text": "Based upon these results, we conclude that amiodarone disrupts hepatic lipid homeostasis and that the increased expression of PPARalpha target genes is secondary to this toxic effect.", "entity1": "amiodarone", "entity2": "disrupts hepatic lipid homeostasis", "span1": [43, 53], "span2": [54, 88]}, "bert_text": "Based upon these results, we conclude that <e1> amiodarone </e1> <e2> disrupts hepatic lipid homeostasis </e2> and that the increased expression of PPARalpha target genes is secondary to this toxic effect.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2690": {"data": {"text": "Based upon these results, we conclude that amiodarone disrupts hepatic lipid homeostasis and that the increased expression of PPARalpha target genes is secondary to this toxic effect.", "entity1": "PPARalpha", "entity2": "disrupts hepatic lipid homeostasis", "span1": [126, 135], "span2": [54, 88]}, "bert_text": "Based upon these results, we conclude that amiodarone disrupts hepatic lipid homeostasis and that the increased expression of <e1> PPARalpha </e1> <e2> disrupts hepatic lipid homeostasis </e2> and that the increased expression of PPARalpha target genes is secondary to this toxic effect.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2691": {"data": {"text": "In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.", "entity1": "fluoxetine", "entity2": "hyperkinetic delirium", "span1": [105, 115], "span2": [49, 70]}, "bert_text": "In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total <e1> fluoxetine </e1> <e2> hyperkinetic delirium </e2> connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2692": {"data": {"text": "In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.", "entity1": "fluoxetine", "entity2": "hyperkinetic delirium", "span1": [117, 127], "span2": [49, 70]}, "bert_text": "In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (<e1> fluoxetine </e1> <e2> hyperkinetic delirium </e2> connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2693": {"data": {"text": "In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.", "entity1": "desmethylfluoxetine", "entity2": "hyperkinetic delirium", "span1": [133, 152], "span2": [49, 70]}, "bert_text": "In this report, we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine (fluoxetine plus <e1> desmethylfluoxetine </e1> <e2> hyperkinetic delirium </e2> connected with a high serum total fluoxetine (fluoxetine plus desmethylfluoxetine) concentration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2694": {"data": {"text": "The annual stroke rate after initiation of warfarin was 2.6%.", "entity1": "warfarin", "entity2": "stroke", "span1": [43, 51], "span2": [11, 17]}, "bert_text": "The annual stroke rate after initiation of <e1> warfarin </e1> <e2> stroke </e2> rate after initiation of warfarin was 2.6%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2695": {"data": {"text": "Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions.", "entity1": "FZP", "entity2": "muscle tremors", "span1": [9, 12], "span2": [102, 116]}, "bert_text": "Signs of <e1> FZP </e1> toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, <e2> muscle tremors </e2> and convulsions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2696": {"data": {"text": "Signs of FZP toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and convulsions.", "entity1": "FZP", "entity2": "convulsions", "span1": [9, 12], "span2": [121, 132]}, "bert_text": "Signs of <e1> FZP </e1> toxocity in cats included excessive salivation, extreme apprehensive behavior, retching, muscle tremors and <e2> convulsions </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2697": {"data": {"text": "Heparin, first used to prevent the clotting of blood in vitro, has been clinically used to treat thrombosis for more than 50 years.", "entity1": "Heparin", "entity2": "thrombosis", "span1": [0, 7], "span2": [97, 107]}, "bert_text": "<e1> Heparin </e1>, first used to prevent the clotting of blood in vitro, has been clinically used to treat <e2> thrombosis </e2> for more than 50 years.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2698": {"data": {"text": "Relationship between nicotine-induced seizures and hippocampal nicotinic receptors.\n", "entity1": "nicotine", "entity2": "seizures", "span1": [21, 29], "span2": [38, 46]}, "bert_text": "Relationship between <e1> nicotine </e1>-induced <e2> seizures </e2> and hippocampal nicotinic receptors.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2699": {"data": {"text": "Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.\n", "entity1": "valsartan", "entity2": "hypertensive", "span1": [14, 23], "span2": [195, 207]}, "bert_text": "Comparison of <e1> valsartan </e1>/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in <e2> hypertensive </e2> adults.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2700": {"data": {"text": "Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.\n", "entity1": "hydrochlorothiazide", "entity2": "hypertensive", "span1": [24, 43], "span2": [195, 207]}, "bert_text": "Comparison of valsartan/<e1> hydrochlorothiazide </e1> combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in <e2> hypertensive </e2> adults.\n", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2701": {"data": {"text": "Flecainide had been started 2 weeks prior for atrial fibrillation.", "entity1": "Flecainide", "entity2": "atrial fibrillation", "span1": [0, 10], "span2": [46, 65]}, "bert_text": "<e1> Flecainide </e1> had been started 2 weeks prior for <e2> atrial fibrillation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2702": {"data": {"text": "Caffeine challenge test in panic disorder and depression with panic attacks.\n", "entity1": "Caffeine", "entity2": "panic disorder", "span1": [0, 8], "span2": [27, 41]}, "bert_text": "<e1> Caffeine </e1> challenge test in <e2> panic disorder </e2> and depression with panic attacks.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2703": {"data": {"text": "Caffeine challenge test in panic disorder and depression with panic attacks.\n", "entity1": "Caffeine", "entity2": "panic attacks", "span1": [0, 8], "span2": [62, 75]}, "bert_text": "<e1> Caffeine </e1> challenge test in panic disorder and depression with <e2> panic attacks </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2704": {"data": {"text": "Caffeine challenge test in panic disorder and depression with panic attacks.\n", "entity1": "Caffeine", "entity2": "depression", "span1": [0, 8], "span2": [46, 56]}, "bert_text": "<e1> Caffeine </e1> challenge test in panic disorder and <e2> depression </e2> with panic attacks.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2705": {"data": {"text": "MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.", "entity1": "glucose", "entity2": "effectiveness", "span1": [38, 45], "span2": [171, 184]}, "bert_text": "MAIN OUTCOME MEASURES: Fasting plasma <e1> glucose </e1> and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose <e2> effectiveness </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"2706": {"data": {"text": "MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.", "entity1": "glucose", "entity2": "effectiveness", "span1": [163, 170], "span2": [171, 184]}, "bert_text": "MAIN OUTCOME MEASURES: Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and <e1> glucose </e1> <e2> effectiveness </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2707": {"data": {"text": "The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.", "entity1": "PCE", "entity2": "glomerulosclerosis", "span1": [61, 64], "span2": [81, 99]}, "bert_text": "The results revealed that the adult offspring kidneys in the <e1> PCE </e1> group exhibited <e2> glomerulosclerosis </e2> as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2708": {"data": {"text": "The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.", "entity1": "PCE", "entity2": "fibrosis", "span1": [61, 64], "span2": [124, 132]}, "bert_text": "The results revealed that the adult offspring kidneys in the <e1> PCE </e1> group exhibited glomerulosclerosis as well as interstitial <e2> fibrosis </e2>, accompanied by elevated levels of serum creatinine and urine protein.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2709": {"data": {"text": "The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.", "entity1": "creatinine", "entity2": "glomerulosclerosis", "span1": [174, 184], "span2": [81, 99]}, "bert_text": "The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum <e1> creatinine </e1> <e2> glomerulosclerosis </e2> as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2710": {"data": {"text": "The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein.", "entity1": "creatinine", "entity2": "fibrosis", "span1": [174, 184], "span2": [124, 132]}, "bert_text": "The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum <e1> creatinine </e1> <e2> fibrosis </e2>, accompanied by elevated levels of serum creatinine and urine protein.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2711": {"data": {"text": "Toxic hepatitis induced by disulfiram in a non-alcoholic.\n", "entity1": "disulfiram", "entity2": "Toxic hepatitis", "span1": [27, 37], "span2": [0, 15]}, "bert_text": "Toxic hepatitis induced by <e1> disulfiram </e1> <e2> Toxic hepatitis </e2> induced by disulfiram in a non-alcoholic.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2712": {"data": {"text": "OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI.", "entity1": "cocaine", "entity2": "chest pain", "span1": [76, 83], "span2": [84, 94]}, "bert_text": "OBJECTIVE: To assess outcomes based on troponin positivity in patients with <e1> cocaine </e1> <e2> chest pain </e2> admitted for exclusion of MI.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2713": {"data": {"text": "OBJECTIVE: To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI.", "entity1": "cocaine", "entity2": "MI", "span1": [76, 83], "span2": [121, 123]}, "bert_text": "OBJECTIVE: To assess outcomes based on troponin positivity in patients with <e1> cocaine </e1> chest pain admitted for exclusion of <e2> MI </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2714": {"data": {"text": "Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma.\n", "entity1": "Quetiapine", "entity2": "neutropenia", "span1": [0, 10], "span2": [19, 30]}, "bert_text": "<e1> Quetiapine </e1>-induced <e2> neutropenia </e2> in a bipolar patient with hepatocellular carcinoma.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2715": {"data": {"text": "Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma.\n", "entity1": "Quetiapine", "entity2": "bipolar", "span1": [0, 10], "span2": [36, 43]}, "bert_text": "<e1> Quetiapine </e1>-induced neutropenia in a <e2> bipolar </e2> patient with hepatocellular carcinoma.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2716": {"data": {"text": "Quetiapine-induced neutropenia in a bipolar patient with hepatocellular carcinoma.\n", "entity1": "Quetiapine", "entity2": "hepatocellular carcinoma", "span1": [0, 10], "span2": [57, 81]}, "bert_text": "<e1> Quetiapine </e1>-induced neutropenia in a bipolar patient with <e2> hepatocellular carcinoma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2717": {"data": {"text": "A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated nephropathy.", "entity1": "guanosine 3',5'-cyclic monophosphate", "entity2": "nephropathy", "span1": [35, 71], "span2": [200, 211]}, "bert_text": "A significant reduction in urinary <e1> guanosine 3',5'-cyclic monophosphate </e1> (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2718": {"data": {"text": "A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in GM-mediated nephropathy.", "entity1": "GM", "entity2": "nephropathy", "span1": [188, 190], "span2": [200, 211]}, "bert_text": "A significant reduction in urinary guanosine 3',5'-cyclic monophosphate (cGMP) excretion and a significant increase in renal cortical renin and endothelin-1 contents were also observed in <e1> GM </e1>-mediated <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2719": {"data": {"text": "By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his lithium-induced nephrogenic DI and developed neurogenic DI secondary to brain trauma.", "entity1": "lithium", "entity2": "nephrogenic DI", "span1": [196, 203], "span2": [212, 226]}, "bert_text": "By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his <e1> lithium </e1>-induced <e2> nephrogenic DI </e2> and developed neurogenic DI secondary to brain trauma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"2720": {"data": {"text": "By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his lithium-induced nephrogenic DI and developed neurogenic DI secondary to brain trauma.", "entity1": "lithium", "entity2": "DI", "span1": [196, 203], "span2": [252, 254]}, "bert_text": "By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his <e1> lithium </e1>-induced nephrogenic DI and developed neurogenic <e2> DI </e2> secondary to brain trauma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2721": {"data": {"text": "By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his lithium-induced nephrogenic DI and developed neurogenic DI secondary to brain trauma.", "entity1": "lithium", "entity2": "brain trauma", "span1": [196, 203], "span2": [268, 280]}, "bert_text": "By combining information from the patient history, the physical examination, and radiologic and laboratory studies, the critical care team demonstrated that the patient had been self-treating his <e1> lithium </e1>-induced nephrogenic DI and developed neurogenic DI secondary to <e2> brain trauma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2722": {"data": {"text": "We report syncope and bradycardia in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram.", "entity1": "dexmedetomidine", "entity2": "syncope", "span1": [96, 111], "span2": [10, 17]}, "bert_text": "We report syncope and bradycardia in an 11-year-old girl following administration of intranasal <e1> dexmedetomidine </e1> <e2> syncope </e2> and bradycardia in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2723": {"data": {"text": "We report syncope and bradycardia in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram.", "entity1": "dexmedetomidine", "entity2": "bradycardia", "span1": [96, 111], "span2": [22, 33]}, "bert_text": "We report syncope and bradycardia in an 11-year-old girl following administration of intranasal <e1> dexmedetomidine </e1> <e2> bradycardia </e2> in an 11-year-old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2724": {"data": {"text": "Given the increasing use of crack cocaine, we sought to examine whether use of this illicit drug has become a risk factor for HIV infection.", "entity1": "crack cocaine", "entity2": "HIV infection", "span1": [28, 41], "span2": [126, 139]}, "bert_text": "Given the increasing use of <e1> crack cocaine </e1>, we sought to examine whether use of this illicit drug has become a risk factor for <e2> HIV infection </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2725": {"data": {"text": "Intradermal glutamate and capsaicin injections: intra- and interindividual variability of provoked hyperalgesia and allodynia.\n", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [26, 35], "span2": [99, 111]}, "bert_text": "Intradermal glutamate and <e1> capsaicin </e1> injections: intra- and interindividual variability of provoked <e2> hyperalgesia </e2> and allodynia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2726": {"data": {"text": "Intradermal glutamate and capsaicin injections: intra- and interindividual variability of provoked hyperalgesia and allodynia.\n", "entity1": "capsaicin", "entity2": "allodynia", "span1": [26, 35], "span2": [116, 125]}, "bert_text": "Intradermal glutamate and <e1> capsaicin </e1> injections: intra- and interindividual variability of provoked hyperalgesia and <e2> allodynia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2727": {"data": {"text": "METHOD: We searched the Eli Lilly and Company's computerized adverse event database for all reported cases of hyponatremia and/or SIADH as of 1 November 1999 that had been reported during the use of vincristine.", "entity1": "vincristine", "entity2": "hyponatremia", "span1": [199, 210], "span2": [110, 122]}, "bert_text": "METHOD: We searched the Eli Lilly and Company's computerized adverse event database for all reported cases of hyponatremia and/or SIADH as of 1 November 1999 that had been reported during the use of <e1> vincristine </e1> <e2> hyponatremia </e2> and/or SIADH as of 1 November 1999 that had been reported during the use of vincristine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2728": {"data": {"text": "Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.\n", "entity1": "5-fluorouracil", "entity2": "hyperammonemic encephalopathy", "span1": [103, 117], "span2": [18, 47]}, "bert_text": "Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of <e1> 5-fluorouracil </e1> <e2> hyperammonemic encephalopathy </e2> in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2729": {"data": {"text": "Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.\n", "entity1": "5-fluorouracil", "entity2": "cancer", "span1": [103, 117], "span2": [51, 57]}, "bert_text": "Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of <e1> 5-fluorouracil </e1> <e2> cancer </e2> patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2730": {"data": {"text": "Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.\n", "entity1": "5-fluorouracil", "entity2": "dehydration", "span1": [103, 117], "span2": [143, 154]}, "bert_text": "Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of <e1> 5-fluorouracil </e1> with the complication of <e2> dehydration </e2> and infection.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2731": {"data": {"text": "Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection.\n", "entity1": "5-fluorouracil", "entity2": "infection", "span1": [103, 117], "span2": [159, 168]}, "bert_text": "Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of <e1> 5-fluorouracil </e1> with the complication of dehydration and <e2> infection </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2732": {"data": {"text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "entity1": "Maleate", "entity2": "renal injury", "span1": [0, 7], "span2": [16, 28]}, "bert_text": "<e1> Maleate </e1>-induced <e2> renal injury </e2> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2733": {"data": {"text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "entity1": "Maleate", "entity2": "kidney injury", "span1": [0, 7], "span2": [246, 259]}, "bert_text": "<e1> Maleate </e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <e2> kidney injury </e2> molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2734": {"data": {"text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "entity1": "Maleate", "entity2": "necrosis", "span1": [0, 7], "span2": [343, 351]}, "bert_text": "<e1> Maleate </e1>-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of <e2> necrosis </e2> and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2735": {"data": {"text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "entity1": "glucose", "entity2": "renal injury", "span1": [123, 130], "span2": [16, 28]}, "bert_text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, <e1> glucose </e1> <e2> renal injury </e2> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2736": {"data": {"text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "entity1": "glucose", "entity2": "kidney injury", "span1": [123, 130], "span2": [246, 259]}, "bert_text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, <e1> glucose </e1>, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <e2> kidney injury </e2> molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2737": {"data": {"text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "entity1": "glucose", "entity2": "necrosis", "span1": [123, 130], "span2": [343, 351]}, "bert_text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, <e1> glucose </e1>, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of <e2> necrosis </e2> and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2738": {"data": {"text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "entity1": "sodium", "entity2": "renal injury", "span1": [132, 138], "span2": [16, 28]}, "bert_text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <e1> sodium </e1> <e2> renal injury </e2> included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2739": {"data": {"text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "entity1": "sodium", "entity2": "kidney injury", "span1": [132, 138], "span2": [246, 259]}, "bert_text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <e1> sodium </e1>, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of <e2> kidney injury </e2> molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2740": {"data": {"text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, sodium, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of necrosis and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "entity1": "sodium", "entity2": "necrosis", "span1": [132, 138], "span2": [343, 351]}, "bert_text": "Maleate-induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein, glucose, <e1> sodium </e1>, neutrophil gelatinase-associated lipocalin (NGAL) and N-acetyl b-D-glucosaminidase (NAG), upregulation of kidney injury molecule (KIM)-1, decrease in renal blood flow and claudin-2 expression besides of <e2> necrosis </e2> and apoptosis of tubular cells on 24 h. Oxidative stress was determined by measuring the oxidation of lipids and proteins and diminution in renal Nrf2 levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2741": {"data": {"text": "Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats.\n", "entity1": "pilocarpine", "entity2": "seizures", "span1": [86, 97], "span2": [65, 73]}, "bert_text": "Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by <e1> pilocarpine </e1> <e2> seizures </e2> produced by pilocarpine in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2742": {"data": {"text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.", "entity1": "Trazodone", "entity2": "catalepsy", "span1": [9, 18], "span2": [55, 64]}, "bert_text": "RESULTS: <e1> Trazodone </e1> at 2.5-20 mg/kg i.p. did not induce <e2> catalepsy </e2>, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"2743": {"data": {"text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.", "entity1": "Trazodone", "entity2": "catalepsy", "span1": [9, 18], "span2": [167, 176]}, "bert_text": "RESULTS: <e1> Trazodone </e1> at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2744": {"data": {"text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [89, 100], "span2": [55, 64]}, "bert_text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize <e1> apomorphine </e1> <e2> catalepsy </e2>, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2745": {"data": {"text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [89, 100], "span2": [167, 176]}, "bert_text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize <e1> apomorphine </e1> (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2746": {"data": {"text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [134, 145], "span2": [55, 64]}, "bert_text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and <e1> apomorphine </e1> <e2> catalepsy </e2>, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"2747": {"data": {"text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [134, 145], "span2": [167, 176]}, "bert_text": "RESULTS: Trazodone at 2.5-20 mg/kg i.p. did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and <e1> apomorphine </e1> (0.05 mg/kg)-induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2748": {"data": {"text": "The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation.", "entity1": "methyldopa", "entity2": "trauma", "span1": [42, 52], "span2": [62, 68]}, "bert_text": "The boy had been treated with intravenous <e1> methyldopa </e1> during a <e2> trauma </e2> admission seven weeks prior to presentation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2749": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizure", "span1": [49, 62], "span2": [7, 14]}, "bert_text": "Median seizure frequency prior to treatment with <e1> levetiracetam </e1> <e2> seizure </e2> frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2750": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizures", "span1": [49, 62], "span2": [68, 76]}, "bert_text": "Median seizure frequency prior to treatment with <e1> levetiracetam </e1> (2.1 <e2> seizures </e2>/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2751": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizure", "span1": [49, 62], "span2": [118, 125]}, "bert_text": "Median seizure frequency prior to treatment with <e1> levetiracetam </e1> (2.1 seizures/mo) was significantly higher than median <e2> seizure </e2> frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2752": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizures", "span1": [49, 62], "span2": [186, 194]}, "bert_text": "Median seizure frequency prior to treatment with <e1> levetiracetam </e1> (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 <e2> seizures </e2>/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2753": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizure", "span1": [49, 62], "span2": [298, 305]}, "bert_text": "Median seizure frequency prior to treatment with <e1> levetiracetam </e1> (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in <e2> seizure </e2> frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2754": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizure", "span1": [156, 169], "span2": [7, 14]}, "bert_text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of <e1> levetiracetam </e1> <e2> seizure </e2> frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2755": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizures", "span1": [156, 169], "span2": [68, 76]}, "bert_text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of <e1> levetiracetam </e1> <e2> seizures </e2>/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2756": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizure", "span1": [156, 169], "span2": [118, 125]}, "bert_text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of <e1> levetiracetam </e1> <e2> seizure </e2> frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2757": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizures", "span1": [156, 169], "span2": [186, 194]}, "bert_text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of <e1> levetiracetam </e1> treatment (0.42 <e2> seizures </e2>/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2758": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizure", "span1": [156, 169], "span2": [298, 305]}, "bert_text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of <e1> levetiracetam </e1> treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in <e2> seizure </e2> frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2759": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizure", "span1": [256, 269], "span2": [7, 14]}, "bert_text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to <e1> levetiracetam </e1> <e2> seizure </e2> frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2760": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizures", "span1": [256, 269], "span2": [68, 76]}, "bert_text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to <e1> levetiracetam </e1> <e2> seizures </e2>/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2761": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizure", "span1": [256, 269], "span2": [118, 125]}, "bert_text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to <e1> levetiracetam </e1> <e2> seizure </e2> frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2762": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizures", "span1": [256, 269], "span2": [186, 194]}, "bert_text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to <e1> levetiracetam </e1> <e2> seizures </e2>/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2763": {"data": {"text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to levetiracetam treatment (ie, reduction in seizure frequency of >or=50%).", "entity1": "levetiracetam", "entity2": "seizure", "span1": [256, 269], "span2": [298, 305]}, "bert_text": "Median seizure frequency prior to treatment with levetiracetam (2.1 seizures/mo) was significantly higher than median seizure frequency after initiation of levetiracetam treatment (0.42 seizures/mo), and 7 of 10 cats were classified as having responded to <e1> levetiracetam </e1> treatment (ie, reduction in <e2> seizure </e2> frequency of >or=50%).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2764": {"data": {"text": "Mice sensitive to the convulsant effects of nicotine had greater alpha-bungarotoxin binding in the hippocampus than seizure insensitive mice.", "entity1": "nicotine", "entity2": "seizure", "span1": [44, 52], "span2": [116, 123]}, "bert_text": "Mice sensitive to the convulsant effects of <e1> nicotine </e1> had greater alpha-bungarotoxin binding in the hippocampus than <e2> seizure </e2> insensitive mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2765": {"data": {"text": "Mice sensitive to the convulsant effects of nicotine had greater alpha-bungarotoxin binding in the hippocampus than seizure insensitive mice.", "entity1": "alpha-bungarotoxin", "entity2": "seizure", "span1": [65, 83], "span2": [116, 123]}, "bert_text": "Mice sensitive to the convulsant effects of nicotine had greater <e1> alpha-bungarotoxin </e1> binding in the hippocampus than <e2> seizure </e2> insensitive mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2766": {"data": {"text": "Cardiac work was significantly reduced during SNP hypotension.", "entity1": "SNP", "entity2": "hypotension", "span1": [46, 49], "span2": [50, 61]}, "bert_text": "Cardiac work was significantly reduced during <e1> SNP </e1> <e2> hypotension </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2767": {"data": {"text": "CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.", "entity1": "Losartan", "entity2": "glomerulosclerosis to end-stage renal disease", "span1": [12, 20], "span2": [84, 129]}, "bert_text": "CONCLUSION: <e1> Losartan </e1> reduces the rate of progression of ADR-induced focal segmental <e2> glomerulosclerosis to end-stage renal disease </e2> in SHR.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2768": {"data": {"text": "CONCLUSION: Losartan reduces the rate of progression of ADR-induced focal segmental glomerulosclerosis to end-stage renal disease in SHR.", "entity1": "ADR", "entity2": "glomerulosclerosis to end-stage renal disease", "span1": [56, 59], "span2": [84, 129]}, "bert_text": "CONCLUSION: Losartan reduces the rate of progression of <e1> ADR </e1>-induced focal segmental <e2> glomerulosclerosis to end-stage renal disease </e2> in SHR.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2769": {"data": {"text": "CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase.", "entity1": "argatroban", "entity2": "renal amyloidosis", "span1": [118, 128], "span2": [35, 52]}, "bert_text": "CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with <e1> argatroban </e1> <e2> renal amyloidosis </e2> and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2770": {"data": {"text": "CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase.", "entity1": "argatroban", "entity2": "SVC syndrome", "span1": [118, 128], "span2": [57, 69]}, "bert_text": "CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with <e1> argatroban </e1> <e2> SVC syndrome </e2> secondary to HITT was successfully treated with argatroban and CDT with alteplase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2771": {"data": {"text": "CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase.", "entity1": "argatroban", "entity2": "HITT", "span1": [118, 128], "span2": [83, 87]}, "bert_text": "CONCLUSION: A 63-year-old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with <e1> argatroban </e1> <e2> HITT </e2> was successfully treated with argatroban and CDT with alteplase.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2772": {"data": {"text": "A patient who developed paraplegia following the intrathecal instillation of methotrexate is discribed.", "entity1": "methotrexate", "entity2": "paraplegia", "span1": [77, 89], "span2": [24, 34]}, "bert_text": "A patient who developed paraplegia following the intrathecal instillation of <e1> methotrexate </e1> <e2> paraplegia </e2> following the intrathecal instillation of methotrexate is discribed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2773": {"data": {"text": "RESULTS: We observed positive associations of Parkinson's disease with ozone (odds ratio = 1.39; 95% CI: 0.98 to 1.98) and fine particulate matter (odds ratio = 1.34; 95% CI: 0.93 to 1.93) in North Carolina but not in Iowa.", "entity1": "ozone", "entity2": "Parkinson's disease", "span1": [71, 76], "span2": [46, 65]}, "bert_text": "RESULTS: We observed positive associations of Parkinson's disease with <e1> ozone </e1> <e2> Parkinson's disease </e2> with ozone (odds ratio = 1.39; 95% CI: 0.98 to 1.98) and fine particulate matter (odds ratio = 1.34; 95% CI: 0.93 to 1.93) in North Carolina but not in Iowa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2774": {"data": {"text": "In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine.\n", "entity1": "vancomycin", "entity2": "nephrotoxicity", "span1": [77, 87], "span2": [96, 110]}, "bert_text": "In vivo evidences suggesting the role of oxidative stress in pathogenesis of <e1> vancomycin </e1>-induced <e2> nephrotoxicity </e2>: protection by erdosteine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2775": {"data": {"text": "In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine.\n", "entity1": "erdosteine", "entity2": "nephrotoxicity", "span1": [126, 136], "span2": [96, 110]}, "bert_text": "In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by <e1> erdosteine </e1> <e2> nephrotoxicity </e2>: protection by erdosteine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2776": {"data": {"text": "METHODS: SE was induced by pilocarpine injection.", "entity1": "pilocarpine", "entity2": "SE", "span1": [27, 38], "span2": [9, 11]}, "bert_text": "METHODS: SE was induced by <e1> pilocarpine </e1> <e2> SE </e2> was induced by pilocarpine injection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2777": {"data": {"text": "There was a significant difference between groups in the haloperidol-induced catalepsy test (p<0.05).", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [57, 68], "span2": [77, 86]}, "bert_text": "There was a significant difference between groups in the <e1> haloperidol </e1>-induced <e2> catalepsy </e2> test (p<0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2778": {"data": {"text": "METHODS: Male pesticide applicators in Iowa and North Carolina reported lifetime diazinon use at enrolment (1993-1997) and follow-up (1998-2005); cancer incidence was assessed through 2010(North Carolina)/2011(Iowa).", "entity1": "diazinon", "entity2": "cancer", "span1": [81, 89], "span2": [146, 152]}, "bert_text": "METHODS: Male pesticide applicators in Iowa and North Carolina reported lifetime <e1> diazinon </e1> use at enrolment (1993-1997) and follow-up (1998-2005); <e2> cancer </e2> incidence was assessed through 2010(North Carolina)/2011(Iowa).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2779": {"data": {"text": "The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism.", "entity1": "meloxicam", "entity2": "hepatitis", "span1": [53, 62], "span2": [20, 29]}, "bert_text": "The acute cytolytic hepatitis occurred rapidly after <e1> meloxicam </e1> <e2> hepatitis </e2> occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2780": {"data": {"text": "The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism.", "entity1": "meloxicam", "entity2": "hypersensitivity", "span1": [53, 62], "span2": [157, 173]}, "bert_text": "The acute cytolytic hepatitis occurred rapidly after <e1> meloxicam </e1> administration and was associated with the development of antinuclear antibodies suggesting a <e2> hypersensitivity </e2> mechanism.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2781": {"data": {"text": "The present study was aimed to determine whether there is an altered regulation of tubular transporters in gentamicin-induced nephropathy.", "entity1": "gentamicin", "entity2": "nephropathy", "span1": [107, 117], "span2": [126, 137]}, "bert_text": "The present study was aimed to determine whether there is an altered regulation of tubular transporters in <e1> gentamicin </e1>-induced <e2> nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2782": {"data": {"text": "Seventy-one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks.", "entity1": "caffeine", "entity2": "panic attacks", "span1": [76, 84], "span2": [126, 139]}, "bert_text": "Seventy-one percent of the patients reported that the behavioral effects of <e1> caffeine </e1> were similar to those experienced during <e2> panic attacks </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2783": {"data": {"text": "A 27-yr-old man developed jaundice 2 wk after exposure to thiabendazole.", "entity1": "thiabendazole", "entity2": "jaundice", "span1": [58, 71], "span2": [26, 34]}, "bert_text": "A 27-yr-old man developed jaundice 2 wk after exposure to <e1> thiabendazole </e1> <e2> jaundice </e2> 2 wk after exposure to thiabendazole.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2784": {"data": {"text": "CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.", "entity1": "dobutamine", "entity2": "coronary artery disease", "span1": [55, 65], "span2": [30, 53]}, "bert_text": "CONCLUSIONS: In patients with coronary artery disease, <e1> dobutamine </e1> <e2> coronary artery disease </e2>, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2785": {"data": {"text": "CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.", "entity1": "dobutamine", "entity2": "ischaemia", "span1": [55, 65], "span2": [74, 83]}, "bert_text": "CONCLUSIONS: In patients with coronary artery disease, <e1> dobutamine </e1> induced <e2> ischaemia </e2> results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2786": {"data": {"text": "CONCLUSIONS: In patients with coronary artery disease, dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction, presumed to be myocardial stunning, similar to that seen after exercise.", "entity1": "dobutamine", "entity2": "left ventricular dysfunction", "span1": [55, 65], "span2": [116, 144]}, "bert_text": "CONCLUSIONS: In patients with coronary artery disease, <e1> dobutamine </e1> induced ischaemia results in prolonged reversible <e2> left ventricular dysfunction </e2>, presumed to be myocardial stunning, similar to that seen after exercise.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2787": {"data": {"text": "This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.", "entity1": "carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure", "entity2": "cortical dysplasia", "span1": [112, 160], "span2": [252, 270]}, "bert_text": "This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to <e1> carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure </e1>] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced <e2> cortical dysplasia </e2>, using histological and biochemical analyses.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2788": {"data": {"text": "This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.", "entity1": "BCNU", "entity2": "cortical dysplasia", "span1": [163, 167], "span2": [252, 270]}, "bert_text": "This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (<e1> BCNU </e1>) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced <e2> cortical dysplasia </e2>, using histological and biochemical analyses.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2789": {"data": {"text": "This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.", "entity1": "BCNU", "entity2": "cortical dysplasia", "span1": [239, 243], "span2": [252, 270]}, "bert_text": "This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar <e1> BCNU </e1>-induced <e2> cortical dysplasia </e2>, using histological and biochemical analyses.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2790": {"data": {"text": "This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses.", "entity1": "melatonin", "entity2": "cortical dysplasia", "span1": [213, 222], "span2": [252, 270]}, "bert_text": "This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous <e1> melatonin </e1> upon cerebellar BCNU-induced <e2> cortical dysplasia </e2>, using histological and biochemical analyses.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2791": {"data": {"text": "Hepatic dysfunction may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine.", "entity1": "quetiapine", "entity2": "Hepatic dysfunction", "span1": [134, 144], "span2": [0, 19]}, "bert_text": "Hepatic dysfunction may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to <e1> quetiapine </e1> <e2> Hepatic dysfunction </e2> may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2792": {"data": {"text": "Hepatic dysfunction may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine.", "entity1": "quetiapine", "entity2": "fever", "span1": [134, 144], "span2": [77, 82]}, "bert_text": "Hepatic dysfunction may be one of the possible risk factors, and concomitant fever may be a diagnostic marker for adverse reaction to <e1> quetiapine </e1> <e2> fever </e2> may be a diagnostic marker for adverse reaction to quetiapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2793": {"data": {"text": "CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure.", "entity1": "Pb", "entity2": "cognitive deficits", "span1": [145, 147], "span2": [119, 137]}, "bert_text": "CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate cognitive deficits due to <e1> Pb </e1> <e2> cognitive deficits </e2> due to Pb exposure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2794": {"data": {"text": "These data suggest that while NO deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels, the impact on veins does not make a major contribution to this form of hypertension.", "entity1": "NO", "entity2": "hypertension", "span1": [30, 32], "span2": [204, 216]}, "bert_text": "These data suggest that while <e1> NO </e1> deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels, the impact on veins does not make a major contribution to this form of <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2795": {"data": {"text": "The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats.", "entity1": "Solidago virgaurea extract", "entity2": "cardiotoxicity", "span1": [77, 103], "span2": [129, 143]}, "bert_text": "The aim of the present study was to investigate the protective effect of the <e1> Solidago virgaurea extract </e1> on isoproterenol-induced <e2> cardiotoxicity </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2796": {"data": {"text": "The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats.", "entity1": "isoproterenol", "entity2": "cardiotoxicity", "span1": [107, 120], "span2": [129, 143]}, "bert_text": "The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on <e1> isoproterenol </e1>-induced <e2> cardiotoxicity </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2797": {"data": {"text": "METHODS: Outcomes were examined in patients admitted for possible MI after cocaine use.", "entity1": "cocaine", "entity2": "MI", "span1": [75, 82], "span2": [66, 68]}, "bert_text": "METHODS: Outcomes were examined in patients admitted for possible MI after <e1> cocaine </e1> <e2> MI </e2> after cocaine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2798": {"data": {"text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.", "entity1": "EACA", "entity2": "intracranial vascular thrombosis", "span1": [209, 213], "span2": [61, 93]}, "bert_text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with <e1> EACA </e1> <e2> intracranial vascular thrombosis </e2> in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2799": {"data": {"text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.", "entity1": "EACA", "entity2": "SAH", "span1": [209, 213], "span2": [111, 114]}, "bert_text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with <e1> EACA </e1> <e2> SAH </e2>, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2800": {"data": {"text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.", "entity1": "EACA", "entity2": "thrombi", "span1": [209, 213], "span2": [148, 155]}, "bert_text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with <e1> EACA </e1> <e2> thrombi </e2> in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2801": {"data": {"text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.", "entity1": "EACA", "entity2": "fibrinolytic syndromes", "span1": [209, 213], "span2": [173, 195]}, "bert_text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with <e1> EACA </e1> <e2> fibrinolytic syndromes </e2> treated with EACA, or other thromboembolic phenomena.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2802": {"data": {"text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA, or other thromboembolic phenomena.", "entity1": "EACA", "entity2": "thromboembolic", "span1": [209, 213], "span2": [224, 238]}, "bert_text": "These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH, arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with <e1> EACA </e1>, or other <e2> thromboembolic </e2> phenomena.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2803": {"data": {"text": "The impact of immune-mediated heparin-induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [30, 37], "span2": [46, 62]}, "bert_text": "The impact of immune-mediated <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2804": {"data": {"text": "The impact of immune-mediated heparin-induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results.", "entity1": "heparin", "entity2": "HIT", "span1": [30, 37], "span2": [72, 75]}, "bert_text": "The impact of immune-mediated <e1> heparin </e1>-induced thrombocytopenia type II (<e2> HIT </e2> type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2805": {"data": {"text": "The impact of immune-mediated heparin-induced thrombocytopenia type II (HIT type II) as a cause of thrombocytopenia after liver transplantation is not yet understood, with few literature citations reporting contradictory results.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [30, 37], "span2": [99, 115]}, "bert_text": "The impact of immune-mediated <e1> heparin </e1>-induced thrombocytopenia type II (HIT type II) as a cause of <e2> thrombocytopenia </e2> after liver transplantation is not yet understood, with few literature citations reporting contradictory results.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2806": {"data": {"text": "The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla.", "entity1": "glucuronyl", "entity2": "unconjugated hyperbilirubinemia", "span1": [84, 94], "span2": [30, 61]}, "bert_text": "The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of <e1> glucuronyl </e1> <e2> unconjugated hyperbilirubinemia </e2> due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2807": {"data": {"text": "The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla.", "entity1": "bilirubin", "entity2": "unconjugated hyperbilirubinemia", "span1": [126, 135], "span2": [30, 61]}, "bert_text": "The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase, leading to marked <e1> bilirubin </e1> <e2> unconjugated hyperbilirubinemia </e2> due to the absence of glucuronyl transferase, leading to marked bilirubin deposition in renal medulla and papilla.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2808": {"data": {"text": "METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.", "entity1": "platinum", "entity2": "NSCLC", "span1": [93, 101], "span2": [26, 31]}, "bert_text": "METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one <e1> platinum </e1> <e2> NSCLC </e2> patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2809": {"data": {"text": "METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.", "entity1": "platinum", "entity2": "toxicity", "span1": [93, 101], "span2": [278, 286]}, "bert_text": "METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one <e1> platinum </e1> based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2810": {"data": {"text": "METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.", "entity1": "RAD001", "entity2": "NSCLC", "span1": [227, 233], "span2": [26, 31]}, "bert_text": "METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received <e1> RAD001 </e1> <e2> NSCLC </e2> patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2811": {"data": {"text": "METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received RAD001 10 mg/day until progression or unacceptable toxicity.", "entity1": "RAD001", "entity2": "toxicity", "span1": [227, 233], "span2": [278, 286]}, "bert_text": "METHODS: Stage IIIb or IV NSCLC patients, with two or fewer prior chemotherapy regimens, one platinum based (stratum 1) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors (stratum 2), received <e1> RAD001 </e1> 10 mg/day until progression or unacceptable <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2812": {"data": {"text": "Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced hearing loss.\n", "entity1": "zinc-superoxide", "entity2": "hearing loss", "span1": [25, 40], "span2": [83, 95]}, "bert_text": "Overexpression of copper/<e1> zinc-superoxide </e1> dismutase protects from kanamycin-induced <e2> hearing loss </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2813": {"data": {"text": "Overexpression of copper/zinc-superoxide dismutase protects from kanamycin-induced hearing loss.\n", "entity1": "kanamycin", "entity2": "hearing loss", "span1": [65, 74], "span2": [83, 95]}, "bert_text": "Overexpression of copper/zinc-superoxide dismutase protects from <e1> kanamycin </e1>-induced <e2> hearing loss </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2814": {"data": {"text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.\n", "entity1": "telaprevir", "entity2": "Rhabdomyolysis", "span1": [68, 78], "span2": [0, 14]}, "bert_text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with <e1> telaprevir </e1> <e2> Rhabdomyolysis </e2> in a hepatitis C virus infected patient treated with telaprevir and simvastatin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2815": {"data": {"text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.\n", "entity1": "telaprevir", "entity2": "hepatitis C virus infected", "span1": [68, 78], "span2": [20, 46]}, "bert_text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with <e1> telaprevir </e1> <e2> hepatitis C virus infected </e2> patient treated with telaprevir and simvastatin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2816": {"data": {"text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.\n", "entity1": "simvastatin", "entity2": "Rhabdomyolysis", "span1": [83, 94], "span2": [0, 14]}, "bert_text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and <e1> simvastatin </e1> <e2> Rhabdomyolysis </e2> in a hepatitis C virus infected patient treated with telaprevir and simvastatin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2817": {"data": {"text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin.\n", "entity1": "simvastatin", "entity2": "hepatitis C virus infected", "span1": [83, 94], "span2": [20, 46]}, "bert_text": "Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and <e1> simvastatin </e1> <e2> hepatitis C virus infected </e2> patient treated with telaprevir and simvastatin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2818": {"data": {"text": "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with non-small cell lung cancer.", "entity1": "Paclitaxel", "entity2": "non-small cell lung cancer", "span1": [0, 10], "span2": [161, 187]}, "bert_text": "<e1> Paclitaxel </e1> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with <e2> non-small cell lung cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2819": {"data": {"text": "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with non-small cell lung cancer.", "entity1": "Taxol", "entity2": "non-small cell lung cancer", "span1": [12, 17], "span2": [161, 187]}, "bert_text": "Paclitaxel (<e1> Taxol </e1>; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with <e2> non-small cell lung cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2820": {"data": {"text": "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with carboplatin in a phase I/II study directed to patients with non-small cell lung cancer.", "entity1": "carboplatin", "entity2": "non-small cell lung cancer", "span1": [101, 112], "span2": [161, 187]}, "bert_text": "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 3-hour infusion was combined with <e1> carboplatin </e1> in a phase I/II study directed to patients with <e2> non-small cell lung cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"2821": {"data": {"text": "CONCLUSION: Tacrolimus and other immunosuppressive agents may be associated with optic nerve toxicity.", "entity1": "Tacrolimus", "entity2": "optic nerve toxicity", "span1": [12, 22], "span2": [81, 101]}, "bert_text": "CONCLUSION: <e1> Tacrolimus </e1> and other immunosuppressive agents may be associated with <e2> optic nerve toxicity </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2822": {"data": {"text": "Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin.\n", "entity1": "diphenylhydantoin", "entity2": "Pure red cell aplasia", "span1": [80, 97], "span2": [0, 21]}, "bert_text": "Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking <e1> diphenylhydantoin </e1> <e2> Pure red cell aplasia </e2>, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2823": {"data": {"text": "Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin.\n", "entity1": "diphenylhydantoin", "entity2": "toxic dermatitis", "span1": [80, 97], "span2": [23, 39]}, "bert_text": "Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking <e1> diphenylhydantoin </e1> <e2> toxic dermatitis </e2> and lymphadenopathy in a patient taking diphenylhydantoin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2824": {"data": {"text": "Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin.\n", "entity1": "diphenylhydantoin", "entity2": "lymphadenopathy", "span1": [80, 97], "span2": [44, 59]}, "bert_text": "Pure red cell aplasia, toxic dermatitis and lymphadenopathy in a patient taking <e1> diphenylhydantoin </e1> <e2> lymphadenopathy </e2> in a patient taking diphenylhydantoin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2825": {"data": {"text": "Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD).", "entity1": "Terfenadine", "entity2": "Torsade de Pointes", "span1": [27, 38], "span2": [83, 101]}, "bert_text": "Finally, the IKr blockers, <e1> Terfenadine </e1> and Citalopram, which are reported to cause <e2> Torsade de Pointes </e2> (TdP) in clinical practice, produced early afterdepolarization (EAD).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2826": {"data": {"text": "Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD).", "entity1": "Terfenadine", "entity2": "TdP", "span1": [27, 38], "span2": [103, 106]}, "bert_text": "Finally, the IKr blockers, <e1> Terfenadine </e1> and Citalopram, which are reported to cause Torsade de Pointes (<e2> TdP </e2>) in clinical practice, produced early afterdepolarization (EAD).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2827": {"data": {"text": "Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD).", "entity1": "Citalopram", "entity2": "Torsade de Pointes", "span1": [43, 53], "span2": [83, 101]}, "bert_text": "Finally, the IKr blockers, Terfenadine and <e1> Citalopram </e1>, which are reported to cause <e2> Torsade de Pointes </e2> (TdP) in clinical practice, produced early afterdepolarization (EAD).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2828": {"data": {"text": "Finally, the IKr blockers, Terfenadine and Citalopram, which are reported to cause Torsade de Pointes (TdP) in clinical practice, produced early afterdepolarization (EAD).", "entity1": "Citalopram", "entity2": "TdP", "span1": [43, 53], "span2": [103, 106]}, "bert_text": "Finally, the IKr blockers, Terfenadine and <e1> Citalopram </e1>, which are reported to cause Torsade de Pointes (<e2> TdP </e2>) in clinical practice, produced early afterdepolarization (EAD).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2829": {"data": {"text": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "entity1": "ribavirin", "entity2": "chronic hepatitis C virus infection", "span1": [90, 99], "span2": [25, 60]}, "bert_text": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with <e1> ribavirin </e1> <e2> chronic hepatitis C virus infection </e2> received triple therapy with ribavirin, pegylated interferon and telaprevir.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2830": {"data": {"text": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "entity1": "pegylated interferon", "entity2": "chronic hepatitis C virus infection", "span1": [101, 121], "span2": [25, 60]}, "bert_text": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, <e1> pegylated interferon </e1> <e2> chronic hepatitis C virus infection </e2> received triple therapy with ribavirin, pegylated interferon and telaprevir.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2831": {"data": {"text": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and telaprevir.", "entity1": "telaprevir", "entity2": "chronic hepatitis C virus infection", "span1": [126, 136], "span2": [25, 60]}, "bert_text": "A 46-year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin, pegylated interferon and <e1> telaprevir </e1> <e2> chronic hepatitis C virus infection </e2> received triple therapy with ribavirin, pegylated interferon and telaprevir.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2832": {"data": {"text": "We conclude that coronary artery or myocardial disease is common (38%) in young asymptomatic chronic cocaine users.", "entity1": "cocaine", "entity2": "coronary artery", "span1": [101, 108], "span2": [17, 32]}, "bert_text": "We conclude that coronary artery or myocardial disease is common (38%) in young asymptomatic chronic <e1> cocaine </e1> <e2> coronary artery </e2> or myocardial disease is common (38%) in young asymptomatic chronic cocaine users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2833": {"data": {"text": "We conclude that coronary artery or myocardial disease is common (38%) in young asymptomatic chronic cocaine users.", "entity1": "cocaine", "entity2": "myocardial disease", "span1": [101, 108], "span2": [36, 54]}, "bert_text": "We conclude that coronary artery or myocardial disease is common (38%) in young asymptomatic chronic <e1> cocaine </e1> <e2> myocardial disease </e2> is common (38%) in young asymptomatic chronic cocaine users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2834": {"data": {"text": "CONCLUSION: Early recognition of optic neuropathy should be considered in patients with ethambutol therapy.", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [88, 98], "span2": [33, 49]}, "bert_text": "CONCLUSION: Early recognition of optic neuropathy should be considered in patients with <e1> ethambutol </e1> <e2> optic neuropathy </e2> should be considered in patients with ethambutol therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2835": {"data": {"text": "CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS.", "entity1": "remifentanil", "entity2": "hypotension", "span1": [276, 288], "span2": [98, 109]}, "bert_text": "CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of <e1> remifentanil </e1> <e2> hypotension </e2> anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2836": {"data": {"text": "CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS.", "entity1": "remifentanil", "entity2": "hypotension", "span1": [276, 288], "span2": [246, 257]}, "bert_text": "CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of <e1> remifentanil </e1> <e2> hypotension </e2> with low doses of remifentanil during TIVA in patients undergoing FESS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2837": {"data": {"text": "CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS.", "entity1": "remifentanil", "entity2": "blood loss", "span1": [276, 288], "span2": [200, 210]}, "bert_text": "CONCLUSION: In summary, our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of <e1> remifentanil </e1> <e2> blood loss </e2> and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2838": {"data": {"text": "Chronic administration of estrogen to the Fischer 344 (F344) rat induces growth of large, hemorrhagic pituitary tumors.", "entity1": "estrogen", "entity2": "hemorrhagic pituitary tumors", "span1": [26, 34], "span2": [90, 118]}, "bert_text": "Chronic administration of <e1> estrogen </e1> to the Fischer 344 (F344) rat induces growth of large, <e2> hemorrhagic pituitary tumors </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2839": {"data": {"text": "OBJECTIVE: This study describes associations of ozone and fine particulate matter with Parkinson's disease observed among farmers in North Carolina and Iowa.", "entity1": "ozone", "entity2": "Parkinson's disease", "span1": [48, 53], "span2": [87, 106]}, "bert_text": "OBJECTIVE: This study describes associations of <e1> ozone </e1> and fine particulate matter with <e2> Parkinson's disease </e2> observed among farmers in North Carolina and Iowa.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2840": {"data": {"text": "Structural abnormalities in the brains of human subjects who use methamphetamine.\n", "entity1": "methamphetamine", "entity2": "Structural abnormalities", "span1": [65, 80], "span2": [0, 24]}, "bert_text": "Structural abnormalities in the brains of human subjects who use <e1> methamphetamine </e1> <e2> Structural abnormalities </e2> in the brains of human subjects who use methamphetamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2841": {"data": {"text": "Therefore, the BNPP-induced reduction in APAP-induced nephrotoxicity appears to be due to inhibition of APAP deacetylation.", "entity1": "BNPP", "entity2": "nephrotoxicity", "span1": [15, 19], "span2": [54, 68]}, "bert_text": "Therefore, the <e1> BNPP </e1>-induced reduction in APAP-induced <e2> nephrotoxicity </e2> appears to be due to inhibition of APAP deacetylation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2842": {"data": {"text": "Therefore, the BNPP-induced reduction in APAP-induced nephrotoxicity appears to be due to inhibition of APAP deacetylation.", "entity1": "APAP", "entity2": "nephrotoxicity", "span1": [41, 45], "span2": [54, 68]}, "bert_text": "Therefore, the BNPP-induced reduction in <e1> APAP </e1>-induced <e2> nephrotoxicity </e2> appears to be due to inhibition of APAP deacetylation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2843": {"data": {"text": "Therefore, the BNPP-induced reduction in APAP-induced nephrotoxicity appears to be due to inhibition of APAP deacetylation.", "entity1": "APAP", "entity2": "nephrotoxicity", "span1": [104, 108], "span2": [54, 68]}, "bert_text": "Therefore, the BNPP-induced reduction in APAP-induced nephrotoxicity appears to be due to inhibition of <e1> APAP </e1> <e2> nephrotoxicity </e2> appears to be due to inhibition of APAP deacetylation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2844": {"data": {"text": "Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [85, 96], "span2": [20, 34]}, "bert_text": "Oxidative stress on cardiotoxicity after treatment with single and multiple doses of <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> after treatment with single and multiple doses of doxorubicin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2845": {"data": {"text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "entity1": "cholesterols", "entity2": "prostate cancer", "span1": [83, 95], "span2": [248, 263]}, "bert_text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma <e1> cholesterols </e1> (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk <e2> prostate cancer </e2> (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2846": {"data": {"text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "entity1": "C", "entity2": "prostate cancer", "span1": [97, 98], "span2": [248, 263]}, "bert_text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (<e1> C </e1>), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk <e2> prostate cancer </e2> (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2847": {"data": {"text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "entity1": "triglycerides", "entity2": "prostate cancer", "span1": [101, 114], "span2": [248, 263]}, "bert_text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), <e1> triglycerides </e1> (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk <e2> prostate cancer </e2> (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2848": {"data": {"text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "entity1": "TG", "entity2": "prostate cancer", "span1": [116, 118], "span2": [248, 263]}, "bert_text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (<e1> TG </e1>), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk <e2> prostate cancer </e2> (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2849": {"data": {"text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "entity1": "cyproterone acetate", "entity2": "prostate cancer", "span1": [323, 342], "span2": [248, 263]}, "bert_text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with <e1> cyproterone acetate </e1> <e2> prostate cancer </e2> (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2850": {"data": {"text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "entity1": "CPA", "entity2": "prostate cancer", "span1": [344, 347], "span2": [248, 263]}, "bert_text": "MATERIALS AND METHODS: We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (<e1> CPA </e1> <e2> prostate cancer </e2> (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2851": {"data": {"text": "Five cases of encephalitis during treatment of loiasis with diethylcarbamazine.\n", "entity1": "diethylcarbamazine", "entity2": "encephalitis", "span1": [60, 78], "span2": [14, 26]}, "bert_text": "Five cases of encephalitis during treatment of loiasis with <e1> diethylcarbamazine </e1> <e2> encephalitis </e2> during treatment of loiasis with diethylcarbamazine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2852": {"data": {"text": "Five cases of encephalitis during treatment of loiasis with diethylcarbamazine.\n", "entity1": "diethylcarbamazine", "entity2": "loiasis", "span1": [60, 78], "span2": [47, 54]}, "bert_text": "Five cases of encephalitis during treatment of loiasis with <e1> diethylcarbamazine </e1> <e2> loiasis </e2> with diethylcarbamazine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2853": {"data": {"text": "The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection.", "entity1": "MSSA", "entity2": "bacteremia", "span1": [34, 38], "span2": [39, 49]}, "bert_text": "The patient experienced relapsing <e1> MSSA </e1> <e2> bacteremia </e2> on day 9, increasing the suspicion for a central nervous system (CNS) infection.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2854": {"data": {"text": "The patient experienced relapsing MSSA bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) infection.", "entity1": "MSSA", "entity2": "infection", "span1": [34, 38], "span2": [120, 129]}, "bert_text": "The patient experienced relapsing <e1> MSSA </e1> bacteremia on day 9, increasing the suspicion for a central nervous system (CNS) <e2> infection </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2855": {"data": {"text": "Evaluation of RAD001 plus standard therapy for metastatic NSCLC continues.", "entity1": "RAD001", "entity2": "NSCLC", "span1": [14, 20], "span2": [58, 63]}, "bert_text": "Evaluation of <e1> RAD001 </e1> plus standard therapy for metastatic <e2> NSCLC </e2> continues.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2856": {"data": {"text": "A metoprolol-terbinafine combination induced bradycardia.\n", "entity1": "metoprolol-terbinafine", "entity2": "bradycardia", "span1": [2, 24], "span2": [45, 56]}, "bert_text": "A <e1> metoprolol-terbinafine </e1> combination induced <e2> bradycardia </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2857": {"data": {"text": "A morphometric study of isoproterenol induced myocardial fibrosis.\n", "entity1": "isoproterenol", "entity2": "myocardial fibrosis", "span1": [24, 37], "span2": [46, 65]}, "bert_text": "A morphometric study of <e1> isoproterenol </e1> induced <e2> myocardial fibrosis </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2858": {"data": {"text": "We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.", "entity1": "galactose", "entity2": "cognitive deficits", "span1": [58, 67], "span2": [97, 115]}, "bert_text": "We have investigated the effects of continuous daily oral <e1> galactose </e1> (200 mg/kg/day) treatment on <e2> cognitive deficits </e2> in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2859": {"data": {"text": "We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.", "entity1": "streptozotocin", "entity2": "cognitive deficits", "span1": [119, 133], "span2": [97, 115]}, "bert_text": "We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in <e1> streptozotocin </e1> <e2> cognitive deficits </e2> in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2860": {"data": {"text": "We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.", "entity1": "STZ", "entity2": "cognitive deficits", "span1": [143, 146], "span2": [97, 115]}, "bert_text": "We have investigated the effects of continuous daily oral galactose (200 mg/kg/day) treatment on cognitive deficits in streptozotocin-induced (<e1> STZ </e1> <e2> cognitive deficits </e2> in streptozotocin-induced (STZ-icv) rat model of sAD, tested by Morris Water Maze and Passive Avoidance test, respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"2861": {"data": {"text": "A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.", "entity1": "vincristine", "entity2": "multiple myeloma", "span1": [113, 124], "span2": [36, 52]}, "bert_text": "A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of <e1> vincristine </e1> <e2> multiple myeloma </e2> was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2862": {"data": {"text": "A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.", "entity1": "doxorubicin", "entity2": "multiple myeloma", "span1": [129, 140], "span2": [36, 52]}, "bert_text": "A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and <e1> doxorubicin </e1> <e2> multiple myeloma </e2> was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2863": {"data": {"text": "A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.", "entity1": "dexamethasone", "entity2": "multiple myeloma", "span1": [160, 173], "span2": [36, 52]}, "bert_text": "A 77-year-old woman with refractory multiple myeloma was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral <e1> dexamethasone </e1> <e2> multiple myeloma </e2> was treated with a 4-day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2864": {"data": {"text": "Nonalcoholic fatty liver disease during valproate therapy.\n", "entity1": "valproate", "entity2": "Nonalcoholic fatty liver disease", "span1": [40, 49], "span2": [0, 32]}, "bert_text": "Nonalcoholic fatty liver disease during <e1> valproate </e1> <e2> Nonalcoholic fatty liver disease </e2> during valproate therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2865": {"data": {"text": "Renal lesions were analyzed in hematoxylin and eosin, periodic acid-Schiff, and Masson's trichrome stains.", "entity1": "periodic acid", "entity2": "Renal lesions", "span1": [54, 67], "span2": [0, 13]}, "bert_text": "Renal lesions were analyzed in hematoxylin and eosin, <e1> periodic acid </e1> <e2> Renal lesions </e2> were analyzed in hematoxylin and eosin, periodic acid-Schiff, and Masson's trichrome stains.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2866": {"data": {"text": "Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal.", "entity1": "Methamphetamine", "entity2": "depressive symptoms", "span1": [0, 15], "span2": [133, 152]}, "bert_text": "<e1> Methamphetamine </e1> (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including <e2> depressive symptoms </e2> during drug withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2867": {"data": {"text": "Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal.", "entity1": "METH", "entity2": "depressive symptoms", "span1": [17, 21], "span2": [133, 152]}, "bert_text": "Methamphetamine (<e1> METH </e1>) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including <e2> depressive symptoms </e2> during drug withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2868": {"data": {"text": "Methamphetamine (METH) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal.", "entity1": "METH", "entity2": "depressive symptoms", "span1": [77, 81], "span2": [133, 152]}, "bert_text": "Methamphetamine (METH) triggers a disruption of the monoaminergic system and <e1> METH </e1> abuse leads to negative emotional states including <e2> depressive symptoms </e2> during drug withdrawal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2869": {"data": {"text": "Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine.\n", "entity1": "desvenlafaxine", "entity2": "inappropriate antidiuretic hormone secretion", "span1": [73, 87], "span2": [12, 56]}, "bert_text": "Syndrome of inappropriate antidiuretic hormone secretion associated with <e1> desvenlafaxine </e1> <e2> inappropriate antidiuretic hormone secretion </e2> associated with desvenlafaxine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2870": {"data": {"text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.", "entity1": "fluoxetine", "entity2": "dyskinesias", "span1": [74, 84], "span2": [134, 145]}, "bert_text": "The results suggest that increased brain serotoninergic transmission with <e1> fluoxetine </e1> may reduce levodopa- or dopamine agonist-induced <e2> dyskinesias </e2> without aggravating parkinsonian motor disability.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2871": {"data": {"text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.", "entity1": "fluoxetine", "entity2": "parkinsonian", "span1": [74, 84], "span2": [166, 178]}, "bert_text": "The results suggest that increased brain serotoninergic transmission with <e1> fluoxetine </e1> may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating <e2> parkinsonian </e2> motor disability.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2872": {"data": {"text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.", "entity1": "levodopa-", "entity2": "dyskinesias", "span1": [96, 105], "span2": [134, 145]}, "bert_text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce <e1> levodopa- </e1> or dopamine agonist-induced <e2> dyskinesias </e2> without aggravating parkinsonian motor disability.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2873": {"data": {"text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.", "entity1": "levodopa-", "entity2": "parkinsonian", "span1": [96, 105], "span2": [166, 178]}, "bert_text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce <e1> levodopa- </e1> or dopamine agonist-induced dyskinesias without aggravating <e2> parkinsonian </e2> motor disability.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2874": {"data": {"text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.", "entity1": "dopamine", "entity2": "dyskinesias", "span1": [109, 117], "span2": [134, 145]}, "bert_text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or <e1> dopamine </e1> agonist-induced <e2> dyskinesias </e2> without aggravating parkinsonian motor disability.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2875": {"data": {"text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.", "entity1": "dopamine", "entity2": "parkinsonian", "span1": [109, 117], "span2": [166, 178]}, "bert_text": "The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or <e1> dopamine </e1> agonist-induced dyskinesias without aggravating <e2> parkinsonian </e2> motor disability.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2876": {"data": {"text": "We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.", "entity1": "trimethoprim-sulfamethoxazole", "entity2": "renal disorders", "span1": [93, 122], "span2": [264, 279]}, "bert_text": "We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed <e1> trimethoprim-sulfamethoxazole </e1> (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and <e2> renal disorders </e2> resulting in referral or hospitalization associated with these drugs.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2877": {"data": {"text": "We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.", "entity1": "TMP-SMZ", "entity2": "renal disorders", "span1": [124, 131], "span2": [264, 279]}, "bert_text": "We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (<e1> TMP-SMZ </e1>), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and <e2> renal disorders </e2> resulting in referral or hospitalization associated with these drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2878": {"data": {"text": "We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.", "entity1": "trimethoprim", "entity2": "renal disorders", "span1": [153, 165], "span2": [264, 279]}, "bert_text": "We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed <e1> trimethoprim </e1> alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and <e2> renal disorders </e2> resulting in referral or hospitalization associated with these drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2879": {"data": {"text": "We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed cephalexin, to estimate the risk of serious liver, blood, skin, and renal disorders resulting in referral or hospitalization associated with these drugs.", "entity1": "cephalexin", "entity2": "renal disorders", "span1": [196, 206], "span2": [264, 279]}, "bert_text": "We conducted a population-based 45-day follow-up study of 232,390 people who were prescribed trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 prescribed trimethoprim alone, and 196,397 prescribed <e1> cephalexin </e1>, to estimate the risk of serious liver, blood, skin, and <e2> renal disorders </e2> resulting in referral or hospitalization associated with these drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2880": {"data": {"text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "entity1": "K(+)-channel", "entity2": "hypoactivity", "span1": [81, 93], "span2": [129, 141]}, "bert_text": "In the motor activity test measured with an Animex-activity meter neither of the <e1> K(+)-channel </e1> blockers affected morphine-induced <e2> hypoactivity </e2>, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"2881": {"data": {"text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "entity1": "K(+)-channel", "entity2": "hyperactivity", "span1": [81, 93], "span2": [211, 224]}, "bert_text": "In the motor activity test measured with an Animex-activity meter neither of the <e1> K(+)-channel </e1> blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"2882": {"data": {"text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "entity1": "K(+)-channel", "entity2": "hypoactivity", "span1": [152, 164], "span2": [129, 141]}, "bert_text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both <e1> K(+)-channel </e1> <e2> hypoactivity </e2>, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2883": {"data": {"text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "entity1": "K(+)-channel", "entity2": "hyperactivity", "span1": [152, 164], "span2": [211, 224]}, "bert_text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both <e1> K(+)-channel </e1> blockers prevented morphine-induced secondary <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2884": {"data": {"text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "entity1": "morphine", "entity2": "hypoactivity", "span1": [112, 120], "span2": [129, 141]}, "bert_text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected <e1> morphine </e1>-induced <e2> hypoactivity </e2>, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2885": {"data": {"text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "entity1": "morphine", "entity2": "hyperactivity", "span1": [112, 120], "span2": [211, 224]}, "bert_text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected <e1> morphine </e1>-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2886": {"data": {"text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "entity1": "morphine", "entity2": "hypoactivity", "span1": [184, 192], "span2": [129, 141]}, "bert_text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented <e1> morphine </e1> <e2> hypoactivity </e2>, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2887": {"data": {"text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented morphine-induced secondary hyperactivity.", "entity1": "morphine", "entity2": "hyperactivity", "span1": [184, 192], "span2": [211, 224]}, "bert_text": "In the motor activity test measured with an Animex-activity meter neither of the K(+)-channel blockers affected morphine-induced hypoactivity, but both K(+)-channel blockers prevented <e1> morphine </e1>-induced secondary <e2> hyperactivity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2888": {"data": {"text": "CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with tacrolimus ointment is heterogeneous.", "entity1": "tacrolimus", "entity2": "dermatitis", "span1": [118, 128], "span2": [71, 81]}, "bert_text": "CONCLUSIONS: Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with <e1> tacrolimus </e1> <e2> dermatitis </e2> as a complication of treatment with tacrolimus ointment is heterogeneous.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2889": {"data": {"text": "The one case of toxic epidermal necrolysis occurred in a patient who took cephalexin.", "entity1": "cephalexin", "entity2": "epidermal necrolysis", "span1": [74, 84], "span2": [22, 42]}, "bert_text": "The one case of toxic epidermal necrolysis occurred in a patient who took <e1> cephalexin </e1> <e2> epidermal necrolysis </e2> occurred in a patient who took cephalexin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2890": {"data": {"text": "Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.", "entity1": "quinine", "entity2": "heart diseases", "span1": [29, 36], "span2": [162, 176]}, "bert_text": "Administration of parenteral <e1> quinine </e1> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have <e2> heart diseases </e2> or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2891": {"data": {"text": "Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.", "entity1": "quinine", "entity2": "hypokalemia", "span1": [29, 36], "span2": [216, 227]}, "bert_text": "Administration of parenteral <e1> quinine </e1> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (<e2> hypokalemia </e2>) which frequently occurs due to vomiting and or diarrhea in malaria cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2892": {"data": {"text": "Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.", "entity1": "quinine", "entity2": "vomiting", "span1": [29, 36], "span2": [260, 268]}, "bert_text": "Administration of parenteral <e1> quinine </e1> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to <e2> vomiting </e2> and or diarrhea in malaria cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2893": {"data": {"text": "Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.", "entity1": "quinine", "entity2": "diarrhea", "span1": [29, 36], "span2": [276, 284]}, "bert_text": "Administration of parenteral <e1> quinine </e1> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or <e2> diarrhea </e2> in malaria cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2894": {"data": {"text": "Administration of parenteral quinine must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in malaria cases.", "entity1": "quinine", "entity2": "malaria", "span1": [29, 36], "span2": [288, 295]}, "bert_text": "Administration of parenteral <e1> quinine </e1> must be done carefully and with good observation because of its pro-arrhythmic effect, especially in older patients who have heart diseases or patients with electrolyte disorder (hypokalemia) which frequently occurs due to vomiting and or diarrhea in <e2> malaria </e2> cases.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2895": {"data": {"text": "In this study, neurocognitive outcomes and neuroradiologic evidence of leukoencephalopathy were compared in children treated with intense central nervous system (CNS)-directed therapy (P9605) versus those receiving fewer CNS-directed treatment days during intensive consolidation (P9201).", "entity1": "P9605", "entity2": "leukoencephalopathy", "span1": [185, 190], "span2": [71, 90]}, "bert_text": "In this study, neurocognitive outcomes and neuroradiologic evidence of leukoencephalopathy were compared in children treated with intense central nervous system (CNS)-directed therapy (<e1> P9605 </e1> <e2> leukoencephalopathy </e2> were compared in children treated with intense central nervous system (CNS)-directed therapy (P9605) versus those receiving fewer CNS-directed treatment days during intensive consolidation (P9201).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2896": {"data": {"text": "Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation.", "entity1": "Methadone", "entity2": "QT prolongation", "span1": [0, 9], "span2": [111, 126]}, "bert_text": "<e1> Methadone </e1> dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to <e2> QT prolongation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2897": {"data": {"text": "Methadone dose, presence of cytochrome P-450 3A4 inhibitors, potassium level, and liver function contribute to QT prolongation.", "entity1": "potassium", "entity2": "QT prolongation", "span1": [61, 70], "span2": [111, 126]}, "bert_text": "Methadone dose, presence of cytochrome P-450 3A4 inhibitors, <e1> potassium </e1> level, and liver function contribute to <e2> QT prolongation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2898": {"data": {"text": "The safety of the zinc acetate allowed us to avoid other potentially toxic chelating drugs; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of Wilson's disease.", "entity1": "zinc acetate", "entity2": "Wilson's disease", "span1": [18, 30], "span2": [194, 210]}, "bert_text": "The safety of the <e1> zinc acetate </e1> allowed us to avoid other potentially toxic chelating drugs; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of <e2> Wilson's disease </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2899": {"data": {"text": "Taken together, these results extend previous studies and demonstrate that cocaine-induced cardiac dysfunction may be due to a mitochondrial defect.", "entity1": "cocaine", "entity2": "cardiac dysfunction", "span1": [75, 82], "span2": [91, 110]}, "bert_text": "Taken together, these results extend previous studies and demonstrate that <e1> cocaine </e1>-induced <e2> cardiac dysfunction </e2> may be due to a mitochondrial defect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2900": {"data": {"text": "The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients.\n", "entity1": "tranexamic acid", "entity2": "convulsive seizures", "span1": [24, 39], "span2": [44, 63]}, "bert_text": "The association between <e1> tranexamic acid </e1> and <e2> convulsive seizures </e2> after cardiac surgery: a multivariate analysis in 11 529 patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2901": {"data": {"text": "Estradiol treatment also increased the arrhythmogenicity of bupivacaine in myocyte cultures, but was only one fourth as potent as progesterone.", "entity1": "Estradiol", "entity2": "arrhythmogenicity", "span1": [0, 9], "span2": [39, 56]}, "bert_text": "<e1> Estradiol </e1> treatment also increased the <e2> arrhythmogenicity </e2> of bupivacaine in myocyte cultures, but was only one fourth as potent as progesterone.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2902": {"data": {"text": "Estradiol treatment also increased the arrhythmogenicity of bupivacaine in myocyte cultures, but was only one fourth as potent as progesterone.", "entity1": "bupivacaine", "entity2": "arrhythmogenicity", "span1": [60, 71], "span2": [39, 56]}, "bert_text": "Estradiol treatment also increased the arrhythmogenicity of <e1> bupivacaine </e1> <e2> arrhythmogenicity </e2> of bupivacaine in myocyte cultures, but was only one fourth as potent as progesterone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2903": {"data": {"text": "Estradiol treatment also increased the arrhythmogenicity of bupivacaine in myocyte cultures, but was only one fourth as potent as progesterone.", "entity1": "progesterone", "entity2": "arrhythmogenicity", "span1": [130, 142], "span2": [39, 56]}, "bert_text": "Estradiol treatment also increased the arrhythmogenicity of bupivacaine in myocyte cultures, but was only one fourth as potent as <e1> progesterone </e1> <e2> arrhythmogenicity </e2> of bupivacaine in myocyte cultures, but was only one fourth as potent as progesterone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2904": {"data": {"text": "The present studies examine the expression and regulation of another receptor known to bind NGF, p75(NTR), after various durations of bladder inflammation induced by cyclophosphamide (CYP).", "entity1": "cyclophosphamide", "entity2": "bladder inflammation", "span1": [166, 182], "span2": [134, 154]}, "bert_text": "The present studies examine the expression and regulation of another receptor known to bind NGF, p75(NTR), after various durations of bladder inflammation induced by <e1> cyclophosphamide </e1> <e2> bladder inflammation </e2> induced by cyclophosphamide (CYP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2905": {"data": {"text": "The present studies examine the expression and regulation of another receptor known to bind NGF, p75(NTR), after various durations of bladder inflammation induced by cyclophosphamide (CYP).", "entity1": "CYP", "entity2": "bladder inflammation", "span1": [184, 187], "span2": [134, 154]}, "bert_text": "The present studies examine the expression and regulation of another receptor known to bind NGF, p75(NTR), after various durations of bladder inflammation induced by cyclophosphamide (<e1> CYP </e1> <e2> bladder inflammation </e2> induced by cyclophosphamide (CYP).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2906": {"data": {"text": "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.\n", "entity1": "Hydroxytyrosol", "entity2": "mitochondrial dysfunction", "span1": [0, 14], "span2": [48, 73]}, "bert_text": "<e1> Hydroxytyrosol </e1> ameliorates oxidative stress and <e2> mitochondrial dysfunction </e2> in doxorubicin-induced cardiotoxicity in rats with breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2907": {"data": {"text": "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.\n", "entity1": "Hydroxytyrosol", "entity2": "cardiotoxicity", "span1": [0, 14], "span2": [97, 111]}, "bert_text": "<e1> Hydroxytyrosol </e1> ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced <e2> cardiotoxicity </e2> in rats with breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2908": {"data": {"text": "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.\n", "entity1": "Hydroxytyrosol", "entity2": "breast cancer", "span1": [0, 14], "span2": [125, 138]}, "bert_text": "<e1> Hydroxytyrosol </e1> ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with <e2> breast cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2909": {"data": {"text": "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.\n", "entity1": "doxorubicin", "entity2": "mitochondrial dysfunction", "span1": [77, 88], "span2": [48, 73]}, "bert_text": "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in <e1> doxorubicin </e1> <e2> mitochondrial dysfunction </e2> in doxorubicin-induced cardiotoxicity in rats with breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2910": {"data": {"text": "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [77, 88], "span2": [97, 111]}, "bert_text": "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in <e1> doxorubicin </e1>-induced <e2> cardiotoxicity </e2> in rats with breast cancer.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2911": {"data": {"text": "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.\n", "entity1": "doxorubicin", "entity2": "breast cancer", "span1": [77, 88], "span2": [125, 138]}, "bert_text": "Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in <e1> doxorubicin </e1>-induced cardiotoxicity in rats with <e2> breast cancer </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2912": {"data": {"text": "But before this event, she was taking zolmitriptan 2-3 times daily for several days because of a persistent migraine headache.", "entity1": "zolmitriptan 2-3", "entity2": "migraine headache", "span1": [38, 54], "span2": [108, 125]}, "bert_text": "But before this event, she was taking <e1> zolmitriptan 2-3 </e1> times daily for several days because of a persistent <e2> migraine headache </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2913": {"data": {"text": "Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.\n", "entity1": "argatroban", "entity2": "thrombocytopenia", "span1": [75, 85], "span2": [113, 129]}, "bert_text": "Reducing harm associated with anticoagulation: practical considerations of <e1> argatroban </e1> therapy in heparin-induced <e2> thrombocytopenia </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2914": {"data": {"text": "Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [97, 104], "span2": [113, 129]}, "bert_text": "Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in <e1> heparin </e1>-induced <e2> thrombocytopenia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2915": {"data": {"text": "Theophylline neurotoxicity in pregnant rats.\n", "entity1": "Theophylline", "entity2": "neurotoxicity", "span1": [0, 12], "span2": [13, 26]}, "bert_text": "<e1> Theophylline </e1> <e2> neurotoxicity </e2> in pregnant rats.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2916": {"data": {"text": "We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated; however, because of the high recurrence rate, patients who develop hoarseness should not be re-challenged.", "entity1": "beclomethasone", "entity2": "hoarseness", "span1": [54, 68], "span2": [163, 173]}, "bert_text": "We conclude that patients may be restarted on inhaled <e1> beclomethasone </e1> when clinically indicated; however, because of the high recurrence rate, patients who develop <e2> hoarseness </e2> should not be re-challenged.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2917": {"data": {"text": "The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa-induced dyskinesia.", "entity1": "levodopa", "entity2": "PD", "span1": [101, 109], "span2": [72, 74]}, "bert_text": "The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without <e1> levodopa </e1> <e2> PD </e2> patients with and without levodopa-induced dyskinesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2918": {"data": {"text": "The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa-induced dyskinesia.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [101, 109], "span2": [118, 128]}, "bert_text": "The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without <e1> levodopa </e1>-induced <e2> dyskinesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2919": {"data": {"text": "DESIGN: A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.", "entity1": "glucose", "entity2": "schizophrenia", "span1": [129, 136], "span2": [66, 79]}, "bert_text": "DESIGN: A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous <e1> glucose </e1> <e2> schizophrenia </e2> evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"2920": {"data": {"text": "As heparin remains one of the most frequently used medications today with potential for HIT with every heparin exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated.", "entity1": "heparin", "entity2": "HIT", "span1": [3, 10], "span2": [88, 91]}, "bert_text": "As <e1> heparin </e1> remains one of the most frequently used medications today with potential for <e2> HIT </e2> with every heparin exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2921": {"data": {"text": "As heparin remains one of the most frequently used medications today with potential for HIT with every heparin exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated.", "entity1": "heparin", "entity2": "HIT", "span1": [103, 110], "span2": [88, 91]}, "bert_text": "As heparin remains one of the most frequently used medications today with potential for HIT with every <e1> heparin </e1> <e2> HIT </e2> with every heparin exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2922": {"data": {"text": "As heparin remains one of the most frequently used medications today with potential for HIT with every heparin exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated.", "entity1": "heparin", "entity2": "HIT", "span1": [185, 192], "span2": [88, 91]}, "bert_text": "As heparin remains one of the most frequently used medications today with potential for HIT with every heparin exposure, a close vigilance of platelet counts must be practiced whenever <e1> heparin </e1> <e2> HIT </e2> with every heparin exposure, a close vigilance of platelet counts must be practiced whenever heparin is initiated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2923": {"data": {"text": "Chronic pre-treatment with metformin reduces post-myocardial infarction cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.", "entity1": "metformin", "entity2": "myocardial infarction", "span1": [27, 36], "span2": [50, 71]}, "bert_text": "Chronic pre-treatment with <e1> metformin </e1> reduces post-<e2> myocardial infarction </e2> cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2924": {"data": {"text": "Chronic pre-treatment with metformin reduces post-myocardial infarction cardiac dysfunction and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.", "entity1": "metformin", "entity2": "cardiac dysfunction", "span1": [27, 36], "span2": [72, 91]}, "bert_text": "Chronic pre-treatment with <e1> metformin </e1> reduces post-myocardial infarction <e2> cardiac dysfunction </e2> and suppresses inflammatory responses, possibly through inhibition of TLR4 activities.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2925": {"data": {"text": "We report a case of acute renal failure in an APL patient treated with ATRA alone.", "entity1": "ATRA", "entity2": "acute renal failure", "span1": [71, 75], "span2": [20, 39]}, "bert_text": "We report a case of acute renal failure in an APL patient treated with <e1> ATRA </e1> <e2> acute renal failure </e2> in an APL patient treated with ATRA alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2926": {"data": {"text": "We report a case of acute renal failure in an APL patient treated with ATRA alone.", "entity1": "ATRA", "entity2": "APL", "span1": [71, 75], "span2": [46, 49]}, "bert_text": "We report a case of acute renal failure in an APL patient treated with <e1> ATRA </e1> <e2> APL </e2> patient treated with ATRA alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2927": {"data": {"text": "However, the Rg1 and Rb1 ginsenosides failed to prevent OIH in either test.", "entity1": "Rg1", "entity2": "OIH", "span1": [13, 16], "span2": [56, 59]}, "bert_text": "However, the <e1> Rg1 </e1> and Rb1 ginsenosides failed to prevent <e2> OIH </e2> in either test.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2928": {"data": {"text": "However, the Rg1 and Rb1 ginsenosides failed to prevent OIH in either test.", "entity1": "Rb1 ginsenosides", "entity2": "OIH", "span1": [21, 37], "span2": [56, 59]}, "bert_text": "However, the Rg1 and <e1> Rb1 ginsenosides </e1> failed to prevent <e2> OIH </e2> in either test.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2929": {"data": {"text": "Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.", "entity1": "cyclophosphamide", "entity2": "hemorrhagic cystitis", "span1": [24, 40], "span2": [50, 70]}, "bert_text": "Although the ability of <e1> cyclophosphamide </e1> to cause <e2> hemorrhagic cystitis </e2> and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2930": {"data": {"text": "Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.", "entity1": "cyclophosphamide", "entity2": "carcinoma", "span1": [24, 40], "span2": [139, 148]}, "bert_text": "Although the ability of <e1> cyclophosphamide </e1> to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade <e2> carcinoma </e2> is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2931": {"data": {"text": "Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with carcinoma of the urinary tract.", "entity1": "cyclophosphamide", "entity2": "carcinoma", "span1": [24, 40], "span2": [226, 235]}, "bert_text": "Although the ability of <e1> cyclophosphamide </e1> to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known, it is less widely appreciated that it is also associated with <e2> carcinoma </e2> of the urinary tract.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2932": {"data": {"text": "As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose Ara-C may be associated with cytokine release.", "entity1": "Ara", "entity2": "TNF", "span1": [148, 151], "span2": [3, 6]}, "bert_text": "As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose <e1> Ara </e1> <e2> TNF </e2> and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose Ara-C may be associated with cytokine release.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2933": {"data": {"text": "As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose Ara-C may be associated with cytokine release.", "entity1": "Ara", "entity2": "septic shock", "span1": [148, 151], "span2": [64, 76]}, "bert_text": "As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose <e1> Ara </e1> <e2> septic shock </e2> and adult respiratory distress syndrome, we hypothesize that high-dose Ara-C may be associated with cytokine release.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2934": {"data": {"text": "As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose Ara-C may be associated with cytokine release.", "entity1": "Ara", "entity2": "respiratory distress syndrome", "span1": [148, 151], "span2": [87, 116]}, "bert_text": "As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome, we hypothesize that high-dose <e1> Ara </e1> <e2> respiratory distress syndrome </e2>, we hypothesize that high-dose Ara-C may be associated with cytokine release.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2935": {"data": {"text": "Two cases of severe delayed neurologic toxicity related to the administration of intrathecal (IT) combination chemotherapy including thiotepa (TSPA) are presented.", "entity1": "thiotepa", "entity2": "neurologic toxicity", "span1": [133, 141], "span2": [28, 47]}, "bert_text": "Two cases of severe delayed neurologic toxicity related to the administration of intrathecal (IT) combination chemotherapy including <e1> thiotepa </e1> <e2> neurologic toxicity </e2> related to the administration of intrathecal (IT) combination chemotherapy including thiotepa (TSPA) are presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2936": {"data": {"text": "Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.", "entity1": "Pentobarbital", "entity2": "brain damage", "span1": [0, 13], "span2": [52, 64]}, "bert_text": "<e1> Pentobarbital </e1>, scopolamine and MK-801 protected the <e2> brain damage </e2> by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2937": {"data": {"text": "Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.", "entity1": "scopolamine", "entity2": "brain damage", "span1": [15, 26], "span2": [52, 64]}, "bert_text": "Pentobarbital, <e1> scopolamine </e1> and MK-801 protected the <e2> brain damage </e2> by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2938": {"data": {"text": "Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.", "entity1": "MK-801", "entity2": "brain damage", "span1": [31, 37], "span2": [52, 64]}, "bert_text": "Pentobarbital, scopolamine and <e1> MK-801 </e1> protected the <e2> brain damage </e2> by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2939": {"data": {"text": "Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.", "entity1": "MK-801-treated", "entity2": "brain damage", "span1": [95, 109], "span2": [52, 64]}, "bert_text": "Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the <e1> MK-801-treated </e1> <e2> brain damage </e2> by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2940": {"data": {"text": "Pentobarbital, scopolamine and MK-801 protected the brain damage by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.", "entity1": "pilocarpine", "entity2": "brain damage", "span1": [68, 79], "span2": [52, 64]}, "bert_text": "Pentobarbital, scopolamine and MK-801 protected the brain damage by <e1> pilocarpine </e1> <e2> brain damage </e2> by pilocarpine, though in the MK-801-treated group, the pyramidal cells of hippocampus appeared darker than normal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2941": {"data": {"text": "CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "entity1": "amiodarone", "entity2": "AF", "span1": [49, 59], "span2": [85, 87]}, "bert_text": "CONCLUSIONS: This study suggests that the use of <e1> amiodarone </e1> in elderly patients with <e2> AF </e2> and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2942": {"data": {"text": "CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "entity1": "amiodarone", "entity2": "MI", "span1": [49, 59], "span2": [103, 105]}, "bert_text": "CONCLUSIONS: This study suggests that the use of <e1> amiodarone </e1> in elderly patients with AF and a previous <e2> MI </e2> increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2943": {"data": {"text": "CONCLUSIONS: This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker.", "entity1": "amiodarone", "entity2": "bradyarrhythmia", "span1": [49, 59], "span2": [128, 143]}, "bert_text": "CONCLUSIONS: This study suggests that the use of <e1> amiodarone </e1> in elderly patients with AF and a previous MI increases the risk of <e2> bradyarrhythmia </e2> requiring a permanent pacemaker.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2944": {"data": {"text": "Central cardiovascular effects of AVP and ANP in normotensive and spontaneously hypertensive rats.\n", "entity1": "AVP", "entity2": "hypertensive", "span1": [34, 37], "span2": [80, 92]}, "bert_text": "Central cardiovascular effects of <e1> AVP </e1> and ANP in normotensive and spontaneously <e2> hypertensive </e2> rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2945": {"data": {"text": "RESULTS: We evaluated 143 patients who received single-agent cisplatin; 97.2% of patients had head and neck cancer as their primary malignancy.", "entity1": "cisplatin", "entity2": "neck cancer", "span1": [61, 70], "span2": [103, 114]}, "bert_text": "RESULTS: We evaluated 143 patients who received single-agent <e1> cisplatin </e1>; 97.2% of patients had head and <e2> neck cancer </e2> as their primary malignancy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2946": {"data": {"text": "RESULTS: We evaluated 143 patients who received single-agent cisplatin; 97.2% of patients had head and neck cancer as their primary malignancy.", "entity1": "cisplatin", "entity2": "malignancy", "span1": [61, 70], "span2": [132, 142]}, "bert_text": "RESULTS: We evaluated 143 patients who received single-agent <e1> cisplatin </e1>; 97.2% of patients had head and neck cancer as their primary <e2> malignancy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2947": {"data": {"text": "Part A, for eight rats in each group brain injury was evaluated by staining tissue using 2,3,5-triphenyltetrazolium chloride and edema was evaluated by microgravimetry.", "entity1": "2,3,5-triphenyltetrazolium chloride", "entity2": "brain injury", "span1": [89, 124], "span2": [37, 49]}, "bert_text": "Part A, for eight rats in each group brain injury was evaluated by staining tissue using <e1> 2,3,5-triphenyltetrazolium chloride </e1> <e2> brain injury </e2> was evaluated by staining tissue using 2,3,5-triphenyltetrazolium chloride and edema was evaluated by microgravimetry.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2948": {"data": {"text": "Part A, for eight rats in each group brain injury was evaluated by staining tissue using 2,3,5-triphenyltetrazolium chloride and edema was evaluated by microgravimetry.", "entity1": "2,3,5-triphenyltetrazolium chloride", "entity2": "edema", "span1": [89, 124], "span2": [129, 134]}, "bert_text": "Part A, for eight rats in each group brain injury was evaluated by staining tissue using <e1> 2,3,5-triphenyltetrazolium chloride </e1> and <e2> edema </e2> was evaluated by microgravimetry.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2949": {"data": {"text": "Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.\n", "entity1": "MPTP", "entity2": "Parkinson's disease", "span1": [34, 38], "span2": [57, 76]}, "bert_text": "Neuropsychiatric behaviors in the <e1> MPTP </e1> marmoset model of <e2> Parkinson's disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2950": {"data": {"text": "Ethambutol-induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn.", "entity1": "Ethambutol", "entity2": "optic neuropathy", "span1": [0, 10], "span2": [25, 41]}, "bert_text": "<e1> Ethambutol </e1>-induced toxic <e2> optic neuropathy </e2> was suspected and tablet ethambutol was withdrawn.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2951": {"data": {"text": "Ethambutol-induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn.", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [67, 77], "span2": [25, 41]}, "bert_text": "Ethambutol-induced toxic optic neuropathy was suspected and tablet <e1> ethambutol </e1> <e2> optic neuropathy </e2> was suspected and tablet ethambutol was withdrawn.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2952": {"data": {"text": "The mechanism of doxorubicin (DOX)-induced cardiotoxicity remains controversial.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [17, 28], "span2": [43, 57]}, "bert_text": "The mechanism of <e1> doxorubicin </e1> (DOX)-induced <e2> cardiotoxicity </e2> remains controversial.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2953": {"data": {"text": "The mechanism of doxorubicin (DOX)-induced cardiotoxicity remains controversial.", "entity1": "DOX)-induced", "entity2": "cardiotoxicity", "span1": [30, 42], "span2": [43, 57]}, "bert_text": "The mechanism of doxorubicin (<e1> DOX)-induced </e1> <e2> cardiotoxicity </e2> remains controversial.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2954": {"data": {"text": "induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [34, 45], "span2": [8, 17]}, "bert_text": "induced catalepsy and antagonized <e1> apomorphine </e1> <e2> catalepsy </e2> and antagonized apomorphine and dexamphetamine stereotypies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2955": {"data": {"text": "induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies.", "entity1": "dexamphetamine", "entity2": "catalepsy", "span1": [50, 64], "span2": [8, 17]}, "bert_text": "induced catalepsy and antagonized apomorphine and <e1> dexamphetamine </e1> <e2> catalepsy </e2> and antagonized apomorphine and dexamphetamine stereotypies.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2956": {"data": {"text": "Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).", "entity1": "ammonium", "entity2": "hyperammonemia", "span1": [14, 22], "span2": [54, 68]}, "bert_text": "Higher plasma <e1> ammonium </e1> levels and more rapid onset of <e2> hyperammonemia </e2> were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2957": {"data": {"text": "Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).", "entity1": "ammonium", "entity2": "infections", "span1": [14, 22], "span2": [109, 119]}, "bert_text": "Higher plasma <e1> ammonium </e1> levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial <e2> infections </e2> (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2958": {"data": {"text": "Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).", "entity1": "5-FU", "entity2": "hyperammonemia", "span1": [227, 231], "span2": [54, 68]}, "bert_text": "Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of <e1> 5-FU </e1> <e2> hyperammonemia </e2> were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2959": {"data": {"text": "Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).", "entity1": "5-FU", "entity2": "infections", "span1": [227, 231], "span2": [109, 119]}, "bert_text": "Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of <e1> 5-FU </e1> <e2> infections </e2> (p=0.003 and 0.0006, respectively) and in nine patients receiving high daily doses (2600 or 1800 mg/m2) of 5-FU (p=0.0001 and < 0.0001, respectively).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2960": {"data": {"text": "This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/galactorrhea.", "entity1": "bromocriptine", "entity2": "hyperprolactinemia", "span1": [19, 32], "span2": [109, 127]}, "bert_text": "This suggests that <e1> bromocriptine </e1> should be further evaluated as potential therapy for neuroleptic-associated <e2> hyperprolactinemia </e2> and amenorrhea/galactorrhea.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2961": {"data": {"text": "This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and amenorrhea/galactorrhea.", "entity1": "bromocriptine", "entity2": "amenorrhea/galactorrhea", "span1": [19, 32], "span2": [132, 155]}, "bert_text": "This suggests that <e1> bromocriptine </e1> should be further evaluated as potential therapy for neuroleptic-associated hyperprolactinemia and <e2> amenorrhea/galactorrhea </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"2962": {"data": {"text": "Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.", "entity1": "TDF", "entity2": "kidney disease", "span1": [68, 71], "span2": [80, 94]}, "bert_text": "Of the 407 Yellow Card records analysed, 106 satisfied criteria for <e1> TDF </e1>-related <e2> kidney disease </e2>, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2963": {"data": {"text": "Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.", "entity1": "TDF", "entity2": "kidney tubular dysfunction", "span1": [68, 71], "span2": [130, 156]}, "bert_text": "Of the 407 Yellow Card records analysed, 106 satisfied criteria for <e1> TDF </e1>-related kidney disease, of which 53 (50%) had features of <e2> kidney tubular dysfunction </e2>, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2964": {"data": {"text": "Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.", "entity1": "TDF", "entity2": "glomerular dysfunction", "span1": [68, 71], "span2": [198, 220]}, "bert_text": "Of the 407 Yellow Card records analysed, 106 satisfied criteria for <e1> TDF </e1>-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of <e2> glomerular dysfunction </e2> and 18 (17%) had Fanconi syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2965": {"data": {"text": "Of the 407 Yellow Card records analysed, 106 satisfied criteria for TDF-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had Fanconi syndrome.", "entity1": "TDF", "entity2": "Fanconi syndrome", "span1": [68, 71], "span2": [238, 254]}, "bert_text": "Of the 407 Yellow Card records analysed, 106 satisfied criteria for <e1> TDF </e1>-related kidney disease, of which 53 (50%) had features of kidney tubular dysfunction, 35 (33%) were found to have features of glomerular dysfunction and 18 (17%) had <e2> Fanconi syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2966": {"data": {"text": "Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.\n", "entity1": "Piperacillin", "entity2": "seizure", "span1": [0, 12], "span2": [32, 39]}, "bert_text": "<e1> Piperacillin </e1>/tazobactam-induced <e2> seizure </e2> rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2967": {"data": {"text": "Piperacillin/tazobactam-induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.\n", "entity1": "tazobactam", "entity2": "seizure", "span1": [13, 23], "span2": [32, 39]}, "bert_text": "Piperacillin/<e1> tazobactam </e1>-induced <e2> seizure </e2> rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2968": {"data": {"text": "After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.", "entity1": "fluoxetine", "entity2": "dyskinesias", "span1": [6, 16], "span2": [102, 113]}, "bert_text": "After <e1> fluoxetine </e1> treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced <e2> dyskinesias </e2> without modification of parkinsonian motor disability.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2969": {"data": {"text": "After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.", "entity1": "fluoxetine", "entity2": "parkinsonian", "span1": [6, 16], "span2": [138, 150]}, "bert_text": "After <e1> fluoxetine </e1> treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of <e2> parkinsonian </e2> motor disability.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2970": {"data": {"text": "After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.", "entity1": "apomorphine", "entity2": "dyskinesias", "span1": [82, 93], "span2": [102, 113]}, "bert_text": "After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of <e1> apomorphine </e1>-induced <e2> dyskinesias </e2> without modification of parkinsonian motor disability.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2971": {"data": {"text": "After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability.", "entity1": "apomorphine", "entity2": "parkinsonian", "span1": [82, 93], "span2": [138, 150]}, "bert_text": "After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of <e1> apomorphine </e1>-induced dyskinesias without modification of <e2> parkinsonian </e2> motor disability.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2972": {"data": {"text": "We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.", "entity1": "acetaminophen", "entity2": "fulminant liver failure", "span1": [46, 59], "span2": [68, 91]}, "bert_text": "We report a case of a 40-year-old female with <e1> acetaminophen </e1>-induced <e2> fulminant liver failure </e2> with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2973": {"data": {"text": "We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.", "entity1": "acetaminophen", "entity2": "AKI", "span1": [46, 59], "span2": [108, 111]}, "bert_text": "We report a case of a 40-year-old female with <e1> acetaminophen </e1>-induced fulminant liver failure with associated <e2> AKI </e2> who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2974": {"data": {"text": "We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.", "entity1": "citrate", "entity2": "fulminant liver failure", "span1": [207, 214], "span2": [68, 91]}, "bert_text": "We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with <e1> citrate </e1> <e2> fulminant liver failure </e2> with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2975": {"data": {"text": "We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.", "entity1": "citrate", "entity2": "AKI", "span1": [207, 214], "span2": [108, 111]}, "bert_text": "We report a case of a 40-year-old female with acetaminophen-induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with <e1> citrate </e1> <e2> AKI </e2> who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2976": {"data": {"text": "DOX-induced cardiac damage presumably results from the formation of free radicals by DOX.", "entity1": "DOX", "entity2": "cardiac damage", "span1": [0, 3], "span2": [12, 26]}, "bert_text": "<e1> DOX </e1>-induced <e2> cardiac damage </e2> presumably results from the formation of free radicals by DOX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2977": {"data": {"text": "DOX-induced cardiac damage presumably results from the formation of free radicals by DOX.", "entity1": "DOX", "entity2": "cardiac damage", "span1": [85, 88], "span2": [12, 26]}, "bert_text": "DOX-induced cardiac damage presumably results from the formation of free radicals by <e1> DOX </e1> <e2> cardiac damage </e2> presumably results from the formation of free radicals by DOX.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2978": {"data": {"text": "contrast material to enable diagnosis of ureteric stones or obstruction in patients with HIV infection who receive indinavir therapy.", "entity1": "indinavir", "entity2": "ureteric stones or obstruction", "span1": [115, 124], "span2": [41, 71]}, "bert_text": "contrast material to enable diagnosis of ureteric stones or obstruction in patients with HIV infection who receive <e1> indinavir </e1> <e2> ureteric stones or obstruction </e2> in patients with HIV infection who receive indinavir therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2979": {"data": {"text": "contrast material to enable diagnosis of ureteric stones or obstruction in patients with HIV infection who receive indinavir therapy.", "entity1": "indinavir", "entity2": "HIV infection", "span1": [115, 124], "span2": [89, 102]}, "bert_text": "contrast material to enable diagnosis of ureteric stones or obstruction in patients with HIV infection who receive <e1> indinavir </e1> <e2> HIV infection </e2> who receive indinavir therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2980": {"data": {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity1": "pethidine", "entity2": "impaired renal and liver function", "span1": [95, 104], "span2": [17, 50]}, "bert_text": "In patients with impaired renal and liver function, and those who need long-term pain control, <e1> pethidine </e1> <e2> impaired renal and liver function </e2>, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2981": {"data": {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity1": "pethidine", "entity2": "pain", "span1": [95, 104], "span2": [81, 85]}, "bert_text": "In patients with impaired renal and liver function, and those who need long-term pain control, <e1> pethidine </e1> <e2> pain </e2> control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2982": {"data": {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity1": "pethidine", "entity2": "neurotoxic", "span1": [95, 104], "span2": [175, 185]}, "bert_text": "In patients with impaired renal and liver function, and those who need long-term pain control, <e1> pethidine </e1> may cause excitatory central nervous system (CNS) effects through its <e2> neurotoxic </e2> metabolite, norpethidine, resulting in irritability and seizure attack.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2983": {"data": {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity1": "pethidine", "entity2": "irritability", "span1": [95, 104], "span2": [225, 237]}, "bert_text": "In patients with impaired renal and liver function, and those who need long-term pain control, <e1> pethidine </e1> may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in <e2> irritability </e2> and seizure attack.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2984": {"data": {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity1": "pethidine", "entity2": "seizure", "span1": [95, 104], "span2": [242, 249]}, "bert_text": "In patients with impaired renal and liver function, and those who need long-term pain control, <e1> pethidine </e1> may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and <e2> seizure </e2> attack.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2985": {"data": {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity1": "norpethidine", "entity2": "impaired renal and liver function", "span1": [198, 210], "span2": [17, 50]}, "bert_text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, <e1> norpethidine </e1> <e2> impaired renal and liver function </e2>, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2986": {"data": {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity1": "norpethidine", "entity2": "pain", "span1": [198, 210], "span2": [81, 85]}, "bert_text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, <e1> norpethidine </e1> <e2> pain </e2> control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2987": {"data": {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity1": "norpethidine", "entity2": "neurotoxic", "span1": [198, 210], "span2": [175, 185]}, "bert_text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, <e1> norpethidine </e1> <e2> neurotoxic </e2> metabolite, norpethidine, resulting in irritability and seizure attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2988": {"data": {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity1": "norpethidine", "entity2": "irritability", "span1": [198, 210], "span2": [225, 237]}, "bert_text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, <e1> norpethidine </e1>, resulting in <e2> irritability </e2> and seizure attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2989": {"data": {"text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, norpethidine, resulting in irritability and seizure attack.", "entity1": "norpethidine", "entity2": "seizure", "span1": [198, 210], "span2": [242, 249]}, "bert_text": "In patients with impaired renal and liver function, and those who need long-term pain control, pethidine may cause excitatory central nervous system (CNS) effects through its neurotoxic metabolite, <e1> norpethidine </e1>, resulting in irritability and <e2> seizure </e2> attack.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2990": {"data": {"text": "It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and hypotension.", "entity1": "halothane", "entity2": "bradycardia", "span1": [64, 73], "span2": [101, 112]}, "bert_text": "It is postulated that this action may have been enhanced during <e1> halothane </e1> anaesthesia with resultant <e2> bradycardia </e2> and hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2991": {"data": {"text": "It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and hypotension.", "entity1": "halothane", "entity2": "hypotension", "span1": [64, 73], "span2": [117, 128]}, "bert_text": "It is postulated that this action may have been enhanced during <e1> halothane </e1> anaesthesia with resultant bradycardia and <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2992": {"data": {"text": "Utility of troponin I in patients with cocaine-associated chest pain.\n", "entity1": "cocaine", "entity2": "chest pain", "span1": [39, 46], "span2": [58, 68]}, "bert_text": "Utility of troponin I in patients with <e1> cocaine </e1>-associated <e2> chest pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2993": {"data": {"text": "Nine months of hyperprolactinemia produced a 50% increase in DA concentrations in the ME over the control group.", "entity1": "DA", "entity2": "hyperprolactinemia", "span1": [61, 63], "span2": [15, 33]}, "bert_text": "Nine months of hyperprolactinemia produced a 50% increase in <e1> DA </e1> <e2> hyperprolactinemia </e2> produced a 50% increase in DA concentrations in the ME over the control group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"2994": {"data": {"text": "The three significant predictors of dyskinesia were duration of levodopa therapy, onset age, and total daily levodopa dose.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [64, 72], "span2": [36, 46]}, "bert_text": "The three significant predictors of dyskinesia were duration of <e1> levodopa </e1> <e2> dyskinesia </e2> were duration of levodopa therapy, onset age, and total daily levodopa dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2995": {"data": {"text": "The three significant predictors of dyskinesia were duration of levodopa therapy, onset age, and total daily levodopa dose.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [109, 117], "span2": [36, 46]}, "bert_text": "The three significant predictors of dyskinesia were duration of levodopa therapy, onset age, and total daily <e1> levodopa </e1> <e2> dyskinesia </e2> were duration of levodopa therapy, onset age, and total daily levodopa dose.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2996": {"data": {"text": "In conclusion, ouabain-induced mania-like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder.", "entity1": "ouabain", "entity2": "mania", "span1": [15, 22], "span2": [31, 36]}, "bert_text": "In conclusion, <e1> ouabain </e1>-induced <e2> mania </e2>-like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2997": {"data": {"text": "In conclusion, ouabain-induced mania-like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder.", "entity1": "ouabain", "entity2": "bipolar disorder", "span1": [15, 22], "span2": [150, 166]}, "bert_text": "In conclusion, <e1> ouabain </e1>-induced mania-like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in <e2> bipolar disorder </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"2998": {"data": {"text": "Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her hypertension.", "entity1": "Imipramine", "entity2": "hypertension", "span1": [105, 115], "span2": [228, 240]}, "bert_text": "Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the <e1> Imipramine </e1> (when she was in florid relapse), we believe that this drug rather than her underlying disease alone caused her <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"2999": {"data": {"text": "For further reduction of HIT type II, the use of intravenous heparin should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight heparin after normalization of platelet count.", "entity1": "heparin", "entity2": "HIT", "span1": [61, 68], "span2": [25, 28]}, "bert_text": "For further reduction of HIT type II, the use of intravenous <e1> heparin </e1> <e2> HIT </e2> type II, the use of intravenous heparin should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight heparin after normalization of platelet count.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3000": {"data": {"text": "For further reduction of HIT type II, the use of intravenous heparin should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight heparin after normalization of platelet count.", "entity1": "low-molecular-weight heparin", "entity2": "HIT", "span1": [149, 177], "span2": [25, 28]}, "bert_text": "For further reduction of HIT type II, the use of intravenous heparin should be avoided and the prophylactic anticoagulation should be performed with <e1> low-molecular-weight heparin </e1> <e2> HIT </e2> type II, the use of intravenous heparin should be avoided and the prophylactic anticoagulation should be performed with low-molecular-weight heparin after normalization of platelet count.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3001": {"data": {"text": "To overcome the adverse effects of neutropenia, tobramycin was given by continuous infusion and combined with intermittent carbenicillin.", "entity1": "tobramycin", "entity2": "neutropenia", "span1": [48, 58], "span2": [35, 46]}, "bert_text": "To overcome the adverse effects of neutropenia, <e1> tobramycin </e1> <e2> neutropenia </e2>, tobramycin was given by continuous infusion and combined with intermittent carbenicillin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3002": {"data": {"text": "To overcome the adverse effects of neutropenia, tobramycin was given by continuous infusion and combined with intermittent carbenicillin.", "entity1": "carbenicillin", "entity2": "neutropenia", "span1": [123, 136], "span2": [35, 46]}, "bert_text": "To overcome the adverse effects of neutropenia, tobramycin was given by continuous infusion and combined with intermittent <e1> carbenicillin </e1> <e2> neutropenia </e2>, tobramycin was given by continuous infusion and combined with intermittent carbenicillin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3003": {"data": {"text": "These findings suggest the hypothesis that the catalepsy that is produced by neuroleptics such as haloperidol is actually mediated by intrinsic central cholinergic systems.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [98, 109], "span2": [47, 56]}, "bert_text": "These findings suggest the hypothesis that the catalepsy that is produced by neuroleptics such as <e1> haloperidol </e1> <e2> catalepsy </e2> that is produced by neuroleptics such as haloperidol is actually mediated by intrinsic central cholinergic systems.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3004": {"data": {"text": "GEM-P is a salvage chemotherapy with relatively high response rates, leading to successful transplantation in appropriate patients, in the treatment of relapsed or refractory HL.", "entity1": "GEM", "entity2": "HL", "span1": [0, 3], "span2": [175, 177]}, "bert_text": "<e1> GEM </e1>-P is a salvage chemotherapy with relatively high response rates, leading to successful transplantation in appropriate patients, in the treatment of relapsed or refractory <e2> HL </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3005": {"data": {"text": "This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.", "entity1": "METH", "entity2": "depressive", "span1": [40, 44], "span2": [5, 15]}, "bert_text": "This depressive-like profile induced by <e1> METH </e1> <e2> depressive </e2>-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3006": {"data": {"text": "This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.", "entity1": "dopamine", "entity2": "depressive", "span1": [192, 200], "span2": [5, 15]}, "bert_text": "This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of <e1> dopamine </e1> <e2> depressive </e2>-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3007": {"data": {"text": "This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.", "entity1": "DOPAC", "entity2": "depressive", "span1": [202, 207], "span2": [5, 15]}, "bert_text": "This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, <e1> DOPAC </e1> <e2> depressive </e2>-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3008": {"data": {"text": "This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.", "entity1": "serotonin", "entity2": "depressive", "span1": [242, 251], "span2": [5, 15]}, "bert_text": "This depressive-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and <e1> serotonin </e1> <e2> depressive </e2>-like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission, indicated by a reduction in the levels of dopamine, DOPAC and HVA, tyrosine hydroxylase and serotonin, observed at both 3 and 49 days post-administration.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3009": {"data": {"text": "Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia.", "entity1": "norethisterone", "entity2": "cystic hyperplasia", "span1": [31, 45], "span2": [98, 116]}, "bert_text": "Two courses of 21 days of 5 mg <e1> norethisterone </e1> daily caused reversion to normal in all 57 cases of <e2> cystic hyperplasia </e2> and 6 of the 8 cases of atypical hyperplasia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3010": {"data": {"text": "Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia.", "entity1": "norethisterone", "entity2": "hyperplasia", "span1": [31, 45], "span2": [150, 161]}, "bert_text": "Two courses of 21 days of 5 mg <e1> norethisterone </e1> daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical <e2> hyperplasia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3011": {"data": {"text": "Five phenotypic characteristics--locomotor activity, righting ability, clonic seizure induction, stress-induced lethality, death without external stress--were scored at various caffeine doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions.", "entity1": "caffeine", "entity2": "clonic seizure", "span1": [177, 185], "span2": [71, 85]}, "bert_text": "Five phenotypic characteristics--locomotor activity, righting ability, clonic seizure induction, stress-induced lethality, death without external stress--were scored at various <e1> caffeine </e1> <e2> clonic seizure </e2> induction, stress-induced lethality, death without external stress--were scored at various caffeine doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3012": {"data": {"text": "Five phenotypic characteristics--locomotor activity, righting ability, clonic seizure induction, stress-induced lethality, death without external stress--were scored at various caffeine doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions.", "entity1": "caffeine", "entity2": "death", "span1": [177, 185], "span2": [123, 128]}, "bert_text": "Five phenotypic characteristics--locomotor activity, righting ability, clonic seizure induction, stress-induced lethality, death without external stress--were scored at various <e1> caffeine </e1> <e2> death </e2> without external stress--were scored at various caffeine doses in drug-naive animals under empirically optimized, rigidly constant experimental conditions.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3013": {"data": {"text": "Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.\n", "entity1": "busulfan", "entity2": "neurotoxicity", "span1": [42, 50], "span2": [15, 28]}, "bert_text": "Dose-dependent neurotoxicity of high-dose <e1> busulfan </e1> <e2> neurotoxicity </e2> of high-dose busulfan in children: a clinical and pharmacological study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3014": {"data": {"text": "RESULTS: Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy.", "entity1": "carboplatin", "entity2": "ocular motility", "span1": [156, 167], "span2": [23, 38]}, "bert_text": "RESULTS: Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon <e1> carboplatin </e1> <e2> ocular motility </e2> was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3015": {"data": {"text": "RESULTS: Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy.", "entity1": "carboplatin", "entity2": "intraocular retinoblastoma", "span1": [156, 167], "span2": [94, 120]}, "bert_text": "RESULTS: Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon <e1> carboplatin </e1> <e2> intraocular retinoblastoma </e2> with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3016": {"data": {"text": "The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.", "entity1": "glibenclamide", "entity2": "CAD", "span1": [118, 131], "span2": [25, 28]}, "bert_text": "The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with <e1> glibenclamide </e1> <e2> CAD </e2> (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3017": {"data": {"text": "The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.", "entity1": "glipizide", "entity2": "CAD", "span1": [164, 173], "span2": [25, 28]}, "bert_text": "The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with <e1> glipizide </e1> <e2> CAD </e2> (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3018": {"data": {"text": "The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.", "entity1": "metformin", "entity2": "CAD", "span1": [239, 248], "span2": [25, 28]}, "bert_text": "The hazard of developing CAD (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with <e1> metformin </e1> <e2> CAD </e2> (95% CI) associated with initial treatment increased by 2.4-fold (1.3-4.3, P=0.004) with glibenclamide; 2-fold (0.9-4.6, P=0.099) with glipizide; 2.9-fold (1.6-5.1, P=0.000) with either, and was unchanged with metformin.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3019": {"data": {"text": "Procaterol, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with bronchial asthma.", "entity1": "Procaterol", "entity2": "bronchial asthma", "span1": [0, 10], "span2": [134, 150]}, "bert_text": "<e1> Procaterol </e1>, a new beta-2 adrenoceptor stimulant, was studied in a double-blind, placebo-controlled, cross-over trial in patients with <e2> bronchial asthma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3020": {"data": {"text": "Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine-induced hypotension and bradycardia.\n", "entity1": "clonidine", "entity2": "hypotension", "span1": [72, 81], "span2": [90, 101]}, "bert_text": "Participation of a bulbospinal serotonergic pathway in the rat brain in <e1> clonidine </e1>-induced <e2> hypotension </e2> and bradycardia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3021": {"data": {"text": "Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine-induced hypotension and bradycardia.\n", "entity1": "clonidine", "entity2": "bradycardia", "span1": [72, 81], "span2": [106, 117]}, "bert_text": "Participation of a bulbospinal serotonergic pathway in the rat brain in <e1> clonidine </e1>-induced hypotension and <e2> bradycardia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3022": {"data": {"text": "CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients.", "entity1": "granisetron", "entity2": "vomiting", "span1": [59, 70], "span2": [100, 108]}, "bert_text": "CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of <e1> granisetron </e1> was effective in controlling <e2> vomiting </e2> in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3023": {"data": {"text": "CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients.", "entity1": "granisetron", "entity2": "vomiting", "span1": [59, 70], "span2": [211, 219]}, "bert_text": "CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of <e1> granisetron </e1> was effective in controlling vomiting in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented <e2> vomiting </e2> in 40% to 47% of patients.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3024": {"data": {"text": "CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients.", "entity1": "cisplatin", "entity2": "vomiting", "span1": [148, 157], "span2": [100, 108]}, "bert_text": "CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received <e1> cisplatin </e1> <e2> vomiting </e2> in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3025": {"data": {"text": "CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received cisplatin at doses greater than 81 mg/m2 and totally prevented vomiting in 40% to 47% of patients.", "entity1": "cisplatin", "entity2": "vomiting", "span1": [148, 157], "span2": [211, 219]}, "bert_text": "CONCLUSION: A single 10-, 20-, or 40-micrograms/kg dose of granisetron was effective in controlling vomiting in 57% to 60% of patients who received <e1> cisplatin </e1> at doses greater than 81 mg/m2 and totally prevented <e2> vomiting </e2> in 40% to 47% of patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3026": {"data": {"text": "We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin.", "entity1": "indomethacin", "entity2": "hyperkalemia", "span1": [153, 165], "span2": [60, 72]}, "bert_text": "We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with <e1> indomethacin </e1> <e2> hyperkalemia </e2> and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3027": {"data": {"text": "We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin.", "entity1": "indomethacin", "entity2": "renal insufficiency", "span1": [153, 165], "span2": [77, 96]}, "bert_text": "We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with <e1> indomethacin </e1> <e2> renal insufficiency </e2> developed after treatment of acute gouty arthritis with indomethacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3028": {"data": {"text": "We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin.", "entity1": "indomethacin", "entity2": "gouty arthritis", "span1": [153, 165], "span2": [132, 147]}, "bert_text": "We describe three patients in whom severe, life-threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with <e1> indomethacin </e1> <e2> gouty arthritis </e2> with indomethacin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3029": {"data": {"text": "Structure-activity and dose-effect relationships of the antagonism of picrotoxin-induced seizures by cholecystokinin, fragments and analogues of cholecystokinin in mice.\n", "entity1": "picrotoxin", "entity2": "seizures", "span1": [70, 80], "span2": [89, 97]}, "bert_text": "Structure-activity and dose-effect relationships of the antagonism of <e1> picrotoxin </e1>-induced <e2> seizures </e2> by cholecystokinin, fragments and analogues of cholecystokinin in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3030": {"data": {"text": "Myotonia congenita (MC) is caused by a defect in the skeletal muscle chloride channel function, which may cause sustained membrane depolarisation.", "entity1": "chloride", "entity2": "Myotonia congenita", "span1": [69, 77], "span2": [0, 18]}, "bert_text": "Myotonia congenita (MC) is caused by a defect in the skeletal muscle <e1> chloride </e1> <e2> Myotonia congenita </e2> (MC) is caused by a defect in the skeletal muscle chloride channel function, which may cause sustained membrane depolarisation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3031": {"data": {"text": "Myotonia congenita (MC) is caused by a defect in the skeletal muscle chloride channel function, which may cause sustained membrane depolarisation.", "entity1": "chloride", "entity2": "MC", "span1": [69, 77], "span2": [20, 22]}, "bert_text": "Myotonia congenita (MC) is caused by a defect in the skeletal muscle <e1> chloride </e1> <e2> MC </e2>) is caused by a defect in the skeletal muscle chloride channel function, which may cause sustained membrane depolarisation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3032": {"data": {"text": "Famotidine is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost.", "entity1": "Famotidine", "entity2": "ulcers", "span1": [0, 10], "span2": [101, 107]}, "bert_text": "<e1> Famotidine </e1> is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress <e2> ulcers </e2> and is showing increasing popularity because of its low cost.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3033": {"data": {"text": "Famotidine is a histamine H2-receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost.", "entity1": "histamine", "entity2": "ulcers", "span1": [16, 25], "span2": [101, 107]}, "bert_text": "Famotidine is a <e1> histamine </e1> H2-receptor antagonist used in inpatient settings for prevention of stress <e2> ulcers </e2> and is showing increasing popularity because of its low cost.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3034": {"data": {"text": "According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.", "entity1": "flecainide", "entity2": "delirium", "span1": [44, 54], "span2": [95, 103]}, "bert_text": "According to the Naranjo probability scale, <e1> flecainide </e1> was the probable cause of the patient's <e2> delirium </e2>; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3035": {"data": {"text": "According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.", "entity1": "flecainide", "entity2": "delirium", "span1": [211, 221], "span2": [95, 103]}, "bert_text": "According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between <e1> flecainide </e1> <e2> delirium </e2>; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3036": {"data": {"text": "According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.", "entity1": "paroxetine", "entity2": "delirium", "span1": [226, 236], "span2": [95, 103]}, "bert_text": "According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and <e1> paroxetine </e1> <e2> delirium </e2>; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3037": {"data": {"text": "Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "entity1": "TMP-SMZ", "entity2": "blood disorders", "span1": [75, 82], "span2": [31, 46]}, "bert_text": "Only five patients experienced blood disorders, one of whom was exposed to <e1> TMP-SMZ </e1> <e2> blood disorders </e2>, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3038": {"data": {"text": "Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "entity1": "TMP-SMZ", "entity2": "erythema multiforme", "span1": [75, 82], "span2": [98, 117]}, "bert_text": "Only five patients experienced blood disorders, one of whom was exposed to <e1> TMP-SMZ </e1>; of seven with <e2> erythema multiforme </e2> and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3039": {"data": {"text": "Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "entity1": "TMP-SMZ", "entity2": "Stevens-Johnson syndrome", "span1": [75, 82], "span2": [122, 146]}, "bert_text": "Only five patients experienced blood disorders, one of whom was exposed to <e1> TMP-SMZ </e1>; of seven with erythema multiforme and <e2> Stevens-Johnson syndrome </e2>, four were exposed to TMP-SMZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3040": {"data": {"text": "Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "entity1": "TMP-SMZ", "entity2": "blood disorders", "span1": [169, 176], "span2": [31, 46]}, "bert_text": "Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to <e1> TMP-SMZ </e1> <e2> blood disorders </e2>, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3041": {"data": {"text": "Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "entity1": "TMP-SMZ", "entity2": "erythema multiforme", "span1": [169, 176], "span2": [98, 117]}, "bert_text": "Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to <e1> TMP-SMZ </e1> <e2> erythema multiforme </e2> and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3042": {"data": {"text": "Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to TMP-SMZ.", "entity1": "TMP-SMZ", "entity2": "Stevens-Johnson syndrome", "span1": [169, 176], "span2": [122, 146]}, "bert_text": "Only five patients experienced blood disorders, one of whom was exposed to TMP-SMZ; of seven with erythema multiforme and Stevens-Johnson syndrome, four were exposed to <e1> TMP-SMZ </e1> <e2> Stevens-Johnson syndrome </e2>, four were exposed to TMP-SMZ.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3043": {"data": {"text": "Ifosfamide related encephalopathy: the need for a timely EEG evaluation.\n", "entity1": "Ifosfamide", "entity2": "encephalopathy", "span1": [0, 10], "span2": [19, 33]}, "bert_text": "<e1> Ifosfamide </e1> related <e2> encephalopathy </e2>: the need for a timely EEG evaluation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3044": {"data": {"text": "Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.\n", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [26, 37], "span2": [8, 22]}, "bert_text": "Reduced cardiotoxicity of <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3045": {"data": {"text": "Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.\n", "entity1": "N-(2-hydroxypropyl)methacrylamide", "entity2": "cardiotoxicity", "span1": [59, 92], "span2": [8, 22]}, "bert_text": "Reduced cardiotoxicity of doxorubicin given in the form of <e1> N-(2-hydroxypropyl)methacrylamide </e1> <e2> cardiotoxicity </e2> of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: and experimental study in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3046": {"data": {"text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.", "entity1": "heparin", "entity2": "renal amyloidosis", "span1": [259, 266], "span2": [42, 59]}, "bert_text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to <e1> heparin </e1> <e2> renal amyloidosis </e2> undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3047": {"data": {"text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.", "entity1": "heparin", "entity2": "deep venous thrombosis", "span1": [259, 266], "span2": [194, 216]}, "bert_text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to <e1> heparin </e1> <e2> deep venous thrombosis </e2> (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3048": {"data": {"text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.", "entity1": "heparin", "entity2": "DVT", "span1": [259, 266], "span2": [218, 221]}, "bert_text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to <e1> heparin </e1> <e2> DVT </e2>) and pulmonary embolism secondary to heparin-induced thrombocytopenia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3049": {"data": {"text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.", "entity1": "heparin", "entity2": "pulmonary embolism", "span1": [259, 266], "span2": [227, 245]}, "bert_text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to <e1> heparin </e1> <e2> pulmonary embolism </e2> secondary to heparin-induced thrombocytopenia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3050": {"data": {"text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to heparin-induced thrombocytopenia.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [259, 266], "span2": [275, 291]}, "bert_text": "SUMMARY: A 63-year-old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper-extremity deep venous thrombosis (DVT) and pulmonary embolism secondary to <e1> heparin </e1>-induced <e2> thrombocytopenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3051": {"data": {"text": "To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.", "entity1": "aconitine", "entity2": "myocardial injury", "span1": [26, 35], "span2": [39, 56]}, "bert_text": "To investigate effects of <e1> aconitine </e1> on <e2> myocardial injury </e2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3052": {"data": {"text": "To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.", "entity1": "aconitine", "entity2": "cytotoxicity", "span1": [26, 35], "span2": [71, 83]}, "bert_text": "To investigate effects of <e1> aconitine </e1> on myocardial injury, we performed <e2> cytotoxicity </e2> assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3053": {"data": {"text": "To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.", "entity1": "lactate", "entity2": "myocardial injury", "span1": [156, 163], "span2": [39, 56]}, "bert_text": "To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured <e1> lactate </e1> <e2> myocardial injury </e2>, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0], "label": 0},
+	"3054": {"data": {"text": "To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.", "entity1": "lactate", "entity2": "cytotoxicity", "span1": [156, 163], "span2": [71, 83]}, "bert_text": "To investigate effects of aconitine on myocardial injury, we performed cytotoxicity assay in neonatal rat ventricular myocytes (NRVMs), as well as measured <e1> lactate </e1> <e2> cytotoxicity </e2> assay in neonatal rat ventricular myocytes (NRVMs), as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0], "label": 0},
+	"3055": {"data": {"text": "Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations.\n", "entity1": "propylthiouracil", "entity2": "Graves' disease", "span1": [131, 147], "span2": [93, 108]}, "bert_text": "Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with <e1> propylthiouracil </e1> <e2> Graves' disease </e2> patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3056": {"data": {"text": "CONCLUSION: There was a high risk of psychosis in patients with methamphetamine dependence.", "entity1": "methamphetamine", "entity2": "psychosis", "span1": [64, 79], "span2": [37, 46]}, "bert_text": "CONCLUSION: There was a high risk of psychosis in patients with <e1> methamphetamine </e1> <e2> psychosis </e2> in patients with methamphetamine dependence.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"3057": {"data": {"text": "People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.\n", "entity1": "warfarin", "entity2": "atrial fibrillation", "span1": [46, 54], "span2": [23, 42]}, "bert_text": "People aged over 75 in atrial fibrillation on <e1> warfarin </e1> <e2> atrial fibrillation </e2> on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3058": {"data": {"text": "People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.\n", "entity1": "warfarin", "entity2": "hemorrhage", "span1": [46, 54], "span2": [74, 84]}, "bert_text": "People aged over 75 in atrial fibrillation on <e1> warfarin </e1>: the rate of major <e2> hemorrhage </e2> and stroke in more than 500 patient-years of follow-up.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3059": {"data": {"text": "People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up.\n", "entity1": "warfarin", "entity2": "stroke", "span1": [46, 54], "span2": [89, 95]}, "bert_text": "People aged over 75 in atrial fibrillation on <e1> warfarin </e1>: the rate of major hemorrhage and <e2> stroke </e2> in more than 500 patient-years of follow-up.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3060": {"data": {"text": "Adriamycin in the cumulative dose of 25 mg/kg evoked fully developed cardiac toxicity.", "entity1": "Adriamycin", "entity2": "cardiac toxicity", "span1": [0, 10], "span2": [69, 85]}, "bert_text": "<e1> Adriamycin </e1> in the cumulative dose of 25 mg/kg evoked fully developed <e2> cardiac toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3061": {"data": {"text": "OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.", "entity1": "warfarin", "entity2": "hemorrhage", "span1": [140, 148], "span2": [48, 58]}, "bert_text": "OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose <e1> warfarin </e1> <e2> hemorrhage </e2> and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3062": {"data": {"text": "OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.", "entity1": "warfarin", "entity2": "stroke", "span1": [140, 148], "span2": [63, 69]}, "bert_text": "OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose <e1> warfarin </e1> <e2> stroke </e2> in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3063": {"data": {"text": "OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose warfarin who had been recently been admitted to hospital.", "entity1": "warfarin", "entity2": "atrial fibrillation", "span1": [140, 148], "span2": [103, 122]}, "bert_text": "OBJECTIVES: To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted-dose <e1> warfarin </e1> <e2> atrial fibrillation </e2> on adjusted-dose warfarin who had been recently been admitted to hospital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3064": {"data": {"text": "Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of aristolochic acids.", "entity1": "aristolochic acids", "entity2": "Nephropathy", "span1": [95, 113], "span2": [0, 11]}, "bert_text": "Nephropathy caused by Chinese herbs has previously been reported, usually involving the use of <e1> aristolochic acids </e1> <e2> Nephropathy </e2> caused by Chinese herbs has previously been reported, usually involving the use of aristolochic acids.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3065": {"data": {"text": "CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.", "entity1": "warfarin", "entity2": "ICH", "span1": [33, 41], "span2": [53, 56]}, "bert_text": "CONCLUSIONS: The excess of MB in <e1> warfarin </e1> users with <e2> ICH </e2> compared to other groups suggests that MB increase the risk of warfarin-associated ICH.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3066": {"data": {"text": "CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.", "entity1": "warfarin", "entity2": "ICH", "span1": [33, 41], "span2": [140, 143]}, "bert_text": "CONCLUSIONS: The excess of MB in <e1> warfarin </e1> users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated <e2> ICH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3067": {"data": {"text": "CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.", "entity1": "warfarin", "entity2": "ICH", "span1": [120, 128], "span2": [53, 56]}, "bert_text": "CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of <e1> warfarin </e1> <e2> ICH </e2> compared to other groups suggests that MB increase the risk of warfarin-associated ICH.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3068": {"data": {"text": "CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin-associated ICH.", "entity1": "warfarin", "entity2": "ICH", "span1": [120, 128], "span2": [140, 143]}, "bert_text": "CONCLUSIONS: The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of <e1> warfarin </e1>-associated <e2> ICH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3069": {"data": {"text": "Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of propofol.\n", "entity1": "bupivacaine", "entity2": "cardiovascular depression", "span1": [17, 28], "span2": [37, 62]}, "bert_text": "Pre-treatment of <e1> bupivacaine </e1>-induced <e2> cardiovascular depression </e2> using different lipid formulations of propofol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3070": {"data": {"text": "Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of propofol.\n", "entity1": "propofol", "entity2": "cardiovascular depression", "span1": [101, 109], "span2": [37, 62]}, "bert_text": "Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of <e1> propofol </e1> <e2> cardiovascular depression </e2> using different lipid formulations of propofol.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3071": {"data": {"text": "Ongoing tubular injury may be a prerequisite for renal injury by melphalan as evidenced by the active urinary sediment.", "entity1": "melphalan", "entity2": "Ongoing tubular injury", "span1": [65, 74], "span2": [0, 22]}, "bert_text": "Ongoing tubular injury may be a prerequisite for renal injury by <e1> melphalan </e1> <e2> Ongoing tubular injury </e2> may be a prerequisite for renal injury by melphalan as evidenced by the active urinary sediment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3072": {"data": {"text": "Ongoing tubular injury may be a prerequisite for renal injury by melphalan as evidenced by the active urinary sediment.", "entity1": "melphalan", "entity2": "renal injury", "span1": [65, 74], "span2": [49, 61]}, "bert_text": "Ongoing tubular injury may be a prerequisite for renal injury by <e1> melphalan </e1> <e2> renal injury </e2> by melphalan as evidenced by the active urinary sediment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3073": {"data": {"text": "At these high doses of CYA, serious cardiotoxicity may occur, but definitive risk factors for the development of such cardiotoxicity have not been described.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [23, 26], "span2": [36, 50]}, "bert_text": "At these high doses of <e1> CYA </e1>, serious <e2> cardiotoxicity </e2> may occur, but definitive risk factors for the development of such cardiotoxicity have not been described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3074": {"data": {"text": "At these high doses of CYA, serious cardiotoxicity may occur, but definitive risk factors for the development of such cardiotoxicity have not been described.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [23, 26], "span2": [118, 132]}, "bert_text": "At these high doses of <e1> CYA </e1>, serious cardiotoxicity may occur, but definitive risk factors for the development of such <e2> cardiotoxicity </e2> have not been described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3075": {"data": {"text": "Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice.\n1.", "entity1": "orphanin FQ", "entity2": "memory impairment", "span1": [11, 22], "span2": [54, 71]}, "bert_text": "Nociceptin/<e1> orphanin FQ </e1> and nocistatin on learning and <e2> memory impairment </e2> induced by scopolamine in mice.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3076": {"data": {"text": "Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice.\n1.", "entity1": "nocistatin", "entity2": "memory impairment", "span1": [27, 37], "span2": [54, 71]}, "bert_text": "Nociceptin/orphanin FQ and <e1> nocistatin </e1> on learning and <e2> memory impairment </e2> induced by scopolamine in mice.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3077": {"data": {"text": "Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice.\n1.", "entity1": "scopolamine", "entity2": "memory impairment", "span1": [83, 94], "span2": [54, 71]}, "bert_text": "Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by <e1> scopolamine </e1> <e2> memory impairment </e2> induced by scopolamine in mice.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3078": {"data": {"text": "BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.", "entity1": "bupivacaine", "entity2": "cardiotoxicity", "span1": [90, 101], "span2": [171, 185]}, "bert_text": "BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of <e1> bupivacaine </e1>, and the lipid content of propofol may alleviate bupivacaine-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3079": {"data": {"text": "BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.", "entity1": "bupivacaine", "entity2": "cardiotoxicity", "span1": [151, 162], "span2": [171, 185]}, "bert_text": "BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate <e1> bupivacaine </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3080": {"data": {"text": "BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity.", "entity1": "propofol", "entity2": "cardiotoxicity", "span1": [128, 136], "span2": [171, 185]}, "bert_text": "BACKGROUND: Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of <e1> propofol </e1> may alleviate bupivacaine-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3081": {"data": {"text": "METHODS: Eighty-eight patients with chronic hepatitis C who received interferon-alpha-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study.", "entity1": "interferon-alpha-2b", "entity2": "chronic hepatitis C", "span1": [69, 88], "span2": [36, 55]}, "bert_text": "METHODS: Eighty-eight patients with chronic hepatitis C who received <e1> interferon-alpha-2b </e1> <e2> chronic hepatitis C </e2> who received interferon-alpha-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3082": {"data": {"text": "METHODS: Eighty-eight patients with chronic hepatitis C who received interferon-alpha-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study.", "entity1": "ribavirin", "entity2": "chronic hepatitis C", "span1": [169, 178], "span2": [36, 55]}, "bert_text": "METHODS: Eighty-eight patients with chronic hepatitis C who received interferon-alpha-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with <e1> ribavirin </e1> <e2> chronic hepatitis C </e2> who received interferon-alpha-2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3083": {"data": {"text": "DATA SYNTHESIS: New evidence from 1 good-quality RCT, 1 good-quality meta-analysis, and 2 fair-quality subanalyses of RCTs demonstrates that aspirin use reduces the number of CVD events in patients without known CVD.", "entity1": "aspirin", "entity2": "CVD", "span1": [141, 148], "span2": [175, 178]}, "bert_text": "DATA SYNTHESIS: New evidence from 1 good-quality RCT, 1 good-quality meta-analysis, and 2 fair-quality subanalyses of RCTs demonstrates that <e1> aspirin </e1> use reduces the number of <e2> CVD </e2> events in patients without known CVD.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3084": {"data": {"text": "DATA SYNTHESIS: New evidence from 1 good-quality RCT, 1 good-quality meta-analysis, and 2 fair-quality subanalyses of RCTs demonstrates that aspirin use reduces the number of CVD events in patients without known CVD.", "entity1": "aspirin", "entity2": "CVD", "span1": [141, 148], "span2": [212, 215]}, "bert_text": "DATA SYNTHESIS: New evidence from 1 good-quality RCT, 1 good-quality meta-analysis, and 2 fair-quality subanalyses of RCTs demonstrates that <e1> aspirin </e1> use reduces the number of CVD events in patients without known <e2> CVD </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3085": {"data": {"text": "The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital.", "entity1": "barium", "entity2": "hypersensitivity", "span1": [35, 41], "span2": [68, 84]}, "bert_text": "The most distinctive aspect of the <e1> barium </e1> effect was a demonstrated <e2> hypersensitivity </e2> of the cardiovascular system to sodium pentobarbital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3086": {"data": {"text": "The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital.", "entity1": "sodium pentobarbital", "entity2": "hypersensitivity", "span1": [117, 137], "span2": [68, 84]}, "bert_text": "The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to <e1> sodium pentobarbital </e1> <e2> hypersensitivity </e2> of the cardiovascular system to sodium pentobarbital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3087": {"data": {"text": "Cutaneous exposure to warfarin-like anticoagulant causing an intracerebral hemorrhage: a case report.\n", "entity1": "warfarin", "entity2": "intracerebral hemorrhage", "span1": [22, 30], "span2": [61, 85]}, "bert_text": "Cutaneous exposure to <e1> warfarin </e1>-like anticoagulant causing an <e2> intracerebral hemorrhage </e2>: a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3088": {"data": {"text": "In fact the concentration of free DPH was normal, the patient presented a retarded morbilliform rash during DPH treatment, the protidogram was normal, and an intradermic DPH injection had no local effect.", "entity1": "DPH", "entity2": "rash", "span1": [34, 37], "span2": [96, 100]}, "bert_text": "In fact the concentration of free <e1> DPH </e1> was normal, the patient presented a retarded morbilliform <e2> rash </e2> during DPH treatment, the protidogram was normal, and an intradermic DPH injection had no local effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3089": {"data": {"text": "In fact the concentration of free DPH was normal, the patient presented a retarded morbilliform rash during DPH treatment, the protidogram was normal, and an intradermic DPH injection had no local effect.", "entity1": "DPH", "entity2": "rash", "span1": [108, 111], "span2": [96, 100]}, "bert_text": "In fact the concentration of free DPH was normal, the patient presented a retarded morbilliform rash during <e1> DPH </e1> <e2> rash </e2> during DPH treatment, the protidogram was normal, and an intradermic DPH injection had no local effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3090": {"data": {"text": "In fact the concentration of free DPH was normal, the patient presented a retarded morbilliform rash during DPH treatment, the protidogram was normal, and an intradermic DPH injection had no local effect.", "entity1": "DPH", "entity2": "rash", "span1": [170, 173], "span2": [96, 100]}, "bert_text": "In fact the concentration of free DPH was normal, the patient presented a retarded morbilliform rash during DPH treatment, the protidogram was normal, and an intradermic <e1> DPH </e1> <e2> rash </e2> during DPH treatment, the protidogram was normal, and an intradermic DPH injection had no local effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3091": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "mefenamic acid", "entity2": "rheumatoid arthritis", "span1": [78, 92], "span2": [40, 60]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of <e1> mefenamic acid </e1> <e2> rheumatoid arthritis </e2> and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3092": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "mefenamic acid", "entity2": "nephropathy", "span1": [78, 92], "span2": [93, 104]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of <e1> mefenamic acid </e1> <e2> nephropathy </e2> in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3093": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "mefenamic acid", "entity2": "hyperkalemia", "span1": [78, 92], "span2": [113, 125]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of <e1> mefenamic acid </e1> nephropathy in whom <e2> hyperkalemia </e2> and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3094": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "mefenamic acid", "entity2": "inappropriate hypoaldosteronism", "span1": [78, 92], "span2": [130, 161]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of <e1> mefenamic acid </e1> nephropathy in whom hyperkalemia and <e2> inappropriate hypoaldosteronism </e2> were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3095": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "indomethacin", "entity2": "rheumatoid arthritis", "span1": [182, 194], "span2": [40, 60]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both <e1> indomethacin </e1> <e2> rheumatoid arthritis </e2> and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3096": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "indomethacin", "entity2": "nephropathy", "span1": [182, 194], "span2": [93, 104]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both <e1> indomethacin </e1> <e2> nephropathy </e2> in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3097": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "indomethacin", "entity2": "hyperkalemia", "span1": [182, 194], "span2": [113, 125]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both <e1> indomethacin </e1> <e2> hyperkalemia </e2> and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3098": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "indomethacin", "entity2": "inappropriate hypoaldosteronism", "span1": [182, 194], "span2": [130, 161]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both <e1> indomethacin </e1> <e2> inappropriate hypoaldosteronism </e2> were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3099": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "naproxen", "entity2": "rheumatoid arthritis", "span1": [199, 207], "span2": [40, 60]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and <e1> naproxen </e1> <e2> rheumatoid arthritis </e2> and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3100": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "naproxen", "entity2": "nephropathy", "span1": [199, 207], "span2": [93, 104]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and <e1> naproxen </e1> <e2> nephropathy </e2> in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3101": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "naproxen", "entity2": "hyperkalemia", "span1": [199, 207], "span2": [113, 125]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and <e1> naproxen </e1> <e2> hyperkalemia </e2> and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3102": {"data": {"text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen, without major decline in renal function.", "entity1": "naproxen", "entity2": "inappropriate hypoaldosteronism", "span1": [199, 207], "span2": [130, 161]}, "bert_text": "We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and <e1> naproxen </e1> <e2> inappropriate hypoaldosteronism </e2> were caused by both indomethacin and naproxen, without major decline in renal function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3103": {"data": {"text": "BACKGROUND: Succinylcholine commonly produces frequent adverse effects, including muscle fasciculation and myalgia.", "entity1": "Succinylcholine", "entity2": "muscle fasciculation", "span1": [12, 27], "span2": [82, 102]}, "bert_text": "BACKGROUND: <e1> Succinylcholine </e1> commonly produces frequent adverse effects, including <e2> muscle fasciculation </e2> and myalgia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3104": {"data": {"text": "BACKGROUND: Succinylcholine commonly produces frequent adverse effects, including muscle fasciculation and myalgia.", "entity1": "Succinylcholine", "entity2": "myalgia", "span1": [12, 27], "span2": [107, 114]}, "bert_text": "BACKGROUND: <e1> Succinylcholine </e1> commonly produces frequent adverse effects, including muscle fasciculation and <e2> myalgia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3105": {"data": {"text": "The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced L-DOPA-induced dyskinesias.", "entity1": "cannabinoid", "entity2": "dyskinesias", "span1": [38, 49], "span2": [149, 160]}, "bert_text": "The results revealed that the lack of <e1> cannabinoid </e1> CB1 receptors increased the severity of motor impairment and DA lesion, and reduced L-DOPA-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3106": {"data": {"text": "The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced L-DOPA-induced dyskinesias.", "entity1": "DA", "entity2": "dyskinesias", "span1": [111, 113], "span2": [149, 160]}, "bert_text": "The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and <e1> DA </e1> lesion, and reduced L-DOPA-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3107": {"data": {"text": "The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced L-DOPA-induced dyskinesias.", "entity1": "L-DOPA", "entity2": "dyskinesias", "span1": [134, 140], "span2": [149, 160]}, "bert_text": "The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion, and reduced <e1> L-DOPA </e1>-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3108": {"data": {"text": "The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).", "entity1": "lindane", "entity2": "convulsion", "span1": [213, 220], "span2": [114, 124]}, "bert_text": "The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower <e1> lindane </e1> <e2> convulsion </e2> incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3109": {"data": {"text": "The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose (4 mg/kg, i.p.).", "entity1": "lindane", "entity2": "convulsion", "span1": [213, 220], "span2": [184, 194]}, "bert_text": "The administration of L-arginine (600, 800 and 1000 mg/kg, i.p.) in dose-dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower <e1> lindane </e1> <e2> convulsion </e2> elicited by lower lindane dose (4 mg/kg, i.p.).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3110": {"data": {"text": "A total of 66 children from 16 Pediatric Oncology Group institutions with \"standard-risk\" acute lymphoblastic leukemia, 1.00 to 9.99 years at diagnosis, without evidence of CNS leukemia at diagnosis were enrolled on ACCL0131: 28 from P9201 and 38 from P9605.", "entity1": "P9605", "entity2": "acute lymphoblastic leukemia", "span1": [252, 257], "span2": [90, 118]}, "bert_text": "A total of 66 children from 16 Pediatric Oncology Group institutions with \"standard-risk\" acute lymphoblastic leukemia, 1.00 to 9.99 years at diagnosis, without evidence of CNS leukemia at diagnosis were enrolled on ACCL0131: 28 from P9201 and 38 from <e1> P9605 </e1> <e2> acute lymphoblastic leukemia </e2>, 1.00 to 9.99 years at diagnosis, without evidence of CNS leukemia at diagnosis were enrolled on ACCL0131: 28 from P9201 and 38 from P9605.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3111": {"data": {"text": "A total of 66 children from 16 Pediatric Oncology Group institutions with \"standard-risk\" acute lymphoblastic leukemia, 1.00 to 9.99 years at diagnosis, without evidence of CNS leukemia at diagnosis were enrolled on ACCL0131: 28 from P9201 and 38 from P9605.", "entity1": "P9605", "entity2": "leukemia", "span1": [252, 257], "span2": [177, 185]}, "bert_text": "A total of 66 children from 16 Pediatric Oncology Group institutions with \"standard-risk\" acute lymphoblastic leukemia, 1.00 to 9.99 years at diagnosis, without evidence of CNS leukemia at diagnosis were enrolled on ACCL0131: 28 from P9201 and 38 from <e1> P9605 </e1> <e2> leukemia </e2> at diagnosis were enrolled on ACCL0131: 28 from P9201 and 38 from P9605.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3112": {"data": {"text": "Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral caffeine challenge test.", "entity1": "caffeine", "entity2": "panic attacks", "span1": [140, 148], "span2": [54, 67]}, "bert_text": "Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral <e1> caffeine </e1> <e2> panic attacks </e2>, no matter if associated with PD or MDP, and hyperreactivity to an oral caffeine challenge test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3113": {"data": {"text": "Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral caffeine challenge test.", "entity1": "caffeine", "entity2": "PD", "span1": [140, 148], "span2": [98, 100]}, "bert_text": "Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral <e1> caffeine </e1> <e2> PD </e2> or MDP, and hyperreactivity to an oral caffeine challenge test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3114": {"data": {"text": "Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral caffeine challenge test.", "entity1": "caffeine", "entity2": "MDP", "span1": [140, 148], "span2": [104, 107]}, "bert_text": "Our data suggest that there is an association between panic attacks, no matter if associated with PD or MDP, and hyperreactivity to an oral <e1> caffeine </e1> <e2> MDP </e2>, and hyperreactivity to an oral caffeine challenge test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3115": {"data": {"text": "Furthermore, dexamethasone-induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork (TM).", "entity1": "dexamethasone", "entity2": "ocular hypertension", "span1": [13, 26], "span2": [35, 54]}, "bert_text": "Furthermore, <e1> dexamethasone </e1>-induced <e2> ocular hypertension </e2> was associated with chronic ER stress of the trabecular meshwork (TM).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3116": {"data": {"text": "These models may also be useful in developing insights into the pathophysiology of aminoglycoside-induced nephrotoxicity.", "entity1": "aminoglycoside", "entity2": "nephrotoxicity", "span1": [83, 97], "span2": [106, 120]}, "bert_text": "These models may also be useful in developing insights into the pathophysiology of <e1> aminoglycoside </e1>-induced <e2> nephrotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3117": {"data": {"text": "Also, digoxin has undesirable effects such as increasing peripheral resistance and myocardial demands, and causing arrhythmias.", "entity1": "digoxin", "entity2": "arrhythmias", "span1": [6, 13], "span2": [115, 126]}, "bert_text": "Also, <e1> digoxin </e1> has undesirable effects such as increasing peripheral resistance and myocardial demands, and causing <e2> arrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3118": {"data": {"text": "Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months.", "entity1": "morphine", "entity2": "seizures", "span1": [107, 115], "span2": [24, 32]}, "bert_text": "Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of <e1> morphine </e1> <e2> seizures </e2> were ruled out and the convulsions stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3119": {"data": {"text": "Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months.", "entity1": "morphine", "entity2": "convulsions", "span1": [107, 115], "span2": [56, 67]}, "bert_text": "Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of <e1> morphine </e1> <e2> convulsions </e2> stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3120": {"data": {"text": "In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4).", "entity1": "malondialdehyde", "entity2": "weight gain", "span1": [167, 182], "span2": [81, 92]}, "bert_text": "In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical <e1> malondialdehyde </e1> <e2> weight gain </e2>, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3121": {"data": {"text": "In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4).", "entity1": "malondialdehyde", "entity2": "proteinuria", "span1": [167, 182], "span2": [110, 121]}, "bert_text": "In normal rats with intact kidneys, rhIGF-I administration (n = 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical <e1> malondialdehyde </e1> <e2> proteinuria </e2>, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n = 4).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3122": {"data": {"text": "Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen.", "entity1": "oestrogen", "entity2": "Cystic hyperplasia", "span1": [49, 58], "span2": [0, 18]}, "bert_text": "Cystic hyperplasia was associated with unopposed <e1> oestrogen </e1> <e2> Cystic hyperplasia </e2> was associated with unopposed oestrogen therapy without progestagen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3123": {"data": {"text": "Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen.", "entity1": "progestagen", "entity2": "Cystic hyperplasia", "span1": [75, 86], "span2": [0, 18]}, "bert_text": "Cystic hyperplasia was associated with unopposed oestrogen therapy without <e1> progestagen </e1> <e2> Cystic hyperplasia </e2> was associated with unopposed oestrogen therapy without progestagen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3124": {"data": {"text": "Our case suggests that troponin elevation could be associated with statin induced rhabdomyolysis, which may warrant further studies.", "entity1": "statin", "entity2": "rhabdomyolysis", "span1": [67, 73], "span2": [82, 96]}, "bert_text": "Our case suggests that troponin elevation could be associated with <e1> statin </e1> induced <e2> rhabdomyolysis </e2>, which may warrant further studies.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3125": {"data": {"text": "The nystagmus of both patients resolved after reduction of the serum carbamazepine levels.", "entity1": "carbamazepine", "entity2": "nystagmus", "span1": [69, 82], "span2": [4, 13]}, "bert_text": "The nystagmus of both patients resolved after reduction of the serum <e1> carbamazepine </e1> <e2> nystagmus </e2> of both patients resolved after reduction of the serum carbamazepine levels.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3126": {"data": {"text": "Propylthiouracil-induced hepatic damage.\n", "entity1": "Propylthiouracil", "entity2": "hepatic damage", "span1": [0, 16], "span2": [25, 39]}, "bert_text": "<e1> Propylthiouracil </e1>-induced <e2> hepatic damage </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3127": {"data": {"text": "Valproic acid (VPA) is effective for the treatment of many types of epilepsy, but its use can be associated with an increase in body weight.", "entity1": "Valproic acid", "entity2": "epilepsy", "span1": [0, 13], "span2": [68, 76]}, "bert_text": "<e1> Valproic acid </e1> (VPA) is effective for the treatment of many types of <e2> epilepsy </e2>, but its use can be associated with an increase in body weight.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3128": {"data": {"text": "Valproic acid (VPA) is effective for the treatment of many types of epilepsy, but its use can be associated with an increase in body weight.", "entity1": "VPA", "entity2": "epilepsy", "span1": [15, 18], "span2": [68, 76]}, "bert_text": "Valproic acid (<e1> VPA </e1>) is effective for the treatment of many types of <e2> epilepsy </e2>, but its use can be associated with an increase in body weight.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3129": {"data": {"text": "Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.", "entity1": "nifedipine", "entity2": "hypertensive psoriatic", "span1": [45, 55], "span2": [70, 92]}, "bert_text": "Our findings indicate that sustained-release <e1> nifedipine </e1> is useful for <e2> hypertensive psoriatic </e2> patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3130": {"data": {"text": "Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.", "entity1": "nifedipine", "entity2": "gingival hyperplasia", "span1": [45, 55], "span2": [196, 216]}, "bert_text": "Our findings indicate that sustained-release <e1> nifedipine </e1> is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for <e2> gingival hyperplasia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3131": {"data": {"text": "Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.", "entity1": "cyclosporin A", "entity2": "hypertensive psoriatic", "span1": [133, 146], "span2": [70, 92]}, "bert_text": "Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with <e1> cyclosporin A </e1> <e2> hypertensive psoriatic </e2> patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3132": {"data": {"text": "Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with cyclosporin A, but that these patients should be monitored for gingival hyperplasia.", "entity1": "cyclosporin A", "entity2": "gingival hyperplasia", "span1": [133, 146], "span2": [196, 216]}, "bert_text": "Our findings indicate that sustained-release nifedipine is useful for hypertensive psoriatic patients under long-term treatment with <e1> cyclosporin A </e1>, but that these patients should be monitored for <e2> gingival hyperplasia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3133": {"data": {"text": "Those of myalgia tend to decrease according to increasing the amount of precurarizing dose of rocuronium, but there was no significance (P = 0.072).", "entity1": "rocuronium", "entity2": "myalgia", "span1": [94, 104], "span2": [9, 16]}, "bert_text": "Those of myalgia tend to decrease according to increasing the amount of precurarizing dose of <e1> rocuronium </e1> <e2> myalgia </e2> tend to decrease according to increasing the amount of precurarizing dose of rocuronium, but there was no significance (P = 0.072).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3134": {"data": {"text": "Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.", "entity1": "biperiden", "entity2": "Bradycardia", "span1": [23, 32], "span2": [0, 11]}, "bert_text": "Bradycardia induced by <e1> biperiden </e1> <e2> Bradycardia </e2> induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3135": {"data": {"text": "Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.", "entity1": "atropine", "entity2": "Bradycardia", "span1": [110, 118], "span2": [0, 11]}, "bert_text": "Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of <e1> atropine </e1> <e2> Bradycardia </e2> induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3136": {"data": {"text": "Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.", "entity1": "muscarine", "entity2": "Bradycardia", "span1": [133, 142], "span2": [0, 11]}, "bert_text": "Bradycardia induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on <e1> muscarine </e1> <e2> Bradycardia </e2> induced by biperiden is attributed to the speed of injection and to a dose-related dual effect of atropine-like drugs on muscarine receptors.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3137": {"data": {"text": "Isoproterenol (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce acute myocardial infarction.", "entity1": "Isoproterenol", "entity2": "myocardial infarction", "span1": [0, 13], "span2": [95, 116]}, "bert_text": "<e1> Isoproterenol </e1> (100mg/kg) was injected subcutaneously on the 13th and 14th days to induce acute <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3138": {"data": {"text": "Asterixis induced by carbamazepine therapy.\n", "entity1": "carbamazepine", "entity2": "Asterixis", "span1": [21, 34], "span2": [0, 9]}, "bert_text": "Asterixis induced by <e1> carbamazepine </e1> <e2> Asterixis </e2> induced by carbamazepine therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3139": {"data": {"text": "A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine-associated chest pain.\n", "entity1": "dobutamine", "entity2": "chest pain", "span1": [38, 48], "span2": [134, 144]}, "bert_text": "A pilot study to assess the safety of <e1> dobutamine </e1> stress echocardiography in the emergency department evaluation of cocaine-associated <e2> chest pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3140": {"data": {"text": "A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine-associated chest pain.\n", "entity1": "cocaine", "entity2": "chest pain", "span1": [115, 122], "span2": [134, 144]}, "bert_text": "A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of <e1> cocaine </e1>-associated <e2> chest pain </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3141": {"data": {"text": "BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-remifentanil total i.v.", "entity1": "propofol-remifentanil", "entity2": "bleeding", "span1": [361, 382], "span2": [113, 121]}, "bert_text": "BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by <e1> propofol-remifentanil </e1> <e2> bleeding </e2> as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-remifentanil total i.v.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3142": {"data": {"text": "BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by propofol-remifentanil total i.v.", "entity1": "propofol-remifentanil", "entity2": "hypotension", "span1": [361, 382], "span2": [327, 338]}, "bert_text": "BACKGROUND: The purpose of this study was to compare surgical conditions, including the amount of intraoperative bleeding as well as intraoperative blood pressure, during functional endoscopic sinus surgery (FESS) using flexible reinforced laryngeal mask airway (FRLMA) versus endotracheal tube (ETT) in maintaining controlled hypotension anesthesia induced by <e1> propofol-remifentanil </e1> <e2> hypotension </e2> anesthesia induced by propofol-remifentanil total i.v.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3143": {"data": {"text": "Phenytoin induced fatal hepatic injury.\n", "entity1": "Phenytoin", "entity2": "hepatic injury", "span1": [0, 9], "span2": [24, 38]}, "bert_text": "<e1> Phenytoin </e1> induced fatal <e2> hepatic injury </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3144": {"data": {"text": "Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death.", "entity1": "STZ", "entity2": "synaptic neurotoxicity", "span1": [108, 111], "span2": [62, 84]}, "bert_text": "Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in <e1> STZ </e1> <e2> synaptic neurotoxicity </e2> are the key factors in STZ induced memory impairment and neuronal cell death.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3145": {"data": {"text": "Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death.", "entity1": "STZ", "entity2": "memory impairment", "span1": [108, 111], "span2": [120, 137]}, "bert_text": "Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in <e1> STZ </e1> induced <e2> memory impairment </e2> and neuronal cell death.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3146": {"data": {"text": "Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death.", "entity1": "STZ", "entity2": "death", "span1": [108, 111], "span2": [156, 161]}, "bert_text": "Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in <e1> STZ </e1> induced memory impairment and neuronal cell <e2> death </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3147": {"data": {"text": "Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.\n", "entity1": "cis-platinum", "entity2": "ovarian cancer", "span1": [50, 62], "span2": [13, 27]}, "bert_text": "Treatment of ovarian cancer with a combination of <e1> cis-platinum </e1> <e2> ovarian cancer </e2> with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3148": {"data": {"text": "Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.\n", "entity1": "adriamycin", "entity2": "ovarian cancer", "span1": [64, 74], "span2": [13, 27]}, "bert_text": "Treatment of ovarian cancer with a combination of cis-platinum, <e1> adriamycin </e1> <e2> ovarian cancer </e2> with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3149": {"data": {"text": "Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.\n", "entity1": "cyclophosphamide", "entity2": "ovarian cancer", "span1": [76, 92], "span2": [13, 27]}, "bert_text": "Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, <e1> cyclophosphamide </e1> <e2> ovarian cancer </e2> with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3150": {"data": {"text": "Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.\n", "entity1": "hexamethylmelamine", "entity2": "ovarian cancer", "span1": [97, 115], "span2": [13, 27]}, "bert_text": "Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and <e1> hexamethylmelamine </e1> <e2> ovarian cancer </e2> with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3151": {"data": {"text": "Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.", "entity1": "Crocin", "entity2": "hyperlipemia", "span1": [0, 6], "span2": [65, 77]}, "bert_text": "<e1> Crocin </e1> reduced inhibition of ERK activation and diazinon-induced <e2> hyperlipemia </e2> and increased levels of LDLr transcript.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3152": {"data": {"text": "Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript.", "entity1": "diazinon", "entity2": "hyperlipemia", "span1": [48, 56], "span2": [65, 77]}, "bert_text": "Crocin reduced inhibition of ERK activation and <e1> diazinon </e1>-induced <e2> hyperlipemia </e2> and increased levels of LDLr transcript.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3153": {"data": {"text": "A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine.", "entity1": "metoprolol", "entity2": "sinus bradycardia", "span1": [175, 185], "span2": [124, 141]}, "bert_text": "A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between <e1> metoprolol </e1> <e2> sinus bradycardia </e2> and the drug interaction between metoprolol and terbinafine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3154": {"data": {"text": "A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and terbinafine.", "entity1": "terbinafine", "entity2": "sinus bradycardia", "span1": [190, 201], "span2": [124, 141]}, "bert_text": "A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient's sinus bradycardia and the drug interaction between metoprolol and <e1> terbinafine </e1> <e2> sinus bradycardia </e2> and the drug interaction between metoprolol and terbinafine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3155": {"data": {"text": "We suggest that DHEA displays typical neuroleptic-like effects, and may be used in the treatment of schizophrenia.", "entity1": "DHEA", "entity2": "schizophrenia", "span1": [16, 20], "span2": [100, 113]}, "bert_text": "We suggest that <e1> DHEA </e1> displays typical neuroleptic-like effects, and may be used in the treatment of <e2> schizophrenia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3156": {"data": {"text": "One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits.", "entity1": "galactose", "entity2": "cognitive deficits", "span1": [18, 27], "span2": [152, 170]}, "bert_text": "One month of oral <e1> galactose </e1> treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced <e2> cognitive deficits </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3157": {"data": {"text": "One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits.", "entity1": "STZ", "entity2": "cognitive deficits", "span1": [70, 73], "span2": [152, 170]}, "bert_text": "One month of oral galactose treatment initiated immediately after the <e1> STZ </e1>-icv administration, successfully prevented development of the STZ-icv-induced <e2> cognitive deficits </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3158": {"data": {"text": "One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the STZ-icv-induced cognitive deficits.", "entity1": "STZ", "entity2": "cognitive deficits", "span1": [136, 139], "span2": [152, 170]}, "bert_text": "One month of oral galactose treatment initiated immediately after the STZ-icv administration, successfully prevented development of the <e1> STZ </e1>-icv-induced <e2> cognitive deficits </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3159": {"data": {"text": "CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with idiopathic epilepsy.", "entity1": "levetiracetam", "entity2": "idiopathic epilepsy", "span1": [59, 72], "span2": [171, 190]}, "bert_text": "CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that <e1> levetiracetam </e1> is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with <e2> idiopathic epilepsy </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3160": {"data": {"text": "CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with idiopathic epilepsy.", "entity1": "phenobarbital", "entity2": "idiopathic epilepsy", "span1": [134, 147], "span2": [171, 190]}, "bert_text": "CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to <e1> phenobarbital </e1> treatment in cats with <e2> idiopathic epilepsy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3161": {"data": {"text": "Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia.", "entity1": "Sirolimus", "entity2": "anemia", "span1": [0, 9], "span2": [118, 124]}, "bert_text": "<e1> Sirolimus </e1>, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant <e2> anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3162": {"data": {"text": "Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia.", "entity1": "rapamycin", "entity2": "anemia", "span1": [33, 42], "span2": [118, 124]}, "bert_text": "Sirolimus, a mammalian target of <e1> rapamycin </e1> inhibitor, has been implicated as playing a special role in posttransplant <e2> anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3163": {"data": {"text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "entity1": "clozapine", "entity2": "schizophrenia", "span1": [128, 137], "span2": [34, 47]}, "bert_text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either <e1> clozapine </e1> <e2> schizophrenia </e2> or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3164": {"data": {"text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "entity1": "clozapine", "entity2": "schizoaffective disorder", "span1": [128, 137], "span2": [51, 75]}, "bert_text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either <e1> clozapine </e1> <e2> schizoaffective disorder </e2>, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3165": {"data": {"text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "entity1": "olanzapine", "entity2": "schizophrenia", "span1": [139, 149], "span2": [34, 47]}, "bert_text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, <e1> olanzapine </e1> <e2> schizophrenia </e2> or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3166": {"data": {"text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "entity1": "olanzapine", "entity2": "schizoaffective disorder", "span1": [139, 149], "span2": [51, 75]}, "bert_text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, <e1> olanzapine </e1> <e2> schizoaffective disorder </e2>, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3167": {"data": {"text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "entity1": "risperidone", "entity2": "schizophrenia", "span1": [154, 165], "span2": [34, 47]}, "bert_text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or <e1> risperidone </e1> <e2> schizophrenia </e2> or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3168": {"data": {"text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "entity1": "risperidone", "entity2": "schizoaffective disorder", "span1": [154, 165], "span2": [51, 75]}, "bert_text": "Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or <e1> risperidone </e1> <e2> schizoaffective disorder </e2>, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3169": {"data": {"text": "Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan.\n", "entity1": "Zolmitriptan", "entity2": "Takotsubo syndrome", "span1": [64, 76], "span2": [0, 18]}, "bert_text": "Takotsubo syndrome (or apical ballooning syndrome) secondary to <e1> Zolmitriptan </e1> <e2> Takotsubo syndrome </e2> (or apical ballooning syndrome) secondary to Zolmitriptan.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3170": {"data": {"text": "Takotsubo syndrome (or apical ballooning syndrome) secondary to Zolmitriptan.\n", "entity1": "Zolmitriptan", "entity2": "apical ballooning syndrome", "span1": [64, 76], "span2": [23, 49]}, "bert_text": "Takotsubo syndrome (or apical ballooning syndrome) secondary to <e1> Zolmitriptan </e1> <e2> apical ballooning syndrome </e2>) secondary to Zolmitriptan.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3171": {"data": {"text": "MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.", "entity1": "MK-801", "entity2": "seizure", "span1": [0, 6], "span2": [130, 137]}, "bert_text": "<e1> MK-801 </e1>, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two <e2> seizure </e2> models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3172": {"data": {"text": "MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.", "entity1": "lithium", "entity2": "seizure", "span1": [166, 173], "span2": [130, 137]}, "bert_text": "MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of <e1> lithium </e1> <e2> seizure </e2> models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3173": {"data": {"text": "MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [178, 189], "span2": [130, 137]}, "bert_text": "MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and <e1> pilocarpine </e1> <e2> seizure </e2> models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3174": {"data": {"text": "MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [227, 238], "span2": [130, 137]}, "bert_text": "MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, was tested for anticonvulsant effects in rats using two seizure models, coadministration of lithium and pilocarpine and administration of a high dose of <e1> pilocarpine </e1> <e2> seizure </e2> models, coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3175": {"data": {"text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "entity1": "rocuronium", "entity2": "fasciculation", "span1": [49, 59], "span2": [95, 108]}, "bert_text": "The current study identified the optimal dose of <e1> rocuronium </e1> to prevent succinylcholine-induced <e2> fasciculation </e2> and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3176": {"data": {"text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "entity1": "rocuronium", "entity2": "myalgia", "span1": [49, 59], "span2": [113, 120]}, "bert_text": "The current study identified the optimal dose of <e1> rocuronium </e1> to prevent succinylcholine-induced fasciculation and <e2> myalgia </e2> and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3177": {"data": {"text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "entity1": "rocuronium", "entity2": "fasciculation", "span1": [152, 162], "span2": [95, 108]}, "bert_text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of <e1> rocuronium </e1> <e2> fasciculation </e2> and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3178": {"data": {"text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "entity1": "rocuronium", "entity2": "myalgia", "span1": [152, 162], "span2": [113, 120]}, "bert_text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of <e1> rocuronium </e1> <e2> myalgia </e2> and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3179": {"data": {"text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "entity1": "succinylcholine", "entity2": "fasciculation", "span1": [71, 86], "span2": [95, 108]}, "bert_text": "The current study identified the optimal dose of rocuronium to prevent <e1> succinylcholine </e1>-induced <e2> fasciculation </e2> and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3180": {"data": {"text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "entity1": "succinylcholine", "entity2": "myalgia", "span1": [71, 86], "span2": [113, 120]}, "bert_text": "The current study identified the optimal dose of rocuronium to prevent <e1> succinylcholine </e1>-induced fasciculation and <e2> myalgia </e2> and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3181": {"data": {"text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "entity1": "succinylcholine", "entity2": "fasciculation", "span1": [197, 212], "span2": [95, 108]}, "bert_text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by <e1> succinylcholine </e1> <e2> fasciculation </e2> and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3182": {"data": {"text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "entity1": "succinylcholine", "entity2": "myalgia", "span1": [197, 212], "span2": [113, 120]}, "bert_text": "The current study identified the optimal dose of rocuronium to prevent succinylcholine-induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by <e1> succinylcholine </e1> <e2> myalgia </e2> and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3183": {"data": {"text": "Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.\n", "entity1": "simvastatin", "entity2": "Rhabdomyolysis", "span1": [35, 46], "span2": [0, 14]}, "bert_text": "Rhabdomyolysis in association with <e1> simvastatin </e1> <e2> Rhabdomyolysis </e2> in association with simvastatin and dosage increment in clarithromycin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3184": {"data": {"text": "Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.\n", "entity1": "clarithromycin", "entity2": "Rhabdomyolysis", "span1": [71, 85], "span2": [0, 14]}, "bert_text": "Rhabdomyolysis in association with simvastatin and dosage increment in <e1> clarithromycin </e1> <e2> Rhabdomyolysis </e2> in association with simvastatin and dosage increment in clarithromycin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3185": {"data": {"text": "To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of RLS.", "entity1": "domperidone", "entity2": "RLS", "span1": [64, 75], "span2": [164, 167]}, "bert_text": "To our knowledge, there is no previous report regarding whether <e1> domperidone </e1>, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of <e2> RLS </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3186": {"data": {"text": "To our knowledge, there is no previous report regarding whether domperidone, a peripheral dopamine D2 receptor antagonist, can also induce or aggravate symptoms of RLS.", "entity1": "dopamine", "entity2": "RLS", "span1": [90, 98], "span2": [164, 167]}, "bert_text": "To our knowledge, there is no previous report regarding whether domperidone, a peripheral <e1> dopamine </e1> D2 receptor antagonist, can also induce or aggravate symptoms of <e2> RLS </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3187": {"data": {"text": "Cardioprotective effect of ethanolic extract of Terminalia chebula fruits (500 mg/kg body wt) was examined in isoproterenol (200 mg/kg body wt) induced myocardial damage in rats.", "entity1": "isoproterenol", "entity2": "myocardial damage", "span1": [110, 123], "span2": [152, 169]}, "bert_text": "Cardioprotective effect of ethanolic extract of Terminalia chebula fruits (500 mg/kg body wt) was examined in <e1> isoproterenol </e1> (200 mg/kg body wt) induced <e2> myocardial damage </e2> in rats.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3188": {"data": {"text": "Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.\n", "entity1": "Cisplatin", "entity2": "Renal Toxicity", "span1": [53, 62], "span2": [9, 23]}, "bert_text": "Rates of Renal Toxicity in Cancer Patients Receiving <e1> Cisplatin </e1> <e2> Renal Toxicity </e2> in Cancer Patients Receiving Cisplatin With and Without Mannitol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3189": {"data": {"text": "Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.\n", "entity1": "Cisplatin", "entity2": "Cancer", "span1": [53, 62], "span2": [27, 33]}, "bert_text": "Rates of Renal Toxicity in Cancer Patients Receiving <e1> Cisplatin </e1> <e2> Cancer </e2> Patients Receiving Cisplatin With and Without Mannitol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3190": {"data": {"text": "Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.\n", "entity1": "Mannitol", "entity2": "Renal Toxicity", "span1": [80, 88], "span2": [9, 23]}, "bert_text": "Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without <e1> Mannitol </e1> <e2> Renal Toxicity </e2> in Cancer Patients Receiving Cisplatin With and Without Mannitol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3191": {"data": {"text": "Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol.\n", "entity1": "Mannitol", "entity2": "Cancer", "span1": [80, 88], "span2": [27, 33]}, "bert_text": "Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without <e1> Mannitol </e1> <e2> Cancer </e2> Patients Receiving Cisplatin With and Without Mannitol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3192": {"data": {"text": "It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors.", "entity1": "prostaglandin", "entity2": "renal disease", "span1": [108, 121], "span2": [30, 43]}, "bert_text": "It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with <e1> prostaglandin </e1> <e2> renal disease </e2> predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3193": {"data": {"text": "It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors.", "entity1": "prostaglandin", "entity2": "type IV renal tubular acidosis", "span1": [108, 121], "span2": [72, 102]}, "bert_text": "It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with <e1> prostaglandin </e1> <e2> type IV renal tubular acidosis </e2> with prostaglandin synthetase inhibitors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3194": {"data": {"text": "Rifampicin-associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis.\n", "entity1": "Rifampicin", "entity2": "glomerulonephritis", "span1": [0, 10], "span2": [44, 62]}, "bert_text": "<e1> Rifampicin </e1>-associated segmental necrotizing <e2> glomerulonephritis </e2> in staphylococcal endocarditis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3195": {"data": {"text": "Rifampicin-associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis.\n", "entity1": "Rifampicin", "entity2": "staphylococcal endocarditis", "span1": [0, 10], "span2": [66, 93]}, "bert_text": "<e1> Rifampicin </e1>-associated segmental necrotizing glomerulonephritis in <e2> staphylococcal endocarditis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3196": {"data": {"text": "Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the nephrotoxicity of amphotericin B.", "entity1": "amphotericin B", "entity2": "NS-718", "span1": [63, 77], "span2": [104, 110]}, "bert_text": "Our in vitro and in vivo results suggest that incorporation of <e1> amphotericin B </e1> into lipid nanospheres of <e2> NS-718 </e2> attenuates the nephrotoxicity of amphotericin B.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3197": {"data": {"text": "Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the nephrotoxicity of amphotericin B.", "entity1": "amphotericin B", "entity2": "nephrotoxicity", "span1": [63, 77], "span2": [126, 140]}, "bert_text": "Our in vitro and in vivo results suggest that incorporation of <e1> amphotericin B </e1> into lipid nanospheres of NS-718 attenuates the <e2> nephrotoxicity </e2> of amphotericin B.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3198": {"data": {"text": "Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the nephrotoxicity of amphotericin B.", "entity1": "amphotericin", "entity2": "NS-718", "span1": [144, 156], "span2": [104, 110]}, "bert_text": "Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the nephrotoxicity of <e1> amphotericin </e1> <e2> NS-718 </e2> attenuates the nephrotoxicity of amphotericin B.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3199": {"data": {"text": "Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the nephrotoxicity of amphotericin B.", "entity1": "amphotericin", "entity2": "nephrotoxicity", "span1": [144, 156], "span2": [126, 140]}, "bert_text": "Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS-718 attenuates the nephrotoxicity of <e1> amphotericin </e1> <e2> nephrotoxicity </e2> of amphotericin B.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3200": {"data": {"text": "Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.\n", "entity1": "bortezomib", "entity2": "Necrotising fasciitis", "span1": [28, 38], "span2": [0, 21]}, "bert_text": "Necrotising fasciitis after <e1> bortezomib </e1> <e2> Necrotising fasciitis </e2> after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3201": {"data": {"text": "Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.\n", "entity1": "bortezomib", "entity2": "Waldenstrom macroglobulinaemia", "span1": [28, 38], "span2": [101, 131]}, "bert_text": "Necrotising fasciitis after <e1> bortezomib </e1> and dexamethasone-containing regimen in an elderly patient of <e2> Waldenstrom macroglobulinaemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3202": {"data": {"text": "Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.\n", "entity1": "dexamethasone", "entity2": "Necrotising fasciitis", "span1": [43, 56], "span2": [0, 21]}, "bert_text": "Necrotising fasciitis after bortezomib and <e1> dexamethasone </e1> <e2> Necrotising fasciitis </e2> after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3203": {"data": {"text": "Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenstrom macroglobulinaemia.\n", "entity1": "dexamethasone", "entity2": "Waldenstrom macroglobulinaemia", "span1": [43, 56], "span2": [101, 131]}, "bert_text": "Necrotising fasciitis after bortezomib and <e1> dexamethasone </e1>-containing regimen in an elderly patient of <e2> Waldenstrom macroglobulinaemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3204": {"data": {"text": "The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.", "entity1": "propofol", "entity2": "cardiotoxicity", "span1": [55, 63], "span2": [125, 139]}, "bert_text": "The aim of this study is to investigate the effects of <e1> propofol </e1> in intralipid or medialipid emulsions on bupivacaine-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3205": {"data": {"text": "The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.", "entity1": "bupivacaine", "entity2": "cardiotoxicity", "span1": [105, 116], "span2": [125, 139]}, "bert_text": "The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on <e1> bupivacaine </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3206": {"data": {"text": "CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.", "entity1": "Crocin", "entity2": "hyperlipemia", "span1": [13, 19], "span2": [86, 98]}, "bert_text": "CONCLUSIONS: <e1> Crocin </e1> may be considered as a novel protective agent in diazinon-induced <e2> hyperlipemia </e2> through modulating of ERK pathway and increase of LDLr expression.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3207": {"data": {"text": "CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.", "entity1": "diazinon", "entity2": "hyperlipemia", "span1": [69, 77], "span2": [86, 98]}, "bert_text": "CONCLUSIONS: Crocin may be considered as a novel protective agent in <e1> diazinon </e1>-induced <e2> hyperlipemia </e2> through modulating of ERK pathway and increase of LDLr expression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3208": {"data": {"text": "This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.", "entity1": "metformin", "entity2": "seizures", "span1": [64, 73], "span2": [77, 85]}, "bert_text": "This study was designed to evaluate the ameliorative effects of <e1> metformin </e1> on <e2> seizures </e2>, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3209": {"data": {"text": "This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.", "entity1": "metformin", "entity2": "cognitive impairment", "span1": [64, 73], "span2": [87, 107]}, "bert_text": "This study was designed to evaluate the ameliorative effects of <e1> metformin </e1> on seizures, <e2> cognitive impairment </e2> and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3210": {"data": {"text": "This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.", "entity1": "pentylenetetrazole", "entity2": "seizures", "span1": [155, 173], "span2": [77, 85]}, "bert_text": "This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in <e1> pentylenetetrazole </e1> <e2> seizures </e2>, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3211": {"data": {"text": "This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.", "entity1": "pentylenetetrazole", "entity2": "cognitive impairment", "span1": [155, 173], "span2": [87, 107]}, "bert_text": "This study was designed to evaluate the ameliorative effects of metformin on seizures, cognitive impairment and brain oxidative stress markers observed in <e1> pentylenetetrazole </e1> <e2> cognitive impairment </e2> and brain oxidative stress markers observed in pentylenetetrazole-induced kindling animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3212": {"data": {"text": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "entity1": "quinine sulfate", "entity2": "blindness", "span1": [175, 190], "span2": [6, 15]}, "bert_text": "Total blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of <e1> quinine sulfate </e1> <e2> blindness </e2> with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of quinine sulfate for leg cramps.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3213": {"data": {"text": "A hemoglobin concentration of <10 g/dL was defined as ribavirin-induced anemia.", "entity1": "ribavirin", "entity2": "anemia", "span1": [54, 63], "span2": [72, 78]}, "bert_text": "A hemoglobin concentration of <10 g/dL was defined as <e1> ribavirin </e1>-induced <e2> anemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3214": {"data": {"text": "This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose methotrexate.", "entity1": "methotrexate", "entity2": "necrotizing leukoencephalopathy", "span1": [251, 263], "span2": [145, 176]}, "bert_text": "This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose <e1> methotrexate </e1> <e2> necrotizing leukoencephalopathy </e2>, which developed from acute lymphoblastic leukemia treated with high-dose methotrexate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3215": {"data": {"text": "This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose methotrexate.", "entity1": "methotrexate", "entity2": "acute lymphoblastic leukemia", "span1": [251, 263], "span2": [199, 227]}, "bert_text": "This report describes unique contrast enhancement of the white matter on T1-weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy, which developed from acute lymphoblastic leukemia treated with high-dose <e1> methotrexate </e1> <e2> acute lymphoblastic leukemia </e2> treated with high-dose methotrexate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3216": {"data": {"text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "entity1": "methotrexate", "entity2": "leukemia", "span1": [345, 357], "span2": [166, 174]}, "bert_text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high <e1> methotrexate </e1> <e2> leukemia </e2>, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3217": {"data": {"text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "entity1": "methotrexate", "entity2": "cerebrospinal leakage", "span1": [345, 357], "span2": [189, 210]}, "bert_text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high <e1> methotrexate </e1> <e2> cerebrospinal leakage </e2>; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3218": {"data": {"text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "entity1": "methotrexate", "entity2": "neurotoxic", "span1": [345, 357], "span2": [450, 460]}, "bert_text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high <e1> methotrexate </e1> doses based on body surface area calculations in older children and adults; the presence of <e2> neurotoxic </e2> preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3219": {"data": {"text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "entity1": "methotrexate", "entity2": "leukemia", "span1": [501, 513], "span2": [166, 174]}, "bert_text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available <e1> methotrexate </e1> <e2> leukemia </e2>, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3220": {"data": {"text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "entity1": "methotrexate", "entity2": "cerebrospinal leakage", "span1": [501, 513], "span2": [189, 210]}, "bert_text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available <e1> methotrexate </e1> <e2> cerebrospinal leakage </e2>; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3221": {"data": {"text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "entity1": "methotrexate", "entity2": "neurotoxic", "span1": [501, 513], "span2": [450, 460]}, "bert_text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available <e1> methotrexate </e1> <e2> neurotoxic </e2> preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3222": {"data": {"text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "entity1": "methotrexate", "entity2": "leukemia", "span1": [556, 568], "span2": [166, 174]}, "bert_text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of <e1> methotrexate </e1> <e2> leukemia </e2>, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3223": {"data": {"text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "entity1": "methotrexate", "entity2": "cerebrospinal leakage", "span1": [556, 568], "span2": [189, 210]}, "bert_text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of <e1> methotrexate </e1> <e2> cerebrospinal leakage </e2>; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3224": {"data": {"text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "entity1": "methotrexate", "entity2": "neurotoxic", "span1": [556, 568], "span2": [450, 460]}, "bert_text": "The following factors appear to predispose to the development of this complication: abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia, and epidural cerebrospinal leakage; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents; and the use of <e1> methotrexate </e1> <e2> neurotoxic </e2> preservatives in commercially available methotrexate preparations and diluents; and the use of methotrexate diluents of unphysiologic pH, ionic content and osmolarity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3225": {"data": {"text": "The results provide new insight into the potential role of ectopic hilar granule cells in the pilocarpine model of temporal lobe epilepsy.", "entity1": "pilocarpine", "entity2": "temporal lobe epilepsy", "span1": [94, 105], "span2": [115, 137]}, "bert_text": "The results provide new insight into the potential role of ectopic hilar granule cells in the <e1> pilocarpine </e1> model of <e2> temporal lobe epilepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3226": {"data": {"text": "In humans, the intracoronary infusion of cocaine sufficient in amount to achieve a high drug concentration in coronary sinus blood causes a deterioration of LV systolic and diastolic performance.", "entity1": "cocaine", "entity2": "LV", "span1": [41, 48], "span2": [157, 159]}, "bert_text": "In humans, the intracoronary infusion of <e1> cocaine </e1> sufficient in amount to achieve a high drug concentration in coronary sinus blood causes a deterioration of <e2> LV </e2> systolic and diastolic performance.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3227": {"data": {"text": "Encephalopathy has been reported in 10-40% of patients receiving high-dose IV ifosfamide.", "entity1": "ifosfamide", "entity2": "Encephalopathy", "span1": [78, 88], "span2": [0, 14]}, "bert_text": "Encephalopathy has been reported in 10-40% of patients receiving high-dose IV <e1> ifosfamide </e1> <e2> Encephalopathy </e2> has been reported in 10-40% of patients receiving high-dose IV ifosfamide.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3228": {"data": {"text": "Periodic monitoring of cerebruspinal fluid methotrexate levels may be predictive of the development of serious neurotoxicity.", "entity1": "methotrexate", "entity2": "neurotoxicity", "span1": [43, 55], "span2": [111, 124]}, "bert_text": "Periodic monitoring of cerebruspinal fluid <e1> methotrexate </e1> levels may be predictive of the development of serious <e2> neurotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3229": {"data": {"text": "Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol.\n", "entity1": "isoproterenol", "entity2": "myocardial injury", "span1": [90, 103], "span2": [61, 78]}, "bert_text": "Protective effect of Terminalia chebula against experimental myocardial injury induced by <e1> isoproterenol </e1> <e2> myocardial injury </e2> induced by isoproterenol.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3230": {"data": {"text": "After sacrifice the hearts of doxorubicin-treated animals were enlarged and the atria were hypertrophic.", "entity1": "doxorubicin", "entity2": "hypertrophic", "span1": [30, 41], "span2": [91, 103]}, "bert_text": "After sacrifice the hearts of <e1> doxorubicin </e1>-treated animals were enlarged and the atria were <e2> hypertrophic </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3231": {"data": {"text": "On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and hyperalgesia.", "entity1": "nocistatin", "entity2": "allodynia", "span1": [19, 29], "span2": [119, 128]}, "bert_text": "On the other hand, <e1> nocistatin </e1> is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced <e2> allodynia </e2> and hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3232": {"data": {"text": "On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and hyperalgesia.", "entity1": "nocistatin", "entity2": "hyperalgesia", "span1": [19, 29], "span2": [133, 145]}, "bert_text": "On the other hand, <e1> nocistatin </e1> is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and <e2> hyperalgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3233": {"data": {"text": "On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and hyperalgesia.", "entity1": "nociceptin", "entity2": "allodynia", "span1": [78, 88], "span2": [119, 128]}, "bert_text": "On the other hand, nocistatin is recently isolated from the same precursor as <e1> nociceptin </e1> and blocks nociceptin-induced <e2> allodynia </e2> and hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3234": {"data": {"text": "On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and hyperalgesia.", "entity1": "nociceptin", "entity2": "hyperalgesia", "span1": [78, 88], "span2": [133, 145]}, "bert_text": "On the other hand, nocistatin is recently isolated from the same precursor as <e1> nociceptin </e1> and blocks nociceptin-induced allodynia and <e2> hyperalgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3235": {"data": {"text": "On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and hyperalgesia.", "entity1": "nociceptin", "entity2": "allodynia", "span1": [100, 110], "span2": [119, 128]}, "bert_text": "On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks <e1> nociceptin </e1>-induced <e2> allodynia </e2> and hyperalgesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3236": {"data": {"text": "On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin-induced allodynia and hyperalgesia.", "entity1": "nociceptin", "entity2": "hyperalgesia", "span1": [100, 110], "span2": [133, 145]}, "bert_text": "On the other hand, nocistatin is recently isolated from the same precursor as nociceptin and blocks <e1> nociceptin </e1>-induced allodynia and <e2> hyperalgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3237": {"data": {"text": "Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "entity1": "cocaine", "entity2": "Mitochondrial impairment", "span1": [40, 47], "span2": [0, 24]}, "bert_text": "Mitochondrial impairment contributes to <e1> cocaine </e1> <e2> Mitochondrial impairment </e2> contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3238": {"data": {"text": "Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "entity1": "cocaine", "entity2": "cardiac dysfunction", "span1": [40, 47], "span2": [56, 75]}, "bert_text": "Mitochondrial impairment contributes to <e1> cocaine </e1>-induced <e2> cardiac dysfunction </e2>: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3239": {"data": {"text": "Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "entity1": "cocaine", "entity2": "cardiac dysfunction", "span1": [40, 47], "span2": [246, 265]}, "bert_text": "Mitochondrial impairment contributes to <e1> cocaine </e1>-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced <e2> cardiac dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3240": {"data": {"text": "Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "entity1": "cocaine", "entity2": "Mitochondrial impairment", "span1": [230, 237], "span2": [0, 24]}, "bert_text": "Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of <e1> cocaine </e1> <e2> Mitochondrial impairment </e2> contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3241": {"data": {"text": "Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "entity1": "cocaine", "entity2": "cardiac dysfunction", "span1": [230, 237], "span2": [56, 75]}, "bert_text": "Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of <e1> cocaine </e1> <e2> cardiac dysfunction </e2>: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3242": {"data": {"text": "Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine-induced cardiac dysfunction.", "entity1": "cocaine", "entity2": "cardiac dysfunction", "span1": [230, 237], "span2": [246, 265]}, "bert_text": "Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: Prevention by the targeted antioxidant MitoQ.\nThe goal of this study was to assess mitochondrial function and ROS production in an experimental model of <e1> cocaine </e1>-induced <e2> cardiac dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3243": {"data": {"text": "After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.", "entity1": "dipyridamole", "entity2": "ischemic ST-segment depression", "span1": [6, 18], "span2": [20, 50]}, "bert_text": "After <e1> dipyridamole </e1>, <e2> ischemic ST-segment depression </e2> (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3244": {"data": {"text": "After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.", "entity1": "dipyridamole", "entity2": "MI", "span1": [6, 18], "span2": [100, 102]}, "bert_text": "After <e1> dipyridamole </e1>, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-<e2> MI </e2> group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3245": {"data": {"text": "After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.", "entity1": "dipyridamole", "entity2": "MI", "span1": [6, 18], "span2": [125, 127]}, "bert_text": "After <e1> dipyridamole </e1>, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-<e2> MI </e2> group, 63% of the INF-MI group and 61% of the total population.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3246": {"data": {"text": "After dipyridamole, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-MI group and 61% of the total population.", "entity1": "dipyridamole", "entity2": "MI", "span1": [6, 18], "span2": [150, 152]}, "bert_text": "After <e1> dipyridamole </e1>, ischemic ST-segment depression (0.05 mV or more) was observed in 84% of the non-MI group, 29% of the ANT-MI group, 63% of the INF-<e2> MI </e2> group and 61% of the total population.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3247": {"data": {"text": "Hypoxaemia resolved quickly on inhaled nitric oxide therapy.", "entity1": "nitric oxide", "entity2": "Hypoxaemia", "span1": [39, 51], "span2": [0, 10]}, "bert_text": "Hypoxaemia resolved quickly on inhaled <e1> nitric oxide </e1> <e2> Hypoxaemia </e2> resolved quickly on inhaled nitric oxide therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3248": {"data": {"text": "Immediately after the administration of levobupivacaine 0.5% with epinephrine 2.5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration.", "entity1": "levobupivacaine", "entity2": "seizures", "span1": [40, 55], "span2": [129, 137]}, "bert_text": "Immediately after the administration of <e1> levobupivacaine </e1> 0.5% with epinephrine 2.5 microgram/mL, the patients developed grand mal <e2> seizures </e2>, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3249": {"data": {"text": "Immediately after the administration of levobupivacaine 0.5% with epinephrine 2.5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration.", "entity1": "epinephrine", "entity2": "seizures", "span1": [66, 77], "span2": [129, 137]}, "bert_text": "Immediately after the administration of levobupivacaine 0.5% with <e1> epinephrine </e1> 2.5 microgram/mL, the patients developed grand mal <e2> seizures </e2>, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3250": {"data": {"text": "Immediately after the administration of levobupivacaine 0.5% with epinephrine 2.5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration.", "entity1": "epinephrine", "entity2": "seizures", "span1": [214, 225], "span2": [129, 137]}, "bert_text": "Immediately after the administration of levobupivacaine 0.5% with epinephrine 2.5 microgram/mL, the patients developed grand mal seizures, despite negative aspiration for blood and no clinical signs of intravenous <e1> epinephrine </e1> <e2> seizures </e2>, despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3251": {"data": {"text": "The dopamine agonist significantly impaired novel word learning compared to placebo.", "entity1": "dopamine", "entity2": "word learning", "span1": [4, 12], "span2": [50, 63]}, "bert_text": "The <e1> dopamine </e1> agonist significantly impaired novel <e2> word learning </e2> compared to placebo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3252": {"data": {"text": "Associations of Ozone and PM2.5 Concentrations With Parkinson's Disease Among Participants in the Agricultural Health Study.\n", "entity1": "Ozone", "entity2": "Parkinson's Disease", "span1": [16, 21], "span2": [52, 71]}, "bert_text": "Associations of <e1> Ozone </e1> and PM2.5 Concentrations With <e2> Parkinson's Disease </e2> Among Participants in the Agricultural Health Study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3253": {"data": {"text": "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the \"real world\" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition.", "entity1": "Lenalidomide", "entity2": "myeloma", "span1": [0, 12], "span2": [91, 98]}, "bert_text": "<e1> Lenalidomide </e1> and dexamethasone (RD) is a standard of care for relapsed/refractory multiple <e2> myeloma </e2> (RRMM), but there is limited published data on its efficacy and safety in the \"real world\" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3254": {"data": {"text": "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the \"real world\" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition.", "entity1": "Lenalidomide", "entity2": "RRMM", "span1": [0, 12], "span2": [100, 104]}, "bert_text": "<e1> Lenalidomide </e1> and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (<e2> RRMM </e2>), but there is limited published data on its efficacy and safety in the \"real world\" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3255": {"data": {"text": "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the \"real world\" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition.", "entity1": "dexamethasone", "entity2": "myeloma", "span1": [17, 30], "span2": [91, 98]}, "bert_text": "Lenalidomide and <e1> dexamethasone </e1> (RD) is a standard of care for relapsed/refractory multiple <e2> myeloma </e2> (RRMM), but there is limited published data on its efficacy and safety in the \"real world\" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3256": {"data": {"text": "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the \"real world\" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition.", "entity1": "dexamethasone", "entity2": "RRMM", "span1": [17, 30], "span2": [100, 104]}, "bert_text": "Lenalidomide and <e1> dexamethasone </e1> (RD) is a standard of care for relapsed/refractory multiple myeloma (<e2> RRMM </e2>), but there is limited published data on its efficacy and safety in the \"real world\" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3257": {"data": {"text": "Cerebellar and oculomotor dysfunction induced by rapid infusion of pethidine.\n", "entity1": "pethidine", "entity2": "oculomotor dysfunction", "span1": [67, 76], "span2": [15, 37]}, "bert_text": "Cerebellar and oculomotor dysfunction induced by rapid infusion of <e1> pethidine </e1> <e2> oculomotor dysfunction </e2> induced by rapid infusion of pethidine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3258": {"data": {"text": "The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.", "entity1": "suxamethonium", "entity2": "jaw rigidity", "span1": [71, 84], "span2": [30, 42]}, "bert_text": "The case shows that prolonged jaw rigidity and myalgia may occur after <e1> suxamethonium </e1> <e2> jaw rigidity </e2> and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3259": {"data": {"text": "The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.", "entity1": "suxamethonium", "entity2": "myalgia", "span1": [71, 84], "span2": [47, 54]}, "bert_text": "The case shows that prolonged jaw rigidity and myalgia may occur after <e1> suxamethonium </e1> <e2> myalgia </e2> may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3260": {"data": {"text": "The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.", "entity1": "pancuronium", "entity2": "jaw rigidity", "span1": [152, 163], "span2": [30, 42]}, "bert_text": "The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with <e1> pancuronium </e1> <e2> jaw rigidity </e2> and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3261": {"data": {"text": "The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.", "entity1": "pancuronium", "entity2": "myalgia", "span1": [152, 163], "span2": [47, 54]}, "bert_text": "The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with <e1> pancuronium </e1> <e2> myalgia </e2> may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3262": {"data": {"text": "All-trans retinoic acid-induced inflammatory myositis in a patient with acute promyelocytic leukemia.\n", "entity1": "All-trans retinoic acid", "entity2": "inflammatory myositis", "span1": [0, 23], "span2": [32, 53]}, "bert_text": "<e1> All-trans retinoic acid </e1>-induced <e2> inflammatory myositis </e2> in a patient with acute promyelocytic leukemia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3263": {"data": {"text": "All-trans retinoic acid-induced inflammatory myositis in a patient with acute promyelocytic leukemia.\n", "entity1": "All-trans retinoic acid", "entity2": "acute promyelocytic leukemia", "span1": [0, 23], "span2": [72, 100]}, "bert_text": "<e1> All-trans retinoic acid </e1>-induced inflammatory myositis in a patient with <e2> acute promyelocytic leukemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3264": {"data": {"text": "Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred.", "entity1": "polyvidone", "entity2": "toxicity", "span1": [21, 31], "span2": [128, 136]}, "bert_text": "Hexabrix and Vasurix <e1> polyvidone </e1> are considered the best contrast media for hysterosalpingography and perhaps because of its low <e2> toxicity </e2> Hexabrix should be preferred.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3265": {"data": {"text": "Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.", "entity1": "Quinine", "entity2": "arrhythmias", "span1": [0, 7], "span2": [138, 149]}, "bert_text": "<e1> Quinine </e1>, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various <e2> arrhythmias </e2>, including severe arrhythmia such as multiple PVC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3266": {"data": {"text": "Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.", "entity1": "Quinine", "entity2": "arrhythmia", "span1": [0, 7], "span2": [168, 178]}, "bert_text": "<e1> Quinine </e1>, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe <e2> arrhythmia </e2> such as multiple PVC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3267": {"data": {"text": "Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.", "entity1": "Quinine", "entity2": "PVC", "span1": [0, 7], "span2": [196, 199]}, "bert_text": "<e1> Quinine </e1>, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple <e2> PVC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3268": {"data": {"text": "Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.", "entity1": "quinidine", "entity2": "arrhythmias", "span1": [14, 23], "span2": [138, 149]}, "bert_text": "Quinine, like <e1> quinidine </e1>, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various <e2> arrhythmias </e2>, including severe arrhythmia such as multiple PVC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3269": {"data": {"text": "Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.", "entity1": "quinidine", "entity2": "arrhythmia", "span1": [14, 23], "span2": [168, 178]}, "bert_text": "Quinine, like <e1> quinidine </e1>, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe <e2> arrhythmia </e2> such as multiple PVC.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3270": {"data": {"text": "Quinine, like quinidine, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple PVC.", "entity1": "quinidine", "entity2": "PVC", "span1": [14, 23], "span2": [196, 199]}, "bert_text": "Quinine, like <e1> quinidine </e1>, is a chincona alkaloid that has anti-arrhythmic property, although it also pro-arrhythmic that can cause various arrhythmias, including severe arrhythmia such as multiple <e2> PVC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3271": {"data": {"text": "Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension.", "entity1": "vasopressin", "entity2": "neurohypophysis", "span1": [23, 34], "span2": [40, 55]}, "bert_text": "Increased secretion of <e1> vasopressin </e1> from <e2> neurohypophysis </e2> also promotes the function of the hormone as a pathogenetic factor in hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3272": {"data": {"text": "Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension.", "entity1": "vasopressin", "entity2": "hypertension", "span1": [23, 34], "span2": [126, 138]}, "bert_text": "Increased secretion of <e1> vasopressin </e1> from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3273": {"data": {"text": "(P < .01) at 3 min after ISO infusion with stenosis.", "entity1": "ISO", "entity2": "stenosis", "span1": [25, 28], "span2": [43, 51]}, "bert_text": "(P < .01) at 3 min after <e1> ISO </e1> infusion with <e2> stenosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3274": {"data": {"text": "Heparin-induced thrombocytopenia: a practical review.\n", "entity1": "Heparin", "entity2": "thrombocytopenia", "span1": [0, 7], "span2": [16, 32]}, "bert_text": "<e1> Heparin </e1>-induced <e2> thrombocytopenia </e2>: a practical review.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3275": {"data": {"text": "Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ-induced diabetic nephropathy.", "entity1": "STZ", "entity2": "diabetic nephropathy", "span1": [119, 122], "span2": [131, 151]}, "bert_text": "Immunoprecipitation/Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in <e1> STZ </e1>-induced <e2> diabetic nephropathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3276": {"data": {"text": "Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.", "entity1": "isoproterenol", "entity2": "tumor", "span1": [27, 40], "span2": [131, 136]}, "bert_text": "Metfromin markedly lowered <e1> isoproterenol </e1>-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), <e2> tumor </e2> necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3277": {"data": {"text": "Metfromin markedly lowered isoproterenol-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor necrosis factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.", "entity1": "isoproterenol", "entity2": "necrosis", "span1": [27, 40], "span2": [137, 145]}, "bert_text": "Metfromin markedly lowered <e1> isoproterenol </e1>-induced elevation in the levels of TLR4 mRNA, myeloid differentiation protein 88 (MyD88), tumor <e2> necrosis </e2> factor-alpha (TNF-a), and interleukin 6 (IL-6) in the heart tissues.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3278": {"data": {"text": "Low doses of pilocarpine caused a pronounced enhancement of the catalepsy that was induced by the dopaminergic blocker, haloperidol.", "entity1": "pilocarpine", "entity2": "catalepsy", "span1": [13, 24], "span2": [64, 73]}, "bert_text": "Low doses of <e1> pilocarpine </e1> caused a pronounced enhancement of the <e2> catalepsy </e2> that was induced by the dopaminergic blocker, haloperidol.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3279": {"data": {"text": "Low doses of pilocarpine caused a pronounced enhancement of the catalepsy that was induced by the dopaminergic blocker, haloperidol.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [120, 131], "span2": [64, 73]}, "bert_text": "Low doses of pilocarpine caused a pronounced enhancement of the catalepsy that was induced by the dopaminergic blocker, <e1> haloperidol </e1> <e2> catalepsy </e2> that was induced by the dopaminergic blocker, haloperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3280": {"data": {"text": "CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis.", "entity1": "bisphosphonate", "entity2": "osteoporosis", "span1": [77, 91], "span2": [43, 55]}, "bert_text": "CONCLUSION: We conclude that patients with osteoporosis can report pain, and <e1> bisphosphonate </e1> <e2> osteoporosis </e2> can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3281": {"data": {"text": "CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis.", "entity1": "bisphosphonate", "entity2": "osteoporosis", "span1": [77, 91], "span2": [166, 178]}, "bert_text": "CONCLUSION: We conclude that patients with osteoporosis can report pain, and <e1> bisphosphonate </e1>-related pain should also be considered before ascribing this complaint to <e2> osteoporosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3282": {"data": {"text": "CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis.", "entity1": "bisphosphonate", "entity2": "pain", "span1": [77, 91], "span2": [67, 71]}, "bert_text": "CONCLUSION: We conclude that patients with osteoporosis can report pain, and <e1> bisphosphonate </e1> <e2> pain </e2>, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3283": {"data": {"text": "CONCLUSION: We conclude that patients with osteoporosis can report pain, and bisphosphonate-related pain should also be considered before ascribing this complaint to osteoporosis.", "entity1": "bisphosphonate", "entity2": "pain", "span1": [77, 91], "span2": [100, 104]}, "bert_text": "CONCLUSION: We conclude that patients with osteoporosis can report pain, and <e1> bisphosphonate </e1>-related <e2> pain </e2> should also be considered before ascribing this complaint to osteoporosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3284": {"data": {"text": "These results demonstrate that hyperprolactinemia specifically affects TIDA neurons and these effects vary, depending on the duration and intensity of hyperprolactinemia.", "entity1": "TIDA", "entity2": "hyperprolactinemia", "span1": [71, 75], "span2": [31, 49]}, "bert_text": "These results demonstrate that hyperprolactinemia specifically affects <e1> TIDA </e1> <e2> hyperprolactinemia </e2> specifically affects TIDA neurons and these effects vary, depending on the duration and intensity of hyperprolactinemia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3285": {"data": {"text": "These results demonstrate that hyperprolactinemia specifically affects TIDA neurons and these effects vary, depending on the duration and intensity of hyperprolactinemia.", "entity1": "TIDA", "entity2": "hyperprolactinemia", "span1": [71, 75], "span2": [151, 169]}, "bert_text": "These results demonstrate that hyperprolactinemia specifically affects <e1> TIDA </e1> neurons and these effects vary, depending on the duration and intensity of <e2> hyperprolactinemia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3286": {"data": {"text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "entity1": "BCNU", "entity2": "tumor", "span1": [6, 10], "span2": [42, 47]}, "bert_text": "Also, <e1> BCNU </e1> administration increased serum <e2> tumor </e2> necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3287": {"data": {"text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "entity1": "BCNU", "entity2": "necrosis", "span1": [6, 10], "span2": [48, 56]}, "bert_text": "Also, <e1> BCNU </e1> administration increased serum tumor <e2> necrosis </e2> factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3288": {"data": {"text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "entity1": "TNFalpha", "entity2": "tumor", "span1": [71, 79], "span2": [42, 47]}, "bert_text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (<e1> TNFalpha </e1> <e2> tumor </e2> necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3289": {"data": {"text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "entity1": "TNFalpha", "entity2": "necrosis", "span1": [71, 79], "span2": [48, 56]}, "bert_text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (<e1> TNFalpha </e1> <e2> necrosis </e2> factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3290": {"data": {"text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "entity1": "MT", "entity2": "tumor", "span1": [94, 96], "span2": [42, 47]}, "bert_text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal <e1> MT </e1> <e2> tumor </e2> necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3291": {"data": {"text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "entity1": "MT", "entity2": "necrosis", "span1": [94, 96], "span2": [48, 56]}, "bert_text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal <e1> MT </e1> <e2> necrosis </e2> factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3292": {"data": {"text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "entity1": "malondialdehyde", "entity2": "tumor", "span1": [101, 116], "span2": [42, 47]}, "bert_text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and <e1> malondialdehyde </e1> <e2> tumor </e2> necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3293": {"data": {"text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "entity1": "malondialdehyde", "entity2": "necrosis", "span1": [101, 116], "span2": [48, 56]}, "bert_text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and <e1> malondialdehyde </e1> <e2> necrosis </e2> factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3294": {"data": {"text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "entity1": "MDA", "entity2": "tumor", "span1": [118, 121], "span2": [42, 47]}, "bert_text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (<e1> MDA </e1> <e2> tumor </e2> necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3295": {"data": {"text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "entity1": "MDA", "entity2": "necrosis", "span1": [118, 121], "span2": [48, 56]}, "bert_text": "Also, BCNU administration increased serum tumor necrosis factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (<e1> MDA </e1> <e2> necrosis </e2> factor-alpha (TNFalpha), hippocampal MT and malondialdehyde (MDA) contents as well as caspase-3 activity in addition to histological alterations.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3296": {"data": {"text": "An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL amyloidosis.\n", "entity1": "everolimus", "entity2": "proteinuria", "span1": [84, 94], "span2": [59, 70]}, "bert_text": "An unexpected diagnosis in a renal-transplant patient with proteinuria treated with <e1> everolimus </e1> <e2> proteinuria </e2> treated with everolimus: AL amyloidosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3297": {"data": {"text": "An unexpected diagnosis in a renal-transplant patient with proteinuria treated with everolimus: AL amyloidosis.\n", "entity1": "everolimus", "entity2": "AL amyloidosis", "span1": [84, 94], "span2": [96, 110]}, "bert_text": "An unexpected diagnosis in a renal-transplant patient with proteinuria treated with <e1> everolimus </e1>: <e2> AL amyloidosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3298": {"data": {"text": "Diffuse skeletal pain after administration of alendronate.\n", "entity1": "alendronate", "entity2": "skeletal pain", "span1": [46, 57], "span2": [8, 21]}, "bert_text": "Diffuse skeletal pain after administration of <e1> alendronate </e1> <e2> skeletal pain </e2> after administration of alendronate.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3299": {"data": {"text": "These results suggest that activation of CB1 receptors offers neuroprotection against dopaminergic lesion and the development of L-DOPA-induced dyskinesias.", "entity1": "L-DOPA", "entity2": "dyskinesias", "span1": [129, 135], "span2": [144, 155]}, "bert_text": "These results suggest that activation of CB1 receptors offers neuroprotection against dopaminergic lesion and the development of <e1> L-DOPA </e1>-induced <e2> dyskinesias </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3300": {"data": {"text": "The association between alcohol consumption and depression was significant (p<0.001).", "entity1": "alcohol", "entity2": "depression", "span1": [24, 31], "span2": [48, 58]}, "bert_text": "The association between <e1> alcohol </e1> consumption and <e2> depression </e2> was significant (p<0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3301": {"data": {"text": "A case of acute hepatitis induced by zidovudine in a 38-year-old patient with AIDS is presented.", "entity1": "zidovudine", "entity2": "hepatitis", "span1": [37, 47], "span2": [16, 25]}, "bert_text": "A case of acute hepatitis induced by <e1> zidovudine </e1> <e2> hepatitis </e2> induced by zidovudine in a 38-year-old patient with AIDS is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3302": {"data": {"text": "A case of acute hepatitis induced by zidovudine in a 38-year-old patient with AIDS is presented.", "entity1": "zidovudine", "entity2": "AIDS", "span1": [37, 47], "span2": [78, 82]}, "bert_text": "A case of acute hepatitis induced by <e1> zidovudine </e1> in a 38-year-old patient with <e2> AIDS </e2> is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3303": {"data": {"text": "The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (DCF).", "entity1": "glyceryl trinitrate", "entity2": "primary dysmenorrhea", "span1": [62, 81], "span2": [123, 143]}, "bert_text": "The aim of the present study was to determine the efficacy of <e1> glyceryl trinitrate </e1> (GTN), an NO donor, in the resolution of <e2> primary dysmenorrhea </e2> in comparison with diclofenac (DCF).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3304": {"data": {"text": "The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (DCF).", "entity1": "GTN", "entity2": "primary dysmenorrhea", "span1": [83, 86], "span2": [123, 143]}, "bert_text": "The aim of the present study was to determine the efficacy of glyceryl trinitrate (<e1> GTN </e1>), an NO donor, in the resolution of <e2> primary dysmenorrhea </e2> in comparison with diclofenac (DCF).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3305": {"data": {"text": "The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (DCF).", "entity1": "NO", "entity2": "primary dysmenorrhea", "span1": [92, 94], "span2": [123, 143]}, "bert_text": "The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an <e1> NO </e1> donor, in the resolution of <e2> primary dysmenorrhea </e2> in comparison with diclofenac (DCF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3306": {"data": {"text": "The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (DCF).", "entity1": "diclofenac", "entity2": "primary dysmenorrhea", "span1": [163, 173], "span2": [123, 143]}, "bert_text": "The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with <e1> diclofenac </e1> <e2> primary dysmenorrhea </e2> in comparison with diclofenac (DCF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3307": {"data": {"text": "The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (DCF).", "entity1": "DCF", "entity2": "primary dysmenorrhea", "span1": [175, 178], "span2": [123, 143]}, "bert_text": "The aim of the present study was to determine the efficacy of glyceryl trinitrate (GTN), an NO donor, in the resolution of primary dysmenorrhea in comparison with diclofenac (<e1> DCF </e1> <e2> primary dysmenorrhea </e2> in comparison with diclofenac (DCF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3308": {"data": {"text": "Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration.\n", "entity1": "phenobarbital", "entity2": "hepatomegaly", "span1": [134, 147], "span2": [115, 127]}, "bert_text": "Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after <e1> phenobarbital </e1> <e2> hepatomegaly </e2> after phenobarbital administration.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3309": {"data": {"text": "However, our findings for both liver cancer and follicular cell lymphoma warrant follow-up to better differentiate effects of metolachlor use from other factors.", "entity1": "metolachlor", "entity2": "liver cancer", "span1": [126, 137], "span2": [31, 43]}, "bert_text": "However, our findings for both liver cancer and follicular cell lymphoma warrant follow-up to better differentiate effects of <e1> metolachlor </e1> <e2> liver cancer </e2> and follicular cell lymphoma warrant follow-up to better differentiate effects of metolachlor use from other factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3310": {"data": {"text": "However, our findings for both liver cancer and follicular cell lymphoma warrant follow-up to better differentiate effects of metolachlor use from other factors.", "entity1": "metolachlor", "entity2": "follicular cell lymphoma", "span1": [126, 137], "span2": [48, 72]}, "bert_text": "However, our findings for both liver cancer and follicular cell lymphoma warrant follow-up to better differentiate effects of <e1> metolachlor </e1> <e2> follicular cell lymphoma </e2> warrant follow-up to better differentiate effects of metolachlor use from other factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3311": {"data": {"text": "The present case is the first carcinoma of the renal pelvis reported in association with cyclophosphamide treatment.", "entity1": "cyclophosphamide", "entity2": "carcinoma of the renal pelvis", "span1": [89, 105], "span2": [30, 59]}, "bert_text": "The present case is the first carcinoma of the renal pelvis reported in association with <e1> cyclophosphamide </e1> <e2> carcinoma of the renal pelvis </e2> reported in association with cyclophosphamide treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3312": {"data": {"text": "We suggest that investigators involved in similar trials pay close attention to pulmonary pressure if hypoxaemia occurs after prophylactic administration of ibuprofen.", "entity1": "ibuprofen", "entity2": "pulmonary pressure if hypoxaemia", "span1": [157, 166], "span2": [80, 112]}, "bert_text": "We suggest that investigators involved in similar trials pay close attention to pulmonary pressure if hypoxaemia occurs after prophylactic administration of <e1> ibuprofen </e1> <e2> pulmonary pressure if hypoxaemia </e2> occurs after prophylactic administration of ibuprofen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3313": {"data": {"text": "Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible cardiomyopathy caused by doxorubicin.", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [132, 143], "span2": [107, 121]}, "bert_text": "Several cytopathic mechanisms have been suggested to mediate the dose-limiting cumulative and irreversible cardiomyopathy caused by <e1> doxorubicin </e1> <e2> cardiomyopathy </e2> caused by doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3314": {"data": {"text": "Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.", "entity1": "Nicotine", "entity2": "anxiety", "span1": [0, 8], "span2": [92, 99]}, "bert_text": "<e1> Nicotine </e1> (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced <e2> anxiety </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3315": {"data": {"text": "Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.", "entity1": "caffeine-", "entity2": "anxiety", "span1": [47, 56], "span2": [92, 99]}, "bert_text": "Nicotine (0.25 mg/kg) pretreatment blocked the <e1> caffeine- </e1> but not pentylenetetrazole-induced <e2> anxiety </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3316": {"data": {"text": "Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not pentylenetetrazole-induced anxiety.", "entity1": "pentylenetetrazole", "entity2": "anxiety", "span1": [65, 83], "span2": [92, 99]}, "bert_text": "Nicotine (0.25 mg/kg) pretreatment blocked the caffeine- but not <e1> pentylenetetrazole </e1>-induced <e2> anxiety </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"3317": {"data": {"text": "BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.", "entity1": "Tacrolimus", "entity2": "rosacea", "span1": [12, 22], "span2": [209, 216]}, "bert_text": "BACKGROUND: <e1> Tacrolimus </e1> ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated <e2> rosacea </e2> and perioral dermatitis.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3318": {"data": {"text": "BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.", "entity1": "Tacrolimus", "entity2": "perioral dermatitis", "span1": [12, 22], "span2": [221, 240]}, "bert_text": "BACKGROUND: <e1> Tacrolimus </e1> ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and <e2> perioral dermatitis </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3319": {"data": {"text": "BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.", "entity1": "steroid", "entity2": "rosacea", "span1": [190, 197], "span2": [209, 216]}, "bert_text": "BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in <e1> steroid </e1>-aggravated <e2> rosacea </e2> and perioral dermatitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3320": {"data": {"text": "BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis.", "entity1": "steroid", "entity2": "perioral dermatitis", "span1": [190, 197], "span2": [221, 240]}, "bert_text": "BACKGROUND: Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in <e1> steroid </e1>-aggravated rosacea and <e2> perioral dermatitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3321": {"data": {"text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "entity1": "bortezomib", "entity2": "Waldenstrom macroglobulinaemia", "span1": [166, 176], "span2": [43, 73]}, "bert_text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with <e1> bortezomib </e1> <e2> Waldenstrom macroglobulinaemia </e2> who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3322": {"data": {"text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "entity1": "bortezomib", "entity2": "necrotising fasciitis", "span1": [166, 176], "span2": [87, 108]}, "bert_text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with <e1> bortezomib </e1> <e2> necrotising fasciitis </e2> without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3323": {"data": {"text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "entity1": "bortezomib", "entity2": "neutropenia", "span1": [166, 176], "span2": [117, 128]}, "bert_text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with <e1> bortezomib </e1> <e2> neutropenia </e2> after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3324": {"data": {"text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "entity1": "dexamethasone", "entity2": "Waldenstrom macroglobulinaemia", "span1": [188, 201], "span2": [43, 73]}, "bert_text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <e1> dexamethasone </e1> <e2> Waldenstrom macroglobulinaemia </e2> who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3325": {"data": {"text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "entity1": "dexamethasone", "entity2": "necrotising fasciitis", "span1": [188, 201], "span2": [87, 108]}, "bert_text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <e1> dexamethasone </e1> <e2> necrotising fasciitis </e2> without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3326": {"data": {"text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "entity1": "dexamethasone", "entity2": "neutropenia", "span1": [188, 201], "span2": [117, 128]}, "bert_text": "We report a case of a 76-year-old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib, high-dose <e1> dexamethasone </e1> <e2> neutropenia </e2> after the combination treatment with bortezomib, high-dose dexamethasone and rituximab.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3327": {"data": {"text": "MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats.\n1.", "entity1": "MK-801", "entity2": "seizure", "span1": [0, 6], "span2": [51, 58]}, "bert_text": "<e1> MK-801 </e1> augments pilocarpine-induced electrographic <e2> seizure </e2> but protects against brain damage in rats.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3328": {"data": {"text": "MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats.\n1.", "entity1": "MK-801", "entity2": "brain damage", "span1": [0, 6], "span2": [80, 92]}, "bert_text": "<e1> MK-801 </e1> augments pilocarpine-induced electrographic seizure but protects against <e2> brain damage </e2> in rats.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3329": {"data": {"text": "MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats.\n1.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [16, 27], "span2": [51, 58]}, "bert_text": "MK-801 augments <e1> pilocarpine </e1>-induced electrographic <e2> seizure </e2> but protects against brain damage in rats.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3330": {"data": {"text": "MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats.\n1.", "entity1": "pilocarpine", "entity2": "brain damage", "span1": [16, 27], "span2": [80, 92]}, "bert_text": "MK-801 augments <e1> pilocarpine </e1>-induced electrographic seizure but protects against <e2> brain damage </e2> in rats.\n1.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3331": {"data": {"text": "The authors examined the anticonvulsant effects of MK-801 on the pilocarpine-induced seizure model.", "entity1": "MK-801", "entity2": "seizure", "span1": [51, 57], "span2": [85, 92]}, "bert_text": "The authors examined the anticonvulsant effects of <e1> MK-801 </e1> on the pilocarpine-induced <e2> seizure </e2> model.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3332": {"data": {"text": "The authors examined the anticonvulsant effects of MK-801 on the pilocarpine-induced seizure model.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [65, 76], "span2": [85, 92]}, "bert_text": "The authors examined the anticonvulsant effects of MK-801 on the <e1> pilocarpine </e1>-induced <e2> seizure </e2> model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3333": {"data": {"text": "Here, the impact of p53 inhibition on acute vs. late-stage DOX cardiotoxicity was examined in a juvenile model.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [59, 62], "span2": [63, 77]}, "bert_text": "Here, the impact of p53 inhibition on acute vs. late-stage <e1> DOX </e1> <e2> cardiotoxicity </e2> was examined in a juvenile model.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3334": {"data": {"text": "Indomethacin-induced hyperkalemia in three patients with gouty arthritis.\n", "entity1": "Indomethacin", "entity2": "hyperkalemia", "span1": [0, 12], "span2": [21, 33]}, "bert_text": "<e1> Indomethacin </e1>-induced <e2> hyperkalemia </e2> in three patients with gouty arthritis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3335": {"data": {"text": "Indomethacin-induced hyperkalemia in three patients with gouty arthritis.\n", "entity1": "Indomethacin", "entity2": "gouty arthritis", "span1": [0, 12], "span2": [57, 72]}, "bert_text": "<e1> Indomethacin </e1>-induced hyperkalemia in three patients with <e2> gouty arthritis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3336": {"data": {"text": "Neuroleptic malignant syndrome and methylphenidate.\n", "entity1": "methylphenidate", "entity2": "Neuroleptic malignant syndrome", "span1": [35, 50], "span2": [0, 30]}, "bert_text": "Neuroleptic malignant syndrome and <e1> methylphenidate </e1> <e2> Neuroleptic malignant syndrome </e2> and methylphenidate.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3337": {"data": {"text": "Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.\n", "entity1": "levodopa", "entity2": "hypotensive", "span1": [46, 54], "span2": [24, 35]}, "bert_text": "Pharmacodynamics of the hypotensive effect of <e1> levodopa </e1> <e2> hypotensive </e2> effect of levodopa in parkinsonian patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3338": {"data": {"text": "Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.\n", "entity1": "levodopa", "entity2": "parkinsonian", "span1": [46, 54], "span2": [58, 70]}, "bert_text": "Pharmacodynamics of the hypotensive effect of <e1> levodopa </e1> in <e2> parkinsonian </e2> patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3339": {"data": {"text": "Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and vasculitis during PTU therapy, or on the incidence of MPO-ANCA in untreated Graves' disease patients.", "entity1": "PTU", "entity2": "vasculitis", "span1": [127, 130], "span2": [109, 119]}, "bert_text": "Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and vasculitis during <e1> PTU </e1> <e2> vasculitis </e2> during PTU therapy, or on the incidence of MPO-ANCA in untreated Graves' disease patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3340": {"data": {"text": "Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and vasculitis during PTU therapy, or on the incidence of MPO-ANCA in untreated Graves' disease patients.", "entity1": "PTU", "entity2": "Graves' disease", "span1": [127, 130], "span2": [185, 200]}, "bert_text": "Nevertheless, there have been no studies on the temporal relationship between the appearance of MPO-ANCA and vasculitis during <e1> PTU </e1> therapy, or on the incidence of MPO-ANCA in untreated <e2> Graves' disease </e2> patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3341": {"data": {"text": "Heparin-induced thrombocytopenia (HIT) remains under-recognized despite its potentially devastating outcomes.", "entity1": "Heparin", "entity2": "thrombocytopenia", "span1": [0, 7], "span2": [16, 32]}, "bert_text": "<e1> Heparin </e1>-induced <e2> thrombocytopenia </e2> (HIT) remains under-recognized despite its potentially devastating outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3342": {"data": {"text": "Heparin-induced thrombocytopenia (HIT) remains under-recognized despite its potentially devastating outcomes.", "entity1": "Heparin", "entity2": "HIT", "span1": [0, 7], "span2": [34, 37]}, "bert_text": "<e1> Heparin </e1>-induced thrombocytopenia (<e2> HIT </e2>) remains under-recognized despite its potentially devastating outcomes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3343": {"data": {"text": ". We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.", "entity1": "trazodone", "entity2": "catalepsy", "span1": [18, 27], "span2": [244, 253]}, "bert_text": ". We suggest that <e1> trazodone </e1> (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3344": {"data": {"text": ". We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.", "entity1": "5-HT", "entity2": "catalepsy", "span1": [66, 70], "span2": [244, 253]}, "bert_text": ". We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the <e1> 5-HT </e1> 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3345": {"data": {"text": ". We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.", "entity1": "5-HT", "entity2": "catalepsy", "span1": [160, 164], "span2": [244, 253]}, "bert_text": ". We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by <e1> 5-HT </e1>, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3346": {"data": {"text": ". We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.", "entity1": "dexamphetamine", "entity2": "catalepsy", "span1": [190, 204], "span2": [244, 253]}, "bert_text": ". We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates <e1> dexamphetamine </e1> stereotypy and antagonizes haloperidol <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3347": {"data": {"text": ". We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [232, 243], "span2": [244, 253]}, "bert_text": ". We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes <e1> haloperidol </e1> <e2> catalepsy </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3348": {"data": {"text": "Pethidine is an opioid that gains its popularity for the effective pain control through acting on the opioid-receptors.", "entity1": "Pethidine", "entity2": "pain", "span1": [0, 9], "span2": [67, 71]}, "bert_text": "<e1> Pethidine </e1> is an opioid that gains its popularity for the effective <e2> pain </e2> control through acting on the opioid-receptors.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3349": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "cisplatin", "entity2": "acute renal injury", "span1": [52, 61], "span2": [70, 88]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates <e1> cisplatin </e1>-induced <e2> acute renal injury </e2>.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3350": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "cisplatin", "entity2": "acute kidney injury", "span1": [52, 61], "span2": [181, 200]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates <e1> cisplatin </e1>-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce <e2> acute kidney injury </e2> due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3351": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "cisplatin", "entity2": "increase the acute tubular necrosis", "span1": [52, 61], "span2": [299, 334]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates <e1> cisplatin </e1>-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, <e2> increase the acute tubular necrosis </e2> score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3352": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "Cisplatin", "entity2": "acute renal injury", "span1": [90, 99], "span2": [70, 88]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\n<e1> Cisplatin </e1> <e2> acute renal injury </e2>.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3353": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "Cisplatin", "entity2": "acute kidney injury", "span1": [90, 99], "span2": [181, 200]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\n<e1> Cisplatin </e1> treatment has been adopted in some chemotherapies; however, this drug can induce <e2> acute kidney injury </e2> due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3354": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "Cisplatin", "entity2": "increase the acute tubular necrosis", "span1": [90, 99], "span2": [299, 334]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\n<e1> Cisplatin </e1> treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, <e2> increase the acute tubular necrosis </e2> score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3355": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "creatinine", "entity2": "acute renal injury", "span1": [278, 288], "span2": [70, 88]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of <e1> creatinine </e1> <e2> acute renal injury </e2>.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3356": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "creatinine", "entity2": "acute kidney injury", "span1": [278, 288], "span2": [181, 200]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of <e1> creatinine </e1> <e2> acute kidney injury </e2> due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3357": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "creatinine", "entity2": "increase the acute tubular necrosis", "span1": [278, 288], "span2": [299, 334]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of <e1> creatinine </e1> and urea, <e2> increase the acute tubular necrosis </e2> score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3358": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "urea", "entity2": "acute renal injury", "span1": [293, 297], "span2": [70, 88]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and <e1> urea </e1> <e2> acute renal injury </e2>.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3359": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "urea", "entity2": "acute kidney injury", "span1": [293, 297], "span2": [181, 200]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and <e1> urea </e1> <e2> acute kidney injury </e2> due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3360": {"data": {"text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and urea, increase the acute tubular necrosis score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "entity1": "urea", "entity2": "increase the acute tubular necrosis", "span1": [293, 297], "span2": [299, 334]}, "bert_text": "Kinin B2 receptor deletion and blockage ameliorates cisplatin-induced acute renal injury.\nCisplatin treatment has been adopted in some chemotherapies; however, this drug can induce acute kidney injury due its ability to negatively affect renal function, augment serum levels of creatinine and <e1> urea </e1>, <e2> increase the acute tubular necrosis </e2> score and up-regulate cytokines (e.g., IL-1b and TNF-a).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3361": {"data": {"text": "The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients.", "entity1": "Aza", "entity2": "infections", "span1": [15, 18], "span2": [45, 55]}, "bert_text": "The randomized <e1> Aza </e1> patients had more overall <e2> infections </e2> (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3362": {"data": {"text": "The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients.", "entity1": "Aza", "entity2": "infections", "span1": [15, 18], "span2": [93, 103]}, "bert_text": "The randomized <e1> Aza </e1> patients had more overall infections (P less than 0.05) and more nonviral <e2> infections </e2> (P less than 0.02) than the randomized cyclosporine patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3363": {"data": {"text": "The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients.", "entity1": "cyclosporine", "entity2": "infections", "span1": [143, 155], "span2": [45, 55]}, "bert_text": "The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized <e1> cyclosporine </e1> <e2> infections </e2> (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3364": {"data": {"text": "The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized cyclosporine patients.", "entity1": "cyclosporine", "entity2": "infections", "span1": [143, 155], "span2": [93, 103]}, "bert_text": "The randomized Aza patients had more overall infections (P less than 0.05) and more nonviral infections (P less than 0.02) than the randomized <e1> cyclosporine </e1> <e2> infections </e2> (P less than 0.02) than the randomized cyclosporine patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3365": {"data": {"text": "This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.", "entity1": "sirolimus", "entity2": "anemia", "span1": [45, 54], "span2": [22, 28]}, "bert_text": "This review considers anemia associated with <e1> sirolimus </e1> <e2> anemia </e2> associated with sirolimus, including its presentation, mechanisms, and management.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3366": {"data": {"text": "Neither propranolol nor B 24/76 could stop the changes in the characteristic myosin isoenzyme pattern of the hypertrophied rat heart.", "entity1": "propranolol", "entity2": "hypertrophied", "span1": [8, 19], "span2": [109, 122]}, "bert_text": "Neither <e1> propranolol </e1> nor B 24/76 could stop the changes in the characteristic myosin isoenzyme pattern of the <e2> hypertrophied </e2> rat heart.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3367": {"data": {"text": "Post-suxamethonium pains in Nigerian surgical patients.\n", "entity1": "suxamethonium", "entity2": "pains", "span1": [5, 18], "span2": [19, 24]}, "bert_text": "Post-<e1> suxamethonium </e1> <e2> pains </e2> in Nigerian surgical patients.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3368": {"data": {"text": "Temocapril did not attenuate proteinuria at 8 days, but it did markedly lower it from weeks 4 to 20.", "entity1": "Temocapril", "entity2": "proteinuria", "span1": [0, 10], "span2": [29, 40]}, "bert_text": "<e1> Temocapril </e1> did not attenuate <e2> proteinuria </e2> at 8 days, but it did markedly lower it from weeks 4 to 20.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3369": {"data": {"text": "Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma.\n", "entity1": "carboplatin", "entity2": "Ocular motility", "span1": [39, 50], "span2": [0, 15]}, "bert_text": "Ocular motility changes after subtenon <e1> carboplatin </e1> <e2> Ocular motility </e2> changes after subtenon carboplatin chemotherapy for retinoblastoma.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3370": {"data": {"text": "Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma.\n", "entity1": "carboplatin", "entity2": "retinoblastoma", "span1": [39, 50], "span2": [68, 82]}, "bert_text": "Ocular motility changes after subtenon <e1> carboplatin </e1> chemotherapy for <e2> retinoblastoma </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3371": {"data": {"text": "Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "entity1": "propranolol", "entity2": "cardiac arrhythmias", "span1": [16, 27], "span2": [74, 93]}, "bert_text": "Both isomers of <e1> propranolol </e1> were capable of preventing adrenaline-induced <e2> cardiac arrhythmias </e2> in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3372": {"data": {"text": "Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "entity1": "-)-propranolol", "entity2": "cardiac arrhythmias", "span1": [154, 168], "span2": [74, 93]}, "bert_text": "Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (<e1> -)-propranolol </e1> <e2> cardiac arrhythmias </e2> in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3373": {"data": {"text": "Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "entity1": "-propranolol", "entity2": "cardiac arrhythmias", "span1": [210, 222], "span2": [74, 93]}, "bert_text": "Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)<e1> -propranolol </e1> <e2> cardiac arrhythmias </e2> in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3374": {"data": {"text": "Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "entity1": "adrenaline", "entity2": "cardiac arrhythmias", "span1": [55, 65], "span2": [74, 93]}, "bert_text": "Both isomers of propranolol were capable of preventing <e1> adrenaline </e1>-induced <e2> cardiac arrhythmias </e2> in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3375": {"data": {"text": "Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "entity1": "halothane", "entity2": "cardiac arrhythmias", "span1": [121, 130], "span2": [74, 93]}, "bert_text": "Both isomers of propranolol were capable of preventing adrenaline-induced cardiac arrhythmias in cats anaesthetized with <e1> halothane </e1> <e2> cardiac arrhythmias </e2> in cats anaesthetized with halothane, but the mean dose of (-)-propranolol was 0.09+/-0.02 mg/kg whereas that of (+)-propranolol was 4.2+/-1.2 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3376": {"data": {"text": "Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month temsirolimus therapy.", "entity1": "temsirolimus", "entity2": "necrotic", "span1": [126, 138], "span2": [77, 85]}, "bert_text": "Moreover, numerous patchy, well-limited fibrotic areas, compatible with post-necrotic tissue repair, were found after 6-month <e1> temsirolimus </e1> <e2> necrotic </e2> tissue repair, were found after 6-month temsirolimus therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3377": {"data": {"text": "It is concluded that intragastric pressure increases significantly during muscle fasciculations caused by suxamethonium in healthy children.", "entity1": "suxamethonium", "entity2": "muscle fasciculations", "span1": [106, 119], "span2": [74, 95]}, "bert_text": "It is concluded that intragastric pressure increases significantly during muscle fasciculations caused by <e1> suxamethonium </e1> <e2> muscle fasciculations </e2> caused by suxamethonium in healthy children.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3378": {"data": {"text": "CONCLUSIONS: The data suggest that neuropsychiatric disorders in PD are more likely an interaction between levodopa and the disease state than a consequence of sensitisation to repeated dopaminergic therapy.", "entity1": "levodopa", "entity2": "neuropsychiatric disorders", "span1": [107, 115], "span2": [35, 61]}, "bert_text": "CONCLUSIONS: The data suggest that neuropsychiatric disorders in PD are more likely an interaction between <e1> levodopa </e1> <e2> neuropsychiatric disorders </e2> in PD are more likely an interaction between levodopa and the disease state than a consequence of sensitisation to repeated dopaminergic therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3379": {"data": {"text": "CONCLUSIONS: The data suggest that neuropsychiatric disorders in PD are more likely an interaction between levodopa and the disease state than a consequence of sensitisation to repeated dopaminergic therapy.", "entity1": "levodopa", "entity2": "PD", "span1": [107, 115], "span2": [65, 67]}, "bert_text": "CONCLUSIONS: The data suggest that neuropsychiatric disorders in PD are more likely an interaction between <e1> levodopa </e1> <e2> PD </e2> are more likely an interaction between levodopa and the disease state than a consequence of sensitisation to repeated dopaminergic therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3380": {"data": {"text": "BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption.", "entity1": "bisphosphonates", "entity2": "Osteoporosis", "span1": [87, 102], "span2": [12, 24]}, "bert_text": "BACKGROUND: Osteoporosis is caused by bone resorption in excess of bone formation, and <e1> bisphosphonates </e1> <e2> Osteoporosis </e2> is caused by bone resorption in excess of bone formation, and bisphosphonates, are used to inhibit bone resorption.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3381": {"data": {"text": "CONCLUSIONS: In CYP-induced cystitis, the expression of P2X3 and NK1 receptors increased in urothelium and/or suburothelium.", "entity1": "CYP", "entity2": "cystitis", "span1": [16, 19], "span2": [28, 36]}, "bert_text": "CONCLUSIONS: In <e1> CYP </e1>-induced <e2> cystitis </e2>, the expression of P2X3 and NK1 receptors increased in urothelium and/or suburothelium.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3382": {"data": {"text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "entity1": "lomustine", "entity2": "toxicity", "span1": [74, 83], "span2": [35, 43]}, "bert_text": "This retrospective study describes toxicity associated with a protocol of <e1> lomustine </e1> <e2> toxicity </e2> associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3383": {"data": {"text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "entity1": "lomustine", "entity2": "lymphoma", "span1": [74, 83], "span2": [131, 139]}, "bert_text": "This retrospective study describes toxicity associated with a protocol of <e1> lomustine </e1> (CCNU) and cyclophosphamide (CTX) in dogs with <e2> lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3384": {"data": {"text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "entity1": "CCNU", "entity2": "toxicity", "span1": [85, 89], "span2": [35, 43]}, "bert_text": "This retrospective study describes toxicity associated with a protocol of lomustine (<e1> CCNU </e1> <e2> toxicity </e2> associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3385": {"data": {"text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "entity1": "CCNU", "entity2": "lymphoma", "span1": [85, 89], "span2": [131, 139]}, "bert_text": "This retrospective study describes toxicity associated with a protocol of lomustine (<e1> CCNU </e1>) and cyclophosphamide (CTX) in dogs with <e2> lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3386": {"data": {"text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "entity1": "cyclophosphamide", "entity2": "toxicity", "span1": [95, 111], "span2": [35, 43]}, "bert_text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and <e1> cyclophosphamide </e1> <e2> toxicity </e2> associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3387": {"data": {"text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "entity1": "cyclophosphamide", "entity2": "lymphoma", "span1": [95, 111], "span2": [131, 139]}, "bert_text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and <e1> cyclophosphamide </e1> (CTX) in dogs with <e2> lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3388": {"data": {"text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "entity1": "CTX", "entity2": "toxicity", "span1": [113, 116], "span2": [35, 43]}, "bert_text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (<e1> CTX </e1> <e2> toxicity </e2> associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3389": {"data": {"text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma.", "entity1": "CTX", "entity2": "lymphoma", "span1": [113, 116], "span2": [131, 139]}, "bert_text": "This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (<e1> CTX </e1>) in dogs with <e2> lymphoma </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3390": {"data": {"text": "Drug-related globus pallidus infarctions are most often associated with heroin.", "entity1": "heroin", "entity2": "infarctions", "span1": [72, 78], "span2": [29, 40]}, "bert_text": "Drug-related globus pallidus infarctions are most often associated with <e1> heroin </e1> <e2> infarctions </e2> are most often associated with heroin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3391": {"data": {"text": "Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.\n", "entity1": "etoposide", "entity2": "neurologic dysfunction", "span1": [45, 54], "span2": [6, 28]}, "bert_text": "Acute neurologic dysfunction after high-dose <e1> etoposide </e1> <e2> neurologic dysfunction </e2> after high-dose etoposide therapy for malignant glioma.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3392": {"data": {"text": "Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma.\n", "entity1": "etoposide", "entity2": "malignant glioma", "span1": [45, 54], "span2": [67, 83]}, "bert_text": "Acute neurologic dysfunction after high-dose <e1> etoposide </e1> therapy for <e2> malignant glioma </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3393": {"data": {"text": "A muscarinic receptor blocker, atropine, disrupted haloperidol-induced catalepsy.", "entity1": "atropine", "entity2": "catalepsy", "span1": [31, 39], "span2": [71, 80]}, "bert_text": "A muscarinic receptor blocker, <e1> atropine </e1>, disrupted haloperidol-induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3394": {"data": {"text": "A muscarinic receptor blocker, atropine, disrupted haloperidol-induced catalepsy.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [51, 62], "span2": [71, 80]}, "bert_text": "A muscarinic receptor blocker, atropine, disrupted <e1> haloperidol </e1>-induced <e2> catalepsy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3395": {"data": {"text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "entity1": "Amphetamine", "entity2": "hyper locomotion", "span1": [0, 11], "span2": [33, 49]}, "bert_text": "<e1> Amphetamine </e1> (3 mg/kg ip) induced <e2> hyper locomotion </e2>, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3396": {"data": {"text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "entity1": "Amphetamine", "entity2": "catalepsy", "span1": [0, 11], "span2": [152, 161]}, "bert_text": "<e1> Amphetamine </e1> (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced <e2> catalepsy </e2> tests were used as animal models of schizophrenia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3397": {"data": {"text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "entity1": "Amphetamine", "entity2": "schizophrenia", "span1": [0, 11], "span2": [198, 211]}, "bert_text": "<e1> Amphetamine </e1> (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of <e2> schizophrenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3398": {"data": {"text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "entity1": "apomorphine", "entity2": "hyper locomotion", "span1": [51, 62], "span2": [33, 49]}, "bert_text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, <e1> apomorphine </e1> <e2> hyper locomotion </e2>, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3399": {"data": {"text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "entity1": "apomorphine", "entity2": "catalepsy", "span1": [51, 62], "span2": [152, 161]}, "bert_text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, <e1> apomorphine </e1> (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced <e2> catalepsy </e2> tests were used as animal models of schizophrenia.", "weak_labels": [1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3400": {"data": {"text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "entity1": "apomorphine", "entity2": "schizophrenia", "span1": [51, 62], "span2": [198, 211]}, "bert_text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, <e1> apomorphine </e1> (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of <e2> schizophrenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3401": {"data": {"text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "entity1": "haloperidol", "entity2": "hyper locomotion", "span1": [117, 128], "span2": [33, 49]}, "bert_text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and <e1> haloperidol </e1> <e2> hyper locomotion </e2>, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3402": {"data": {"text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [117, 128], "span2": [152, 161]}, "bert_text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and <e1> haloperidol </e1> (1.5 mg/kg sc) induced <e2> catalepsy </e2> tests were used as animal models of schizophrenia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3403": {"data": {"text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia.", "entity1": "haloperidol", "entity2": "schizophrenia", "span1": [117, 128], "span2": [198, 211]}, "bert_text": "Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and <e1> haloperidol </e1> (1.5 mg/kg sc) induced catalepsy tests were used as animal models of <e2> schizophrenia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3404": {"data": {"text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "entity1": "cisplatin", "entity2": "hypotension", "span1": [129, 138], "span2": [28, 39]}, "bert_text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with <e1> cisplatin </e1> <e2> hypotension </e2>, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3405": {"data": {"text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "entity1": "cisplatin", "entity2": "colorectal carcinoma", "span1": [129, 138], "span2": [83, 103]}, "bert_text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with <e1> cisplatin </e1> <e2> colorectal carcinoma </e2> while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3406": {"data": {"text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "entity1": "CDDP", "entity2": "hypotension", "span1": [140, 144], "span2": [28, 39]}, "bert_text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (<e1> CDDP </e1> <e2> hypotension </e2>, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3407": {"data": {"text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "entity1": "CDDP", "entity2": "colorectal carcinoma", "span1": [140, 144], "span2": [83, 103]}, "bert_text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (<e1> CDDP </e1> <e2> colorectal carcinoma </e2> while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3408": {"data": {"text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "entity1": "5-fluorouracil", "entity2": "hypotension", "span1": [150, 164], "span2": [28, 39]}, "bert_text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and <e1> 5-fluorouracil </e1> <e2> hypotension </e2>, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3409": {"data": {"text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "entity1": "5-fluorouracil", "entity2": "colorectal carcinoma", "span1": [150, 164], "span2": [83, 103]}, "bert_text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and <e1> 5-fluorouracil </e1> <e2> colorectal carcinoma </e2> while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3410": {"data": {"text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "entity1": "5-FU", "entity2": "hypotension", "span1": [166, 170], "span2": [28, 39]}, "bert_text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (<e1> 5-FU </e1> <e2> hypotension </e2>, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3411": {"data": {"text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "entity1": "5-FU", "entity2": "colorectal carcinoma", "span1": [166, 170], "span2": [83, 103]}, "bert_text": "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (<e1> 5-FU </e1> <e2> colorectal carcinoma </e2> while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3412": {"data": {"text": "The findings indicate that thalidomide may be an option for patients who have failed other forms of therapy, provided close follow-up is maintained for development of peripheral neuropathy.", "entity1": "thalidomide", "entity2": "peripheral neuropathy", "span1": [27, 38], "span2": [167, 188]}, "bert_text": "The findings indicate that <e1> thalidomide </e1> may be an option for patients who have failed other forms of therapy, provided close follow-up is maintained for development of <e2> peripheral neuropathy </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3413": {"data": {"text": "4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.", "entity1": "oestrogen", "entity2": "endometrial carcinoma", "span1": [127, 136], "span2": [11, 32]}, "bert_text": "4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed <e1> oestrogen </e1> <e2> endometrial carcinoma </e2> referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3414": {"data": {"text": "4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.", "entity1": "oestrogen", "entity2": "hyperplasia", "span1": [127, 136], "span2": [189, 200]}, "bert_text": "4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed <e1> oestrogen </e1> therapy and the difficulty in distinguishing severe <e2> hyperplasia </e2> from malignancy.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3415": {"data": {"text": "4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy.", "entity1": "oestrogen", "entity2": "malignancy", "span1": [127, 136], "span2": [206, 216]}, "bert_text": "4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed <e1> oestrogen </e1> therapy and the difficulty in distinguishing severe hyperplasia from <e2> malignancy </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3416": {"data": {"text": "Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.", "entity1": "bilirubin", "entity2": "seizures", "span1": [211, 220], "span2": [65, 73]}, "bert_text": "Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total <e1> bilirubin </e1> <e2> seizures </e2> after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3417": {"data": {"text": "Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.", "entity1": "bilirubin", "entity2": "end-stage liver disease", "span1": [211, 220], "span2": [120, 143]}, "bert_text": "Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total <e1> bilirubin </e1> <e2> end-stage liver disease </e2> score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3418": {"data": {"text": "Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.", "entity1": "TAC", "entity2": "seizures", "span1": [247, 250], "span2": [65, 73]}, "bert_text": "Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough <e1> TAC </e1> <e2> seizures </e2> after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3419": {"data": {"text": "Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.", "entity1": "TAC", "entity2": "end-stage liver disease", "span1": [247, 250], "span2": [120, 143]}, "bert_text": "Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender, pediatric end-stage liver disease score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough <e1> TAC </e1> <e2> end-stage liver disease </e2> score before surgery, Child-Pugh score before surgery, serum total bilirubin after surgery, and trough TAC level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3420": {"data": {"text": "Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.\n", "entity1": "heroin", "entity2": "Rhabdomyolysis", "span1": [46, 52], "span2": [0, 14]}, "bert_text": "Rhabdomyolysis and brain ischemic stroke in a <e1> heroin </e1> <e2> Rhabdomyolysis </e2> and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3421": {"data": {"text": "Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.\n", "entity1": "heroin", "entity2": "ischemic stroke", "span1": [46, 52], "span2": [25, 40]}, "bert_text": "Rhabdomyolysis and brain ischemic stroke in a <e1> heroin </e1> <e2> ischemic stroke </e2> in a heroin-dependent male under methadone maintenance therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3422": {"data": {"text": "Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.\n", "entity1": "methadone", "entity2": "Rhabdomyolysis", "span1": [74, 83], "span2": [0, 14]}, "bert_text": "Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under <e1> methadone </e1> <e2> Rhabdomyolysis </e2> and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3423": {"data": {"text": "Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy.\n", "entity1": "methadone", "entity2": "ischemic stroke", "span1": [74, 83], "span2": [25, 40]}, "bert_text": "Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under <e1> methadone </e1> <e2> ischemic stroke </e2> in a heroin-dependent male under methadone maintenance therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3424": {"data": {"text": "Dobutamine induced ischaemia could therefore be used to study the pathophysiology of this phenomenon further in patients with coronary artery disease.", "entity1": "Dobutamine", "entity2": "ischaemia", "span1": [0, 10], "span2": [19, 28]}, "bert_text": "<e1> Dobutamine </e1> induced <e2> ischaemia </e2> could therefore be used to study the pathophysiology of this phenomenon further in patients with coronary artery disease.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3425": {"data": {"text": "Dobutamine induced ischaemia could therefore be used to study the pathophysiology of this phenomenon further in patients with coronary artery disease.", "entity1": "Dobutamine", "entity2": "coronary artery disease", "span1": [0, 10], "span2": [126, 149]}, "bert_text": "<e1> Dobutamine </e1> induced ischaemia could therefore be used to study the pathophysiology of this phenomenon further in patients with <e2> coronary artery disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3426": {"data": {"text": "<120 mm Hg; creatinine, > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with diabetes) generally tolerated the high-dose strategy.", "entity1": "creatinine", "entity2": "diabetes", "span1": [12, 22], "span2": [105, 113]}, "bert_text": "<120 mm Hg; <e1> creatinine </e1>, > or =132.6 micromol/L [> or =1.5 mg/dL]; age, > or =70 years; and patients with <e2> diabetes </e2>) generally tolerated the high-dose strategy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3427": {"data": {"text": "Acute renal failure after high-dose methotrexate therapy in a patient with ileostomy.\n", "entity1": "methotrexate", "entity2": "Acute renal failure", "span1": [36, 48], "span2": [0, 19]}, "bert_text": "Acute renal failure after high-dose <e1> methotrexate </e1> <e2> Acute renal failure </e2> after high-dose methotrexate therapy in a patient with ileostomy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3428": {"data": {"text": "The aim of this work is to call attention to the risk of tacrolimus use in patients with SSc.", "entity1": "tacrolimus", "entity2": "SSc", "span1": [57, 67], "span2": [89, 92]}, "bert_text": "The aim of this work is to call attention to the risk of <e1> tacrolimus </e1> use in patients with <e2> SSc </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3429": {"data": {"text": "CONCLUSIONS: The prevalence of levodopa-induced dyskinesia in our patients was 44%.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [31, 39], "span2": [48, 58]}, "bert_text": "CONCLUSIONS: The prevalence of <e1> levodopa </e1>-induced <e2> dyskinesia </e2> in our patients was 44%.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3430": {"data": {"text": "Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.\n", "entity1": "carboplatin", "entity2": "squamous cell carcinoma", "span1": [18, 29], "span2": [83, 106]}, "bert_text": "Phase II study of <e1> carboplatin </e1> and liposomal doxorubicin in patients with recurrent <e2> squamous cell carcinoma </e2> of the cervix.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3431": {"data": {"text": "Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.\n", "entity1": "doxorubicin", "entity2": "squamous cell carcinoma", "span1": [44, 55], "span2": [83, 106]}, "bert_text": "Phase II study of carboplatin and liposomal <e1> doxorubicin </e1> in patients with recurrent <e2> squamous cell carcinoma </e2> of the cervix.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3432": {"data": {"text": "Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).", "entity1": "NVP", "entity2": "rash", "span1": [45, 48], "span2": [102, 106]}, "bert_text": "Among the patients with 1 year of follow-up, <e1> NVP </e1> therapy was significantly associated with developing <e2> rash </e2> and d4T therapy with developing peripheral neuropathy (p < 0.05).", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3433": {"data": {"text": "Among the patients with 1 year of follow-up, NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy (p < 0.05).", "entity1": "NVP", "entity2": "peripheral neuropathy", "span1": [45, 48], "span2": [139, 160]}, "bert_text": "Among the patients with 1 year of follow-up, <e1> NVP </e1> therapy was significantly associated with developing rash and d4T therapy with developing <e2> peripheral neuropathy </e2> (p < 0.05).", "weak_labels": [1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3434": {"data": {"text": "Although both dl-sotalol and azimilide rarely induced EADs in canine left ventricles, they produced frequent EADs in rabbits, in which more pronounced QT prolongation was seen.", "entity1": "sotalol", "entity2": "QT prolongation", "span1": [17, 24], "span2": [151, 166]}, "bert_text": "Although both dl-<e1> sotalol </e1> and azimilide rarely induced EADs in canine left ventricles, they produced frequent EADs in rabbits, in which more pronounced <e2> QT prolongation </e2> was seen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3435": {"data": {"text": "Although both dl-sotalol and azimilide rarely induced EADs in canine left ventricles, they produced frequent EADs in rabbits, in which more pronounced QT prolongation was seen.", "entity1": "azimilide", "entity2": "QT prolongation", "span1": [29, 38], "span2": [151, 166]}, "bert_text": "Although both dl-sotalol and <e1> azimilide </e1> rarely induced EADs in canine left ventricles, they produced frequent EADs in rabbits, in which more pronounced <e2> QT prolongation </e2> was seen.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3436": {"data": {"text": "Physical training decreases susceptibility to subsequent pilocarpine-induced seizures in the rat.\n", "entity1": "pilocarpine", "entity2": "seizures", "span1": [57, 68], "span2": [77, 85]}, "bert_text": "Physical training decreases susceptibility to subsequent <e1> pilocarpine </e1>-induced <e2> seizures </e2> in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3437": {"data": {"text": "Cardiotoxicity that was thought to be related to CYA occurred in 1/32 (3%) of patients in Group 1 and in 13/52 (25%) patients in Group 2 (P less than 0.025).", "entity1": "CYA", "entity2": "Cardiotoxicity", "span1": [49, 52], "span2": [0, 14]}, "bert_text": "Cardiotoxicity that was thought to be related to <e1> CYA </e1> <e2> Cardiotoxicity </e2> that was thought to be related to CYA occurred in 1/32 (3%) of patients in Group 1 and in 13/52 (25%) patients in Group 2 (P less than 0.025).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3438": {"data": {"text": "Early paracentral visual field loss in patients taking hydroxychloroquine.\n", "entity1": "hydroxychloroquine", "entity2": "paracentral visual field loss", "span1": [55, 73], "span2": [6, 35]}, "bert_text": "Early paracentral visual field loss in patients taking <e1> hydroxychloroquine </e1> <e2> paracentral visual field loss </e2> in patients taking hydroxychloroquine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3439": {"data": {"text": "The effects of progesterone treatment on bupivacaine arrhythmogenicity in beating rat heart myocyte cultures and on anesthetized rats were determined.", "entity1": "progesterone", "entity2": "arrhythmogenicity", "span1": [15, 27], "span2": [53, 70]}, "bert_text": "The effects of <e1> progesterone </e1> treatment on bupivacaine <e2> arrhythmogenicity </e2> in beating rat heart myocyte cultures and on anesthetized rats were determined.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3440": {"data": {"text": "The effects of progesterone treatment on bupivacaine arrhythmogenicity in beating rat heart myocyte cultures and on anesthetized rats were determined.", "entity1": "bupivacaine", "entity2": "arrhythmogenicity", "span1": [41, 52], "span2": [53, 70]}, "bert_text": "The effects of progesterone treatment on <e1> bupivacaine </e1> <e2> arrhythmogenicity </e2> in beating rat heart myocyte cultures and on anesthetized rats were determined.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3441": {"data": {"text": "There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.", "entity1": "VCM", "entity2": "atrophy", "span1": [135, 138], "span2": [96, 103]}, "bert_text": "There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in <e1> VCM </e1> <e2> atrophy </e2>, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3442": {"data": {"text": "There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.", "entity1": "VCM", "entity2": "necrosis", "span1": [135, 138], "span2": [123, 131]}, "bert_text": "There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in <e1> VCM </e1> <e2> necrosis </e2> in VCM-treated rats more than those of the control and the erdosteine groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3443": {"data": {"text": "There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.", "entity1": "erdosteine", "entity2": "atrophy", "span1": [191, 201], "span2": [96, 103]}, "bert_text": "There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the <e1> erdosteine </e1> <e2> atrophy </e2>, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3444": {"data": {"text": "There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the erdosteine groups.", "entity1": "erdosteine", "entity2": "necrosis", "span1": [191, 201], "span2": [123, 131]}, "bert_text": "There were a significant dilatation of tubular lumens, extensive epithelial cell vacuolization, atrophy, desquamation, and necrosis in VCM-treated rats more than those of the control and the <e1> erdosteine </e1> <e2> necrosis </e2> in VCM-treated rats more than those of the control and the erdosteine groups.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3445": {"data": {"text": "Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure.", "entity1": "anthraquinone", "entity2": "renal injury", "span1": [53, 66], "span2": [95, 107]}, "bert_text": "Although a causal relationship between the use of an <e1> anthraquinone </e1>-containing herbal agent and <e2> renal injury </e2> remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3446": {"data": {"text": "Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure.", "entity1": "anthraquinone", "entity2": "interstitial nephropathy", "span1": [53, 66], "span2": [154, 178]}, "bert_text": "Although a causal relationship between the use of an <e1> anthraquinone </e1>-containing herbal agent and renal injury remains to be proven, phytotherapy-associated <e2> interstitial nephropathy </e2> should be considered in patients who present with unexplained renal failure.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3447": {"data": {"text": "Although a causal relationship between the use of an anthraquinone-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained renal failure.", "entity1": "anthraquinone", "entity2": "renal failure", "span1": [53, 66], "span2": [241, 254]}, "bert_text": "Although a causal relationship between the use of an <e1> anthraquinone </e1>-containing herbal agent and renal injury remains to be proven, phytotherapy-associated interstitial nephropathy should be considered in patients who present with unexplained <e2> renal failure </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3448": {"data": {"text": "RESULTS: Among 167 methadone maintenance patients, the prevalence of QTc prolongation to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects.", "entity1": "methadone", "entity2": "QTc prolongation", "span1": [19, 28], "span2": [69, 85]}, "bert_text": "RESULTS: Among 167 <e1> methadone </e1> maintenance patients, the prevalence of <e2> QTc prolongation </e2> to 0.50 second((1/2)) or longer was 16.2% compared with 0% in 80 control subjects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3449": {"data": {"text": "OBJECTIVE: To review the natural history and ocular and systemic adverse effects of patients taking hydroxychloroquine sulfate who attended an ophthalmic screening program.", "entity1": "hydroxychloroquine", "entity2": "ocular", "span1": [100, 118], "span2": [45, 51]}, "bert_text": "OBJECTIVE: To review the natural history and ocular and systemic adverse effects of patients taking <e1> hydroxychloroquine </e1> <e2> ocular </e2> and systemic adverse effects of patients taking hydroxychloroquine sulfate who attended an ophthalmic screening program.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3450": {"data": {"text": "Serotonin reuptake inhibitors, paranoia, and the ventral basal ganglia.\n", "entity1": "Serotonin", "entity2": "paranoia", "span1": [0, 9], "span2": [31, 39]}, "bert_text": "<e1> Serotonin </e1> reuptake inhibitors, <e2> paranoia </e2>, and the ventral basal ganglia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3451": {"data": {"text": "Antidepressants have previously been associated with paranoid reactions in psychiatric patients.", "entity1": "Antidepressants", "entity2": "psychiatric", "span1": [0, 15], "span2": [75, 86]}, "bert_text": "<e1> Antidepressants </e1> have previously been associated with paranoid reactions in <e2> psychiatric </e2> patients.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3452": {"data": {"text": "Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients.\n", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [59, 67], "span2": [87, 106]}, "bert_text": "Association of common genetic variants of HOMER1 gene with <e1> levodopa </e1> adverse effects in <e2> Parkinson's disease </e2> patients.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3453": {"data": {"text": "SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.", "entity1": "SRL", "entity2": "proteinuria", "span1": [0, 3], "span2": [27, 38]}, "bert_text": "<e1> SRL </e1>-treated rats presented <e2> proteinuria </e2> and NGAL (serum and urinary) as the best markers of renal impairment.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3454": {"data": {"text": "SRL-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of renal impairment.", "entity1": "SRL", "entity2": "renal impairment", "span1": [0, 3], "span2": [91, 107]}, "bert_text": "<e1> SRL </e1>-treated rats presented proteinuria and NGAL (serum and urinary) as the best markers of <e2> renal impairment </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3455": {"data": {"text": "Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.", "entity1": "Losartan", "entity2": "nephropathy", "span1": [0, 8], "span2": [70, 81]}, "bert_text": "<e1> Losartan </e1> reduced uraemia and increased urea clearance in advanced ADR <e2> nephropathy </e2> in SHR.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3456": {"data": {"text": "Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.", "entity1": "urea", "entity2": "nephropathy", "span1": [39, 43], "span2": [70, 81]}, "bert_text": "Losartan reduced uraemia and increased <e1> urea </e1> clearance in advanced ADR <e2> nephropathy </e2> in SHR.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3457": {"data": {"text": "Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR.", "entity1": "ADR", "entity2": "nephropathy", "span1": [66, 69], "span2": [70, 81]}, "bert_text": "Losartan reduced uraemia and increased urea clearance in advanced <e1> ADR </e1> <e2> nephropathy </e2> in SHR.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3458": {"data": {"text": "Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.", "entity1": "Mefenamic acid", "entity2": "seizures", "span1": [0, 14], "span2": [44, 52]}, "bert_text": "<e1> Mefenamic acid </e1>, 26 (22-30) mg/kg, prevented <e2> seizures </e2> and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3459": {"data": {"text": "Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.", "entity1": "Mefenamic acid", "entity2": "seizure", "span1": [0, 14], "span2": [77, 84]}, "bert_text": "<e1> Mefenamic acid </e1>, 26 (22-30) mg/kg, prevented seizures and protected rats from <e2> seizure </e2>-related brain damage induced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3460": {"data": {"text": "Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.", "entity1": "Mefenamic acid", "entity2": "brain damage", "span1": [0, 14], "span2": [93, 105]}, "bert_text": "<e1> Mefenamic acid </e1>, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related <e2> brain damage </e2> induced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3461": {"data": {"text": "Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [117, 128], "span2": [44, 52]}, "bert_text": "Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by <e1> pilocarpine </e1> <e2> seizures </e2> and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3462": {"data": {"text": "Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.", "entity1": "pilocarpine", "entity2": "seizure", "span1": [117, 128], "span2": [77, 84]}, "bert_text": "Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by <e1> pilocarpine </e1> <e2> seizure </e2>-related brain damage induced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3463": {"data": {"text": "Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by pilocarpine, 380 mg/kg.", "entity1": "pilocarpine", "entity2": "brain damage", "span1": [117, 128], "span2": [93, 105]}, "bert_text": "Mefenamic acid, 26 (22-30) mg/kg, prevented seizures and protected rats from seizure-related brain damage induced by <e1> pilocarpine </e1> <e2> brain damage </e2> induced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3464": {"data": {"text": "BACKGROUND: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH).", "entity1": "appetite suppressants", "entity2": "primary pulmonary hypertension", "span1": [23, 44], "span2": [99, 129]}, "bert_text": "BACKGROUND: The use of <e1> appetite suppressants </e1> in Europe has been associated with the development of <e2> primary pulmonary hypertension </e2> (PPH).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3465": {"data": {"text": "BACKGROUND: The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension (PPH).", "entity1": "appetite suppressants", "entity2": "PPH", "span1": [23, 44], "span2": [131, 134]}, "bert_text": "BACKGROUND: The use of <e1> appetite suppressants </e1> in Europe has been associated with the development of primary pulmonary hypertension (<e2> PPH </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3466": {"data": {"text": "Haloperidol failed to prevent amphetamine-induced seizures, but did lower the mortality rate at most doses tested.", "entity1": "Haloperidol", "entity2": "seizures", "span1": [0, 11], "span2": [50, 58]}, "bert_text": "<e1> Haloperidol </e1> failed to prevent amphetamine-induced <e2> seizures </e2>, but did lower the mortality rate at most doses tested.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3467": {"data": {"text": "Haloperidol failed to prevent amphetamine-induced seizures, but did lower the mortality rate at most doses tested.", "entity1": "amphetamine", "entity2": "seizures", "span1": [30, 41], "span2": [50, 58]}, "bert_text": "Haloperidol failed to prevent <e1> amphetamine </e1>-induced <e2> seizures </e2>, but did lower the mortality rate at most doses tested.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3468": {"data": {"text": "Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension.", "entity1": "nitrendipine", "entity2": "hypertension", "span1": [41, 53], "span2": [175, 187]}, "bert_text": "Once or twice daily dosage possible with <e1> nitrendipine </e1> and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3469": {"data": {"text": "Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule, which encourages patient compliance in long-term therapy of hypertension.", "entity1": "nisoldipine", "entity2": "hypertension", "span1": [58, 69], "span2": [175, 187]}, "bert_text": "Once or twice daily dosage possible with nitrendipine and <e1> nisoldipine </e1> offers a convenient administration schedule, which encourages patient compliance in long-term therapy of <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3470": {"data": {"text": "Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.\n", "entity1": "ibuprofen", "entity2": "Pulmonary hypertension", "span1": [29, 38], "span2": [0, 22]}, "bert_text": "Pulmonary hypertension after <e1> ibuprofen </e1> <e2> Pulmonary hypertension </e2> after ibuprofen prophylaxis in very preterm infants.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3471": {"data": {"text": "The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.\n", "entity1": "Vigabatrin", "entity2": "visual field defects", "span1": [23, 33], "span2": [45, 65]}, "bert_text": "The natural history of <e1> Vigabatrin </e1> associated <e2> visual field defects </e2> in patients electing to continue their medication.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3472": {"data": {"text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.", "entity1": "fentanyl", "entity2": "myoclonus", "span1": [94, 102], "span2": [188, 197]}, "bert_text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of <e1> fentanyl </e1>, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3473": {"data": {"text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.", "entity1": "fentanyl", "entity2": "myoclonus", "span1": [136, 144], "span2": [188, 197]}, "bert_text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of <e1> fentanyl </e1> and midazolam to prevent etomidate-induced <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3474": {"data": {"text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.", "entity1": "midazolam", "entity2": "myoclonus", "span1": [104, 113], "span2": [188, 197]}, "bert_text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, <e1> midazolam </e1>, and a combination of fentanyl and midazolam to prevent etomidate-induced <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3475": {"data": {"text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.", "entity1": "midazolam", "entity2": "myoclonus", "span1": [149, 158], "span2": [188, 197]}, "bert_text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and <e1> midazolam </e1> to prevent etomidate-induced <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3476": {"data": {"text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus.", "entity1": "etomidate", "entity2": "myoclonus", "span1": [170, 179], "span2": [188, 197]}, "bert_text": "BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent <e1> etomidate </e1>-induced <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3477": {"data": {"text": "Scopolamine, but not methyl scopolamine (1 and 3 mg/kg), induced an amnesia as measured by latency and duration parameters.", "entity1": "Scopolamine", "entity2": "amnesia", "span1": [0, 11], "span2": [68, 75]}, "bert_text": "<e1> Scopolamine </e1>, but not methyl scopolamine (1 and 3 mg/kg), induced an <e2> amnesia </e2> as measured by latency and duration parameters.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3478": {"data": {"text": "Scopolamine, but not methyl scopolamine (1 and 3 mg/kg), induced an amnesia as measured by latency and duration parameters.", "entity1": "methyl scopolamine", "entity2": "amnesia", "span1": [21, 39], "span2": [68, 75]}, "bert_text": "Scopolamine, but not <e1> methyl scopolamine </e1> (1 and 3 mg/kg), induced an <e2> amnesia </e2> as measured by latency and duration parameters.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3479": {"data": {"text": "Skin rash is a well-known complication of diphenylhydantoin treatment as is benign and malignant lymphadenopathy.", "entity1": "diphenylhydantoin", "entity2": "Skin rash", "span1": [42, 59], "span2": [0, 9]}, "bert_text": "Skin rash is a well-known complication of <e1> diphenylhydantoin </e1> <e2> Skin rash </e2> is a well-known complication of diphenylhydantoin treatment as is benign and malignant lymphadenopathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3480": {"data": {"text": "Skin rash is a well-known complication of diphenylhydantoin treatment as is benign and malignant lymphadenopathy.", "entity1": "diphenylhydantoin", "entity2": "malignant lymphadenopathy", "span1": [42, 59], "span2": [87, 112]}, "bert_text": "Skin rash is a well-known complication of <e1> diphenylhydantoin </e1> treatment as is benign and <e2> malignant lymphadenopathy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3481": {"data": {"text": "The effect of recombinant human insulin-like growth factor-I on chronic puromycin aminonucleoside nephropathy in rats.\n", "entity1": "puromycin aminonucleoside", "entity2": "nephropathy", "span1": [72, 97], "span2": [98, 109]}, "bert_text": "The effect of recombinant human insulin-like growth factor-I on chronic <e1> puromycin aminonucleoside </e1> <e2> nephropathy </e2> in rats.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3482": {"data": {"text": "Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic bladder irritation.\n", "entity1": "nitric oxide", "entity2": "bladder irritation", "span1": [33, 45], "span2": [102, 120]}, "bert_text": "Increased expression of neuronal <e1> nitric oxide </e1> synthase in bladder afferent pathways following chronic <e2> bladder irritation </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3483": {"data": {"text": "CONCLUSION: We observed that DHEA reduced locomotor activity and increased catalepsy at both doses, while it had no effect on climbing behavior.", "entity1": "DHEA", "entity2": "catalepsy", "span1": [29, 33], "span2": [75, 84]}, "bert_text": "CONCLUSION: We observed that <e1> DHEA </e1> reduced locomotor activity and increased <e2> catalepsy </e2> at both doses, while it had no effect on climbing behavior.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3484": {"data": {"text": "Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria.(ABSTRACT TRUNCATED AT 250 WORDS)", "entity1": "creatine", "entity2": "Myositis", "span1": [148, 156], "span2": [0, 8]}, "bert_text": "Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high <e1> creatine </e1> <e2> Myositis </e2>, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria.(ABSTRACT TRUNCATED AT 250 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3485": {"data": {"text": "Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria.(ABSTRACT TRUNCATED AT 250 WORDS)", "entity1": "creatine", "entity2": "rhabdomyolysis", "span1": [148, 156], "span2": [202, 216]}, "bert_text": "Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high <e1> creatine </e1> phosphokinase (769 U/liter); no patients had <e2> rhabdomyolysis </e2> or myoglobinuria.(ABSTRACT TRUNCATED AT 250 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1], "label": 0},
+	"3486": {"data": {"text": "Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high creatine phosphokinase (769 U/liter); no patients had rhabdomyolysis or myoglobinuria.(ABSTRACT TRUNCATED AT 250 WORDS)", "entity1": "creatine", "entity2": "myoglobinuria.(ABSTRACT", "span1": [148, 156], "span2": [220, 243]}, "bert_text": "Myositis, attributable to the drug combination and symptomatic enough to discontinue it, occurred in 3% of patients, and in 1% with concurrent high <e1> creatine </e1> phosphokinase (769 U/liter); no patients had rhabdomyolysis or <e2> myoglobinuria.(ABSTRACT </e2> TRUNCATED AT 250 WORDS)", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3487": {"data": {"text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.", "entity1": "carvedilol", "entity2": "mitochondrial dysfunction", "span1": [40, 50], "span2": [190, 215]}, "bert_text": "It is concluded that this protection by <e1> carvedilol </e1> against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting <e2> mitochondrial dysfunction </e2> and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3488": {"data": {"text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.", "entity1": "carvedilol", "entity2": "cardiomyopathy", "span1": [40, 50], "span2": [220, 234]}, "bert_text": "It is concluded that this protection by <e1> carvedilol </e1> against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and <e2> cardiomyopathy </e2> that accompanies long-term doxorubicin therapy in cancer patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3489": {"data": {"text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.", "entity1": "carvedilol", "entity2": "cancer", "span1": [40, 50], "span2": [285, 291]}, "bert_text": "It is concluded that this protection by <e1> carvedilol </e1> against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in <e2> cancer </e2> patients.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3490": {"data": {"text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.", "entity1": "doxorubicin", "entity2": "mitochondrial dysfunction", "span1": [262, 273], "span2": [190, 215]}, "bert_text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term <e1> doxorubicin </e1> <e2> mitochondrial dysfunction </e2> and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3491": {"data": {"text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [262, 273], "span2": [220, 234]}, "bert_text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term <e1> doxorubicin </e1> <e2> cardiomyopathy </e2> that accompanies long-term doxorubicin therapy in cancer patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3492": {"data": {"text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term doxorubicin therapy in cancer patients.", "entity1": "doxorubicin", "entity2": "cancer", "span1": [262, 273], "span2": [285, 291]}, "bert_text": "It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose-limiting mitochondrial dysfunction and cardiomyopathy that accompanies long-term <e1> doxorubicin </e1> therapy in <e2> cancer </e2> patients.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3493": {"data": {"text": "Reported herein is an autopsy case of valvular heart disease, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with amiodarone for a long time.", "entity1": "amiodarone", "entity2": "valvular heart disease", "span1": [172, 182], "span2": [38, 60]}, "bert_text": "Reported herein is an autopsy case of valvular heart disease, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with <e1> amiodarone </e1> <e2> valvular heart disease </e2>, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with amiodarone for a long time.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3494": {"data": {"text": "Reported herein is an autopsy case of valvular heart disease, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with amiodarone for a long time.", "entity1": "amiodarone", "entity2": "proteinuria", "span1": [172, 182], "span2": [126, 137]}, "bert_text": "Reported herein is an autopsy case of valvular heart disease, in a patient who developed a lung mass (1.5 cm in diameter) and proteinuria (2.76 g/day) after treatment with <e1> amiodarone </e1> <e2> proteinuria </e2> (2.76 g/day) after treatment with amiodarone for a long time.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3495": {"data": {"text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.", "entity1": "clonidine", "entity2": "cataleptic", "span1": [14, 23], "span2": [132, 142]}, "bert_text": "The effect of <e1> clonidine </e1>, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on <e2> cataleptic </e2> effect of morphine, codine and fentanyl was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3496": {"data": {"text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.", "entity1": "naphazoline", "entity2": "cataleptic", "span1": [25, 36], "span2": [132, 142]}, "bert_text": "The effect of clonidine, <e1> naphazoline </e1> and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on <e2> cataleptic </e2> effect of morphine, codine and fentanyl was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3497": {"data": {"text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.", "entity1": "xylometazoline", "entity2": "cataleptic", "span1": [41, 55], "span2": [132, 142]}, "bert_text": "The effect of clonidine, naphazoline and <e1> xylometazoline </e1> on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on <e2> cataleptic </e2> effect of morphine, codine and fentanyl was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3498": {"data": {"text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.", "entity1": "morphine", "entity2": "cataleptic", "span1": [80, 88], "span2": [132, 142]}, "bert_text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by <e1> morphine </e1>, codeine, fentanyl and pentazocine, and on <e2> cataleptic </e2> effect of morphine, codine and fentanyl was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3499": {"data": {"text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.", "entity1": "morphine", "entity2": "cataleptic", "span1": [153, 161], "span2": [132, 142]}, "bert_text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of <e1> morphine </e1> <e2> cataleptic </e2> effect of morphine, codine and fentanyl was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3500": {"data": {"text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.", "entity1": "codeine", "entity2": "cataleptic", "span1": [90, 97], "span2": [132, 142]}, "bert_text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, <e1> codeine </e1>, fentanyl and pentazocine, and on <e2> cataleptic </e2> effect of morphine, codine and fentanyl was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3501": {"data": {"text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.", "entity1": "fentanyl", "entity2": "cataleptic", "span1": [99, 107], "span2": [132, 142]}, "bert_text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, <e1> fentanyl </e1> and pentazocine, and on <e2> cataleptic </e2> effect of morphine, codine and fentanyl was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3502": {"data": {"text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.", "entity1": "fentanyl", "entity2": "cataleptic", "span1": [174, 182], "span2": [132, 142]}, "bert_text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and <e1> fentanyl </e1> <e2> cataleptic </e2> effect of morphine, codine and fentanyl was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3503": {"data": {"text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and pentazocine, and on cataleptic effect of morphine, codine and fentanyl was studied in rats.", "entity1": "pentazocine", "entity2": "cataleptic", "span1": [112, 123], "span2": [132, 142]}, "bert_text": "The effect of clonidine, naphazoline and xylometazoline on analgesia induced by morphine, codeine, fentanyl and <e1> pentazocine </e1>, and on <e2> cataleptic </e2> effect of morphine, codine and fentanyl was studied in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3504": {"data": {"text": "A frequently fatal, although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic (hypersensitivity) myocarditis.", "entity1": "carbamazepine", "entity2": "hypersensitivity", "span1": [63, 76], "span2": [106, 122]}, "bert_text": "A frequently fatal, although exceptionally rare side effect of <e1> carbamazepine </e1> is necrotizing eosinophilic (<e2> hypersensitivity </e2>) myocarditis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3505": {"data": {"text": "A frequently fatal, although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic (hypersensitivity) myocarditis.", "entity1": "carbamazepine", "entity2": "myocarditis", "span1": [63, 76], "span2": [124, 135]}, "bert_text": "A frequently fatal, although exceptionally rare side effect of <e1> carbamazepine </e1> is necrotizing eosinophilic (hypersensitivity) <e2> myocarditis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3506": {"data": {"text": "Microinjections of gamma-vinyl-GABA, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by pilocarpine, 380 mg/kg.", "entity1": "gamma-vinyl", "entity2": "convulsions", "span1": [19, 30], "span2": [127, 138]}, "bert_text": "Microinjections of <e1> gamma-vinyl </e1>-GABA, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of <e2> convulsions </e2> produced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3507": {"data": {"text": "Microinjections of gamma-vinyl-GABA, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by pilocarpine, 380 mg/kg.", "entity1": "GABA", "entity2": "convulsions", "span1": [31, 35], "span2": [127, 138]}, "bert_text": "Microinjections of gamma-vinyl-<e1> GABA </e1>, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of <e2> convulsions </e2> produced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3508": {"data": {"text": "Microinjections of gamma-vinyl-GABA, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by pilocarpine, 380 mg/kg.", "entity1": "pilocarpine", "entity2": "convulsions", "span1": [151, 162], "span2": [127, 138]}, "bert_text": "Microinjections of gamma-vinyl-GABA, 5 micrograms, into the dorsal striatum, bilaterally, failed to prevent the development of convulsions produced by <e1> pilocarpine </e1> <e2> convulsions </e2> produced by pilocarpine, 380 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3509": {"data": {"text": "During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased. Recoveries of heart rate and left ventricular end-diastolic pressure were not shown within 60 min after SNP had been stopped.", "entity1": "SNP", "entity2": "hypotension", "span1": [31, 34], "span2": [7, 18]}, "bert_text": "During hypotension produced by <e1> SNP </e1> <e2> hypotension </e2> produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased. Recoveries of heart rate and left ventricular end-diastolic pressure were not shown within 60 min after SNP had been stopped.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3510": {"data": {"text": "During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased. Recoveries of heart rate and left ventricular end-diastolic pressure were not shown within 60 min after SNP had been stopped.", "entity1": "SNP", "entity2": "hypotension", "span1": [605, 608], "span2": [7, 18]}, "bert_text": "During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased. Recoveries of heart rate and left ventricular end-diastolic pressure were not shown within 60 min after <e1> SNP </e1> <e2> hypotension </e2> produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased. Recoveries of heart rate and left ventricular end-diastolic pressure were not shown within 60 min after SNP had been stopped.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3511": {"data": {"text": "During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased. Recoveries of heart rate and left ventricular end-diastolic pressure were not shown within 60 min after SNP had been stopped.", "entity1": "oxygen", "entity2": "hypotension", "span1": [324, 330], "span2": [7, 18]}, "bert_text": "During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and <e1> oxygen </e1> <e2> hypotension </e2> produced by SNP similar decreases were observed in mean pulmonary arterial pressure (p less than 0.01), central venous pressure (p less than 0.001), left ventricular end-diastolic pressure (p less than 0.01), total peripheral resistance (p less than 0.001), rate pressure product (p less than 0.001), and oxygen content difference between arterial and mixed venous blood (p less than 0.05), while heart rate (p less than 0.001) and cardiac output (p less than 0.05) were increased. Recoveries of heart rate and left ventricular end-diastolic pressure were not shown within 60 min after SNP had been stopped.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3512": {"data": {"text": "CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after pilocarpine-induced SE.", "entity1": "CCL2", "entity2": "SE", "span1": [40, 44], "span2": [107, 109]}, "bert_text": "CONCLUSION: The data show that CCR2 and <e1> CCL2 </e1> are up-regulated in the hippocampus after pilocarpine-induced <e2> SE </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3513": {"data": {"text": "CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after pilocarpine-induced SE.", "entity1": "pilocarpine", "entity2": "SE", "span1": [87, 98], "span2": [107, 109]}, "bert_text": "CONCLUSION: The data show that CCR2 and CCL2 are up-regulated in the hippocampus after <e1> pilocarpine </e1>-induced <e2> SE </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3514": {"data": {"text": "Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats.\n", "entity1": "Streptozotocin", "entity2": "neurotoxicity", "span1": [68, 82], "span2": [35, 48]}, "bert_text": "Glial activation and post-synaptic neurotoxicity: the key events in <e1> Streptozotocin </e1> <e2> neurotoxicity </e2>: the key events in Streptozotocin (ICV) induced memory impairment in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3515": {"data": {"text": "Glial activation and post-synaptic neurotoxicity: the key events in Streptozotocin (ICV) induced memory impairment in rats.\n", "entity1": "Streptozotocin", "entity2": "memory impairment", "span1": [68, 82], "span2": [97, 114]}, "bert_text": "Glial activation and post-synaptic neurotoxicity: the key events in <e1> Streptozotocin </e1> (ICV) induced <e2> memory impairment </e2> in rats.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3516": {"data": {"text": "Cluster analysis showed a random distribution of lesions in the PAN glomeruli in concordance with the random localization of mesangial areas with dysfunction in this model.", "entity1": "PAN", "entity2": "dysfunction", "span1": [64, 67], "span2": [146, 157]}, "bert_text": "Cluster analysis showed a random distribution of lesions in the <e1> PAN </e1> glomeruli in concordance with the random localization of mesangial areas with <e2> dysfunction </e2> in this model.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3517": {"data": {"text": "Quantitative, real-time polymerase chain reaction also demonstrated significant increases (P < or = 0.01) in p75(NTR) mRNA in DRG with intermediate and chronic CYP-induced cystitis.", "entity1": "CYP", "entity2": "cystitis", "span1": [160, 163], "span2": [172, 180]}, "bert_text": "Quantitative, real-time polymerase chain reaction also demonstrated significant increases (P < or = 0.01) in p75(NTR) mRNA in DRG with intermediate and chronic <e1> CYP </e1>-induced <e2> cystitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3518": {"data": {"text": "CYP-induced cystitis increased (P < or = 0.001) p75(NTR) expression in the superficial lateral and medial dorsal horn in L1-L2 and L6-S1 spinal segments.", "entity1": "CYP", "entity2": "cystitis", "span1": [0, 3], "span2": [12, 20]}, "bert_text": "<e1> CYP </e1>-induced <e2> cystitis </e2> increased (P < or = 0.001) p75(NTR) expression in the superficial lateral and medial dorsal horn in L1-L2 and L6-S1 spinal segments.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3519": {"data": {"text": "CONCLUSIONS: GLS combined with cTnT may provide a reliable and non-invasive method to predict cardiac dysfunction in patients receiving anthracycline-based chemotherapy.", "entity1": "anthracycline", "entity2": "cardiac dysfunction", "span1": [136, 149], "span2": [94, 113]}, "bert_text": "CONCLUSIONS: GLS combined with cTnT may provide a reliable and non-invasive method to predict cardiac dysfunction in patients receiving <e1> anthracycline </e1> <e2> cardiac dysfunction </e2> in patients receiving anthracycline-based chemotherapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3520": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "lidocaine", "entity2": "MI", "span1": [39, 48], "span2": [86, 88]}, "bert_text": ". RESULTS: Of 29 patients who received <e1> lidocaine </e1> in the setting of cocaine-associated <e2> MI </e2>, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3521": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "lidocaine", "entity2": "ventricular tachycardia", "span1": [39, 48], "span2": [136, 159]}, "bert_text": ". RESULTS: Of 29 patients who received <e1> lidocaine </e1> in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, <e2> ventricular tachycardia </e2>, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3522": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "lidocaine", "entity2": "ventricular fibrillation", "span1": [39, 48], "span2": [164, 188]}, "bert_text": ". RESULTS: Of 29 patients who received <e1> lidocaine </e1> in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or <e2> ventricular fibrillation </e2>; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3523": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "lidocaine", "entity2": "seizures", "span1": [39, 48], "span2": [205, 213]}, "bert_text": ". RESULTS: Of 29 patients who received <e1> lidocaine </e1> in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced <e2> seizures </e2> after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3524": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "lidocaine", "entity2": "MI", "span1": [238, 247], "span2": [86, 88]}, "bert_text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of <e1> lidocaine </e1> <e2> MI </e2>, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3525": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "lidocaine", "entity2": "ventricular tachycardia", "span1": [238, 247], "span2": [136, 159]}, "bert_text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of <e1> lidocaine </e1> <e2> ventricular tachycardia </e2>, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3526": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "lidocaine", "entity2": "ventricular fibrillation", "span1": [238, 247], "span2": [164, 188]}, "bert_text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of <e1> lidocaine </e1> <e2> ventricular fibrillation </e2>; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3527": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "lidocaine", "entity2": "seizures", "span1": [238, 247], "span2": [205, 213]}, "bert_text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of <e1> lidocaine </e1> <e2> seizures </e2> after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3528": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "cocaine", "entity2": "MI", "span1": [67, 74], "span2": [86, 88]}, "bert_text": ". RESULTS: Of 29 patients who received lidocaine in the setting of <e1> cocaine </e1>-associated <e2> MI </e2>, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3529": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "cocaine", "entity2": "ventricular tachycardia", "span1": [67, 74], "span2": [136, 159]}, "bert_text": ". RESULTS: Of 29 patients who received lidocaine in the setting of <e1> cocaine </e1>-associated MI, no patient died; exhibited bradydysrhythmias, <e2> ventricular tachycardia </e2>, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3530": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "cocaine", "entity2": "ventricular fibrillation", "span1": [67, 74], "span2": [164, 188]}, "bert_text": ". RESULTS: Of 29 patients who received lidocaine in the setting of <e1> cocaine </e1>-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or <e2> ventricular fibrillation </e2>; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3531": {"data": {"text": ". RESULTS: Of 29 patients who received lidocaine in the setting of cocaine-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced seizures after administration of lidocaine (95% confidence interval, 0% to 11%).", "entity1": "cocaine", "entity2": "seizures", "span1": [67, 74], "span2": [205, 213]}, "bert_text": ". RESULTS: Of 29 patients who received lidocaine in the setting of <e1> cocaine </e1>-associated MI, no patient died; exhibited bradydysrhythmias, ventricular tachycardia, or ventricular fibrillation; or experienced <e2> seizures </e2> after administration of lidocaine (95% confidence interval, 0% to 11%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3532": {"data": {"text": "P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.\n", "entity1": "anthracycline", "entity2": "cardiotoxicity", "span1": [38, 51], "span2": [52, 66]}, "bert_text": "P53 inhibition exacerbates late-stage <e1> anthracycline </e1> <e2> cardiotoxicity </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3533": {"data": {"text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\"", "entity1": "EACA", "entity2": "thrombi", "span1": [95, 99], "span2": [27, 34]}, "bert_text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, <e1> EACA </e1> <e2> thrombi </e2> are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\"", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3534": {"data": {"text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\"", "entity1": "EACA", "entity2": "thrombi", "span1": [95, 99], "span2": [155, 162]}, "bert_text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, <e1> EACA </e1> should not be implicated in the pathogenesis of fibrin <e2> thrombi </e2> in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\"", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3535": {"data": {"text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\"", "entity1": "EACA", "entity2": "fibrinolytic disorders", "span1": [95, 99], "span2": [71, 93]}, "bert_text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, <e1> EACA </e1> <e2> fibrinolytic disorders </e2>, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\"", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3536": {"data": {"text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\"", "entity1": "EACA", "entity2": "intravascular coagulation", "span1": [95, 99], "span2": [193, 218]}, "bert_text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, <e1> EACA </e1> should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated <e2> intravascular coagulation </e2> or other \"consumption coagulopathies.\"", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3537": {"data": {"text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption coagulopathies.\"", "entity1": "EACA", "entity2": "coagulopathies", "span1": [95, 99], "span2": [241, 255]}, "bert_text": "Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders, <e1> EACA </e1> should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \"consumption <e2> coagulopathies </e2>.\"", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3538": {"data": {"text": "Factors associated with the development of fulminant hepatic failure were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001).", "entity1": "bilirubin", "entity2": "fulminant hepatic failure", "span1": [211, 220], "span2": [43, 68]}, "bert_text": "Factors associated with the development of fulminant hepatic failure were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma <e1> bilirubin </e1> <e2> fulminant hepatic failure </e2> were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3539": {"data": {"text": "Factors associated with the development of fulminant hepatic failure were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001).", "entity1": "bilirubin", "entity2": "hepatocellular damage", "span1": [211, 220], "span2": [124, 145]}, "bert_text": "Factors associated with the development of fulminant hepatic failure were female sex (OR = 25; 95% CI: 4.1-151; P < .0001), hepatocellular damage (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma <e1> bilirubin </e1> <e2> hepatocellular damage </e2> (OR = 7.9; 95% CI: 1.6-37; P < .009), and higher baseline plasma bilirubin value (OR = 1.15; 95% CI: 1.09-1.22; P < .0001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3540": {"data": {"text": "Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy.\n", "entity1": "Heparin", "entity2": "thrombocytopenia", "span1": [0, 7], "span2": [16, 32]}, "bert_text": "<e1> Heparin </e1>-induced <e2> thrombocytopenia </e2>, paradoxical thromboembolism, and other side effects of heparin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3541": {"data": {"text": "Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy.\n", "entity1": "Heparin", "entity2": "thromboembolism", "span1": [0, 7], "span2": [46, 61]}, "bert_text": "<e1> Heparin </e1>-induced thrombocytopenia, paradoxical <e2> thromboembolism </e2>, and other side effects of heparin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3542": {"data": {"text": "Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [89, 96], "span2": [16, 32]}, "bert_text": "Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of <e1> heparin </e1> <e2> thrombocytopenia </e2>, paradoxical thromboembolism, and other side effects of heparin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3543": {"data": {"text": "Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy.\n", "entity1": "heparin", "entity2": "thromboembolism", "span1": [89, 96], "span2": [46, 61]}, "bert_text": "Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of <e1> heparin </e1> <e2> thromboembolism </e2>, and other side effects of heparin therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3544": {"data": {"text": "Intraperitoneal injection of pilocarpine (400 mg/kg) induced tonic and clonic seizure.", "entity1": "pilocarpine", "entity2": "clonic seizure", "span1": [29, 40], "span2": [71, 85]}, "bert_text": "Intraperitoneal injection of <e1> pilocarpine </e1> (400 mg/kg) induced tonic and <e2> clonic seizure </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3545": {"data": {"text": "Pure red cell aplasia associated with diphenylhydantoin medication has been reported in 3 patients.", "entity1": "diphenylhydantoin", "entity2": "Pure red cell aplasia", "span1": [38, 55], "span2": [0, 21]}, "bert_text": "Pure red cell aplasia associated with <e1> diphenylhydantoin </e1> <e2> Pure red cell aplasia </e2> associated with diphenylhydantoin medication has been reported in 3 patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3546": {"data": {"text": "We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.", "entity1": "ibuprofen", "entity2": "hypoxaemia", "span1": [49, 58], "span2": [32, 42]}, "bert_text": "We report three cases of severe hypoxaemia after <e1> ibuprofen </e1> <e2> hypoxaemia </e2> after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3547": {"data": {"text": "We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.", "entity1": "ibuprofen", "entity2": "patent ductus arteriosus", "span1": [49, 58], "span2": [140, 164]}, "bert_text": "We report three cases of severe hypoxaemia after <e1> ibuprofen </e1> administration during a randomised controlled trial of prophylactic treatment of <e2> patent ductus arteriosus </e2> with ibuprofen in premature infants born at less than 28 weeks of gestation.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3548": {"data": {"text": "We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.", "entity1": "ibuprofen", "entity2": "hypoxaemia", "span1": [170, 179], "span2": [32, 42]}, "bert_text": "We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with <e1> ibuprofen </e1> <e2> hypoxaemia </e2> after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3549": {"data": {"text": "We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation.", "entity1": "ibuprofen", "entity2": "patent ductus arteriosus", "span1": [170, 179], "span2": [140, 164]}, "bert_text": "We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with <e1> ibuprofen </e1> <e2> patent ductus arteriosus </e2> with ibuprofen in premature infants born at less than 28 weeks of gestation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3550": {"data": {"text": "Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.", "entity1": "Flurothyl", "entity2": "hypothermia", "span1": [0, 9], "span2": [25, 36]}, "bert_text": "<e1> Flurothyl </e1> ether produced <e2> hypothermia </e2> which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3551": {"data": {"text": "Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.", "entity1": "Flurothyl", "entity2": "hypothermia", "span1": [0, 9], "span2": [128, 139]}, "bert_text": "<e1> Flurothyl </e1> ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of <e2> hypothermia </e2> to seizure induction was unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3552": {"data": {"text": "Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.", "entity1": "Flurothyl", "entity2": "seizure", "span1": [0, 9], "span2": [143, 150]}, "bert_text": "<e1> Flurothyl </e1> ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to <e2> seizure </e2> induction was unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3553": {"data": {"text": "Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.", "entity1": "flurothyl", "entity2": "hypothermia", "span1": [79, 88], "span2": [25, 36]}, "bert_text": "Flurothyl ether produced hypothermia which was correlated with the duration of <e1> flurothyl </e1> <e2> hypothermia </e2> which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3554": {"data": {"text": "Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.", "entity1": "flurothyl", "entity2": "hypothermia", "span1": [79, 88], "span2": [128, 139]}, "bert_text": "Flurothyl ether produced hypothermia which was correlated with the duration of <e1> flurothyl </e1> exposure; however, the relationship of <e2> hypothermia </e2> to seizure induction was unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3555": {"data": {"text": "Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure; however, the relationship of hypothermia to seizure induction was unclear.", "entity1": "flurothyl", "entity2": "seizure", "span1": [79, 88], "span2": [143, 150]}, "bert_text": "Flurothyl ether produced hypothermia which was correlated with the duration of <e1> flurothyl </e1> exposure; however, the relationship of hypothermia to <e2> seizure </e2> induction was unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3556": {"data": {"text": "CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.", "entity1": "doxorubicin", "entity2": "toxicity", "span1": [36, 47], "span2": [72, 80]}, "bert_text": "CONCLUSION: This modified liposomal <e1> doxorubicin </e1> regimen results in less <e2> toxicity </e2> (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3557": {"data": {"text": "CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.", "entity1": "doxorubicin", "entity2": "stomatitis", "span1": [36, 47], "span2": [82, 92]}, "bert_text": "CONCLUSION: This modified liposomal <e1> doxorubicin </e1> regimen results in less toxicity (<e2> stomatitis </e2>, hand-foot syndrome) than the standard FDA-approved dose schedule.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3558": {"data": {"text": "CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.", "entity1": "doxorubicin", "entity2": "hand-foot syndrome", "span1": [36, 47], "span2": [94, 112]}, "bert_text": "CONCLUSION: This modified liposomal <e1> doxorubicin </e1> regimen results in less toxicity (stomatitis, <e2> hand-foot syndrome </e2>) than the standard FDA-approved dose schedule.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3559": {"data": {"text": "CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.", "entity1": "FDA", "entity2": "toxicity", "span1": [132, 135], "span2": [72, 80]}, "bert_text": "CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard <e1> FDA </e1> <e2> toxicity </e2> (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3560": {"data": {"text": "CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.", "entity1": "FDA", "entity2": "stomatitis", "span1": [132, 135], "span2": [82, 92]}, "bert_text": "CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard <e1> FDA </e1> <e2> stomatitis </e2>, hand-foot syndrome) than the standard FDA-approved dose schedule.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3561": {"data": {"text": "CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard FDA-approved dose schedule.", "entity1": "FDA", "entity2": "hand-foot syndrome", "span1": [132, 135], "span2": [94, 112]}, "bert_text": "CONCLUSION: This modified liposomal doxorubicin regimen results in less toxicity (stomatitis, hand-foot syndrome) than the standard <e1> FDA </e1> <e2> hand-foot syndrome </e2>) than the standard FDA-approved dose schedule.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3562": {"data": {"text": "CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.", "entity1": "bupivacaine", "entity2": "pain", "span1": [40, 51], "span2": [158, 162]}, "bert_text": "CONCLUSIONS: These results suggest that <e1> bupivacaine </e1> stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and <e2> pain </e2> after the local anesthetic effect dissipates.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3563": {"data": {"text": "CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates.", "entity1": "PGE2", "entity2": "pain", "span1": [138, 142], "span2": [158, 162]}, "bert_text": "CONCLUSIONS: These results suggest that bupivacaine stimulates COX-2 gene expression after tissue injury, which is associated with higher <e1> PGE2 </e1> production and <e2> pain </e2> after the local anesthetic effect dissipates.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3564": {"data": {"text": "The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the neuropathy model (mg/kg; mean, SEM).", "entity1": "morphine", "entity2": "neuropathy", "span1": [20, 28], "span2": [183, 193]}, "bert_text": "The ED50 values for <e1> morphine </e1> when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the <e2> neuropathy </e2> model (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3565": {"data": {"text": "The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the neuropathy model (mg/kg; mean, SEM).", "entity1": "CNSB002", "entity2": "neuropathy", "span1": [60, 67], "span2": [183, 193]}, "bert_text": "The ED50 values for morphine when given in combination with <e1> CNSB002 </e1> (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the <e2> neuropathy </e2> model (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3566": {"data": {"text": "The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the carrageenan model and 1.37 (1.23) in the neuropathy model (mg/kg; mean, SEM).", "entity1": "carrageenan", "entity2": "neuropathy", "span1": [142, 153], "span2": [183, 193]}, "bert_text": "The ED50 values for morphine when given in combination with CNSB002 (5 mg/kg) were less than the maximum nonsedating dose: 0.56 (1.55) in the <e1> carrageenan </e1> model and 1.37 (1.23) in the <e2> neuropathy </e2> model (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"3567": {"data": {"text": "After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease.", "entity1": "CPA", "entity2": "coronary heart disease", "span1": [31, 34], "span2": [108, 130]}, "bert_text": "After a period of 2.5 years on <e1> CPA </e1> treatment, four patients out of twenty-four were found to be affected by <e2> coronary heart disease </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3568": {"data": {"text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "entity1": "Argatroban", "entity2": "thrombosis", "span1": [0, 10], "span2": [104, 114]}, "bert_text": "<e1> Argatroban </e1> is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of <e2> thrombosis </e2> in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3569": {"data": {"text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "entity1": "Argatroban", "entity2": "thrombocytopenia", "span1": [0, 10], "span2": [134, 150]}, "bert_text": "<e1> Argatroban </e1> is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced <e2> thrombocytopenia </e2> (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3570": {"data": {"text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "entity1": "Argatroban", "entity2": "HIT", "span1": [0, 10], "span2": [152, 155]}, "bert_text": "<e1> Argatroban </e1> is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (<e2> HIT </e2>) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3571": {"data": {"text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "entity1": "Argatroban", "entity2": "HIT", "span1": [0, 10], "span2": [193, 196]}, "bert_text": "<e1> Argatroban </e1> is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of <e2> HIT </e2> undergoing percutaneous coronary intervention (PCI).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3572": {"data": {"text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "entity1": "heparin", "entity2": "thrombosis", "span1": [118, 125], "span2": [104, 114]}, "bert_text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in <e1> heparin </e1> <e2> thrombosis </e2> in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"3573": {"data": {"text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [118, 125], "span2": [134, 150]}, "bert_text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3574": {"data": {"text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "entity1": "heparin", "entity2": "HIT", "span1": [118, 125], "span2": [152, 155]}, "bert_text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in <e1> heparin </e1>-induced thrombocytopenia (<e2> HIT </e2>) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3575": {"data": {"text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin-induced thrombocytopenia (HIT) and for patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI).", "entity1": "heparin", "entity2": "HIT", "span1": [118, 125], "span2": [193, 196]}, "bert_text": "Argatroban is a hepatically metabolized, direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in <e1> heparin </e1>-induced thrombocytopenia (HIT) and for patients with or at risk of <e2> HIT </e2> undergoing percutaneous coronary intervention (PCI).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3576": {"data": {"text": "Paclitaxel and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines.", "entity1": "Paclitaxel", "entity2": "cytotoxicity", "span1": [0, 10], "span2": [44, 56]}, "bert_text": "<e1> Paclitaxel </e1> and 5-fluorouracil have additive <e2> cytotoxicity </e2> in MCF-7 cell lines.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3577": {"data": {"text": "Paclitaxel and 5-fluorouracil have additive cytotoxicity in MCF-7 cell lines.", "entity1": "5-fluorouracil", "entity2": "cytotoxicity", "span1": [15, 29], "span2": [44, 56]}, "bert_text": "Paclitaxel and <e1> 5-fluorouracil </e1> have additive <e2> cytotoxicity </e2> in MCF-7 cell lines.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3578": {"data": {"text": "Examination of CCL2 expression showed that it was elevated in the hippocampus following SE.", "entity1": "CCL2", "entity2": "SE", "span1": [15, 19], "span2": [88, 90]}, "bert_text": "Examination of <e1> CCL2 </e1> expression showed that it was elevated in the hippocampus following <e2> SE </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3579": {"data": {"text": "Multivariate analysis showed that trough TAC level was the only independent risk factor associated with the seizures.", "entity1": "TAC", "entity2": "seizures", "span1": [41, 44], "span2": [108, 116]}, "bert_text": "Multivariate analysis showed that trough <e1> TAC </e1> level was the only independent risk factor associated with the <e2> seizures </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3580": {"data": {"text": "A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and spironolactone 100 mg/d.", "entity1": "verapamil", "entity2": "hyperaldosteronism", "span1": [61, 70], "span2": [25, 43]}, "bert_text": "A 54-year-old woman with hyperaldosteronism was treated with <e1> verapamil </e1> <e2> hyperaldosteronism </e2> was treated with verapamil 480 mg/d and spironolactone 100 mg/d.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3581": {"data": {"text": "A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and spironolactone 100 mg/d.", "entity1": "spironolactone", "entity2": "hyperaldosteronism", "span1": [84, 98], "span2": [25, 43]}, "bert_text": "A 54-year-old woman with hyperaldosteronism was treated with verapamil 480 mg/d and <e1> spironolactone </e1> <e2> hyperaldosteronism </e2> was treated with verapamil 480 mg/d and spironolactone 100 mg/d.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3582": {"data": {"text": "Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.\n", "entity1": "desferrioxamine", "entity2": "Acute renal failure", "span1": [49, 64], "span2": [0, 19]}, "bert_text": "Acute renal failure occurring during intravenous <e1> desferrioxamine </e1> <e2> Acute renal failure </e2> occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3583": {"data": {"text": "Serological evidence for Epstein Barr Virus infection was found in 20% of 65 cyclosporine patients studied.", "entity1": "cyclosporine", "entity2": "Epstein Barr Virus infection", "span1": [77, 89], "span2": [25, 53]}, "bert_text": "Serological evidence for Epstein Barr Virus infection was found in 20% of 65 <e1> cyclosporine </e1> <e2> Epstein Barr Virus infection </e2> was found in 20% of 65 cyclosporine patients studied.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3584": {"data": {"text": "BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias.", "entity1": "amiodarone", "entity2": "bradyarrhythmia", "span1": [53, 63], "span2": [30, 45]}, "bert_text": "BACKGROUND: Reports of severe bradyarrhythmia during <e1> amiodarone </e1> <e2> bradyarrhythmia </e2> during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3585": {"data": {"text": "BACKGROUND: Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with ventricular arrhythmias.", "entity1": "amiodarone", "entity2": "ventricular arrhythmias", "span1": [53, 63], "span2": [173, 196]}, "bert_text": "BACKGROUND: Reports of severe bradyarrhythmia during <e1> amiodarone </e1> therapy are infrequent and limited to studies assessing the therapy's use in the management of patients with <e2> ventricular arrhythmias </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3586": {"data": {"text": "These data show that CD-832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832.", "entity1": "ISO", "entity2": "myocardial ischemia", "span1": [64, 67], "span2": [37, 56]}, "bert_text": "These data show that CD-832 improves myocardial ischemia during <e1> ISO </e1> <e2> myocardial ischemia </e2> during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3587": {"data": {"text": "These data show that CD-832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832.", "entity1": "ISO", "entity2": "stenosis", "span1": [64, 67], "span2": [82, 90]}, "bert_text": "These data show that CD-832 improves myocardial ischemia during <e1> ISO </e1> infusion with <e2> stenosis </e2> and suggest that the negative chronotropic property of CD-832 plays a major role in the beneficial effects of CD-832.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3588": {"data": {"text": "High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed.", "entity1": "methotrexate", "entity2": "Burkitt lymphoma", "span1": [10, 22], "span2": [62, 78]}, "bert_text": "High-dose <e1> methotrexate </e1> (HD-MTX) is an important treatment for <e2> Burkitt lymphoma </e2>, but can cause hepatic and renal toxicity when its clearance is delayed.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3589": {"data": {"text": "High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed.", "entity1": "methotrexate", "entity2": "renal toxicity", "span1": [10, 22], "span2": [106, 120]}, "bert_text": "High-dose <e1> methotrexate </e1> (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and <e2> renal toxicity </e2> when its clearance is delayed.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3590": {"data": {"text": "High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed.", "entity1": "HD-MTX", "entity2": "Burkitt lymphoma", "span1": [24, 30], "span2": [62, 78]}, "bert_text": "High-dose methotrexate (<e1> HD-MTX </e1>) is an important treatment for <e2> Burkitt lymphoma </e2>, but can cause hepatic and renal toxicity when its clearance is delayed.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3591": {"data": {"text": "High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed.", "entity1": "HD-MTX", "entity2": "renal toxicity", "span1": [24, 30], "span2": [106, 120]}, "bert_text": "High-dose methotrexate (<e1> HD-MTX </e1>) is an important treatment for Burkitt lymphoma, but can cause hepatic and <e2> renal toxicity </e2> when its clearance is delayed.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3592": {"data": {"text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [122, 125], "span2": [51, 65]}, "bert_text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free <e1> DOX </e1> <e2> cardiotoxicity </e2> were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3593": {"data": {"text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [122, 125], "span2": [292, 306]}, "bert_text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free <e1> DOX </e1> or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3594": {"data": {"text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [168, 171], "span2": [51, 65]}, "bert_text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free <e1> DOX </e1> <e2> cardiotoxicity </e2> were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3595": {"data": {"text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [168, 171], "span2": [292, 306]}, "bert_text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free <e1> DOX </e1>; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3596": {"data": {"text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [280, 283], "span2": [51, 65]}, "bert_text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with <e1> DOX </e1> <e2> cardiotoxicity </e2> were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3597": {"data": {"text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [280, 283], "span2": [292, 306]}, "bert_text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with <e1> DOX </e1>-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3598": {"data": {"text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "entity1": "HPMA", "entity2": "cardiotoxicity", "span1": [144, 148], "span2": [51, 65]}, "bert_text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of <e1> HPMA </e1> <e2> cardiotoxicity </e2> were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3599": {"data": {"text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced cardiotoxicity.", "entity1": "HPMA", "entity2": "cardiotoxicity", "span1": [144, 148], "span2": [292, 306]}, "bert_text": "Throughout the study (20 weeks), deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of <e1> HPMA </e1> copolymer and free DOX; in these cases, histological investigations revealed marked changes in the heart that were consistent with DOX-induced <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3600": {"data": {"text": "Studies of human subjects who have used MA chronically have revealed deficits in dopaminergic and serotonergic systems and cerebral metabolic abnormalities.", "entity1": "MA", "entity2": "deficits", "span1": [40, 42], "span2": [69, 77]}, "bert_text": "Studies of human subjects who have used <e1> MA </e1> chronically have revealed <e2> deficits </e2> in dopaminergic and serotonergic systems and cerebral metabolic abnormalities.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3601": {"data": {"text": "Studies of human subjects who have used MA chronically have revealed deficits in dopaminergic and serotonergic systems and cerebral metabolic abnormalities.", "entity1": "MA", "entity2": "cerebral metabolic abnormalities", "span1": [40, 42], "span2": [123, 155]}, "bert_text": "Studies of human subjects who have used <e1> MA </e1> chronically have revealed deficits in dopaminergic and serotonergic systems and <e2> cerebral metabolic abnormalities </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3602": {"data": {"text": "D-Glucarates were effective against renal damage induced by peptide antibiotics as well as various aminoglycoside antibitocis.", "entity1": "aminoglycoside", "entity2": "renal damage", "span1": [99, 113], "span2": [36, 48]}, "bert_text": "D-Glucarates were effective against renal damage induced by peptide antibiotics as well as various <e1> aminoglycoside </e1> <e2> renal damage </e2> induced by peptide antibiotics as well as various aminoglycoside antibitocis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3603": {"data": {"text": "dl-Sotalol preferentially prolonged action potential duration (APD) in M cells dose-dependently (1 to 100 micromol/L), leading to QT prolongation and an increase in TDR.", "entity1": "Sotalol", "entity2": "QT prolongation", "span1": [3, 10], "span2": [130, 145]}, "bert_text": "dl-<e1> Sotalol </e1> preferentially prolonged action potential duration (APD) in M cells dose-dependently (1 to 100 micromol/L), leading to <e2> QT prolongation </e2> and an increase in TDR.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3604": {"data": {"text": "Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes", "entity1": "Bortezomib", "entity2": "myeloma", "span1": [0, 10], "span2": [94, 101]}, "bert_text": "<e1> Bortezomib </e1> and dexamethasone as salvage therapy in patients with relapsed/refractory multiple <e2> myeloma </e2>: analysis of long-term clinical outcomes", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3605": {"data": {"text": "Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes", "entity1": "dexamethasone", "entity2": "myeloma", "span1": [15, 28], "span2": [94, 101]}, "bert_text": "Bortezomib and <e1> dexamethasone </e1> as salvage therapy in patients with relapsed/refractory multiple <e2> myeloma </e2>: analysis of long-term clinical outcomes", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3606": {"data": {"text": "It evokes convulsions mainly trough the blockage of GABA(A) receptors.", "entity1": "GABA(A", "entity2": "convulsions", "span1": [52, 58], "span2": [10, 21]}, "bert_text": "It evokes convulsions mainly trough the blockage of <e1> GABA(A </e1> <e2> convulsions </e2> mainly trough the blockage of GABA(A) receptors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3607": {"data": {"text": "A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug.", "entity1": "cocaine", "entity2": "manic", "span1": [14, 21], "span2": [157, 162]}, "bert_text": "A 30-year-old <e1> cocaine </e1>-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became <e2> manic </e2> during his second week on the study drug.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3608": {"data": {"text": "A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug.", "entity1": "diethylpropion", "entity2": "manic", "span1": [129, 143], "span2": [157, 162]}, "bert_text": "A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication <e1> diethylpropion </e1> (DEP) became <e2> manic </e2> during his second week on the study drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3609": {"data": {"text": "A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (DEP) became manic during his second week on the study drug.", "entity1": "DEP", "entity2": "manic", "span1": [145, 148], "span2": [157, 162]}, "bert_text": "A 30-year-old cocaine-dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion (<e1> DEP </e1>) became <e2> manic </e2> during his second week on the study drug.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3610": {"data": {"text": "Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss.", "entity1": "PPARalpha-/-", "entity2": "weight loss", "span1": [41, 53], "span2": [130, 141]}, "bert_text": "Compared to wild-type mice, treatment of <e1> PPARalpha-/- </e1> mice with amiodarone resulted in an increased rate and extent of total body <e2> weight loss </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3611": {"data": {"text": "Compared to wild-type mice, treatment of PPARalpha-/- mice with amiodarone resulted in an increased rate and extent of total body weight loss.", "entity1": "amiodarone", "entity2": "weight loss", "span1": [64, 74], "span2": [130, 141]}, "bert_text": "Compared to wild-type mice, treatment of PPARalpha-/- mice with <e1> amiodarone </e1> resulted in an increased rate and extent of total body <e2> weight loss </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3612": {"data": {"text": "The lung mass was highly suspected to be lung cancer on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an amiodarone-related lesion.", "entity1": "amiodarone", "entity2": "lung cancer", "span1": [310, 320], "span2": [41, 52]}, "bert_text": "The lung mass was highly suspected to be lung cancer on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an <e1> amiodarone </e1> <e2> lung cancer </e2> on CT and positron emission tomography, but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra-alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies, indicating that it was an amiodarone-related lesion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3613": {"data": {"text": "However, a 38% remission rate has been recently reported in refractory MCL treated with temsirolimus, a mTOR inhibitor.", "entity1": "temsirolimus", "entity2": "MCL", "span1": [88, 100], "span2": [71, 74]}, "bert_text": "However, a 38% remission rate has been recently reported in refractory MCL treated with <e1> temsirolimus </e1> <e2> MCL </e2> treated with temsirolimus, a mTOR inhibitor.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3614": {"data": {"text": "The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with fluoxetine, are reported here.", "entity1": "fluoxetine", "entity2": "mania", "span1": [109, 119], "span2": [75, 80]}, "bert_text": "The cases of five depressed adolescents, 14-16 years of age, who developed mania during pharmacotherapy with <e1> fluoxetine </e1> <e2> mania </e2> during pharmacotherapy with fluoxetine, are reported here.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3615": {"data": {"text": "Severe nelarabine neurotoxicity in a patient who received concurrent intrathecal (IT) chemotherapy is reported.", "entity1": "nelarabine", "entity2": "neurotoxicity", "span1": [7, 17], "span2": [18, 31]}, "bert_text": "Severe <e1> nelarabine </e1> <e2> neurotoxicity </e2> in a patient who received concurrent intrathecal (IT) chemotherapy is reported.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3616": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "5-fluorouracil", "entity2": "gastric cancer", "span1": [47, 61], "span2": [158, 172]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of <e1> 5-fluorouracil </e1> (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced <e2> gastric cancer </e2> (AGC) has shown to be effective, with low toxicity.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3617": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "5-fluorouracil", "entity2": "AGC", "span1": [47, 61], "span2": [174, 177]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of <e1> 5-fluorouracil </e1> (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (<e2> AGC </e2>) has shown to be effective, with low toxicity.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3618": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "5-fluorouracil", "entity2": "low toxicity", "span1": [47, 61], "span2": [211, 223]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of <e1> 5-fluorouracil </e1> (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with <e2> low toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3619": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "5-FU", "entity2": "gastric cancer", "span1": [63, 67], "span2": [158, 172]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (<e1> 5-FU </e1>) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced <e2> gastric cancer </e2> (AGC) has shown to be effective, with low toxicity.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3620": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "5-FU", "entity2": "AGC", "span1": [63, 67], "span2": [174, 177]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (<e1> 5-FU </e1>) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (<e2> AGC </e2>) has shown to be effective, with low toxicity.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3621": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "5-FU", "entity2": "low toxicity", "span1": [63, 67], "span2": [211, 223]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (<e1> 5-FU </e1>) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with <e2> low toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3622": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "folinic acid", "entity2": "gastric cancer", "span1": [73, 85], "span2": [158, 172]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and <e1> folinic acid </e1> (FA) as part of several new multidrug chemotherapy regimens in advanced <e2> gastric cancer </e2> (AGC) has shown to be effective, with low toxicity.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3623": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "folinic acid", "entity2": "AGC", "span1": [73, 85], "span2": [174, 177]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and <e1> folinic acid </e1> (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (<e2> AGC </e2>) has shown to be effective, with low toxicity.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3624": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "folinic acid", "entity2": "low toxicity", "span1": [73, 85], "span2": [211, 223]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and <e1> folinic acid </e1> (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with <e2> low toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3625": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "FA", "entity2": "gastric cancer", "span1": [87, 89], "span2": [158, 172]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (<e1> FA </e1>) as part of several new multidrug chemotherapy regimens in advanced <e2> gastric cancer </e2> (AGC) has shown to be effective, with low toxicity.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3626": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "FA", "entity2": "AGC", "span1": [87, 89], "span2": [174, 177]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (<e1> FA </e1>) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (<e2> AGC </e2>) has shown to be effective, with low toxicity.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3627": {"data": {"text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (FA) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with low toxicity.", "entity1": "FA", "entity2": "low toxicity", "span1": [87, 89], "span2": [211, 223]}, "bert_text": "BACKGROUND: The 24-hour continuous infusion of 5-fluorouracil (5-FU) and folinic acid (<e1> FA </e1>) as part of several new multidrug chemotherapy regimens in advanced gastric cancer (AGC) has shown to be effective, with <e2> low toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3628": {"data": {"text": "On the other hand, the clonidine-induced bradycardia was antagonized by prior bilateral vagotomy, but not spinal transection.", "entity1": "clonidine", "entity2": "bradycardia", "span1": [23, 32], "span2": [41, 52]}, "bert_text": "On the other hand, the <e1> clonidine </e1>-induced <e2> bradycardia </e2> was antagonized by prior bilateral vagotomy, but not spinal transection.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3629": {"data": {"text": "Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.", "entity1": "Nafcillin", "entity2": "meningitis", "span1": [0, 9], "span2": [84, 94]}, "bert_text": "<e1> Nafcillin </e1> was discontinued and daptomycin 9 mg/kg daily was initiated for suspected <e2> meningitis </e2> and was continued until the patient's death on day 16.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3630": {"data": {"text": "Nafcillin was discontinued and daptomycin 9 mg/kg daily was initiated for suspected meningitis and was continued until the patient's death on day 16.", "entity1": "daptomycin", "entity2": "meningitis", "span1": [31, 41], "span2": [84, 94]}, "bert_text": "Nafcillin was discontinued and <e1> daptomycin </e1> 9 mg/kg daily was initiated for suspected <e2> meningitis </e2> and was continued until the patient's death on day 16.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3631": {"data": {"text": "This is the first published report documenting the preferential in vivo binding of estrogen to nuclei of cells in estrogen induced hamster renal carcinomas.", "entity1": "estrogen", "entity2": "hamster renal carcinomas", "span1": [83, 91], "span2": [131, 155]}, "bert_text": "This is the first published report documenting the preferential in vivo binding of <e1> estrogen </e1> to nuclei of cells in estrogen induced <e2> hamster renal carcinomas </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3632": {"data": {"text": "This is the first published report documenting the preferential in vivo binding of estrogen to nuclei of cells in estrogen induced hamster renal carcinomas.", "entity1": "estrogen", "entity2": "hamster renal carcinomas", "span1": [114, 122], "span2": [131, 155]}, "bert_text": "This is the first published report documenting the preferential in vivo binding of estrogen to nuclei of cells in <e1> estrogen </e1> induced <e2> hamster renal carcinomas </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3633": {"data": {"text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.", "entity1": "sodium salicylate", "entity2": "seizures", "span1": [101, 118], "span2": [183, 191]}, "bert_text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, <e1> sodium salicylate </e1>, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on <e2> seizures </e2> produced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3634": {"data": {"text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.", "entity1": "phenylbutazone", "entity2": "seizures", "span1": [120, 134], "span2": [183, 191]}, "bert_text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, <e1> phenylbutazone </e1>, indomethacin, ibuprofen and mefenamic acid, on <e2> seizures </e2> produced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3635": {"data": {"text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.", "entity1": "indomethacin", "entity2": "seizures", "span1": [136, 148], "span2": [183, 191]}, "bert_text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, <e1> indomethacin </e1>, ibuprofen and mefenamic acid, on <e2> seizures </e2> produced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3636": {"data": {"text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.", "entity1": "ibuprofen", "entity2": "seizures", "span1": [150, 159], "span2": [183, 191]}, "bert_text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, <e1> ibuprofen </e1> and mefenamic acid, on <e2> seizures </e2> produced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3637": {"data": {"text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.", "entity1": "mefenamic acid", "entity2": "seizures", "span1": [164, 178], "span2": [183, 191]}, "bert_text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and <e1> mefenamic acid </e1>, on <e2> seizures </e2> produced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3638": {"data": {"text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by pilocarpine.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [204, 215], "span2": [183, 191]}, "bert_text": "The present study was designed to investigate the effect of 5 non-steroidal anti-inflammatory drugs, sodium salicylate, phenylbutazone, indomethacin, ibuprofen and mefenamic acid, on seizures produced by <e1> pilocarpine </e1> <e2> seizures </e2> produced by pilocarpine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3639": {"data": {"text": "(P < .01) at 3 min after ISO infusion with stenosis.", "entity1": "ISO", "entity2": "stenosis", "span1": [25, 28], "span2": [43, 51]}, "bert_text": "(P < .01) at 3 min after <e1> ISO </e1> infusion with <e2> stenosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3640": {"data": {"text": "However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true.", "entity1": "nefiracetam", "entity2": "amnesia", "span1": [27, 38], "span2": [79, 86]}, "bert_text": "However, administration of <e1> nefiracetam </e1> during training completely reversed the <e2> amnesia </e2> induced by apomorphine at the 10h post-training time and the converse was also true.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3641": {"data": {"text": "However, administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post-training time and the converse was also true.", "entity1": "apomorphine", "entity2": "amnesia", "span1": [98, 109], "span2": [79, 86]}, "bert_text": "However, administration of nefiracetam during training completely reversed the amnesia induced by <e1> apomorphine </e1> <e2> amnesia </e2> induced by apomorphine at the 10h post-training time and the converse was also true.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3642": {"data": {"text": "The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced hyperactivity was examined in mice.", "entity1": "adenosine", "entity2": "hyperactivity", "span1": [17, 26], "span2": [96, 109]}, "bert_text": "The influence of <e1> adenosine </e1> receptor agonists and antagonists on cocaine-and amphetamine-induced <e2> hyperactivity </e2> was examined in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3643": {"data": {"text": "The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced hyperactivity was examined in mice.", "entity1": "cocaine", "entity2": "hyperactivity", "span1": [64, 71], "span2": [96, 109]}, "bert_text": "The influence of adenosine receptor agonists and antagonists on <e1> cocaine </e1>-and amphetamine-induced <e2> hyperactivity </e2> was examined in mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3644": {"data": {"text": "The influence of adenosine receptor agonists and antagonists on cocaine-and amphetamine-induced hyperactivity was examined in mice.", "entity1": "amphetamine", "entity2": "hyperactivity", "span1": [76, 87], "span2": [96, 109]}, "bert_text": "The influence of adenosine receptor agonists and antagonists on cocaine-and <e1> amphetamine </e1>-induced <e2> hyperactivity </e2> was examined in mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3645": {"data": {"text": "Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes?", "entity1": "aspirin", "entity2": "increase gastrointestinal bleeding", "span1": [5, 12], "span2": [13, 47]}, "bert_text": "Does <e1> aspirin </e1> <e2> increase gastrointestinal bleeding </e2> or hemorrhagic strokes?", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3646": {"data": {"text": "Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes?", "entity1": "aspirin", "entity2": "hemorrhagic strokes", "span1": [5, 12], "span2": [51, 70]}, "bert_text": "Does <e1> aspirin </e1> increase gastrointestinal bleeding or <e2> hemorrhagic strokes </e2>?", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3647": {"data": {"text": "Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 (SIS3) were performed in MMECs and in STZ-induced diabetic nephropathy in Tie2-Cre;Loxp-EGFP mice.", "entity1": "STZ", "entity2": "diabetic nephropathy", "span1": [118, 121], "span2": [130, 150]}, "bert_text": "Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 (SIS3) were performed in MMECs and in <e1> STZ </e1>-induced <e2> diabetic nephropathy </e2> in Tie2-Cre;Loxp-EGFP mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3648": {"data": {"text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "entity1": "platinum", "entity2": "ovarian", "span1": [108, 116], "span2": [37, 44]}, "bert_text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with <e1> platinum </e1> <e2> ovarian </e2> or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3649": {"data": {"text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "entity1": "platinum", "entity2": "fallopian tube cancers", "span1": [108, 116], "span2": [48, 70]}, "bert_text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with <e1> platinum </e1> <e2> fallopian tube cancers </e2> or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3650": {"data": {"text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "entity1": "platinum", "entity2": "carcinoma", "span1": [108, 116], "span2": [93, 102]}, "bert_text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with <e1> platinum </e1> <e2> carcinoma </e2> with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3651": {"data": {"text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "entity1": "paclitaxel", "entity2": "ovarian", "span1": [117, 127], "span2": [37, 44]}, "bert_text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/<e1> paclitaxel </e1> <e2> ovarian </e2> or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3652": {"data": {"text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "entity1": "paclitaxel", "entity2": "fallopian tube cancers", "span1": [117, 127], "span2": [48, 70]}, "bert_text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/<e1> paclitaxel </e1> <e2> fallopian tube cancers </e2> or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3653": {"data": {"text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "entity1": "paclitaxel", "entity2": "carcinoma", "span1": [117, 127], "span2": [93, 102]}, "bert_text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/<e1> paclitaxel </e1> <e2> carcinoma </e2> with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3654": {"data": {"text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "entity1": "doxorubicin", "entity2": "ovarian", "span1": [298, 309], "span2": [37, 44]}, "bert_text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal <e1> doxorubicin </e1> <e2> ovarian </e2> or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3655": {"data": {"text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "entity1": "doxorubicin", "entity2": "fallopian tube cancers", "span1": [298, 309], "span2": [48, 70]}, "bert_text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal <e1> doxorubicin </e1> <e2> fallopian tube cancers </e2> or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3656": {"data": {"text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "entity1": "doxorubicin", "entity2": "carcinoma", "span1": [298, 309], "span2": [93, 102]}, "bert_text": "METHODS AND MATERIALS: Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal <e1> doxorubicin </e1> <e2> carcinoma </e2> with platinum/paclitaxel-refractory disease (stable or progressive disease following treatment with these agents or previous objective response <3 months in duration) were treated with liposomal doxorubicin at a dose of 40 mg/m(2) q 4 weeks.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3657": {"data": {"text": "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.", "entity1": "calcium carbonate", "entity2": "hypoparathyroidism", "span1": [77, 94], "span2": [37, 55]}, "bert_text": "This article presents a patient with hypoparathyroidism who was treated with <e1> calcium carbonate </e1> <e2> hypoparathyroidism </e2> who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3658": {"data": {"text": "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.", "entity1": "calcium carbonate", "entity2": "milk-alkali syndrome", "span1": [77, 94], "span2": [158, 178]}, "bert_text": "This article presents a patient with hypoparathyroidism who was treated with <e1> calcium carbonate </e1> and calcitriol resulting in two admissions to the hospital for <e2> milk-alkali syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3659": {"data": {"text": "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.", "entity1": "calcitriol", "entity2": "hypoparathyroidism", "span1": [99, 109], "span2": [37, 55]}, "bert_text": "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and <e1> calcitriol </e1> <e2> hypoparathyroidism </e2> who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3660": {"data": {"text": "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk-alkali syndrome.", "entity1": "calcitriol", "entity2": "milk-alkali syndrome", "span1": [99, 109], "span2": [158, 178]}, "bert_text": "This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and <e1> calcitriol </e1> resulting in two admissions to the hospital for <e2> milk-alkali syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3661": {"data": {"text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "entity1": "D-AmB.", "entity2": "NS-718", "span1": [133, 139], "span2": [16, 22]}, "bert_text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with <e1> D-AmB. </e1> <e2> NS-718 </e2> resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3662": {"data": {"text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "entity1": "D-AmB.", "entity2": "NS-718", "span1": [133, 139], "span2": [297, 303]}, "bert_text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with <e1> D-AmB. </e1> Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of <e2> NS-718 </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3663": {"data": {"text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "entity1": "D-AmB", "entity2": "NS-718", "span1": [243, 248], "span2": [16, 22]}, "bert_text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of <e1> D-AmB </e1> <e2> NS-718 </e2> resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3664": {"data": {"text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "entity1": "D-AmB", "entity2": "NS-718", "span1": [243, 248], "span2": [297, 303]}, "bert_text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of <e1> D-AmB </e1> 3 mg/kg but not in those given the same dose of <e2> NS-718 </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3665": {"data": {"text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "entity1": "urea", "entity2": "NS-718", "span1": [152, 156], "span2": [16, 22]}, "bert_text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood <e1> urea </e1> <e2> NS-718 </e2> resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3666": {"data": {"text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "entity1": "urea", "entity2": "NS-718", "span1": [152, 156], "span2": [297, 303]}, "bert_text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood <e1> urea </e1> and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of <e2> NS-718 </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3667": {"data": {"text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "entity1": "creatinine", "entity2": "NS-718", "span1": [161, 171], "span2": [16, 22]}, "bert_text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and <e1> creatinine </e1> <e2> NS-718 </e2> resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3668": {"data": {"text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and creatinine concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of NS-718.", "entity1": "creatinine", "entity2": "NS-718", "span1": [161, 171], "span2": [297, 303]}, "bert_text": "Incubation with NS-718 resulted in significantly less damage of cultured human renal proximal tubular epithelial cells compared with D-AmB. Serum blood urea and <e1> creatinine </e1> concentrations increased significantly in rats given an iv infusion of D-AmB 3 mg/kg but not in those given the same dose of <e2> NS-718 </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3669": {"data": {"text": "This study demonstrates that hydroxytyrosol protect rat heart damage provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations.", "entity1": "hydroxytyrosol", "entity2": "heart damage", "span1": [29, 43], "span2": [56, 68]}, "bert_text": "This study demonstrates that <e1> hydroxytyrosol </e1> protect rat <e2> heart damage </e2> provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3670": {"data": {"text": "This study demonstrates that hydroxytyrosol protect rat heart damage provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations.", "entity1": "doxorubicin", "entity2": "heart damage", "span1": [81, 92], "span2": [56, 68]}, "bert_text": "This study demonstrates that hydroxytyrosol protect rat heart damage provoked by <e1> doxorubicin </e1> <e2> heart damage </e2> provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3671": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [21, 24], "span2": [25, 39]}, "bert_text": "We conclude that the <e1> CYA </e1> <e2> cardiotoxicity </e2> correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3672": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [21, 24], "span2": [287, 301]}, "bert_text": "We conclude that the <e1> CYA </e1> cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of <e2> cardiotoxicity </e2> than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3673": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "aplastic anemia", "span1": [21, 24], "span2": [126, 141]}, "bert_text": "We conclude that the <e1> CYA </e1> cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with <e2> aplastic anemia </e2> and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3674": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "immunodeficiencies", "span1": [21, 24], "span2": [146, 164]}, "bert_text": "We conclude that the <e1> CYA </e1> cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and <e2> immunodeficiencies </e2> can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3675": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [56, 59], "span2": [25, 39]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with <e1> CYA </e1> <e2> cardiotoxicity </e2> correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3676": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [56, 59], "span2": [287, 301]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with <e1> CYA </e1> dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of <e2> cardiotoxicity </e2> than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3677": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "aplastic anemia", "span1": [56, 59], "span2": [126, 141]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with <e1> CYA </e1> dosage as calculated by body surface area, and that patients with <e2> aplastic anemia </e2> and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3678": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "immunodeficiencies", "span1": [56, 59], "span2": [146, 164]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with <e1> CYA </e1> dosage as calculated by body surface area, and that patients with aplastic anemia and <e2> immunodeficiencies </e2> can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3679": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [223, 226], "span2": [25, 39]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a <e1> CYA </e1> <e2> cardiotoxicity </e2> correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3680": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [223, 226], "span2": [287, 301]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a <e1> CYA </e1> dose of 1.55 g/m2/d for four days with a lower incidence of <e2> cardiotoxicity </e2> than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3681": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "aplastic anemia", "span1": [223, 226], "span2": [126, 141]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a <e1> CYA </e1> <e2> aplastic anemia </e2> and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3682": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "immunodeficiencies", "span1": [223, 226], "span2": [146, 164]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a <e1> CYA </e1> <e2> immunodeficiencies </e2> can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3683": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [322, 325], "span2": [25, 39]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose <e1> CYA </e1> <e2> cardiotoxicity </e2> correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3684": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "cardiotoxicity", "span1": [322, 325], "span2": [287, 301]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose <e1> CYA </e1> <e2> cardiotoxicity </e2> than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3685": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "aplastic anemia", "span1": [322, 325], "span2": [126, 141]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose <e1> CYA </e1> <e2> aplastic anemia </e2> and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3686": {"data": {"text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "entity1": "CYA", "entity2": "immunodeficiencies", "span1": [322, 325], "span2": [146, 164]}, "bert_text": "We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area, and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose <e1> CYA </e1> <e2> immunodeficiencies </e2> can be effectively prepared for bone marrow grafting at a CYA dose of 1.55 g/m2/d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3687": {"data": {"text": "Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy.", "entity1": "PAN", "entity2": "growth failure", "span1": [140, 143], "span2": [104, 118]}, "bert_text": "Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic <e1> PAN </e1> <e2> growth failure </e2> in rats with chronic PAN nephropathy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3688": {"data": {"text": "Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy.", "entity1": "PAN", "entity2": "nephropathy", "span1": [140, 143], "span2": [144, 155]}, "bert_text": "Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic <e1> PAN </e1> <e2> nephropathy </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"3689": {"data": {"text": "In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (MMC) we found a low toxicity rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "entity1": "5-FU", "entity2": "toxicity", "span1": [49, 53], "span2": [95, 103]}, "bert_text": "In a previous phase II study with 3-weekly bolus <e1> 5-FU </e1>, FA and mitomycin C (MMC) we found a low <e2> toxicity </e2> rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3690": {"data": {"text": "In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (MMC) we found a low toxicity rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "entity1": "FA", "entity2": "toxicity", "span1": [55, 57], "span2": [95, 103]}, "bert_text": "In a previous phase II study with 3-weekly bolus 5-FU, <e1> FA </e1> and mitomycin C (MMC) we found a low <e2> toxicity </e2> rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3691": {"data": {"text": "In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (MMC) we found a low toxicity rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "entity1": "mitomycin C", "entity2": "toxicity", "span1": [62, 73], "span2": [95, 103]}, "bert_text": "In a previous phase II study with 3-weekly bolus 5-FU, FA and <e1> mitomycin C </e1> (MMC) we found a low <e2> toxicity </e2> rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3692": {"data": {"text": "In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (MMC) we found a low toxicity rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "entity1": "MMC", "entity2": "toxicity", "span1": [75, 78], "span2": [95, 103]}, "bert_text": "In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (<e1> MMC </e1>) we found a low <e2> toxicity </e2> rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3693": {"data": {"text": "In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (MMC) we found a low toxicity rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "entity1": "FAM", "entity2": "toxicity", "span1": [173, 176], "span2": [95, 103]}, "bert_text": "In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (MMC) we found a low toxicity rate and response rates comparable to those of regimens such as ELF, <e1> FAM </e1> <e2> toxicity </e2> rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3694": {"data": {"text": "In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (MMC) we found a low toxicity rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "entity1": "FAMTX", "entity2": "toxicity", "span1": [180, 185], "span2": [95, 103]}, "bert_text": "In a previous phase II study with 3-weekly bolus 5-FU, FA and mitomycin C (MMC) we found a low toxicity rate and response rates comparable to those of regimens such as ELF, FAM or <e1> FAMTX </e1> <e2> toxicity </e2> rate and response rates comparable to those of regimens such as ELF, FAM or FAMTX, and a promising median overall survival.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3695": {"data": {"text": "D-ribose in the multiple doses of 200 mg/kg did not influence ADR cardiotoxicity.", "entity1": "D-ribose", "entity2": "cardiotoxicity", "span1": [0, 8], "span2": [66, 80]}, "bert_text": "<e1> D-ribose </e1> in the multiple doses of 200 mg/kg did not influence ADR <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3696": {"data": {"text": "D-ribose in the multiple doses of 200 mg/kg did not influence ADR cardiotoxicity.", "entity1": "ADR", "entity2": "cardiotoxicity", "span1": [62, 65], "span2": [66, 80]}, "bert_text": "D-ribose in the multiple doses of 200 mg/kg did not influence <e1> ADR </e1> <e2> cardiotoxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3697": {"data": {"text": "From February, 1998 to September, 2000 we recruited 33 patients with AGC to receive weekly 24-hour 5-FU 2,600 mg/m(2) preceded by 2-hour FA 500 mg/m(2) for 6 weeks, followed by a 2-week rest period.", "entity1": "5-FU", "entity2": "AGC", "span1": [99, 103], "span2": [69, 72]}, "bert_text": "From February, 1998 to September, 2000 we recruited 33 patients with AGC to receive weekly 24-hour <e1> 5-FU </e1> <e2> AGC </e2> to receive weekly 24-hour 5-FU 2,600 mg/m(2) preceded by 2-hour FA 500 mg/m(2) for 6 weeks, followed by a 2-week rest period.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3698": {"data": {"text": "From February, 1998 to September, 2000 we recruited 33 patients with AGC to receive weekly 24-hour 5-FU 2,600 mg/m(2) preceded by 2-hour FA 500 mg/m(2) for 6 weeks, followed by a 2-week rest period.", "entity1": "FA", "entity2": "AGC", "span1": [137, 139], "span2": [69, 72]}, "bert_text": "From February, 1998 to September, 2000 we recruited 33 patients with AGC to receive weekly 24-hour 5-FU 2,600 mg/m(2) preceded by 2-hour <e1> FA </e1> <e2> AGC </e2> to receive weekly 24-hour 5-FU 2,600 mg/m(2) preceded by 2-hour FA 500 mg/m(2) for 6 weeks, followed by a 2-week rest period.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3699": {"data": {"text": "Four types of experimental arrhythmia are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.", "entity1": "BaCl2", "entity2": "arrhythmia", "span1": [53, 58], "span2": [27, 37]}, "bert_text": "Four types of experimental arrhythmia are used--with <e1> BaCl2 </e1> <e2> arrhythmia </e2> are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3700": {"data": {"text": "Four types of experimental arrhythmia are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.", "entity1": "chloroform-adrenaline", "entity2": "arrhythmia", "span1": [65, 86], "span2": [27, 37]}, "bert_text": "Four types of experimental arrhythmia are used--with BaCl2, with <e1> chloroform-adrenaline </e1> <e2> arrhythmia </e2> are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3701": {"data": {"text": "Four types of experimental arrhythmia are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.", "entity1": "aconitine", "entity2": "arrhythmia", "span1": [117, 126], "span2": [27, 37]}, "bert_text": "Four types of experimental arrhythmia are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with <e1> aconitine </e1> <e2> arrhythmia </e2> are used--with BaCl2, with chloroform-adrenaline, with strophantine G and with aconitine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3702": {"data": {"text": "After the administration of nifekalant hydrochloride, sustained VT was terminated.", "entity1": "nifekalant hydrochloride", "entity2": "VT", "span1": [28, 52], "span2": [64, 66]}, "bert_text": "After the administration of <e1> nifekalant hydrochloride </e1>, sustained <e2> VT </e2> was terminated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3703": {"data": {"text": "Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.", "entity1": "olanzapine", "entity2": "weight gain", "span1": [88, 98], "span2": [42, 53]}, "bert_text": "Both medications caused substantial rapid weight gain, but weight gain was greater with <e1> olanzapine </e1> <e2> weight gain </e2>, but weight gain was greater with olanzapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3704": {"data": {"text": "Both medications caused substantial rapid weight gain, but weight gain was greater with olanzapine.", "entity1": "olanzapine", "entity2": "weight gain", "span1": [88, 98], "span2": [59, 70]}, "bert_text": "Both medications caused substantial rapid weight gain, but weight gain was greater with <e1> olanzapine </e1> <e2> weight gain </e2> was greater with olanzapine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3705": {"data": {"text": "DESIGN: A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and dobutamine induced ischaemia.", "entity1": "dobutamine", "entity2": "ischaemia", "span1": [125, 135], "span2": [144, 153]}, "bert_text": "DESIGN: A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and <e1> dobutamine </e1> induced <e2> ischaemia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3706": {"data": {"text": "As anticipated, animals exhibited a progressive increase in levodopa-induced motor fluctuations, dyskinesia and wearing-off, that correlated with the duration of levodopa therapy.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [60, 68], "span2": [97, 107]}, "bert_text": "As anticipated, animals exhibited a progressive increase in <e1> levodopa </e1>-induced motor fluctuations, <e2> dyskinesia </e2> and wearing-off, that correlated with the duration of levodopa therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3707": {"data": {"text": "As anticipated, animals exhibited a progressive increase in levodopa-induced motor fluctuations, dyskinesia and wearing-off, that correlated with the duration of levodopa therapy.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [162, 170], "span2": [97, 107]}, "bert_text": "As anticipated, animals exhibited a progressive increase in levodopa-induced motor fluctuations, dyskinesia and wearing-off, that correlated with the duration of <e1> levodopa </e1> <e2> dyskinesia </e2> and wearing-off, that correlated with the duration of levodopa therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3708": {"data": {"text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "entity1": "doxorubicin", "entity2": "ovarian", "span1": [27, 38], "span2": [86, 93]}, "bert_text": "Phase 2 trial of liposomal <e1> doxorubicin </e1> (40 mg/m(2)) in platinum/paclitaxel-refractory <e2> ovarian </e2> and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3709": {"data": {"text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "entity1": "doxorubicin", "entity2": "fallopian tube cancers", "span1": [27, 38], "span2": [98, 120]}, "bert_text": "Phase 2 trial of liposomal <e1> doxorubicin </e1> (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and <e2> fallopian tube cancers </e2> and primary carcinoma of the peritoneum.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3710": {"data": {"text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "entity1": "doxorubicin", "entity2": "carcinoma", "span1": [27, 38], "span2": [133, 142]}, "bert_text": "Phase 2 trial of liposomal <e1> doxorubicin </e1> (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary <e2> carcinoma </e2> of the peritoneum.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3711": {"data": {"text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "entity1": "platinum", "entity2": "ovarian", "span1": [55, 63], "span2": [86, 93]}, "bert_text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in <e1> platinum </e1>/paclitaxel-refractory <e2> ovarian </e2> and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3712": {"data": {"text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "entity1": "platinum", "entity2": "fallopian tube cancers", "span1": [55, 63], "span2": [98, 120]}, "bert_text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in <e1> platinum </e1>/paclitaxel-refractory ovarian and <e2> fallopian tube cancers </e2> and primary carcinoma of the peritoneum.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3713": {"data": {"text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "entity1": "platinum", "entity2": "carcinoma", "span1": [55, 63], "span2": [133, 142]}, "bert_text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in <e1> platinum </e1>/paclitaxel-refractory ovarian and fallopian tube cancers and primary <e2> carcinoma </e2> of the peritoneum.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3714": {"data": {"text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "entity1": "paclitaxel", "entity2": "ovarian", "span1": [64, 74], "span2": [86, 93]}, "bert_text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/<e1> paclitaxel </e1>-refractory <e2> ovarian </e2> and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3715": {"data": {"text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "entity1": "paclitaxel", "entity2": "fallopian tube cancers", "span1": [64, 74], "span2": [98, 120]}, "bert_text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/<e1> paclitaxel </e1>-refractory ovarian and <e2> fallopian tube cancers </e2> and primary carcinoma of the peritoneum.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3716": {"data": {"text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.\n", "entity1": "paclitaxel", "entity2": "carcinoma", "span1": [64, 74], "span2": [133, 142]}, "bert_text": "Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/<e1> paclitaxel </e1>-refractory ovarian and fallopian tube cancers and primary <e2> carcinoma </e2> of the peritoneum.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3717": {"data": {"text": "Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.", "entity1": "Nitric oxide", "entity2": "epilepsy", "span1": [0, 12], "span2": [207, 215]}, "bert_text": "<e1> Nitric oxide </e1> (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different <e2> epilepsy </e2> models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3718": {"data": {"text": "Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.", "entity1": "NO", "entity2": "epilepsy", "span1": [14, 16], "span2": [207, 215]}, "bert_text": "Nitric oxide (<e1> NO </e1>), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different <e2> epilepsy </e2> models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3719": {"data": {"text": "Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of NO syntheses (NOS), and L-NAME (NOS inhibitor) observed in different epilepsy models.", "entity1": "NO", "entity2": "epilepsy", "span1": [138, 140], "span2": [207, 215]}, "bert_text": "Nitric oxide (NO), gaseous neurotransmitter, has contradictor role in epileptogenesis due to opposite effects of L-arginine, precursor of <e1> NO </e1> syntheses (NOS), and L-NAME (NOS inhibitor) observed in different <e2> epilepsy </e2> models.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3720": {"data": {"text": "A patient with transfusion-dependent thalassemia was undergoing home intravenous desferrioxamine (DFX) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy.", "entity1": "desferrioxamine", "entity2": "thalassemia", "span1": [81, 96], "span2": [37, 48]}, "bert_text": "A patient with transfusion-dependent thalassemia was undergoing home intravenous <e1> desferrioxamine </e1> <e2> thalassemia </e2> was undergoing home intravenous desferrioxamine (DFX) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3721": {"data": {"text": "A patient with transfusion-dependent thalassemia was undergoing home intravenous desferrioxamine (DFX) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy.", "entity1": "DFX", "entity2": "thalassemia", "span1": [98, 101], "span2": [37, 48]}, "bert_text": "A patient with transfusion-dependent thalassemia was undergoing home intravenous desferrioxamine (<e1> DFX </e1> <e2> thalassemia </e2> was undergoing home intravenous desferrioxamine (DFX) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3722": {"data": {"text": "Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.\n", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [31, 39], "span2": [48, 58]}, "bert_text": "Risk factors and predictors of <e1> levodopa </e1>-induced <e2> dyskinesia </e2> among multiethnic Malaysians with Parkinson's disease.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3723": {"data": {"text": "Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson's disease.\n", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [31, 39], "span2": [93, 112]}, "bert_text": "Risk factors and predictors of <e1> levodopa </e1>-induced dyskinesia among multiethnic Malaysians with <e2> Parkinson's disease </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3724": {"data": {"text": "Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [18, 26], "span2": [39, 58]}, "bert_text": "Chronic pulsatile <e1> levodopa </e1> therapy for <e2> Parkinson's disease </e2> (PD) leads to the development of motor fluctuations and dyskinesia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3725": {"data": {"text": "Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.", "entity1": "levodopa", "entity2": "PD", "span1": [18, 26], "span2": [60, 62]}, "bert_text": "Chronic pulsatile <e1> levodopa </e1> therapy for Parkinson's disease (<e2> PD </e2>) leads to the development of motor fluctuations and dyskinesia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3726": {"data": {"text": "Chronic pulsatile levodopa therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and dyskinesia.", "entity1": "levodopa", "entity2": "dyskinesia", "span1": [18, 26], "span2": [115, 125]}, "bert_text": "Chronic pulsatile <e1> levodopa </e1> therapy for Parkinson's disease (PD) leads to the development of motor fluctuations and <e2> dyskinesia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3727": {"data": {"text": "We saw no association between metolachlor use and incidence of all cancers combined (n = 5,701 with a 5-year lag) or most site-specific cancers.", "entity1": "metolachlor", "entity2": "cancers", "span1": [30, 41], "span2": [67, 74]}, "bert_text": "We saw no association between <e1> metolachlor </e1> use and incidence of all <e2> cancers </e2> combined (n = 5,701 with a 5-year lag) or most site-specific cancers.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3728": {"data": {"text": "We saw no association between metolachlor use and incidence of all cancers combined (n = 5,701 with a 5-year lag) or most site-specific cancers.", "entity1": "metolachlor", "entity2": "cancers", "span1": [30, 41], "span2": [136, 143]}, "bert_text": "We saw no association between <e1> metolachlor </e1> use and incidence of all cancers combined (n = 5,701 with a 5-year lag) or most site-specific <e2> cancers </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3729": {"data": {"text": "It is recommended that all cases of methamphetamine dependence should be screened for psychotic symptoms.", "entity1": "methamphetamine", "entity2": "psychotic symptoms", "span1": [36, 51], "span2": [86, 104]}, "bert_text": "It is recommended that all cases of <e1> methamphetamine </e1> dependence should be screened for <e2> psychotic symptoms </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3730": {"data": {"text": "Delayed toxicity of cyclophosphamide on the bladder of DBA/2 and C57BL/6 female mouse.\n", "entity1": "cyclophosphamide", "entity2": "toxicity", "span1": [20, 36], "span2": [8, 16]}, "bert_text": "Delayed toxicity of <e1> cyclophosphamide </e1> <e2> toxicity </e2> of cyclophosphamide on the bladder of DBA/2 and C57BL/6 female mouse.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3731": {"data": {"text": "Thus, the precipitating cause of convulsions was believed to be an overdose of TNA.", "entity1": "TNA", "entity2": "convulsions", "span1": [79, 82], "span2": [33, 44]}, "bert_text": "Thus, the precipitating cause of convulsions was believed to be an overdose of <e1> TNA </e1> <e2> convulsions </e2> was believed to be an overdose of TNA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3732": {"data": {"text": "Thus, the precipitating cause of convulsions was believed to be an overdose of TNA.", "entity1": "TNA", "entity2": "overdose", "span1": [79, 82], "span2": [67, 75]}, "bert_text": "Thus, the precipitating cause of convulsions was believed to be an overdose of <e1> TNA </e1> <e2> overdose </e2> of TNA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3733": {"data": {"text": "Effect of alkylxanthines on gentamicin-induced acute renal failure in the rat.\n", "entity1": "gentamicin", "entity2": "acute renal failure", "span1": [28, 38], "span2": [47, 66]}, "bert_text": "Effect of alkylxanthines on <e1> gentamicin </e1>-induced <e2> acute renal failure </e2> in the rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3734": {"data": {"text": "We report a case of acute renal failure after HD-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.", "entity1": "MTX", "entity2": "acute renal failure", "span1": [49, 52], "span2": [20, 39]}, "bert_text": "We report a case of acute renal failure after HD-<e1> MTX </e1> <e2> acute renal failure </e2> after HD-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3735": {"data": {"text": "We report a case of acute renal failure after HD-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.", "entity1": "MTX", "entity2": "HD", "span1": [49, 52], "span2": [46, 48]}, "bert_text": "We report a case of acute renal failure after HD-<e1> MTX </e1> <e2> HD </e2>-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3736": {"data": {"text": "We report a case of acute renal failure after HD-MTX therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for congenital biliary atresia.", "entity1": "MTX", "entity2": "congenital biliary atresia", "span1": [49, 52], "span2": [183, 209]}, "bert_text": "We report a case of acute renal failure after HD-<e1> MTX </e1> therapy in a patient with ileostomy, The patient was a 3-year-old boy who had received a living-related liver transplantation for <e2> congenital biliary atresia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3737": {"data": {"text": "Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.\n", "entity1": "dobutamine", "entity2": "Torsade de pointes", "span1": [72, 82], "span2": [0, 18]}, "bert_text": "Torsade de pointes ventricular tachycardia during low dose intermittent <e1> dobutamine </e1> <e2> Torsade de pointes </e2> ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3738": {"data": {"text": "Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.\n", "entity1": "dobutamine", "entity2": "ventricular tachycardia", "span1": [72, 82], "span2": [19, 42]}, "bert_text": "Torsade de pointes ventricular tachycardia during low dose intermittent <e1> dobutamine </e1> <e2> ventricular tachycardia </e2> during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3739": {"data": {"text": "Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.\n", "entity1": "dobutamine", "entity2": "dilated cardiomyopathy", "span1": [72, 82], "span2": [111, 133]}, "bert_text": "Torsade de pointes ventricular tachycardia during low dose intermittent <e1> dobutamine </e1> treatment in a patient with <e2> dilated cardiomyopathy </e2> and congestive heart failure.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3740": {"data": {"text": "Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure.\n", "entity1": "dobutamine", "entity2": "congestive heart failure", "span1": [72, 82], "span2": [138, 162]}, "bert_text": "Torsade de pointes ventricular tachycardia during low dose intermittent <e1> dobutamine </e1> treatment in a patient with dilated cardiomyopathy and <e2> congestive heart failure </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3741": {"data": {"text": "Intracranial injection of an acetylcholine-synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol.", "entity1": "acetylcholine", "entity2": "catalepsy", "span1": [29, 42], "span2": [93, 102]}, "bert_text": "Intracranial injection of an <e1> acetylcholine </e1>-synthesis inhibitor, hemicholinium, prevented the <e2> catalepsy </e2> that is usually induced by haloperidol.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3742": {"data": {"text": "Intracranial injection of an acetylcholine-synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol.", "entity1": "hemicholinium", "entity2": "catalepsy", "span1": [64, 77], "span2": [93, 102]}, "bert_text": "Intracranial injection of an acetylcholine-synthesis inhibitor, <e1> hemicholinium </e1>, prevented the <e2> catalepsy </e2> that is usually induced by haloperidol.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3743": {"data": {"text": "Intracranial injection of an acetylcholine-synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by haloperidol.", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [130, 141], "span2": [93, 102]}, "bert_text": "Intracranial injection of an acetylcholine-synthesis inhibitor, hemicholinium, prevented the catalepsy that is usually induced by <e1> haloperidol </e1> <e2> catalepsy </e2> that is usually induced by haloperidol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3744": {"data": {"text": "Animal model of mania induced by ouabain: Evidence of oxidative stress in submitochondrial particles of the rat brain.\n", "entity1": "ouabain", "entity2": "mania", "span1": [33, 40], "span2": [16, 21]}, "bert_text": "Animal model of mania induced by <e1> ouabain </e1> <e2> mania </e2> induced by ouabain: Evidence of oxidative stress in submitochondrial particles of the rat brain.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3745": {"data": {"text": "Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.\n", "entity1": "Gemfibrozil-lovastatin", "entity2": "hyperlipoproteinemias", "span1": [0, 22], "span2": [43, 64]}, "bert_text": "<e1> Gemfibrozil-lovastatin </e1> therapy for primary <e2> hyperlipoproteinemias </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3746": {"data": {"text": "RESULTS: Four patients with corneal ulcers associated with crack cocaine use were reviewed.", "entity1": "crack cocaine", "entity2": "corneal ulcers", "span1": [59, 72], "span2": [28, 42]}, "bert_text": "RESULTS: Four patients with corneal ulcers associated with <e1> crack cocaine </e1> <e2> corneal ulcers </e2> associated with crack cocaine use were reviewed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3747": {"data": {"text": "Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.\n", "entity1": "Nefiracetam", "entity2": "amnesia", "span1": [0, 11], "span2": [51, 58]}, "bert_text": "<e1> Nefiracetam </e1> (DM-9384) reverses apomorphine-induced <e2> amnesia </e2> of a passive avoidance response: delayed emergence of the memory retention effects.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3748": {"data": {"text": "Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.\n", "entity1": "DM-9384", "entity2": "amnesia", "span1": [13, 20], "span2": [51, 58]}, "bert_text": "Nefiracetam (<e1> DM-9384 </e1>) reverses apomorphine-induced <e2> amnesia </e2> of a passive avoidance response: delayed emergence of the memory retention effects.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3749": {"data": {"text": "Nefiracetam (DM-9384) reverses apomorphine-induced amnesia of a passive avoidance response: delayed emergence of the memory retention effects.\n", "entity1": "apomorphine", "entity2": "amnesia", "span1": [31, 42], "span2": [51, 58]}, "bert_text": "Nefiracetam (DM-9384) reverses <e1> apomorphine </e1>-induced <e2> amnesia </e2> of a passive avoidance response: delayed emergence of the memory retention effects.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3750": {"data": {"text": "We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment.", "entity1": "tacrolimus", "entity2": "dermatitis", "span1": [72, 82], "span2": [25, 35]}, "bert_text": "We report on rosaceiform dermatitis as a complication of treatment with <e1> tacrolimus </e1> <e2> dermatitis </e2> as a complication of treatment with tacrolimus ointment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3751": {"data": {"text": "Drug-Induced Acute Liver Injury Within 12 Hours After Fluvastatin Therapy.\n", "entity1": "Fluvastatin", "entity2": "Drug-Induced Acute Liver Injury", "span1": [54, 65], "span2": [0, 31]}, "bert_text": "Drug-Induced Acute Liver Injury Within 12 Hours After <e1> Fluvastatin </e1> <e2> Drug-Induced Acute Liver Injury </e2> Within 12 Hours After Fluvastatin Therapy.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3752": {"data": {"text": "Paraplegia following intrathecal methotrexate: report of a case and review of the literature.\n", "entity1": "methotrexate", "entity2": "Paraplegia", "span1": [33, 45], "span2": [0, 10]}, "bert_text": "Paraplegia following intrathecal <e1> methotrexate </e1> <e2> Paraplegia </e2> following intrathecal methotrexate: report of a case and review of the literature.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3753": {"data": {"text": "analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction (MI).", "entity1": "digoxin", "entity2": "myocardial infarction", "span1": [107, 114], "span2": [144, 165]}, "bert_text": "analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that <e1> digoxin </e1> may increase mortality after <e2> myocardial infarction </e2> (MI).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3754": {"data": {"text": "analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction (MI).", "entity1": "digoxin", "entity2": "MI", "span1": [107, 114], "span2": [167, 169]}, "bert_text": "analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that <e1> digoxin </e1> may increase mortality after myocardial infarction (<e2> MI </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3755": {"data": {"text": "Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol.", "entity1": "cisplatin", "entity2": "hypertension", "span1": [87, 96], "span2": [126, 138]}, "bert_text": "Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) <e1> cisplatin </e1> every 3 weeks and those with <e2> hypertension </e2> are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3756": {"data": {"text": "Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [87, 96], "span2": [167, 181]}, "bert_text": "Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) <e1> cisplatin </e1> every 3 weeks and those with hypertension are at the greatest risk of <e2> nephrotoxicity </e2> and would benefit from the addition of mannitol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3757": {"data": {"text": "Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol.", "entity1": "mannitol", "entity2": "hypertension", "span1": [221, 229], "span2": [126, 138]}, "bert_text": "Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of <e1> mannitol </e1> <e2> hypertension </e2> are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3758": {"data": {"text": "Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol.", "entity1": "mannitol", "entity2": "nephrotoxicity", "span1": [221, 229], "span2": [167, 181]}, "bert_text": "Our analysis suggests that those patients receiving the dosing schedule of 100 mg/m(2) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of <e1> mannitol </e1> <e2> nephrotoxicity </e2> and would benefit from the addition of mannitol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"3759": {"data": {"text": "Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).", "entity1": "metformin", "entity2": "myocardial infarction", "span1": [21, 30], "span2": [58, 79]}, "bert_text": "Acute treatment with <e1> metformin </e1> has a protective effect in <e2> myocardial infarction </e2> by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3760": {"data": {"text": "Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).", "entity1": "AMP", "entity2": "myocardial infarction", "span1": [142, 145], "span2": [58, 79]}, "bert_text": "Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of <e1> AMP </e1> <e2> myocardial infarction </e2> by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3761": {"data": {"text": "Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).", "entity1": "AMPK", "entity2": "myocardial infarction", "span1": [172, 176], "span2": [58, 79]}, "bert_text": "Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP-activated protein kinase (<e1> AMPK </e1> <e2> myocardial infarction </e2> by suppression of inflammatory responses due to activation of AMP-activated protein kinase (AMPK).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3762": {"data": {"text": "After the addition of a minimal dose of clonidine (0.15 mg bid), she developed complete AV block and severe hypotension, which resolved upon cessation of all medications.", "entity1": "clonidine", "entity2": "AV block", "span1": [40, 49], "span2": [88, 96]}, "bert_text": "After the addition of a minimal dose of <e1> clonidine </e1> (0.15 mg bid), she developed complete <e2> AV block </e2> and severe hypotension, which resolved upon cessation of all medications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3763": {"data": {"text": "After the addition of a minimal dose of clonidine (0.15 mg bid), she developed complete AV block and severe hypotension, which resolved upon cessation of all medications.", "entity1": "clonidine", "entity2": "hypotension", "span1": [40, 49], "span2": [108, 119]}, "bert_text": "After the addition of a minimal dose of <e1> clonidine </e1> (0.15 mg bid), she developed complete AV block and severe <e2> hypotension </e2>, which resolved upon cessation of all medications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3764": {"data": {"text": "The number of p75(NTR)-immunoreactive (-IR) cells in the lumbosacral dorsal root ganglia (DRG) also increased (P < or = 0.05) with CYP-induced cystitis (acute, intermediate, and chronic).", "entity1": "CYP", "entity2": "cystitis", "span1": [131, 134], "span2": [143, 151]}, "bert_text": "The number of p75(NTR)-immunoreactive (-IR) cells in the lumbosacral dorsal root ganglia (DRG) also increased (P < or = 0.05) with <e1> CYP </e1>-induced <e2> cystitis </e2> (acute, intermediate, and chronic).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3765": {"data": {"text": "One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d,l-sotalol.", "entity1": "l-sotalol", "entity2": "cardiac disease", "span1": [126, 135], "span2": [31, 46]}, "bert_text": "One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d,<e1> l-sotalol </e1> <e2> cardiac disease </e2> had recurrent torsades de pointes after 2 years of successful treatment with d,l-sotalol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3766": {"data": {"text": "One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d,l-sotalol.", "entity1": "l-sotalol", "entity2": "torsades de pointes", "span1": [126, 135], "span2": [61, 80]}, "bert_text": "One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d,<e1> l-sotalol </e1> <e2> torsades de pointes </e2> after 2 years of successful treatment with d,l-sotalol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3767": {"data": {"text": "Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.\n", "entity1": "indomethacin", "entity2": "Hyperkalemia", "span1": [24, 36], "span2": [0, 12]}, "bert_text": "Hyperkalemia induced by <e1> indomethacin </e1> <e2> Hyperkalemia </e2> induced by indomethacin and naproxen and reversed by fludrocortisone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3768": {"data": {"text": "Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.\n", "entity1": "naproxen", "entity2": "Hyperkalemia", "span1": [41, 49], "span2": [0, 12]}, "bert_text": "Hyperkalemia induced by indomethacin and <e1> naproxen </e1> <e2> Hyperkalemia </e2> induced by indomethacin and naproxen and reversed by fludrocortisone.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3769": {"data": {"text": "Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone.\n", "entity1": "fludrocortisone", "entity2": "Hyperkalemia", "span1": [66, 81], "span2": [0, 12]}, "bert_text": "Hyperkalemia induced by indomethacin and naproxen and reversed by <e1> fludrocortisone </e1> <e2> Hyperkalemia </e2> induced by indomethacin and naproxen and reversed by fludrocortisone.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3770": {"data": {"text": "STUDY OBJECTIVE: Chest pain in the setting of cocaine use poses a diagnostic dilemma.", "entity1": "cocaine", "entity2": "Chest pain", "span1": [46, 53], "span2": [17, 27]}, "bert_text": "STUDY OBJECTIVE: Chest pain in the setting of <e1> cocaine </e1> <e2> Chest pain </e2> in the setting of cocaine use poses a diagnostic dilemma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3771": {"data": {"text": "Although several new anticoagulant drugs are in development, heparin remains the anticoagulant of choice to treat acute thrombotic episodes.", "entity1": "heparin", "entity2": "thrombotic", "span1": [61, 68], "span2": [120, 130]}, "bert_text": "Although several new anticoagulant drugs are in development, <e1> heparin </e1> remains the anticoagulant of choice to treat acute <e2> thrombotic </e2> episodes.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3772": {"data": {"text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "entity1": "Dobutamine", "entity2": "ischemia", "span1": [0, 10], "span2": [105, 113]}, "bert_text": "<e1> Dobutamine </e1> stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac <e2> ischemia </e2>. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3773": {"data": {"text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "entity1": "Dobutamine", "entity2": "chest pain", "span1": [0, 10], "span2": [332, 342]}, "bert_text": "<e1> Dobutamine </e1> stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated <e2> chest pain </e2>. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3774": {"data": {"text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "entity1": "dobutamine", "entity2": "ischemia", "span1": [178, 188], "span2": [105, 113]}, "bert_text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of <e1> dobutamine </e1> <e2> ischemia </e2>. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3775": {"data": {"text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "entity1": "dobutamine", "entity2": "chest pain", "span1": [178, 188], "span2": [332, 342]}, "bert_text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of <e1> dobutamine </e1> in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated <e2> chest pain </e2>. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3776": {"data": {"text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "entity1": "cocaine", "entity2": "ischemia", "span1": [207, 214], "span2": [105, 113]}, "bert_text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of <e1> cocaine </e1> <e2> ischemia </e2>. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3777": {"data": {"text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "entity1": "cocaine", "entity2": "chest pain", "span1": [207, 214], "span2": [332, 342]}, "bert_text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of <e1> cocaine </e1> use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated <e2> chest pain </e2>. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3778": {"data": {"text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "entity1": "cocaine", "entity2": "ischemia", "span1": [313, 320], "span2": [105, 113]}, "bert_text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with <e1> cocaine </e1> <e2> ischemia </e2>. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3779": {"data": {"text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine-associated chest pain. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "entity1": "cocaine", "entity2": "chest pain", "span1": [313, 320], "span2": [332, 342]}, "bert_text": "Dobutamine stress echocardiography (DSE) is a widely available and sensitive test for evaluating cardiac ischemia. Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use, we conducted a pilot study to assess the safety of DSE in emergency department patients with <e1> cocaine </e1>-associated <e2> chest pain </e2>. METHODS: A prospective case series was conducted in the intensive diagnostic and treatment unit in the ED of an urban tertiary-care teaching hospital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3780": {"data": {"text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.", "entity1": "mirtazapine", "entity2": "depressed", "span1": [105, 116], "span2": [26, 35]}, "bert_text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after <e1> mirtazapine </e1> <e2> depressed </e2> patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3781": {"data": {"text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.", "entity1": "mirtazapine", "entity2": "dyspepsia", "span1": [105, 116], "span2": [71, 80]}, "bert_text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after <e1> mirtazapine </e1> <e2> dyspepsia </e2> who developed RLS after mirtazapine had been added to his domperidone therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3782": {"data": {"text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.", "entity1": "mirtazapine", "entity2": "RLS", "span1": [105, 116], "span2": [95, 98]}, "bert_text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after <e1> mirtazapine </e1> <e2> RLS </e2> after mirtazapine had been added to his domperidone therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3783": {"data": {"text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.", "entity1": "domperidone", "entity2": "depressed", "span1": [139, 150], "span2": [26, 35]}, "bert_text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his <e1> domperidone </e1> <e2> depressed </e2> patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3784": {"data": {"text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.", "entity1": "domperidone", "entity2": "dyspepsia", "span1": [139, 150], "span2": [71, 80]}, "bert_text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his <e1> domperidone </e1> <e2> dyspepsia </e2> who developed RLS after mirtazapine had been added to his domperidone therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3785": {"data": {"text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy.", "entity1": "domperidone", "entity2": "RLS", "span1": [139, 150], "span2": [95, 98]}, "bert_text": "The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his <e1> domperidone </e1> <e2> RLS </e2> after mirtazapine had been added to his domperidone therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3786": {"data": {"text": "When tested in a multivariate regression analysis, tranexamic acid was a strong independent predictor of seizures (OR 14.3, 95% CI 5.5-36.7; p < 0.001).", "entity1": "tranexamic acid", "entity2": "seizures", "span1": [51, 66], "span2": [105, 113]}, "bert_text": "When tested in a multivariate regression analysis, <e1> tranexamic acid </e1> was a strong independent predictor of <e2> seizures </e2> (OR 14.3, 95% CI 5.5-36.7; p < 0.001).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3787": {"data": {"text": "Vasopressin as a possible contributor to hypertension.\n", "entity1": "Vasopressin", "entity2": "hypertension", "span1": [0, 11], "span2": [41, 53]}, "bert_text": "<e1> Vasopressin </e1> as a possible contributor to <e2> hypertension </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3788": {"data": {"text": "Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.\n", "entity1": "sirolimus", "entity2": "nephropathy", "span1": [14, 23], "span2": [57, 68]}, "bert_text": "Conversion to <e1> sirolimus </e1> ameliorates cyclosporine-induced <e2> nephropathy </e2> in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3789": {"data": {"text": "Conversion to sirolimus ameliorates cyclosporine-induced nephropathy in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.\n", "entity1": "cyclosporine", "entity2": "nephropathy", "span1": [36, 48], "span2": [57, 68]}, "bert_text": "Conversion to sirolimus ameliorates <e1> cyclosporine </e1>-induced <e2> nephropathy </e2> in the rat: focus on serum, urine, gene, and protein renal expression biomarkers.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3790": {"data": {"text": "The studies were performed using an experimental model of isoproterenol-induced heart hypertrophy in rats.", "entity1": "isoproterenol", "entity2": "heart hypertrophy", "span1": [58, 71], "span2": [80, 97]}, "bert_text": "The studies were performed using an experimental model of <e1> isoproterenol </e1>-induced <e2> heart hypertrophy </e2> in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3791": {"data": {"text": "Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women.", "entity1": "Alendronate", "entity2": "osteoporosis", "span1": [0, 11], "span2": [84, 96]}, "bert_text": "<e1> Alendronate </e1>, a biphosphonate, is effective for both the treatment and prevention of <e2> osteoporosis </e2> in postmenopausal women.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3792": {"data": {"text": "Alendronate, a biphosphonate, is effective for both the treatment and prevention of osteoporosis in postmenopausal women.", "entity1": "biphosphonate", "entity2": "osteoporosis", "span1": [15, 28], "span2": [84, 96]}, "bert_text": "Alendronate, a <e1> biphosphonate </e1>, is effective for both the treatment and prevention of <e2> osteoporosis </e2> in postmenopausal women.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3793": {"data": {"text": "Rifampicin was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and fever with chills and rigors.", "entity1": "Rifampicin", "entity2": "nausea", "span1": [0, 10], "span2": [120, 126]}, "bert_text": "<e1> Rifampicin </e1> was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like <e2> nausea </e2>, vomiting and fever with chills and rigors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3794": {"data": {"text": "Rifampicin was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and fever with chills and rigors.", "entity1": "Rifampicin", "entity2": "vomiting", "span1": [0, 10], "span2": [128, 136]}, "bert_text": "<e1> Rifampicin </e1> was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, <e2> vomiting </e2> and fever with chills and rigors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3795": {"data": {"text": "Rifampicin was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and fever with chills and rigors.", "entity1": "Rifampicin", "entity2": "fever", "span1": [0, 10], "span2": [141, 146]}, "bert_text": "<e1> Rifampicin </e1> was administered thrice as one of the 3-4 drug regimen and each time he developed untoward side effects like nausea, vomiting and <e2> fever </e2> with chills and rigors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3796": {"data": {"text": "Initial evaluation confirmed FHF from acetaminophen and cerebral edema.", "entity1": "acetaminophen", "entity2": "FHF", "span1": [38, 51], "span2": [29, 32]}, "bert_text": "Initial evaluation confirmed FHF from <e1> acetaminophen </e1> <e2> FHF </e2> from acetaminophen and cerebral edema.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3797": {"data": {"text": "Initial evaluation confirmed FHF from acetaminophen and cerebral edema.", "entity1": "acetaminophen", "entity2": "cerebral edema", "span1": [38, 51], "span2": [56, 70]}, "bert_text": "Initial evaluation confirmed FHF from <e1> acetaminophen </e1> and <e2> cerebral edema </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3798": {"data": {"text": "The incidence and intensity of muscle fasciculations caused by suxamethonium were significantly greater in the control than in the alfentanil group.", "entity1": "suxamethonium", "entity2": "muscle fasciculations", "span1": [63, 76], "span2": [31, 52]}, "bert_text": "The incidence and intensity of muscle fasciculations caused by <e1> suxamethonium </e1> <e2> muscle fasciculations </e2> caused by suxamethonium were significantly greater in the control than in the alfentanil group.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3799": {"data": {"text": "The incidence and intensity of muscle fasciculations caused by suxamethonium were significantly greater in the control than in the alfentanil group.", "entity1": "alfentanil", "entity2": "muscle fasciculations", "span1": [131, 141], "span2": [31, 52]}, "bert_text": "The incidence and intensity of muscle fasciculations caused by suxamethonium were significantly greater in the control than in the <e1> alfentanil </e1> <e2> muscle fasciculations </e2> caused by suxamethonium were significantly greater in the control than in the alfentanil group.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3800": {"data": {"text": "Only a handful of cases of ATRA-induced myositis in children have been reported, and none in the radiology literature.", "entity1": "ATRA", "entity2": "myositis", "span1": [27, 31], "span2": [40, 48]}, "bert_text": "Only a handful of cases of <e1> ATRA </e1>-induced <e2> myositis </e2> in children have been reported, and none in the radiology literature.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3801": {"data": {"text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "entity1": "lithium", "entity2": "hypercalcemias", "span1": [117, 124], "span2": [27, 41]}, "bert_text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-<e1> lithium </e1> <e2> hypercalcemias </e2> or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3802": {"data": {"text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "entity1": "lithium", "entity2": "hypercalcemias", "span1": [117, 124], "span2": [147, 161]}, "bert_text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-<e1> lithium </e1>-treated patients with <e2> hypercalcemias </e2> related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3803": {"data": {"text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "entity1": "lithium", "entity2": "hypercalcemia", "span1": [117, 124], "span2": [265, 278]}, "bert_text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-<e1> lithium </e1>-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated <e2> hypercalcemia </e2> (group B).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3804": {"data": {"text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "entity1": "lithium", "entity2": "malignancies", "span1": [117, 124], "span2": [173, 185]}, "bert_text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-<e1> lithium </e1>-treated patients with hypercalcemias related to <e2> malignancies </e2> and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3805": {"data": {"text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "entity1": "lithium", "entity2": "hypercalcemias", "span1": [246, 253], "span2": [27, 41]}, "bert_text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with <e1> lithium </e1> <e2> hypercalcemias </e2> or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3806": {"data": {"text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "entity1": "lithium", "entity2": "hypercalcemias", "span1": [246, 253], "span2": [147, 161]}, "bert_text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with <e1> lithium </e1> <e2> hypercalcemias </e2> related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3807": {"data": {"text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "entity1": "lithium", "entity2": "hypercalcemia", "span1": [246, 253], "span2": [265, 278]}, "bert_text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with <e1> lithium </e1>-associated <e2> hypercalcemia </e2> (group B).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3808": {"data": {"text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "entity1": "lithium", "entity2": "malignancies", "span1": [246, 253], "span2": [173, 185]}, "bert_text": "After eliminating spurious hypercalcemias or those associated with intravenous fluids, the authors identified 18 non-lithium-treated patients with hypercalcemias related to malignancies and other medical conditions (group A) and 12 patients with <e1> lithium </e1> <e2> malignancies </e2> and other medical conditions (group A) and 12 patients with lithium-associated hypercalcemia (group B).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3809": {"data": {"text": "Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats.\n", "entity1": "MK-801", "entity2": "status epilepticus", "span1": [26, 32], "span2": [69, 87]}, "bert_text": "Anticonvulsant actions of <e1> MK-801 </e1> on the lithium-pilocarpine model of <e2> status epilepticus </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3810": {"data": {"text": "Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats.\n", "entity1": "lithium", "entity2": "status epilepticus", "span1": [40, 47], "span2": [69, 87]}, "bert_text": "Anticonvulsant actions of MK-801 on the <e1> lithium </e1>-pilocarpine model of <e2> status epilepticus </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3811": {"data": {"text": "Anticonvulsant actions of MK-801 on the lithium-pilocarpine model of status epilepticus in rats.\n", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [48, 59], "span2": [69, 87]}, "bert_text": "Anticonvulsant actions of MK-801 on the lithium-<e1> pilocarpine </e1> model of <e2> status epilepticus </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3812": {"data": {"text": "In 1 patient, marked hypertension was induced by propranolol and the drug had to be withdrawn.", "entity1": "propranolol", "entity2": "hypertension", "span1": [49, 60], "span2": [21, 33]}, "bert_text": "In 1 patient, marked hypertension was induced by <e1> propranolol </e1> <e2> hypertension </e2> was induced by propranolol and the drug had to be withdrawn.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3813": {"data": {"text": "Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents.", "entity1": "fluoxetine", "entity2": "mania", "span1": [127, 137], "span2": [146, 151]}, "bert_text": "Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to <e1> fluoxetine </e1> induced <e2> mania </e2> in adolescents.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3814": {"data": {"text": "Focal cerebral ischemia in rats: effect of phenylephrine-induced hypertension during reperfusion.\n", "entity1": "phenylephrine", "entity2": "cerebral ischemia", "span1": [43, 56], "span2": [6, 23]}, "bert_text": "Focal cerebral ischemia in rats: effect of <e1> phenylephrine </e1> <e2> cerebral ischemia </e2> in rats: effect of phenylephrine-induced hypertension during reperfusion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3815": {"data": {"text": "Focal cerebral ischemia in rats: effect of phenylephrine-induced hypertension during reperfusion.\n", "entity1": "phenylephrine", "entity2": "hypertension", "span1": [43, 56], "span2": [65, 77]}, "bert_text": "Focal cerebral ischemia in rats: effect of <e1> phenylephrine </e1>-induced <e2> hypertension </e2> during reperfusion.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3816": {"data": {"text": "To quantify this population, the total number of ectopic hilar granule cells was estimated using unbiased stereology at different times after pilocarpine-induced status epilepticus.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [142, 153], "span2": [162, 180]}, "bert_text": "To quantify this population, the total number of ectopic hilar granule cells was estimated using unbiased stereology at different times after <e1> pilocarpine </e1>-induced <e2> status epilepticus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3817": {"data": {"text": "After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.", "entity1": "phenylephrine", "entity2": "middle cerebral artery occlusion", "span1": [110, 123], "span2": [27, 59]}, "bert_text": "After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of <e1> phenylephrine </e1> <e2> middle cerebral artery occlusion </e2> in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3818": {"data": {"text": "After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.", "entity1": "phenylephrine", "entity2": "hypertensive", "span1": [110, 123], "span2": [77, 89]}, "bert_text": "After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of <e1> phenylephrine </e1> <e2> hypertensive </e2> rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3819": {"data": {"text": "After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.", "entity1": "phenylephrine", "entity2": "hypertension", "span1": [110, 123], "span2": [132, 144]}, "bert_text": "After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of <e1> phenylephrine </e1>-induced <e2> hypertension </e2> on ischemic brain injury and blood-brain barrier permeability was determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3820": {"data": {"text": "After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of phenylephrine-induced hypertension on ischemic brain injury and blood-brain barrier permeability was determined.", "entity1": "phenylephrine", "entity2": "ischemic brain injury", "span1": [110, 123], "span2": [148, 169]}, "bert_text": "After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats, the effect of <e1> phenylephrine </e1>-induced hypertension on <e2> ischemic brain injury </e2> and blood-brain barrier permeability was determined.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3821": {"data": {"text": "They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine.", "entity1": "catecholamines", "entity2": "hypersensitivity", "span1": [43, 57], "span2": [139, 155]}, "bert_text": "They all exhibited markedly reduced plasma <e1> catecholamines </e1> and plasma renin activity in both recumbent and upright positions and had marked <e2> hypersensitivity </e2> to the pressor effects of infused norepinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3822": {"data": {"text": "They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine.", "entity1": "norepinephrine", "entity2": "hypersensitivity", "span1": [190, 204], "span2": [139, 155]}, "bert_text": "They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused <e1> norepinephrine </e1> <e2> hypersensitivity </e2> to the pressor effects of infused norepinephrine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3823": {"data": {"text": "Amiodarone-induced torsade de pointes during bladder irrigation: an unusual presentation--a case report.\n", "entity1": "Amiodarone", "entity2": "torsade de pointes", "span1": [0, 10], "span2": [19, 37]}, "bert_text": "<e1> Amiodarone </e1>-induced <e2> torsade de pointes </e2> during bladder irrigation: an unusual presentation--a case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3824": {"data": {"text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity1": "aspirin", "entity2": "GI bleeding", "span1": [15, 22], "span2": [306, 317]}, "bert_text": "Among users of <e1> aspirin </e1>, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/<e2> GI bleeding </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3825": {"data": {"text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity1": "aspirin", "entity2": "GI bleeding", "span1": [247, 254], "span2": [306, 317]}, "bert_text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of <e1> aspirin </e1>, naproxen seemed to carry the highest risk for AMI/<e2> GI bleeding </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3826": {"data": {"text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity1": "rofecoxib", "entity2": "GI bleeding", "span1": [35, 44], "span2": [306, 317]}, "bert_text": "Among users of aspirin, they were: <e1> rofecoxib </e1> 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/<e2> GI bleeding </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3827": {"data": {"text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity1": "celecoxib", "entity2": "GI bleeding", "span1": [64, 73], "span2": [306, 317]}, "bert_text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), <e1> celecoxib </e1> 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/<e2> GI bleeding </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3828": {"data": {"text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity1": "ibuprofen", "entity2": "GI bleeding", "span1": [93, 102], "span2": [306, 317]}, "bert_text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), <e1> ibuprofen </e1> 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/<e2> GI bleeding </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3829": {"data": {"text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity1": "diclofenac", "entity2": "GI bleeding", "span1": [122, 132], "span2": [306, 317]}, "bert_text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), <e1> diclofenac </e1> 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/<e2> GI bleeding </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3830": {"data": {"text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity1": "naproxen", "entity2": "GI bleeding", "span1": [152, 160], "span2": [306, 317]}, "bert_text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), <e1> naproxen </e1> 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/<e2> GI bleeding </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3831": {"data": {"text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity1": "naproxen", "entity2": "GI bleeding", "span1": [256, 264], "span2": [306, 317]}, "bert_text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, <e1> naproxen </e1> seemed to carry the highest risk for AMI/<e2> GI bleeding </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3832": {"data": {"text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity1": "acetaminophen", "entity2": "GI bleeding", "span1": [183, 196], "span2": [306, 317]}, "bert_text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and <e1> acetaminophen </e1> 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/<e2> GI bleeding </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3833": {"data": {"text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for AMI/GI bleeding.", "entity1": "AMI", "entity2": "GI bleeding", "span1": [302, 305], "span2": [306, 317]}, "bert_text": "Among users of aspirin, they were: rofecoxib 1.73 (1.52, 1.98), celecoxib 1.34 (1.19, 1.52), ibuprofen 1.51 (0.95, 2.41), diclofenac 1.69 (1.35, 2.10), naproxen 1.35 (0.97, 1.88) and acetaminophen 1.29 (1.17, 1.42). CONCLUSION: Among non-users of aspirin, naproxen seemed to carry the highest risk for <e1> AMI </e1>/<e2> GI bleeding </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3834": {"data": {"text": "The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina.", "entity1": "nisoldipine", "entity2": "angina", "span1": [40, 51], "span2": [107, 113]}, "bert_text": "The coronary vasodilating properties of <e1> nisoldipine </e1> have led to the investigation of this agent for use in <e2> angina </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3835": {"data": {"text": "Furthermore, Rg1 showed a tendency to aggravate OIH in the acetic acid-induced writhing test.", "entity1": "Rg1", "entity2": "OIH", "span1": [13, 16], "span2": [48, 51]}, "bert_text": "Furthermore, <e1> Rg1 </e1> showed a tendency to aggravate <e2> OIH </e2> in the acetic acid-induced writhing test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3836": {"data": {"text": "Furthermore, Rg1 showed a tendency to aggravate OIH in the acetic acid-induced writhing test.", "entity1": "acetic acid", "entity2": "OIH", "span1": [59, 70], "span2": [48, 51]}, "bert_text": "Furthermore, Rg1 showed a tendency to aggravate OIH in the <e1> acetic acid </e1> <e2> OIH </e2> in the acetic acid-induced writhing test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3837": {"data": {"text": "Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating lithium-induced polyuria.", "entity1": "lithium", "entity2": "polyuria", "span1": [115, 122], "span2": [131, 139]}, "bert_text": "Targeting an alternative signaling pathway, such as PKC-mediated signaling, may be an effective method of treating <e1> lithium </e1>-induced <e2> polyuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3838": {"data": {"text": "Comparison of the effect of oxitropium bromide and of slow-release theophylline on nocturnal asthma.\n", "entity1": "oxitropium bromide", "entity2": "nocturnal asthma", "span1": [28, 46], "span2": [83, 99]}, "bert_text": "Comparison of the effect of <e1> oxitropium bromide </e1> and of slow-release theophylline on <e2> nocturnal asthma </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3839": {"data": {"text": "Comparison of the effect of oxitropium bromide and of slow-release theophylline on nocturnal asthma.\n", "entity1": "theophylline", "entity2": "nocturnal asthma", "span1": [67, 79], "span2": [83, 99]}, "bert_text": "Comparison of the effect of oxitropium bromide and of slow-release <e1> theophylline </e1> on <e2> nocturnal asthma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3840": {"data": {"text": "Corneal ulcers associated with aerosolized crack cocaine use.\n", "entity1": "crack cocaine", "entity2": "Corneal ulcers", "span1": [43, 56], "span2": [0, 14]}, "bert_text": "Corneal ulcers associated with aerosolized <e1> crack cocaine </e1> <e2> Corneal ulcers </e2> associated with aerosolized crack cocaine use.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3841": {"data": {"text": "Two cases of propylthiouracil-induced liver damage have been observed.", "entity1": "propylthiouracil", "entity2": "liver damage", "span1": [13, 29], "span2": [38, 50]}, "bert_text": "Two cases of <e1> propylthiouracil </e1>-induced <e2> liver damage </e2> have been observed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3842": {"data": {"text": "Among 3,129 dobutamine stress echocardiographic studies, a hypertensive response, defined as systolic blood pressure (BP) > or = 220 mm Hg and/or diastolic BP > or = 110 mm Hg, occurred in 30 patients (1%).", "entity1": "3,129 dobutamine", "entity2": "hypertensive", "span1": [6, 22], "span2": [59, 71]}, "bert_text": "Among <e1> 3,129 dobutamine </e1> stress echocardiographic studies, a <e2> hypertensive </e2> response, defined as systolic blood pressure (BP) > or = 220 mm Hg and/or diastolic BP > or = 110 mm Hg, occurred in 30 patients (1%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3843": {"data": {"text": "Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.\n", "entity1": "Chloroacetaldehyde", "entity2": "nephropathy", "span1": [0, 18], "span2": [92, 103]}, "bert_text": "<e1> Chloroacetaldehyde </e1> as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide <e2> nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3844": {"data": {"text": "Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.\n", "entity1": "thiol", "entity2": "nephropathy", "span1": [65, 70], "span2": [92, 103]}, "bert_text": "Chloroacetaldehyde as a sulfhydryl reagent: the role of critical <e1> thiol </e1> groups in ifosfamide <e2> nephropathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3845": {"data": {"text": "Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.\n", "entity1": "ifosfamide", "entity2": "nephropathy", "span1": [81, 91], "span2": [92, 103]}, "bert_text": "Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in <e1> ifosfamide </e1> <e2> nephropathy </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3846": {"data": {"text": "In conclusion, glutamate and capsaicin yield reproducible hyperalgesic and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena.", "entity1": "capsaicin", "entity2": "hyperalgesic", "span1": [29, 38], "span2": [58, 70]}, "bert_text": "In conclusion, glutamate and <e1> capsaicin </e1> yield reproducible <e2> hyperalgesic </e2> and allodynic responses, and the present model is well suited for basic research, as well as for assessing the modulation of central phenomena.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3847": {"data": {"text": "The authors induced myodystrophy in the rat by giving it a diet lacking in vitamin E. The pharmacological characteristics of vitamin E and the degenerative changes brought about by its deficiency, especially in the muscles, are illustrated.", "entity1": "vitamin E.", "entity2": "myodystrophy", "span1": [75, 85], "span2": [20, 32]}, "bert_text": "The authors induced myodystrophy in the rat by giving it a diet lacking in <e1> vitamin E. </e1> <e2> myodystrophy </e2> in the rat by giving it a diet lacking in vitamin E. The pharmacological characteristics of vitamin E and the degenerative changes brought about by its deficiency, especially in the muscles, are illustrated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3848": {"data": {"text": "The authors induced myodystrophy in the rat by giving it a diet lacking in vitamin E. The pharmacological characteristics of vitamin E and the degenerative changes brought about by its deficiency, especially in the muscles, are illustrated.", "entity1": "vitamin E", "entity2": "myodystrophy", "span1": [125, 134], "span2": [20, 32]}, "bert_text": "The authors induced myodystrophy in the rat by giving it a diet lacking in vitamin E. The pharmacological characteristics of <e1> vitamin E </e1> <e2> myodystrophy </e2> in the rat by giving it a diet lacking in vitamin E. The pharmacological characteristics of vitamin E and the degenerative changes brought about by its deficiency, especially in the muscles, are illustrated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3849": {"data": {"text": "A Case of Sudden Cardiac Death due to Pilsicainide-Induced Torsades de Pointes.\n", "entity1": "Pilsicainide", "entity2": "Sudden Cardiac Death", "span1": [38, 50], "span2": [10, 30]}, "bert_text": "A Case of Sudden Cardiac Death due to <e1> Pilsicainide </e1> <e2> Sudden Cardiac Death </e2> due to Pilsicainide-Induced Torsades de Pointes.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3850": {"data": {"text": "A Case of Sudden Cardiac Death due to Pilsicainide-Induced Torsades de Pointes.\n", "entity1": "Pilsicainide", "entity2": "Torsades de Pointes", "span1": [38, 50], "span2": [59, 78]}, "bert_text": "A Case of Sudden Cardiac Death due to <e1> Pilsicainide </e1>-Induced <e2> Torsades de Pointes </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3851": {"data": {"text": "Acute toxicity studies of ACC-9653 and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i.v.", "entity1": "ACC-9653", "entity2": "toxicity", "span1": [26, 34], "span2": [6, 14]}, "bert_text": "Acute toxicity studies of <e1> ACC-9653 </e1> <e2> toxicity </e2> studies of ACC-9653 and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i.v.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3852": {"data": {"text": "Acute toxicity studies of ACC-9653 and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i.v.", "entity1": "phenytoin sodium", "entity2": "toxicity", "span1": [39, 55], "span2": [6, 14]}, "bert_text": "Acute toxicity studies of ACC-9653 and <e1> phenytoin sodium </e1> <e2> toxicity </e2> studies of ACC-9653 and phenytoin sodium were carried out in mice, rats, rabbits, and dogs by i.v.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3853": {"data": {"text": "Does domperidone potentiate mirtazapine-associated restless legs syndrome?\n", "entity1": "domperidone potentiate mirtazapine", "entity2": "restless legs syndrome", "span1": [5, 39], "span2": [51, 73]}, "bert_text": "Does <e1> domperidone potentiate mirtazapine </e1>-associated <e2> restless legs syndrome </e2>?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3854": {"data": {"text": "AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity.", "entity1": "Doxorubicin", "entity2": "cancer", "span1": [6, 17], "span2": [45, 51]}, "bert_text": "AIMS: <e1> Doxorubicin </e1> (DOX) is an effective anti-<e2> cancer </e2> therapeutic, but is associated with both acute and late-stage cardiotoxicity.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3855": {"data": {"text": "AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity.", "entity1": "Doxorubicin", "entity2": "cardiotoxicity", "span1": [6, 17], "span2": [114, 128]}, "bert_text": "AIMS: <e1> Doxorubicin </e1> (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage <e2> cardiotoxicity </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3856": {"data": {"text": "AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity.", "entity1": "DOX", "entity2": "cancer", "span1": [19, 22], "span2": [45, 51]}, "bert_text": "AIMS: Doxorubicin (<e1> DOX </e1>) is an effective anti-<e2> cancer </e2> therapeutic, but is associated with both acute and late-stage cardiotoxicity.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3857": {"data": {"text": "AIMS: Doxorubicin (DOX) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage cardiotoxicity.", "entity1": "DOX", "entity2": "cardiotoxicity", "span1": [19, 22], "span2": [114, 128]}, "bert_text": "AIMS: Doxorubicin (<e1> DOX </e1>) is an effective anti-cancer therapeutic, but is associated with both acute and late-stage <e2> cardiotoxicity </e2>.", "weak_labels": [1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3858": {"data": {"text": "There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "entity1": "warfarin", "entity2": "ICH", "span1": [34, 42], "span2": [66, 69]}, "bert_text": "There was also an excess of MB in <e1> warfarin </e1> users vs nonusers with <e2> ICH </e2> (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3859": {"data": {"text": "There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "entity1": "warfarin", "entity2": "IS", "span1": [34, 42], "span2": [138, 140]}, "bert_text": "There was also an excess of MB in <e1> warfarin </e1> users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with <e2> IS </e2>/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"3860": {"data": {"text": "There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "entity1": "warfarin", "entity2": "TIA", "span1": [34, 42], "span2": [141, 144]}, "bert_text": "There was also an excess of MB in <e1> warfarin </e1> users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/<e2> TIA </e2> (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3861": {"data": {"text": "There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "entity1": "warfarin", "entity2": "ICH", "span1": [118, 126], "span2": [66, 69]}, "bert_text": "There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in <e1> warfarin </e1> <e2> ICH </e2> (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3862": {"data": {"text": "There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "entity1": "warfarin", "entity2": "IS", "span1": [118, 126], "span2": [138, 140]}, "bert_text": "There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in <e1> warfarin </e1> users with <e2> IS </e2>/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"3863": {"data": {"text": "There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in warfarin users with IS/TIA (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "entity1": "warfarin", "entity2": "TIA", "span1": [118, 126], "span2": [141, 144]}, "bert_text": "There was also an excess of MB in warfarin users vs nonusers with ICH (OR, 2.7; 95% CI, 1.6-4.4; P<0.001) but none in <e1> warfarin </e1> users with IS/<e2> TIA </e2> (OR, 1.3; 95% CI, 0.9-1.7; P=0.33; P difference=0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"3864": {"data": {"text": "Ninety-six patients were not given anticonvulsive prophylaxis; 7 (7.5%) developed seizures during the 4 days of the busulfan course or within 24 h after the last dosing.", "entity1": "busulfan", "entity2": "seizures", "span1": [116, 124], "span2": [82, 90]}, "bert_text": "Ninety-six patients were not given anticonvulsive prophylaxis; 7 (7.5%) developed seizures during the 4 days of the <e1> busulfan </e1> <e2> seizures </e2> during the 4 days of the busulfan course or within 24 h after the last dosing.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3865": {"data": {"text": "A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and oral contraceptives is reported in a young female patient with a locked-in syndrome.", "entity1": "oral contraceptives", "entity2": "aneurysm", "span1": [110, 129], "span2": [34, 42]}, "bert_text": "A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and <e1> oral contraceptives </e1> <e2> aneurysm </e2> of the basilar artery in association with hypertension, smoke, and oral contraceptives is reported in a young female patient with a locked-in syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3866": {"data": {"text": "A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and oral contraceptives is reported in a young female patient with a locked-in syndrome.", "entity1": "oral contraceptives", "entity2": "hypertension", "span1": [110, 129], "span2": [85, 97]}, "bert_text": "A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension, smoke, and <e1> oral contraceptives </e1> <e2> hypertension </e2>, smoke, and oral contraceptives is reported in a young female patient with a locked-in syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3867": {"data": {"text": "Although statins are generally well-tolerated drugs, recent cases of drug-induced liver injury associated with their use have been reported.", "entity1": "statins", "entity2": "liver injury", "span1": [9, 16], "span2": [82, 94]}, "bert_text": "Although <e1> statins </e1> are generally well-tolerated drugs, recent cases of drug-induced <e2> liver injury </e2> associated with their use have been reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3868": {"data": {"text": "These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension.", "entity1": "labetalol", "entity2": "hypotension", "span1": [28, 37], "span2": [64, 75]}, "bert_text": "These results indicate that <e1> labetalol </e1> induces easily adjustable <e2> hypotension </e2> without compensatory tachycardia and rebound hypertension.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3869": {"data": {"text": "These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension.", "entity1": "labetalol", "entity2": "tachycardia", "span1": [28, 37], "span2": [97, 108]}, "bert_text": "These results indicate that <e1> labetalol </e1> induces easily adjustable hypotension without compensatory <e2> tachycardia </e2> and rebound hypertension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3870": {"data": {"text": "These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension.", "entity1": "labetalol", "entity2": "hypertension", "span1": [28, 37], "span2": [121, 133]}, "bert_text": "These results indicate that <e1> labetalol </e1> induces easily adjustable hypotension without compensatory tachycardia and rebound <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3871": {"data": {"text": "In the absence of amiodarone therapy, a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia.", "entity1": "amiodarone", "entity2": "TdP", "span1": [18, 28], "span2": [81, 84]}, "bert_text": "In the absence of <e1> amiodarone </e1> therapy, a second bladder irrigation did not induce <e2> TdP </e2> despite hypokalemia and hypomagnesemia.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"3872": {"data": {"text": "In the absence of amiodarone therapy, a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia.", "entity1": "amiodarone", "entity2": "hypokalemia", "span1": [18, 28], "span2": [93, 104]}, "bert_text": "In the absence of <e1> amiodarone </e1> therapy, a second bladder irrigation did not induce TdP despite <e2> hypokalemia </e2> and hypomagnesemia.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"3873": {"data": {"text": "In the absence of amiodarone therapy, a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia.", "entity1": "amiodarone", "entity2": "hypomagnesemia", "span1": [18, 28], "span2": [109, 123]}, "bert_text": "In the absence of <e1> amiodarone </e1> therapy, a second bladder irrigation did not induce TdP despite hypokalemia and <e2> hypomagnesemia </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3874": {"data": {"text": "Because no other factors related to this patient changed significantly, the delirium experienced by this patient possibly resulted from misoprostol therapy.", "entity1": "misoprostol", "entity2": "delirium", "span1": [136, 147], "span2": [76, 84]}, "bert_text": "Because no other factors related to this patient changed significantly, the delirium experienced by this patient possibly resulted from <e1> misoprostol </e1> <e2> delirium </e2> experienced by this patient possibly resulted from misoprostol therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3875": {"data": {"text": "In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.", "entity1": "metformin", "entity2": "cardiac dysfunction", "span1": [63, 72], "span2": [76, 95]}, "bert_text": "In the present study, the effect of chronic pre-treatment with <e1> metformin </e1> on <e2> cardiac dysfunction </e2> and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3876": {"data": {"text": "In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.", "entity1": "metformin", "entity2": "myocardial infarction", "span1": [63, 72], "span2": [149, 170]}, "bert_text": "In the present study, the effect of chronic pre-treatment with <e1> metformin </e1> on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following <e2> myocardial infarction </e2> and their relation with AMPK were assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3877": {"data": {"text": "In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.", "entity1": "AMPK", "entity2": "cardiac dysfunction", "span1": [195, 199], "span2": [76, 95]}, "bert_text": "In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with <e1> AMPK </e1> <e2> cardiac dysfunction </e2> and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3878": {"data": {"text": "In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with AMPK were assessed.", "entity1": "AMPK", "entity2": "myocardial infarction", "span1": [195, 199], "span2": [149, 170]}, "bert_text": "In the present study, the effect of chronic pre-treatment with metformin on cardiac dysfunction and toll-like receptor 4 (TLR4) activities following myocardial infarction and their relation with <e1> AMPK </e1> <e2> myocardial infarction </e2> and their relation with AMPK were assessed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3879": {"data": {"text": "Patients with this response more often had a history of hypertension and had higher resting systolic and diastolic BP before dobutamine infusion.", "entity1": "dobutamine", "entity2": "hypertension", "span1": [125, 135], "span2": [56, 68]}, "bert_text": "Patients with this response more often had a history of hypertension and had higher resting systolic and diastolic BP before <e1> dobutamine </e1> <e2> hypertension </e2> and had higher resting systolic and diastolic BP before dobutamine infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3880": {"data": {"text": "In addition to methadone dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for QT prolongation.", "entity1": "methadone", "entity2": "QT prolongation", "span1": [15, 24], "span2": [135, 150]}, "bert_text": "In addition to <e1> methadone </e1> dose, 15 demographic, biological, and pharmacological variables were considered as potential risk factors for <e2> QT prolongation </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3881": {"data": {"text": "In addition to experiencing hypercalcemic episodes with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/-", "entity1": "calcium", "entity2": "hypercalcemic episodes", "span1": [61, 68], "span2": [28, 50]}, "bert_text": "In addition to experiencing hypercalcemic episodes with peak <e1> calcium </e1> <e2> hypercalcemic episodes </e2> with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3882": {"data": {"text": "In addition to experiencing hypercalcemic episodes with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/-", "entity1": "calcium", "entity2": "hypercalcemic episodes", "span1": [200, 207], "span2": [28, 50]}, "bert_text": "In addition to experiencing hypercalcemic episodes with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean <e1> calcium </e1> <e2> hypercalcemic episodes </e2> with peak calcium values of 2.7 to 3.8 mmol/L (10.7 to 15.0 mg/dL), patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch, compared with the mean value obtained during the 7 months of observation after the switch (2.4 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3883": {"data": {"text": "Only phenytoin sodium displayed in vitro antiarrhythmic activity against strophanthidin-induced arrhythmias in guinea pig right atria.", "entity1": "phenytoin sodium", "entity2": "arrhythmias", "span1": [5, 21], "span2": [96, 107]}, "bert_text": "Only <e1> phenytoin sodium </e1> displayed in vitro antiarrhythmic activity against strophanthidin-induced <e2> arrhythmias </e2> in guinea pig right atria.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3884": {"data": {"text": "Only phenytoin sodium displayed in vitro antiarrhythmic activity against strophanthidin-induced arrhythmias in guinea pig right atria.", "entity1": "strophanthidin", "entity2": "arrhythmias", "span1": [73, 87], "span2": [96, 107]}, "bert_text": "Only phenytoin sodium displayed in vitro antiarrhythmic activity against <e1> strophanthidin </e1>-induced <e2> arrhythmias </e2> in guinea pig right atria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3885": {"data": {"text": "Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.\n", "entity1": "pilocarpine", "entity2": "seizures", "span1": [39, 50], "span2": [18, 26]}, "bert_text": "Susceptibility to seizures produced by <e1> pilocarpine </e1> <e2> seizures </e2> produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3886": {"data": {"text": "Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.\n", "entity1": "isoniazid", "entity2": "seizures", "span1": [83, 92], "span2": [18, 26]}, "bert_text": "Susceptibility to seizures produced by pilocarpine in rats after microinjection of <e1> isoniazid </e1> <e2> seizures </e2> produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3887": {"data": {"text": "Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.\n", "entity1": "gamma-vinyl-GABA", "entity2": "seizures", "span1": [96, 112], "span2": [18, 26]}, "bert_text": "Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or <e1> gamma-vinyl-GABA </e1> <e2> seizures </e2> produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3888": {"data": {"text": "By inhibiting the cytochrome P450 2D6, terbinafine had decreased metoprolol's clearance, leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia.", "entity1": "terbinafine", "entity2": "sinus bradycardia", "span1": [39, 50], "span2": [169, 186]}, "bert_text": "By inhibiting the cytochrome P450 2D6, <e1> terbinafine </e1> had decreased metoprolol's clearance, leading in metoprolol accumulation which has resulted in clinically significant <e2> sinus bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3889": {"data": {"text": "By inhibiting the cytochrome P450 2D6, terbinafine had decreased metoprolol's clearance, leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia.", "entity1": "metoprolol's", "entity2": "sinus bradycardia", "span1": [65, 77], "span2": [169, 186]}, "bert_text": "By inhibiting the cytochrome P450 2D6, terbinafine had decreased <e1> metoprolol's </e1> clearance, leading in metoprolol accumulation which has resulted in clinically significant <e2> sinus bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3890": {"data": {"text": "By inhibiting the cytochrome P450 2D6, terbinafine had decreased metoprolol's clearance, leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia.", "entity1": "metoprolol", "entity2": "sinus bradycardia", "span1": [100, 110], "span2": [169, 186]}, "bert_text": "By inhibiting the cytochrome P450 2D6, terbinafine had decreased metoprolol's clearance, leading in <e1> metoprolol </e1> accumulation which has resulted in clinically significant <e2> sinus bradycardia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3891": {"data": {"text": "An adverse drug interaction with piroxicam, which she took occasionally, may have exacerbated the coagulopathy.", "entity1": "piroxicam", "entity2": "coagulopathy", "span1": [33, 42], "span2": [98, 110]}, "bert_text": "An adverse drug interaction with <e1> piroxicam </e1>, which she took occasionally, may have exacerbated the <e2> coagulopathy </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3892": {"data": {"text": "Patients were eligible for DSE if they had used cocaine within 24 hours preceding the onset of chest pain and had a normal ECG and tropinin I level.", "entity1": "cocaine", "entity2": "chest pain", "span1": [48, 55], "span2": [95, 105]}, "bert_text": "Patients were eligible for DSE if they had used <e1> cocaine </e1> within 24 hours preceding the onset of <e2> chest pain </e2> and had a normal ECG and tropinin I level.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3893": {"data": {"text": "The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac.", "entity1": "diclofenac", "entity2": "renal injury", "span1": [110, 120], "span2": [4, 16]}, "bert_text": "The renal injury was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, <e1> diclofenac </e1> <e2> renal injury </e2> was probably aggravated by the concomitant intake of a non-steroidal anti-inflammatory drug, diclofenac.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3894": {"data": {"text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "entity1": "risperidone", "entity2": "chronic renal failure", "span1": [114, 125], "span2": [15, 36]}, "bert_text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of <e1> risperidone </e1> <e2> chronic renal failure </e2> (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3895": {"data": {"text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "entity1": "risperidone", "entity2": "CRF", "span1": [114, 125], "span2": [38, 41]}, "bert_text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of <e1> risperidone </e1> <e2> CRF </e2>) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3896": {"data": {"text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "entity1": "risperidone", "entity2": "neuroleptic malignant syndrome", "span1": [114, 125], "span2": [53, 83]}, "bert_text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of <e1> risperidone </e1> <e2> neuroleptic malignant syndrome </e2> (NMS) after administration of risperidone and levomepromazine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3897": {"data": {"text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "entity1": "risperidone", "entity2": "NMS", "span1": [114, 125], "span2": [85, 88]}, "bert_text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of <e1> risperidone </e1> <e2> NMS </e2>) after administration of risperidone and levomepromazine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3898": {"data": {"text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "entity1": "levomepromazine", "entity2": "chronic renal failure", "span1": [130, 145], "span2": [15, 36]}, "bert_text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and <e1> levomepromazine </e1> <e2> chronic renal failure </e2> (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3899": {"data": {"text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "entity1": "levomepromazine", "entity2": "CRF", "span1": [130, 145], "span2": [38, 41]}, "bert_text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and <e1> levomepromazine </e1> <e2> CRF </e2>) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3900": {"data": {"text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "entity1": "levomepromazine", "entity2": "neuroleptic malignant syndrome", "span1": [130, 145], "span2": [53, 83]}, "bert_text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and <e1> levomepromazine </e1> <e2> neuroleptic malignant syndrome </e2> (NMS) after administration of risperidone and levomepromazine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3901": {"data": {"text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and levomepromazine.", "entity1": "levomepromazine", "entity2": "NMS", "span1": [130, 145], "span2": [85, 88]}, "bert_text": "A patient with chronic renal failure (CRF) developed neuroleptic malignant syndrome (NMS) after administration of risperidone and <e1> levomepromazine </e1> <e2> NMS </e2>) after administration of risperidone and levomepromazine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3902": {"data": {"text": "Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction.\n", "entity1": "lidocaine", "entity2": "myocardial infarction", "span1": [19, 28], "span2": [65, 86]}, "bert_text": "Clinical safety of <e1> lidocaine </e1> in patients with cocaine-associated <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3903": {"data": {"text": "Clinical safety of lidocaine in patients with cocaine-associated myocardial infarction.\n", "entity1": "cocaine", "entity2": "myocardial infarction", "span1": [46, 53], "span2": [65, 86]}, "bert_text": "Clinical safety of lidocaine in patients with <e1> cocaine </e1>-associated <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3904": {"data": {"text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.", "entity1": "granisetron", "entity2": "nausea", "span1": [88, 99], "span2": [252, 258]}, "bert_text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of <e1> granisetron </e1> (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced <e2> nausea </e2> and vomiting.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3905": {"data": {"text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.", "entity1": "granisetron", "entity2": "vomiting", "span1": [88, 99], "span2": [263, 271]}, "bert_text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of <e1> granisetron </e1> (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and <e2> vomiting </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3906": {"data": {"text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.", "entity1": "Kytril", "entity2": "nausea", "span1": [101, 107], "span2": [252, 258]}, "bert_text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (<e1> Kytril </e1>; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced <e2> nausea </e2> and vomiting.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3907": {"data": {"text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.", "entity1": "Kytril", "entity2": "vomiting", "span1": [101, 107], "span2": [263, 271]}, "bert_text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (<e1> Kytril </e1>; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and <e2> vomiting </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3908": {"data": {"text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.", "entity1": "cisplatin", "entity2": "nausea", "span1": [234, 243], "span2": [252, 258]}, "bert_text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of <e1> cisplatin </e1>-induced <e2> nausea </e2> and vomiting.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3909": {"data": {"text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting.", "entity1": "cisplatin", "entity2": "vomiting", "span1": [234, 243], "span2": [263, 271]}, "bert_text": "PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of <e1> cisplatin </e1>-induced nausea and <e2> vomiting </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3910": {"data": {"text": "There are many strategies to prevent this toxicity, including the use of mannitol as a nephroprotectant in combination with hydration.", "entity1": "mannitol", "entity2": "toxicity", "span1": [73, 81], "span2": [42, 50]}, "bert_text": "There are many strategies to prevent this toxicity, including the use of <e1> mannitol </e1> <e2> toxicity </e2>, including the use of mannitol as a nephroprotectant in combination with hydration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"3911": {"data": {"text": "The long-term safety of danazol in women with hereditary angioedema.\n", "entity1": "danazol", "entity2": "hereditary angioedema", "span1": [24, 31], "span2": [46, 67]}, "bert_text": "The long-term safety of <e1> danazol </e1> in women with <e2> hereditary angioedema </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3912": {"data": {"text": "Valproate-induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment.", "entity1": "Valproate", "entity2": "hyperammonemic encephalopathy", "span1": [0, 9], "span2": [18, 47]}, "bert_text": "<e1> Valproate </e1>-induced <e2> hyperammonemic encephalopathy </e2> is an uncommon but serious effect of valproate treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3913": {"data": {"text": "Valproate-induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment.", "entity1": "valproate", "entity2": "hyperammonemic encephalopathy", "span1": [85, 94], "span2": [18, 47]}, "bert_text": "Valproate-induced hyperammonemic encephalopathy is an uncommon but serious effect of <e1> valproate </e1> <e2> hyperammonemic encephalopathy </e2> is an uncommon but serious effect of valproate treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3914": {"data": {"text": "In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.", "entity1": "Streptozotocin", "entity2": "synaptic toxicity", "span1": [84, 98], "span2": [59, 76]}, "bert_text": "In the present study the role of glial activation and post synaptic toxicity in ICV <e1> Streptozotocin </e1> <e2> synaptic toxicity </e2> in ICV Streptozotocin (STZ) induced memory impaired rats was explored.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3915": {"data": {"text": "In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.", "entity1": "Streptozotocin", "entity2": "memory impaired", "span1": [84, 98], "span2": [113, 128]}, "bert_text": "In the present study the role of glial activation and post synaptic toxicity in ICV <e1> Streptozotocin </e1> (STZ) induced <e2> memory impaired </e2> rats was explored.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3916": {"data": {"text": "In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.", "entity1": "STZ", "entity2": "synaptic toxicity", "span1": [100, 103], "span2": [59, 76]}, "bert_text": "In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1> STZ </e1> <e2> synaptic toxicity </e2> in ICV Streptozotocin (STZ) induced memory impaired rats was explored.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3917": {"data": {"text": "In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (STZ) induced memory impaired rats was explored.", "entity1": "STZ", "entity2": "memory impaired", "span1": [100, 103], "span2": [113, 128]}, "bert_text": "In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin (<e1> STZ </e1>) induced <e2> memory impaired </e2> rats was explored.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3918": {"data": {"text": "The seizures were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient.", "entity1": "sodium thiopental", "entity2": "seizures", "span1": [44, 61], "span2": [4, 12]}, "bert_text": "The seizures were successfully treated with <e1> sodium thiopental </e1> <e2> seizures </e2> were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3919": {"data": {"text": "The seizures were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient.", "entity1": "succinylcholine", "entity2": "seizures", "span1": [77, 92], "span2": [4, 12]}, "bert_text": "The seizures were successfully treated with sodium thiopental in addition to <e1> succinylcholine </e1> <e2> seizures </e2> were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3920": {"data": {"text": "These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.", "entity1": "dopamine", "entity2": "death", "span1": [53, 61], "span2": [90, 95]}, "bert_text": "These data suggest a protective role for the central <e1> dopamine </e1> blocker haloperidol against <e2> death </e2> from high-dose amphetamine exposure without reducing the incidence of seizures.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3921": {"data": {"text": "These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.", "entity1": "dopamine", "entity2": "seizures", "span1": [53, 61], "span2": [166, 174]}, "bert_text": "These data suggest a protective role for the central <e1> dopamine </e1> blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3922": {"data": {"text": "These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.", "entity1": "haloperidol", "entity2": "death", "span1": [70, 81], "span2": [90, 95]}, "bert_text": "These data suggest a protective role for the central dopamine blocker <e1> haloperidol </e1> against <e2> death </e2> from high-dose amphetamine exposure without reducing the incidence of seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3923": {"data": {"text": "These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.", "entity1": "haloperidol", "entity2": "seizures", "span1": [70, 81], "span2": [166, 174]}, "bert_text": "These data suggest a protective role for the central dopamine blocker <e1> haloperidol </e1> against death from high-dose amphetamine exposure without reducing the incidence of <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3924": {"data": {"text": "These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.", "entity1": "amphetamine", "entity2": "death", "span1": [111, 122], "span2": [90, 95]}, "bert_text": "These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose <e1> amphetamine </e1> <e2> death </e2> from high-dose amphetamine exposure without reducing the incidence of seizures.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3925": {"data": {"text": "These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose amphetamine exposure without reducing the incidence of seizures.", "entity1": "amphetamine", "entity2": "seizures", "span1": [111, 122], "span2": [166, 174]}, "bert_text": "These data suggest a protective role for the central dopamine blocker haloperidol against death from high-dose <e1> amphetamine </e1> exposure without reducing the incidence of <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3926": {"data": {"text": "Patients who are candidates for long-term cyclophosphamide treatment should be routinely evaluated for obstructive uropathy.", "entity1": "cyclophosphamide", "entity2": "obstructive uropathy", "span1": [42, 58], "span2": [103, 123]}, "bert_text": "Patients who are candidates for long-term <e1> cyclophosphamide </e1> treatment should be routinely evaluated for <e2> obstructive uropathy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3927": {"data": {"text": "Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.", "entity1": "Levodopa", "entity2": "Parkinson's disease", "span1": [0, 8], "span2": [55, 74]}, "bert_text": "<e1> Levodopa </e1> is the most effective symptomatic therapy for <e2> Parkinson's disease </e2>, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3928": {"data": {"text": "Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.", "entity1": "Levodopa", "entity2": "dyskinesia", "span1": [0, 8], "span2": [164, 174]}, "bert_text": "<e1> Levodopa </e1> is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, <e2> dyskinesia </e2> and visual hallucinations.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3929": {"data": {"text": "Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations.", "entity1": "Levodopa", "entity2": "visual hallucinations", "span1": [0, 8], "span2": [179, 200]}, "bert_text": "<e1> Levodopa </e1> is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and <e2> visual hallucinations </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3930": {"data": {"text": "Central nervous system toxicity following the administration of levobupivacaine for lumbar plexus block: A report of two cases.\n", "entity1": "levobupivacaine", "entity2": "Central nervous system toxicity", "span1": [64, 79], "span2": [0, 31]}, "bert_text": "Central nervous system toxicity following the administration of <e1> levobupivacaine </e1> <e2> Central nervous system toxicity </e2> following the administration of levobupivacaine for lumbar plexus block: A report of two cases.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3931": {"data": {"text": "Two patients with leprosy who developed hemolysis and acute renal failure following rifampin are reported.", "entity1": "rifampin", "entity2": "leprosy", "span1": [84, 92], "span2": [18, 25]}, "bert_text": "Two patients with leprosy who developed hemolysis and acute renal failure following <e1> rifampin </e1> <e2> leprosy </e2> who developed hemolysis and acute renal failure following rifampin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3932": {"data": {"text": "Two patients with leprosy who developed hemolysis and acute renal failure following rifampin are reported.", "entity1": "rifampin", "entity2": "hemolysis", "span1": [84, 92], "span2": [40, 49]}, "bert_text": "Two patients with leprosy who developed hemolysis and acute renal failure following <e1> rifampin </e1> <e2> hemolysis </e2> and acute renal failure following rifampin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3933": {"data": {"text": "Two patients with leprosy who developed hemolysis and acute renal failure following rifampin are reported.", "entity1": "rifampin", "entity2": "acute renal failure", "span1": [84, 92], "span2": [54, 73]}, "bert_text": "Two patients with leprosy who developed hemolysis and acute renal failure following <e1> rifampin </e1> <e2> acute renal failure </e2> following rifampin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3934": {"data": {"text": "In experiment set up 1: Memory deficit was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration.", "entity1": "STZ", "entity2": "Memory deficit", "span1": [95, 98], "span2": [24, 38]}, "bert_text": "In experiment set up 1: Memory deficit was found in Morris water maze test on 14-16 days after <e1> STZ </e1> <e2> Memory deficit </e2> was found in Morris water maze test on 14-16 days after STZ (ICV; 3mg/Kg) administration.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3935": {"data": {"text": "Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known neurotoxic effects.", "entity1": "Lindane", "entity2": "neurotoxic", "span1": [0, 7], "span2": [82, 92]}, "bert_text": "<e1> Lindane </e1> (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known <e2> neurotoxic </e2> effects.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3936": {"data": {"text": "Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known neurotoxic effects.", "entity1": "gamma-hexachlorocyclohexane", "entity2": "neurotoxic", "span1": [9, 36], "span2": [82, 92]}, "bert_text": "Lindane (<e1> gamma-hexachlorocyclohexane </e1>) is an organochlorine insecticide with known <e2> neurotoxic </e2> effects.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3937": {"data": {"text": "Lindane (gamma-hexachlorocyclohexane) is an organochlorine insecticide with known neurotoxic effects.", "entity1": "organochlorine", "entity2": "neurotoxic", "span1": [44, 58], "span2": [82, 92]}, "bert_text": "Lindane (gamma-hexachlorocyclohexane) is an <e1> organochlorine </e1> insecticide with known <e2> neurotoxic </e2> effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3938": {"data": {"text": "To determine the prevalence of heart disease in outpatient young asymptomatic chronic cocaine users, 35 cocaine users and 32 age-matched controls underwent resting and exercise electrocardiography (ECG) and Doppler echocardiography.", "entity1": "cocaine", "entity2": "heart disease", "span1": [86, 93], "span2": [31, 44]}, "bert_text": "To determine the prevalence of heart disease in outpatient young asymptomatic chronic <e1> cocaine </e1> <e2> heart disease </e2> in outpatient young asymptomatic chronic cocaine users, 35 cocaine users and 32 age-matched controls underwent resting and exercise electrocardiography (ECG) and Doppler echocardiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3939": {"data": {"text": "To determine the prevalence of heart disease in outpatient young asymptomatic chronic cocaine users, 35 cocaine users and 32 age-matched controls underwent resting and exercise electrocardiography (ECG) and Doppler echocardiography.", "entity1": "cocaine", "entity2": "heart disease", "span1": [104, 111], "span2": [31, 44]}, "bert_text": "To determine the prevalence of heart disease in outpatient young asymptomatic chronic cocaine users, 35 <e1> cocaine </e1> <e2> heart disease </e2> in outpatient young asymptomatic chronic cocaine users, 35 cocaine users and 32 age-matched controls underwent resting and exercise electrocardiography (ECG) and Doppler echocardiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3940": {"data": {"text": "The mean H concentration during hypotension in the inspiratory gas was 0.7 +/-", "entity1": "H", "entity2": "hypotension", "span1": [9, 10], "span2": [32, 43]}, "bert_text": "The mean <e1> H </e1> concentration during <e2> hypotension </e2> in the inspiratory gas was 0.7 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3941": {"data": {"text": "Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.\n", "entity1": "5-hydroxytryptamine-3", "entity2": "nausea", "span1": [48, 69], "span2": [112, 118]}, "bert_text": "Efficacy and safety of granisetron, a selective <e1> 5-hydroxytryptamine-3 </e1> receptor antagonist, in the prevention of <e2> nausea </e2> and vomiting induced by high-dose cisplatin.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3942": {"data": {"text": "Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.\n", "entity1": "5-hydroxytryptamine-3", "entity2": "vomiting", "span1": [48, 69], "span2": [123, 131]}, "bert_text": "Efficacy and safety of granisetron, a selective <e1> 5-hydroxytryptamine-3 </e1> receptor antagonist, in the prevention of nausea and <e2> vomiting </e2> induced by high-dose cisplatin.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3943": {"data": {"text": "Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.\n", "entity1": "cisplatin", "entity2": "nausea", "span1": [153, 162], "span2": [112, 118]}, "bert_text": "Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose <e1> cisplatin </e1> <e2> nausea </e2> and vomiting induced by high-dose cisplatin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3944": {"data": {"text": "Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.\n", "entity1": "cisplatin", "entity2": "vomiting", "span1": [153, 162], "span2": [123, 131]}, "bert_text": "Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose <e1> cisplatin </e1> <e2> vomiting </e2> induced by high-dose cisplatin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3945": {"data": {"text": "We examined the case of a lithium-treated patient who had recurrent hypercalcemia to better understand the disease process.", "entity1": "lithium", "entity2": "hypercalcemia", "span1": [26, 33], "span2": [68, 81]}, "bert_text": "We examined the case of a <e1> lithium </e1>-treated patient who had recurrent <e2> hypercalcemia </e2> to better understand the disease process.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3946": {"data": {"text": "We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.", "entity1": "CCK-8", "entity2": "amnesia", "span1": [33, 38], "span2": [81, 88]}, "bert_text": "We have previously reported that <e1> CCK-8 </e1> significantly alleviated morphine-induced <e2> amnesia </e2> and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3947": {"data": {"text": "We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.", "entity1": "morphine", "entity2": "amnesia", "span1": [64, 72], "span2": [81, 88]}, "bert_text": "We have previously reported that CCK-8 significantly alleviated <e1> morphine </e1>-induced <e2> amnesia </e2> and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3948": {"data": {"text": "We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.", "entity1": "morphine", "entity2": "amnesia", "span1": [166, 174], "span2": [81, 88]}, "bert_text": "We have previously reported that CCK-8 significantly alleviated morphine-induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in <e1> morphine </e1> <e2> amnesia </e2> and reversed spine density decreases in the CA1 region of the hippocampus in morphine-treated animals.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3949": {"data": {"text": "Tranexamic acid (TNA) 1 g 8-hourly was administered to her to control bleeding per vaginum.", "entity1": "Tranexamic acid", "entity2": "bleeding", "span1": [0, 15], "span2": [70, 78]}, "bert_text": "<e1> Tranexamic acid </e1> (TNA) 1 g 8-hourly was administered to her to control <e2> bleeding </e2> per vaginum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3950": {"data": {"text": "Tranexamic acid (TNA) 1 g 8-hourly was administered to her to control bleeding per vaginum.", "entity1": "TNA", "entity2": "bleeding", "span1": [17, 20], "span2": [70, 78]}, "bert_text": "Tranexamic acid (<e1> TNA </e1>) 1 g 8-hourly was administered to her to control <e2> bleeding </e2> per vaginum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3951": {"data": {"text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "entity1": "rifampicin", "entity2": "IE", "span1": [170, 180], "span2": [52, 54]}, "bert_text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with <e1> rifampicin </e1> <e2> IE </e2> who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3952": {"data": {"text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "entity1": "rifampicin", "entity2": "acute renal failure", "span1": [170, 180], "span2": [69, 88]}, "bert_text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with <e1> rifampicin </e1> <e2> acute renal failure </e2> secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3953": {"data": {"text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "entity1": "rifampicin", "entity2": "necrotising glomerulonephritis", "span1": [170, 180], "span2": [114, 144]}, "bert_text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with <e1> rifampicin </e1> <e2> necrotising glomerulonephritis </e2> while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3954": {"data": {"text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "entity1": "rifampicin", "entity2": "IE", "span1": [239, 249], "span2": [52, 54]}, "bert_text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of <e1> rifampicin </e1> <e2> IE </e2> who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3955": {"data": {"text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "entity1": "rifampicin", "entity2": "acute renal failure", "span1": [239, 249], "span2": [69, 88]}, "bert_text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of <e1> rifampicin </e1> <e2> acute renal failure </e2> secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3956": {"data": {"text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "entity1": "rifampicin", "entity2": "necrotising glomerulonephritis", "span1": [239, 249], "span2": [114, 144]}, "bert_text": "We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin, and review the literature regarding this complication of <e1> rifampicin </e1> <e2> necrotising glomerulonephritis </e2> while being treated with rifampicin, and review the literature regarding this complication of rifampicin therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3957": {"data": {"text": "Normoammonemic encephalopathy: solely valproate induced or multiple mechanisms?\n", "entity1": "valproate", "entity2": "encephalopathy", "span1": [38, 47], "span2": [15, 29]}, "bert_text": "Normoammonemic encephalopathy: solely <e1> valproate </e1> <e2> encephalopathy </e2>: solely valproate induced or multiple mechanisms?\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3958": {"data": {"text": "Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.", "entity1": "Adrenaline", "entity2": "hypertension", "span1": [0, 10], "span2": [19, 31]}, "bert_text": "<e1> Adrenaline </e1>-induced <e2> hypertension </e2> was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3959": {"data": {"text": "Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.", "entity1": "adrenaline", "entity2": "hypertension", "span1": [161, 171], "span2": [19, 31]}, "bert_text": "Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving <e1> adrenaline </e1> <e2> hypertension </e2> was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3960": {"data": {"text": "Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.", "entity1": "triphenyltetrazolium", "entity2": "hypertension", "span1": [87, 107], "span2": [19, 31]}, "bert_text": "Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using <e1> triphenyltetrazolium </e1> <e2> hypertension </e2> was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3961": {"data": {"text": "Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.", "entity1": "TTC", "entity2": "hypertension", "span1": [109, 112], "span2": [19, 31]}, "bert_text": "Adrenaline-induced hypertension was used to destroy the BBB, which was evaluated using triphenyltetrazolium (<e1> TTC </e1> <e2> hypertension </e2> was used to destroy the BBB, which was evaluated using triphenyltetrazolium (TTC) staining of the brain slices just after giving adrenaline for 30 s.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3962": {"data": {"text": "Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, fludrocortisone was added, correcting the hyperkalemia and allowing indomethacin therapy to be continued safely.", "entity1": "fludrocortisone", "entity2": "hyperkalemia", "span1": [82, 97], "span2": [124, 136]}, "bert_text": "Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, <e1> fludrocortisone </e1> was added, correcting the <e2> hyperkalemia </e2> and allowing indomethacin therapy to be continued safely.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3963": {"data": {"text": "Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, fludrocortisone was added, correcting the hyperkalemia and allowing indomethacin therapy to be continued safely.", "entity1": "indomethacin", "entity2": "hyperkalemia", "span1": [150, 162], "span2": [124, 136]}, "bert_text": "Because he was unable to discontinue nonsteroidal anti-inflammatory drug therapy, fludrocortisone was added, correcting the hyperkalemia and allowing <e1> indomethacin </e1> <e2> hyperkalemia </e2> and allowing indomethacin therapy to be continued safely.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"3964": {"data": {"text": "CONCLUSIONS: Supratherapeutic flecainide plasma concentrations may cause delirium.", "entity1": "flecainide", "entity2": "delirium", "span1": [30, 40], "span2": [73, 81]}, "bert_text": "CONCLUSIONS: Supratherapeutic <e1> flecainide </e1> plasma concentrations may cause <e2> delirium </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3965": {"data": {"text": "Adenosine antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (ARF).", "entity1": "Adenosine", "entity2": "ischaemic and nephrotoxic", "span1": [0, 9], "span2": [74, 99]}, "bert_text": "<e1> Adenosine </e1> antagonists have been previously shown to be of benefit in some <e2> ischaemic and nephrotoxic </e2> models of acute renal failure (ARF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3966": {"data": {"text": "Adenosine antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (ARF).", "entity1": "Adenosine", "entity2": "acute renal failure", "span1": [0, 9], "span2": [110, 129]}, "bert_text": "<e1> Adenosine </e1> antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of <e2> acute renal failure </e2> (ARF).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3967": {"data": {"text": "Adenosine antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (ARF).", "entity1": "Adenosine", "entity2": "ARF", "span1": [0, 9], "span2": [131, 134]}, "bert_text": "<e1> Adenosine </e1> antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure (<e2> ARF </e2>).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3968": {"data": {"text": "Long-term oestrogen-only HT also significantly increased the risk of stroke and gallbladder disease.", "entity1": "oestrogen", "entity2": "stroke", "span1": [10, 19], "span2": [69, 75]}, "bert_text": "Long-term <e1> oestrogen </e1>-only HT also significantly increased the risk of <e2> stroke </e2> and gallbladder disease.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3969": {"data": {"text": "Long-term oestrogen-only HT also significantly increased the risk of stroke and gallbladder disease.", "entity1": "oestrogen", "entity2": "gallbladder disease", "span1": [10, 19], "span2": [80, 99]}, "bert_text": "Long-term <e1> oestrogen </e1>-only HT also significantly increased the risk of stroke and <e2> gallbladder disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"3970": {"data": {"text": "Our findings have implications for the provision of alcohol use interventions and psychological resources to improve the health of women with HIV.", "entity1": "alcohol", "entity2": "HIV", "span1": [52, 59], "span2": [142, 145]}, "bert_text": "Our findings have implications for the provision of <e1> alcohol </e1> use interventions and psychological resources to improve the health of women with <e2> HIV </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3971": {"data": {"text": "The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).", "entity1": "VAL", "entity2": "hypokalemia", "span1": [44, 47], "span2": [17, 28]}, "bert_text": "The incidence of hypokalemia was lower with <e1> VAL </e1> <e2> hypokalemia </e2> was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3972": {"data": {"text": "The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).", "entity1": "HCTZ", "entity2": "hypokalemia", "span1": [48, 52], "span2": [17, 28]}, "bert_text": "The incidence of hypokalemia was lower with VAL/<e1> HCTZ </e1> <e2> hypokalemia </e2> was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3973": {"data": {"text": "The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).", "entity1": "HCTZ", "entity2": "hypokalemia", "span1": [88, 92], "span2": [17, 28]}, "bert_text": "The incidence of hypokalemia was lower with VAL/HCTZ combinations (1.8%-6.1%) than with <e1> HCTZ </e1> <e2> hypokalemia </e2> was lower with VAL/HCTZ combinations (1.8%-6.1%) than with HCTZ monotherapies (7.1%-13.3%).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3974": {"data": {"text": "CONCLUSION: Subacute exposure to PDN induced anxiety and reactivity of microglia.", "entity1": "PDN", "entity2": "anxiety", "span1": [33, 36], "span2": [45, 52]}, "bert_text": "CONCLUSION: Subacute exposure to <e1> PDN </e1> induced <e2> anxiety </e2> and reactivity of microglia.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3975": {"data": {"text": "CONCLUSION: Established visual field defects presumed to be due to Vigabatrin therapy did not usually progress in spite of continuing use of the medication.", "entity1": "Vigabatrin", "entity2": "visual field defects", "span1": [67, 77], "span2": [24, 44]}, "bert_text": "CONCLUSION: Established visual field defects presumed to be due to <e1> Vigabatrin </e1> <e2> visual field defects </e2> presumed to be due to Vigabatrin therapy did not usually progress in spite of continuing use of the medication.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3976": {"data": {"text": "Here, we describe the case of a 15-year-old girl who was on a long-term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation.", "entity1": "valproate", "entity2": "epilepsy", "span1": [85, 94], "span2": [102, 110]}, "bert_text": "Here, we describe the case of a 15-year-old girl who was on a long-term therapy with <e1> valproate </e1> due to <e2> epilepsy </e2> and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3977": {"data": {"text": "Here, we describe the case of a 15-year-old girl who was on a long-term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation.", "entity1": "valproate", "entity2": "impaired consciousness", "span1": [85, 94], "span2": [124, 146]}, "bert_text": "Here, we describe the case of a 15-year-old girl who was on a long-term therapy with <e1> valproate </e1> due to epilepsy and revealed <e2> impaired consciousness </e2> with hyperammonemia 12 days after renal transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3978": {"data": {"text": "Here, we describe the case of a 15-year-old girl who was on a long-term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation.", "entity1": "valproate", "entity2": "hyperammonemia", "span1": [85, 94], "span2": [152, 166]}, "bert_text": "Here, we describe the case of a 15-year-old girl who was on a long-term therapy with <e1> valproate </e1> due to epilepsy and revealed impaired consciousness with <e2> hyperammonemia </e2> 12 days after renal transplantation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3979": {"data": {"text": "A 1-year-old female presented with neuroleptic malignant syndrome probably caused by methylphenidate.", "entity1": "methylphenidate", "entity2": "neuroleptic malignant syndrome", "span1": [85, 100], "span2": [35, 65]}, "bert_text": "A 1-year-old female presented with neuroleptic malignant syndrome probably caused by <e1> methylphenidate </e1> <e2> neuroleptic malignant syndrome </e2> probably caused by methylphenidate.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3980": {"data": {"text": "Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment.\n", "entity1": "ethambutol", "entity2": "peripheral neuropathy", "span1": [48, 58], "span2": [19, 40]}, "bert_text": "Optochiasmatic and peripheral neuropathy due to <e1> ethambutol </e1> <e2> peripheral neuropathy </e2> due to ethambutol overtreatment.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3981": {"data": {"text": "Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.\n", "entity1": "Sotalol", "entity2": "coronary spasm", "span1": [0, 7], "span2": [16, 30]}, "bert_text": "<e1> Sotalol </e1>-induced <e2> coronary spasm </e2> in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3982": {"data": {"text": "Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.\n", "entity1": "Sotalol", "entity2": "dilated cardiomyopathy", "span1": [0, 7], "span2": [49, 71]}, "bert_text": "<e1> Sotalol </e1>-induced coronary spasm in a patient with <e2> dilated cardiomyopathy </e2> associated with sustained ventricular tachycardia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3983": {"data": {"text": "Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia.\n", "entity1": "Sotalol", "entity2": "ventricular tachycardia", "span1": [0, 7], "span2": [98, 121]}, "bert_text": "<e1> Sotalol </e1>-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained <e2> ventricular tachycardia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3984": {"data": {"text": "Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.", "entity1": "temsirolimus", "entity2": "MCL", "span1": [104, 116], "span2": [58, 61]}, "bert_text": "Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after <e1> temsirolimus </e1> <e2> MCL </e2> who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3985": {"data": {"text": "Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment, and a progression-free survival of 10 months.", "entity1": "temsirolimus", "entity2": "tumor", "span1": [104, 116], "span2": [70, 75]}, "bert_text": "Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after <e1> temsirolimus </e1> <e2> tumor </e2> regression two months after temsirolimus treatment, and a progression-free survival of 10 months.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"3986": {"data": {"text": "There was a direct relationship between CHP concentration and patients' ratings of pain on an analogue scale.", "entity1": "CHP", "entity2": "pain", "span1": [40, 43], "span2": [83, 87]}, "bert_text": "There was a direct relationship between <e1> CHP </e1> concentration and patients' ratings of <e2> pain </e2> on an analogue scale.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"3987": {"data": {"text": "STZ causes increased expression of GFAP, CD11b and TNF-a indicating glial activation and neuroinflammation.", "entity1": "STZ", "entity2": "TNF", "span1": [0, 3], "span2": [51, 54]}, "bert_text": "<e1> STZ </e1> causes increased expression of GFAP, CD11b and <e2> TNF </e2>-a indicating glial activation and neuroinflammation.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3988": {"data": {"text": "The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.\n", "entity1": "bupivacaine", "entity2": "pain", "span1": [28, 39], "span2": [118, 122]}, "bert_text": "The differential effects of <e1> bupivacaine </e1> and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and <e2> pain </e2> in a clinical pain model.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3989": {"data": {"text": "The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.\n", "entity1": "bupivacaine", "entity2": "pain", "span1": [28, 39], "span2": [137, 141]}, "bert_text": "The differential effects of <e1> bupivacaine </e1> and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical <e2> pain </e2> model.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3990": {"data": {"text": "The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.\n", "entity1": "lidocaine", "entity2": "pain", "span1": [44, 53], "span2": [118, 122]}, "bert_text": "The differential effects of bupivacaine and <e1> lidocaine </e1> on prostaglandin E2 release, cyclooxygenase gene expression and <e2> pain </e2> in a clinical pain model.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3991": {"data": {"text": "The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.\n", "entity1": "lidocaine", "entity2": "pain", "span1": [44, 53], "span2": [137, 141]}, "bert_text": "The differential effects of bupivacaine and <e1> lidocaine </e1> on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical <e2> pain </e2> model.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3992": {"data": {"text": "The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.\n", "entity1": "prostaglandin E2", "entity2": "pain", "span1": [57, 73], "span2": [118, 122]}, "bert_text": "The differential effects of bupivacaine and lidocaine on <e1> prostaglandin E2 </e1> release, cyclooxygenase gene expression and <e2> pain </e2> in a clinical pain model.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3993": {"data": {"text": "The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model.\n", "entity1": "prostaglandin E2", "entity2": "pain", "span1": [57, 73], "span2": [137, 141]}, "bert_text": "The differential effects of bupivacaine and lidocaine on <e1> prostaglandin E2 </e1> release, cyclooxygenase gene expression and pain in a clinical <e2> pain </e2> model.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3994": {"data": {"text": "Four (10.8%) patients in the conventional group and 1 (2.7%) in the unilateral group, P= 0.17 required epinephrine infusion to treat hypotension.", "entity1": "epinephrine", "entity2": "hypotension", "span1": [103, 114], "span2": [133, 144]}, "bert_text": "Four (10.8%) patients in the conventional group and 1 (2.7%) in the unilateral group, P= 0.17 required <e1> epinephrine </e1> infusion to treat <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3995": {"data": {"text": "OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [45, 54], "span2": [63, 77]}, "bert_text": "OBJECTIVE: We aimed to evaluate the rates of <e1> cisplatin </e1>-induced <e2> nephrotoxicity </e2> in cancer patients receiving single-agent cisplatin with and without mannitol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3996": {"data": {"text": "OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.", "entity1": "cisplatin", "entity2": "cancer", "span1": [45, 54], "span2": [81, 87]}, "bert_text": "OBJECTIVE: We aimed to evaluate the rates of <e1> cisplatin </e1>-induced nephrotoxicity in <e2> cancer </e2> patients receiving single-agent cisplatin with and without mannitol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3997": {"data": {"text": "OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.", "entity1": "cisplatin", "entity2": "nephrotoxicity", "span1": [120, 129], "span2": [63, 77]}, "bert_text": "OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent <e1> cisplatin </e1> <e2> nephrotoxicity </e2> in cancer patients receiving single-agent cisplatin with and without mannitol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3998": {"data": {"text": "OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.", "entity1": "cisplatin", "entity2": "cancer", "span1": [120, 129], "span2": [81, 87]}, "bert_text": "OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent <e1> cisplatin </e1> <e2> cancer </e2> patients receiving single-agent cisplatin with and without mannitol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"3999": {"data": {"text": "OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.", "entity1": "mannitol", "entity2": "nephrotoxicity", "span1": [147, 155], "span2": [63, 77]}, "bert_text": "OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without <e1> mannitol </e1> <e2> nephrotoxicity </e2> in cancer patients receiving single-agent cisplatin with and without mannitol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4000": {"data": {"text": "OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without mannitol.", "entity1": "mannitol", "entity2": "cancer", "span1": [147, 155], "span2": [81, 87]}, "bert_text": "OBJECTIVE: We aimed to evaluate the rates of cisplatin-induced nephrotoxicity in cancer patients receiving single-agent cisplatin with and without <e1> mannitol </e1> <e2> cancer </e2> patients receiving single-agent cisplatin with and without mannitol.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4001": {"data": {"text": "We examined the potential role of prostaglandins in the development of analgesic nephropathy in the Gunn strain of rat.", "entity1": "prostaglandins", "entity2": "nephropathy", "span1": [34, 48], "span2": [81, 92]}, "bert_text": "We examined the potential role of <e1> prostaglandins </e1> in the development of analgesic <e2> nephropathy </e2> in the Gunn strain of rat.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4002": {"data": {"text": "The incidence of hospitalisation for TDF kidney adverse effects was high, particularly amongst patients with features of Fanconi syndrome.", "entity1": "TDF", "entity2": "Fanconi syndrome", "span1": [37, 40], "span2": [121, 137]}, "bert_text": "The incidence of hospitalisation for <e1> TDF </e1> kidney adverse effects was high, particularly amongst patients with features of <e2> Fanconi syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4003": {"data": {"text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "entity1": "3,4-methylenedioxymethamphetamine", "entity2": "Depression", "span1": [83, 116], "span2": [0, 10]}, "bert_text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of <e1> 3,4-methylenedioxymethamphetamine </e1> <e2> Depression </e2>, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4004": {"data": {"text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "entity1": "3,4-methylenedioxymethamphetamine", "entity2": "impulsiveness", "span1": [83, 116], "span2": [12, 25]}, "bert_text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of <e1> 3,4-methylenedioxymethamphetamine </e1> <e2> impulsiveness </e2>, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4005": {"data": {"text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "entity1": "MDMA", "entity2": "Depression", "span1": [118, 122], "span2": [0, 10]}, "bert_text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (<e1> MDMA </e1> <e2> Depression </e2>, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4006": {"data": {"text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "entity1": "MDMA", "entity2": "impulsiveness", "span1": [118, 122], "span2": [12, 25]}, "bert_text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (<e1> MDMA </e1> <e2> impulsiveness </e2>, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4007": {"data": {"text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "entity1": "ecstasy", "entity2": "Depression", "span1": [124, 131], "span2": [0, 10]}, "bert_text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, <e1> ecstasy </e1> <e2> Depression </e2>, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4008": {"data": {"text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "entity1": "ecstasy", "entity2": "impulsiveness", "span1": [124, 131], "span2": [12, 25]}, "bert_text": "Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, <e1> ecstasy </e1> <e2> impulsiveness </e2>, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4009": {"data": {"text": "Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.\n", "entity1": "HPA", "entity2": "hypothalamic", "span1": [57, 60], "span2": [25, 37]}, "bert_text": "Basal functioning of the hypothalamic-pituitary-adrenal (<e1> HPA </e1> <e2> hypothalamic </e2>-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4010": {"data": {"text": "Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.\n", "entity1": "ecstasy", "entity2": "hypothalamic", "span1": [110, 117], "span2": [25, 37]}, "bert_text": "Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational <e1> ecstasy </e1> <e2> hypothalamic </e2>-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4011": {"data": {"text": "OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine.", "entity1": "flecainide", "entity2": "delirium", "span1": [33, 43], "span2": [52, 60]}, "bert_text": "OBJECTIVE: To describe a case of <e1> flecainide </e1>-induced <e2> delirium </e2> associated with a pharmacokinetic drug interaction with paroxetine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4012": {"data": {"text": "OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with paroxetine.", "entity1": "paroxetine", "entity2": "delirium", "span1": [117, 127], "span2": [52, 60]}, "bert_text": "OBJECTIVE: To describe a case of flecainide-induced delirium associated with a pharmacokinetic drug interaction with <e1> paroxetine </e1> <e2> delirium </e2> associated with a pharmacokinetic drug interaction with paroxetine.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4013": {"data": {"text": "BACKGROUND: Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular cancers.", "entity1": "Ifosfamide", "entity2": "cancers", "span1": [12, 22], "span2": [89, 96]}, "bert_text": "BACKGROUND: <e1> Ifosfamide </e1> is an alkylating agent useful in the treatment of a wide range of <e2> cancers </e2> including sarcomas, lymphoma, gynecologic and testicular cancers.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4014": {"data": {"text": "BACKGROUND: Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular cancers.", "entity1": "Ifosfamide", "entity2": "cancers", "span1": [12, 22], "span2": [154, 161]}, "bert_text": "BACKGROUND: <e1> Ifosfamide </e1> is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular <e2> cancers </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4015": {"data": {"text": "BACKGROUND: Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular cancers.", "entity1": "Ifosfamide", "entity2": "sarcomas", "span1": [12, 22], "span2": [107, 115]}, "bert_text": "BACKGROUND: <e1> Ifosfamide </e1> is an alkylating agent useful in the treatment of a wide range of cancers including <e2> sarcomas </e2>, lymphoma, gynecologic and testicular cancers.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4016": {"data": {"text": "BACKGROUND: Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, lymphoma, gynecologic and testicular cancers.", "entity1": "Ifosfamide", "entity2": "lymphoma", "span1": [12, 22], "span2": [117, 125]}, "bert_text": "BACKGROUND: <e1> Ifosfamide </e1> is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas, <e2> lymphoma </e2>, gynecologic and testicular cancers.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4017": {"data": {"text": "The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin-induced seizures and mortality.", "entity1": "CCK-5-8", "entity2": "seizures", "span1": [12, 19], "span2": [188, 196]}, "bert_text": "The peptide <e1> CCK-5-8 </e1> had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin-induced <e2> seizures </e2> and mortality.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4018": {"data": {"text": "The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin-induced seizures and mortality.", "entity1": "diazepam", "entity2": "seizures", "span1": [141, 149], "span2": [188, 196]}, "bert_text": "The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, <e1> diazepam </e1>, totally prevented picrotoxin-induced <e2> seizures </e2> and mortality.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4019": {"data": {"text": "The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin-induced seizures and mortality.", "entity1": "picrotoxin", "entity2": "seizures", "span1": [169, 179], "span2": [188, 196]}, "bert_text": "The peptide CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides, 3.2 mumol/kg and larger doses of the reference drug, diazepam, totally prevented <e1> picrotoxin </e1>-induced <e2> seizures </e2> and mortality.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4020": {"data": {"text": "After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.", "entity1": "5-FU", "entity2": "pain", "span1": [75, 79], "span2": [119, 123]}, "bert_text": "After admission, the patient received a continuous intravenous infusion of <e1> 5-FU </e1> (1000 mg/day), during which precordial <e2> pain </e2> with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4021": {"data": {"text": "After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.", "entity1": "5-FU", "entity2": "right bundle branch block", "span1": [75, 79], "span2": [129, 154]}, "bert_text": "After admission, the patient received a continuous intravenous infusion of <e1> 5-FU </e1> (1000 mg/day), during which precordial pain with <e2> right bundle branch block </e2> occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4022": {"data": {"text": "After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.", "entity1": "FBAL", "entity2": "pain", "span1": [196, 200], "span2": [119, 123]}, "bert_text": "After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum <e1> FBAL </e1> <e2> pain </e2> with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4023": {"data": {"text": "After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.", "entity1": "FBAL", "entity2": "right bundle branch block", "span1": [196, 200], "span2": [129, 154]}, "bert_text": "After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum <e1> FBAL </e1> <e2> right bundle branch block </e2> occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4024": {"data": {"text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "entity1": "glibenclamide", "entity2": "diabetes", "span1": [58, 71], "span2": [44, 52]}, "bert_text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with <e1> glibenclamide </e1> <e2> diabetes </e2> with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"4025": {"data": {"text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "entity1": "glibenclamide", "entity2": "CAD", "span1": [58, 71], "span2": [122, 125]}, "bert_text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with <e1> glibenclamide </e1> or glipizide is associated with increased risk of <e2> CAD </e2> in comparison to gliclazide or glimepiride.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4026": {"data": {"text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "entity1": "glipizide", "entity2": "diabetes", "span1": [75, 84], "span2": [44, 52]}, "bert_text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or <e1> glipizide </e1> <e2> diabetes </e2> with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"4027": {"data": {"text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "entity1": "glipizide", "entity2": "CAD", "span1": [75, 84], "span2": [122, 125]}, "bert_text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or <e1> glipizide </e1> is associated with increased risk of <e2> CAD </e2> in comparison to gliclazide or glimepiride.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4028": {"data": {"text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "entity1": "gliclazide", "entity2": "diabetes", "span1": [143, 153], "span2": [44, 52]}, "bert_text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to <e1> gliclazide </e1> <e2> diabetes </e2> with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"4029": {"data": {"text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "entity1": "gliclazide", "entity2": "CAD", "span1": [143, 153], "span2": [122, 125]}, "bert_text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to <e1> gliclazide </e1> <e2> CAD </e2> in comparison to gliclazide or glimepiride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"4030": {"data": {"text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "entity1": "glimepiride", "entity2": "diabetes", "span1": [157, 168], "span2": [44, 52]}, "bert_text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or <e1> glimepiride </e1> <e2> diabetes </e2> with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0], "label": 0},
+	"4031": {"data": {"text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride.", "entity1": "glimepiride", "entity2": "CAD", "span1": [157, 168], "span2": [122, 125]}, "bert_text": "CONCLUSIONS: Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or <e1> glimepiride </e1> <e2> CAD </e2> in comparison to gliclazide or glimepiride.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 0},
+	"4032": {"data": {"text": "Caution is recommended in combining clonidine and verapamil therapy, even in patients who do not have sinus or AV node dysfunction.", "entity1": "clonidine", "entity2": "AV node dysfunction", "span1": [36, 45], "span2": [111, 130]}, "bert_text": "Caution is recommended in combining <e1> clonidine </e1> and verapamil therapy, even in patients who do not have sinus or <e2> AV node dysfunction </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1], "label": 0},
+	"4033": {"data": {"text": "Caution is recommended in combining clonidine and verapamil therapy, even in patients who do not have sinus or AV node dysfunction.", "entity1": "verapamil", "entity2": "AV node dysfunction", "span1": [50, 59], "span2": [111, 130]}, "bert_text": "Caution is recommended in combining clonidine and <e1> verapamil </e1> therapy, even in patients who do not have sinus or <e2> AV node dysfunction </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1], "label": 0},
+	"4034": {"data": {"text": "AChE activity was significantly decreased in the hippocampus of mice with BPA compared to control mice, whereas no difference was found in the prefrontal cortex, hypothalamus and cerebellum.", "entity1": "BPA", "entity2": "hypothalamus", "span1": [74, 77], "span2": [162, 174]}, "bert_text": "AChE activity was significantly decreased in the hippocampus of mice with <e1> BPA </e1> compared to control mice, whereas no difference was found in the prefrontal cortex, <e2> hypothalamus </e2> and cerebellum.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4035": {"data": {"text": "Azathioprine-induced suicidal erythrocyte death.\n", "entity1": "Azathioprine", "entity2": "death", "span1": [0, 12], "span2": [42, 47]}, "bert_text": "<e1> Azathioprine </e1>-induced suicidal erythrocyte <e2> death </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4036": {"data": {"text": "RATIONALE: Ecstasy (MDMA) is a psychostimulant drug which is increasingly associated with psychobiological dysfunction. While some recent studies suggest acute changes in neuroendocrine function, less is known about long-term changes in HPA functionality in recreational users.", "entity1": "Ecstasy", "entity2": "psychobiological dysfunction", "span1": [11, 18], "span2": [90, 118]}, "bert_text": "RATIONALE: <e1> Ecstasy </e1> (MDMA) is a psychostimulant drug which is increasingly associated with <e2> psychobiological dysfunction </e2>. While some recent studies suggest acute changes in neuroendocrine function, less is known about long-term changes in HPA functionality in recreational users.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4037": {"data": {"text": "RATIONALE: Ecstasy (MDMA) is a psychostimulant drug which is increasingly associated with psychobiological dysfunction. While some recent studies suggest acute changes in neuroendocrine function, less is known about long-term changes in HPA functionality in recreational users.", "entity1": "MDMA", "entity2": "psychobiological dysfunction", "span1": [20, 24], "span2": [90, 118]}, "bert_text": "RATIONALE: Ecstasy (<e1> MDMA </e1>) is a psychostimulant drug which is increasingly associated with <e2> psychobiological dysfunction </e2>. While some recent studies suggest acute changes in neuroendocrine function, less is known about long-term changes in HPA functionality in recreational users.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4038": {"data": {"text": ".\nBortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).", "entity1": "Bortezomib", "entity2": "multiple myeloma", "span1": [2, 12], "span2": [94, 110]}, "bert_text": ".\n<e1> Bortezomib </e1> (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) <e2> multiple myeloma </e2> (MM).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4039": {"data": {"text": ".\nBortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).", "entity1": "Bortezomib", "entity2": "MM", "span1": [2, 12], "span2": [112, 114]}, "bert_text": ".\n<e1> Bortezomib </e1> (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (<e2> MM </e2>).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4040": {"data": {"text": ".\nBortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).", "entity1": "bort)-dexamethasone", "entity2": "multiple myeloma", "span1": [14, 33], "span2": [94, 110]}, "bert_text": ".\nBortezomib (<e1> bort)-dexamethasone </e1> (dex) is an effective therapy for relapsed/refractory (R/R) <e2> multiple myeloma </e2> (MM).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4041": {"data": {"text": ".\nBortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).", "entity1": "bort)-dexamethasone", "entity2": "MM", "span1": [14, 33], "span2": [112, 114]}, "bert_text": ".\nBortezomib (<e1> bort)-dexamethasone </e1> (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (<e2> MM </e2>).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4042": {"data": {"text": ".\nBortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).", "entity1": "dex", "entity2": "multiple myeloma", "span1": [35, 38], "span2": [94, 110]}, "bert_text": ".\nBortezomib (bort)-dexamethasone (<e1> dex </e1>) is an effective therapy for relapsed/refractory (R/R) <e2> multiple myeloma </e2> (MM).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4043": {"data": {"text": ".\nBortezomib (bort)-dexamethasone (dex) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (MM).", "entity1": "dex", "entity2": "MM", "span1": [35, 38], "span2": [112, 114]}, "bert_text": ".\nBortezomib (bort)-dexamethasone (<e1> dex </e1>) is an effective therapy for relapsed/refractory (R/R) multiple myeloma (<e2> MM </e2>).", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4044": {"data": {"text": "Two neonates suffered from generalized seizures during the course of intravenous morphine sulfate for post-operative analgesia.", "entity1": "morphine sulfate", "entity2": "seizures", "span1": [81, 97], "span2": [39, 47]}, "bert_text": "Two neonates suffered from generalized seizures during the course of intravenous <e1> morphine sulfate </e1> <e2> seizures </e2> during the course of intravenous morphine sulfate for post-operative analgesia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4045": {"data": {"text": "Two neonates suffered from generalized seizures during the course of intravenous morphine sulfate for post-operative analgesia.", "entity1": "morphine sulfate", "entity2": "analgesia", "span1": [81, 97], "span2": [117, 126]}, "bert_text": "Two neonates suffered from generalized seizures during the course of intravenous <e1> morphine sulfate </e1> for post-operative <e2> analgesia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4046": {"data": {"text": "We describe a case of progressive loss of vision associated with linezolid therapy.", "entity1": "linezolid", "entity2": "loss of vision", "span1": [65, 74], "span2": [34, 48]}, "bert_text": "We describe a case of progressive loss of vision associated with <e1> linezolid </e1> <e2> loss of vision </e2> associated with linezolid therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4047": {"data": {"text": "PURPOSE: To report the treatment outcomes of the fluocinolone acetonide intravitreal implant (0.59 mg) in patients with birdshot retinochoroidopathy whose disease is refractory or intolerant to conventional immunomodulatory therapy.", "entity1": "fluocinolone acetonide", "entity2": "birdshot retinochoroidopathy whose disease", "span1": [49, 71], "span2": [120, 162]}, "bert_text": "PURPOSE: To report the treatment outcomes of the <e1> fluocinolone acetonide </e1> intravitreal implant (0.59 mg) in patients with <e2> birdshot retinochoroidopathy whose disease </e2> is refractory or intolerant to conventional immunomodulatory therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4048": {"data": {"text": "Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.", "entity1": "OCs", "entity2": "VTE", "span1": [55, 58], "span2": [19, 22]}, "bert_text": "Of the 83 cases of VTE associated with use of combined <e1> OCs </e1> <e2> VTE </e2> associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4049": {"data": {"text": "Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.", "entity1": "OCs", "entity2": "vein thrombosis", "span1": [55, 58], "span2": [85, 100]}, "bert_text": "Of the 83 cases of VTE associated with use of combined <e1> OCs </e1>, 43 were recorded as deep-<e2> vein thrombosis </e2>, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4050": {"data": {"text": "Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.", "entity1": "OCs", "entity2": "venous thrombosis", "span1": [55, 58], "span2": [142, 159]}, "bert_text": "Of the 83 cases of VTE associated with use of combined <e1> OCs </e1>, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as <e2> venous thrombosis </e2> not otherwise specified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4051": {"data": {"text": "Of the 83 cases of VTE associated with use of combined OCs, 43 were recorded as deep-vein thrombosis, 35 as pulmonary thrombosis, and five as venous thrombosis not otherwise specified.", "entity1": "OCs", "entity2": "pulmonary thrombosis", "span1": [55, 58], "span2": [108, 128]}, "bert_text": "Of the 83 cases of VTE associated with use of combined <e1> OCs </e1>, 43 were recorded as deep-vein thrombosis, 35 as <e2> pulmonary thrombosis </e2>, and five as venous thrombosis not otherwise specified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4052": {"data": {"text": "These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures.", "entity1": "NO", "entity2": "seizures", "span1": [42, 44], "span2": [107, 115]}, "bert_text": "These results support the conclusion that <e1> NO </e1> plays a role of endogenous convulsant in rat model of lindane <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4053": {"data": {"text": "These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures.", "entity1": "lindane", "entity2": "seizures", "span1": [99, 106], "span2": [107, 115]}, "bert_text": "These results support the conclusion that NO plays a role of endogenous convulsant in rat model of <e1> lindane </e1> <e2> seizures </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4054": {"data": {"text": "Troponin I levels positively correlated with delayed and peak gadolinium contrast enhancement, histopathological grading, and diastolic dysfunction.", "entity1": "gadolinium", "entity2": "diastolic dysfunction", "span1": [62, 72], "span2": [126, 147]}, "bert_text": "Troponin I levels positively correlated with delayed and peak <e1> gadolinium </e1> contrast enhancement, histopathological grading, and <e2> diastolic dysfunction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4055": {"data": {"text": "5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients.", "entity1": "5-Fluorouracil", "entity2": "breast cancer", "span1": [0, 14], "span2": [148, 161]}, "bert_text": "<e1> 5-Fluorouracil </e1> plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic <e2> breast cancer </e2> patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4056": {"data": {"text": "5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients.", "entity1": "folinic acid", "entity2": "breast cancer", "span1": [20, 32], "span2": [148, 161]}, "bert_text": "5-Fluorouracil plus <e1> folinic acid </e1> and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic <e2> breast cancer </e2> patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4057": {"data": {"text": "5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients.", "entity1": "paclitaxel", "entity2": "breast cancer", "span1": [37, 47], "span2": [148, 161]}, "bert_text": "5-Fluorouracil plus folinic acid and <e1> paclitaxel </e1> (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic <e2> breast cancer </e2> patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4058": {"data": {"text": "5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients.", "entity1": "Taxol", "entity2": "breast cancer", "span1": [49, 54], "span2": [148, 161]}, "bert_text": "5-Fluorouracil plus folinic acid and paclitaxel (<e1> Taxol </e1>; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic <e2> breast cancer </e2> patients.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4059": {"data": {"text": "Torsades de pointes occurred early during treatment even with low doses of oral d,l-sotalol.", "entity1": "sotalol", "entity2": "Torsades de pointes", "span1": [84, 91], "span2": [0, 19]}, "bert_text": "Torsades de pointes occurred early during treatment even with low doses of oral d,l-<e1> sotalol </e1> <e2> Torsades de pointes </e2> occurred early during treatment even with low doses of oral d,l-sotalol.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4060": {"data": {"text": "Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.", "entity1": "doxorubicin", "entity2": "cardiac toxicity", "span1": [31, 42], "span2": [62, 78]}, "bert_text": "Herein, we investigate whether <e1> doxorubicin </e1>-associated chronic <e2> cardiac toxicity </e2> can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4061": {"data": {"text": "Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.", "entity1": "doxorubicin", "entity2": "breast cancer", "span1": [31, 42], "span2": [147, 160]}, "bert_text": "Herein, we investigate whether <e1> doxorubicin </e1>-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4062": {"data": {"text": "Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.", "entity1": "hydroxytyrosol", "entity2": "cardiac toxicity", "span1": [119, 133], "span2": [62, 78]}, "bert_text": "Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant <e1> hydroxytyrosol </e1> <e2> cardiac toxicity </e2> can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4063": {"data": {"text": "Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer.", "entity1": "hydroxytyrosol", "entity2": "breast cancer", "span1": [119, 133], "span2": [147, 160]}, "bert_text": "Herein, we investigate whether doxorubicin-associated chronic cardiac toxicity can be ameliorated with the antioxidant <e1> hydroxytyrosol </e1> in rats with <e2> breast cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4064": {"data": {"text": "We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or seizure patterns.", "entity1": "eslicarbazepine acetate", "entity2": "seizures", "span1": [51, 74], "span2": [116, 124]}, "bert_text": "We have studied the effects of oral treatment with <e1> eslicarbazepine acetate </e1> on a whole-animal model in which partial <e2> seizures </e2> can be elicited repeatedly on different days without changes in threshold or seizure patterns.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4065": {"data": {"text": "We have studied the effects of oral treatment with eslicarbazepine acetate on a whole-animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or seizure patterns.", "entity1": "eslicarbazepine acetate", "entity2": "seizure", "span1": [51, 74], "span2": [202, 209]}, "bert_text": "We have studied the effects of oral treatment with <e1> eslicarbazepine acetate </e1> on a whole-animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or <e2> seizure </e2> patterns.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4066": {"data": {"text": "Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.\n", "entity1": "Chemokine CCL2", "entity2": "status epilepticus", "span1": [0, 14], "span2": [100, 118]}, "bert_text": "<e1> Chemokine CCL2 </e1> and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced <e2> status epilepticus </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4067": {"data": {"text": "Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus.\n", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [80, 91], "span2": [100, 118]}, "bert_text": "Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following <e1> pilocarpine </e1>-induced <e2> status epilepticus </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4068": {"data": {"text": "Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.", "entity1": "Memantine", "entity2": "death", "span1": [20, 29], "span2": [139, 144]}, "bert_text": "Oral treatment with <e1> Memantine </e1> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell <e2> death </e2> and post synaptic neurotoxicity in rat brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4069": {"data": {"text": "Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.", "entity1": "Memantine", "entity2": "synaptic neurotoxicity", "span1": [20, 29], "span2": [154, 176]}, "bert_text": "Oral treatment with <e1> Memantine </e1> (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post <e2> synaptic neurotoxicity </e2> in rat brain.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4070": {"data": {"text": "Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.", "entity1": "Ibuprofen", "entity2": "death", "span1": [44, 53], "span2": [139, 144]}, "bert_text": "Oral treatment with Memantine (10mg/kg) and <e1> Ibuprofen </e1> (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell <e2> death </e2> and post synaptic neurotoxicity in rat brain.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4071": {"data": {"text": "Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.", "entity1": "Ibuprofen", "entity2": "synaptic neurotoxicity", "span1": [44, 53], "span2": [154, 176]}, "bert_text": "Oral treatment with Memantine (10mg/kg) and <e1> Ibuprofen </e1> (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post <e2> synaptic neurotoxicity </e2> in rat brain.", "weak_labels": [1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4072": {"data": {"text": "Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.", "entity1": "STZ", "entity2": "death", "span1": [94, 97], "span2": [139, 144]}, "bert_text": "Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1> STZ </e1> induced glial activation, apoptotic cell <e2> death </e2> and post synaptic neurotoxicity in rat brain.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4073": {"data": {"text": "Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated STZ induced glial activation, apoptotic cell death and post synaptic neurotoxicity in rat brain.", "entity1": "STZ", "entity2": "synaptic neurotoxicity", "span1": [94, 97], "span2": [154, 176]}, "bert_text": "Oral treatment with Memantine (10mg/kg) and Ibuprofen (50 mg/kg) daily for 13 days attenuated <e1> STZ </e1> induced glial activation, apoptotic cell death and post <e2> synaptic neurotoxicity </e2> in rat brain.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4074": {"data": {"text": "Patients who had ARI after high-dose melphalan underwent dialysis more often (P = 0.007), and had a worse 1-year survival (P = 0.03). CONCLUSION", "entity1": "melphalan", "entity2": "ARI", "span1": [37, 46], "span2": [17, 20]}, "bert_text": "Patients who had ARI after high-dose <e1> melphalan </e1> <e2> ARI </e2> after high-dose melphalan underwent dialysis more often (P = 0.007), and had a worse 1-year survival (P = 0.03). CONCLUSION", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4075": {"data": {"text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "entity1": "bupivacaine", "entity2": "pain", "span1": [13, 24], "span2": [69, 73]}, "bert_text": "RESULTS: The <e1> bupivacaine </e1>/rofecoxib group reported significantly less <e2> pain </e2>, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4076": {"data": {"text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "entity1": "bupivacaine", "entity2": "pain", "span1": [13, 24], "span2": [247, 251]}, "bert_text": "RESULTS: The <e1> bupivacaine </e1>/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more <e2> pain </e2> at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4077": {"data": {"text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "entity1": "bupivacaine", "entity2": "pain", "span1": [193, 204], "span2": [69, 73]}, "bert_text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the <e1> bupivacaine </e1> <e2> pain </e2>, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4078": {"data": {"text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "entity1": "bupivacaine", "entity2": "pain", "span1": [193, 204], "span2": [247, 251]}, "bert_text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the <e1> bupivacaine </e1>/placebo group reported significantly more <e2> pain </e2> at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4079": {"data": {"text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "entity1": "rofecoxib", "entity2": "pain", "span1": [25, 34], "span2": [69, 73]}, "bert_text": "RESULTS: The bupivacaine/<e1> rofecoxib </e1> group reported significantly less <e2> pain </e2>, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4080": {"data": {"text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "entity1": "rofecoxib", "entity2": "pain", "span1": [25, 34], "span2": [247, 251]}, "bert_text": "RESULTS: The bupivacaine/<e1> rofecoxib </e1> group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more <e2> pain </e2> at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4081": {"data": {"text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "entity1": "PGE2", "entity2": "pain", "span1": [264, 268], "span2": [69, 73]}, "bert_text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and <e1> PGE2 </e1> <e2> pain </e2>, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4082": {"data": {"text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "entity1": "PGE2", "entity2": "pain", "span1": [264, 268], "span2": [247, 251]}, "bert_text": "RESULTS: The bupivacaine/rofecoxib group reported significantly less pain, as assessed by a visual analog scale, compared with the other three treatment groups over the first 4 h. However, the bupivacaine/placebo group reported significantly more pain at 24 h and <e1> PGE2 </e1> <e2> pain </e2> at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4083": {"data": {"text": "RESULTS: We observed elevated lung cancer risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of diazinon use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08).", "entity1": "diazinon", "entity2": "lung cancer", "span1": [164, 172], "span2": [30, 41]}, "bert_text": "RESULTS: We observed elevated lung cancer risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of <e1> diazinon </e1> <e2> lung cancer </e2> risks (N=283) among applicators with the greatest number of LT (RR=1.60; 95% CI 1.11 to 2.31; Ptrend=0.02) and IW days of diazinon use (RR=1.41; 95% CI 0.98 to 2.04; Ptrend=0.08).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4084": {"data": {"text": "Etoposide (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies.", "entity1": "Etoposide", "entity2": "tumors", "span1": [0, 9], "span2": [67, 73]}, "bert_text": "<e1> Etoposide </e1> (VP-16-213) has been used in the treatment of many solid <e2> tumors </e2> and hematologic malignancies.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4085": {"data": {"text": "Etoposide (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies.", "entity1": "Etoposide", "entity2": "hematologic malignancies", "span1": [0, 9], "span2": [78, 102]}, "bert_text": "<e1> Etoposide </e1> (VP-16-213) has been used in the treatment of many solid tumors and <e2> hematologic malignancies </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4086": {"data": {"text": "Etoposide (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies.", "entity1": "VP-16-213", "entity2": "tumors", "span1": [11, 20], "span2": [67, 73]}, "bert_text": "Etoposide (<e1> VP-16-213 </e1>) has been used in the treatment of many solid <e2> tumors </e2> and hematologic malignancies.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4087": {"data": {"text": "Etoposide (VP-16-213) has been used in the treatment of many solid tumors and hematologic malignancies.", "entity1": "VP-16-213", "entity2": "hematologic malignancies", "span1": [11, 20], "span2": [78, 102]}, "bert_text": "Etoposide (<e1> VP-16-213 </e1>) has been used in the treatment of many solid tumors and <e2> hematologic malignancies </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4088": {"data": {"text": "0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial calcium-loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from doxorubicin-treated rats.", "entity1": "calcium", "entity2": "cardiac mitochondria", "span1": [89, 96], "span2": [19, 39]}, "bert_text": "0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial <e1> calcium </e1> <e2> cardiac mitochondria </e2> isolated from saline-treated rats. Mitochondrial calcium-loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from doxorubicin-treated rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4089": {"data": {"text": "0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial calcium-loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from doxorubicin-treated rats.", "entity1": "calcium", "entity2": "cardiac mitochondria", "span1": [89, 96], "span2": [177, 197]}, "bert_text": "0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial <e1> calcium </e1>-loading capacity and the activity of NADH-dehydrogenase were also suppressed in <e2> cardiac mitochondria </e2> from doxorubicin-treated rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4090": {"data": {"text": "0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial calcium-loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from doxorubicin-treated rats.", "entity1": "doxorubicin", "entity2": "cardiac mitochondria", "span1": [203, 214], "span2": [19, 39]}, "bert_text": "0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial calcium-loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from <e1> doxorubicin </e1> <e2> cardiac mitochondria </e2> isolated from saline-treated rats. Mitochondrial calcium-loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from doxorubicin-treated rats.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4091": {"data": {"text": "0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial calcium-loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from doxorubicin-treated rats.", "entity1": "doxorubicin", "entity2": "cardiac mitochondria", "span1": [203, 214], "span2": [177, 197]}, "bert_text": "0.4) compared with cardiac mitochondria isolated from saline-treated rats. Mitochondrial calcium-loading capacity and the activity of NADH-dehydrogenase were also suppressed in cardiac mitochondria from <e1> doxorubicin </e1> <e2> cardiac mitochondria </e2> from doxorubicin-treated rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4092": {"data": {"text": "This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH.", "entity1": "EACA", "entity2": "SAH", "span1": [30, 34], "span2": [61, 64]}, "bert_text": "This occlusion occurred after <e1> EACA </e1> therapy in a patient with <e2> SAH </e2> and histopathological documentation of recurrent SAH.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4093": {"data": {"text": "This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH.", "entity1": "EACA", "entity2": "SAH", "span1": [30, 34], "span2": [114, 117]}, "bert_text": "This occlusion occurred after <e1> EACA </e1> therapy in a patient with SAH and histopathological documentation of recurrent <e2> SAH </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4094": {"data": {"text": "CONCLUSIONS: Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult.", "entity1": "carboplatin", "entity2": "fibrosis", "span1": [22, 33], "span2": [78, 86]}, "bert_text": "CONCLUSIONS: Subtenon <e1> carboplatin </e1> chemotherapy is associated with significant <e2> fibrosis </e2> of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult.", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4095": {"data": {"text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "entity1": "carrageenan", "entity2": "hyperalgesia", "span1": [106, 117], "span2": [46, 58]}, "bert_text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the <e1> carrageenan </e1> <e2> hyperalgesia </e2> (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4096": {"data": {"text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "entity1": "carrageenan", "entity2": "neuropathy", "span1": [106, 117], "span2": [176, 186]}, "bert_text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the <e1> carrageenan </e1> model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced <e2> neuropathy </e2> model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4097": {"data": {"text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "entity1": "STZ", "entity2": "hyperalgesia", "span1": [164, 167], "span2": [46, 58]}, "bert_text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the <e1> STZ </e1> <e2> hyperalgesia </e2> (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4098": {"data": {"text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "entity1": "STZ", "entity2": "neuropathy", "span1": [164, 167], "span2": [176, 186]}, "bert_text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the <e1> STZ </e1>-induced <e2> neuropathy </e2> model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4099": {"data": {"text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "entity1": "CNSB002", "entity2": "hyperalgesia", "span1": [197, 204], "span2": [46, 58]}, "bert_text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for <e1> CNSB002 </e1> <e2> hyperalgesia </e2> (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4100": {"data": {"text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "entity1": "CNSB002", "entity2": "neuropathy", "span1": [197, 204], "span2": [176, 186]}, "bert_text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for <e1> CNSB002 </e1> <e2> neuropathy </e2> model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4101": {"data": {"text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "entity1": "morphine", "entity2": "hyperalgesia", "span1": [209, 217], "span2": [46, 58]}, "bert_text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and <e1> morphine </e1> <e2> hyperalgesia </e2> (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4102": {"data": {"text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "entity1": "morphine", "entity2": "neuropathy", "span1": [209, 217], "span2": [176, 186]}, "bert_text": "The doses calculated to cause 50% reversal of hyperalgesia (ED50) were 7.54 (1.81) and 4.83 (1.54) in the carrageenan model and 44.18 (1.37) and 9.14 (1.24) in the STZ-induced neuropathy model for CNSB002 and <e1> morphine </e1> <e2> neuropathy </e2> model for CNSB002 and morphine, respectively (mg/kg; mean, SEM).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4103": {"data": {"text": "In conclusion, hyperammonemic encephalopathy can occur in patients receiving continuous infusion of 5-FU.", "entity1": "5-FU", "entity2": "hyperammonemic encephalopathy", "span1": [100, 104], "span2": [15, 44]}, "bert_text": "In conclusion, hyperammonemic encephalopathy can occur in patients receiving continuous infusion of <e1> 5-FU </e1> <e2> hyperammonemic encephalopathy </e2> can occur in patients receiving continuous infusion of 5-FU.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4104": {"data": {"text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "entity1": "acetaminophen", "entity2": "graft failure", "span1": [153, 166], "span2": [107, 120]}, "bert_text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (<e1> acetaminophen </e1> <e2> graft failure </e2> or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4105": {"data": {"text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "entity1": "acetaminophen", "entity2": "ALF", "span1": [153, 166], "span2": [175, 178]}, "bert_text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (<e1> acetaminophen </e1>-induced <e2> ALF </e2> 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4106": {"data": {"text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "entity1": "acetaminophen", "entity2": "ALF", "span1": [153, 166], "span2": [230, 233]}, "bert_text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (<e1> acetaminophen </e1>-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced <e2> ALF </e2> 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4107": {"data": {"text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "entity1": "acetaminophen", "entity2": "CLD", "span1": [153, 166], "span2": [244, 247]}, "bert_text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (<e1> acetaminophen </e1>-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; <e2> CLD </e2> 93%, 82%: P>0.6 log rank).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4108": {"data": {"text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "entity1": "acetaminophen", "entity2": "graft failure", "span1": [208, 221], "span2": [107, 120]}, "bert_text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-<e1> acetaminophen </e1> <e2> graft failure </e2> or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4109": {"data": {"text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "entity1": "acetaminophen", "entity2": "ALF", "span1": [208, 221], "span2": [175, 178]}, "bert_text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-<e1> acetaminophen </e1> <e2> ALF </e2> 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4110": {"data": {"text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "entity1": "acetaminophen", "entity2": "ALF", "span1": [208, 221], "span2": [230, 233]}, "bert_text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-<e1> acetaminophen </e1>-induced <e2> ALF </e2> 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4111": {"data": {"text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-acetaminophen-induced ALF 88%, 78%; CLD 93%, 82%: P>0.6 log rank).", "entity1": "acetaminophen", "entity2": "CLD", "span1": [208, 221], "span2": [244, 247]}, "bert_text": "During follow-up (median 5 years), there were no significant differences in rejection (acute and chronic), graft failure or survival between the groups (acetaminophen-induced ALF 1 year 87%, 5 years 75%; non-<e1> acetaminophen </e1>-induced ALF 88%, 78%; <e2> CLD </e2> 93%, 82%: P>0.6 log rank).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4112": {"data": {"text": "Although the patient's renal function was not highly impaired and the dose of pilsicainide was low, the plasma concentration of pilsicainide may have been high, which can produce torsades de pointes in the octogenarian.", "entity1": "pilsicainide", "entity2": "torsades de pointes", "span1": [78, 90], "span2": [179, 198]}, "bert_text": "Although the patient's renal function was not highly impaired and the dose of <e1> pilsicainide </e1> was low, the plasma concentration of pilsicainide may have been high, which can produce <e2> torsades de pointes </e2> in the octogenarian.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4113": {"data": {"text": "Although the patient's renal function was not highly impaired and the dose of pilsicainide was low, the plasma concentration of pilsicainide may have been high, which can produce torsades de pointes in the octogenarian.", "entity1": "pilsicainide", "entity2": "torsades de pointes", "span1": [128, 140], "span2": [179, 198]}, "bert_text": "Although the patient's renal function was not highly impaired and the dose of pilsicainide was low, the plasma concentration of <e1> pilsicainide </e1> may have been high, which can produce <e2> torsades de pointes </e2> in the octogenarian.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4114": {"data": {"text": "CONCLUSION: Our data suggest that Asian patients may be at increased risk of hyponatremia and/or SIADH associated with vincristine use.", "entity1": "vincristine", "entity2": "hyponatremia", "span1": [119, 130], "span2": [77, 89]}, "bert_text": "CONCLUSION: Our data suggest that Asian patients may be at increased risk of hyponatremia and/or SIADH associated with <e1> vincristine </e1> <e2> hyponatremia </e2> and/or SIADH associated with vincristine use.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"4115": {"data": {"text": "The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.", "entity1": "betaine", "entity2": "myocardial ischemia", "span1": [78, 85], "span2": [95, 114]}, "bert_text": "The present study was designed to investigate the cardioprotective effects of <e1> betaine </e1> on acute <e2> myocardial ischemia </e2> induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4116": {"data": {"text": "Cephalothin-induced immune hemolytic anemia.\n", "entity1": "Cephalothin", "entity2": "hemolytic anemia", "span1": [0, 11], "span2": [27, 43]}, "bert_text": "<e1> Cephalothin </e1>-induced immune <e2> hemolytic anemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4117": {"data": {"text": "The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene.", "entity1": "PPARalpha-/-", "entity2": "hepatomegaly", "span1": [87, 99], "span2": [51, 63]}, "bert_text": "The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [<e1> PPARalpha-/- </e1> <e2> hepatomegaly </e2> in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4118": {"data": {"text": "The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene.", "entity1": "PPARalpha", "entity2": "hepatomegaly", "span1": [196, 205], "span2": [51, 63]}, "bert_text": "The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional <e1> PPARalpha </e1> <e2> hepatomegaly </e2> in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4119": {"data": {"text": "The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene.", "entity1": "amiodarone", "entity2": "hepatomegaly", "span1": [136, 146], "span2": [51, 63]}, "bert_text": "The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of <e1> amiodarone </e1> <e2> hepatomegaly </e2> in PPARalpha knockout [PPARalpha-/-] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4120": {"data": {"text": "The clonidine-induced hypotension was antagonized by prior spinal transection, but not bilateral vagotomy.", "entity1": "clonidine", "entity2": "hypotension", "span1": [4, 13], "span2": [22, 33]}, "bert_text": "The <e1> clonidine </e1>-induced <e2> hypotension </e2> was antagonized by prior spinal transection, but not bilateral vagotomy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4121": {"data": {"text": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "entity1": "warfarin", "entity2": "intercerebral hematoma", "span1": [40, 48], "span2": [10, 32]}, "bert_text": "A case of intercerebral hematoma due to <e1> warfarin </e1> <e2> intercerebral hematoma </e2> due to warfarin-induced coagulopathy is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4122": {"data": {"text": "A case of intercerebral hematoma due to warfarin-induced coagulopathy is presented.", "entity1": "warfarin", "entity2": "coagulopathy", "span1": [40, 48], "span2": [57, 69]}, "bert_text": "A case of intercerebral hematoma due to <e1> warfarin </e1>-induced <e2> coagulopathy </e2> is presented.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4123": {"data": {"text": "Increased anxiogenic effects of caffeine in panic disorders.\n", "entity1": "caffeine", "entity2": "panic disorders", "span1": [32, 40], "span2": [44, 59]}, "bert_text": "Increased anxiogenic effects of <e1> caffeine </e1> in <e2> panic disorders </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4124": {"data": {"text": "Medical and psychiatric outcomes for patients transplanted for acetaminophen-induced acute liver failure: a case-control study.\n", "entity1": "acetaminophen", "entity2": "psychiatric", "span1": [63, 76], "span2": [12, 23]}, "bert_text": "Medical and psychiatric outcomes for patients transplanted for <e1> acetaminophen </e1> <e2> psychiatric </e2> outcomes for patients transplanted for acetaminophen-induced acute liver failure: a case-control study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4125": {"data": {"text": "Medical and psychiatric outcomes for patients transplanted for acetaminophen-induced acute liver failure: a case-control study.\n", "entity1": "acetaminophen", "entity2": "acute liver failure", "span1": [63, 76], "span2": [85, 104]}, "bert_text": "Medical and psychiatric outcomes for patients transplanted for <e1> acetaminophen </e1>-induced <e2> acute liver failure </e2>: a case-control study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4126": {"data": {"text": "A 33-year-old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin.", "entity1": "heroin", "entity2": "rhabdomyolysis", "span1": [95, 101], "span2": [33, 47]}, "bert_text": "A 33-year-old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous <e1> heroin </e1> <e2> rhabdomyolysis </e2> and cerebral ischemic stroke after intravenous heroin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4127": {"data": {"text": "A 33-year-old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin.", "entity1": "heroin", "entity2": "cerebral ischemic stroke", "span1": [95, 101], "span2": [52, 76]}, "bert_text": "A 33-year-old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous <e1> heroin </e1> <e2> cerebral ischemic stroke </e2> after intravenous heroin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4128": {"data": {"text": "Effects of ginsenosides on opioid-induced hyperalgesia in mice.\n", "entity1": "ginsenosides", "entity2": "hyperalgesia", "span1": [11, 23], "span2": [42, 54]}, "bert_text": "Effects of <e1> ginsenosides </e1> on opioid-induced <e2> hyperalgesia </e2> in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4129": {"data": {"text": "BACKGROUND: Prolonged administration of indinavir is associated with the occurrence of a variety of renal complications in adults.", "entity1": "indinavir", "entity2": "renal complications", "span1": [40, 49], "span2": [100, 119]}, "bert_text": "BACKGROUND: Prolonged administration of <e1> indinavir </e1> is associated with the occurrence of a variety of <e2> renal complications </e2> in adults.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4130": {"data": {"text": "Thalidomide and sensory neurotoxicity: a neurophysiological study.\n", "entity1": "Thalidomide", "entity2": "neurotoxicity", "span1": [0, 11], "span2": [24, 37]}, "bert_text": "<e1> Thalidomide </e1> and sensory <e2> neurotoxicity </e2>: a neurophysiological study.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4131": {"data": {"text": "Doxorubicin treatment also caused a decrease in RCR for liver mitochondria (3.9 +/-", "entity1": "Doxorubicin", "entity2": "liver mitochondria", "span1": [0, 11], "span2": [56, 74]}, "bert_text": "<e1> Doxorubicin </e1> treatment also caused a decrease in RCR for <e2> liver mitochondria </e2> (3.9 +/-", "weak_labels": [1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4132": {"data": {"text": "Bilateral basal ganglia infarcts after the use of cocaine, without concurrent heroin use, have never been reported.", "entity1": "cocaine", "entity2": "ganglia infarcts", "span1": [50, 57], "span2": [16, 32]}, "bert_text": "Bilateral basal ganglia infarcts after the use of <e1> cocaine </e1> <e2> ganglia infarcts </e2> after the use of cocaine, without concurrent heroin use, have never been reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4133": {"data": {"text": "Bilateral basal ganglia infarcts after the use of cocaine, without concurrent heroin use, have never been reported.", "entity1": "heroin", "entity2": "ganglia infarcts", "span1": [78, 84], "span2": [16, 32]}, "bert_text": "Bilateral basal ganglia infarcts after the use of cocaine, without concurrent <e1> heroin </e1> <e2> ganglia infarcts </e2> after the use of cocaine, without concurrent heroin use, have never been reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4134": {"data": {"text": "The data suggest that the dipyridamole-induced myocardial ischemia is caused by the inhomogenous distribution of myocardial blood flow.", "entity1": "dipyridamole", "entity2": "myocardial ischemia", "span1": [26, 38], "span2": [47, 66]}, "bert_text": "The data suggest that the <e1> dipyridamole </e1>-induced <e2> myocardial ischemia </e2> is caused by the inhomogenous distribution of myocardial blood flow.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4135": {"data": {"text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "entity1": "GFC", "entity2": "seizure", "span1": [40, 43], "span2": [86, 93]}, "bert_text": "The present study aimed to evaluate the <e1> GFC </e1> effects at doses of 25, 50 or 75 mg/kg on <e2> seizure </e2> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4136": {"data": {"text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "entity1": "GFC", "entity2": "seizures", "span1": [40, 43], "span2": [329, 337]}, "bert_text": "The present study aimed to evaluate the <e1> GFC </e1> effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4137": {"data": {"text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "entity1": "amino acid", "entity2": "seizure", "span1": [167, 177], "span2": [86, 93]}, "bert_text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on <e1> amino acid </e1> <e2> seizure </e2> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4138": {"data": {"text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "entity1": "amino acid", "entity2": "seizures", "span1": [167, 177], "span2": [329, 337]}, "bert_text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on <e1> amino acid </e1> (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4139": {"data": {"text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "entity1": "r-aminobutyric acid", "entity2": "seizure", "span1": [179, 198], "span2": [86, 93]}, "bert_text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (<e1> r-aminobutyric acid </e1> <e2> seizure </e2> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4140": {"data": {"text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "entity1": "r-aminobutyric acid", "entity2": "seizures", "span1": [179, 198], "span2": [329, 337]}, "bert_text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (<e1> r-aminobutyric acid </e1> (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4141": {"data": {"text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "entity1": "GABA", "entity2": "seizure", "span1": [200, 204], "span2": [86, 93]}, "bert_text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (<e1> GABA </e1> <e2> seizure </e2> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4142": {"data": {"text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "entity1": "GABA", "entity2": "seizures", "span1": [200, 204], "span2": [329, 337]}, "bert_text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (<e1> GABA </e1>), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4143": {"data": {"text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "entity1": "glutathione", "entity2": "seizure", "span1": [232, 243], "span2": [86, 93]}, "bert_text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and <e1> glutathione </e1> <e2> seizure </e2> parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4144": {"data": {"text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and glutathione) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after seizures.", "entity1": "glutathione", "entity2": "seizures", "span1": [232, 243], "span2": [329, 337]}, "bert_text": "The present study aimed to evaluate the GFC effects at doses of 25, 50 or 75 mg/kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid (r-aminobutyric acid (GABA), glutamine, aspartate and <e1> glutathione </e1>) levels as well as on acetylcholinesterase (AChE) activity in mice hippocampus after <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4145": {"data": {"text": "Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and paclitaxel-refractory ovarian cancer.", "entity1": "platinum-", "entity2": "ovarian cancer", "span1": [94, 103], "span2": [130, 144]}, "bert_text": "Definite, although limited, antineoplastic activity is observed in patients with well-defined <e1> platinum- </e1> and paclitaxel-refractory <e2> ovarian cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4146": {"data": {"text": "Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and paclitaxel-refractory ovarian cancer.", "entity1": "paclitaxel", "entity2": "ovarian cancer", "span1": [108, 118], "span2": [130, 144]}, "bert_text": "Definite, although limited, antineoplastic activity is observed in patients with well-defined platinum- and <e1> paclitaxel </e1>-refractory <e2> ovarian cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4147": {"data": {"text": "The trimethaphan-induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/-", "entity1": "trimethaphan", "entity2": "hypotension", "span1": [4, 16], "span2": [25, 36]}, "bert_text": "The <e1> trimethaphan </e1>-induced <e2> hypotension </e2> was accompanied by a significant bradycardia in lesioned rats (-32 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4148": {"data": {"text": "The trimethaphan-induced hypotension was accompanied by a significant bradycardia in lesioned rats (-32 +/-", "entity1": "trimethaphan", "entity2": "bradycardia", "span1": [4, 16], "span2": [70, 81]}, "bert_text": "The <e1> trimethaphan </e1>-induced hypotension was accompanied by a significant <e2> bradycardia </e2> in lesioned rats (-32 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4149": {"data": {"text": "CIN was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline.", "entity1": "creatinine", "entity2": "CIN", "span1": [40, 50], "span2": [0, 3]}, "bert_text": "CIN was defined as an increase in serum <e1> creatinine </e1> <e2> CIN </e2> was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4150": {"data": {"text": "CIN was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline.", "entity1": "Cr", "entity2": "CIN", "span1": [52, 54], "span2": [0, 3]}, "bert_text": "CIN was defined as an increase in serum creatinine (<e1> Cr </e1> <e2> CIN </e2> was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4151": {"data": {"text": "CIN was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline.", "entity1": "Cr", "entity2": "CIN", "span1": [94, 96], "span2": [0, 3]}, "bert_text": "CIN was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of <e1> Cr </e1> <e2> CIN </e2> was defined as an increase in serum creatinine (Cr) of 0.5 mg/dl or more, or elevation of Cr to 25 % over baseline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4152": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "oral contraceptives", "entity2": "venous thromboembolism", "span1": [146, 165], "span2": [88, 110]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used <e1> oral contraceptives </e1> <e2> venous thromboembolism </e2> (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4153": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "oral contraceptives", "entity2": "VTE", "span1": [146, 165], "span2": [112, 115]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used <e1> oral contraceptives </e1> <e2> VTE </e2>) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4154": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "OCs", "entity2": "venous thromboembolism", "span1": [167, 170], "span2": [88, 110]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (<e1> OCs </e1> <e2> venous thromboembolism </e2> (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4155": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "OCs", "entity2": "VTE", "span1": [167, 170], "span2": [112, 115]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (<e1> OCs </e1> <e2> VTE </e2>) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4156": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "OCs", "entity2": "venous thromboembolism", "span1": [259, 262], "span2": [88, 110]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of <e1> OCs </e1> <e2> venous thromboembolism </e2> (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4157": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "OCs", "entity2": "VTE", "span1": [259, 262], "span2": [112, 115]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of <e1> OCs </e1> <e2> VTE </e2>) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4158": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "progestagens gestodene", "entity2": "venous thromboembolism", "span1": [204, 226], "span2": [88, 110]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation <e1> progestagens gestodene </e1> <e2> venous thromboembolism </e2> (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4159": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "progestagens gestodene", "entity2": "VTE", "span1": [204, 226], "span2": [112, 115]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation <e1> progestagens gestodene </e1> <e2> VTE </e2>) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4160": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "desogestrel", "entity2": "venous thromboembolism", "span1": [230, 241], "span2": [88, 110]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or <e1> desogestrel </e1> <e2> venous thromboembolism </e2> (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4161": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "desogestrel", "entity2": "VTE", "span1": [230, 241], "span2": [112, 115]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or <e1> desogestrel </e1> <e2> VTE </e2>) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4162": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "progestagens", "entity2": "venous thromboembolism", "span1": [292, 304], "span2": [88, 110]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation <e1> progestagens </e1> <e2> venous thromboembolism </e2> (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4163": {"data": {"text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "entity1": "progestagens", "entity2": "VTE", "span1": [292, 304], "span2": [112, 115]}, "bert_text": "BACKGROUND: Four studies published since December, 1995, reported that the incidence of venous thromboembolism (VTE) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation <e1> progestagens </e1> <e2> VTE </e2>) was higher in women who used oral contraceptives (OCs) containing the third-generation progestagens gestodene or desogestrel than in users of OCs containing second-generation progestagens.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4164": {"data": {"text": "Oxidative stress is involved in several processes including cancer, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin.", "entity1": "doxorubicin", "entity2": "cancer", "span1": [175, 186], "span2": [60, 66]}, "bert_text": "Oxidative stress is involved in several processes including cancer, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as <e1> doxorubicin </e1> <e2> cancer </e2>, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4165": {"data": {"text": "Oxidative stress is involved in several processes including cancer, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin.", "entity1": "doxorubicin", "entity2": "cardiovascular disease", "span1": [175, 186], "span2": [78, 100]}, "bert_text": "Oxidative stress is involved in several processes including cancer, aging and cardiovascular disease, and has been shown to potentiate the therapeutic effect of drugs such as <e1> doxorubicin </e1> <e2> cardiovascular disease </e2>, and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4166": {"data": {"text": "Fatal aplastic anemia in a patient treated with carbamazepine.\n", "entity1": "carbamazepine", "entity2": "aplastic anemia", "span1": [48, 61], "span2": [6, 21]}, "bert_text": "Fatal aplastic anemia in a patient treated with <e1> carbamazepine </e1> <e2> aplastic anemia </e2> in a patient treated with carbamazepine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4167": {"data": {"text": "A case of phenytoin (DPH) encephalopathy with increasing seizures and EEG and mental changes is described.", "entity1": "phenytoin", "entity2": "encephalopathy", "span1": [10, 19], "span2": [26, 40]}, "bert_text": "A case of <e1> phenytoin </e1> (DPH) <e2> encephalopathy </e2> with increasing seizures and EEG and mental changes is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4168": {"data": {"text": "A case of phenytoin (DPH) encephalopathy with increasing seizures and EEG and mental changes is described.", "entity1": "phenytoin", "entity2": "seizures", "span1": [10, 19], "span2": [57, 65]}, "bert_text": "A case of <e1> phenytoin </e1> (DPH) encephalopathy with increasing <e2> seizures </e2> and EEG and mental changes is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4169": {"data": {"text": "A case of phenytoin (DPH) encephalopathy with increasing seizures and EEG and mental changes is described.", "entity1": "DPH", "entity2": "encephalopathy", "span1": [21, 24], "span2": [26, 40]}, "bert_text": "A case of phenytoin (<e1> DPH </e1>) <e2> encephalopathy </e2> with increasing seizures and EEG and mental changes is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4170": {"data": {"text": "A case of phenytoin (DPH) encephalopathy with increasing seizures and EEG and mental changes is described.", "entity1": "DPH", "entity2": "seizures", "span1": [21, 24], "span2": [57, 65]}, "bert_text": "A case of phenytoin (<e1> DPH </e1>) encephalopathy with increasing <e2> seizures </e2> and EEG and mental changes is described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4171": {"data": {"text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "entity1": "VNR", "entity2": "cardiotoxic", "span1": [12, 15], "span2": [72, 83]}, "bert_text": "The risk of <e1> VNR </e1> cardiac events was similar to vindesine (VDS) and other <e2> cardiotoxic </e2> drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4172": {"data": {"text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "entity1": "vindesine", "entity2": "cardiotoxic", "span1": [46, 55], "span2": [72, 83]}, "bert_text": "The risk of VNR cardiac events was similar to <e1> vindesine </e1> (VDS) and other <e2> cardiotoxic </e2> drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4173": {"data": {"text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "entity1": "VDS", "entity2": "cardiotoxic", "span1": [57, 60], "span2": [72, 83]}, "bert_text": "The risk of VNR cardiac events was similar to vindesine (<e1> VDS </e1>) and other <e2> cardiotoxic </e2> drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4174": {"data": {"text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "entity1": "fluorouracil", "entity2": "cardiotoxic", "span1": [91, 103], "span2": [72, 83]}, "bert_text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [<e1> fluorouracil </e1> <e2> cardiotoxic </e2> drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4175": {"data": {"text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "entity1": "anthracyclines", "entity2": "cardiotoxic", "span1": [105, 119], "span2": [72, 83]}, "bert_text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, <e1> anthracyclines </e1> <e2> cardiotoxic </e2> drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4176": {"data": {"text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "entity1": "gemcitabine", "entity2": "cardiotoxic", "span1": [121, 132], "span2": [72, 83]}, "bert_text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, <e1> gemcitabine </e1> <e2> cardiotoxic </e2> drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4177": {"data": {"text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "entity1": "GEM", "entity2": "cardiotoxic", "span1": [134, 137], "span2": [72, 83]}, "bert_text": "The risk of VNR cardiac events was similar to vindesine (VDS) and other cardiotoxic drugs [fluorouracil, anthracyclines, gemcitabine (<e1> GEM </e1> <e2> cardiotoxic </e2> drugs [fluorouracil, anthracyclines, gemcitabine (GEM) em leader ].", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4178": {"data": {"text": "Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: an updated analysis.\n", "entity1": "organophosphate", "entity2": "tumours", "span1": [70, 85], "span2": [19, 26]}, "bert_text": "Incidence of solid tumours among pesticide applicators exposed to the <e1> organophosphate </e1> <e2> tumours </e2> among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: an updated analysis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4179": {"data": {"text": "Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: an updated analysis.\n", "entity1": "diazinon", "entity2": "tumours", "span1": [98, 106], "span2": [19, 26]}, "bert_text": "Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide <e1> diazinon </e1> <e2> tumours </e2> among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study: an updated analysis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4180": {"data": {"text": "Direct thrombin inhibitors are appropriate, evidence-based alternatives to heparin in patients with a history of HIT, who need to undergo percutaneous coronary intervention.", "entity1": "heparin", "entity2": "HIT", "span1": [75, 82], "span2": [113, 116]}, "bert_text": "Direct thrombin inhibitors are appropriate, evidence-based alternatives to <e1> heparin </e1> in patients with a history of <e2> HIT </e2>, who need to undergo percutaneous coronary intervention.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4181": {"data": {"text": "Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.", "entity1": "capsaicin", "entity2": "pain", "span1": [40, 49], "span2": [94, 98]}, "bert_text": "Intradermal injections of glutamate and <e1> capsaicin </e1> are attractive to use in human experimental <e2> pain </e2> models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4182": {"data": {"text": "Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.", "entity1": "capsaicin", "entity2": "hyperalgesia", "span1": [40, 49], "span2": [114, 126]}, "bert_text": "Intradermal injections of glutamate and <e1> capsaicin </e1> are attractive to use in human experimental pain models because <e2> hyperalgesia </e2> and allodynia mimic isolated aspects of clinical pain disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4183": {"data": {"text": "Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.", "entity1": "capsaicin", "entity2": "allodynia", "span1": [40, 49], "span2": [131, 140]}, "bert_text": "Intradermal injections of glutamate and <e1> capsaicin </e1> are attractive to use in human experimental pain models because hyperalgesia and <e2> allodynia </e2> mimic isolated aspects of clinical pain disorders.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4184": {"data": {"text": "Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders.", "entity1": "capsaicin", "entity2": "pain disorders", "span1": [40, 49], "span2": [176, 190]}, "bert_text": "Intradermal injections of glutamate and <e1> capsaicin </e1> are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical <e2> pain disorders </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4185": {"data": {"text": "Transmural myocardial infarction with sumatriptan.\n", "entity1": "sumatriptan", "entity2": "myocardial infarction", "span1": [38, 49], "span2": [11, 32]}, "bert_text": "Transmural myocardial infarction with <e1> sumatriptan </e1> <e2> myocardial infarction </e2> with sumatriptan.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4186": {"data": {"text": ": The timing of renal injury strongly suggests melphalan as the causative agent.", "entity1": "melphalan", "entity2": "renal injury", "span1": [47, 56], "span2": [16, 28]}, "bert_text": ": The timing of renal injury strongly suggests <e1> melphalan </e1> <e2> renal injury </e2> strongly suggests melphalan as the causative agent.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4187": {"data": {"text": "Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.\n", "entity1": "indinavir", "entity2": "sterile leukocyturia", "span1": [145, 154], "span2": [11, 31]}, "bert_text": "Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with <e1> indinavir </e1> <e2> sterile leukocyturia </e2> is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4188": {"data": {"text": "Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.\n", "entity1": "indinavir", "entity2": "impaired renal function", "span1": [145, 154], "span2": [51, 74]}, "bert_text": "Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with <e1> indinavir </e1> <e2> impaired renal function </e2> in human immunodeficiency virus type 1-infected children treated with indinavir.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4189": {"data": {"text": "Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.\n", "entity1": "indinavir", "entity2": "human immunodeficiency virus type 1-infected", "span1": [145, 154], "span2": [78, 122]}, "bert_text": "Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with <e1> indinavir </e1> <e2> human immunodeficiency virus type 1-infected </e2> children treated with indinavir.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4190": {"data": {"text": "Left ventricular function (assessed by echocardiography) showed that PPA increased the stroke volume 30% (from 62.5 +/-", "entity1": "PPA", "entity2": "stroke", "span1": [69, 72], "span2": [87, 93]}, "bert_text": "Left ventricular function (assessed by echocardiography) showed that <e1> PPA </e1> increased the <e2> stroke </e2> volume 30% (from 62.5 +/-", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4191": {"data": {"text": "The role of nitric oxide in convulsions induced by lindane in rats.\n", "entity1": "nitric oxide", "entity2": "convulsions", "span1": [12, 24], "span2": [28, 39]}, "bert_text": "The role of <e1> nitric oxide </e1> in <e2> convulsions </e2> induced by lindane in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4192": {"data": {"text": "The role of nitric oxide in convulsions induced by lindane in rats.\n", "entity1": "lindane", "entity2": "convulsions", "span1": [51, 58], "span2": [28, 39]}, "bert_text": "The role of nitric oxide in convulsions induced by <e1> lindane </e1> <e2> convulsions </e2> induced by lindane in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4193": {"data": {"text": "Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition.", "entity1": "potassium", "entity2": "PVC", "span1": [127, 136], "span2": [60, 63]}, "bert_text": "Three hours later the patient felt better, the frequency of PVC reduced to 4 - 5 x/minute and on the third day ECG was normal, <e1> potassium </e1> <e2> PVC </e2> reduced to 4 - 5 x/minute and on the third day ECG was normal, potassium level was 3.34 meq/L. He was discharged on 7th day in good condition.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4194": {"data": {"text": "Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.\n", "entity1": "paracetamol", "entity2": "acute liver failure", "span1": [72, 83], "span2": [45, 64]}, "bert_text": "Increased serum soluble Fas in patients with acute liver failure due to <e1> paracetamol </e1> <e2> acute liver failure </e2> due to paracetamol overdose.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4195": {"data": {"text": "Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.\n", "entity1": "paracetamol", "entity2": "overdose", "span1": [72, 83], "span2": [84, 92]}, "bert_text": "Increased serum soluble Fas in patients with acute liver failure due to <e1> paracetamol </e1> <e2> overdose </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4196": {"data": {"text": "In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.", "entity1": "carbamazepine", "entity2": "asterixis", "span1": [149, 162], "span2": [108, 117]}, "bert_text": "In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding <e1> carbamazepine </e1> <e2> asterixis </e2> was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4197": {"data": {"text": "In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.", "entity1": "CBZ", "entity2": "asterixis", "span1": [164, 167], "span2": [108, 117]}, "bert_text": "In this report we present four patients treated with a combination of different psychotropic drugs, in whom asterixis was triggered either by adding carbamazepine (<e1> CBZ </e1> <e2> asterixis </e2> was triggered either by adding carbamazepine (CBZ) to a treatment regimen, or by increasing its dosage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4198": {"data": {"text": "However, it would seem prudent not to use mefenamic acid in hypothyroid patients until the hypothyroidism has been corrected.", "entity1": "mefenamic acid", "entity2": "hypothyroid", "span1": [42, 56], "span2": [60, 71]}, "bert_text": "However, it would seem prudent not to use <e1> mefenamic acid </e1> in <e2> hypothyroid </e2> patients until the hypothyroidism has been corrected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4199": {"data": {"text": "However, it would seem prudent not to use mefenamic acid in hypothyroid patients until the hypothyroidism has been corrected.", "entity1": "mefenamic acid", "entity2": "hypothyroidism", "span1": [42, 56], "span2": [91, 105]}, "bert_text": "However, it would seem prudent not to use <e1> mefenamic acid </e1> in hypothyroid patients until the <e2> hypothyroidism </e2> has been corrected.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4200": {"data": {"text": "We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine.", "entity1": "carbamazepine", "entity2": "hypersensitivity myocarditis", "span1": [80, 93], "span2": [20, 48]}, "bert_text": "We report a case of hypersensitivity myocarditis secondary to administration of <e1> carbamazepine </e1> <e2> hypersensitivity myocarditis </e2> secondary to administration of carbamazepine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4201": {"data": {"text": "Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.\n", "entity1": "6-hydroxydopamine", "entity2": "dyskinesias", "span1": [27, 44], "span2": [79, 90]}, "bert_text": "Increased vulnerability to <e1> 6-hydroxydopamine </e1> lesion and reduced development of <e2> dyskinesias </e2> in mice lacking CB1 cannabinoid receptors.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4202": {"data": {"text": "Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors.\n", "entity1": "CB1 cannabinoid", "entity2": "dyskinesias", "span1": [107, 122], "span2": [79, 90]}, "bert_text": "Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking <e1> CB1 cannabinoid </e1> <e2> dyskinesias </e2> in mice lacking CB1 cannabinoid receptors.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4203": {"data": {"text": "Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.\n", "entity1": "dronedarone", "entity2": "myocardial infarction", "span1": [42, 53], "span2": [94, 115]}, "bert_text": "Hemodynamic and antiadrenergic effects of <e1> dronedarone </e1> and amiodarone in animals with a healed <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4204": {"data": {"text": "Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.\n", "entity1": "amiodarone", "entity2": "myocardial infarction", "span1": [58, 68], "span2": [94, 115]}, "bert_text": "Hemodynamic and antiadrenergic effects of dronedarone and <e1> amiodarone </e1> in animals with a healed <e2> myocardial infarction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4205": {"data": {"text": "In this study, status epilepticus was induced by systemic injection of pilocarpine in rats.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [71, 82], "span2": [15, 33]}, "bert_text": "In this study, status epilepticus was induced by systemic injection of <e1> pilocarpine </e1> <e2> status epilepticus </e2> was induced by systemic injection of pilocarpine in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4206": {"data": {"text": "Subtenon carboplatin is not free of toxicity, and its use is best restricted to specific indications.", "entity1": "carboplatin", "entity2": "toxicity", "span1": [9, 20], "span2": [36, 44]}, "bert_text": "Subtenon <e1> carboplatin </e1> is not free of <e2> toxicity </e2>, and its use is best restricted to specific indications.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4207": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "cardiovascular disease", "span1": [135, 142], "span2": [188, 210]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of <e1> aspirin </e1> versus control for the primary prevention of <e2> cardiovascular disease </e2> (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4208": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "CVD", "span1": [135, 142], "span2": [212, 215]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of <e1> aspirin </e1> versus control for the primary prevention of cardiovascular disease (<e2> CVD </e2>) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4209": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "CVD", "span1": [135, 142], "span2": [411, 414]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of <e1> aspirin </e1> versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known <e2> CVD </e2>?", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4210": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "strokes", "span1": [135, 142], "span2": [311, 318]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of <e1> aspirin </e1> versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, <e2> strokes </e2>, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4211": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "stroke", "span1": [135, 142], "span2": [356, 362]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of <e1> aspirin </e1> versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or <e2> stroke </e2>, or all-cause mortality in adults without known CVD?", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4212": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "death", "span1": [135, 142], "span2": [320, 325]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of <e1> aspirin </e1> versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, <e2> death </e2> from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4213": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "cardiovascular disease", "span1": [271, 278], "span2": [188, 210]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does <e1> aspirin </e1> <e2> cardiovascular disease </e2> (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4214": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "CVD", "span1": [271, 278], "span2": [212, 215]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does <e1> aspirin </e1> <e2> CVD </e2>) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4215": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "CVD", "span1": [271, 278], "span2": [411, 414]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does <e1> aspirin </e1> decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known <e2> CVD </e2>?", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4216": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "strokes", "span1": [271, 278], "span2": [311, 318]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does <e1> aspirin </e1> decrease coronary heart events, <e2> strokes </e2>, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4217": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "stroke", "span1": [271, 278], "span2": [356, 362]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does <e1> aspirin </e1> decrease coronary heart events, strokes, death from coronary heart events or <e2> stroke </e2>, or all-cause mortality in adults without known CVD?", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4218": {"data": {"text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does aspirin decrease coronary heart events, strokes, death from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "entity1": "aspirin", "entity2": "death", "span1": [271, 278], "span2": [320, 325]}, "bert_text": "STUDY SELECTION: English-language randomized, controlled trials (RCTs); case-control studies; meta-analyses; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease (CVD) were selected to answer the following questions: Does <e1> aspirin </e1> decrease coronary heart events, strokes, <e2> death </e2> from coronary heart events or stroke, or all-cause mortality in adults without known CVD?", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4219": {"data": {"text": "Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to remoxipride-induced aplastic anemia.\n", "entity1": "remoxipride", "entity2": "aplastic anemia", "span1": [26, 37], "span2": [153, 168]}, "bert_text": "Induction of apoptosis by <e1> remoxipride </e1> metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to remoxipride-induced <e2> aplastic anemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4220": {"data": {"text": "Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to remoxipride-induced aplastic anemia.\n", "entity1": "remoxipride", "entity2": "aplastic anemia", "span1": [133, 144], "span2": [153, 168]}, "bert_text": "Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19- human bone marrow progenitor cells: potential relevance to <e1> remoxipride </e1>-induced <e2> aplastic anemia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4221": {"data": {"text": "The antipsychotic agent, remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide] has been associated with acquired aplastic anemia.", "entity1": "remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide", "entity2": "aplastic anemia", "span1": [25, 112], "span2": [148, 163]}, "bert_text": "The antipsychotic agent, <e1> remoxipride [(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz amide </e1>] has been associated with acquired <e2> aplastic anemia </e2>.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4222": {"data": {"text": "Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.\n", "entity1": "Carvedilol", "entity2": "cardiomyopathy", "span1": [0, 10], "span2": [62, 76]}, "bert_text": "<e1> Carvedilol </e1> protects against doxorubicin-induced mitochondrial <e2> cardiomyopathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4223": {"data": {"text": "Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.\n", "entity1": "doxorubicin", "entity2": "cardiomyopathy", "span1": [28, 39], "span2": [62, 76]}, "bert_text": "Carvedilol protects against <e1> doxorubicin </e1>-induced mitochondrial <e2> cardiomyopathy </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4224": {"data": {"text": "Posttransplant anemia: the role of sirolimus.\n", "entity1": "sirolimus", "entity2": "anemia", "span1": [35, 44], "span2": [15, 21]}, "bert_text": "Posttransplant anemia: the role of <e1> sirolimus </e1> <e2> anemia </e2>: the role of sirolimus.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4225": {"data": {"text": "This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression.", "entity1": "amitriptyline", "entity2": "encephalopathy", "span1": [74, 87], "span2": [32, 46]}, "bert_text": "This report describes a case of encephalopathy developed in the course of <e1> amitriptyline </e1> <e2> encephalopathy </e2> developed in the course of amitriptyline therapy, during a remission of unipolar depression.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4226": {"data": {"text": "This report describes a case of encephalopathy developed in the course of amitriptyline therapy, during a remission of unipolar depression.", "entity1": "amitriptyline", "entity2": "unipolar depression", "span1": [74, 87], "span2": [119, 138]}, "bert_text": "This report describes a case of encephalopathy developed in the course of <e1> amitriptyline </e1> therapy, during a remission of <e2> unipolar depression </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4227": {"data": {"text": "This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.", "entity1": "dobutamine", "entity2": "torsade de pointes", "span1": [78, 88], "span2": [15, 33]}, "bert_text": "This report of torsade de pointes ventricular tachycardia during intermittent <e1> dobutamine </e1> <e2> torsade de pointes </e2> ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4228": {"data": {"text": "This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.", "entity1": "dobutamine", "entity2": "ventricular tachycardia", "span1": [78, 88], "span2": [34, 57]}, "bert_text": "This report of torsade de pointes ventricular tachycardia during intermittent <e1> dobutamine </e1> <e2> ventricular tachycardia </e2> during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4229": {"data": {"text": "This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.", "entity1": "dobutamine", "entity2": "arrhythmias", "span1": [78, 88], "span2": [138, 149]}, "bert_text": "This report of torsade de pointes ventricular tachycardia during intermittent <e1> dobutamine </e1> supports the hypothesis that unpredictable fatal <e2> arrhythmias </e2> may occur even with low doses and in patients with no history of significant rhythm disturbances.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4230": {"data": {"text": "This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances.", "entity1": "dobutamine", "entity2": "rhythm disturbances", "span1": [78, 88], "span2": [227, 246]}, "bert_text": "This report of torsade de pointes ventricular tachycardia during intermittent <e1> dobutamine </e1> supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant <e2> rhythm disturbances </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4231": {"data": {"text": "Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.\n", "entity1": "epirubicin", "entity2": "atrioventricular block", "span1": [71, 81], "span2": [15, 37]}, "bert_text": "Peri-operative atrioventricular block as a result of chemotherapy with <e1> epirubicin </e1> <e2> atrioventricular block </e2> as a result of chemotherapy with epirubicin and paclitaxel.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4232": {"data": {"text": "Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.\n", "entity1": "paclitaxel", "entity2": "atrioventricular block", "span1": [86, 96], "span2": [15, 37]}, "bert_text": "Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and <e1> paclitaxel </e1> <e2> atrioventricular block </e2> as a result of chemotherapy with epirubicin and paclitaxel.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4233": {"data": {"text": "Half log incremental doses of intravenous methoxamine or placebo (saline) were administered to a group of women with genuine stress incontinence while measuring maximum urethral pressure (MUP), blood pressure, heart rate, and symptomatic side effects.", "entity1": "methoxamine", "entity2": "stress incontinence", "span1": [42, 53], "span2": [125, 144]}, "bert_text": "Half log incremental doses of intravenous <e1> methoxamine </e1> or placebo (saline) were administered to a group of women with genuine <e2> stress incontinence </e2> while measuring maximum urethral pressure (MUP), blood pressure, heart rate, and symptomatic side effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4234": {"data": {"text": "Stereological methods reveal the robust size and stability of ectopic hilar granule cells after pilocarpine-induced status epilepticus in the adult rat.\n", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [96, 107], "span2": [116, 134]}, "bert_text": "Stereological methods reveal the robust size and stability of ectopic hilar granule cells after <e1> pilocarpine </e1>-induced <e2> status epilepticus </e2> in the adult rat.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4235": {"data": {"text": "To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [248, 259], "span2": [218, 236]}, "bert_text": "To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by <e1> pilocarpine </e1> <e2> status epilepticus </e2> induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4236": {"data": {"text": "To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.", "entity1": "Pilo", "entity2": "status epilepticus", "span1": [261, 265], "span2": [218, 236]}, "bert_text": "To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (<e1> Pilo </e1> <e2> status epilepticus </e2> induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4237": {"data": {"text": "To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.", "entity1": "cycloheximide", "entity2": "status epilepticus", "span1": [300, 313], "span2": [218, 236]}, "bert_text": "To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with <e1> cycloheximide </e1> <e2> status epilepticus </e2> induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4238": {"data": {"text": "To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.", "entity1": "CHX", "entity2": "status epilepticus", "span1": [315, 318], "span2": [218, 236]}, "bert_text": "To investigate how GAP43 expression (GAP43-ir) correlates with MFS, we assessed the intensity (densitometry) and extension (width) of GAP43-ir in the inner molecular layer of the dentate gyrus (IML) of rats subject to status epilepticus induced by pilocarpine (Pilo), previously injected or not with cycloheximide (<e1> CHX </e1> <e2> status epilepticus </e2> induced by pilocarpine (Pilo), previously injected or not with cycloheximide (CHX), which has been shown to inhibit MFS.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4239": {"data": {"text": "The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.", "entity1": "amiodarone", "entity2": "pulmonary lesion", "span1": [83, 93], "span2": [102, 118]}, "bert_text": "The present case highlights the possibility that differential diagnosis between an <e1> amiodarone </e1>-related <e2> pulmonary lesion </e2> and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4240": {"data": {"text": "The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.", "entity1": "amiodarone", "entity2": "membranous glomerulonephritis", "span1": [83, 93], "span2": [190, 219]}, "bert_text": "The present case highlights the possibility that differential diagnosis between an <e1> amiodarone </e1>-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that <e2> membranous glomerulonephritis </e2> might be another possible complication of amiodarone treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4241": {"data": {"text": "The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.", "entity1": "amiodarone", "entity2": "pulmonary lesion", "span1": [262, 272], "span2": [102, 118]}, "bert_text": "The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of <e1> amiodarone </e1> <e2> pulmonary lesion </e2> and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4242": {"data": {"text": "The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment.", "entity1": "amiodarone", "entity2": "membranous glomerulonephritis", "span1": [262, 272], "span2": [190, 219]}, "bert_text": "The present case highlights the possibility that differential diagnosis between an amiodarone-related pulmonary lesion and a neoplasm can be very difficult radiologically, and suggests that membranous glomerulonephritis might be another possible complication of <e1> amiodarone </e1> <e2> membranous glomerulonephritis </e2> might be another possible complication of amiodarone treatment.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4243": {"data": {"text": "Incidence of heparin-induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [13, 20], "span2": [29, 45]}, "bert_text": "Incidence of <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> type II and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4244": {"data": {"text": "p75NTR expression in rat urinary bladder sensory neurons and spinal cord with cyclophosphamide-induced cystitis.\n", "entity1": "cyclophosphamide", "entity2": "cystitis", "span1": [78, 94], "span2": [103, 111]}, "bert_text": "p75NTR expression in rat urinary bladder sensory neurons and spinal cord with <e1> cyclophosphamide </e1>-induced <e2> cystitis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4245": {"data": {"text": "CONCLUSIONS: RAD001 10 mg/day was well tolerated, showing modest clinical activity in pretreated NSCLC.", "entity1": "RAD001", "entity2": "NSCLC", "span1": [13, 19], "span2": [97, 102]}, "bert_text": "CONCLUSIONS: <e1> RAD001 </e1> 10 mg/day was well tolerated, showing modest clinical activity in pretreated <e2> NSCLC </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4246": {"data": {"text": "The diagnosis of metronidazole toxicity was made by the MRI findings and supported clinically.", "entity1": "metronidazole", "entity2": "toxicity", "span1": [17, 30], "span2": [31, 39]}, "bert_text": "The diagnosis of <e1> metronidazole </e1> <e2> toxicity </e2> was made by the MRI findings and supported clinically.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4247": {"data": {"text": "A case of postoperative anxiety due to low dose droperidol used with patient-controlled analgesia.\n", "entity1": "droperidol", "entity2": "postoperative anxiety", "span1": [48, 58], "span2": [10, 31]}, "bert_text": "A case of postoperative anxiety due to low dose <e1> droperidol </e1> <e2> postoperative anxiety </e2> due to low dose droperidol used with patient-controlled analgesia.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4248": {"data": {"text": "A case of postoperative anxiety due to low dose droperidol used with patient-controlled analgesia.\n", "entity1": "droperidol", "entity2": "analgesia", "span1": [48, 58], "span2": [88, 97]}, "bert_text": "A case of postoperative anxiety due to low dose <e1> droperidol </e1> used with patient-controlled <e2> analgesia </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4249": {"data": {"text": "ANIMALS: 12 cats suspected to have idiopathic epilepsy that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital.", "entity1": "phenobarbital", "entity2": "idiopathic epilepsy", "span1": [87, 100], "span2": [35, 54]}, "bert_text": "ANIMALS: 12 cats suspected to have idiopathic epilepsy that was poorly controlled with <e1> phenobarbital </e1> <e2> idiopathic epilepsy </e2> that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4250": {"data": {"text": "ANIMALS: 12 cats suspected to have idiopathic epilepsy that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital.", "entity1": "phenobarbital", "entity2": "idiopathic epilepsy", "span1": [160, 173], "span2": [35, 54]}, "bert_text": "ANIMALS: 12 cats suspected to have idiopathic epilepsy that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with <e1> phenobarbital </e1> <e2> idiopathic epilepsy </e2> that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4251": {"data": {"text": "Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs.\n", "entity1": "crack cocaine", "entity2": "HIV infection", "span1": [11, 24], "span2": [46, 59]}, "bert_text": "Smoking of <e1> crack cocaine </e1> as a risk factor for <e2> HIV infection </e2> among people who use injection drugs.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4252": {"data": {"text": "Thus it appears that the difference between seizure sensitive and insensitive animals may be due to a difference in hippocampal nicotinic receptor concentration as measured with alpha-bungarotoxin binding.", "entity1": "alpha-bungarotoxin", "entity2": "seizure", "span1": [178, 196], "span2": [44, 51]}, "bert_text": "Thus it appears that the difference between seizure sensitive and insensitive animals may be due to a difference in hippocampal nicotinic receptor concentration as measured with <e1> alpha-bungarotoxin </e1> <e2> seizure </e2> sensitive and insensitive animals may be due to a difference in hippocampal nicotinic receptor concentration as measured with alpha-bungarotoxin binding.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1], "label": 0},
+	"4253": {"data": {"text": "BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.", "entity1": "glucose", "entity2": "diabetes mellitus", "span1": [230, 237], "span2": [45, 62]}, "bert_text": "BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting <e1> glucose </e1> <e2> diabetes mellitus </e2> may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4254": {"data": {"text": "BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.", "entity1": "glucose", "entity2": "diabetes", "span1": [230, 237], "span2": [293, 301]}, "bert_text": "BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting <e1> glucose </e1> metabolism or simply increasing known risk factors for <e2> diabetes </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4255": {"data": {"text": "BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.", "entity1": "glucose", "entity2": "schizophrenia", "span1": [230, 237], "span2": [98, 111]}, "bert_text": "BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting <e1> glucose </e1> <e2> schizophrenia </e2> treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4256": {"data": {"text": "BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.", "entity1": "glucose", "entity2": "metabolism", "span1": [230, 237], "span2": [238, 248]}, "bert_text": "BACKGROUND: While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting <e1> glucose </e1> <e2> metabolism </e2> or simply increasing known risk factors for diabetes.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4257": {"data": {"text": "RESULTS: Of the 80 patients studied, ARI developed in 18.8% of the patients after high-dose melphalan.", "entity1": "melphalan", "entity2": "ARI", "span1": [92, 101], "span2": [37, 40]}, "bert_text": "RESULTS: Of the 80 patients studied, ARI developed in 18.8% of the patients after high-dose <e1> melphalan </e1> <e2> ARI </e2> developed in 18.8% of the patients after high-dose melphalan.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4258": {"data": {"text": "We conclude that the dipyridamole ECG test is as useful as the exercise ECG test for the assessment of coronary artery disease.", "entity1": "dipyridamole", "entity2": "coronary artery disease", "span1": [21, 33], "span2": [103, 126]}, "bert_text": "We conclude that the <e1> dipyridamole </e1> ECG test is as useful as the exercise ECG test for the assessment of <e2> coronary artery disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4259": {"data": {"text": "A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used.", "entity1": "ondansetron", "entity2": "postoperative nausea and vomiting", "span1": [160, 171], "span2": [45, 78]}, "bert_text": "A 41-year-old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where <e1> ondansetron </e1> <e2> postoperative nausea and vomiting </e2> presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4260": {"data": {"text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "entity1": "flumazenil", "entity2": "seizures", "span1": [156, 166], "span2": [17, 25]}, "bert_text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of <e1> flumazenil </e1> <e2> seizures </e2> (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4261": {"data": {"text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "entity1": "flumazenil", "entity2": "death", "span1": [156, 166], "span2": [51, 56]}, "bert_text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of <e1> flumazenil </e1> <e2> death </e2> (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4262": {"data": {"text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "entity1": "cocaine", "entity2": "seizures", "span1": [224, 231], "span2": [17, 25]}, "bert_text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of <e1> cocaine </e1> <e2> seizures </e2> (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4263": {"data": {"text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "entity1": "cocaine", "entity2": "death", "span1": [224, 231], "span2": [51, 56]}, "bert_text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of <e1> cocaine </e1> <e2> death </e2> (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4264": {"data": {"text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "entity1": "diazepam", "entity2": "seizures", "span1": [236, 244], "span2": [17, 25]}, "bert_text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and <e1> diazepam </e1> <e2> seizures </e2> (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4265": {"data": {"text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "entity1": "diazepam", "entity2": "death", "span1": [236, 244], "span2": [51, 56]}, "bert_text": "Animal behavior, seizures (time to and incidence), death (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and <e1> diazepam </e1> <e2> death </e2> (time to and incidence), and cortical EEG tracings were recorded. INTERVENTIONS: Administration of flumazenil to animals after they had received a combination dose of cocaine and diazepam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4266": {"data": {"text": "The present study examines the safety and tolerability of high- compared with low-dose lisinopril in CHF.", "entity1": "lisinopril", "entity2": "CHF", "span1": [87, 97], "span2": [101, 104]}, "bert_text": "The present study examines the safety and tolerability of high- compared with low-dose <e1> lisinopril </e1> in <e2> CHF </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4267": {"data": {"text": "These results indicate that non-steroidal anti-inflammatory drugs differentially modulate the threshold for pilocarpine-induced seizures.", "entity1": "pilocarpine", "entity2": "seizures", "span1": [108, 119], "span2": [128, 136]}, "bert_text": "These results indicate that non-steroidal anti-inflammatory drugs differentially modulate the threshold for <e1> pilocarpine </e1>-induced <e2> seizures </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4268": {"data": {"text": "An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced myopathy were observed. Niacin extended-release/lovastatin 1,000/40 mg, dosed as initial therapy, was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes.", "entity1": "creatine", "entity2": "myopathy", "span1": [15, 23], "span2": [136, 144]}, "bert_text": "An increase of <e1> creatine </e1> phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced <e2> myopathy </e2> were observed. Niacin extended-release/lovastatin 1,000/40 mg, dosed as initial therapy, was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4269": {"data": {"text": "An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced myopathy were observed. Niacin extended-release/lovastatin 1,000/40 mg, dosed as initial therapy, was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes.", "entity1": "Niacin", "entity2": "myopathy", "span1": [160, 166], "span2": [136, 144]}, "bert_text": "An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced myopathy were observed. <e1> Niacin </e1> <e2> myopathy </e2> were observed. Niacin extended-release/lovastatin 1,000/40 mg, dosed as initial therapy, was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4270": {"data": {"text": "An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced myopathy were observed. Niacin extended-release/lovastatin 1,000/40 mg, dosed as initial therapy, was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes.", "entity1": "lovastatin", "entity2": "myopathy", "span1": [184, 194], "span2": [136, 144]}, "bert_text": "An increase of creatine phosphokinase to >5 times the upper limit of normal occurred in 0.24% of patients, and no cases of drug-induced myopathy were observed. Niacin extended-release/<e1> lovastatin </e1> <e2> myopathy </e2> were observed. Niacin extended-release/lovastatin 1,000/40 mg, dosed as initial therapy, was associated with good compliance and safety and had very low incidences of increased liver and muscle enzymes.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 0},
+	"4271": {"data": {"text": "CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.", "entity1": "warfarin", "entity2": "hemorrhage", "span1": [160, 168], "span2": [30, 40]}, "bert_text": "CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on <e1> warfarin </e1> <e2> hemorrhage </e2> was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4272": {"data": {"text": "CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.", "entity1": "warfarin", "entity2": "stroke", "span1": [160, 168], "span2": [145, 151]}, "bert_text": "CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on <e1> warfarin </e1> <e2> stroke </e2> rate on warfarin was low, demonstrating how effective warfarin treatment is.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4273": {"data": {"text": "CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.", "entity1": "warfarin", "entity2": "hemorrhage", "span1": [206, 214], "span2": [30, 40]}, "bert_text": "CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective <e1> warfarin </e1> <e2> hemorrhage </e2> was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4274": {"data": {"text": "CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective warfarin treatment is.", "entity1": "warfarin", "entity2": "stroke", "span1": [206, 214], "span2": [145, 151]}, "bert_text": "CONCLUSION: The rate of major hemorrhage was high in this old, frail group, but excluding fatalities, resulted in no long-term sequelae, and the stroke rate on warfarin was low, demonstrating how effective <e1> warfarin </e1> <e2> stroke </e2> rate on warfarin was low, demonstrating how effective warfarin treatment is.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4275": {"data": {"text": "Recurrent myocardial infarction in a postpartum patient receiving bromocriptine.\n", "entity1": "bromocriptine", "entity2": "myocardial infarction", "span1": [66, 79], "span2": [10, 31]}, "bert_text": "Recurrent myocardial infarction in a postpartum patient receiving <e1> bromocriptine </e1> <e2> myocardial infarction </e2> in a postpartum patient receiving bromocriptine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4276": {"data": {"text": "We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to meloxicam.", "entity1": "meloxicam", "entity2": "rheumatoid arthritis", "span1": [112, 121], "span2": [44, 64]}, "bert_text": "We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to <e1> meloxicam </e1> <e2> rheumatoid arthritis </e2> who developed acute cytolytic hepatitis due to meloxicam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4277": {"data": {"text": "We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to meloxicam.", "entity1": "meloxicam", "entity2": "hepatitis", "span1": [112, 121], "span2": [95, 104]}, "bert_text": "We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to <e1> meloxicam </e1> <e2> hepatitis </e2> due to meloxicam.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4278": {"data": {"text": "Medial changes in arterial spasm induced by L-norepinephrine.\n", "entity1": "L-norepinephrine", "entity2": "spasm", "span1": [44, 60], "span2": [27, 32]}, "bert_text": "Medial changes in arterial spasm induced by <e1> L-norepinephrine </e1> <e2> spasm </e2> induced by L-norepinephrine.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4279": {"data": {"text": "Inhibition of nuclear factor-kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin.\n", "entity1": "gentamicin", "entity2": "tubulointerstitial nephritis", "span1": [98, 108], "span2": [58, 86]}, "bert_text": "Inhibition of nuclear factor-kappaB activation attenuates tubulointerstitial nephritis induced by <e1> gentamicin </e1> <e2> tubulointerstitial nephritis </e2> induced by gentamicin.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4280": {"data": {"text": "Experimental hypertension created by the removal of NO, however, involves mechanisms in addition to decreased arterial vasodilator activity.", "entity1": "NO", "entity2": "hypertension", "span1": [52, 54], "span2": [13, 25]}, "bert_text": "Experimental hypertension created by the removal of <e1> NO </e1> <e2> hypertension </e2> created by the removal of NO, however, involves mechanisms in addition to decreased arterial vasodilator activity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4281": {"data": {"text": "Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal seizures which occurred after 28 and 30 minutes respectively.", "entity1": "aminophylline", "entity2": "seizures", "span1": [117, 130], "span2": [154, 162]}, "bert_text": "Sprague-Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of <e1> aminophylline </e1> until onset of maximal <e2> seizures </e2> which occurred after 28 and 30 minutes respectively.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4282": {"data": {"text": "Levels were significantly greater in patients with acute liver failure due to paracetamol overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).", "entity1": "paracetamol", "entity2": "acute liver failure", "span1": [78, 89], "span2": [51, 70]}, "bert_text": "Levels were significantly greater in patients with acute liver failure due to <e1> paracetamol </e1> <e2> acute liver failure </e2> due to paracetamol overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4283": {"data": {"text": "Levels were significantly greater in patients with acute liver failure due to paracetamol overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).", "entity1": "paracetamol", "entity2": "overdose", "span1": [78, 89], "span2": [90, 98]}, "bert_text": "Levels were significantly greater in patients with acute liver failure due to <e1> paracetamol </e1> <e2> overdose </e2> (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4284": {"data": {"text": "Levels were significantly greater in patients with acute liver failure due to paracetamol overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E hepatitis (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).", "entity1": "paracetamol", "entity2": "hepatitis", "span1": [78, 89], "span2": [179, 188]}, "bert_text": "Levels were significantly greater in patients with acute liver failure due to <e1> paracetamol </e1> overdose (median, 28.7 U/mL; range, 12.8-52.7 U/mL, n = 17) than those due to non-A to E <e2> hepatitis </e2> (median, 12.5 U/mL; range, 6.9-46.0 U/mL, n = 7, P < 0.01).", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4285": {"data": {"text": "As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus", "entity1": "ICRF-187", "entity2": "toxicity", "span1": [103, 111], "span2": [30, 38]}, "bert_text": "As this schedule exerted more toxicity than needed to investigate protective agents, the protection of <e1> ICRF-187 </e1> <e2> toxicity </e2> than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4286": {"data": {"text": "As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus", "entity1": "ICRF-187", "entity2": "toxicity", "span1": [103, 111], "span2": [168, 176]}, "bert_text": "As this schedule exerted more toxicity than needed to investigate protective agents, the protection of <e1> ICRF-187 </e1> was determined using a dose schedule with lower general <e2> toxicity </e2> (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4287": {"data": {"text": "As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus", "entity1": "doxorubicin", "entity2": "toxicity", "span1": [204, 215], "span2": [30, 38]}, "bert_text": "As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg <e1> doxorubicin </e1> <e2> toxicity </e2> than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4288": {"data": {"text": "As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus", "entity1": "doxorubicin", "entity2": "toxicity", "span1": [204, 215], "span2": [168, 176]}, "bert_text": "As this schedule exerted more toxicity than needed to investigate protective agents, the protection of ICRF-187 was determined using a dose schedule with lower general toxicity (6 weekly doses of 4 mg/kg <e1> doxorubicin </e1> <e2> toxicity </e2> (6 weekly doses of 4 mg/kg doxorubicin given i.v. plus", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4289": {"data": {"text": "Hypotension induced by both peptides was significantly attenuated by glibenclamide, which abolished a levcromakalim-produced decrease in arterial blood pressure.", "entity1": "glibenclamide", "entity2": "Hypotension", "span1": [69, 82], "span2": [0, 11]}, "bert_text": "Hypotension induced by both peptides was significantly attenuated by <e1> glibenclamide </e1> <e2> Hypotension </e2> induced by both peptides was significantly attenuated by glibenclamide, which abolished a levcromakalim-produced decrease in arterial blood pressure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4290": {"data": {"text": "BACKGROUND: Animals treated with gentamicin can show residual areas of interstitial fibrosis in the renal cortex.", "entity1": "gentamicin", "entity2": "interstitial fibrosis", "span1": [33, 43], "span2": [71, 92]}, "bert_text": "BACKGROUND: Animals treated with <e1> gentamicin </e1> can show residual areas of <e2> interstitial fibrosis </e2> in the renal cortex.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4291": {"data": {"text": "Headache was significantly increased by GTN but not by DCF.", "entity1": "GTN", "entity2": "Headache", "span1": [40, 43], "span2": [0, 8]}, "bert_text": "Headache was significantly increased by <e1> GTN </e1> <e2> Headache </e2> was significantly increased by GTN but not by DCF.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4292": {"data": {"text": "Headache was significantly increased by GTN but not by DCF.", "entity1": "DCF", "entity2": "Headache", "span1": [55, 58], "span2": [0, 8]}, "bert_text": "Headache was significantly increased by GTN but not by <e1> DCF </e1> <e2> Headache </e2> was significantly increased by GTN but not by DCF.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4293": {"data": {"text": "mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine sodium 63 mmol/L, consistent with a diagnosis of SIADH.", "entity1": "sodium", "entity2": "SIADH", "span1": [85, 91], "span2": [134, 139]}, "bert_text": "mmol/L, serum osmolality was 263 mosmol/kg, urine osmolality 410 mosmol/kg and urine <e1> sodium </e1> 63 mmol/L, consistent with a diagnosis of <e2> SIADH </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4294": {"data": {"text": "CONCLUSIONS: High-dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy.", "entity1": "daptomycin", "entity2": "bacteremia", "span1": [23, 33], "span2": [72, 82]}, "bert_text": "CONCLUSIONS: High-dose <e1> daptomycin </e1> may be an alternative option for MSSA <e2> bacteremia </e2> with or without a CNS source in patients who have failed or cannot tolerate standard therapy.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4295": {"data": {"text": "CONCLUSIONS: High-dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy.", "entity1": "MSSA", "entity2": "bacteremia", "span1": [67, 71], "span2": [72, 82]}, "bert_text": "CONCLUSIONS: High-dose daptomycin may be an alternative option for <e1> MSSA </e1> <e2> bacteremia </e2> with or without a CNS source in patients who have failed or cannot tolerate standard therapy.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4296": {"data": {"text": "UNASSIGNED: Metolachlor, a widely used herbicide, is classified as a Group C carcinogen by the U.S. Environmental Protection Agency based on increased liver neoplasms in female rats.", "entity1": "herbicide", "entity2": "liver neoplasms", "span1": [39, 48], "span2": [151, 166]}, "bert_text": "UNASSIGNED: Metolachlor, a widely used <e1> herbicide </e1>, is classified as a Group C carcinogen by the U.S. Environmental Protection Agency based on increased <e2> liver neoplasms </e2> in female rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4297": {"data": {"text": "An 84-year-old male received oral pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later.", "entity1": "pilsicainide", "entity2": "atrial fibrillation", "span1": [34, 46], "span2": [133, 152]}, "bert_text": "An 84-year-old male received oral <e1> pilsicainide </e1>, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal <e2> atrial fibrillation </e2> to a sinus rhythm; the patient developed sudden cardiac death two days later.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4298": {"data": {"text": "An 84-year-old male received oral pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later.", "entity1": "pilsicainide", "entity2": "sudden cardiac death", "span1": [34, 46], "span2": [194, 214]}, "bert_text": "An 84-year-old male received oral <e1> pilsicainide </e1>, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed <e2> sudden cardiac death </e2> two days later.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4299": {"data": {"text": "An 84-year-old male received oral pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later.", "entity1": "sodium", "entity2": "atrial fibrillation", "span1": [55, 61], "span2": [133, 152]}, "bert_text": "An 84-year-old male received oral pilsicainide, a pure <e1> sodium </e1> channel blocker with slow recovery kinetics, to convert his paroxysmal <e2> atrial fibrillation </e2> to a sinus rhythm; the patient developed sudden cardiac death two days later.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4300": {"data": {"text": "An 84-year-old male received oral pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed sudden cardiac death two days later.", "entity1": "sodium", "entity2": "sudden cardiac death", "span1": [55, 61], "span2": [194, 214]}, "bert_text": "An 84-year-old male received oral pilsicainide, a pure <e1> sodium </e1> channel blocker with slow recovery kinetics, to convert his paroxysmal atrial fibrillation to a sinus rhythm; the patient developed <e2> sudden cardiac death </e2> two days later.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4301": {"data": {"text": "Proteinuria is an expected complication in transplant patients treated with mammalian target of rapamycin inhibitors (mTOR-i).", "entity1": "rapamycin inhibitors", "entity2": "Proteinuria", "span1": [96, 116], "span2": [0, 11]}, "bert_text": "Proteinuria is an expected complication in transplant patients treated with mammalian target of <e1> rapamycin inhibitors </e1> <e2> Proteinuria </e2> is an expected complication in transplant patients treated with mammalian target of rapamycin inhibitors (mTOR-i).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4302": {"data": {"text": "Morphine-induced seizures in newborn infants.\n", "entity1": "Morphine", "entity2": "seizures", "span1": [0, 8], "span2": [17, 25]}, "bert_text": "<e1> Morphine </e1>-induced <e2> seizures </e2> in newborn infants.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4303": {"data": {"text": "The results of this study indicate that progesterone can potentiate bupivacaine arrhythmogenicity both in vivo and in vitro.", "entity1": "progesterone", "entity2": "arrhythmogenicity", "span1": [40, 52], "span2": [80, 97]}, "bert_text": "The results of this study indicate that <e1> progesterone </e1> can potentiate bupivacaine <e2> arrhythmogenicity </e2> both in vivo and in vitro.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4304": {"data": {"text": "The results of this study indicate that progesterone can potentiate bupivacaine arrhythmogenicity both in vivo and in vitro.", "entity1": "bupivacaine", "entity2": "arrhythmogenicity", "span1": [68, 79], "span2": [80, 97]}, "bert_text": "The results of this study indicate that progesterone can potentiate <e1> bupivacaine </e1> <e2> arrhythmogenicity </e2> both in vivo and in vitro.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4305": {"data": {"text": "CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.", "entity1": "acetaminophen", "entity2": "FHF", "span1": [57, 70], "span2": [29, 32]}, "bert_text": "CONCLUSION: In patients with FHF and cerebral edema from <e1> acetaminophen </e1> <e2> FHF </e2> and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4306": {"data": {"text": "CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.", "entity1": "acetaminophen", "entity2": "cerebral edema", "span1": [57, 70], "span2": [37, 51]}, "bert_text": "CONCLUSION: In patients with FHF and cerebral edema from <e1> acetaminophen </e1> <e2> cerebral edema </e2> from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4307": {"data": {"text": "CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.", "entity1": "acetaminophen", "entity2": "overdose", "span1": [57, 70], "span2": [71, 79]}, "bert_text": "CONCLUSION: In patients with FHF and cerebral edema from <e1> acetaminophen </e1> <e2> overdose </e2>, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4308": {"data": {"text": "CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.", "entity1": "acetaminophen", "entity2": "hypothermia", "span1": [57, 70], "span2": [103, 114]}, "bert_text": "CONCLUSION: In patients with FHF and cerebral edema from <e1> acetaminophen </e1> overdose, prolonged therapeutic <e2> hypothermia </e2> could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4309": {"data": {"text": "OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.", "entity1": "Diazinon", "entity2": "lung cancer", "span1": [11, 19], "span2": [116, 127]}, "bert_text": "OBJECTIVE: <e1> Diazinon </e1>, a common organophosphate insecticide with genotoxic properties, was previously associated with <e2> lung cancer </e2> in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4310": {"data": {"text": "OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.", "entity1": "Diazinon", "entity2": "cancer", "span1": [11, 19], "span2": [247, 253]}, "bert_text": "OBJECTIVE: <e1> Diazinon </e1>, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated <e2> cancer </e2> risk.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4311": {"data": {"text": "OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.", "entity1": "diazinon", "entity2": "lung cancer", "span1": [227, 235], "span2": [116, 127]}, "bert_text": "OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined <e1> diazinon </e1> <e2> lung cancer </e2> in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4312": {"data": {"text": "OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.", "entity1": "diazinon", "entity2": "cancer", "span1": [227, 235], "span2": [247, 253]}, "bert_text": "OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined <e1> diazinon </e1>-associated <e2> cancer </e2> risk.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4313": {"data": {"text": "OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.", "entity1": "organophosphate", "entity2": "lung cancer", "span1": [30, 45], "span2": [116, 127]}, "bert_text": "OBJECTIVE: Diazinon, a common <e1> organophosphate </e1> insecticide with genotoxic properties, was previously associated with <e2> lung cancer </e2> in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4314": {"data": {"text": "OBJECTIVE: Diazinon, a common organophosphate insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated cancer risk.", "entity1": "organophosphate", "entity2": "cancer", "span1": [30, 45], "span2": [247, 253]}, "bert_text": "OBJECTIVE: Diazinon, a common <e1> organophosphate </e1> insecticide with genotoxic properties, was previously associated with lung cancer in the Agricultural Health Study (AHS) cohort, but few other epidemiological studies have examined diazinon-associated <e2> cancer </e2> risk.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4315": {"data": {"text": "It is concluded that advanced pregnancy has a negligible effect on the neurotoxic response to theophylline in rats.", "entity1": "theophylline", "entity2": "neurotoxic", "span1": [94, 106], "span2": [71, 81]}, "bert_text": "It is concluded that advanced pregnancy has a negligible effect on the neurotoxic response to <e1> theophylline </e1> <e2> neurotoxic </e2> response to theophylline in rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4316": {"data": {"text": "Therefore, urinary acidification could be an option to prevent IFO nephropathy in patients.", "entity1": "IFO", "entity2": "nephropathy", "span1": [63, 66], "span2": [67, 78]}, "bert_text": "Therefore, urinary acidification could be an option to prevent <e1> IFO </e1> <e2> nephropathy </e2> in patients.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4317": {"data": {"text": "Children with persistent sterile leukocyturia more frequently had an increase in serum creatinine levels of >50% above normal.", "entity1": "creatinine", "entity2": "sterile leukocyturia", "span1": [87, 97], "span2": [25, 45]}, "bert_text": "Children with persistent sterile leukocyturia more frequently had an increase in serum <e1> creatinine </e1> <e2> sterile leukocyturia </e2> more frequently had an increase in serum creatinine levels of >50% above normal.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4318": {"data": {"text": "OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.", "entity1": "valsartan", "entity2": "hypertension", "span1": [68, 77], "span2": [182, 194]}, "bert_text": "OBJECTIVE: This study investigated the efficacy and tolerability of <e1> valsartan </e1> (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4319": {"data": {"text": "OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.", "entity1": "VAL", "entity2": "hypertension", "span1": [79, 82], "span2": [182, 194]}, "bert_text": "OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (<e1> VAL </e1>) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4320": {"data": {"text": "OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.", "entity1": "hydrochlorothiazide", "entity2": "hypertension", "span1": [87, 106], "span2": [182, 194]}, "bert_text": "OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or <e1> hydrochlorothiazide </e1> (HCTZ)-monotherapy and higher-dose combinations in patients with essential <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4321": {"data": {"text": "OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (HCTZ)-monotherapy and higher-dose combinations in patients with essential hypertension.", "entity1": "HCTZ)-monotherapy", "entity2": "hypertension", "span1": [108, 125], "span2": [182, 194]}, "bert_text": "OBJECTIVE: This study investigated the efficacy and tolerability of valsartan (VAL) or hydrochlorothiazide (<e1> HCTZ)-monotherapy </e1> and higher-dose combinations in patients with essential <e2> hypertension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4322": {"data": {"text": "As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.", "entity1": "dihydropyridine", "entity2": "angina", "span1": [13, 28], "span2": [89, 95]}, "bert_text": "As the first <e1> dihydropyridine </e1> available for use in the United States, nifedipine controls <e2> angina </e2> and hypertension with minimal depression of cardiac function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4323": {"data": {"text": "As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.", "entity1": "dihydropyridine", "entity2": "hypertension", "span1": [13, 28], "span2": [100, 112]}, "bert_text": "As the first <e1> dihydropyridine </e1> available for use in the United States, nifedipine controls angina and <e2> hypertension </e2> with minimal depression of cardiac function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4324": {"data": {"text": "As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.", "entity1": "dihydropyridine", "entity2": "depression", "span1": [13, 28], "span2": [126, 136]}, "bert_text": "As the first <e1> dihydropyridine </e1> available for use in the United States, nifedipine controls angina and hypertension with minimal <e2> depression </e2> of cardiac function.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4325": {"data": {"text": "As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.", "entity1": "nifedipine", "entity2": "angina", "span1": [69, 79], "span2": [89, 95]}, "bert_text": "As the first dihydropyridine available for use in the United States, <e1> nifedipine </e1> controls <e2> angina </e2> and hypertension with minimal depression of cardiac function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4326": {"data": {"text": "As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.", "entity1": "nifedipine", "entity2": "hypertension", "span1": [69, 79], "span2": [100, 112]}, "bert_text": "As the first dihydropyridine available for use in the United States, <e1> nifedipine </e1> controls angina and <e2> hypertension </e2> with minimal depression of cardiac function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4327": {"data": {"text": "As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function.", "entity1": "nifedipine", "entity2": "depression", "span1": [69, 79], "span2": [126, 136]}, "bert_text": "As the first dihydropyridine available for use in the United States, <e1> nifedipine </e1> controls angina and hypertension with minimal <e2> depression </e2> of cardiac function.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4328": {"data": {"text": "We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS.", "entity1": "diazinon", "entity2": "cancer", "span1": [16, 24], "span2": [38, 44]}, "bert_text": "We used updated <e1> diazinon </e1> exposure and <e2> cancer </e2> incidence information to evaluate solid tumour risk in the AHS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4329": {"data": {"text": "We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS.", "entity1": "diazinon", "entity2": "tumour", "span1": [16, 24], "span2": [85, 91]}, "bert_text": "We used updated <e1> diazinon </e1> exposure and cancer incidence information to evaluate solid <e2> tumour </e2> risk in the AHS.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4330": {"data": {"text": "The patient tolerated the procedure well without any signs of citrate toxicity and maintained adequate anticoagulation for patency of the dialysis circuit.", "entity1": "citrate", "entity2": "toxicity", "span1": [62, 69], "span2": [70, 78]}, "bert_text": "The patient tolerated the procedure well without any signs of <e1> citrate </e1> <e2> toxicity </e2> and maintained adequate anticoagulation for patency of the dialysis circuit.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4331": {"data": {"text": "The purpose of this investigation was to determine whether the neurotoxicity of theophylline is altered in advanced pregnancy.", "entity1": "theophylline", "entity2": "neurotoxicity", "span1": [80, 92], "span2": [63, 76]}, "bert_text": "The purpose of this investigation was to determine whether the neurotoxicity of <e1> theophylline </e1> <e2> neurotoxicity </e2> of theophylline is altered in advanced pregnancy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4332": {"data": {"text": "Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/creatinine ratio and by microscopic hematuria.", "entity1": "creatinine", "entity2": "sterile leukocyturia", "span1": [100, 110], "span2": [11, 31]}, "bert_text": "Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/<e1> creatinine </e1> <e2> sterile leukocyturia </e2> was frequently associated with a mild increase in the urine albumin/creatinine ratio and by microscopic hematuria.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4333": {"data": {"text": "Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/creatinine ratio and by microscopic hematuria.", "entity1": "creatinine", "entity2": "hematuria", "span1": [100, 110], "span2": [136, 145]}, "bert_text": "Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/<e1> creatinine </e1> ratio and by microscopic <e2> hematuria </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4334": {"data": {"text": "We present a case where a patient developed features of encephalopathy following prolonged metronidazole intake.", "entity1": "metronidazole", "entity2": "encephalopathy", "span1": [91, 104], "span2": [56, 70]}, "bert_text": "We present a case where a patient developed features of encephalopathy following prolonged <e1> metronidazole </e1> <e2> encephalopathy </e2> following prolonged metronidazole intake.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4335": {"data": {"text": "Rechallenge of patients who developed oral candidiasis or hoarseness with beclomethasone dipropionate.\n", "entity1": "beclomethasone dipropionate", "entity2": "oral candidiasis", "span1": [74, 101], "span2": [38, 54]}, "bert_text": "Rechallenge of patients who developed oral candidiasis or hoarseness with <e1> beclomethasone dipropionate </e1> <e2> oral candidiasis </e2> or hoarseness with beclomethasone dipropionate.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4336": {"data": {"text": "Potentiation of bupivacaine arrhythmia in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level.", "entity1": "bupivacaine", "entity2": "arrhythmia", "span1": [16, 27], "span2": [28, 38]}, "bert_text": "Potentiation of <e1> bupivacaine </e1> <e2> arrhythmia </e2> in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4337": {"data": {"text": "Use of propranolol in the treatment of idiopathic orthostatic hypotension.\n", "entity1": "propranolol", "entity2": "idiopathic orthostatic hypotension", "span1": [7, 18], "span2": [39, 73]}, "bert_text": "Use of <e1> propranolol </e1> in the treatment of <e2> idiopathic orthostatic hypotension </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4338": {"data": {"text": "Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.", "entity1": "triglyceride", "entity2": "Depressed", "span1": [31, 43], "span2": [0, 9]}, "bert_text": "Depressed hepatic secretion of <e1> triglyceride </e1> <e2> Depressed </e2> hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4339": {"data": {"text": "Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.", "entity1": "triglyceride", "entity2": "Depressed", "span1": [96, 108], "span2": [0, 9]}, "bert_text": "Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic <e1> triglyceride </e1> <e2> Depressed </e2> hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4340": {"data": {"text": "Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.", "entity1": "triglyceride", "entity2": "Depressed", "span1": [190, 202], "span2": [0, 9]}, "bert_text": "Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the <e1> triglyceride </e1> <e2> Depressed </e2> hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4341": {"data": {"text": "Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.", "entity1": "tetracycline", "entity2": "Depressed", "span1": [235, 247], "span2": [0, 9]}, "bert_text": "Depressed hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to <e1> tetracycline </e1> <e2> Depressed </e2> hepatic secretion of triglyceride accounted only for 30 to 50% of accumulated hepatic triglyceride, indicating that additional mechanisms must be involved in the production of the triglyceride-rich fatty liver in response to tetracycline.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4342": {"data": {"text": "Microscopic evaluation revealed that treatment with DOX alone induced significant cardiac damage in comparison to the saline control group (P<0.001).", "entity1": "DOX", "entity2": "cardiac damage", "span1": [52, 55], "span2": [82, 96]}, "bert_text": "Microscopic evaluation revealed that treatment with <e1> DOX </e1> alone induced significant <e2> cardiac damage </e2> in comparison to the saline control group (P<0.001).", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4343": {"data": {"text": "Five cases of encephalitis following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.", "entity1": "diethylcarbamazine", "entity2": "encephalitis", "span1": [52, 70], "span2": [14, 26]}, "bert_text": "Five cases of encephalitis following treatment with <e1> diethylcarbamazine </e1> <e2> encephalitis </e2> following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4344": {"data": {"text": "Five cases of encephalitis following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.", "entity1": "diethylcarbamazine", "entity2": "Loa loa filariasis", "span1": [52, 70], "span2": [118, 136]}, "bert_text": "Five cases of encephalitis following treatment with <e1> diethylcarbamazine </e1> (DEC) were observed in Congolese patients with <e2> Loa loa filariasis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4345": {"data": {"text": "Five cases of encephalitis following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.", "entity1": "DEC", "entity2": "encephalitis", "span1": [72, 75], "span2": [14, 26]}, "bert_text": "Five cases of encephalitis following treatment with diethylcarbamazine (<e1> DEC </e1> <e2> encephalitis </e2> following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4346": {"data": {"text": "Five cases of encephalitis following treatment with diethylcarbamazine (DEC) were observed in Congolese patients with Loa loa filariasis.", "entity1": "DEC", "entity2": "Loa loa filariasis", "span1": [72, 75], "span2": [118, 136]}, "bert_text": "Five cases of encephalitis following treatment with diethylcarbamazine (<e1> DEC </e1>) were observed in Congolese patients with <e2> Loa loa filariasis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4347": {"data": {"text": "Penicillin anaphylaxis.\n", "entity1": "Penicillin", "entity2": "anaphylaxis", "span1": [0, 10], "span2": [11, 22]}, "bert_text": "<e1> Penicillin </e1> <e2> anaphylaxis </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4348": {"data": {"text": "Histologic evidence of cardiotoxicity scored as grade III was only observed at a dose of 1.0 mg doxorubicin/kg.", "entity1": "doxorubicin", "entity2": "cardiotoxicity", "span1": [96, 107], "span2": [23, 37]}, "bert_text": "Histologic evidence of cardiotoxicity scored as grade III was only observed at a dose of 1.0 mg <e1> doxorubicin </e1> <e2> cardiotoxicity </e2> scored as grade III was only observed at a dose of 1.0 mg doxorubicin/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4349": {"data": {"text": "The purpose of the present study was to compare influence of central arginine vasopressin (AVP) and of atrial natriuretic peptide (ANP) on control of arterial blood pressure (MAP) and heart rate (HR) in normotensive (WKY) and spontaneously hypertensive (SHR) rats.", "entity1": "arginine vasopressin", "entity2": "hypertensive", "span1": [69, 89], "span2": [240, 252]}, "bert_text": "The purpose of the present study was to compare influence of central <e1> arginine vasopressin </e1> (AVP) and of atrial natriuretic peptide (ANP) on control of arterial blood pressure (MAP) and heart rate (HR) in normotensive (WKY) and spontaneously <e2> hypertensive </e2> (SHR) rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4350": {"data": {"text": "The purpose of the present study was to compare influence of central arginine vasopressin (AVP) and of atrial natriuretic peptide (ANP) on control of arterial blood pressure (MAP) and heart rate (HR) in normotensive (WKY) and spontaneously hypertensive (SHR) rats.", "entity1": "AVP", "entity2": "hypertensive", "span1": [91, 94], "span2": [240, 252]}, "bert_text": "The purpose of the present study was to compare influence of central arginine vasopressin (<e1> AVP </e1>) and of atrial natriuretic peptide (ANP) on control of arterial blood pressure (MAP) and heart rate (HR) in normotensive (WKY) and spontaneously <e2> hypertensive </e2> (SHR) rats.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4351": {"data": {"text": "Therefore, when prescribing statins, the possibility of hepatic damage should be taken into account.", "entity1": "statins", "entity2": "hepatic damage", "span1": [28, 35], "span2": [56, 70]}, "bert_text": "Therefore, when prescribing <e1> statins </e1>, the possibility of <e2> hepatic damage </e2> should be taken into account.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4352": {"data": {"text": "It is concluded that curcumin is able to attenuate in vivo maleate-induced nephropathy and in vitro cell damage.", "entity1": "curcumin", "entity2": "nephropathy", "span1": [21, 29], "span2": [75, 86]}, "bert_text": "It is concluded that <e1> curcumin </e1> is able to attenuate in vivo maleate-induced <e2> nephropathy </e2> and in vitro cell damage.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4353": {"data": {"text": "It is concluded that curcumin is able to attenuate in vivo maleate-induced nephropathy and in vitro cell damage.", "entity1": "maleate", "entity2": "nephropathy", "span1": [59, 66], "span2": [75, 86]}, "bert_text": "It is concluded that curcumin is able to attenuate in vivo <e1> maleate </e1>-induced <e2> nephropathy </e2> and in vitro cell damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4354": {"data": {"text": "High-dose MP may be contraindicated in patients with known heart disease.", "entity1": "MP", "entity2": "heart disease", "span1": [10, 12], "span2": [59, 72]}, "bert_text": "High-dose <e1> MP </e1> may be contraindicated in patients with known <e2> heart disease </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4355": {"data": {"text": "Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali.", "entity1": "calcium", "entity2": "Milk-alkali syndrome", "span1": [132, 139], "span2": [0, 20]}, "bert_text": "Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of <e1> calcium </e1> <e2> Milk-alkali syndrome </e2> was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4356": {"data": {"text": "Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali.", "entity1": "calcium", "entity2": "peptic ulcer disease", "span1": [132, 139], "span2": [89, 109]}, "bert_text": "Milk-alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of <e1> calcium </e1> <e2> peptic ulcer disease </e2> with large amounts of calcium and alkali.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4357": {"data": {"text": "These brain substrates may help account for the symptoms of MA abuse, providing therapeutic targets for drug-induced brain injury.", "entity1": "MA", "entity2": "brain injury", "span1": [60, 62], "span2": [117, 129]}, "bert_text": "These brain substrates may help account for the symptoms of <e1> MA </e1> abuse, providing therapeutic targets for drug-induced <e2> brain injury </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4358": {"data": {"text": "Pupillometric changes while on DEP, especially changes in the total power of pupillary oscillation, were dramatically different than those observed in the eight other study subjects who did not become manic.", "entity1": "DEP", "entity2": "pupillary oscillation", "span1": [31, 34], "span2": [77, 98]}, "bert_text": "Pupillometric changes while on <e1> DEP </e1>, especially changes in the total power of <e2> pupillary oscillation </e2>, were dramatically different than those observed in the eight other study subjects who did not become manic.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4359": {"data": {"text": "Pupillometric changes while on DEP, especially changes in the total power of pupillary oscillation, were dramatically different than those observed in the eight other study subjects who did not become manic.", "entity1": "DEP", "entity2": "manic", "span1": [31, 34], "span2": [201, 206]}, "bert_text": "Pupillometric changes while on <e1> DEP </e1>, especially changes in the total power of pupillary oscillation, were dramatically different than those observed in the eight other study subjects who did not become <e2> manic </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1], "label": 1},
+	"4360": {"data": {"text": "CONCLUSION: Primary hyperparathyroidism is a rare but potentially life-threatening side effect of long-term lithium therapy.", "entity1": "lithium", "entity2": "Primary hyperparathyroidism", "span1": [108, 115], "span2": [12, 39]}, "bert_text": "CONCLUSION: Primary hyperparathyroidism is a rare but potentially life-threatening side effect of long-term <e1> lithium </e1> <e2> Primary hyperparathyroidism </e2> is a rare but potentially life-threatening side effect of long-term lithium therapy.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4361": {"data": {"text": "Aconitine-induced Ca2+ overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats.\n", "entity1": "Aconitine", "entity2": "arrhythmia", "span1": [0, 9], "span2": [39, 49]}, "bert_text": "<e1> Aconitine </e1>-induced Ca2+ overload causes <e2> arrhythmia </e2> and triggers apoptosis through p38 MAPK signaling pathway in rats.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4362": {"data": {"text": "Aconitine-induced Ca2+ overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats.\n", "entity1": "Ca2", "entity2": "arrhythmia", "span1": [18, 21], "span2": [39, 49]}, "bert_text": "Aconitine-induced <e1> Ca2 </e1>+ overload causes <e2> arrhythmia </e2> and triggers apoptosis through p38 MAPK signaling pathway in rats.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4363": {"data": {"text": "Naloxone (0.3, 1, 3, and 10 mg/kg) injected prior to training attenuated the retention deficit with a peak of activity at 3 mg/kg.", "entity1": "Naloxone", "entity2": "retention deficit", "span1": [0, 8], "span2": [77, 94]}, "bert_text": "<e1> Naloxone </e1> (0.3, 1, 3, and 10 mg/kg) injected prior to training attenuated the <e2> retention deficit </e2> with a peak of activity at 3 mg/kg.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4364": {"data": {"text": "Rats treated with 500 ppm quinacrine hydrochloride in the diet all developed a high incidence of left atrial thrombosis.", "entity1": "quinacrine hydrochloride", "entity2": "atrial thrombosis", "span1": [26, 50], "span2": [102, 119]}, "bert_text": "Rats treated with 500 ppm <e1> quinacrine hydrochloride </e1> in the diet all developed a high incidence of left <e2> atrial thrombosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4365": {"data": {"text": "A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with fluvastatin.", "entity1": "fluvastatin", "entity2": "liver damage", "span1": [109, 120], "span2": [40, 52]}, "bert_text": "A 52-year-old Chinese man reported with liver damage, which appeared 12 hours after beginning treatment with <e1> fluvastatin </e1> <e2> liver damage </e2>, which appeared 12 hours after beginning treatment with fluvastatin.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4366": {"data": {"text": "Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis.", "entity1": "rifampicin", "entity2": "Segmental necrotising glomerulonephritis", "span1": [78, 88], "span2": [0, 40]}, "bert_text": "Segmental necrotising glomerulonephritis has been reported as complication of <e1> rifampicin </e1> <e2> Segmental necrotising glomerulonephritis </e2> has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4367": {"data": {"text": "Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis.", "entity1": "rifampicin", "entity2": "tuberculosis", "span1": [78, 88], "span2": [133, 145]}, "bert_text": "Segmental necrotising glomerulonephritis has been reported as complication of <e1> rifampicin </e1> therapy in patients receiving treatment for <e2> tuberculosis </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4368": {"data": {"text": "BACKGROUND: Little is known about the possible role that smoking crack cocaine has on the incidence of HIV infection.", "entity1": "smoking crack cocaine", "entity2": "HIV infection", "span1": [57, 78], "span2": [103, 116]}, "bert_text": "BACKGROUND: Little is known about the possible role that <e1> smoking crack cocaine </e1> has on the incidence of <e2> HIV infection </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4369": {"data": {"text": "A case of bilateral optic neuropathy in a patient on tacrolimus (FK506) therapy after liver transplantation.\n", "entity1": "tacrolimus", "entity2": "optic neuropathy", "span1": [53, 63], "span2": [20, 36]}, "bert_text": "A case of bilateral optic neuropathy in a patient on <e1> tacrolimus </e1> <e2> optic neuropathy </e2> in a patient on tacrolimus (FK506) therapy after liver transplantation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4370": {"data": {"text": "A case of bilateral optic neuropathy in a patient on tacrolimus (FK506) therapy after liver transplantation.\n", "entity1": "FK506", "entity2": "optic neuropathy", "span1": [65, 70], "span2": [20, 36]}, "bert_text": "A case of bilateral optic neuropathy in a patient on tacrolimus (<e1> FK506 </e1> <e2> optic neuropathy </e2> in a patient on tacrolimus (FK506) therapy after liver transplantation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4371": {"data": {"text": "Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.\n", "entity1": "nitric-oxide", "entity2": "catalepsy", "span1": [26, 38], "span2": [78, 87]}, "bert_text": "Sub-chronic inhibition of <e1> nitric-oxide </e1> synthesis modifies haloperidol-induced <e2> catalepsy </e2> and the number of NADPH-diaphorase neurons in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4372": {"data": {"text": "Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.\n", "entity1": "haloperidol", "entity2": "catalepsy", "span1": [58, 69], "span2": [78, 87]}, "bert_text": "Sub-chronic inhibition of nitric-oxide synthesis modifies <e1> haloperidol </e1>-induced <e2> catalepsy </e2> and the number of NADPH-diaphorase neurons in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4373": {"data": {"text": "Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.\n", "entity1": "NADPH", "entity2": "catalepsy", "span1": [106, 111], "span2": [78, 87]}, "bert_text": "Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of <e1> NADPH </e1> <e2> catalepsy </e2> and the number of NADPH-diaphorase neurons in mice.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4374": {"data": {"text": "Neurologic toxicities have been described with IT-methotrexate, IT-cytosine arabinoside and IT-TSPA.", "entity1": "methotrexate", "entity2": "Neurologic toxicities", "span1": [50, 62], "span2": [0, 21]}, "bert_text": "Neurologic toxicities have been described with IT-<e1> methotrexate </e1> <e2> Neurologic toxicities </e2> have been described with IT-methotrexate, IT-cytosine arabinoside and IT-TSPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4375": {"data": {"text": "Neurologic toxicities have been described with IT-methotrexate, IT-cytosine arabinoside and IT-TSPA.", "entity1": "cytosine arabinoside", "entity2": "Neurologic toxicities", "span1": [67, 87], "span2": [0, 21]}, "bert_text": "Neurologic toxicities have been described with IT-methotrexate, IT-<e1> cytosine arabinoside </e1> <e2> Neurologic toxicities </e2> have been described with IT-methotrexate, IT-cytosine arabinoside and IT-TSPA.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4376": {"data": {"text": "After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.", "entity1": "ISO", "entity2": "stenosis", "span1": [18, 21], "span2": [36, 44]}, "bert_text": "After the control <e1> ISO </e1> infusion with <e2> stenosis </e2> was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4377": {"data": {"text": "After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.", "entity1": "ISO", "entity2": "stenosis", "span1": [283, 286], "span2": [36, 44]}, "bert_text": "After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third <e1> ISO </e1> <e2> stenosis </e2> was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4378": {"data": {"text": "After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.", "entity1": "nifedipine", "entity2": "stenosis", "span1": [129, 139], "span2": [36, 44]}, "bert_text": "After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), <e1> nifedipine </e1> <e2> stenosis </e2> was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4379": {"data": {"text": "After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.", "entity1": "diltiazem", "entity2": "stenosis", "span1": [178, 187], "span2": [36, 44]}, "bert_text": "After the control ISO infusion with stenosis was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or <e1> diltiazem </e1> <e2> stenosis </e2> was performed, equihypotensive doses of CD-832 (3 and 10 micrograms/kg/min, n = 7), nifedipine (1 and 3 micrograms/kg/min, n = 9) or diltiazem (10 and 30 micrograms/kg/min, n = 7) were infused 5 min before and during the second and third ISO infusion.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4380": {"data": {"text": "METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.", "entity1": "carboplatin", "entity2": "squamous cell cervical carcinoma", "span1": [28, 39], "span2": [222, 254]}, "bert_text": "METHODS: The combination of <e1> carboplatin </e1> (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent <e2> squamous cell cervical carcinoma </e2> to determine antitumor activity and toxicity profile.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4381": {"data": {"text": "METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.", "entity1": "carboplatin", "entity2": "toxicity", "span1": [28, 39], "span2": [291, 299]}, "bert_text": "METHODS: The combination of <e1> carboplatin </e1> (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and <e2> toxicity </e2> profile.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4382": {"data": {"text": "METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.", "entity1": "doxorubicin", "entity2": "squamous cell cervical carcinoma", "span1": [100, 111], "span2": [222, 254]}, "bert_text": "METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal <e1> doxorubicin </e1> (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent <e2> squamous cell cervical carcinoma </e2> to determine antitumor activity and toxicity profile.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4383": {"data": {"text": "METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.", "entity1": "doxorubicin", "entity2": "toxicity", "span1": [100, 111], "span2": [291, 299]}, "bert_text": "METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal <e1> doxorubicin </e1> (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and <e2> toxicity </e2> profile.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4384": {"data": {"text": "METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.", "entity1": "Doxil", "entity2": "squamous cell cervical carcinoma", "span1": [113, 118], "span2": [222, 254]}, "bert_text": "METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (<e1> Doxil </e1>; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent <e2> squamous cell cervical carcinoma </e2> to determine antitumor activity and toxicity profile.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4385": {"data": {"text": "METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (Doxil; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile.", "entity1": "Doxil", "entity2": "toxicity", "span1": [113, 118], "span2": [291, 299]}, "bert_text": "METHODS: The combination of carboplatin (area under the concentration curve [AUC], 5) and liposomal doxorubicin (<e1> Doxil </e1>; starting dose, 40 mg/m(2)) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and <e2> toxicity </e2> profile.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4386": {"data": {"text": "There was no change in hepatic tissue total glutathione following intestinal ischemia-reperfusion injury.", "entity1": "glutathione", "entity2": "intestinal ischemia-reperfusion injury", "span1": [44, 55], "span2": [66, 104]}, "bert_text": "There was no change in hepatic tissue total <e1> glutathione </e1> following <e2> intestinal ischemia-reperfusion injury </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4387": {"data": {"text": "OBJECTIVE: To assess pharmacokinetics, efficacy, and tolerability of oral levetiracetam administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected idiopathic epilepsy.", "entity1": "levetiracetam", "entity2": "idiopathic epilepsy", "span1": [74, 87], "span2": [183, 202]}, "bert_text": "OBJECTIVE: To assess pharmacokinetics, efficacy, and tolerability of oral <e1> levetiracetam </e1> administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected <e2> idiopathic epilepsy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4388": {"data": {"text": "OBJECTIVE: To assess pharmacokinetics, efficacy, and tolerability of oral levetiracetam administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected idiopathic epilepsy.", "entity1": "phenobarbital", "entity2": "idiopathic epilepsy", "span1": [118, 131], "span2": [183, 202]}, "bert_text": "OBJECTIVE: To assess pharmacokinetics, efficacy, and tolerability of oral levetiracetam administered as an adjunct to <e1> phenobarbital </e1> treatment in cats with poorly controlled suspected <e2> idiopathic epilepsy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4389": {"data": {"text": "The laboratory data revealed normal plasma electrolyte and ammonia levels but leukocytosis.", "entity1": "ammonia", "entity2": "leukocytosis", "span1": [59, 66], "span2": [78, 90]}, "bert_text": "The laboratory data revealed normal plasma electrolyte and <e1> ammonia </e1> levels but <e2> leukocytosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4390": {"data": {"text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "entity1": "prostaglandin", "entity2": "renal damage", "span1": [21, 34], "span2": [77, 89]}, "bert_text": "The changes in renal <e1> prostaglandin </e1> synthesis were accompanied by evidence of <e2> renal damage </e2> in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4391": {"data": {"text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "entity1": "prostaglandin", "entity2": "hematuria", "span1": [21, 34], "span2": [181, 190]}, "bert_text": "The changes in renal <e1> prostaglandin </e1> synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of <e2> hematuria </e2> (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4392": {"data": {"text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "entity1": "aspirin", "entity2": "renal damage", "span1": [93, 100], "span2": [77, 89]}, "bert_text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in <e1> aspirin </e1> <e2> renal damage </e2> in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4393": {"data": {"text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "entity1": "aspirin", "entity2": "hematuria", "span1": [93, 100], "span2": [181, 190]}, "bert_text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in <e1> aspirin </e1>-treated jj but not jJ rats as evidenced by: increased incidence and severity of <e2> hematuria </e2> (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "weak_labels": [-1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4394": {"data": {"text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "entity1": "aspirin", "entity2": "renal damage", "span1": [371, 378], "span2": [77, 89]}, "bert_text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or <e1> aspirin </e1> <e2> renal damage </e2> in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4395": {"data": {"text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "entity1": "aspirin", "entity2": "hematuria", "span1": [371, 378], "span2": [181, 190]}, "bert_text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or <e1> aspirin </e1> <e2> hematuria </e2> (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4396": {"data": {"text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "entity1": "creatinine", "entity2": "renal damage", "span1": [227, 237], "span2": [77, 89]}, "bert_text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum <e1> creatinine </e1> <e2> renal damage </e2> in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4397": {"data": {"text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "entity1": "creatinine", "entity2": "hematuria", "span1": [227, 237], "span2": [181, 190]}, "bert_text": "The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin-treated jj but not jJ rats as evidenced by: increased incidence and severity of hematuria (p less than 0.01); increased serum <e1> creatinine </e1> <e2> hematuria </e2> (p less than 0.01); increased serum creatinine (p less than 0.05); and increase in outer medullary histopathologic lesions (p less than 0.005 compared to either sham-treated jj or aspirin-treated jJ).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4398": {"data": {"text": "Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of Aza patients.", "entity1": "cyclosporine", "entity2": "Cytomegalovirus", "span1": [98, 110], "span2": [0, 15]}, "bert_text": "Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of <e1> cyclosporine </e1> <e2> Cytomegalovirus </e2> (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of Aza patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4399": {"data": {"text": "Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of Aza patients.", "entity1": "cyclosporine", "entity2": "CMV", "span1": [98, 110], "span2": [17, 20]}, "bert_text": "Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of <e1> cyclosporine </e1> <e2> CMV </e2>) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of Aza patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4400": {"data": {"text": "Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of Aza patients.", "entity1": "Aza", "entity2": "Cytomegalovirus", "span1": [131, 134], "span2": [0, 15]}, "bert_text": "Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of <e1> Aza </e1> <e2> Cytomegalovirus </e2> (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of Aza patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4401": {"data": {"text": "Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of Aza patients.", "entity1": "Aza", "entity2": "CMV", "span1": [131, 134], "span2": [17, 20]}, "bert_text": "Cytomegalovirus (CMV) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of <e1> Aza </e1> <e2> CMV </e2>) shedding or serological rises in antibody titer, or both occurred in 78% of cyclosporine patients and 76% of Aza patients.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4402": {"data": {"text": "Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination?", "entity1": "etomidate", "entity2": "myoclonus", "span1": [14, 23], "span2": [32, 41]}, "bert_text": "Prevention of <e1> etomidate </e1>-induced <e2> myoclonus </e2>: which is superior: Fentanyl, midazolam, or a combination?", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4403": {"data": {"text": "Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination?", "entity1": "Fentanyl", "entity2": "myoclonus", "span1": [62, 70], "span2": [32, 41]}, "bert_text": "Prevention of etomidate-induced myoclonus: which is superior: <e1> Fentanyl </e1> <e2> myoclonus </e2>: which is superior: Fentanyl, midazolam, or a combination?", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4404": {"data": {"text": "Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination?", "entity1": "midazolam", "entity2": "myoclonus", "span1": [72, 81], "span2": [32, 41]}, "bert_text": "Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, <e1> midazolam </e1> <e2> myoclonus </e2>: which is superior: Fentanyl, midazolam, or a combination?", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4405": {"data": {"text": "CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.", "entity1": "fentanyl", "entity2": "myoclonus", "span1": [48, 56], "span2": [144, 153]}, "bert_text": "CONCLUSIONS: We conclude that pretreatment with <e1> fentanyl </e1> or combination of fentanyl and midazolam was effective in preventing etomidate-induced <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4406": {"data": {"text": "CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.", "entity1": "fentanyl", "entity2": "myoclonus", "span1": [75, 83], "span2": [144, 153]}, "bert_text": "CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of <e1> fentanyl </e1> and midazolam was effective in preventing etomidate-induced <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4407": {"data": {"text": "CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.", "entity1": "midazolam", "entity2": "myoclonus", "span1": [88, 97], "span2": [144, 153]}, "bert_text": "CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and <e1> midazolam </e1> was effective in preventing etomidate-induced <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, 0, 0, 0, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1], "label": 0},
+	"4408": {"data": {"text": "CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.", "entity1": "etomidate", "entity2": "myoclonus", "span1": [126, 135], "span2": [144, 153]}, "bert_text": "CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing <e1> etomidate </e1>-induced <e2> myoclonus </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 0, -1], "label": 1},
+	"4409": {"data": {"text": "Studies of risk factors for aminoglycoside nephrotoxicity.\n", "entity1": "aminoglycoside", "entity2": "nephrotoxicity", "span1": [28, 42], "span2": [43, 57]}, "bert_text": "Studies of risk factors for <e1> aminoglycoside </e1> <e2> nephrotoxicity </e2>.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4410": {"data": {"text": "Protective effect of clentiazem against epinephrine-induced cardiac injury in rats.\n", "entity1": "clentiazem", "entity2": "cardiac injury", "span1": [21, 31], "span2": [60, 74]}, "bert_text": "Protective effect of <e1> clentiazem </e1> against epinephrine-induced <e2> cardiac injury </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4411": {"data": {"text": "Protective effect of clentiazem against epinephrine-induced cardiac injury in rats.\n", "entity1": "epinephrine", "entity2": "cardiac injury", "span1": [40, 51], "span2": [60, 74]}, "bert_text": "Protective effect of clentiazem against <e1> epinephrine </e1>-induced <e2> cardiac injury </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4412": {"data": {"text": "VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.", "entity1": "VCM", "entity2": "renal tubular injury", "span1": [0, 3], "span2": [149, 169]}, "bert_text": "<e1> VCM </e1> administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of <e2> renal tubular injury </e2>) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4413": {"data": {"text": "VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.", "entity1": "malondialdehyde", "entity2": "renal tubular injury", "span1": [65, 80], "span2": [149, 169]}, "bert_text": "VCM administration to control rats significantly increased renal <e1> malondialdehyde </e1> (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of <e2> renal tubular injury </e2>) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4414": {"data": {"text": "VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.", "entity1": "MDA", "entity2": "renal tubular injury", "span1": [82, 85], "span2": [149, 169]}, "bert_text": "VCM administration to control rats significantly increased renal malondialdehyde (<e1> MDA </e1>) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of <e2> renal tubular injury </e2>) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4415": {"data": {"text": "VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.", "entity1": "superoxide", "entity2": "renal tubular injury", "span1": [195, 205], "span2": [149, 169]}, "bert_text": "VCM administration to control rats significantly increased renal malondialdehyde (MDA) and urinary N-acetyl-beta-d-glucosaminidase (NAG, a marker of renal tubular injury) excretion but decreased <e1> superoxide </e1> <e2> renal tubular injury </e2>) excretion but decreased superoxide dismutase (SOD) and catalase (CAT) activities.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4416": {"data": {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity1": "Curcumin", "entity2": "nephrotoxicity", "span1": [0, 8], "span2": [34, 48]}, "bert_text": "<e1> Curcumin </e1> prevents maleate-induced <e2> nephrotoxicity </e2>: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4417": {"data": {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity1": "Curcumin", "entity2": "renal injury", "span1": [0, 8], "span2": [284, 296]}, "bert_text": "<e1> Curcumin </e1> prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the <e2> renal injury </e2> induced by maleate was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4418": {"data": {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity1": "curcumin", "entity2": "nephrotoxicity", "span1": [236, 244], "span2": [34, 48]}, "bert_text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant <e1> curcumin </e1> <e2> nephrotoxicity </e2>: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4419": {"data": {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity1": "curcumin", "entity2": "renal injury", "span1": [236, 244], "span2": [284, 296]}, "bert_text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant <e1> curcumin </e1> (120 mg/Kg/day for 6 days) against the <e2> renal injury </e2> induced by maleate was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4420": {"data": {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity1": "maleate", "entity2": "nephrotoxicity", "span1": [18, 25], "span2": [34, 48]}, "bert_text": "Curcumin prevents <e1> maleate </e1>-induced <e2> nephrotoxicity </e2>: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4421": {"data": {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity1": "maleate", "entity2": "renal injury", "span1": [18, 25], "span2": [284, 296]}, "bert_text": "Curcumin prevents <e1> maleate </e1>-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the <e2> renal injury </e2> induced by maleate was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4422": {"data": {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity1": "maleate", "entity2": "nephrotoxicity", "span1": [308, 315], "span2": [34, 48]}, "bert_text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by <e1> maleate </e1> <e2> nephrotoxicity </e2>: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4423": {"data": {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity1": "maleate", "entity2": "renal injury", "span1": [308, 315], "span2": [284, 296]}, "bert_text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by <e1> maleate </e1> <e2> renal injury </e2> induced by maleate was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4424": {"data": {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity1": "oxygen", "entity2": "nephrotoxicity", "span1": [119, 125], "span2": [34, 48]}, "bert_text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial <e1> oxygen </e1> <e2> nephrotoxicity </e2>: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 0},
+	"4425": {"data": {"text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial oxygen consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the renal injury induced by maleate was evaluated.", "entity1": "oxygen", "entity2": "renal injury", "span1": [119, 125], "span2": [284, 296]}, "bert_text": "Curcumin prevents maleate-induced nephrotoxicity: relation to hemodynamic alterations, oxidative stress, mitochondrial <e1> oxygen </e1> consumption and activity of respiratory complex I.\nThe potential protective effect of the dietary antioxidant curcumin (120 mg/Kg/day for 6 days) against the <e2> renal injury </e2> induced by maleate was evaluated.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4426": {"data": {"text": "This study aimed to demonstrate the induction to glomerulosclerosis in adult offspring by PCE and its intrauterine programming mechanisms.", "entity1": "PCE", "entity2": "glomerulosclerosis", "span1": [90, 93], "span2": [49, 67]}, "bert_text": "This study aimed to demonstrate the induction to glomerulosclerosis in adult offspring by <e1> PCE </e1> <e2> glomerulosclerosis </e2> in adult offspring by PCE and its intrauterine programming mechanisms.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4427": {"data": {"text": "These data give support to the hypothesis that the pathogenesis of Vigabatrin-associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose-dependent toxicity.", "entity1": "Vigabatrin", "entity2": "visual field defects", "span1": [67, 77], "span2": [89, 109]}, "bert_text": "These data give support to the hypothesis that the pathogenesis of <e1> Vigabatrin </e1>-associated <e2> visual field defects </e2> may be an idiosyncratic adverse drug reaction rather than dose-dependent toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4428": {"data": {"text": "These data give support to the hypothesis that the pathogenesis of Vigabatrin-associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose-dependent toxicity.", "entity1": "Vigabatrin", "entity2": "toxicity", "span1": [67, 77], "span2": [183, 191]}, "bert_text": "These data give support to the hypothesis that the pathogenesis of <e1> Vigabatrin </e1>-associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose-dependent <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4429": {"data": {"text": "GFC produced an increased latency to first seizure, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice.", "entity1": "GFC", "entity2": "seizure", "span1": [0, 3], "span2": [43, 50]}, "bert_text": "<e1> GFC </e1> produced an increased latency to first <e2> seizure </e2>, at doses 25mg/kg (20.12 + 2.20 min), 50mg/kg (20.95 + 2.21 min) or 75 mg/kg (23.43 + 1.99 min) when compared with seized mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4430": {"data": {"text": "Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.", "entity1": "suxamethonium", "entity2": "apnea", "span1": [104, 117], "span2": [63, 68]}, "bert_text": "Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (<e1> suxamethonium </e1> <e2> apnea </e2> after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4431": {"data": {"text": "Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.", "entity1": "mivacurium", "entity2": "apnea", "span1": [121, 131], "span2": [63, 68]}, "bert_text": "Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or <e1> mivacurium </e1> <e2> apnea </e2> after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4432": {"data": {"text": "This complication appears to represent a significant new toxicity of high-dose etoposide therapy for malignant glioma.", "entity1": "etoposide", "entity2": "toxicity", "span1": [79, 88], "span2": [57, 65]}, "bert_text": "This complication appears to represent a significant new toxicity of high-dose <e1> etoposide </e1> <e2> toxicity </e2> of high-dose etoposide therapy for malignant glioma.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4433": {"data": {"text": "This complication appears to represent a significant new toxicity of high-dose etoposide therapy for malignant glioma.", "entity1": "etoposide", "entity2": "malignant glioma", "span1": [79, 88], "span2": [101, 117]}, "bert_text": "This complication appears to represent a significant new toxicity of high-dose <e1> etoposide </e1> therapy for <e2> malignant glioma </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4434": {"data": {"text": "Flurothyl seizure testing proved to be a rapid and reliable technique with which to evaluate seizure susceptibility.", "entity1": "Flurothyl", "entity2": "seizure", "span1": [0, 9], "span2": [10, 17]}, "bert_text": "<e1> Flurothyl </e1> <e2> seizure </e2> testing proved to be a rapid and reliable technique with which to evaluate seizure susceptibility.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4435": {"data": {"text": "Flurothyl seizure testing proved to be a rapid and reliable technique with which to evaluate seizure susceptibility.", "entity1": "Flurothyl", "entity2": "seizure", "span1": [0, 9], "span2": [93, 100]}, "bert_text": "<e1> Flurothyl </e1> seizure testing proved to be a rapid and reliable technique with which to evaluate <e2> seizure </e2> susceptibility.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4436": {"data": {"text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "entity1": "methylprednisolone acetate", "entity2": "retinal artery", "span1": [152, 178], "span2": [39, 53]}, "bert_text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with <e1> methylprednisolone acetate </e1> <e2> retinal artery </e2> and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4437": {"data": {"text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "entity1": "methylprednisolone acetate", "entity2": "blindness", "span1": [152, 178], "span2": [91, 100]}, "bert_text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with <e1> methylprednisolone acetate </e1> <e2> blindness </e2> following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4438": {"data": {"text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "entity1": "lidocaine", "entity2": "retinal artery", "span1": [199, 208], "span2": [39, 53]}, "bert_text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with <e1> lidocaine </e1> <e2> retinal artery </e2> and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4439": {"data": {"text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "entity1": "lidocaine", "entity2": "blindness", "span1": [199, 208], "span2": [91, 100]}, "bert_text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with <e1> lidocaine </e1> <e2> blindness </e2> following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4440": {"data": {"text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "entity1": "epinephrine", "entity2": "retinal artery", "span1": [210, 221], "span2": [39, 53]}, "bert_text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, <e1> epinephrine </e1> <e2> retinal artery </e2> and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4441": {"data": {"text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "entity1": "epinephrine", "entity2": "blindness", "span1": [210, 221], "span2": [91, 100]}, "bert_text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, <e1> epinephrine </e1> <e2> blindness </e2> following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4442": {"data": {"text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "entity1": "penicillin", "entity2": "retinal artery", "span1": [226, 236], "span2": [39, 53]}, "bert_text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or <e1> penicillin </e1> <e2> retinal artery </e2> and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4443": {"data": {"text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "entity1": "penicillin", "entity2": "blindness", "span1": [226, 236], "span2": [91, 100]}, "bert_text": "Two well-documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or <e1> penicillin </e1> <e2> blindness </e2> following head and neck soft-tissue injection with methylprednisolone acetate in combination with lidocaine, epinephrine, or penicillin are reported.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4444": {"data": {"text": "Morphological evaluation of the effect of d-ribose on adriamycin-evoked cardiotoxicity in rats.\n", "entity1": "d-ribose", "entity2": "cardiotoxicity", "span1": [42, 50], "span2": [72, 86]}, "bert_text": "Morphological evaluation of the effect of <e1> d-ribose </e1> on adriamycin-evoked <e2> cardiotoxicity </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4445": {"data": {"text": "Morphological evaluation of the effect of d-ribose on adriamycin-evoked cardiotoxicity in rats.\n", "entity1": "adriamycin", "entity2": "cardiotoxicity", "span1": [54, 64], "span2": [72, 86]}, "bert_text": "Morphological evaluation of the effect of d-ribose on <e1> adriamycin </e1>-evoked <e2> cardiotoxicity </e2> in rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4446": {"data": {"text": "Thus, temsirolimus reduced tumor burden through associated cytostatic and anti-angiogenic effects.", "entity1": "temsirolimus", "entity2": "tumor", "span1": [6, 18], "span2": [27, 32]}, "bert_text": "Thus, <e1> temsirolimus </e1> reduced <e2> tumor </e2> burden through associated cytostatic and anti-angiogenic effects.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4447": {"data": {"text": "Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of rifampicin for Staphylococcal infections.", "entity1": "rifampicin", "entity2": "infections", "span1": [109, 119], "span2": [25, 35]}, "bert_text": "Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of <e1> rifampicin </e1> <e2> infections </e2> such as infective endocarditis (IE) has led to an increase in the use of rifampicin for Staphylococcal infections.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4448": {"data": {"text": "Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of rifampicin for Staphylococcal infections.", "entity1": "rifampicin", "entity2": "infective endocarditis", "span1": [109, 119], "span2": [44, 66]}, "bert_text": "Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of <e1> rifampicin </e1> <e2> infective endocarditis </e2> (IE) has led to an increase in the use of rifampicin for Staphylococcal infections.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4449": {"data": {"text": "Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of rifampicin for Staphylococcal infections.", "entity1": "rifampicin", "entity2": "IE", "span1": [109, 119], "span2": [68, 70]}, "bert_text": "Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of <e1> rifampicin </e1> <e2> IE </e2>) has led to an increase in the use of rifampicin for Staphylococcal infections.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4450": {"data": {"text": "Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of rifampicin for Staphylococcal infections.", "entity1": "rifampicin", "entity2": "Staphylococcal infections", "span1": [109, 119], "span2": [124, 149]}, "bert_text": "Changing epidemiology of infections such as infective endocarditis (IE) has led to an increase in the use of <e1> rifampicin </e1> for <e2> Staphylococcal infections </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4451": {"data": {"text": "GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.\n", "entity1": "GEM", "entity2": "Hodgkin lymphoma", "span1": [0, 3], "span2": [58, 74]}, "bert_text": "<e1> GEM </e1>-P chemotherapy is active in the treatment of relapsed <e2> Hodgkin lymphoma </e2>.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4452": {"data": {"text": "Patterns of sulfadiazine acute nephrotoxicity.\n", "entity1": "sulfadiazine", "entity2": "nephrotoxicity", "span1": [12, 24], "span2": [31, 45]}, "bert_text": "Patterns of <e1> sulfadiazine </e1> acute <e2> nephrotoxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4453": {"data": {"text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.", "entity1": "CCB", "entity2": "SHR", "span1": [0, 3], "span2": [27, 30]}, "bert_text": "<e1> CCB </e1> was reduced in WKY and <e2> SHR </e2> after LV administration of AVP during SN-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4454": {"data": {"text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.", "entity1": "CCB", "entity2": "LV", "span1": [0, 3], "span2": [37, 39]}, "bert_text": "<e1> CCB </e1> was reduced in WKY and SHR after <e2> LV </e2> administration of AVP during SN-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4455": {"data": {"text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.", "entity1": "CCB", "entity2": "hypotension", "span1": [0, 3], "span2": [80, 91]}, "bert_text": "<e1> CCB </e1> was reduced in WKY and SHR after LV administration of AVP during SN-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4456": {"data": {"text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.", "entity1": "AVP", "entity2": "SHR", "span1": [58, 61], "span2": [27, 30]}, "bert_text": "CCB was reduced in WKY and SHR after LV administration of <e1> AVP </e1> <e2> SHR </e2> after LV administration of AVP during SN-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4457": {"data": {"text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.", "entity1": "AVP", "entity2": "LV", "span1": [58, 61], "span2": [37, 39]}, "bert_text": "CCB was reduced in WKY and SHR after LV administration of <e1> AVP </e1> <e2> LV </e2> administration of AVP during SN-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4458": {"data": {"text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.", "entity1": "AVP", "entity2": "hypotension", "span1": [58, 61], "span2": [80, 91]}, "bert_text": "CCB was reduced in WKY and SHR after LV administration of <e1> AVP </e1> during SN-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4459": {"data": {"text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.", "entity1": "SN", "entity2": "SHR", "span1": [69, 71], "span2": [27, 30]}, "bert_text": "CCB was reduced in WKY and SHR after LV administration of AVP during <e1> SN </e1> <e2> SHR </e2> after LV administration of AVP during SN-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4460": {"data": {"text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.", "entity1": "SN", "entity2": "LV", "span1": [69, 71], "span2": [37, 39]}, "bert_text": "CCB was reduced in WKY and SHR after LV administration of AVP during <e1> SN </e1> <e2> LV </e2> administration of AVP during SN-induced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4461": {"data": {"text": "CCB was reduced in WKY and SHR after LV administration of AVP during SN-induced hypotension.", "entity1": "SN", "entity2": "hypotension", "span1": [69, 71], "span2": [80, 91]}, "bert_text": "CCB was reduced in WKY and SHR after LV administration of AVP during <e1> SN </e1>-induced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4462": {"data": {"text": "Lamivudine is a novel 2',3'-dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo.", "entity1": "Lamivudine", "entity2": "hepatitis B", "span1": [0, 10], "span2": [92, 103]}, "bert_text": "<e1> Lamivudine </e1> is a novel 2',3'-dideoxy cytosine analogue that has potent inhibitory effects on <e2> hepatitis B </e2> virus replication in vitro and in vivo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4463": {"data": {"text": "Lamivudine is a novel 2',3'-dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo.", "entity1": "2',3'-dideoxy cytosine", "entity2": "hepatitis B", "span1": [22, 44], "span2": [92, 103]}, "bert_text": "Lamivudine is a novel <e1> 2',3'-dideoxy cytosine </e1> analogue that has potent inhibitory effects on <e2> hepatitis B </e2> virus replication in vitro and in vivo.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4464": {"data": {"text": "The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity.", "entity1": "carvedilol", "entity2": "hepatic mitochondrial bioenergetic dysfunction", "span1": [68, 78], "span2": [200, 246]}, "bert_text": "The objective of this investigation was to test the hypothesis that <e1> carvedilol </e1>, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and <e2> hepatic mitochondrial bioenergetic dysfunction </e2> associated with subchronic doxorubicin toxicity.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4465": {"data": {"text": "The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity.", "entity1": "carvedilol", "entity2": "toxicity", "span1": [68, 78], "span2": [286, 294]}, "bert_text": "The objective of this investigation was to test the hypothesis that <e1> carvedilol </e1>, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin <e2> toxicity </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4466": {"data": {"text": "The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity.", "entity1": "doxorubicin", "entity2": "hepatic mitochondrial bioenergetic dysfunction", "span1": [274, 285], "span2": [200, 246]}, "bert_text": "The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic <e1> doxorubicin </e1> <e2> hepatic mitochondrial bioenergetic dysfunction </e2> associated with subchronic doxorubicin toxicity.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4467": {"data": {"text": "The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity.", "entity1": "doxorubicin", "entity2": "toxicity", "span1": [274, 285], "span2": [286, 294]}, "bert_text": "The objective of this investigation was to test the hypothesis that carvedilol, a nonselective beta-adrenergic receptor antagonist with potent antioxidant properties, protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic <e1> doxorubicin </e1> <e2> toxicity </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4468": {"data": {"text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "entity1": "omeprazole", "entity2": "ulcer", "span1": [51, 61], "span2": [22, 27]}, "bert_text": "Although with current ulcer therapy (H-2 blockers, <e1> omeprazole </e1> <e2> ulcer </e2> therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4469": {"data": {"text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "entity1": "omeprazole", "entity2": "milk-alkali syndrome", "span1": [51, 61], "span2": [97, 117]}, "bert_text": "Although with current ulcer therapy (H-2 blockers, <e1> omeprazole </e1>, and sucralfate), the frequency of <e2> milk-alkali syndrome </e2> has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4470": {"data": {"text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "entity1": "omeprazole", "entity2": "hypercalcemia", "span1": [51, 61], "span2": [168, 181]}, "bert_text": "Although with current ulcer therapy (H-2 blockers, <e1> omeprazole </e1>, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of <e2> hypercalcemia </e2>, alkalosis, and renal impairment remains the hallmark of the syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4471": {"data": {"text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "entity1": "omeprazole", "entity2": "alkalosis", "span1": [51, 61], "span2": [183, 192]}, "bert_text": "Although with current ulcer therapy (H-2 blockers, <e1> omeprazole </e1>, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, <e2> alkalosis </e2>, and renal impairment remains the hallmark of the syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4472": {"data": {"text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "entity1": "omeprazole", "entity2": "renal impairment remains the hallmark of the syndrome", "span1": [51, 61], "span2": [198, 251]}, "bert_text": "Although with current ulcer therapy (H-2 blockers, <e1> omeprazole </e1>, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and <e2> renal impairment remains the hallmark of the syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4473": {"data": {"text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "entity1": "sucralfate", "entity2": "ulcer", "span1": [67, 77], "span2": [22, 27]}, "bert_text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and <e1> sucralfate </e1> <e2> ulcer </e2> therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4474": {"data": {"text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "entity1": "sucralfate", "entity2": "milk-alkali syndrome", "span1": [67, 77], "span2": [97, 117]}, "bert_text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and <e1> sucralfate </e1>), the frequency of <e2> milk-alkali syndrome </e2> has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4475": {"data": {"text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "entity1": "sucralfate", "entity2": "hypercalcemia", "span1": [67, 77], "span2": [168, 181]}, "bert_text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and <e1> sucralfate </e1>), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of <e2> hypercalcemia </e2>, alkalosis, and renal impairment remains the hallmark of the syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4476": {"data": {"text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "entity1": "sucralfate", "entity2": "alkalosis", "span1": [67, 77], "span2": [183, 192]}, "bert_text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and <e1> sucralfate </e1>), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, <e2> alkalosis </e2>, and renal impairment remains the hallmark of the syndrome.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4477": {"data": {"text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and sucralfate), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and renal impairment remains the hallmark of the syndrome.", "entity1": "sucralfate", "entity2": "renal impairment remains the hallmark of the syndrome", "span1": [67, 77], "span2": [198, 251]}, "bert_text": "Although with current ulcer therapy (H-2 blockers, omeprazole, and <e1> sucralfate </e1>), the frequency of milk-alkali syndrome has decreased significantly, the classic triad of hypercalcemia, alkalosis, and <e2> renal impairment remains the hallmark of the syndrome </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4478": {"data": {"text": "The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2.35 (1.17-4.72)].", "entity1": "aspirin", "entity2": "ESRD", "span1": [33, 40], "span2": [12, 16]}, "bert_text": "The risk of ESRD associated with <e1> aspirin </e1> <e2> ESRD </e2> associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2.35 (1.17-4.72)].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 0], "label": 1},
+	"4479": {"data": {"text": "The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [2.35 (1.17-4.72)].", "entity1": "aspirin", "entity2": "vascular nephropathy", "span1": [33, 40], "span2": [159, 179]}, "bert_text": "The risk of ESRD associated with <e1> aspirin </e1> was related to the cumulated dose and duration of use, and it was particularly high among the subset of patients with <e2> vascular nephropathy </e2> as underlying disease [2.35 (1.17-4.72)].", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4480": {"data": {"text": "METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.", "entity1": "levodopa", "entity2": "Parkinson's disease", "span1": [157, 165], "span2": [52, 71]}, "bert_text": "METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and <e1> levodopa </e1> <e2> Parkinson's disease </e2> (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4481": {"data": {"text": "METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.", "entity1": "levodopa", "entity2": "bradykinesia", "span1": [157, 165], "span2": [129, 141]}, "bert_text": "METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and <e1> levodopa </e1> <e2> bradykinesia </e2>, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4482": {"data": {"text": "METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.", "entity1": "levodopa", "entity2": "rigidity", "span1": [157, 165], "span2": [143, 151]}, "bert_text": "METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and <e1> levodopa </e1> <e2> rigidity </e2>, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4483": {"data": {"text": "METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and levodopa-induced dyskinesias underwent bilateral implantation of electrodes in the STN.", "entity1": "levodopa", "entity2": "dyskinesias", "span1": [157, 165], "span2": [174, 185]}, "bert_text": "METHOD: Twenty-three patients suffering from severe Parkinson's disease (Stages III-V on Hoehn and Yahr scale) and, particularly bradykinesia, rigidity, and <e1> levodopa </e1>-induced <e2> dyskinesias </e2> underwent bilateral implantation of electrodes in the STN.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4484": {"data": {"text": "Here, we report a case of prolonged neuromuscular block after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.", "entity1": "suxamethonium", "entity2": "neuromuscular block", "span1": [80, 93], "span2": [36, 55]}, "bert_text": "Here, we report a case of prolonged neuromuscular block after administration of <e1> suxamethonium </e1> <e2> neuromuscular block </e2> after administration of suxamethonium leading to the discovery of a novel BCHE variant (c.695T>A, p.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4485": {"data": {"text": "Improvement by denopamine (TA-064) of pentobarbital-induced cardiac failure in the dog heart-lung preparation.\n", "entity1": "denopamine", "entity2": "cardiac failure", "span1": [15, 25], "span2": [60, 75]}, "bert_text": "Improvement by <e1> denopamine </e1> (TA-064) of pentobarbital-induced <e2> cardiac failure </e2> in the dog heart-lung preparation.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4486": {"data": {"text": "Improvement by denopamine (TA-064) of pentobarbital-induced cardiac failure in the dog heart-lung preparation.\n", "entity1": "TA-064", "entity2": "cardiac failure", "span1": [27, 33], "span2": [60, 75]}, "bert_text": "Improvement by denopamine (<e1> TA-064 </e1>) of pentobarbital-induced <e2> cardiac failure </e2> in the dog heart-lung preparation.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4487": {"data": {"text": "Improvement by denopamine (TA-064) of pentobarbital-induced cardiac failure in the dog heart-lung preparation.\n", "entity1": "pentobarbital", "entity2": "cardiac failure", "span1": [38, 51], "span2": [60, 75]}, "bert_text": "Improvement by denopamine (TA-064) of <e1> pentobarbital </e1>-induced <e2> cardiac failure </e2> in the dog heart-lung preparation.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4488": {"data": {"text": "The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in gentamicin-induced ARF.", "entity1": "adenosine", "entity2": "ARF", "span1": [118, 127], "span2": [196, 199]}, "bert_text": "The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that <e1> adenosine </e1> plays little, if any, pathophysiological role in gentamicin-induced <e2> ARF </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4489": {"data": {"text": "The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in gentamicin-induced ARF.", "entity1": "gentamicin", "entity2": "ARF", "span1": [177, 187], "span2": [196, 199]}, "bert_text": "The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little, if any, pathophysiological role in <e1> gentamicin </e1>-induced <e2> ARF </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4490": {"data": {"text": "RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.", "entity1": "RAD001", "entity2": "NSCLC", "span1": [0, 6], "span2": [101, 106]}, "bert_text": "<e1> RAD001 </e1>, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in <e2> NSCLC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4491": {"data": {"text": "RAD001, an oral inhibitor of the mammalian target of rapamycin (mTOR), has shown phase I efficacy in NSCLC.", "entity1": "rapamycin", "entity2": "NSCLC", "span1": [53, 62], "span2": [101, 106]}, "bert_text": "RAD001, an oral inhibitor of the mammalian target of <e1> rapamycin </e1> (mTOR), has shown phase I efficacy in <e2> NSCLC </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4492": {"data": {"text": "In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine.", "entity1": "valproate", "entity2": "hemiparesis", "span1": [145, 154], "span2": [90, 101]}, "bert_text": "In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on <e1> valproate </e1> <e2> hemiparesis </e2> with facial droop, and had been started on valproate for presumed hemiplegic migraine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4493": {"data": {"text": "In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on valproate for presumed hemiplegic migraine.", "entity1": "valproate", "entity2": "hemiplegic migraine", "span1": [145, 154], "span2": [168, 187]}, "bert_text": "In the preceding months, the patient had a number of admissions with transient unilateral hemiparesis with facial droop, and had been started on <e1> valproate </e1> for presumed <e2> hemiplegic migraine </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4494": {"data": {"text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "entity1": "S-312-d", "entity2": "convulsions", "span1": [44, 51], "span2": [101, 112]}, "bert_text": "Although moderate anticonvulsant effects of <e1> S-312-d </e1> in higher doses were observed against the clonic <e2> convulsions </e2> induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4495": {"data": {"text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "entity1": "S-312-d", "entity2": "convulsions", "span1": [44, 51], "span2": [219, 230]}, "bert_text": "Although moderate anticonvulsant effects of <e1> S-312-d </e1> in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in <e2> convulsions </e2> induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"4496": {"data": {"text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "entity1": "pentylenetetrazole", "entity2": "convulsions", "span1": [124, 142], "span2": [101, 112]}, "bert_text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by <e1> pentylenetetrazole </e1> <e2> convulsions </e2> induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4497": {"data": {"text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "entity1": "pentylenetetrazole", "entity2": "convulsions", "span1": [124, 142], "span2": [219, 230]}, "bert_text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by <e1> pentylenetetrazole </e1> (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in <e2> convulsions </e2> induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 1},
+	"4498": {"data": {"text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "entity1": "bemegride", "entity2": "convulsions", "span1": [163, 172], "span2": [101, 112]}, "bert_text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or <e1> bemegride </e1> <e2> convulsions </e2> induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4499": {"data": {"text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "entity1": "bemegride", "entity2": "convulsions", "span1": [163, 172], "span2": [219, 230]}, "bert_text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or <e1> bemegride </e1> (40 mg/kg, s.c.), no effects were observed in <e2> convulsions </e2> induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 1},
+	"4500": {"data": {"text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "entity1": "picrotoxin", "entity2": "convulsions", "span1": [264, 274], "span2": [101, 112]}, "bert_text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, <e1> picrotoxin </e1> <e2> convulsions </e2> induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4501": {"data": {"text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "entity1": "picrotoxin", "entity2": "convulsions", "span1": [264, 274], "span2": [219, 230]}, "bert_text": "Although moderate anticonvulsant effects of S-312-d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole (85 mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no effects were observed in convulsions induced by N-methyl-D-aspartate, <e1> picrotoxin </e1> <e2> convulsions </e2> induced by N-methyl-D-aspartate, picrotoxin, or electroshock in Slc:ddY mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 1},
+	"4502": {"data": {"text": "Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.", "entity1": "bromocriptine", "entity2": "psychiatric", "span1": [153, 166], "span2": [11, 22]}, "bert_text": "Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with <e1> bromocriptine </e1> <e2> psychiatric </e2> outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4503": {"data": {"text": "Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.", "entity1": "bromocriptine", "entity2": "hyperprolactinemia", "span1": [153, 166], "span2": [40, 58]}, "bert_text": "Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with <e1> bromocriptine </e1> <e2> hyperprolactinemia </e2> and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4504": {"data": {"text": "Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.", "entity1": "bromocriptine", "entity2": "amenorrhea", "span1": [153, 166], "span2": [63, 73]}, "bert_text": "Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with <e1> bromocriptine </e1> <e2> amenorrhea </e2>/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4505": {"data": {"text": "Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine.", "entity1": "bromocriptine", "entity2": "oligomenorrhea", "span1": [153, 166], "span2": [74, 88]}, "bert_text": "Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea/oligomenorrhea associated with their neuroleptic medications were treated with <e1> bromocriptine </e1> <e2> oligomenorrhea </e2> associated with their neuroleptic medications were treated with bromocriptine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4506": {"data": {"text": "Since most of Wilson's disease penicillamine-treated patients do not seem to develop this skin lesion, it could be conceivable that a specific genetic factor is involved in drug response.", "entity1": "penicillamine", "entity2": "Wilson's disease", "span1": [31, 44], "span2": [14, 30]}, "bert_text": "Since most of Wilson's disease <e1> penicillamine </e1> <e2> Wilson's disease </e2> penicillamine-treated patients do not seem to develop this skin lesion, it could be conceivable that a specific genetic factor is involved in drug response.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4507": {"data": {"text": "The authors conclude by affirming the undoubted efficacy of the anabolizing steroids in experimental myopathic disease, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the \"regeneration\" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown.", "entity1": "steroids", "entity2": "myopathic disease", "span1": [76, 84], "span2": [101, 118]}, "bert_text": "The authors conclude by affirming the undoubted efficacy of the anabolizing <e1> steroids </e1> in experimental <e2> myopathic disease </e2>, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the \"regeneration\" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4508": {"data": {"text": "The authors conclude by affirming the undoubted efficacy of the anabolizing steroids in experimental myopathic disease, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the \"regeneration\" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown.", "entity1": "vitamin E", "entity2": "myopathic disease", "span1": [503, 512], "span2": [101, 118]}, "bert_text": "The authors conclude by affirming the undoubted efficacy of the anabolizing steroids in experimental myopathic disease, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the \"regeneration\" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of <e1> vitamin E </e1> <e2> myopathic disease </e2>, but they have reservations as to the transfer of the results into the human field, where high dosage cannot be carried out continuously because of the effects of the drug on virility; because the tissue injury too often occurs at an irreversible stage vis-a-vis the \"regeneration\" of the muscle tissue; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4509": {"data": {"text": "High trough TAC level was the predominant factor that contributed to seizures in the early post-operative period after pediatric LT.", "entity1": "TAC", "entity2": "seizures", "span1": [12, 15], "span2": [69, 77]}, "bert_text": "High trough <e1> TAC </e1> level was the predominant factor that contributed to <e2> seizures </e2> in the early post-operative period after pediatric LT.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4510": {"data": {"text": "BACKGROUND: In dogs, a large amount of intravenous cocaine causes a profound deterioration of left ventricular (LV) systolic function and an increase in LV end-diastolic pressure.", "entity1": "cocaine", "entity2": "LV", "span1": [51, 58], "span2": [112, 114]}, "bert_text": "BACKGROUND: In dogs, a large amount of intravenous <e1> cocaine </e1> causes a profound deterioration of left ventricular (<e2> LV </e2>) systolic function and an increase in LV end-diastolic pressure.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4511": {"data": {"text": "BACKGROUND: In dogs, a large amount of intravenous cocaine causes a profound deterioration of left ventricular (LV) systolic function and an increase in LV end-diastolic pressure.", "entity1": "cocaine", "entity2": "LV", "span1": [51, 58], "span2": [153, 155]}, "bert_text": "BACKGROUND: In dogs, a large amount of intravenous <e1> cocaine </e1> causes a profound deterioration of left ventricular (LV) systolic function and an increase in <e2> LV </e2> end-diastolic pressure.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4512": {"data": {"text": "This study shows that 17alpha-ethinylestradiol (EE)-induced intrahepatic cholestasis in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis.", "entity1": "17alpha-ethinylestradiol", "entity2": "intrahepatic cholestasis", "span1": [22, 46], "span2": [60, 84]}, "bert_text": "This study shows that <e1> 17alpha-ethinylestradiol </e1> (EE)-induced <e2> intrahepatic cholestasis </e2> in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4513": {"data": {"text": "This study shows that 17alpha-ethinylestradiol (EE)-induced intrahepatic cholestasis in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis.", "entity1": "EE)-induced", "entity2": "intrahepatic cholestasis", "span1": [48, 59], "span2": [60, 84]}, "bert_text": "This study shows that 17alpha-ethinylestradiol (<e1> EE)-induced </e1> <e2> intrahepatic cholestasis </e2> in rats is associated with selective inhibition of the neutral pathway of bile salt (BS) synthesis.", "weak_labels": [-1, 1, 1, -1, -1, -1, -1, 1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4514": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "hypotension", "span1": [118, 127], "span2": [135, 146]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the <e1> lidocaine </e1> group, <e2> hypotension </e2> occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4515": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "asystole", "span1": [118, 127], "span2": [237, 245]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the <e1> lidocaine </e1> group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from <e2> asystole </e2>, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4516": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "myocardial infarction", "span1": [118, 127], "span2": [380, 401]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the <e1> lidocaine </e1> group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4517": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "hypotension", "span1": [198, 207], "span2": [135, 146]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received <e1> lidocaine </e1> <e2> hypotension </e2> occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4518": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "asystole", "span1": [198, 207], "span2": [237, 245]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received <e1> lidocaine </e1>, and four patients died from <e2> asystole </e2>, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4519": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "myocardial infarction", "span1": [198, 207], "span2": [380, 401]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received <e1> lidocaine </e1>, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4520": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "hypotension", "span1": [269, 278], "span2": [135, 146]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had <e1> lidocaine </e1> <e2> hypotension </e2> occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4521": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "asystole", "span1": [269, 278], "span2": [237, 245]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had <e1> lidocaine </e1> <e2> asystole </e2>, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4522": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "myocardial infarction", "span1": [269, 278], "span2": [380, 401]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had <e1> lidocaine </e1>. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4523": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "hypotension", "span1": [321, 330], "span2": [135, 146]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of <e1> lidocaine </e1> <e2> hypotension </e2> occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4524": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "asystole", "span1": [321, 330], "span2": [237, 245]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of <e1> lidocaine </e1> <e2> asystole </e2>, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4525": {"data": {"text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction.", "entity1": "lidocaine", "entity2": "myocardial infarction", "span1": [321, 330], "span2": [380, 401]}, "bert_text": "During the 1-hour study period, the incidence of central nervous system side effects was significantly greater in the lidocaine group, hypotension occurred in 11 patients, nine of whom had received lidocaine, and four patients died from asystole, three of whom had had lidocaine. We cannot advocate the administration of <e1> lidocaine </e1> prophylactically in the early hours of suspected <e2> myocardial infarction </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4526": {"data": {"text": "In the animals treated with threshold doses of picrotoxin, the average number of seizures was 2.3+/-1.2, and average seizure duration was 39.5+/-8.4s.", "entity1": "picrotoxin", "entity2": "seizures", "span1": [47, 57], "span2": [81, 89]}, "bert_text": "In the animals treated with threshold doses of <e1> picrotoxin </e1>, the average number of <e2> seizures </e2> was 2.3+/-1.2, and average seizure duration was 39.5+/-8.4s.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4527": {"data": {"text": "In the animals treated with threshold doses of picrotoxin, the average number of seizures was 2.3+/-1.2, and average seizure duration was 39.5+/-8.4s.", "entity1": "picrotoxin", "entity2": "seizure", "span1": [47, 57], "span2": [117, 124]}, "bert_text": "In the animals treated with threshold doses of <e1> picrotoxin </e1>, the average number of seizures was 2.3+/-1.2, and average <e2> seizure </e2> duration was 39.5+/-8.4s.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4528": {"data": {"text": "S-312-d may be useful in the therapy of certain types of human epilepsy.", "entity1": "S-312-d", "entity2": "epilepsy", "span1": [0, 7], "span2": [63, 71]}, "bert_text": "<e1> S-312-d </e1> may be useful in the therapy of certain types of human <e2> epilepsy </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4529": {"data": {"text": "Hypertensive response during dobutamine stress echocardiography.\n", "entity1": "dobutamine", "entity2": "Hypertensive", "span1": [29, 39], "span2": [0, 12]}, "bert_text": "Hypertensive response during <e1> dobutamine </e1> <e2> Hypertensive </e2> response during dobutamine stress echocardiography.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4530": {"data": {"text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "entity1": "propylthiouracil", "entity2": "hepatitis", "span1": [13, 29], "span2": [47, 56]}, "bert_text": "Two cases of <e1> propylthiouracil </e1>-associated acute <e2> hepatitis </e2>, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4531": {"data": {"text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "entity1": "propylthiouracil", "entity2": "hepatocellular necrosis", "span1": [13, 29], "span2": [99, 122]}, "bert_text": "Two cases of <e1> propylthiouracil </e1>-associated acute hepatitis, one case of fatal methimazole-associated <e2> hepatocellular necrosis </e2> and one case of propylthiouracil-associated lupus-like syndrome are described.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4532": {"data": {"text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "entity1": "propylthiouracil", "entity2": "lupus-like syndrome", "span1": [13, 29], "span2": [167, 186]}, "bert_text": "Two cases of <e1> propylthiouracil </e1>-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated <e2> lupus-like syndrome </e2> are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4533": {"data": {"text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "entity1": "propylthiouracil", "entity2": "hepatitis", "span1": [139, 155], "span2": [47, 56]}, "bert_text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of <e1> propylthiouracil </e1> <e2> hepatitis </e2>, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4534": {"data": {"text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "entity1": "propylthiouracil", "entity2": "hepatocellular necrosis", "span1": [139, 155], "span2": [99, 122]}, "bert_text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of <e1> propylthiouracil </e1> <e2> hepatocellular necrosis </e2> and one case of propylthiouracil-associated lupus-like syndrome are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4535": {"data": {"text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "entity1": "propylthiouracil", "entity2": "lupus-like syndrome", "span1": [139, 155], "span2": [167, 186]}, "bert_text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of <e1> propylthiouracil </e1>-associated <e2> lupus-like syndrome </e2> are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4536": {"data": {"text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "entity1": "methimazole", "entity2": "hepatitis", "span1": [76, 87], "span2": [47, 56]}, "bert_text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal <e1> methimazole </e1> <e2> hepatitis </e2>, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4537": {"data": {"text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "entity1": "methimazole", "entity2": "hepatocellular necrosis", "span1": [76, 87], "span2": [99, 122]}, "bert_text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal <e1> methimazole </e1>-associated <e2> hepatocellular necrosis </e2> and one case of propylthiouracil-associated lupus-like syndrome are described.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4538": {"data": {"text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal methimazole-associated hepatocellular necrosis and one case of propylthiouracil-associated lupus-like syndrome are described.", "entity1": "methimazole", "entity2": "lupus-like syndrome", "span1": [76, 87], "span2": [167, 186]}, "bert_text": "Two cases of propylthiouracil-associated acute hepatitis, one case of fatal <e1> methimazole </e1>-associated hepatocellular necrosis and one case of propylthiouracil-associated <e2> lupus-like syndrome </e2> are described.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4539": {"data": {"text": "The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations.", "entity1": "OC", "entity2": "VTE", "span1": [78, 80], "span2": [18, 21]}, "bert_text": "The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any <e1> OC </e1> <e2> VTE </e2> per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4540": {"data": {"text": "The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations.", "entity1": "OCs", "entity2": "VTE", "span1": [117, 120], "span2": [18, 21]}, "bert_text": "The crude rate of VTE per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation <e1> OCs </e1> <e2> VTE </e2> per 10,000 woman-years was 4.10 in current users of any OC, 3.10 in users of second-generation OCs, and 4.96 in users of third-generation preparations.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4541": {"data": {"text": "A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis.", "entity1": "cyclophosphamide", "entity2": "right hydroureteronephrosis", "span1": [156, 172], "span2": [25, 52]}, "bert_text": "A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih <e1> cyclophosphamide </e1> <e2> right hydroureteronephrosis </e2> due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4542": {"data": {"text": "A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis.", "entity1": "cyclophosphamide", "entity2": "hematuria", "span1": [156, 172], "span2": [106, 115]}, "bert_text": "A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih <e1> cyclophosphamide </e1> <e2> hematuria </e2> after being treated for five years wtih cyclophosphamide for cerebral vasculitis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4543": {"data": {"text": "A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis.", "entity1": "cyclophosphamide", "entity2": "cerebral vasculitis", "span1": [156, 172], "span2": [177, 196]}, "bert_text": "A 47-year-old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih <e1> cyclophosphamide </e1> for <e2> cerebral vasculitis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4544": {"data": {"text": "Univariate analysis identified age, hypoalbuminemia, heavy proteinuria, diuretic use, and urine sediment score (>3) as risk factors.", "entity1": "diuretic", "entity2": "hypoalbuminemia", "span1": [72, 80], "span2": [36, 51]}, "bert_text": "Univariate analysis identified age, hypoalbuminemia, heavy proteinuria, <e1> diuretic </e1> <e2> hypoalbuminemia </e2>, heavy proteinuria, diuretic use, and urine sediment score (>3) as risk factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4545": {"data": {"text": "Univariate analysis identified age, hypoalbuminemia, heavy proteinuria, diuretic use, and urine sediment score (>3) as risk factors.", "entity1": "diuretic", "entity2": "proteinuria", "span1": [72, 80], "span2": [59, 70]}, "bert_text": "Univariate analysis identified age, hypoalbuminemia, heavy proteinuria, <e1> diuretic </e1> <e2> proteinuria </e2>, diuretic use, and urine sediment score (>3) as risk factors.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4546": {"data": {"text": "Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.\n", "entity1": "argatroban", "entity2": "thrombocytopenia", "span1": [7, 17], "span2": [112, 128]}, "bert_text": "Use of <e1> argatroban </e1> and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced <e2> thrombocytopenia </e2> with thrombosis.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4547": {"data": {"text": "Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.\n", "entity1": "argatroban", "entity2": "thrombosis", "span1": [7, 17], "span2": [134, 144]}, "bert_text": "Use of <e1> argatroban </e1> and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with <e2> thrombosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4548": {"data": {"text": "Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.\n", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [96, 103], "span2": [112, 128]}, "bert_text": "Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with <e1> heparin </e1>-induced <e2> thrombocytopenia </e2> with thrombosis.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4549": {"data": {"text": "Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.\n", "entity1": "heparin", "entity2": "thrombosis", "span1": [96, 103], "span2": [134, 144]}, "bert_text": "Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with <e1> heparin </e1>-induced thrombocytopenia with <e2> thrombosis </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4550": {"data": {"text": "To report a sinus bradycardia induced by metoprolol and terbinafine drug-drug interaction and its management.", "entity1": "metoprolol", "entity2": "sinus bradycardia", "span1": [41, 51], "span2": [12, 29]}, "bert_text": "To report a sinus bradycardia induced by <e1> metoprolol </e1> <e2> sinus bradycardia </e2> induced by metoprolol and terbinafine drug-drug interaction and its management.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4551": {"data": {"text": "To report a sinus bradycardia induced by metoprolol and terbinafine drug-drug interaction and its management.", "entity1": "terbinafine", "entity2": "sinus bradycardia", "span1": [56, 67], "span2": [12, 29]}, "bert_text": "To report a sinus bradycardia induced by metoprolol and <e1> terbinafine </e1> <e2> sinus bradycardia </e2> induced by metoprolol and terbinafine drug-drug interaction and its management.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4552": {"data": {"text": "A group of doctors in Boston warn that the protease inhibitor Viracept may cause an irregular heart beat, known as bradycardia, in people with HIV.", "entity1": "Viracept", "entity2": "bradycardia", "span1": [62, 70], "span2": [115, 126]}, "bert_text": "A group of doctors in Boston warn that the protease inhibitor <e1> Viracept </e1> may cause an irregular heart beat, known as <e2> bradycardia </e2>, in people with HIV.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4553": {"data": {"text": "The incidence of neurotoxicity may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia, in older children and adults, and in the presence of epidural leakage.", "entity1": "methotrexate", "entity2": "neurotoxicity", "span1": [74, 86], "span2": [17, 30]}, "bert_text": "The incidence of neurotoxicity may be reduced by employing lower doses of <e1> methotrexate </e1> <e2> neurotoxicity </e2> may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia, in older children and adults, and in the presence of epidural leakage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4554": {"data": {"text": "The incidence of neurotoxicity may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia, in older children and adults, and in the presence of epidural leakage.", "entity1": "methotrexate", "entity2": "leukemia", "span1": [74, 86], "span2": [129, 137]}, "bert_text": "The incidence of neurotoxicity may be reduced by employing lower doses of <e1> methotrexate </e1> in the presence of central nervous system <e2> leukemia </e2>, in older children and adults, and in the presence of epidural leakage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4555": {"data": {"text": "In contrast, haloperidol demonstrated an ability to reduce cocaine-induced seizures without significantly reducing mortality.", "entity1": "haloperidol", "entity2": "seizures", "span1": [13, 24], "span2": [75, 83]}, "bert_text": "In contrast, <e1> haloperidol </e1> demonstrated an ability to reduce cocaine-induced <e2> seizures </e2> without significantly reducing mortality.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4556": {"data": {"text": "In contrast, haloperidol demonstrated an ability to reduce cocaine-induced seizures without significantly reducing mortality.", "entity1": "cocaine", "entity2": "seizures", "span1": [59, 66], "span2": [75, 83]}, "bert_text": "In contrast, haloperidol demonstrated an ability to reduce <e1> cocaine </e1>-induced <e2> seizures </e2> without significantly reducing mortality.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4557": {"data": {"text": "RESULTS: All patients had optic neuropathy between 1 to 6 months (mean = 2.9 months) after starting ethambutol therapy at a dosage ranging from 13 to 20 mg/kg/day (mean = 17 mg/kg/day).", "entity1": "ethambutol", "entity2": "optic neuropathy", "span1": [100, 110], "span2": [26, 42]}, "bert_text": "RESULTS: All patients had optic neuropathy between 1 to 6 months (mean = 2.9 months) after starting <e1> ethambutol </e1> <e2> optic neuropathy </e2> between 1 to 6 months (mean = 2.9 months) after starting ethambutol therapy at a dosage ranging from 13 to 20 mg/kg/day (mean = 17 mg/kg/day).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4558": {"data": {"text": "We undertook an open-label study using thalidomide 100 mg once daily for up to 6 months in 20 men with androgen-independent prostate cancer.", "entity1": "thalidomide", "entity2": "prostate cancer", "span1": [39, 50], "span2": [124, 139]}, "bert_text": "We undertook an open-label study using <e1> thalidomide </e1> 100 mg once daily for up to 6 months in 20 men with androgen-independent <e2> prostate cancer </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4559": {"data": {"text": "PATIENTS AND METHODS: Clinical and electrophysiological data in 12 female patients with CLE during treatment with thalidomide and up to 47 months after discontinuation of treatment were analysed.", "entity1": "thalidomide", "entity2": "CLE", "span1": [114, 125], "span2": [88, 91]}, "bert_text": "PATIENTS AND METHODS: Clinical and electrophysiological data in 12 female patients with CLE during treatment with <e1> thalidomide </e1> <e2> CLE </e2> during treatment with thalidomide and up to 47 months after discontinuation of treatment were analysed.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4560": {"data": {"text": "Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.", "entity1": "sulfadiazine", "entity2": "oliguria", "span1": [21, 33], "span2": [49, 57]}, "bert_text": "Under treatment with <e1> sulfadiazine </e1> they developed <e2> oliguria </e2>, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4561": {"data": {"text": "Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.", "entity1": "sulfadiazine", "entity2": "abdominal pain", "span1": [21, 33], "span2": [59, 73]}, "bert_text": "Under treatment with <e1> sulfadiazine </e1> they developed oliguria, <e2> abdominal pain </e2>, renal failure and showed multiple radiolucent renal calculi in echography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4562": {"data": {"text": "Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.", "entity1": "sulfadiazine", "entity2": "renal failure", "span1": [21, 33], "span2": [75, 88]}, "bert_text": "Under treatment with <e1> sulfadiazine </e1> they developed oliguria, abdominal pain, <e2> renal failure </e2> and showed multiple radiolucent renal calculi in echography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4563": {"data": {"text": "Under treatment with sulfadiazine they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent renal calculi in echography.", "entity1": "sulfadiazine", "entity2": "renal calculi", "span1": [21, 33], "span2": [121, 134]}, "bert_text": "Under treatment with <e1> sulfadiazine </e1> they developed oliguria, abdominal pain, renal failure and showed multiple radiolucent <e2> renal calculi </e2> in echography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4564": {"data": {"text": "OBJECTIVE: To report a case of syndrome of inappropriate anti-diuretic hormone (SIADH) secretion associated with desvenlafaxine.", "entity1": "desvenlafaxine", "entity2": "SIADH", "span1": [113, 127], "span2": [80, 85]}, "bert_text": "OBJECTIVE: To report a case of syndrome of inappropriate anti-diuretic hormone (SIADH) secretion associated with <e1> desvenlafaxine </e1> <e2> SIADH </e2>) secretion associated with desvenlafaxine.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4565": {"data": {"text": "The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear.", "entity1": "methotrexate", "entity2": "toxicity", "span1": [12, 24], "span2": [136, 144]}, "bert_text": "The role of <e1> methotrexate </e1> contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal methotrexate <e2> toxicity </e2> is unclear.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4566": {"data": {"text": "The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear.", "entity1": "methotrexate", "entity2": "toxicity", "span1": [123, 135], "span2": [136, 144]}, "bert_text": "The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal <e1> methotrexate </e1> <e2> toxicity </e2> is unclear.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4567": {"data": {"text": "The role of methotrexate contaminants, local folate deficiency, and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear.", "entity1": "folate", "entity2": "toxicity", "span1": [45, 51], "span2": [136, 144]}, "bert_text": "The role of methotrexate contaminants, local <e1> folate </e1> deficiency, and cranial irradiation in the pathogenesis of intrathecal methotrexate <e2> toxicity </e2> is unclear.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4568": {"data": {"text": "Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.", "entity1": "acetylcholine", "entity2": "hypotension", "span1": [98, 111], "span2": [48, 59]}, "bert_text": "Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of <e1> acetylcholine </e1> <e2> hypotension </e2>, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4569": {"data": {"text": "Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.", "entity1": "acetylcholine", "entity2": "hypotension", "span1": [98, 111], "span2": [127, 138]}, "bert_text": "Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of <e1> acetylcholine </e1> (ACh)-produced <e2> hypotension </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4570": {"data": {"text": "Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.", "entity1": "ACh)-produced", "entity2": "hypotension", "span1": [113, 126], "span2": [48, 59]}, "bert_text": "Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine (<e1> ACh)-produced </e1> <e2> hypotension </e2>, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4571": {"data": {"text": "Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine (ACh)-produced hypotension.", "entity1": "ACh)-produced", "entity2": "hypotension", "span1": [113, 126], "span2": [127, 138]}, "bert_text": "Oxyhemoglobin did not affect helodermin-induced hypotension, whereas it shortened the duration of acetylcholine (<e1> ACh)-produced </e1> <e2> hypotension </e2>.", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4572": {"data": {"text": "In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a caffeine-free (placebo) solution were administered in a coffee form and anxiety scales were applied before and after each test.", "entity1": "caffeine", "entity2": "anxiety", "span1": [86, 94], "span2": [173, 180]}, "bert_text": "In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg <e1> caffeine </e1> and a caffeine-free (placebo) solution were administered in a coffee form and <e2> anxiety </e2> scales were applied before and after each test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4573": {"data": {"text": "In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a caffeine-free (placebo) solution were administered in a coffee form and anxiety scales were applied before and after each test.", "entity1": "caffeine", "entity2": "anxiety", "span1": [101, 109], "span2": [173, 180]}, "bert_text": "In a randomized double-blind experiment performed in 2 occasions 7 days apart, 480 mg caffeine and a <e1> caffeine </e1>-free (placebo) solution were administered in a coffee form and <e2> anxiety </e2> scales were applied before and after each test.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4574": {"data": {"text": "Amiodarone-induced myxoedema coma.\n", "entity1": "Amiodarone", "entity2": "myxoedema coma", "span1": [0, 10], "span2": [19, 33]}, "bert_text": "<e1> Amiodarone </e1>-induced <e2> myxoedema coma </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4575": {"data": {"text": "Bradycardia occurred in a 45-year-old male patient who was Viracept in combination with other anti-HIV drugs.", "entity1": "Viracept", "entity2": "Bradycardia", "span1": [59, 67], "span2": [0, 11]}, "bert_text": "Bradycardia occurred in a 45-year-old male patient who was <e1> Viracept </e1> <e2> Bradycardia </e2> occurred in a 45-year-old male patient who was Viracept in combination with other anti-HIV drugs.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4576": {"data": {"text": "OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.", "entity1": "Quetiapine", "entity2": "blood dyscrasias", "span1": [11, 21], "span2": [117, 133]}, "bert_text": "OBJECTIVE: <e1> Quetiapine </e1> is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing <e2> blood dyscrasias </e2>, especially neutropenia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4577": {"data": {"text": "OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.", "entity1": "Quetiapine", "entity2": "neutropenia", "span1": [11, 21], "span2": [146, 157]}, "bert_text": "OBJECTIVE: <e1> Quetiapine </e1> is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially <e2> neutropenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 1},
+	"4578": {"data": {"text": "OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.", "entity1": "dibenzothiazepine", "entity2": "blood dyscrasias", "span1": [27, 44], "span2": [117, 133]}, "bert_text": "OBJECTIVE: Quetiapine is a <e1> dibenzothiazepine </e1> derivative, similar to clozapine, which has the highest risk of causing <e2> blood dyscrasias </e2>, especially neutropenia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4579": {"data": {"text": "OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.", "entity1": "dibenzothiazepine", "entity2": "neutropenia", "span1": [27, 44], "span2": [146, 157]}, "bert_text": "OBJECTIVE: Quetiapine is a <e1> dibenzothiazepine </e1> derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially <e2> neutropenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4580": {"data": {"text": "OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.", "entity1": "clozapine", "entity2": "blood dyscrasias", "span1": [68, 77], "span2": [117, 133]}, "bert_text": "OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to <e1> clozapine </e1>, which has the highest risk of causing <e2> blood dyscrasias </e2>, especially neutropenia.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4581": {"data": {"text": "OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to clozapine, which has the highest risk of causing blood dyscrasias, especially neutropenia.", "entity1": "clozapine", "entity2": "neutropenia", "span1": [68, 77], "span2": [146, 157]}, "bert_text": "OBJECTIVE: Quetiapine is a dibenzothiazepine derivative, similar to <e1> clozapine </e1>, which has the highest risk of causing blood dyscrasias, especially <e2> neutropenia </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4582": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "p-aminophenol", "entity2": "nephrotoxicity", "span1": [12, 25], "span2": [51, 65]}, "bert_text": "The role of <e1> p-aminophenol </e1> in acetaminophen-induced <e2> nephrotoxicity </e2>: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4583": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "p-aminophenol", "entity2": "nephrotoxicity", "span1": [12, 25], "span2": [141, 155]}, "bert_text": "The role of <e1> p-aminophenol </e1> in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol <e2> nephrotoxicity </e2> and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4584": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "acetaminophen", "entity2": "nephrotoxicity", "span1": [29, 42], "span2": [51, 65]}, "bert_text": "The role of p-aminophenol in <e1> acetaminophen </e1>-induced <e2> nephrotoxicity </e2>: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4585": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "acetaminophen", "entity2": "nephrotoxicity", "span1": [29, 42], "span2": [141, 155]}, "bert_text": "The role of p-aminophenol in <e1> acetaminophen </e1>-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol <e2> nephrotoxicity </e2> and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4586": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "acetaminophen", "entity2": "nephrotoxicity", "span1": [109, 122], "span2": [51, 65]}, "bert_text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on <e1> acetaminophen </e1> <e2> nephrotoxicity </e2>: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4587": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "acetaminophen", "entity2": "nephrotoxicity", "span1": [109, 122], "span2": [141, 155]}, "bert_text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on <e1> acetaminophen </e1> and p-aminophenol <e2> nephrotoxicity </e2> and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4588": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "bis(p-nitrophenyl", "entity2": "nephrotoxicity", "span1": [77, 94], "span2": [51, 65]}, "bert_text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of <e1> bis(p-nitrophenyl </e1> <e2> nephrotoxicity </e2>: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4589": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "bis(p-nitrophenyl", "entity2": "nephrotoxicity", "span1": [77, 94], "span2": [141, 155]}, "bert_text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of <e1> bis(p-nitrophenyl </e1>) phosphate on acetaminophen and p-aminophenol <e2> nephrotoxicity </e2> and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4590": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "phosphate", "entity2": "nephrotoxicity", "span1": [96, 105], "span2": [51, 65]}, "bert_text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) <e1> phosphate </e1> <e2> nephrotoxicity </e2>: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4591": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "phosphate", "entity2": "nephrotoxicity", "span1": [96, 105], "span2": [141, 155]}, "bert_text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) <e1> phosphate </e1> on acetaminophen and p-aminophenol <e2> nephrotoxicity </e2> and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4592": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "aminophenol", "entity2": "nephrotoxicity", "span1": [129, 140], "span2": [51, 65]}, "bert_text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-<e1> aminophenol </e1> <e2> nephrotoxicity </e2>: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4593": {"data": {"text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-aminophenol nephrotoxicity and metabolism in Fischer 344 rats.\n", "entity1": "aminophenol", "entity2": "nephrotoxicity", "span1": [129, 140], "span2": [141, 155]}, "bert_text": "The role of p-aminophenol in acetaminophen-induced nephrotoxicity: effect of bis(p-nitrophenyl) phosphate on acetaminophen and p-<e1> aminophenol </e1> <e2> nephrotoxicity </e2> and metabolism in Fischer 344 rats.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4594": {"data": {"text": "Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).", "entity1": "Lidocaine", "entity2": "ventricular tachycardia", "span1": [0, 9], "span2": [110, 133]}, "bert_text": "<e1> Lidocaine </e1>, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained <e2> ventricular tachycardia </e2>, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 0], "label": 0},
+	"4595": {"data": {"text": "Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).", "entity1": "Lidocaine", "entity2": "arrhythmias", "span1": [0, 9], "span2": [217, 228]}, "bert_text": "<e1> Lidocaine </e1>, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning <e2> arrhythmias </e2> between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4596": {"data": {"text": "Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).", "entity1": "lidocaine", "entity2": "ventricular tachycardia", "span1": [283, 292], "span2": [110, 133]}, "bert_text": "Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of <e1> lidocaine </e1> <e2> ventricular tachycardia </e2>, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, 1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, 0], "label": 0},
+	"4597": {"data": {"text": "Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).", "entity1": "lidocaine", "entity2": "arrhythmias", "span1": [283, 292], "span2": [217, 228]}, "bert_text": "Lidocaine, given in a 300 mg dose intramuscularly followed by 100 mg intravenously, did not prevent sustained ventricular tachycardia, although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of <e1> lidocaine </e1> <e2> arrhythmias </e2> between 15 and 45 minutes after the administration of lidocaine (p less than 0.05).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0], "label": 0},
+	"4598": {"data": {"text": "These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.", "entity1": "PCE", "entity2": "dysplasia of fetal kidneys", "span1": [32, 35], "span2": [49, 75]}, "bert_text": "These results demonstrated that <e1> PCE </e1> could induce <e2> dysplasia of fetal kidneys </e2> as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4599": {"data": {"text": "These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.", "entity1": "PCE", "entity2": "glomerulosclerosis", "span1": [32, 35], "span2": [87, 105]}, "bert_text": "These results demonstrated that <e1> PCE </e1> could induce dysplasia of fetal kidneys as well as <e2> glomerulosclerosis </e2> of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4600": {"data": {"text": "These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.", "entity1": "PCE", "entity2": "glomerulosclerosis", "span1": [32, 35], "span2": [223, 241]}, "bert_text": "These results demonstrated that <e1> PCE </e1> could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult <e2> glomerulosclerosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4601": {"data": {"text": "Trimethoprim-induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.\n", "entity1": "Trimethoprim", "entity2": "hemolytic anemia", "span1": [0, 12], "span2": [28, 44]}, "bert_text": "<e1> Trimethoprim </e1>-induced immune <e2> hemolytic anemia </e2> in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4602": {"data": {"text": "Trimethoprim-induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction.\n", "entity1": "Trimethoprim", "entity2": "hemolytic transfusion reaction", "span1": [0, 12], "span2": [100, 130]}, "bert_text": "<e1> Trimethoprim </e1>-induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute <e2> hemolytic transfusion reaction </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4603": {"data": {"text": "Patients who were using a higher dose of levodopa had a greater OPSE and a trend toward a smaller oral transit time (Pearson's correlation, P = 0.01 and 0.08, respectively).", "entity1": "levodopa", "entity2": "OPSE", "span1": [41, 49], "span2": [64, 68]}, "bert_text": "Patients who were using a higher dose of <e1> levodopa </e1> had a greater <e2> OPSE </e2> and a trend toward a smaller oral transit time (Pearson's correlation, P = 0.01 and 0.08, respectively).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4604": {"data": {"text": "Carbimazole induced ANCA positive vasculitis.\n", "entity1": "Carbimazole", "entity2": "vasculitis", "span1": [0, 11], "span2": [34, 44]}, "bert_text": "<e1> Carbimazole </e1> induced ANCA positive <e2> vasculitis </e2>.\n", "weak_labels": [1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4605": {"data": {"text": "This first case of meloxicam related liver toxicity demonstrates the potential of this drug to induce hepatic damage.", "entity1": "meloxicam", "entity2": "toxicity", "span1": [19, 28], "span2": [43, 51]}, "bert_text": "This first case of <e1> meloxicam </e1> related liver <e2> toxicity </e2> demonstrates the potential of this drug to induce hepatic damage.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4606": {"data": {"text": "This first case of meloxicam related liver toxicity demonstrates the potential of this drug to induce hepatic damage.", "entity1": "meloxicam", "entity2": "hepatic damage", "span1": [19, 28], "span2": [102, 116]}, "bert_text": "This first case of <e1> meloxicam </e1> related liver toxicity demonstrates the potential of this drug to induce <e2> hepatic damage </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4607": {"data": {"text": "Acute heart failure was induced by propranolol and volume loading after weaning from cardiopulmonary bypass; an absence of MR was confirmed by echocardiography.", "entity1": "propranolol", "entity2": "heart failure", "span1": [35, 46], "span2": [6, 19]}, "bert_text": "Acute heart failure was induced by <e1> propranolol </e1> <e2> heart failure </e2> was induced by propranolol and volume loading after weaning from cardiopulmonary bypass; an absence of MR was confirmed by echocardiography.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, 1, -1, 1, 1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4608": {"data": {"text": "Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices.", "entity1": "urea", "entity2": "necrosis", "span1": [51, 55], "span2": [186, 194]}, "bert_text": "Renal function was assessed by biochemical (plasma <e1> urea </e1> and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of <e2> necrosis </e2>) indices.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4609": {"data": {"text": "Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices.", "entity1": "creatinine", "entity2": "necrosis", "span1": [60, 70], "span2": [186, 194]}, "bert_text": "Renal function was assessed by biochemical (plasma urea and <e1> creatinine </e1>), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of <e2> necrosis </e2>) indices.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4610": {"data": {"text": "Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [14C]p-aminohippuric acid clearances) and morphological (degree of necrosis) indices.", "entity1": "14C]p-aminohippuric acid", "entity2": "necrosis", "span1": [120, 144], "span2": [186, 194]}, "bert_text": "Renal function was assessed by biochemical (plasma urea and creatinine), functional (urine analysis and [3H]inulin and [<e1> 14C]p-aminohippuric acid </e1> clearances) and morphological (degree of <e2> necrosis </e2>) indices.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4611": {"data": {"text": "CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine-related chest pain.", "entity1": "dobutamine", "entity2": "chest pain", "span1": [65, 75], "span2": [126, 136]}, "bert_text": "CONCLUSION: No exaggerated adrenergic response was detected when <e1> dobutamine </e1> was administered to patients with cocaine-related <e2> chest pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4612": {"data": {"text": "CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine-related chest pain.", "entity1": "cocaine", "entity2": "chest pain", "span1": [110, 117], "span2": [126, 136]}, "bert_text": "CONCLUSION: No exaggerated adrenergic response was detected when dobutamine was administered to patients with <e1> cocaine </e1>-related <e2> chest pain </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4613": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [30, 37], "span2": [72, 88]}, "bert_text": "Important untoward effects of <e1> heparin </e1> therapy including heparin-induced <e2> thrombocytopenia </e2>, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4614": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [30, 37], "span2": [183, 199]}, "bert_text": "Important untoward effects of <e1> heparin </e1> therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than <e2> thrombocytopenia </e2> and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4615": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "osteoporosis", "span1": [30, 37], "span2": [109, 121]}, "bert_text": "Important untoward effects of <e1> heparin </e1> therapy including heparin-induced thrombocytopenia, heparin-associated <e2> osteoporosis </e2>, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4616": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "eosinophilia", "span1": [30, 37], "span2": [123, 135]}, "bert_text": "Important untoward effects of <e1> heparin </e1> therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, <e2> eosinophilia </e2>, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4617": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "allergic", "span1": [30, 37], "span2": [153, 161]}, "bert_text": "Important untoward effects of <e1> heparin </e1> therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, <e2> allergic </e2> reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4618": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "alopecia", "span1": [30, 37], "span2": [204, 212]}, "bert_text": "Important untoward effects of <e1> heparin </e1> therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and <e2> alopecia </e2> will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4619": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [56, 63], "span2": [72, 88]}, "bert_text": "Important untoward effects of heparin therapy including <e1> heparin </e1>-induced <e2> thrombocytopenia </e2>, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4620": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [56, 63], "span2": [183, 199]}, "bert_text": "Important untoward effects of heparin therapy including <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than <e2> thrombocytopenia </e2> and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4621": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "osteoporosis", "span1": [56, 63], "span2": [109, 121]}, "bert_text": "Important untoward effects of heparin therapy including <e1> heparin </e1>-induced thrombocytopenia, heparin-associated <e2> osteoporosis </e2>, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4622": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "eosinophilia", "span1": [56, 63], "span2": [123, 135]}, "bert_text": "Important untoward effects of heparin therapy including <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, <e2> eosinophilia </e2>, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4623": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "allergic", "span1": [56, 63], "span2": [153, 161]}, "bert_text": "Important untoward effects of heparin therapy including <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, <e2> allergic </e2> reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4624": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "alopecia", "span1": [56, 63], "span2": [204, 212]}, "bert_text": "Important untoward effects of heparin therapy including <e1> heparin </e1>-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and <e2> alopecia </e2> will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4625": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [90, 97], "span2": [72, 88]}, "bert_text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, <e1> heparin </e1> <e2> thrombocytopenia </e2>, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"4626": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "thrombocytopenia", "span1": [90, 97], "span2": [183, 199]}, "bert_text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than <e2> thrombocytopenia </e2> and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4627": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "osteoporosis", "span1": [90, 97], "span2": [109, 121]}, "bert_text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, <e1> heparin </e1>-associated <e2> osteoporosis </e2>, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4628": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "eosinophilia", "span1": [90, 97], "span2": [123, 135]}, "bert_text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, <e2> eosinophilia </e2>, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4629": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "allergic", "span1": [90, 97], "span2": [153, 161]}, "bert_text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, eosinophilia, skin reactions, <e2> allergic </e2> reactions other than thrombocytopenia and alopecia will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4630": {"data": {"text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, heparin-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and alopecia will be discussed in this article.", "entity1": "heparin", "entity2": "alopecia", "span1": [90, 97], "span2": [204, 212]}, "bert_text": "Important untoward effects of heparin therapy including heparin-induced thrombocytopenia, <e1> heparin </e1>-associated osteoporosis, eosinophilia, skin reactions, allergic reactions other than thrombocytopenia and <e2> alopecia </e2> will be discussed in this article.", "weak_labels": [-1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4631": {"data": {"text": "From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified.", "entity1": "5-fluorouracil", "entity2": "cancer", "span1": [135, 149], "span2": [22, 28]}, "bert_text": "From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of <e1> 5-fluorouracil </e1> <e2> cancer </e2> patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4632": {"data": {"text": "From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified.", "entity1": "5-fluorouracil", "entity2": "hyperammonemic encephalopathy", "span1": [135, 149], "span2": [71, 100]}, "bert_text": "From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of <e1> 5-fluorouracil </e1> <e2> hyperammonemic encephalopathy </e2> related to continuous infusion of 5-fluorouracil (5-FU) were identified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4633": {"data": {"text": "From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified.", "entity1": "5-FU", "entity2": "cancer", "span1": [151, 155], "span2": [22, 28]}, "bert_text": "From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (<e1> 5-FU </e1> <e2> cancer </e2> patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4634": {"data": {"text": "From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (5-FU) were identified.", "entity1": "5-FU", "entity2": "hyperammonemic encephalopathy", "span1": [151, 155], "span2": [71, 100]}, "bert_text": "From 1986 to 1998, 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5-fluorouracil (<e1> 5-FU </e1> <e2> hyperammonemic encephalopathy </e2> related to continuous infusion of 5-fluorouracil (5-FU) were identified.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4635": {"data": {"text": "5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.\n", "entity1": "5-Fluorouracil", "entity2": "cardiotoxicity", "span1": [0, 14], "span2": [15, 29]}, "bert_text": "<e1> 5-Fluorouracil </e1> <e2> cardiotoxicity </e2> induced by alpha-fluoro-beta-alanine.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4636": {"data": {"text": "5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.\n", "entity1": "alpha-fluoro-beta-alanine", "entity2": "cardiotoxicity", "span1": [41, 66], "span2": [15, 29]}, "bert_text": "5-Fluorouracil cardiotoxicity induced by <e1> alpha-fluoro-beta-alanine </e1> <e2> cardiotoxicity </e2> induced by alpha-fluoro-beta-alanine.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, 1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4637": {"data": {"text": "Our findings showed that pubertal BPA exposure increased anxiety-like behavior, which may be associated with decreased AChE activity of the hippocampus in adult male mice.", "entity1": "BPA", "entity2": "anxiety", "span1": [34, 37], "span2": [57, 64]}, "bert_text": "Our findings showed that pubertal <e1> BPA </e1> exposure increased <e2> anxiety </e2>-like behavior, which may be associated with decreased AChE activity of the hippocampus in adult male mice.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4638": {"data": {"text": "A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.", "entity1": "metoprolol", "entity2": "coronary artery disease", "span1": [31, 41], "span2": [64, 87]}, "bert_text": "A 63 year-old Caucasian man on <e1> metoprolol </e1> 200 mg/day for stable <e2> coronary artery disease </e2> was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4639": {"data": {"text": "A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.", "entity1": "metoprolol", "entity2": "onychomycosis", "span1": [31, 41], "span2": [154, 167]}, "bert_text": "A 63 year-old Caucasian man on <e1> metoprolol </e1> 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for <e2> onychomycosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4640": {"data": {"text": "A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.", "entity1": "terbinafine", "entity2": "coronary artery disease", "span1": [127, 138], "span2": [64, 87]}, "bert_text": "A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral <e1> terbinafine </e1> <e2> coronary artery disease </e2> was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4641": {"data": {"text": "A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral terbinafine 250 mg/day for onychomycosis.", "entity1": "terbinafine", "entity2": "onychomycosis", "span1": [127, 138], "span2": [154, 167]}, "bert_text": "A 63 year-old Caucasian man on metoprolol 200 mg/day for stable coronary artery disease was prescribed a 90-day course of oral <e1> terbinafine </e1> 250 mg/day for <e2> onychomycosis </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4642": {"data": {"text": "OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with propylthiouracil (PTU).", "entity1": "propylthiouracil", "entity2": "vasculitis", "span1": [167, 183], "span2": [83, 93]}, "bert_text": "OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with <e1> propylthiouracil </e1> <e2> vasculitis </e2> has been reported in patients with Graves' disease who were treated with propylthiouracil (PTU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4643": {"data": {"text": "OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with propylthiouracil (PTU).", "entity1": "propylthiouracil", "entity2": "Graves' disease", "span1": [167, 183], "span2": [129, 144]}, "bert_text": "OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with <e1> propylthiouracil </e1> <e2> Graves' disease </e2> who were treated with propylthiouracil (PTU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4644": {"data": {"text": "OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with propylthiouracil (PTU).", "entity1": "PTU", "entity2": "vasculitis", "span1": [185, 188], "span2": [83, 93]}, "bert_text": "OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with propylthiouracil (<e1> PTU </e1> <e2> vasculitis </e2> has been reported in patients with Graves' disease who were treated with propylthiouracil (PTU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4645": {"data": {"text": "OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with propylthiouracil (PTU).", "entity1": "PTU", "entity2": "Graves' disease", "span1": [185, 188], "span2": [129, 144]}, "bert_text": "OBJECTIVE: Myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-positive vasculitis has been reported in patients with Graves' disease who were treated with propylthiouracil (<e1> PTU </e1> <e2> Graves' disease </e2> who were treated with propylthiouracil (PTU).", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4646": {"data": {"text": "Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation.", "entity1": "bortezomib", "entity2": "infections", "span1": [85, 95], "span2": [63, 73]}, "bert_text": "Physicians should recognise the possibility of fatal bacterial infections related to <e1> bortezomib </e1> <e2> infections </e2> related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4647": {"data": {"text": "Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation.", "entity1": "dexamethasone", "entity2": "infections", "span1": [111, 124], "span2": [63, 73]}, "bert_text": "Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high-dose <e1> dexamethasone </e1> <e2> infections </e2> related to bortezomib plus high-dose dexamethasone in elderly patients, and we believe this case warrants further investigation.", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4648": {"data": {"text": "RESULTS: A total of 59 patients with cocaine-associated chest pain were evaluated.", "entity1": "cocaine", "entity2": "chest pain", "span1": [37, 44], "span2": [56, 66]}, "bert_text": "RESULTS: A total of 59 patients with <e1> cocaine </e1>-associated <e2> chest pain </e2> were evaluated.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4649": {"data": {"text": "Three patients had acute viral myocarditis, one had a carbamazepine-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.", "entity1": "carbamazepine", "entity2": "viral myocarditis", "span1": [54, 67], "span2": [25, 42]}, "bert_text": "Three patients had acute viral myocarditis, one had a <e1> carbamazepine </e1> <e2> viral myocarditis </e2>, one had a carbamazepine-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4650": {"data": {"text": "Three patients had acute viral myocarditis, one had a carbamazepine-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.", "entity1": "carbamazepine", "entity2": "eosinophilic myocarditis", "span1": [54, 67], "span2": [82, 106]}, "bert_text": "Three patients had acute viral myocarditis, one had a <e1> carbamazepine </e1>-induced acute <e2> eosinophilic myocarditis </e2>, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4651": {"data": {"text": "Three patients had acute viral myocarditis, one had a carbamazepine-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.", "entity1": "carbamazepine", "entity2": "cardiac hemosiderosis", "span1": [54, 67], "span2": [120, 141]}, "bert_text": "Three patients had acute viral myocarditis, one had a <e1> carbamazepine </e1>-induced acute eosinophilic myocarditis, and one had <e2> cardiac hemosiderosis </e2> resulting in acute cardiogenic shock.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4652": {"data": {"text": "Three patients had acute viral myocarditis, one had a carbamazepine-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute cardiogenic shock.", "entity1": "carbamazepine", "entity2": "cardiogenic shock", "span1": [54, 67], "span2": [161, 178]}, "bert_text": "Three patients had acute viral myocarditis, one had a <e1> carbamazepine </e1>-induced acute eosinophilic myocarditis, and one had cardiac hemosiderosis resulting in acute <e2> cardiogenic shock </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4653": {"data": {"text": "Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.\n", "entity1": "galactose", "entity2": "cognitive deficits", "span1": [15, 24], "span2": [44, 62]}, "bert_text": "Long-term oral <e1> galactose </e1> treatment prevents <e2> cognitive deficits </e2> in male Wistar rats treated intracerebroventricularly with streptozotocin.\n", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4654": {"data": {"text": "Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin.\n", "entity1": "streptozotocin", "entity2": "cognitive deficits", "span1": [122, 136], "span2": [44, 62]}, "bert_text": "Long-term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with <e1> streptozotocin </e1> <e2> cognitive deficits </e2> in male Wistar rats treated intracerebroventricularly with streptozotocin.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, 0, -1, -1], "label": 1},
+	"4655": {"data": {"text": "CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN.", "entity1": "sodium chloride", "entity2": "CIN", "span1": [65, 80], "span2": [174, 177]}, "bert_text": "CONCLUSION: There was no significant difference between isotonic <e1> sodium chloride </e1>, sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of <e2> CIN </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4656": {"data": {"text": "CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN.", "entity1": "sodium chloride", "entity2": "CIN", "span1": [114, 129], "span2": [174, 177]}, "bert_text": "CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic <e1> sodium chloride </e1> with diltiazem application in prevention of <e2> CIN </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4657": {"data": {"text": "CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN.", "entity1": "sodium bicarbonate", "entity2": "CIN", "span1": [82, 100], "span2": [174, 177]}, "bert_text": "CONCLUSION: There was no significant difference between isotonic sodium chloride, <e1> sodium bicarbonate </e1> and isotonic sodium chloride with diltiazem application in prevention of <e2> CIN </e2>.", "weak_labels": [-1, -1, -1, -1, 0, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4658": {"data": {"text": "CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with diltiazem application in prevention of CIN.", "entity1": "diltiazem", "entity2": "CIN", "span1": [135, 144], "span2": [174, 177]}, "bert_text": "CONCLUSION: There was no significant difference between isotonic sodium chloride, sodium bicarbonate and isotonic sodium chloride with <e1> diltiazem </e1> application in prevention of <e2> CIN </e2>.", "weak_labels": [-1, -1, -1, 0, 0, -1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4659": {"data": {"text": "This was further supported by results showing that nonconvulsive doses of NMDA and pilocarpine were synergistic, resulting in status epilepticus and subsequent mortality.", "entity1": "pilocarpine", "entity2": "status epilepticus", "span1": [83, 94], "span2": [126, 144]}, "bert_text": "This was further supported by results showing that nonconvulsive doses of NMDA and <e1> pilocarpine </e1> were synergistic, resulting in <e2> status epilepticus </e2> and subsequent mortality.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4660": {"data": {"text": "The enhancement of aminonucleoside nephrosis by the co-administration of protamine.\n", "entity1": "aminonucleoside", "entity2": "nephrosis", "span1": [19, 34], "span2": [35, 44]}, "bert_text": "The enhancement of <e1> aminonucleoside </e1> <e2> nephrosis </e2> by the co-administration of protamine.\n", "weak_labels": [-1, 1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4661": {"data": {"text": "The enhancement of aminonucleoside nephrosis by the co-administration of protamine.\n", "entity1": "protamine", "entity2": "nephrosis", "span1": [73, 82], "span2": [35, 44]}, "bert_text": "The enhancement of aminonucleoside nephrosis by the co-administration of <e1> protamine </e1> <e2> nephrosis </e2> by the co-administration of protamine.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4662": {"data": {"text": "A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity.\n", "entity1": "trimethoprim-sulfamethoxazole", "entity2": "drug toxicity", "span1": [44, 73], "span2": [125, 138]}, "bert_text": "A large population-based follow-up study of <e1> trimethoprim-sulfamethoxazole </e1>, trimethoprim, and cephalexin for uncommon serious <e2> drug toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, 0, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4663": {"data": {"text": "A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity.\n", "entity1": "trimethoprim", "entity2": "drug toxicity", "span1": [75, 87], "span2": [125, 138]}, "bert_text": "A large population-based follow-up study of trimethoprim-sulfamethoxazole, <e1> trimethoprim </e1>, and cephalexin for uncommon serious <e2> drug toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4664": {"data": {"text": "A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity.\n", "entity1": "cephalexin", "entity2": "drug toxicity", "span1": [93, 103], "span2": [125, 138]}, "bert_text": "A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and <e1> cephalexin </e1> for uncommon serious <e2> drug toxicity </e2>.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4665": {"data": {"text": "MRI-based maps suggest that chronic methamphetamine abuse causes a selective pattern of cerebral deterioration that contributes to impaired memory performance.", "entity1": "methamphetamine", "entity2": "impaired memory", "span1": [36, 51], "span2": [131, 146]}, "bert_text": "MRI-based maps suggest that chronic <e1> methamphetamine </e1> abuse causes a selective pattern of cerebral deterioration that contributes to <e2> impaired memory </e2> performance.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4666": {"data": {"text": "Suxamethonium-induced jaw stiffness and myalgia associated with atypical cholinesterase: case report.\n", "entity1": "Suxamethonium", "entity2": "jaw stiffness", "span1": [0, 13], "span2": [22, 35]}, "bert_text": "<e1> Suxamethonium </e1>-induced <e2> jaw stiffness </e2> and myalgia associated with atypical cholinesterase: case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4667": {"data": {"text": "Suxamethonium-induced jaw stiffness and myalgia associated with atypical cholinesterase: case report.\n", "entity1": "Suxamethonium", "entity2": "myalgia", "span1": [0, 13], "span2": [40, 47]}, "bert_text": "<e1> Suxamethonium </e1>-induced jaw stiffness and <e2> myalgia </e2> associated with atypical cholinesterase: case report.\n", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4668": {"data": {"text": "We describe a 47-year-old woman with an acute myocardial infarction after administration of sumatriptan 6 mg subcutaneously for cluster headache.", "entity1": "sumatriptan", "entity2": "myocardial infarction", "span1": [92, 103], "span2": [46, 67]}, "bert_text": "We describe a 47-year-old woman with an acute myocardial infarction after administration of <e1> sumatriptan </e1> <e2> myocardial infarction </e2> after administration of sumatriptan 6 mg subcutaneously for cluster headache.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4669": {"data": {"text": "We describe a 47-year-old woman with an acute myocardial infarction after administration of sumatriptan 6 mg subcutaneously for cluster headache.", "entity1": "sumatriptan", "entity2": "cluster headache", "span1": [92, 103], "span2": [128, 144]}, "bert_text": "We describe a 47-year-old woman with an acute myocardial infarction after administration of <e1> sumatriptan </e1> 6 mg subcutaneously for <e2> cluster headache </e2>.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 0, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4670": {"data": {"text": "We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester.", "entity1": "isotretinoin", "entity2": "multiple congenital anomalies", "span1": [120, 132], "span2": [32, 61]}, "bert_text": "We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to <e1> isotretinoin </e1> <e2> multiple congenital anomalies </e2> (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0},
+	"4671": {"data": {"text": "We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester.", "entity1": "isotretinoin", "entity2": "anotia", "span1": [120, 132], "span2": [63, 69]}, "bert_text": "We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to <e1> isotretinoin </e1> <e2> anotia </e2> and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 1},
+	"4672": {"data": {"text": "We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to isotretinoin within the first trimester.", "entity1": "isotretinoin", "entity2": "malformation", "span1": [120, 132], "span2": [87, 99]}, "bert_text": "We report a newborn infant with multiple congenital anomalies (anotia and Taussig-Bing malformation) due to exposure to <e1> isotretinoin </e1> <e2> malformation </e2>) due to exposure to isotretinoin within the first trimester.", "weak_labels": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, 1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "label": 0}
+}
\ No newline at end of file